PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33497755-5	2021	This study investigated effect of DEHP exposure during juvenile period on DNA methylation (global DNA methylation/DNMT1 expression) and inflammation (IL-17A, IL-6, MCP-1, TNF-alpha) in CD4 + T cells/CD11c + DCs and cortex, and autism-like symptoms (three-chambered sociability test, self-grooming and marble burying test) in asocial BTBR and social C57 mice at adulthood.	Diethylhexyl Phthalate	34-38	CD4 antigen	Mus musculus	185-188
33662364-7	2021	Results demonstrated, MviN-c could significantly induce IFN- gamma response in immunized mice, however, showed higher proficiency towards Th2 immune induction marked by IL-4 induction and significant CD4+ T-cell differentiation compared to the vector control group.	mvin-c	22-28	CD4 antigen	Mus musculus	200-203
33894646-3	2021	CD4 + T cells play a crucial role in EAO induction.	nitecapone	37-40	CD4 antigen	Mus musculus	0-3
34039371-16	2021	CONCLUSIONS: miR-20a suppresses the differentiation of antigen-specific CD4+ T cells into Tregs in EAE by decreasing the expression of Map3k9.	tregs	90-95	CD4 antigen	Mus musculus	72-75
34051632-0	2021	All-trans-retinoic acid restores CD4+ T cell response after sepsis by inhibiting the expansion and activation of myeloid-derived suppressor cells.	Tretinoin	0-23	CD4 antigen	Mus musculus	33-36
34051632-6	2021	ATRA administration eventually reduced mortality of secondary infection by Legionella pneumophila in CLP-surviving mice, which might be associated with the restoration of CD4+ T cells proliferating and secreting activity.	Tretinoin	0-4	CD4 antigen	Mus musculus	171-174
34051632-7	2021	CONCLUSION: ATRA can restore CD4+ T cells dysfunction in sepsis by modulating the expansion and function of MDSCs and therefore provides a potential therapy that targets the immunosuppressive state of sepsis.	Tretinoin	12-16	CD4 antigen	Mus musculus	29-32
34018697-12	2021	TBI-mediated CD4 protein production was attenuated by naltrexone in WT mice, but not in KO mice.	Naltrexone	54-64	CD4 antigen	Mus musculus	13-16
34009457-7	2021	Limonin significantly (p < 0.05) increased T cells (CD4 and CD8) and B cells (CD19) in spleen tissues.	limonin	0-7	CD4 antigen	Mus musculus	52-55
34019804-3	2021	We employed new-generation SRG-15 humanized mice, supporting natural killer (NK) cell and Fc-effector functions to demonstrate that brief treatment with CD4mc and CD4i-Abs significantly decreases HIV-1 replication, the virus reservoir and viral rebound after ART interruption.	srg-15	27-33	CD4 antigen	Mus musculus	153-156
34015361-5	2021	Treatment with rapamycin increased frequencies of monocytic myeloid-derived suppressor cells (M-MDSCs), augmented the immunosuppressive activity of M-MDSCs on T cells through indoleamine 2,3-dioxygenase pathway and shifted CD4+ T cells towards regulatory T cells in obese graft recipients.	Sirolimus	15-24	CD4 antigen	Mus musculus	223-226
33988885-0	2021	The parasite cytokine mimic Hp-TGM potently replicates the regulatory effects of TGF-beta on murine CD4+ T cells.	tgm	31-34	CD4 antigen	Mus musculus	100-103
34054817-7	2021	In two syngeneic mouse tumor models, the intraperitoneal administration of PDI-1 reduced the growth of tumors derived from human PD-L1-transfected mouse lung cancer and melanoma cells; increased and decreased the abundance of tumor-infiltrating CD8+ and FoxP3+ CD4+ T cells, respectively; decreased the abundance of PD-L1-expressing tumor cells, and increased the production of inflammatory cytokines.	pdi-1	75-80	CD4 antigen	Mus musculus	261-264
33987830-5	2021	Finally, we demonstrated that Gm40600 promoted the Ahnak-mediated calcium signaling pathway by interacting with Ahnak to maintain a cytoplasmic lateral location of Ahnak in CD4+ T cells.	Calcium	66-73	CD4 antigen	Mus musculus	173-176
33993100-9	2021	TE administration did not affect the expression of IL-10 and the Tbet genes, and increased the expression levels of IFN-gamma and FOXP3 in CD4+ lymphocytes.	Tellurium	0-2	CD4 antigen	Mus musculus	139-142
34007158-0	2021	FTY720 Inhibits the Development of Collagen-Induced Arthritis in Mice by Suppressing the Recruitment of CD4+ T Lymphocytes.	Fingolimod Hydrochloride	0-6	CD4 antigen	Mus musculus	104-107
34007158-8	2021	Results: In vivo experiments showed that FTY720 inhibited the recruitment of CD4+ lymphocytes in the affected joints of CIA mice.	Fingolimod Hydrochloride	41-47	CD4 antigen	Mus musculus	77-80
34007158-12	2021	Conclusion: Our findings demonstrated that oral administration of FTY720 exerted beneficial effects in CIA mice by inhibiting CD4+ T lymphocyte recruitment to the affected joints.	Fingolimod Hydrochloride	66-72	CD4 antigen	Mus musculus	126-129
33630763-6	2021	In a murine model of CBD, the addition of LPS to Be oxide exposure enhanced CCL4 and CCL3 secretion in the lung and significantly increased the number and percentage of CD4+ T cells specific for the HLA-DP2-CCL/Be epitope.	beryllium oxide	49-57	CD4 antigen	Mus musculus	169-172
33945915-7	2021	Decreased CD19+, CD4+ and CD8+ lymphocytes in the peripheral blood of allogenic TRAMP-C1 mice were significantly elevated by Rut administration.	rutecarpine	125-128	CD4 antigen	Mus musculus	17-20
32917984-3	2021	In an experimental mouse model of crescentic glomerulonephritis induced by an anti-glomerular basement membrane antibody, Tregs started to accumulate in the kidney on day 10 of disease onset and remained at high levels (~30-35% of CD4+ T cells) during the late stage (days 21-90), which correlated with stable disease control.	tregs	122-127	CD4 antigen	Mus musculus	231-234
33398468-4	2021	Ro-31-8425 (free or released by MSCs) suppressed the proliferation of CD4+ T cells in vitro following polyclonal and antigen-specific stimulation.	Ro 31-8425	0-10	CD4 antigen	Mus musculus	70-73
33828301-4	2021	CD4+ T effector (Teff) cells upregulate expression of the xenobiotic transporter MDR1 (encoded by Abcb1a) in the siLP to prevent bile acid toxicity and suppress Crohn"s disease-like small bowel inflammation4.	Bile Acids and Salts	129-138	CD4 antigen	Mus musculus	0-3
33981308-5	2021	Except for inhibiting the expression of epidermal differentiation related proteins, Ebosin significantly increased the percentage of CD4+Foxp3+CD25+ Tregs and decreased CD4+IL17A+ Th17 cells in psoriatic mice.	ebosin	84-90	CD4 antigen	Mus musculus	133-136
33981308-5	2021	Except for inhibiting the expression of epidermal differentiation related proteins, Ebosin significantly increased the percentage of CD4+Foxp3+CD25+ Tregs and decreased CD4+IL17A+ Th17 cells in psoriatic mice.	ebosin	84-90	CD4 antigen	Mus musculus	169-172
33878733-7	2021	WS-fed mice showed a decrease in malondialdehyde and an increase in superoxide dismutase levels in the brain; additionally, IL-6 and TNF-alpha levels significantly decreased, whereas IL-2 levels and the proportion of lymphocytes, CD3+CD8+ T, and CD4+IFNgamma+T cells increased in WS-fed mice.	H-TRP-SER-OH	0-2	CD4 antigen	Mus musculus	246-249
33883646-8	2021	Moreover, nalfurafine administration twice daily reduced the numbers of infiltrating leukocytes, neutrophils, macrophages, and interferon-gamma-producing CD4+ T cells in the neovascularized corneas.	TRK 820	10-21	CD4 antigen	Mus musculus	154-157
33887578-9	2021	Our data suggest that anti-OX40L combined with Rapa and a low dose of IL-2 can suppress Tm, modulate CD4 and CD8 Tregs, and induce long-term heart allograft survival in sensitized mice.	Sirolimus	47-51	CD4 antigen	Mus musculus	101-104
33876188-8	2021	Treg deletion and depletion offset the effect of decitabine in restoring CD4+ T cell subpopulations in ITP mice.	Decitabine	49-59	CD4 antigen	Mus musculus	73-76
33876205-6	2021	HOD-specific CD4 T cells displayed similar proliferation and activation following transfusion of HOD RBCs into wild type or MZ B cell deficient recipients, suggesting that IgG formation is not dependent on MZ B cell-mediated CD4 T cell activation.	Boron	102-103	CD4 antigen	Mus musculus	13-16
33959215-11	2021	KB suppressed the differentiation to Tregs from naive CD4+ T cells.	tregs	37-42	CD4 antigen	Mus musculus	54-57
33866609-10	2021	PilVax immunisation resulted in an unexpected increase in the numbers of CD3+ CD4- CD8- (double negative, DN) T cells in the lungs of vaccinated mice.	pilvax	0-6	CD4 antigen	Mus musculus	78-81
33923548-4	2021	The Flu/THSP vector was safe and stimulated a systemic TB-specific CD4+ and CD8+ T-cell immune response after intranasal immunization in mice.	thsp	8-12	CD4 antigen	Mus musculus	67-70
33948372-4	2021	MiR-15a/16-deficient mice had many CD4+NKG2D+ T cells, which produced TGF-beta1 and IL-10 and inhibited the IFN-gamma production of CD8+ T cells.	mir-15a	0-7	CD4 antigen	Mus musculus	35-38
33581203-6	2021	In vitro stimulation of splenocytes from mice vaccinated with alginate-chitosan-encapsulated KLM-gamma resulted in lymphocyte proliferation, increase of proportion of memory CD4+ and CD8+ T cell and production of IL-10 and IFN-gamma.	Alginates	62-70	CD4 antigen	Mus musculus	174-177
33581203-6	2021	In vitro stimulation of splenocytes from mice vaccinated with alginate-chitosan-encapsulated KLM-gamma resulted in lymphocyte proliferation, increase of proportion of memory CD4+ and CD8+ T cell and production of IL-10 and IFN-gamma.	Chitosan	71-79	CD4 antigen	Mus musculus	174-177
33581203-6	2021	In vitro stimulation of splenocytes from mice vaccinated with alginate-chitosan-encapsulated KLM-gamma resulted in lymphocyte proliferation, increase of proportion of memory CD4+ and CD8+ T cell and production of IL-10 and IFN-gamma.	klm-gamma	93-102	CD4 antigen	Mus musculus	174-177
33853825-6	2021	Depletion of CD4+ or CD8+ T cells, either at the time of AU-011 treatment or secondary tumor re-challenge of tumor-free mice, indicated that both cell populations are vital to AU-011"s ability to eradicate primary tumors and induce long-lasting anti-tumor protection.	au-011	57-63	CD4 antigen	Mus musculus	13-16
33853825-6	2021	Depletion of CD4+ or CD8+ T cells, either at the time of AU-011 treatment or secondary tumor re-challenge of tumor-free mice, indicated that both cell populations are vital to AU-011"s ability to eradicate primary tumors and induce long-lasting anti-tumor protection.	au-011	176-182	CD4 antigen	Mus musculus	13-16
33936096-5	2021	The nanovaccine induced robust antigen-specific Th1 (IFN-gamma, IL-2) and IL-17 cytokines plus CD4+ proliferating T-cells and memory (CD44high CD62Lhigh) and effector (CD44high CD62Llow) phenotypes in immunized mice.	nanovaccine	4-15	CD4 antigen	Mus musculus	95-98
33927721-5	2021	In addition, baricitinib treatment downregulated the proportion of interferon-gamma+CD4+ Th1 and interleukin-17+CD4+ Th17 cells, decreased the levels of retinoic acid-related orphan receptor gamma t and T-bet mRNA, inhibited lymphocyte proliferation, and decreased the expression of proinflammatory cytokines and chemokines in the spleen of mice with EAE.	baricitinib	13-24	CD4 antigen	Mus musculus	84-87
33927721-5	2021	In addition, baricitinib treatment downregulated the proportion of interferon-gamma+CD4+ Th1 and interleukin-17+CD4+ Th17 cells, decreased the levels of retinoic acid-related orphan receptor gamma t and T-bet mRNA, inhibited lymphocyte proliferation, and decreased the expression of proinflammatory cytokines and chemokines in the spleen of mice with EAE.	baricitinib	13-24	CD4 antigen	Mus musculus	112-115
33667382-0	2021	Cytoplasmic DNA sensing by KU complex in aged CD4+ T cell potentiates T cell activation and aging-related autoimmune inflammation.	ku complex	27-37	CD4 antigen	Mus musculus	46-49
33667382-4	2021	Here, we found KU complex abundantly expressed in the cytoplasm, where it recognized accumulated cytoplasmic DNA in aged human and mouse CD4+ T cells.	ku complex	15-25	CD4 antigen	Mus musculus	137-140
33573506-10	2021	Coexpression of CD4/IFN-gamma was confirmed in lungs of animals that consumed PFM continuously.	PFM	78-81	CD4 antigen	Mus musculus	16-19
33609620-7	2021	Finally, we demonstrated that MPA-TG was significantly more effective than MPA at inhibiting CD4+ and CD8+ T cell proliferation in the MLN of mice in response to an oral ovalbumin antigen challenge.	mpa-tg	30-36	CD4 antigen	Mus musculus	93-96
33609620-7	2021	Finally, we demonstrated that MPA-TG was significantly more effective than MPA at inhibiting CD4+ and CD8+ T cell proliferation in the MLN of mice in response to an oral ovalbumin antigen challenge.	Mycophenolic Acid	30-33	CD4 antigen	Mus musculus	93-96
33897706-5	2021	First, we investigated the impact of alphaIL-21R on CD4+ T cell proliferation and apoptosis.	alphail-21r	37-48	CD4 antigen	Mus musculus	52-55
33918403-0	2021	Ex Vivo High Salt Activated Tumor-Primed CD4+T Lymphocytes Exert a Potent Anti-Cancer Response.	Salts	13-17	CD4 antigen	Mus musculus	41-44
33918403-3	2021	In our current study, we analyzed the ability of salt treatment to induce ex vivo expansion of tumor-primed CD4 (cluster of differentiation 4)+T cells to an effector phenotype.	Salts	49-53	CD4 antigen	Mus musculus	108-111
33918403-8	2021	Importantly, the high salt expanded CD4+T cells retained tumor-specificity, as demonstrated by higher in vitro cytotoxicity against Py230 breast cancer cells and reduced in vivo syngeneic tumor growth.	Salts	22-26	CD4 antigen	Mus musculus	36-39
33918403-9	2021	Metabolic studies revealed that high salt treatment enhanced the glycolytic reserve and basal mitochondrial oxidation of CD4+T cells, suggesting a role of high salt in enhanced pro-growth anabolic metabolism needed for inflammatory differentiation.	Salts	37-41	CD4 antigen	Mus musculus	121-124
33918403-9	2021	Metabolic studies revealed that high salt treatment enhanced the glycolytic reserve and basal mitochondrial oxidation of CD4+T cells, suggesting a role of high salt in enhanced pro-growth anabolic metabolism needed for inflammatory differentiation.	Salts	160-164	CD4 antigen	Mus musculus	121-124
33918403-11	2021	Using a transgenic murine model, we demonstrated that CD4 specific TonEBP/NFAT5 knock out (CD4cre/creNFAT5flox/flox) abrogated the induction of the effector phenotype and anti-tumor efficiency of CD4+T cells following high salt treatment.	Salts	223-227	CD4 antigen	Mus musculus	54-57
33918403-11	2021	Using a transgenic murine model, we demonstrated that CD4 specific TonEBP/NFAT5 knock out (CD4cre/creNFAT5flox/flox) abrogated the induction of the effector phenotype and anti-tumor efficiency of CD4+T cells following high salt treatment.	Salts	223-227	CD4 antigen	Mus musculus	91-94
33918403-11	2021	Using a transgenic murine model, we demonstrated that CD4 specific TonEBP/NFAT5 knock out (CD4cre/creNFAT5flox/flox) abrogated the induction of the effector phenotype and anti-tumor efficiency of CD4+T cells following high salt treatment.	Salts	223-227	CD4 antigen	Mus musculus	91-94
33918403-12	2021	Taken together, our data suggest that high salt-mediated ex vivo expansion of tumor-primed CD4+T cells could induce effective tumor specific anti-cancer responses, which may have a novel cell-based cancer immunotherapeutic application.	Salts	43-47	CD4 antigen	Mus musculus	91-94
33555623-3	2021	EXPERIMENTAL APPROACH: For in vitro study, Jurkat cells and mouse CD4+ T cells were used in present study to show whether kamepferol prevents T cell activation and its underlying mechanism.	kamepferol	122-132	CD4 antigen	Mus musculus	66-69
33555623-5	2021	KEY RESULTS: We explored pre-treatment with kaempferol reduces the CD69 expression and pro-inflammatory cytokines production including IL-2 from activated Jurkat cells and murine CD4+ T cells without cytotoxicity.	kaempferol	44-54	CD4 antigen	Mus musculus	179-182
33742689-4	2021	First, we showed by in vitro experiments that ALA favors the polarization of mice CD4 + T cells toward Tregs.	Thioctic Acid	46-49	CD4 antigen	Mus musculus	82-85
33742689-4	2021	First, we showed by in vitro experiments that ALA favors the polarization of mice CD4 + T cells toward Tregs.	tregs	103-108	CD4 antigen	Mus musculus	82-85
33079282-0	2021	Linoleic acid inhibits in vitro function of human and murine dendritic cells, CD4+T cells and retinal pigment epithelial cells.	Linoleic Acid	0-13	CD4 antigen	Mus musculus	78-81
33149278-7	2021	Flow cytometry and histological analysis showed increased activation of CD4+ and CD8+ T cells in  6/GM/IL12-treated mice.	Gentamicins	100-102	CD4 antigen	Mus musculus	72-75
33648937-12	2021	Finally, we confirmed that the CDDO-Im-mediated induction of IL-22 production in CD4+ T cells was abrogated in CD4-specific Ahr knockout mice (AhrCD4 ).	1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole	31-38	CD4 antigen	Mus musculus	81-84
33648937-12	2021	Finally, we confirmed that the CDDO-Im-mediated induction of IL-22 production in CD4+ T cells was abrogated in CD4-specific Ahr knockout mice (AhrCD4 ).	1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole	31-38	CD4 antigen	Mus musculus	111-114
33648937-13	2021	CH-223191, a specific AhR antagonist, inhibits CDDO-Im-induced IL-22 production in CD4+ T cells, which further confirmed the AhR-dependent regulation.	2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	0-9	CD4 antigen	Mus musculus	83-86
33648937-13	2021	CH-223191, a specific AhR antagonist, inhibits CDDO-Im-induced IL-22 production in CD4+ T cells, which further confirmed the AhR-dependent regulation.	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	47-51	CD4 antigen	Mus musculus	83-86
33504590-7	2021	In mouse peripheral CD4+CD25+ Treg cells induced by a lectin stimulation, IL-10 expression and secretion were enhanced by the treatment with TRAM-34, together with the up-regulation of E4BP4, KLF4, and Blimp1.	TRAM 34	141-148	CD4 antigen	Mus musculus	20-23
33022372-0	2021	Triazolopyrimidine derivative NK026680 and donor-specific transfusion induces CD4+CD25+Foxp3+ T cells and ameliorates allograft rejection in an antigen-specific manner.	triazolopyrimidine	0-18	CD4 antigen	Mus musculus	78-81
33581286-8	2021	An increase in autophagy enhanced the inhibitory effects of Tregs on CD4+ T cells and dendritic cells (DCs) in vivo and in vitro.	tregs	60-65	CD4 antigen	Mus musculus	69-72
33788130-7	2021	In established EAE mice, 100 mg/kg 9,10-Anhydrodehydroartemisinin (ADART) effectively reduced CNS and peripheral immune system infiltration inflammatory cells including CD4+ IFN-gamma+ Th1 cells and CD4+ IL-17A+ Th17 cells.	anhydrodihydroartemisinin	35-65	CD4 antigen	Mus musculus	169-172
33788130-7	2021	In established EAE mice, 100 mg/kg 9,10-Anhydrodehydroartemisinin (ADART) effectively reduced CNS and peripheral immune system infiltration inflammatory cells including CD4+ IFN-gamma+ Th1 cells and CD4+ IL-17A+ Th17 cells.	anhydrodihydroartemisinin	35-65	CD4 antigen	Mus musculus	199-202
33788130-7	2021	In established EAE mice, 100 mg/kg 9,10-Anhydrodehydroartemisinin (ADART) effectively reduced CNS and peripheral immune system infiltration inflammatory cells including CD4+ IFN-gamma+ Th1 cells and CD4+ IL-17A+ Th17 cells.	adart	67-72	CD4 antigen	Mus musculus	169-172
33788130-7	2021	In established EAE mice, 100 mg/kg 9,10-Anhydrodehydroartemisinin (ADART) effectively reduced CNS and peripheral immune system infiltration inflammatory cells including CD4+ IFN-gamma+ Th1 cells and CD4+ IL-17A+ Th17 cells.	adart	67-72	CD4 antigen	Mus musculus	199-202
33734700-9	2021	Notably, the results confirmed that l-arabinose treatment increased CD4+ Foxp3+ T cell populations and Treg-related factors associated with increased expression of IL-2 and activation of STAT5 in gliadin-sensitized mice.	Arabinose	36-47	CD4 antigen	Mus musculus	68-71
33784418-0	2021	CD4+ T cells regulate glucose homeostasis independent of adipose tissue dysfunction in mice.	Glucose	22-29	CD4 antigen	Mus musculus	0-3
33780353-7	2021	More importantly, APAP treatment counteracts the increase in Cd8+ and the reduction in Cd4+ T lymphocytes observed in the liver with age.	Acetaminophen	18-22	CD4 antigen	Mus musculus	87-90
33152425-10	2021	RESULTS: Carvacrol attenuated lung tissue damage, the proportions of Th1, Th2, Th17 and Treg in CD4+ T cells and the relative proportions of Th1/Th2 and Th17/Treg cells.	carvacrol	9-18	CD4 antigen	Mus musculus	96-99
33463362-11	2021	Mechanistically, cardiac pressure overload resulted in ROS dependent dendritic cell accumulation of IsoLG-protein adducts which induced robust CD4+ T cell proliferation.	Reactive Oxygen Species	55-58	CD4 antigen	Mus musculus	143-146
33463362-12	2021	Conclusions: Collectively, our study demonstrates an important role of ROS-induced formation of IsoLG-modified cardiac neoantigens that lead to TCR-dependent CD4+ T cell activation within the heart.	Reactive Oxygen Species	71-74	CD4 antigen	Mus musculus	158-161
33742464-7	2022	Treatment with Baicalin could ameliorate tumor immunosuppressive environment by downregulation of PD-L1 expression and proportion of myeloid-derived suppressor cells (MDSCs) and upregulation of percent of CD4+ and CD8+ T cells in CT26 tumors, thus improving anti-tumor immunity.	baicalin	15-23	CD4 antigen	Mus musculus	205-208
33632562-5	2021	Moreover, MVA-AE boosting generated multifunctional lung CD4+ T cells responding to ESAT-6, which were not, as expected, detected in control mice given BCG, and elevated Ag85A-specific circulating antibody responses.	esat-6	84-90	CD4 antigen	Mus musculus	57-60
33733518-6	2021	Furthermore, CQMUH-011 could maintain the balance of CD3+ CD4+ /CD3+ CD8+ and decrease the percentages of CD8+ CD69+ and CD4+ CD25+/- CD69+ T-cells in the splenocytes of ConA-challenged mice.	cqmuh-011	13-22	CD4 antigen	Mus musculus	58-61
33733518-6	2021	Furthermore, CQMUH-011 could maintain the balance of CD3+ CD4+ /CD3+ CD8+ and decrease the percentages of CD8+ CD69+ and CD4+ CD25+/- CD69+ T-cells in the splenocytes of ConA-challenged mice.	cqmuh-011	13-22	CD4 antigen	Mus musculus	121-124
33733518-8	2021	In conclusion, CQMUH-011 exerts potential protective effects against ConA-induced hepatitis, which may be partially attributed to its inhibition of T cells, especially the suppression of the proliferation of CD4+ CD25- CD69+ and CD8+ CD69+ subsets in the spleen.	cqmuh-011	15-24	CD4 antigen	Mus musculus	208-211
33841688-5	2021	RESULTS: The CD4+ cell concentration in the 4NQO group was significantly higher than that in the other four groups (P<0.05).	4-Nitroquinoline-1-oxide	44-48	CD4 antigen	Mus musculus	13-16
33556388-11	2021	Based on our in vivo and in vitro experiments, we suggest that ZEA, DON, and ZEA + DON inhibit the expression of costimulatory molecules on CD4+ T cell, and inhibit the IL-4R-mediated Th2 cell differentiation.	Zearalenone	63-66	CD4 antigen	Mus musculus	140-143
33556388-11	2021	Based on our in vivo and in vitro experiments, we suggest that ZEA, DON, and ZEA + DON inhibit the expression of costimulatory molecules on CD4+ T cell, and inhibit the IL-4R-mediated Th2 cell differentiation.	deoxynivalenol	68-71	CD4 antigen	Mus musculus	140-143
33556388-11	2021	Based on our in vivo and in vitro experiments, we suggest that ZEA, DON, and ZEA + DON inhibit the expression of costimulatory molecules on CD4+ T cell, and inhibit the IL-4R-mediated Th2 cell differentiation.	zea + don	77-86	CD4 antigen	Mus musculus	140-143
33450316-5	2021	Studies of the underlying mechanism of action further revealed that BRNPs negatively regulated the differentiation of naive CD4+ T cells into T helper 17 (Th17) cells by inhibiting maturation of APCs through scavenging of reactive oxygen species (ROS) overproduced in both dendritic cells (DCs) and macrophages upon antigen uptake.	Reactive Oxygen Species	222-245	CD4 antigen	Mus musculus	124-127
33666790-9	2021	CS-BCG-PSN-OVA was found in vitro to be able to inhibit OVA-induced T-cell proliferation and upregulate the proportion of CD4+CD25+Foxp3+ T cells.	cs-bcg-psn-ova	0-14	CD4 antigen	Mus musculus	122-125
33737937-9	2021	These PTCy doses were observed to spare significant levels of CD4+ FoxP3+ (Tregs) which were found to be functional and could readily receive stimulating signals leading to their in vivo expansion via TNFRSF25 and CD25 agonists.	ptcy	6-10	CD4 antigen	Mus musculus	62-65
33513343-0	2021	Paeoniflorin ameliorates murine lupus nephritis by increasing CD4+Foxp3+ Treg cells via enhancing mTNFalpha-TNFR2 pathway.	peoniflorin	0-12	CD4 antigen	Mus musculus	62-65
33460958-5	2021	Moreover, L-Cysteine treatment reduced cerebral infiltration of CD4 T cells 7 days following HI insult.	Cysteine	10-20	CD4 antigen	Mus musculus	64-67
33460958-6	2021	Furthermore, CD4 T cell subset analysis revealed that L-Cysteine treatment decreased Th1 and Th2 counts, while increased Th17/Th2 ratio.	Cysteine	54-64	CD4 antigen	Mus musculus	13-16
32418220-8	2021	Treatment with 5-ASA decreases alcohol-induced liver injury and reverses gut inflammation by the suppression of CD4+ /RORgammat+ /IL-17A+ cells.	5-Aminosalicylic acid	15-20	CD4 antigen	Mus musculus	112-115
33428991-5	2021	This phenomenon might be explained by an inhibition of the DN-to-DP-cell transition and stimulation of DP cell conversion into CD4+ /CD8+ SP thymocytes.	dp	103-105	CD4 antigen	Mus musculus	127-130
33451905-8	2021	Furthermore, tofacitinib suppressed adaptive and innate immune responses by reducing splenocytes, total lymphocytes, CD4+ T helper cells (especially Th2 and Th17 subtypes), IL-6-producing effector B cells, PDCA-1+ dendritic cells in the spleen, and infiltration of F4/80+, CD206+ and CD163+ macrophages in the skin and lungs.	tofacitinib	13-24	CD4 antigen	Mus musculus	117-120
33658304-14	2021	In in vitro assays, we demonstrated that dasatinib blocks proliferation and transforming growth factor beta-driven conversion of effector CD4+ cells into Tregs through targeting of phospholymphocyte-specific protein tyrosine kinase and downstream effectors pSTAT5 and pSMAD3.	Dasatinib	41-50	CD4 antigen	Mus musculus	138-141
33402685-8	2021	Administering of miR-199a-5p-EVs elevated platelet counts and decreased the proportion of Th17/CD4+T cells in mice with ITP.	mir-199a-5p-evs	17-32	CD4 antigen	Mus musculus	95-98
32681027-3	2021	Here, we found that under homeostatic conditions the NR Liver X receptor (LXR), a sensor of cholesterol metabolites, regulates RORgammat+ CD4 T cells in the intestine draining mesenteric lymph node (MLN).	Cholesterol	92-103	CD4 antigen	Mus musculus	138-141
33529880-10	2021	Analyses on the APBC-treated mice further revealed drastically elevated levels of infiltrating CD4+ and CD8+ T cells, and inflammatory cytokines production in tumor microenvironment.	apbc	16-20	CD4 antigen	Mus musculus	95-98
33124100-4	2021	Capsidiol resulted in a significant reduction in the anti-CD3/CD28 (alphaCD3/CD28)-induced IFN-gamma+ CD4+ (Th1) and IFN-gamma+ CD8+ (Tc1) populations as well as in the production of cytokines (IFN-gamma, IL-17A, IL-6, IL-2, TNF-alpha, and IP-10).	capsidiol	0-9	CD4 antigen	Mus musculus	102-105
33124777-8	2021	In addition, CD73 expressing ERCs showed tissue protective function via the regulation of adenosine receptor expression which was related to the infiltration of CD4+ and CD8+ cells in the allografts.	Adenosine	90-99	CD4 antigen	Mus musculus	161-164
33368686-0	2021	PJ34, a PARP1 inhibitor, attenuates acute allograft rejection after murine heart transplantation via regulating the CD4+ T lymphocyte response.	N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride	0-4	CD4 antigen	Mus musculus	116-119
33368686-12	2021	Modulating the CD4+ T lymphocyte response with PJ34 could attenuate acute allografts rejection after murine heart transplantation.	N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride	47-51	CD4 antigen	Mus musculus	15-18
33652118-10	2021	Dysregulated PDL1+B cells induced cell death of activated CD4+ T cells in DSS-treated Bmal1-/- mice.	Dextran Sulfate	74-77	CD4 antigen	Mus musculus	58-61
33637761-3	2021	Here, we show conditional deletion of METTL3 (a methyltransferase catalyzing mRNA N6-methyladenosine (m6A) modification) in CD4+ T cells impairs TFH differentiation and germinal center responses in a cell-intrinsic manner in mice.	N-methyladenosine	82-100	CD4 antigen	Mus musculus	124-127
33637761-3	2021	Here, we show conditional deletion of METTL3 (a methyltransferase catalyzing mRNA N6-methyladenosine (m6A) modification) in CD4+ T cells impairs TFH differentiation and germinal center responses in a cell-intrinsic manner in mice.	N-methyladenosine	102-105	CD4 antigen	Mus musculus	124-127
32976550-6	2021	In vitro, inducible Treg differentiation from naive CD4+ T cells was enhanced by IRX4204; in vivo, IRX4204 increased the conversion of donor Foxp3- T cells into peripheral Foxp3+ Tregs in GVHD mice.	treg	20-24	CD4 antigen	Mus musculus	52-55
33717151-3	2021	In this study, we investigated the effect of SOD3 on anti-CD3/CD28- or phorbol myristate acetate (PMA) and ionomycin (ION)-mediated activation of mouse naive CD4+ T cells.	Ionomycin	107-116	CD4 antigen	Mus musculus	158-161
33717151-7	2021	Whereas, the use of DETCA, a known inhibitor of SOD3 activity, found to nullify the inhibitory effect of SOD3 on CD4+T cell activation of both SOD3 KO and wild-type mice.	3,17-diacetoxyestra-1,3,5(10)-trien-2-carboxylic acid	20-25	CD4 antigen	Mus musculus	113-116
33732240-7	2021	Most importantly, berberine treatment protected myocardial cells by decreasing CD4+ and CD8+ T cell infiltration and by inhibiting T cell function in allografts.	Berberine	18-27	CD4 antigen	Mus musculus	79-82
33708223-5	2021	Here we hypothesise that tryptophan acts as a rheostat of kynurenine-mediated immunosuppression by competing with kynurenine for entry into immune T-cells through the amino acid transporter called System L. This hypothesis stems from the observations that elevated tryptophan levels in TDO-knockout mice relieve immunosuppression instigated by IDO1, and that the vacancy of System L transporter modulates kynurenine entry into CD4+ T-cells.	Tryptophan	25-35	CD4 antigen	Mus musculus	427-430
33708223-5	2021	Here we hypothesise that tryptophan acts as a rheostat of kynurenine-mediated immunosuppression by competing with kynurenine for entry into immune T-cells through the amino acid transporter called System L. This hypothesis stems from the observations that elevated tryptophan levels in TDO-knockout mice relieve immunosuppression instigated by IDO1, and that the vacancy of System L transporter modulates kynurenine entry into CD4+ T-cells.	Kynurenine	58-68	CD4 antigen	Mus musculus	427-430
33631896-0	2021	[Role of Orai 1-mediated store-operated calcium entry in the immune function of CD4+ T cells in septic mice].	Calcium	40-47	CD4 antigen	Mus musculus	80-83
33631896-1	2021	Objective: To investigate the role of Orai1-mediated store-operated calcium entry in the immune damage of CD4+ T cells in septic mice.	Calcium	68-75	CD4 antigen	Mus musculus	106-109
33631896-19	2021	Conclusion: Orai1-mediated store-operated calcium entry can alleviate the immune dysfunction of CD4+ T cells in septic mice.	Calcium	42-49	CD4 antigen	Mus musculus	96-99
33616474-9	2021	BMDCs treated with NPHEL46-61/Rapa suppressed antigen-specific CD4+ T cell proliferation while promoted the differentiation of these CD4+ T cell to Tregs in vitro.	nphel46-61	19-29	CD4 antigen	Mus musculus	63-66
33616474-9	2021	BMDCs treated with NPHEL46-61/Rapa suppressed antigen-specific CD4+ T cell proliferation while promoted the differentiation of these CD4+ T cell to Tregs in vitro.	nphel46-61	19-29	CD4 antigen	Mus musculus	133-136
33616474-9	2021	BMDCs treated with NPHEL46-61/Rapa suppressed antigen-specific CD4+ T cell proliferation while promoted the differentiation of these CD4+ T cell to Tregs in vitro.	tregs	148-153	CD4 antigen	Mus musculus	133-136
33602234-8	2021	The effect of GW559090 on non-adherent, adherent, and migrated CD4+ T cell subsets across a central nervous system (CNS) endothelium was further assayed in vitro and quantitated by flow cytometry.	GW559090	14-22	CD4 antigen	Mus musculus	63-66
33671196-5	2021	Our results demonstrated that 5-AIQ-treated BTBR mice had significantly increased numbers of CXCR6+FOXP3+, CXCR6+IL-10+, and CXCR6+Helios+ cells and decreased numbers of CD4+GATA3+, CD4+IL-9+, and CD4+IL-17A+ cells as compared with those in untreated BTBR mice.	5-aminoisoquinolinone	30-35	CD4 antigen	Mus musculus	170-173
33671196-5	2021	Our results demonstrated that 5-AIQ-treated BTBR mice had significantly increased numbers of CXCR6+FOXP3+, CXCR6+IL-10+, and CXCR6+Helios+ cells and decreased numbers of CD4+GATA3+, CD4+IL-9+, and CD4+IL-17A+ cells as compared with those in untreated BTBR mice.	5-aminoisoquinolinone	30-35	CD4 antigen	Mus musculus	182-185
33671196-5	2021	Our results demonstrated that 5-AIQ-treated BTBR mice had significantly increased numbers of CXCR6+FOXP3+, CXCR6+IL-10+, and CXCR6+Helios+ cells and decreased numbers of CD4+GATA3+, CD4+IL-9+, and CD4+IL-17A+ cells as compared with those in untreated BTBR mice.	5-aminoisoquinolinone	30-35	CD4 antigen	Mus musculus	182-185
33671196-5	2021	Our results demonstrated that 5-AIQ-treated BTBR mice had significantly increased numbers of CXCR6+FOXP3+, CXCR6+IL-10+, and CXCR6+Helios+ cells and decreased numbers of CD4+GATA3+, CD4+IL-9+, and CD4+IL-17A+ cells as compared with those in untreated BTBR mice.	btbr	44-48	CD4 antigen	Mus musculus	170-173
33671196-5	2021	Our results demonstrated that 5-AIQ-treated BTBR mice had significantly increased numbers of CXCR6+FOXP3+, CXCR6+IL-10+, and CXCR6+Helios+ cells and decreased numbers of CD4+GATA3+, CD4+IL-9+, and CD4+IL-17A+ cells as compared with those in untreated BTBR mice.	btbr	44-48	CD4 antigen	Mus musculus	182-185
33671196-5	2021	Our results demonstrated that 5-AIQ-treated BTBR mice had significantly increased numbers of CXCR6+FOXP3+, CXCR6+IL-10+, and CXCR6+Helios+ cells and decreased numbers of CD4+GATA3+, CD4+IL-9+, and CD4+IL-17A+ cells as compared with those in untreated BTBR mice.	btbr	44-48	CD4 antigen	Mus musculus	182-185
33526701-4	2021	In vivo oblique NIR-II SIM was performed noninvasively for 3D volumetric multiplexed molecular imaging of the CT26 tumor microenvironment in mice, longitudinally mapping out CD4, CD8, and OX40 at the single-cell level in response to immunotherapy by cytosine-phosphate-guanine (CpG), a Toll-like receptor 9 (TLR-9) agonist combined with OX40 antibody treatment.	nir-ii	16-22	CD4 antigen	Mus musculus	174-177
33566938-8	2021	IFN-gamma expression raised in BALB/c CD4+CD25+ and CD4+CD25- for CE and ES, respectively.	Einsteinium	73-75	CD4 antigen	Mus musculus	38-41
33566938-8	2021	IFN-gamma expression raised in BALB/c CD4+CD25+ and CD4+CD25- for CE and ES, respectively.	Einsteinium	73-75	CD4 antigen	Mus musculus	52-55
33566938-9	2021	ES-stimulated-DCs increased CD4+CD25+ Foxp3+ and CD8+CD25- Foxp3+ expression in T cells.	Einsteinium	0-2	CD4 antigen	Mus musculus	28-31
33539546-9	2021	Exposure of primed CD4+ T cells to CD83/OVA-carrying exosomes promoted antigen-specific Treg generation.	treg	88-92	CD4 antigen	Mus musculus	19-22
33497523-9	2021	Moreover, DON diminished cytokine production and proliferation of old CD4+ T cells in vivo leading to a significantly prolonged allograft survival specifically in old recipients.	Diazooxonorleucine	10-13	CD4 antigen	Mus musculus	70-73
33159886-9	2021	Oltipraz diet significantly decreased nitrotyrosine and 4-HNE, decreased the expression of IL-1beta and TNF-alpha mRNA transcripts, while decreasing the frequency of CD45+CD4+ cells in LGs and significantly increasing conjunctival goblet cell density compared to a standard diet.	oltipraz	0-8	CD4 antigen	Mus musculus	166-169
32409965-10	2021	In murine PC models, intraperitoneal CMP-001 treatment elicited an anti-tumor immune response including an increase in chemokines (RANTES and MIP-1beta), pro-inflammatory cytokines (IFNgamma, interleukin 6 [IL-6], and IL-12), and peritoneal/tumor immune infiltration (CD4+/CD8+ T and natural killer [NK] cells).	Cytidine Monophosphate	37-40	CD4 antigen	Mus musculus	268-271
33341059-5	2021	By analyzing the immune system of immunosuppressed BALB/C mice induced by hydrocortisone, we found an increase of CD4+ and CD8+ lymphocytes in the spleens of mice after BSHY treatment.	Hydrocortisone	74-88	CD4 antigen	Mus musculus	114-117
33341059-5	2021	By analyzing the immune system of immunosuppressed BALB/C mice induced by hydrocortisone, we found an increase of CD4+ and CD8+ lymphocytes in the spleens of mice after BSHY treatment.	bshy	169-173	CD4 antigen	Mus musculus	114-117
33203696-6	2021	In the pancreas, BB-Cl-amidine treatment preserved insulin production and was associated with a less destructive immune infiltrate, characterized by reduced frequencies of effector memory CD4+ T cells and a modest reduction in the frequency of IFNgamma-producing CD4+ and CD8+ T cells.	BB-Cl-Amidine	17-30	CD4 antigen	Mus musculus	188-191
33203696-6	2021	In the pancreas, BB-Cl-amidine treatment preserved insulin production and was associated with a less destructive immune infiltrate, characterized by reduced frequencies of effector memory CD4+ T cells and a modest reduction in the frequency of IFNgamma-producing CD4+ and CD8+ T cells.	BB-Cl-Amidine	17-30	CD4 antigen	Mus musculus	263-266
33359261-0	2021	An exacerbated metabolism and mitochondrial reactive oxygen species contribute to mitochondrial alterations and apoptosis in CD4 T cells during the acute phase of Trypanosoma cruzi infection.	Oxygen	53-59	CD4 antigen	Mus musculus	125-128
33359261-5	2021	CD4 T cells from all groups showed increased glucose uptake after stimulation.	Glucose	45-52	CD4 antigen	Mus musculus	0-3
33597887-6	2020	Importantly, curcumin significantly restored the percentages of naive, TCM, and TEM cells and their CD4+ and CD8+ subpopulations.	Curcumin	13-21	CD4 antigen	Mus musculus	100-103
33341737-7	2021	Naive CD4 T cells were cultured under Treg and Th17-skewing conditions in vitro in the presence of pitavastatin.	pitavastatin	99-111	CD4 antigen	Mus musculus	6-9
32653301-5	2021	Mice with an H2s haplotype showed increased numbers of autoreactive CD4+ T cells and elevated IL-21- and IFN-gamma-production, associated with a higher frequency of IgG autoantibodies with an agalactosylated, proinflammatory N-glycan moiety.	Deuterium	13-16	CD4 antigen	Mus musculus	68-71
33545490-13	2021	In particular, sophoricoside suppressed the differentiation of naive CD4+ T cells into Th cell subsets, including Th1, Th2, and Th17, by inhibiting the expression of their subset-specific master transcription factors, leading to suppression of the expression and production of these cell subset-specific cytokines.	sophoricoside	15-28	CD4 antigen	Mus musculus	69-72
33545490-14	2021	CONCLUSION: Sophoricoside can improve AD-like allergic skin diseases mainly by inhibiting pathogenic CD4+ T cell differentiation and immune responses.	sophoricoside	12-25	CD4 antigen	Mus musculus	101-104
33317684-8	2021	Using a 3H-thymidine incorporation assay, isolated CD4+CD25+ Tregs induced by the different treatments suppressed the proliferation of CD4+CD25- T cells.	3h-thymidine	8-20	CD4 antigen	Mus musculus	51-54
33317684-8	2021	Using a 3H-thymidine incorporation assay, isolated CD4+CD25+ Tregs induced by the different treatments suppressed the proliferation of CD4+CD25- T cells.	3h-thymidine	8-20	CD4 antigen	Mus musculus	135-138
33515397-7	2021	Besides, serum levels of IL-2 and IL-6, percentages of CD3+CD4+ T lymphocytes and ratio of CD4+/CD8+ in peripheral blood were elevated in high- and medium-dose EEVLB groups compared with the model group (P<0.05).	eevlb	160-165	CD4 antigen	Mus musculus	91-94
33516262-12	2021	RESULTS: Fingolimod significantly increased the frequency of Tregs within the CD4+ T cell population in blood and spleen post-ischaemia in all three mouse cohorts compared to untreated ischemic mice.	Fingolimod Hydrochloride	9-19	CD4 antigen	Mus musculus	78-81
32790346-10	2021	Mice were immunized with a VLP bearing the aryl mannoside and a peptide antigen (Qbeta-Ova-Man540) had antigen-specific responses, including the production of CD4+ T cells producing the activating cytokines interferon-gamma and tumor necrosis factor-alpha.	aryl mannoside	43-57	CD4 antigen	Mus musculus	159-162
33564301-10	2021	A tremendous rise of the CD3+/CD8+ count and a significant decrease of CD3+CD4+/CD3+CD8+ ratios were found in the 5-FU group and were both reversed by Lcr35.	Fluorouracil	114-118	CD4 antigen	Mus musculus	75-78
33569008-4	2020	In the current study, we tested the ability of tryptamine to ameliorate symptoms of experimental autoimmune encephalomyelitis (EAE), a murine model of MS. We found that tryptamine administration attenuated clinical signs of paralysis in EAE mice, decreased the number of infiltrating CD4+ T cells in the CNS, Th17 cells, and RORgamma T cells while increasing FoxP3+Tregs.	tryptamine	169-179	CD4 antigen	Mus musculus	284-287
33473182-7	2021	We found that fingolimod administration significantly enhanced the gut barrier (evidenced by enhanced expression of tight junction proteins and reduced intestinal permeability), attenuated intestinal microbial dysbiosis (evidenced by the reduction of enteric pathogenic Proteobacteria clusters), as well as intestinal immune dysfunction (evidenced by inhibition of CD4+ cells activation, reduction of T helper type 1 cells and macrophages, and the expansion of regulatory T cells).	Fingolimod Hydrochloride	14-24	CD4 antigen	Mus musculus	365-368
33473182-8	2021	We further revealed that fingolimod administration suppressed the activation of CD4+ cells and the differentiation of T helper type 1 cells, promoted the expansion of regulatory T cells in the pancreas, which might contribute to the maintenance of pancreatic immune tolerance and the reduction of T1D incidence.	Fingolimod Hydrochloride	25-35	CD4 antigen	Mus musculus	80-83
33477499-5	2021	BBPE-treated BMDCs promoted naive CD4+ and CD8+ T-cell proliferation and activation.	bbpe	0-4	CD4 antigen	Mus musculus	34-37
33488068-7	2021	Furthermore, subcutaneous vaccination with H2O2-inactivated RE88-pVLT33-OVA (2 x 109 CFU/mouse) induced greater activation of splenic T cells and more extensive tumor infiltration with CD4+/CD8+ T cells compared with 10 microg ovalbumin (positive control).	Hydrogen Peroxide	43-47	CD4 antigen	Mus musculus	185-188
33439292-7	2021	Anti-tumor activity of CBL0137 was abrogated in CD8+ T cell depleted mice but only partially lost when natural killer or CD4+ T cells were depleted.	CBLC137	23-30	CD4 antigen	Mus musculus	121-124
33492357-1	2021	Purpose: To evaluate the role of CD4+ T helper cells in benzalkonium chloride (BAC)-induced ocular surface disorder in C57BL/6 mice.	Benzalkonium Compounds	56-77	CD4 antigen	Mus musculus	33-36
33492357-1	2021	Purpose: To evaluate the role of CD4+ T helper cells in benzalkonium chloride (BAC)-induced ocular surface disorder in C57BL/6 mice.	Benzalkonium Compounds	79-82	CD4 antigen	Mus musculus	33-36
33492357-11	2021	Conclusions: Topical application of BAC induced a dry-eye-like ocular surface disorder partly through the CD4+ T cell-mediated inflammatory response.	Benzalkonium Compounds	36-39	CD4 antigen	Mus musculus	106-109
33241667-3	2021	This paper presents a first proof-of-concept that demonstrates the feasibility of activated effector/memory CD4+ helper T cells (CD4+ TEM cells) as carriers for the delivery of polymer nanoparticles across the BBB.	Polymers	177-184	CD4 antigen	Mus musculus	108-111
33241667-3	2021	This paper presents a first proof-of-concept that demonstrates the feasibility of activated effector/memory CD4+ helper T cells (CD4+ TEM cells) as carriers for the delivery of polymer nanoparticles across the BBB.	Polymers	177-184	CD4 antigen	Mus musculus	129-132
33241667-4	2021	This study shows that CD4+ TEM cells can be decorated with poly(ethylene glycol)-modified polystyrene nanoparticles using thiol-maleimide coupling chemistry, resulting in the immobilization of  105 nanoparticles per cell as determined by confocal microscopy.	Polyethylene Glycols	59-80	CD4 antigen	Mus musculus	22-25
33241667-4	2021	This study shows that CD4+ TEM cells can be decorated with poly(ethylene glycol)-modified polystyrene nanoparticles using thiol-maleimide coupling chemistry, resulting in the immobilization of  105 nanoparticles per cell as determined by confocal microscopy.	Polystyrenes	90-101	CD4 antigen	Mus musculus	22-25
33241667-4	2021	This study shows that CD4+ TEM cells can be decorated with poly(ethylene glycol)-modified polystyrene nanoparticles using thiol-maleimide coupling chemistry, resulting in the immobilization of  105 nanoparticles per cell as determined by confocal microscopy.	Sulfhydryl Compounds	122-127	CD4 antigen	Mus musculus	22-25
33241667-4	2021	This study shows that CD4+ TEM cells can be decorated with poly(ethylene glycol)-modified polystyrene nanoparticles using thiol-maleimide coupling chemistry, resulting in the immobilization of  105 nanoparticles per cell as determined by confocal microscopy.	maleimide	128-137	CD4 antigen	Mus musculus	22-25
33254020-0	2021	Sophoricoside from Sophora japonica ameliorates allergic asthma by preventing mast cell activation and CD4+ T cell differentiation in ovalbumin-induced mice.	sophoricoside	0-13	CD4 antigen	Mus musculus	103-106
33254020-8	2021	In addition, sophoricoside decreased differentiation of naive CD4+ T cells into T helper type 1 (Th1), Th2, and Th17 cells.	sophoricoside	13-26	CD4 antigen	Mus musculus	62-65
33254020-9	2021	Overall, we demonstrated that sophoricoside improved allergic asthma by suppressing mast cell activation and CD4+ T cell differentiation.	sophoricoside	30-43	CD4 antigen	Mus musculus	109-112
32439267-12	2021	TE significantly inhibited lipid accumulation, decreased proliferation, induced apoptosis and increased CD4+ T cell survival in HFD mice.	Tellurium	0-2	CD4 antigen	Mus musculus	104-107
32927162-11	2021	In addition, nicotine-inhibited CD69-CD4+SP cells and the Bcl10/p-p65 pathway have been reversed by an autophagy inhibitor.	Nicotine	13-21	CD4 antigen	Mus musculus	37-40
33010248-7	2021	Mice were given N-acetylcysteine (NAC) to prevent loss of CD4+ T cells from liver.	Acetylcysteine	16-32	CD4 antigen	Mus musculus	58-61
33010248-7	2021	Mice were given N-acetylcysteine (NAC) to prevent loss of CD4+ T cells from liver.	Acetylcysteine	34-37	CD4 antigen	Mus musculus	58-61
33010248-11	2021	In mice with steatohepatitis given NAC, which prevents loss of CD4+ T cells, M30 and aOX40 were able slow growth of hepatic tumors.	Acetylcysteine	35-38	CD4 antigen	Mus musculus	63-66
33272847-0	2021	Borneol inhibits CD4 + T cells proliferation by down-regulating miR-26a and miR-142-3p to attenuate asthma.	142-3p	80-86	CD4 antigen	Mus musculus	17-20
33272847-14	2021	miR-26a and miR-142-3p promoted CD4 + T cells proliferation in vitro through targeting Pten.	mir-142-3p	12-22	CD4 antigen	Mus musculus	32-35
32936899-9	2021	Targeting this pathway with a combined therapy of BRAF inhibitor PLX4032 and anti-PD-1 antibody efficiently blocked tumor growth by increasing CD4+ T-cell infiltration in a transgenic PTC mouse model.	Vemurafenib	65-72	CD4 antigen	Mus musculus	143-146
33378664-8	2020	Collectively, our study identifies CD4+ T cell KLF10 as an essential regulator of obesity and insulin resistance by altering Treg metabolism and mobilization.	treg	125-129	CD4 antigen	Mus musculus	35-38
33373420-7	2020	Assessment of T cell responses at 10 dpi showed a decrease in the number of total and activated (CD44hi) CD4+ and CD8+ T cells at the site of infection (BAL and lung) in triclosan exposed mice compared to controls.	Triclosan	170-179	CD4 antigen	Mus musculus	97-100
33373420-9	2020	Reductions in the Th1 transcription factor T-bet were seen in both activated and tetramer+ CD4+ and CD8+ T cells in the lungs of triclosan exposed infected mice, indicating reduced Th1 polarization and providing a potential mechanism for numerical reduction in T cells.	Triclosan	129-138	CD4 antigen	Mus musculus	91-94
33305564-7	2020	In vivo cdG@RMSN-PEG-TA enhanced infiltration of leukocytes, including CD11c+ dendritic cells, F4/80+ macrophages, CD4+ T cells, and CD8+ T cells within the tumor microenvironment (TME), resulting in dramatic tumor growth inhibition in 4T1 breast tumor-bearing Balb/c mice.	cdg	8-11	CD4 antigen	Mus musculus	115-118
33305564-7	2020	In vivo cdG@RMSN-PEG-TA enhanced infiltration of leukocytes, including CD11c+ dendritic cells, F4/80+ macrophages, CD4+ T cells, and CD8+ T cells within the tumor microenvironment (TME), resulting in dramatic tumor growth inhibition in 4T1 breast tumor-bearing Balb/c mice.	peg-ta	17-23	CD4 antigen	Mus musculus	115-118
33414785-7	2020	The nano2/4 was most effective in eliciting an early activation and production of IFN-gamma by CD4+T effector/effector memory (TEM) cells and cytolytic perforin (PFN) and granzyme B (GZB) molecules by CD4+ and CD8+ TEM subsets at 10 days pi that was followed by robust expansion of CD4+ and CD8+ TEM and TCM cells with further increase in IFN-gamma production at 21 days pi.	ifn-gamma	82-91	CD4 antigen	Mus musculus	95-98
33414785-7	2020	The nano2/4 was most effective in eliciting an early activation and production of IFN-gamma by CD4+T effector/effector memory (TEM) cells and cytolytic perforin (PFN) and granzyme B (GZB) molecules by CD4+ and CD8+ TEM subsets at 10 days pi that was followed by robust expansion of CD4+ and CD8+ TEM and TCM cells with further increase in IFN-gamma production at 21 days pi.	ifn-gamma	82-91	CD4 antigen	Mus musculus	201-204
33414785-7	2020	The nano2/4 was most effective in eliciting an early activation and production of IFN-gamma by CD4+T effector/effector memory (TEM) cells and cytolytic perforin (PFN) and granzyme B (GZB) molecules by CD4+ and CD8+ TEM subsets at 10 days pi that was followed by robust expansion of CD4+ and CD8+ TEM and TCM cells with further increase in IFN-gamma production at 21 days pi.	ifn-gamma	82-91	CD4 antigen	Mus musculus	201-204
33288832-4	2020	Furthermore, sublingual antigenic application primarily induces antigen-specific CD4+Foxp3+ Treg cells in draining ManLNs, in which it is severely impaired in the absence of cDCs.	manlns	115-121	CD4 antigen	Mus musculus	81-84
33365029-6	2020	Furthermore, Inarigivir led to a Capsase-1 and NOD2- dependent increase in the ability of BCG-infected APCs to present an Ag85B-p25 epitope to CD4 T cells in vitro.	Inarigivir	13-23	CD4 antigen	Mus musculus	143-146
33344239-6	2020	In parallel, iron application inhibited the activation, expansion and survival of cytotoxic CD8+ T cells and of CD4+ T helper cells type 1 and significantly reduced the efficacy of the investigated anti-cancer treatments.	Iron	13-17	CD4 antigen	Mus musculus	112-115
33007409-8	2020	Our data display that ITK signaling is involved in IMQ-induced psoriatic inflammation as paralleled by enhancement of p-ITK, NFATc1, p-NFkB and p-STAT3 in CD4+ T cells.	Imiquimod	51-54	CD4 antigen	Mus musculus	155-158
32556443-6	2020	Depletion of CD4+ or CD8+ T cells abrogated the anti-tumor effect of pAc/emm55.	emm55	73-78	CD4 antigen	Mus musculus	13-16
32652562-2	2020	However, the role for Th17/Th1 (CD4+ T cells co-expressing IFNgamma and IL-17A) cells in EAU is not yet understood.	Water	89-92	CD4 antigen	Mus musculus	32-35
32737949-6	2020	Glycosphingolipids of CD4+ T cells and splenic dendritic cells from wild-type and scurfy mice were then analyzed by multiplexed capillary gel electrophoresis coupled to laser-induced fluorescence detection (xCGE-LIF).	Glycosphingolipids	0-18	CD4 antigen	Mus musculus	22-25
32472435-10	2020	PF-treated DCs diminished TH17 differentiation (4.26% in vitro and 1.64% in vivo) and decreased IL-17 expression (P < 0.05) while inducing CD4+CD25+Foxp3+ Treg differentiation (7.82% in vitro and 6.85% in vivo) and increasing Foxp3 and IL-10 production (P < 0.05).	peoniflorin	0-2	CD4 antigen	Mus musculus	139-142
33037327-9	2020	Activated CD4+ T cells from obese mice had increased glucose uptake and oxygen consumption rate (OCR), compared to T cells from lean controls, indicating increased mitochondrial oxidation of glucose.	Glucose	53-60	CD4 antigen	Mus musculus	10-13
33037327-9	2020	Activated CD4+ T cells from obese mice had increased glucose uptake and oxygen consumption rate (OCR), compared to T cells from lean controls, indicating increased mitochondrial oxidation of glucose.	Oxygen	72-78	CD4 antigen	Mus musculus	10-13
33037327-9	2020	Activated CD4+ T cells from obese mice had increased glucose uptake and oxygen consumption rate (OCR), compared to T cells from lean controls, indicating increased mitochondrial oxidation of glucose.	Glucose	191-198	CD4 antigen	Mus musculus	10-13
33037327-10	2020	Treatment of isolated CD4+ T cells with metformin was found to inhibit OCR in vitro and alter the expression of several activation markers.	Metformin	40-49	CD4 antigen	Mus musculus	22-25
33023784-0	2020	Imiquimod-induced dermatitis impairs thymic tolerance of autoreactive CD4+ T cells to desmoglein 3.	Imiquimod	0-9	CD4 antigen	Mus musculus	70-73
33023784-12	2020	Although Dsg3-sepcific transgenic thymocytes was usually deleted in the thymus under physiological condition by central tolerance, Dsg3-sepcific transgenic CD4+CD8- thymocytes significantly increased in number under imiquimod-induced dermatitis.	Imiquimod	216-225	CD4 antigen	Mus musculus	156-159
33185498-5	2020	Furthermore, we found that RMFE increased the level of heme oxygenase-1 (HO-1) through ERK and p38 pathways, reducing IL-2 production and CD4+ T cell proliferation, and inhibited STAT6 phosphorylation.	rmfe	27-31	CD4 antigen	Mus musculus	138-141
33185498-6	2020	Therefore, this study suggested that RMFE could be an effective treatment of AD induced by Th2-mediated immune responses by suppressing proliferation of CD4+ T cells via increased HO-1.	rmfe	37-41	CD4 antigen	Mus musculus	153-156
33185498-6	2020	Therefore, this study suggested that RMFE could be an effective treatment of AD induced by Th2-mediated immune responses by suppressing proliferation of CD4+ T cells via increased HO-1.	th2	91-94	CD4 antigen	Mus musculus	153-156
33356705-5	2020	In the abortion-prone mouse model, E5564 significantly increased the proportion of CD4+CD25+Foxp3+ Tregs, decreased the inflammatory response, and increased Foxp3 mRNA and protein expression.	E5564	35-40	CD4 antigen	Mus musculus	83-86
33356705-7	2020	CONCLUSIONS: These data suggest that CD4+CD25+Foxp3+ Tregs regulate immune homeostasis in URSA via the TLR4/nuclear factor-kappaB pathway, and that the TLR4 antagonist E5564 may be a novel and potential drug for treating URSA.	E5564	168-173	CD4 antigen	Mus musculus	37-40
32827664-0	2020	Dietary long-chain n-3 PUFA mitigate CD4+ T cell/adipocyte inflammatory interactions in co-culture models of obese adipose tissue.	Nitrogen	10-11	CD4 antigen	Mus musculus	37-40
33126029-8	2020	Transfer of CD4+ mesLNCs additionally increased adrenal weight and secretion of IL-6 from in vitro anti-CD3 stimulated mesLNCs in recipients administered with DSS.	Dextran Sulfate	159-162	CD4 antigen	Mus musculus	12-15
33424253-5	2020	Herein, an in silico, in vitro and in vivo approach identified Flavipin (3,4,5-trihydroxy-6-methylphthalaldehyde) as an Ahr agonist that induces the expression of Ahr downstream genes in mouse CD4+ T cells and CD11b+ macrophages.	flavipin	63-71	CD4 antigen	Mus musculus	193-196
33424253-5	2020	Herein, an in silico, in vitro and in vivo approach identified Flavipin (3,4,5-trihydroxy-6-methylphthalaldehyde) as an Ahr agonist that induces the expression of Ahr downstream genes in mouse CD4+ T cells and CD11b+ macrophages.	3,4,5-trihydroxy-6-methylphthalaldehyde	73-112	CD4 antigen	Mus musculus	193-196
33424253-8	2020	In EAE, Flavipin ameliorated disease severity, with reduced CD4+IL-17+ T cells, IL-6 and TNF-alpha and increased CD4+FoxP3+ T cells.	flavipin	8-16	CD4 antigen	Mus musculus	60-63
33424253-8	2020	In EAE, Flavipin ameliorated disease severity, with reduced CD4+IL-17+ T cells, IL-6 and TNF-alpha and increased CD4+FoxP3+ T cells.	flavipin	8-16	CD4 antigen	Mus musculus	113-116
33424253-10	2020	RNA interference showed that the modulatory effects of Flavipin on pro- and anti-inflammatory mediators in CD4+ T cells and macrophages were Ahr- and/or Arid5a-dependent.	flavipin	55-63	CD4 antigen	Mus musculus	107-110
33364577-2	2021	Oral administration of beta-elemene, contained in various foodstuffs, downregulated expressions of inflammatory cytokines and increased Foxp3+CD4+ T cells in adipose tissue of obese mice.	beta-elemene	23-35	CD4 antigen	Mus musculus	142-145
33364577-4	2021	Instead, beta-elemene increased Foxp3+CD4+ T cell population enhancing gene expressions of transforming growth factor beta 1, retinaldehyde dehydrogenase 2, integrin alphavbeta8, and interleukin-10 in intestinal dendritic cells (DCs) in vivo and in vitro.	beta-elemene	9-21	CD4 antigen	Mus musculus	38-41
33304583-11	2020	CD4LVFOXP3 cells prevent hyper-proliferation of CD4+ memory T cells in the FOXP3-deficient IPEX-like hu-mice.	ipex	91-95	CD4 antigen	Mus musculus	0-3
33255287-0	2020	Rapamycin Eyedrops Increased CD4+Foxp3+ Cells and Prevented Goblet Cell Loss in the Aged Ocular Surface.	Sirolimus	0-9	CD4 antigen	Mus musculus	29-32
33255287-7	2020	In the lacrimal gland and draining lymph nodes, we also observed a significant increase in the CD45+CD4+Foxp3+ cells in the rapamycin-treated mice.	Sirolimus	124-133	CD4 antigen	Mus musculus	95-98
33223504-0	2020	Exposure to ozone impacted Th1/Th2 imbalance of CD4+ T cells and apoptosis of ASMCs underlying asthmatic progression by activating lncRNA PVT1-miR-15a-5p/miR-29c-3p signaling.	Ozone	12-17	CD4 antigen	Mus musculus	48-51
32998997-5	2020	Here we show that microparticle-mediated intratumoral delivery of NAMPT inhibitor GMX1778 induces specific immunologic changes in the tumor microenvironment of murine GBM, characterized by upregulation of immune checkpoint PD-L1, recruitment of CD3+, CD4+, and CD8+ T cells, and reduction of M2-polarized immunosuppressive macrophages.	N-(6-chlorophenoxyhexyl)-N''-cyano-N''-4-pyridylguanidine	82-89	CD4 antigen	Mus musculus	251-254
33262765-3	2020	We have previously reported an insulin-reactive CD4+ T cell, (designated 2H6).	2h6	73-76	CD4 antigen	Mus musculus	48-51
33183330-8	2020	MRS5980 also attenuated TBI-induced CD4+ and CD8+ T cell influx.	mrs5980	0-7	CD4 antigen	Mus musculus	36-39
33298945-4	2020	Using the G12D KRAS mutations as neoantigens, we found that vaccination of mice with naked synthetic peptides harboring the G12D mutation with CpG adjuvant stimulated mainly CD4+ T cell responses with limited tumor growth inhibition.	Peptides	101-109	CD4 antigen	Mus musculus	174-177
33298945-4	2020	Using the G12D KRAS mutations as neoantigens, we found that vaccination of mice with naked synthetic peptides harboring the G12D mutation with CpG adjuvant stimulated mainly CD4+ T cell responses with limited tumor growth inhibition.	cpg adjuvant	143-155	CD4 antigen	Mus musculus	174-177
33182776-7	2020	Furthermore, LPS-stimulated mature DCs exhibited limited capability to prime antigen-specific CD4+ and T-cell proliferation, cytokine secretions, and co-stimulatory molecule expressions when treated with crotonoside.	isoguanine	204-215	CD4 antigen	Mus musculus	94-97
33240275-8	2020	An individual comparison of the CD4 T cell responses during Mtb infection revealed that ESAT-6-specific T cells were more terminally differentiated than the other immunodominant antigens and immunization with the ESAT-6 containing vaccine led to substantially greater reduction in the overall T cell differentiation status.	esat-6	88-94	CD4 antigen	Mus musculus	32-35
33154574-7	2021	Consequently, depletion of CD4+ T cells or blockade of IL-10 receptor function using specific antibodies in mice completely blocked the protective effects of flo8 mutant priming against C. albicans infection.	flo8	158-162	CD4 antigen	Mus musculus	27-30
32900241-0	2020	CD4+ T-Cell Endogenous Cystathionine gamma Lyase-Hydrogen Sulfide Attenuates Hypertension by Sulfhydrating Liver Kinase B1 to Promote T Regulatory Cell Differentiation and Proliferation.	Hydrogen Sulfide	49-65	CD4 antigen	Mus musculus	0-3
32900241-1	2020	Background: Hydrogen sulfide (H2S) has anti-hypertension and anti-inflammatory effects, and its endogenous-generation key enzyme cystathionine gamma lyase (CSE) is expressed in CD4+ T cells.	Hydrogen Sulfide	12-28	CD4 antigen	Mus musculus	177-180
32900241-1	2020	Background: Hydrogen sulfide (H2S) has anti-hypertension and anti-inflammatory effects, and its endogenous-generation key enzyme cystathionine gamma lyase (CSE) is expressed in CD4+ T cells.	Deuterium	30-33	CD4 antigen	Mus musculus	177-180
33148324-0	2020	hPMSCs protects against D-galactose-induced oxidative damage of CD4+ T cells through activating Akt-mediated Nrf2 antioxidant signaling.	Galactose	24-35	CD4 antigen	Mus musculus	64-67
33153189-6	2020	We show that murine blood-stage antigen MSP4/5 from Plasmodium yoelii could be chemically conjugated to pIONPs and the use of these conjugates as immunogens led to the induction of both specific antibodies and IFNgamma CD4+ T cells reactive to MSP4/5 in mice, comparable to responses to MSP4/5 mixed with classical adjuvants (e.g., CpG or Alum) that preferentially induce Th1 or Th2 cells individually.	pionps	104-110	CD4 antigen	Mus musculus	219-222
33204731-10	2020	The proportion of CD4+CD25+Foxp3+ Treg in the transplanted tumor tissues of mice in the solanine treatment group was significantly lower than that in the control group.	Solanine	88-96	CD4 antigen	Mus musculus	18-21
33204731-12	2020	Conclusion: Solanine may enhance the antitumor immune response by downregulating the proportion of CD4+CD25+ Treg and the expression of Foxp3 and TGFbeta in tumor tissues.	Solanine	12-20	CD4 antigen	Mus musculus	99-102
32808016-7	2020	Splenic CD4 T cell activation by particulate antigens is increased in mice with higher cDC2 density in the MZ, including in neonatal mice.	4-(4-bromophenyl)-2,3-dihydro-N,3-bis(3,4,5-trimethoxyphenyl)-2-oxoidmi-dazole-1-carboxamide	107-109	CD4 antigen	Mus musculus	8-11
32865844-2	2020	In the present study, the in vivo effects of ATRA, calcitriol, and their combinations on the expression of murine CD4+ T cell cytokines and their specific transcription factors in experimental autoimmune encephalomyelitis (EAE)-induced mice were explored.	Calcitriol	51-61	CD4 antigen	Mus musculus	114-117
32865844-2	2020	In the present study, the in vivo effects of ATRA, calcitriol, and their combinations on the expression of murine CD4+ T cell cytokines and their specific transcription factors in experimental autoimmune encephalomyelitis (EAE)-induced mice were explored.	Tretinoin	45-49	CD4 antigen	Mus musculus	114-117
32515542-5	2020	Results showed that the AgNPs and silver ion decreased the number of CD4+ CD25+ Treg cells which were the important cells in the immune system, thereby disrupting the balance of normal immune tolerance function, activated the inflammatory responses, together with the reductive production of placental immunoregulatory genes, and the expression of inflammatory factors in the placenta in the Ag-treated groups increased.	Silver	34-40	CD4 antigen	Mus musculus	69-72
32964554-4	2020	Upon co-stimulation with anti-CD3 and anti-CD28 antibodies, PSB inhibited CD4+ T cell proliferation and differentiation into Th1 cells.	pterostilbene	60-63	CD4 antigen	Mus musculus	74-77
32968441-8	2020	Additionally, BMMSCs co-cultured with CD4+ T cells from OVX mice presented with reduced levels of osteogenic differentiation and lower ALP activity, less calcium deposition and reduced expression of Runx2 and OCN compared with sham mice.	Calcium	154-161	CD4 antigen	Mus musculus	38-41
32329062-8	2020	We also demonstrated that the frequency of CD4+ CD25+ Foxp3+ cells was significantly higher in the spleen of hADSC-treated mice than EAE control mice (p = .023).	hadsc	109-114	CD4 antigen	Mus musculus	43-46
32948683-7	2020	PD-1 and CTLA-4 were upregulated on tumor-infiltrating CD4+ and CD8+ T cells in irradiated and nonirradiated tumors, suggesting that immune checkpoint inhibitors could be beneficial after LRT and Foxp3+ Treg depletion.	treg	203-207	CD4 antigen	Mus musculus	55-58
33154149-6	2020	This correlated with a significant increase in the number of CD4 and CD8 T cells of NAM+GEM-treated tumors, and CD4 and CD8 T cell responses to tumor-associated antigen survivin, most likely through epitope spreading.	gemcitabine	88-91	CD4 antigen	Mus musculus	61-64
33154149-7	2020	In vivo depletions of T cells demonstrated the involvement of CD4 T cells in the eradication of the tumor by NAM+GEM treatment.	gemcitabine	113-116	CD4 antigen	Mus musculus	62-65
32794350-5	2020	In the immunized mice, TIO3 formulated in microbial vaccines dramatically reduced surface-bound TGF-beta2 expression on CD4+ T cells and CD19+ B cells in the lymph node (LN) cells and spleen cells; up-regulated the expression of CD40, CD80, CD86, and MHC II molecules on CD19+ B cells and CD11c+ dendritic cells; and promoted IFN-gamma production in CD4+ T cells and CD8+ T cells in the LN cells.	tio3	23-27	CD4 antigen	Mus musculus	120-123
32721249-1	2020	Objective: The purpose of this study was to evaluate the potential of voclosporin (VOS) in preventing goblet cell (GC) loss and modulating interferon-gamma (IFN-gamma) producing CD4+ T cells in the mouse desiccating stress (DS) dry eye model.	voclosporin	70-81	CD4 antigen	Mus musculus	178-181
32941674-6	2020	Administration of Y-27632 into immunocompetent Balb/c mice bearing breast tumors suppressed tumor progression and enhanced CD4+ and CD8+ T cell infiltration.	Y 27632	18-25	CD4 antigen	Mus musculus	123-126
32901341-5	2020	Tumour-bearing mice treated with ESPs had significantly higher CD3+, CD4+, and CD8+ T cell counts than those treated with Freund"s adjuvant.	esps	33-37	CD4 antigen	Mus musculus	69-72
32946839-6	2020	Treatment with DL-2-difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, diminished GATA3 expression in CD4+ T cells under Th2-skewed conditions.	dl-2-difluoromethylornithine	15-43	CD4 antigen	Mus musculus	123-126
32946839-6	2020	Treatment with DL-2-difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, diminished GATA3 expression in CD4+ T cells under Th2-skewed conditions.	Eflornithine	45-49	CD4 antigen	Mus musculus	123-126
32946839-6	2020	Treatment with DL-2-difluoromethylornithine (DFMO), an inhibitor of polyamine biosynthesis, diminished GATA3 expression in CD4+ T cells under Th2-skewed conditions.	Polyamines	68-77	CD4 antigen	Mus musculus	123-126
32946839-7	2020	Supplementation of exogenous polyamines rescued GATA3 downregulation caused by DFMO treatment in CD4+ T cells.	Polyamines	29-39	CD4 antigen	Mus musculus	97-100
32946839-7	2020	Supplementation of exogenous polyamines rescued GATA3 downregulation caused by DFMO treatment in CD4+ T cells.	Eflornithine	79-83	CD4 antigen	Mus musculus	97-100
32946839-9	2020	Depletion of intracellular polyamines reduced GATA3 expression but increased IL-9-producing CD4+ T cells under both Th2 and Th9-skewing conditions.	Polyamines	27-37	CD4 antigen	Mus musculus	92-95
32946839-10	2020	Furthermore, oral administration of DFMO increased IL-9-producing CD4+ T cells in small intestine in mice.	Eflornithine	36-40	CD4 antigen	Mus musculus	66-69
33150044-3	2020	Previous studies have demonstrated that resveratrol exerts its anti-cancer effects by downregulating CD4+Foxp3+ and M2-like macrophages, two key immunoregulatory cells that maintain the immunosuppressive tumor microenvironment.	Resveratrol	40-51	CD4 antigen	Mus musculus	101-104
33463118-0	2020	Immunomodulatory Effects of Calcitriol through DNA Methylation Alteration of FOXP3 in the CD4+ T Cells of Mice.	Calcitriol	28-38	CD4 antigen	Mus musculus	90-93
33463118-8	2020	Vitamin D Intervention significantly (p<0.05) could increase the expression of Foxp3, IL-10, and TGF-beta1 gene in the CD4+ T cells of mice comparing with the control group.	Vitamin D	0-9	CD4 antigen	Mus musculus	119-122
33067238-3	2020	Here, we report that targeting lung antigen-presenting cells (APCs) via antigen-loaded poly(lactide-co-glycolide) particles modulates lung CD4+ T cells to tolerize murine experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis.	Polyglactin 910	87-113	CD4 antigen	Mus musculus	139-142
33082710-5	2020	We further determined the effect of baicalein on naive CD4+ T cell differentiation in vitro by magnetic cell separation and drug intervention.	baicalein	36-45	CD4 antigen	Mus musculus	55-58
32736253-7	2020	The combination therapy (RT + Ch/gamma-PGA NPs) synergistically impaired 4T1 tumor progression, which was associated with a significant primary tumor growth and splenomegaly reduction, a decrease in the percentage of splenic immunosuppressive myeloid cells and an increase in antitumoral CD4+IFN-gamma+ population.	poly(gamma-glutamic acid)	33-42	CD4 antigen	Mus musculus	288-291
32912432-6	2020	In addition, GA diminished the increase in the numbers of CD4+CD69+ and CD8+CD69+ T cells and dendritic cells induced by bleomycin, and reduced the residence of inflammatory cells in the lung tissues.	galangin	13-15	CD4 antigen	Mus musculus	58-61
32912432-6	2020	In addition, GA diminished the increase in the numbers of CD4+CD69+ and CD8+CD69+ T cells and dendritic cells induced by bleomycin, and reduced the residence of inflammatory cells in the lung tissues.	Bleomycin	121-130	CD4 antigen	Mus musculus	58-61
32608014-8	2020	The apoptosis of pancreatic beta cells, the infiltration of mononuclear macrophages, CD4 and CD8 positive T-cells in islets was reduced by OGT2115 in streptozotocin-treated mice, but OGT2115 did not alter the direct streptozotocin-induced damage in vitro.	OGT 2115	139-146	CD4 antigen	Mus musculus	85-88
32608014-8	2020	The apoptosis of pancreatic beta cells, the infiltration of mononuclear macrophages, CD4 and CD8 positive T-cells in islets was reduced by OGT2115 in streptozotocin-treated mice, but OGT2115 did not alter the direct streptozotocin-induced damage in vitro.	Streptozocin	150-164	CD4 antigen	Mus musculus	85-88
32718625-5	2020	Our experimental results demonstrated that LNT-CaCO3 significantly enhanced lymphocyte proliferation, and boosted the frequency of CD69 + B cells and the ratio of CD4+ to CD8 + T cells in spleen lymphocytes.	Calcium Carbonate	47-52	CD4 antigen	Mus musculus	163-166
32853967-10	2020	HMGB1 modulated the suppressive function of Tregs as follows: reduction in the number of the cells and the activity of Tregs, the secretion of anti-inflammatory cytokines (IL-10, TGF-beta) from Tregs, the production of IL-2 from CD4+ T cells and CD11c+ DCs, and the M2 polarization of macrophages, as well as inducing proinflammatory response of macrophages.	tregs	44-49	CD4 antigen	Mus musculus	229-232
32562271-8	2020	Heparin promoted functional CD4+ CD25+ forkhead box protein 3 (FoxP3)+ Treg generation from naive CD4+ T cells, increased interleukin (IL)-2 production and enhanced the activation of pre-existing Tregs with IL-2.	Heparin	0-7	CD4 antigen	Mus musculus	28-31
32562271-8	2020	Heparin promoted functional CD4+ CD25+ forkhead box protein 3 (FoxP3)+ Treg generation from naive CD4+ T cells, increased interleukin (IL)-2 production and enhanced the activation of pre-existing Tregs with IL-2.	Heparin	0-7	CD4 antigen	Mus musculus	98-101
32562271-8	2020	Heparin promoted functional CD4+ CD25+ forkhead box protein 3 (FoxP3)+ Treg generation from naive CD4+ T cells, increased interleukin (IL)-2 production and enhanced the activation of pre-existing Tregs with IL-2.	treg	71-75	CD4 antigen	Mus musculus	98-101
32750449-7	2020	GTPs decreased the protein expression levels of myeloperoxidase, F4/80 and neutrophil, as determined by immunohistochemical analysis, and T lymphocytes (CD4 and CD8) contents as determined by immunofluorescence analysis, in the liver.	gtps	0-4	CD4 antigen	Mus musculus	153-156
32535666-9	2020	In vitro, CD4+CD25+FOXP3+ Treg cells from naive CD4+ T cells, STAT5 proportion, and IL-35 expression increased after curcumin treatment.	Curcumin	117-125	CD4 antigen	Mus musculus	10-13
32535666-9	2020	In vitro, CD4+CD25+FOXP3+ Treg cells from naive CD4+ T cells, STAT5 proportion, and IL-35 expression increased after curcumin treatment.	Curcumin	117-125	CD4 antigen	Mus musculus	48-51
32198648-0	2020	Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood.	Docetaxel	32-41	CD4 antigen	Mus musculus	101-104
33060147-11	2020	The antitumor effect of CMP-001+anti-PD-1 was accompanied by increased interferon gamma (IFNgamma)+ CD4+/CD8+ T cells compared with control-treated mice.	Cytidine Monophosphate	24-27	CD4 antigen	Mus musculus	100-103
33115943-10	2020	In PDA mice models, treatment with GEM prior to ENO1 DNA vaccination unleashed CD4 antitumor activity and strongly impaired tumor progression compared with mice that were vaccinated or GEM-treated alone.	gemcitabine	35-38	CD4 antigen	Mus musculus	79-82
32421784-6	2020	Stimulation of CD4+CD25+ Tregs with LPS markedly upregulated the expression of these cytokines, particularly IL-36beta.	tregs	25-30	CD4 antigen	Mus musculus	15-18
33054539-4	2020	CHA significantly increased the ratio of CD4+/CD8+, T cell subsets in PP, and MLN of IL-10 KO mice.	Chlorogenic Acid	0-3	CD4 antigen	Mus musculus	41-44
32610072-0	2020	A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85:15 nanoparticles augments CD4+ effector (CD44high CD62Llow) and memory (CD44high CD62Lhigh) T-cells in immunized mice.	nanovaccine	2-13	CD4 antigen	Mus musculus	106-109
32909489-10	2020	Comparatively, the lower SA-based doses of Au/AuNP caused more modest elevations in BAL lymphocyte influx (predominantly CD4+ phenotype), exposure-dependent increases in serum IgE, and selective expansion/activation of LN CD4+ T-cells and B-cells.	sa	25-27	CD4 antigen	Mus musculus	121-124
32909489-10	2020	Comparatively, the lower SA-based doses of Au/AuNP caused more modest elevations in BAL lymphocyte influx (predominantly CD4+ phenotype), exposure-dependent increases in serum IgE, and selective expansion/activation of LN CD4+ T-cells and B-cells.	sa	25-27	CD4 antigen	Mus musculus	222-225
32687860-0	2020	MiR-669b-3p regulates CD4+ T cell function by down-regulating indoleamine-2, 3-dioxygenase.	1H-indol-2-amine	62-73	CD4 antigen	Mus musculus	22-25
32687860-6	2020	Using mixed lymphocyte reaction assay, we showed that miR-669b-3p increased proliferation stimulation index and inhibited apoptosis in CD4+ T cells.	mir-669b-3p	54-65	CD4 antigen	Mus musculus	135-138
33148380-0	2020	[Inorganic arsenic exposure suppresses immunomodulatory effect of renal CD4+ T lymphocytes in mice].	inorganic arsenic	1-18	CD4 antigen	Mus musculus	72-75
33148380-1	2020	Objective To investigate the effects of inorganic arsenic exposure on the differentiation of renal CD4+T lymphocytes and the possible mechanism.	Arsenic	50-57	CD4 antigen	Mus musculus	99-102
32972499-12	2020	Moreover, the percentage of CD4+ T cells declined in the splenic lymphocytes of Graves" disease mice treated with 5 mg of DHT (19.90%+-3.985% vs. 24.05%+-2.587%; t=2.804, P=0.012).	Dihydrotestosterone	122-125	CD4 antigen	Mus musculus	28-31
32998896-2	2020	One way to therapeutically harness the immunosuppressive actions of Tregs is to stimulate the proliferative expansion of TNFR2-expressing CD4+Foxp3+ Tregs via transmembrane TNF (tmTNF).	tregs	68-73	CD4 antigen	Mus musculus	138-141
32993182-5	2020	In addition, increases in the CD4 and CD8 T cells was induced in the spleens of the mice treated with Al2O3 FPs, which differentiated into interferon-gamma (IFN-gamma)-producing helper T1 (Th1) and cytotoxic T1 (Tc1) cells.	Aluminum Oxide	102-107	CD4 antigen	Mus musculus	30-33
33072069-10	2020	Moreover, MrTsTPX2 could promote CD4+ T cells polarized into Th2 type in vitro.	th2	61-64	CD4 antigen	Mus musculus	33-36
32971817-9	2020	FACS analysis of lymph nodes revealed a decrease in the percentage of CD19+ B cells and an increase in total percentage of CD3+ T cells, CD3+ CD4+ T helpers, and naive and effector memory cells in disulfiram-treated mice.	Disulfiram	197-207	CD4 antigen	Mus musculus	142-145
32710956-7	2020	A reduction of small intestinal CD4+ IELs (TCRalphabeta+, CD8alphaalpha+) was found following As3+ exposure, whereas U produced widespread suppression of CD4- IEL subsets (TCRalphabeta+ and TCRgammadelta+).	as3+	94-98	CD4 antigen	Mus musculus	32-35
32894141-11	2020	Liothyronine could enhance the function of CD4+ and CD8+ T cells in PBMCs.	Triiodothyronine	0-12	CD4 antigen	Mus musculus	43-46
32894141-14	2020	The immune cell depletion model showed that the anti-tumor effects of liothyronine depends on CD4+ T cells, CD8+ T cells and NK cells.	Triiodothyronine	70-82	CD4 antigen	Mus musculus	94-97
33013877-6	2020	Further Treg-enrichment (~80%) of the AgX population indicated FoxP3+CD25hiCD4+ Treg played a key role in EAU-suppression while FoxP3-CD25lo/-CD4+ T cells did not.	treg	8-12	CD4 antigen	Mus musculus	75-78
33013877-6	2020	Further Treg-enrichment (~80%) of the AgX population indicated FoxP3+CD25hiCD4+ Treg played a key role in EAU-suppression while FoxP3-CD25lo/-CD4+ T cells did not.	Water	106-109	CD4 antigen	Mus musculus	75-78
32869536-4	2020	METHODS: We analyzed in vitro the immunomodulatory effects of FTS on various CD4+ T-cell functions such as activation, proliferation, T-helper polarization, and production of proinflammatory cytokines.	farnesylthiosalicylic acid	62-65	CD4 antigen	Mus musculus	77-80
32869536-10	2020	Importantly, in vivo generation of collagen type-II specific effector CD4+ T cells was likewise repressed by FTS therapy.	farnesylthiosalicylic acid	109-112	CD4 antigen	Mus musculus	70-73
32501144-3	2020	The mice immunized with CTB-ClfA221-550 plus CpG and Alum adjuvant exhibited significantly stronger CD4+ T cell responses for IFN-gamma, IL-2, IL-4, and IL-17 and displayed the higher proliferation response of splenic lymphocytes than the control groups, in addition, these mice generated the strongest humoral immune response against ClfA221-550 among all groups.	alum adjuvant	53-66	CD4 antigen	Mus musculus	100-103
32328672-5	2020	The combination therapy (PC-SA-DOX) is superior to free DOX in enhancing the anti-tumor immune effect on CD4-positive and CD8-positive T cells for IFN-gamma, IL-2 and TNF-alpha production in sera and splenic culture supernatants of B16F10 tumor-induced mice.	Doxorubicin	31-34	CD4 antigen	Mus musculus	105-108
32615414-6	2020	It triggered IL-10 production and allowed the endocytosis of FITC-coupled antigens followed by their presentation to CD4+ T cells.	Fluorescein-5-isothiocyanate	61-65	CD4 antigen	Mus musculus	117-120
32989233-5	2020	Oral administration of these gmLAB suppressed body weight reduction and exacerbation of the disease activity index score in mice with acute colitis and decreased the number of CD4+ IL-17A+ cells in the mesenteric lymph nodes.	gmlab	29-34	CD4 antigen	Mus musculus	176-179
32570034-9	2020	Further study showed that Gemcitabine treatment also increases CD8+ and CD4+ T cells proportion, PD-1 and PD-L1 expression in LLC mouse model.	gemcitabine	26-37	CD4 antigen	Mus musculus	72-75
32536579-12	2020	Mice overexpressing Id1 in CD4+ T cells possessed significantly higher Treg levels in spleen and lower autoantibody concentrations in serum.	treg	71-75	CD4 antigen	Mus musculus	27-30
32727889-3	2020	DLD is conserved in all pathogenic Leishmania species, is expressed by both the promastigote and amastigote stages of the parasite, and elicits strong CD4+ T cell responses in mice infected with L. major We generated I-Ab-DLD63-79 tetramer and identified DLD-specific CD4+ T cells at clonal level.	i-ab	217-221	CD4 antigen	Mus musculus	151-154
32727889-3	2020	DLD is conserved in all pathogenic Leishmania species, is expressed by both the promastigote and amastigote stages of the parasite, and elicits strong CD4+ T cell responses in mice infected with L. major We generated I-Ab-DLD63-79 tetramer and identified DLD-specific CD4+ T cells at clonal level.	i-ab	217-221	CD4 antigen	Mus musculus	268-271
32691886-6	2020	Compared with normal control mice, the thymus epithelium of the D-gal treated mice had structural changes, the number of senescent cells increased, and the number of CD4+ T cells decreased and CD8+ T cells increased.	Galactose	64-69	CD4 antigen	Mus musculus	166-169
32691886-7	2020	After RSV administration by gavage for 6 weeks, it was found that RSV improved surface phenotypes of D-gal treated mice, and recovered thymus function by maintaining the ratio of CD4+ and CD8+ cells.	Resveratrol	66-69	CD4 antigen	Mus musculus	179-182
32527950-8	2020	B16-OVA tumor-derived TECs induced immunosuppressive CD4+ T cells that suppressed OVA-specific CD8+ T cell proliferation via inhibitory cytokines, including IL-10 and TGF-beta.	tecs	22-26	CD4 antigen	Mus musculus	53-56
32908937-6	2020	GA also suppressed the mRNA levels of IL-6, TNF-alpha, IL-17, IL-23, and IL-1beta in the skin and increased the proportion of CD4+ Foxp3+ regulatory T cells (Tregs) in both lymph nodes and spleens.	18alpha-glycyrrhetinic acid	0-2	CD4 antigen	Mus musculus	126-129
32825651-9	2020	Immunophenotyping of lung immune cells revealed an increased number of dendritic cells, CD4+ T cells, and CD19+ B cells in the VG/PG-exposed group compared to air, irrespective of the presence of vanilla flavoring.	Propylene Glycol	130-132	CD4 antigen	Mus musculus	88-91
32821440-4	2020	ChimeraT/saponin vaccine stimulated significantly higher levels of IFN-gamma, IL-12, and GM-CSF cytokines by both murine CD4+ and CD8+ T cells, with correspondingly low levels of IL-4 and IL-10.	Saponins	9-16	CD4 antigen	Mus musculus	121-124
32903436-8	2020	Similar reductions in functional capacity and protection were noted for the endogenous OVA323-specific memory CD4 T cell population in sepsis survivors upon Lm-OVA challenge.	ova323	87-93	CD4 antigen	Mus musculus	110-113
32851124-9	2020	In addition, trametinib suppressed functional differentiation of naive CD4+ T cells in recipients.	trametinib	13-23	CD4 antigen	Mus musculus	71-74
32851124-13	2020	Conclusions: Trametinib delayed islet graft rejection by inhibiting functional differentiation of naive CD4+ T cells and regulating inflammatory cytokines.	trametinib	13-23	CD4 antigen	Mus musculus	104-107
32441280-6	2020	betaCD-NH2-Rapa complexes (CRCs) enriched the fraction of CD4+CD25+FoxP3+ mouse T (mT) cells and human T (hT) cells up to 6-fold and up to 2-fold respectively and suppressed the overall expansion of effector T cells by 5-fold in both species.	betacd-nh2-rapa	0-15	CD4 antigen	Mus musculus	58-61
32788917-9	2020	Using GPI-anchored ZZ to couple anti-CD4 antibodies to liposomes, we created immunoliposomes with a binding efficiency of 75% to CD4+ cells in splenocytes and minimal off-target binding.	zz	19-21	CD4 antigen	Mus musculus	37-40
32788917-9	2020	Using GPI-anchored ZZ to couple anti-CD4 antibodies to liposomes, we created immunoliposomes with a binding efficiency of 75% to CD4+ cells in splenocytes and minimal off-target binding.	zz	19-21	CD4 antigen	Mus musculus	129-132
32302678-7	2020	Here we report an increased expression of a subset of CD4+ T cells in rodent models of PD, including MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mice and DSP-4 [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride]/6-hydroxydopamine rats, which produced higher levels of perforin and granzyme B - typically found in cytotoxic T cells.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	101-105	CD4 antigen	Mus musculus	54-57
32302678-7	2020	Here we report an increased expression of a subset of CD4+ T cells in rodent models of PD, including MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mice and DSP-4 [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride]/6-hydroxydopamine rats, which produced higher levels of perforin and granzyme B - typically found in cytotoxic T cells.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	107-151	CD4 antigen	Mus musculus	54-57
32302678-7	2020	Here we report an increased expression of a subset of CD4+ T cells in rodent models of PD, including MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mice and DSP-4 [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride]/6-hydroxydopamine rats, which produced higher levels of perforin and granzyme B - typically found in cytotoxic T cells.	dsp-4 [n-(2-chloroethyl)-n-ethyl-2-bromobenzylamine hydrochloride	162-227	CD4 antigen	Mus musculus	54-57
32302678-7	2020	Here we report an increased expression of a subset of CD4+ T cells in rodent models of PD, including MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mice and DSP-4 [N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride]/6-hydroxydopamine rats, which produced higher levels of perforin and granzyme B - typically found in cytotoxic T cells.	Oxidopamine	229-246	CD4 antigen	Mus musculus	54-57
32302678-8	2020	Importantly, the CD4+ cytotoxic subtype was attenuated following calpain inhibition in MPTP mice, suggesting that calpain and this distinct CD4+ T cell subset may have critical roles in the inflammatory process, disease progression, and neurodegeneration in PD.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	87-91	CD4 antigen	Mus musculus	17-20
32302678-8	2020	Importantly, the CD4+ cytotoxic subtype was attenuated following calpain inhibition in MPTP mice, suggesting that calpain and this distinct CD4+ T cell subset may have critical roles in the inflammatory process, disease progression, and neurodegeneration in PD.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	87-91	CD4 antigen	Mus musculus	140-143
31906749-0	2020	Acetylcholine regulates the development of experimental autoimmune encephalomyelitis via the CD4+ cells proliferation and differentiation.	Acetylcholine	0-13	CD4 antigen	Mus musculus	93-96
32468024-9	2020	In conclusion, the present study suggested that decitabine could alleviate DSS-induced impaired colon barrier and the weight loss, mucus and bloody stools in mice by releasing the inhibitory factor IL-10, reducing the pro-inflammatory factor IL-17, activating CD4+ Foxp3+ T cells and inhibiting the activation of the MAPK pathway.	Decitabine	48-58	CD4 antigen	Mus musculus	260-263
32468024-9	2020	In conclusion, the present study suggested that decitabine could alleviate DSS-induced impaired colon barrier and the weight loss, mucus and bloody stools in mice by releasing the inhibitory factor IL-10, reducing the pro-inflammatory factor IL-17, activating CD4+ Foxp3+ T cells and inhibiting the activation of the MAPK pathway.	Dextran Sulfate	75-78	CD4 antigen	Mus musculus	260-263
32591389-3	2020	During T cell development, N-glycan branching is required for positive selection of thymocytes, inhibiting both death by neglect and negative selection via enhanced surface retention of the CD4/CD8 coreceptors and limiting TCR clustering/signaling, respectively.	n-glycan	27-35	CD4 antigen	Mus musculus	190-193
32703489-0	2020	PARP-1 inhibitor-AG14361 suppresses acute allograft rejection via stabilizing CD4+FoxP3+ regulatory T cells.	1-(4-dimethylaminomethylphenyl)-8,9-dihydro-7H-2,7,9a-benzo(cd)azulen-6-one	17-24	CD4 antigen	Mus musculus	78-81
32731626-3	2020	Compared with the control group, the FIE-SP groups showed significantly increased ratios of T lymphocyte surface markers CD4+/CD8+ and major histocompatibility complex (MHC)I/MHCII, as well as increased concentrations of immunoglobulin (Ig)A and IgG.	fie-sp	37-43	CD4 antigen	Mus musculus	121-124
32694579-7	2020	Furthermore, MMC preconditioning significantly suppressed the mRNA expression of proinflammatory cytokines into the transplant site and induced the differentiation of regulatory T cells with the ability to suppress CD4+ T cell-mediated immune responses.	Mitomycin	13-16	CD4 antigen	Mus musculus	215-218
32704531-7	2020	We also show that in an aggressive and metastatic cisplatin-resistant variant (EMT6-CDDP), CTX140 1q6d is superior and invokes an influx of intra-tumoral CD4+ and CD8+ T cells.	emt6-cddp	79-88	CD4 antigen	Mus musculus	154-157
32765495-0	2020	Corrigendum: A New Immunosuppressive Molecule Emodin Induces both CD4+FoxP3+ and CD8+CD122+ Regulatory T Cells and Suppresses Murine Allograft Rejection.	Emodin	46-52	CD4 antigen	Mus musculus	66-69
32551517-6	2020	A significantly enhanced immune response of the DOX/PEG2k-Fmoc-1-MT micelles was observed with the decreasing tryptophan/kynurenine ratio in blood and tumor tissue, promoting effector CD4+ and CD8+ T cells while reducing regulatory T cell (Tregs) expression.	Doxorubicin	48-51	CD4 antigen	Mus musculus	184-187
32551517-6	2020	A significantly enhanced immune response of the DOX/PEG2k-Fmoc-1-MT micelles was observed with the decreasing tryptophan/kynurenine ratio in blood and tumor tissue, promoting effector CD4+ and CD8+ T cells while reducing regulatory T cell (Tregs) expression.	peg2k	52-57	CD4 antigen	Mus musculus	184-187
32646370-10	2020	We found that EGR2 inhibition significantly reduced IFNgamma production in PMA and ionomycin activated MRL-lpr lupus CD4+ T cells, but not control MRL CD4+ T cells.	Ionomycin	83-92	CD4 antigen	Mus musculus	117-120
32454027-5	2020	However, despite demonstrating limited in vitro efficacy, only HIV-resistant CAR4 T cells expressing the 4-1BBzeta ICD exhibited profound expansion, concomitant with reduced rebound viremia after antiretroviral therapy (ART) cessation and protection of CD4+ T cells (CAR-) from HIV-induced depletion in humanized mice.	4-1bbzeta	105-114	CD4 antigen	Mus musculus	253-256
32640548-10	2020	Histological assessment of CD4/CD8 expression actually showed decreased levels up to 10 days after treatment with OXi4503 (50 mg/kg).	Oxi 4503	114-121	CD4 antigen	Mus musculus	27-30
32330480-8	2020	Moreover, in vitro assays showed that Tregs from NOD mice exhibited reduced ability to suppress proliferation of CD4+CD25- responder T cells when compared with B6 and BALB/c mice.	tregs	38-43	CD4 antigen	Mus musculus	113-116
32304993-7	2020	AMG487 significantly alleviated joint inflammation by decreasing GITR+CD25+, GITR+CD45+, GITR+IL-9+, GITR+NF-kappaB+ CD45+CD4+, CD45+CCR6+, CD45+IL-6+ cells, CD45+IL-17A+, and CD45+IL-21+, and increasing GITR+Foxp3+ and GITR+STAT6+ cells.	N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido(2,3-d)pyrimidin-2-yl)ethyl)-N-pyridin-3-ylmethyl-2-(4-trifluoromethoxyphenyl)acetamide	0-6	CD4 antigen	Mus musculus	82-85
32413737-6	2020	Costunolide markedly attenuated DSS-induced body weight loss, colonic shortening, elevation in disease activity index, and pathological damage of colon, and decreased the number of CD4+ T cells in colon tissues.	costunolide	0-11	CD4 antigen	Mus musculus	181-184
31847649-0	2020	Acetylcholine regulates the development of experimental autoimmune encephalomyelitis via the CD4+ cells proliferation and differentiation.	Acetylcholine	0-13	CD4 antigen	Mus musculus	93-96
32654768-9	2020	These findings underscore the potential of RASV delivered Sf2a O-antigen for induction of robust CD4+ T-cell and IgG responses and warrant further studies toward the development of Shigella vaccine candidates with RASV strains.	rasv	43-47	CD4 antigen	Mus musculus	97-100
32654768-9	2020	These findings underscore the potential of RASV delivered Sf2a O-antigen for induction of robust CD4+ T-cell and IgG responses and warrant further studies toward the development of Shigella vaccine candidates with RASV strains.	sf2a o-antigen	58-72	CD4 antigen	Mus musculus	97-100
32580680-8	2020	After treatment, the spleen CD3+CD4-CD8- T and CD19+ B cells of two-dose mesenchymal stem cell-treated mice were significantly lower than those of the phosphate-buffered saline control.	Phosphate-Buffered Saline	151-176	CD4 antigen	Mus musculus	32-35
32632229-3	2020	Treatment of the animals with anti-erythrocyte antibodies significantly improved the targeting of CD4+ cells in vivo with fluorescent anti-CD4-antibody-conjugated nanoparticles, the magnetically guided delivery of ferrofluid nanoparticles to subcutaneous tumour allografts and xenografts, and the treatment of subcutaneous tumour allografts with magnetically guided liposomes loaded with doxorubicin and magnetite or with clinically approved "stealthy" doxorubicin liposomes.	Doxorubicin	388-399	CD4 antigen	Mus musculus	98-101
32632229-3	2020	Treatment of the animals with anti-erythrocyte antibodies significantly improved the targeting of CD4+ cells in vivo with fluorescent anti-CD4-antibody-conjugated nanoparticles, the magnetically guided delivery of ferrofluid nanoparticles to subcutaneous tumour allografts and xenografts, and the treatment of subcutaneous tumour allografts with magnetically guided liposomes loaded with doxorubicin and magnetite or with clinically approved "stealthy" doxorubicin liposomes.	Doxorubicin	388-399	CD4 antigen	Mus musculus	139-142
32632229-3	2020	Treatment of the animals with anti-erythrocyte antibodies significantly improved the targeting of CD4+ cells in vivo with fluorescent anti-CD4-antibody-conjugated nanoparticles, the magnetically guided delivery of ferrofluid nanoparticles to subcutaneous tumour allografts and xenografts, and the treatment of subcutaneous tumour allografts with magnetically guided liposomes loaded with doxorubicin and magnetite or with clinically approved "stealthy" doxorubicin liposomes.	Ferrosoferric Oxide	404-413	CD4 antigen	Mus musculus	98-101
32632229-3	2020	Treatment of the animals with anti-erythrocyte antibodies significantly improved the targeting of CD4+ cells in vivo with fluorescent anti-CD4-antibody-conjugated nanoparticles, the magnetically guided delivery of ferrofluid nanoparticles to subcutaneous tumour allografts and xenografts, and the treatment of subcutaneous tumour allografts with magnetically guided liposomes loaded with doxorubicin and magnetite or with clinically approved "stealthy" doxorubicin liposomes.	Ferrosoferric Oxide	404-413	CD4 antigen	Mus musculus	139-142
32632229-3	2020	Treatment of the animals with anti-erythrocyte antibodies significantly improved the targeting of CD4+ cells in vivo with fluorescent anti-CD4-antibody-conjugated nanoparticles, the magnetically guided delivery of ferrofluid nanoparticles to subcutaneous tumour allografts and xenografts, and the treatment of subcutaneous tumour allografts with magnetically guided liposomes loaded with doxorubicin and magnetite or with clinically approved "stealthy" doxorubicin liposomes.	Doxorubicin	453-464	CD4 antigen	Mus musculus	98-101
32632229-3	2020	Treatment of the animals with anti-erythrocyte antibodies significantly improved the targeting of CD4+ cells in vivo with fluorescent anti-CD4-antibody-conjugated nanoparticles, the magnetically guided delivery of ferrofluid nanoparticles to subcutaneous tumour allografts and xenografts, and the treatment of subcutaneous tumour allografts with magnetically guided liposomes loaded with doxorubicin and magnetite or with clinically approved "stealthy" doxorubicin liposomes.	Doxorubicin	453-464	CD4 antigen	Mus musculus	139-142
32499651-3	2020	Here, using shared synteny to guide loss-of-function analysis of homologues of human enhancers in mice, we show that the prominent autoimmune and allergic disease risk locus at chromosome 11q13.52-7 contains a distal enhancer that is functional in CD4+ regulatory T (Treg) cells and required for Treg-mediated suppression of colitis.	treg	267-271	CD4 antigen	Mus musculus	248-251
32724457-9	2020	Besides decreasing the frequencies of the CD4+ and CD8+ effector T cells, especially IFN-gamma producing T cells, CQ also increased the proportion of regulatory T cells in the spleen.	Chloroquine	114-116	CD4 antigen	Mus musculus	42-45
32571324-2	2020	The present study aims to investigate whether mitochondrial apoptosis in aplastic anemia could be corrected by ASP by adjusting an abnormal level of regulatory T cell (Treg)/ IL-17 secreting CD4 T cell (Th17) ratio.	Aspartic Acid	111-114	CD4 antigen	Mus musculus	191-194
32580518-5	2020	We found that oral administration of fucoidans significantly attenuated PM-induced lipid peroxidation and infiltration of inflammatory cells like F4/80+ macrophages, Gr-1+ granulocytes, and CD4+ T lymphocytes.	fucoidan	37-46	CD4 antigen	Mus musculus	190-193
32788926-4	2020	In this study, we demonstrate that treatment with rhBNP provided protection for mice against myocardial IR injury as manifested by reduced infarct size and well-preserved myocardial, attenuated inflammatory infiltration and CD4+ T cell proliferation function, and inhibited expression of proinflammatory related genes.	rhbnp	50-55	CD4 antigen	Mus musculus	224-227
32523011-3	2020	The NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) administered after blast blocked BBB disruption and prevented CD4+ T-cell infiltration into cerebellum.	NG-Nitroarginine Methyl Ester	18-52	CD4 antigen	Mus musculus	124-127
32523011-3	2020	The NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME) administered after blast blocked BBB disruption and prevented CD4+ T-cell infiltration into cerebellum.	NG-Nitroarginine Methyl Ester	54-60	CD4 antigen	Mus musculus	124-127
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	Resveratrol	0-11	CD4 antigen	Mus musculus	139-142
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	Resveratrol	0-11	CD4 antigen	Mus musculus	165-168
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	Azoxymethane	43-46	CD4 antigen	Mus musculus	139-142
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	Azoxymethane	43-46	CD4 antigen	Mus musculus	165-168
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	dextran sodium sulphate	52-75	CD4 antigen	Mus musculus	139-142
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	dextran sodium sulphate	52-75	CD4 antigen	Mus musculus	165-168
32526927-4	2020	Resveratrol treatment in the azoxymethane (AOM) and dextran sodium sulphate (DSS) CRC murine model caused an increase in anti-inflammatory CD4 + FOXP3 + (Tregs) and CD4 + IL10 + cells, a decrease in proinflammatory Th1 and Th17 cells, and attenuated CRC development.	dss	77-80	CD4 antigen	Mus musculus	139-142
32503684-7	2020	RESULTS: Decreased autoantibody production and GC formation are observed when Ezh2-deficient CD4+ T cells are used instead of wild-type (WT) to induce cGVHD and when mice that receive allogeneic WT donor T cells to induce cGVHD are treated with GSK503, an Ezh2-specific inhibitor.	GSK503	245-251	CD4 antigen	Mus musculus	93-96
32281417-0	2020	TCR+CD4-CD8- (double negative) T cells protect from cisplatin-induced renal epithelial cell apoptosis and acute kidney injury.	Cisplatin	52-61	CD4 antigen	Mus musculus	4-7
32333445-6	2020	The CD4+ CD25+ Foxp3+ T cells were significantly reduced in SUS mice.	2-Deoxy-3,6-Di-O-Sulfo-2-(Sulfoamino)-Alpha-D-Glucopyranose	60-63	CD4 antigen	Mus musculus	4-7
32220806-7	2020	The subset of pathogenic CD4+ T cell subset including CD4+IFN-gamma+ (Th1) and CD4+IL-17A+ (Th17) were also suppressed by andrographolide sulfonate.	andrographolide sulfonate	122-147	CD4 antigen	Mus musculus	25-28
32220806-7	2020	The subset of pathogenic CD4+ T cell subset including CD4+IFN-gamma+ (Th1) and CD4+IL-17A+ (Th17) were also suppressed by andrographolide sulfonate.	andrographolide sulfonate	122-147	CD4 antigen	Mus musculus	54-57
32220806-7	2020	The subset of pathogenic CD4+ T cell subset including CD4+IFN-gamma+ (Th1) and CD4+IL-17A+ (Th17) were also suppressed by andrographolide sulfonate.	andrographolide sulfonate	122-147	CD4 antigen	Mus musculus	54-57
32251961-8	2020	Tipifarnib also suppressed Con A-induced activation of CD4+ cells (but not CD8+ T cells) in the liver and spleen, and also reversed the Con A-induced decrease of natural killer T (NKT) cells in the liver.	tipifarnib	0-10	CD4 antigen	Mus musculus	55-58
32251961-9	2020	Tipifarnib significantly inhibited IFN-gamma production and STAT1 phosphorylation from CD4+ T cells (but not CD8+ T and NKT cells) in the liver at 2 h post-Con A administration.	tipifarnib	0-10	CD4 antigen	Mus musculus	87-90
32251961-10	2020	Tipifarnib significantly inhibited IFN-gamma production by splenic CD4+ T cells at 48 h post-Con A injection in vitro.	tipifarnib	0-10	CD4 antigen	Mus musculus	67-70
32251961-10	2020	Tipifarnib significantly inhibited IFN-gamma production by splenic CD4+ T cells at 48 h post-Con A injection in vitro.	post-con a	88-98	CD4 antigen	Mus musculus	67-70
32251961-12	2020	In conclusion, tipifarnib inhibited IFN-gamma derived from Con A-induced CD4+ T cell activation due to downregulated STAT1 phosphorylation, suggesting that Tipifarnib can protect against AIH.	tipifarnib	15-25	CD4 antigen	Mus musculus	73-76
32251961-12	2020	In conclusion, tipifarnib inhibited IFN-gamma derived from Con A-induced CD4+ T cell activation due to downregulated STAT1 phosphorylation, suggesting that Tipifarnib can protect against AIH.	tipifarnib	156-166	CD4 antigen	Mus musculus	73-76
31904843-13	2020	Moreover, metformin-treated Ad-MSCs inhibited CD4-CD8- T-cell expansion and Th17/Treg cell ratio.	Metformin	10-19	CD4 antigen	Mus musculus	46-49
32696738-10	2020	In vitro and in vivo experiments showed that oridonin inhibited the proliferation of myelin antigen reactive CD4+ T cells and induced their apoptosis.	oridonin	45-53	CD4 antigen	Mus musculus	109-112
32466783-9	2020	Intraperitoneal injection of McAb-proB (100 mug) before LPS treatment significantly alleviated cognitive dysfunction, inhibited the downregulation of meningeal (P = 0.0264) and peripheral (P = 0.0080) CD4+ T cells, and normalized the gene expression of cytokines in the meninges.	mcab-prob	29-38	CD4 antigen	Mus musculus	201-204
32508962-0	2020	Resveratrol ameliorates atherosclerosis induced by high-fat diet and LPS in ApoE-/- mice and inhibits the activation of CD4+ T cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	120-123
32508962-13	2020	Conclusion: These results indicated that RES ameliorated AS induced by HFD companied with LPS in ApoE-/- mice, inhibited the proliferation and activation of CD4+ T cells and regulated the expression of Dnmt1 and Dnmt3b.	Resveratrol	41-44	CD4 antigen	Mus musculus	157-160
32282001-8	2020	Intratumoral injection of MWCNT-DOX and MWCNT-CpG with subsequent NIR irradiation resulted in a significant delay in tumor progression in melanoma bearing mice, along with an increased number of CD4+ and CD8+ T cells in the spleen, draining lymph nodes and tumor tissues.	Doxorubicin	32-35	CD4 antigen	Mus musculus	195-198
32443586-7	2020	We have found that cyclophosphamide significantly decreased the expression of T cell genes, such as CD3 (cluster of differentiation 3) and CD4, and reduced their infiltration into mouse lung tissues.	Cyclophosphamide	19-35	CD4 antigen	Mus musculus	139-142
32159777-4	2020	Prednisolone disrupted the expected expansion of CD4+ T cells in early pregnancy, inhibiting generation of both regulatory T cells (Treg cells) and effector T cells and suppressing IFNG required for T cell functional competence.	Prednisolone	0-12	CD4 antigen	Mus musculus	49-52
32423130-3	2020	In vitro study showed that DTT-COS1 and DTT-COS12 had immunological activity increasing the ratio of CD8/CD4 T cells.	cos12	44-49	CD4 antigen	Mus musculus	105-108
32423130-5	2020	Furthermore, regarding tumor microenvironment (TME) immunomodulation, DTT-COS1 treatment increased the proportion of CD4+ effector T cells (Teff) and decreased the expression of a suppressive cytokine.	dtt-cos1	70-78	CD4 antigen	Mus musculus	117-120
32468788-6	2020	In addition, the effect of SjHSP40 on CD4+ T-cell subset differentiation was examined using flow cytometry.	sjhsp40	27-34	CD4 antigen	Mus musculus	38-41
32255768-1	2020	Chronic beryllium disease (CBD) is a metal hypersensitivity/autoimmune disease in which damage-associated molecular patterns (DAMPs) promote a break in T cell tolerance and expansion of Be2+/self-peptide reactive CD4+ T cells.	Beryllium	8-17	CD4 antigen	Mus musculus	213-216
32255768-7	2020	In mice exposed to Be, TNFalpha promoted release of both DAMPs and was required for the mobilization of immunogenic DCs, expansion of Be-reactive CD4+ T cells and pulmonary inflammation in a mouse model of CBD.	Beryllium	19-21	CD4 antigen	Mus musculus	146-149
32255768-7	2020	In mice exposed to Be, TNFalpha promoted release of both DAMPs and was required for the mobilization of immunogenic DCs, expansion of Be-reactive CD4+ T cells and pulmonary inflammation in a mouse model of CBD.	Beryllium	134-136	CD4 antigen	Mus musculus	146-149
32392825-6	2020	In an ex vivo study, piperine also inhibited the phosphorylation of STAT6 on the CD4+ T cells isolated from splenocytes of BALB/c mice, and piperine suppressed IL-4-induced CCL26 mRNA expression and STAT6 phosphorylation in human keratinocytes resulting in the inhibition of infiltration of CCR3+ cells into inflammatory lesions.	piperine	21-29	CD4 antigen	Mus musculus	81-84
32375831-0	2020	Arsenic trioxide ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice by inducing CD4+ T cell apoptosis.	Arsenic Trioxide	0-16	CD4 antigen	Mus musculus	99-102
32375831-12	2020	Moreover, the number and proportion of CD4+ T cells in the spinal cord, spleen, and peripheral blood were reduced in ATO-treated EAE mice.	Arsenic Trioxide	117-120	CD4 antigen	Mus musculus	39-42
32375831-13	2020	Finally, ATO induced CD4+ T cell apoptosis via the mitochondrial pathway both in vitro and in vivo.	Arsenic Trioxide	9-12	CD4 antigen	Mus musculus	21-24
32004976-0	2020	Curcumin regulates the differentiation of naive CD4+T cells and activates IL-10 immune modulation against acute lung injury in mice.	Curcumin	0-8	CD4 antigen	Mus musculus	48-51
32004976-19	2020	CONCLUSIONS: Curcumin can reduce the degree of severity of ALI and uncontrolled inflammation through promoting the differentiation of naive CD4 + T cells to CD4+ CD25+ FOXP3+ Tregs.	Curcumin	13-21	CD4 antigen	Mus musculus	140-143
32004976-19	2020	CONCLUSIONS: Curcumin can reduce the degree of severity of ALI and uncontrolled inflammation through promoting the differentiation of naive CD4 + T cells to CD4+ CD25+ FOXP3+ Tregs.	Curcumin	13-21	CD4 antigen	Mus musculus	157-160
32301289-3	2020	DMY treatment significantly inhibits atherosclerotic lesion formation, proinflammatory gene expression and the influx of lesional macrophages and CD4-positive T cells in the vessel wall and hepatic inflammation, whereas increases nitric oxide (NO) production and improves lipid metabolism in apolipoprotein E-deficient (Apoe- / - ) mice.	dihydromyricetin	0-3	CD4 antigen	Mus musculus	146-149
32355314-6	2020	Ccl2 shRNA treatment of targeted EAE suppressed the migration of CD4+ lymphocytes and alleviated the motor deficits of EAE.	EAE	33-36	CD4 antigen	Mus musculus	65-68
32355314-7	2020	Our findings indicate that neuronal activation in EAE promotes the migration of CCR2+ CD4+ lymphocytes and that neuronal silencing with an inhibitory DREADD alleviates clinical and molecular markers of disease.	EAE	50-53	CD4 antigen	Mus musculus	86-89
32275817-0	2020	Ginsenoside Rg3 Alleviates Complete Freund"s Adjuvant-Induced Rheumatoid Arthritis in Mice by Regulating CD4+CD25+Foxp3+Treg Cells.	ginsenoside Rg3	0-15	CD4 antigen	Mus musculus	105-108
32431496-11	2020	More robust CD4+ and CD8+ T cell proliferation and activation (characterized by high expression of CD107a, CD69 and ICOS) was observed in mice vaccinated with MSN-treated DCs.	mannostatin A	159-162	CD4 antigen	Mus musculus	12-15
32494661-2	2020	We showed that genetic or pharmacological inhibition of Vps34 kinase activity using SB02024 or SAR405 (Vps34i) decreased the tumor growth and improved mice survival in multiple tumor models by inducing an infiltration of NK, CD8+, and CD4+ T effector cells in melanoma and CRC tumors.	sb02024	84-91	CD4 antigen	Mus musculus	235-238
32494661-2	2020	We showed that genetic or pharmacological inhibition of Vps34 kinase activity using SB02024 or SAR405 (Vps34i) decreased the tumor growth and improved mice survival in multiple tumor models by inducing an infiltration of NK, CD8+, and CD4+ T effector cells in melanoma and CRC tumors.	SAR405	95-101	CD4 antigen	Mus musculus	235-238
32411131-5	2020	After isoniazid treatment, there was a significant reduction in dominant antigen ESAT6-reactive CD4+ or TB10.4-reactive CD8+ T cells in the lungs and spleens of mice.	Isoniazid	6-15	CD4 antigen	Mus musculus	96-99
32477103-7	2020	Donepezil and memantine exerted protective effects against CD4+CD28+ cell decrease caused by aging and reduced the pro-inflammatory factors TNF-alpha, IL-1beta, and G-CSF in plasma.	Donepezil	0-9	CD4 antigen	Mus musculus	59-62
32477103-7	2020	Donepezil and memantine exerted protective effects against CD4+CD28+ cell decrease caused by aging and reduced the pro-inflammatory factors TNF-alpha, IL-1beta, and G-CSF in plasma.	Memantine	14-23	CD4 antigen	Mus musculus	59-62
32326142-9	2020	Flow cytometric analysis showed a significant increase (p < 0.01) in cytotoxic CD8 and CD4+ T-cells in the TME of the tripartite treatment groups.	1,1,1-TRIS(HYDROXYMETHYL)ETHANE	107-110	CD4 antigen	Mus musculus	87-90
32326142-9	2020	Flow cytometric analysis showed a significant increase (p < 0.01) in cytotoxic CD8 and CD4+ T-cells in the TME of the tripartite treatment groups.	tripartite	118-128	CD4 antigen	Mus musculus	87-90
32373130-7	2020	In addition, reduced MHC II expression on macrophages pretreated with rM180 impaired the expression of T cell activation markers CD25 and CD69, T cell proliferation ability, and IL-2 production by allogenic CD4+ T lymphocytes in mixed lymphocyte reaction assay.	rm180	70-75	CD4 antigen	Mus musculus	207-210
32317681-5	2020	The ex vivo study showed that TAC-loaded NPs caused a significant suppression of the proliferation of CD4+ and CD8+ cells, which was comparable to the control formulation (Prograf).	Tacrolimus	30-33	CD4 antigen	Mus musculus	102-105
32300202-7	2020	In CDDO-Me-treated mice, both the absolute number and proportion of splenic CD4+ T cells were reduced, while the proportion of CD8+ T cells was significantly increased in both tumors and spleen.	bardoxolone methyl	3-10	CD4 antigen	Mus musculus	76-79
32300202-8	2020	Moreover, mice fed CDDO-Me demonstrated significant reductions in numbers of CD4+ Foxp3+ regulatory T cells within tumors.	bardoxolone methyl	19-26	CD4 antigen	Mus musculus	77-80
31926193-6	2020	While the UA-liposomes were not generally toxic towards 4T1 triple negative breast cancer cells, they could effectively modulate CD4+CD25+Foxp3+ T cells from 4T1 tumor bearing mouse by inhibiting STAT5 phosphorylation and IL-10 secretion.	ursolic acid	10-12	CD4 antigen	Mus musculus	129-132
32290071-4	2020	EGCG ameliorated immunosuppression by significantly decreasing the accumulation of myeloid-derived suppressor cells (MDSCs) and increasing the proportions of CD4+ and CD8+ T cells in spleen and tumor sites in 4T1 breast tumor-bearing mice.	epigallocatechin gallate	0-4	CD4 antigen	Mus musculus	158-161
32290120-0	2020	Intravenous Arginine Administration Benefits CD4+ T-Cell Homeostasis and Attenuates Liver Inflammation in Mice with Polymicrobial Sepsis.	Arginine	12-20	CD4 antigen	Mus musculus	45-48
32290120-1	2020	This study investigated the effects of a single dose of arginine (Arg) administration at the beginning of sepsis on CD4+ T-cell regulation and liver inflammation in C57BL/6J mice.	Arginine	56-64	CD4 antigen	Mus musculus	116-119
32290120-1	2020	This study investigated the effects of a single dose of arginine (Arg) administration at the beginning of sepsis on CD4+ T-cell regulation and liver inflammation in C57BL/6J mice.	Arginine	66-69	CD4 antigen	Mus musculus	116-119
32290120-9	2020	Compared to the SS group, Arg administration resulted in maintained circulating and para-aortic lymph node CD4+ T cells, an increased Th1/Th2 ratio, and a reduced Th17/Treg ratio post-CLP.	Arginine	26-29	CD4 antigen	Mus musculus	107-110
32290120-11	2020	These results suggest that a single dose of Arg administered after CLP increased Arg availability, sustained CD4+ T-cell populations, elicited more-balanced Th1/Th2/Th17/Treg polarization in the circulation and the para-aortic lymph nodes, and attenuated liver inflammation in sepsis.	Arginine	44-47	CD4 antigen	Mus musculus	109-112
32240221-8	2020	Extensive analysis of chemokine expression in gonadal fat and adipose CD4+CD25+T cells revealed several chemokine signals related to female-specific VAT-Treg accumulation such as CCL24, CCR6, and CXCR3.	treg	153-157	CD4 antigen	Mus musculus	70-73
31062080-8	2020	Expression of C-C motif chemokine receptor 5 by activated CD4+ T cells was promoted and prolonged in the GLN-supplemented group.	Glutamine	105-108	CD4 antigen	Mus musculus	58-61
31062080-13	2020	CONCLUSIONS: GLN supplementation in diabetic mice may exert more-balanced polarization of CD4+ T cells, monocytes, and macrophages, thus attenuating inflammatory responses and contributing to muscle regeneration after limb ischemia.	Glutamine	13-16	CD4 antigen	Mus musculus	90-93
32087088-3	2020	Here, we compared two different published tamoxifen-inducible CD4-CreERT2 mouse lines for their suitability to study the dynamics of T follicular helper (Tfh) cell responses in vivo.	Tamoxifen	42-51	CD4 antigen	Mus musculus	62-65
32062080-0	2020	Astilbin promotes the induction of regulatory NK1.1- CD4+ NKG2D+ T cells through the PI3K, STAT3, and MAPK signaling pathways.	astilbin	0-8	CD4 antigen	Mus musculus	53-56
32062080-3	2020	Whether astilbin directly promotes the induction of NK1.1- CD4+ NKG2D+ T cells and whether these astilbin-stimulated T cells exert an immune-regulatory role remain unclear.	astilbin	8-16	CD4 antigen	Mus musculus	59-62
32062080-4	2020	Here, we show that astilbin efficiently induces the production of NK1.1- CD4+ NKG2D+ T cells with high expressions of TGF-beta1, IL-10, CCR6, and CCR9 in a dose-dependent manner ex vivo.	astilbin	19-27	CD4 antigen	Mus musculus	73-76
32062080-6	2020	Intraperitoneal injection of astilbin ameliorates the severity of colitis with an increase in the frequency of NK1.1- CD4+ NKG2D+ T cells in the colon tissue of DSS-treated mice.	astilbin	29-37	CD4 antigen	Mus musculus	118-121
32062080-7	2020	Moreover, adoptive transfer of NK1.1- CD4+ NKG2D+ T cells induced by astilbin remarkably protects against the onset of DSS-induced colitis.	astilbin	69-77	CD4 antigen	Mus musculus	38-41
32062080-8	2020	Finally, the PI3K, STAT3, and MAPK signaling pathways are involved in the induction of NK1.1- CD4+ NKG2D+ T cells by astilbin.	astilbin	117-125	CD4 antigen	Mus musculus	94-97
32178513-8	2020	Both PA and G-PA changed CD4+ and CD8+ T cells percentages in some lymphoid tissues; however, this did not impact cytokines production by splenocyte cultures evidenced by the stimulation of Th1, Th2, and Th17 cells.	Protactinium	5-7	CD4 antigen	Mus musculus	25-28
32178513-8	2020	Both PA and G-PA changed CD4+ and CD8+ T cells percentages in some lymphoid tissues; however, this did not impact cytokines production by splenocyte cultures evidenced by the stimulation of Th1, Th2, and Th17 cells.	g-pa	12-16	CD4 antigen	Mus musculus	25-28
31884896-5	2020	Idelalisib treatment induced thymic involution, decreased CD4+/CD8+ T-cell population, and increased CD4-/CD8- T-cell population.	idelalisib	0-10	CD4 antigen	Mus musculus	58-61
31884896-5	2020	Idelalisib treatment induced thymic involution, decreased CD4+/CD8+ T-cell population, and increased CD4-/CD8- T-cell population.	idelalisib	0-10	CD4 antigen	Mus musculus	101-104
32111734-5	2020	After BDC2.5mim/calcitriol liposome administration, adoptive transfer of CD4+ T cells suppressed the development of diabetes in NOD severe combined immunodeficiency mice receiving diabetogenic splenocytes.	Calcitriol	16-26	CD4 antigen	Mus musculus	73-76
32111734-8	2020	Thus, liposomes encapsulating the single CD4+ peptide, BDC2.5mim, and calcitriol induce ChgA-specific CD4+ T cells that regulate CD4+ and CD8+ self-antigen specificities and autoimmune diabetes in NOD mice.	bdc2.5mim	55-64	CD4 antigen	Mus musculus	102-105
32111734-8	2020	Thus, liposomes encapsulating the single CD4+ peptide, BDC2.5mim, and calcitriol induce ChgA-specific CD4+ T cells that regulate CD4+ and CD8+ self-antigen specificities and autoimmune diabetes in NOD mice.	bdc2.5mim	55-64	CD4 antigen	Mus musculus	102-105
32111734-8	2020	Thus, liposomes encapsulating the single CD4+ peptide, BDC2.5mim, and calcitriol induce ChgA-specific CD4+ T cells that regulate CD4+ and CD8+ self-antigen specificities and autoimmune diabetes in NOD mice.	Calcitriol	70-80	CD4 antigen	Mus musculus	102-105
32111734-8	2020	Thus, liposomes encapsulating the single CD4+ peptide, BDC2.5mim, and calcitriol induce ChgA-specific CD4+ T cells that regulate CD4+ and CD8+ self-antigen specificities and autoimmune diabetes in NOD mice.	Calcitriol	70-80	CD4 antigen	Mus musculus	102-105
32122995-0	2020	Cutting Edge: Activation-Induced Iron Flux Controls CD4 T Cell Proliferation by Promoting Proper IL-2R Signaling and Mitochondrial Function.	Iron	33-37	CD4 antigen	Mus musculus	52-55
32122995-2	2020	However, the mechanisms by which iron controls CD4 T cell activation and expansion remain poorly understood.	Iron	33-37	CD4 antigen	Mus musculus	47-50
32122995-3	2020	In this study, we show that stimulation of CD4 T cells from C57BL/6 mice not only decreases total and labile iron levels but also leads to changes in the expression of iron homeostatic machinery.	Iron	109-113	CD4 antigen	Mus musculus	43-46
32122995-3	2020	In this study, we show that stimulation of CD4 T cells from C57BL/6 mice not only decreases total and labile iron levels but also leads to changes in the expression of iron homeostatic machinery.	Iron	168-172	CD4 antigen	Mus musculus	43-46
32122995-4	2020	Additionally, restraining iron availability in vitro severely inhibited CD4 T cell proliferation and cell cycle progression.	Iron	26-30	CD4 antigen	Mus musculus	72-75
32226027-4	2020	CIT resulted in a dramatic expansion of cytotoxic CD4+ and CD8+ T cells and a subsequent reduction in viral loads.	cit	0-3	CD4 antigen	Mus musculus	50-53
32214351-6	2020	Furthermore, in B16-F10 melanoma-bearing mice, PCC0208025 presented the antitumor effects, enhanced IFN-gamma levels in plasma, increased the frequency of CD3+CD8+ T and CD8+IFN-gamma+ T and the ratios of CD8+/Treg, and deceased the CD4+CD25+CD127low/- (Treg) number in tumor.	pcc0208025	47-57	CD4 antigen	Mus musculus	233-236
32241050-27	2020	(7) On the 8th day post transplantation, the percentages of CD4(+) CD25(+) Foxp3(+) Treg in spleen of mice in BMSCs alone group and BMSCs+ IL-17 group were significantly higher than the percentage of PBS control group (P<0.01), and the percentage of CD4(+) CD25(+) Foxp3(+) Treg in spleen of mice in BMSCs+ IL-17 group was significantly higher than that of BMSCs alone group (P<0.01).	pbs	200-203	CD4 antigen	Mus musculus	60-63
32256194-6	2020	Moreover, these DCreg can regulate the development of EAU by promoting CD4+CD25+Foxp3+ regulatory T cells.	Water	54-57	CD4 antigen	Mus musculus	71-74
31951976-6	2020	These effects, especially in the catalpol high dose group, were associated with elevated CD4+ CXC-R5+ PD-1+ Foxp3+ T follicular regulatory (Tfr) cells (1.572 % vs 1.118 %, P = 0.0005) and a higher ratio of Tfr cells to T follicular helper (Tfh) cells (2.137 vs 1.541, P = 0.0007).	catalpol	33-41	CD4 antigen	Mus musculus	89-92
31953245-4	2020	Combined NIR-PIT with CD44- and CD25-targeted agents has the potential to directly eliminate tumor cells and also amplify the immune response by removing FOXP3+CD25+CD4+ Tregs from the TME.	tregs	170-175	CD4 antigen	Mus musculus	22-25
31953157-8	2020	KEY FINDINGS: Adding PTX and TQ to CIS significantly reduced Notch1, Hes1, Jagged1, beta-catenin, TNF-alpha, IL-6, IFN-gamma, and VEGF with increment in IL-2, CD4, CD8, and apoptotic cells.	Pentoxifylline	21-24	CD4 antigen	Mus musculus	159-162
31953157-8	2020	KEY FINDINGS: Adding PTX and TQ to CIS significantly reduced Notch1, Hes1, Jagged1, beta-catenin, TNF-alpha, IL-6, IFN-gamma, and VEGF with increment in IL-2, CD4, CD8, and apoptotic cells.	thymoquinone	29-31	CD4 antigen	Mus musculus	159-162
32102363-6	2020	Cell analysis using flow cytometry showed that (R)-salbutamol decreased the proportion of CD4+ Th17+ T cells (Th17), whereas it increased the percentage of CD25+ Foxp3+ regulatory T cells (Tregs) in the spleens.	Levalbuterol	47-61	CD4 antigen	Mus musculus	90-93
31771884-8	2020	We found that SAU ameliorated TNBS-induced mouse colitis and inflammatory responses in mucosal tissues and peripheral blood CD4+ T cells from IBD patients.	sauchinone	14-17	CD4 antigen	Mus musculus	124-127
31771884-8	2020	We found that SAU ameliorated TNBS-induced mouse colitis and inflammatory responses in mucosal tissues and peripheral blood CD4+ T cells from IBD patients.	Trinitrobenzenesulfonic Acid	30-34	CD4 antigen	Mus musculus	124-127
32174773-8	2020	Results: Cluster of differentiation (CD)4+ T cells were significantly less expressed in dexmedetomidine and propofol groups, compared with the corresponding control groups [34.08 +- 5.63% in the dexmedetomidine group vs. 59.74 +- 8.64% in the CD group, p < 0.05; 25.28 +- 7.28% in the propofol group vs. 61.12 +- 2.70% in the Cp group, p < 0.05].	Dexmedetomidine	88-103	CD4 antigen	Mus musculus	36-41
32174773-8	2020	Results: Cluster of differentiation (CD)4+ T cells were significantly less expressed in dexmedetomidine and propofol groups, compared with the corresponding control groups [34.08 +- 5.63% in the dexmedetomidine group vs. 59.74 +- 8.64% in the CD group, p < 0.05; 25.28 +- 7.28% in the propofol group vs. 61.12 +- 2.70% in the Cp group, p < 0.05].	Propofol	108-116	CD4 antigen	Mus musculus	36-41
32174773-8	2020	Results: Cluster of differentiation (CD)4+ T cells were significantly less expressed in dexmedetomidine and propofol groups, compared with the corresponding control groups [34.08 +- 5.63% in the dexmedetomidine group vs. 59.74 +- 8.64% in the CD group, p < 0.05; 25.28 +- 7.28% in the propofol group vs. 61.12 +- 2.70% in the Cp group, p < 0.05].	Dexmedetomidine	195-210	CD4 antigen	Mus musculus	36-41
32174773-8	2020	Results: Cluster of differentiation (CD)4+ T cells were significantly less expressed in dexmedetomidine and propofol groups, compared with the corresponding control groups [34.08 +- 5.63% in the dexmedetomidine group vs. 59.74 +- 8.64% in the CD group, p < 0.05; 25.28 +- 7.28% in the propofol group vs. 61.12 +- 2.70% in the Cp group, p < 0.05].	Propofol	285-293	CD4 antigen	Mus musculus	36-41
32174773-9	2020	Apoptosis of CD4+ T cells was increased significantly in dexmedetomidine and propofol groups, compared with the corresponding control groups.	Dexmedetomidine	57-72	CD4 antigen	Mus musculus	13-16
32174773-9	2020	Apoptosis of CD4+ T cells was increased significantly in dexmedetomidine and propofol groups, compared with the corresponding control groups.	Propofol	77-85	CD4 antigen	Mus musculus	13-16
32174773-12	2020	Conclusion: Repetitive exposure to dexmedetomidine and propofol reduced the expression of CD4+ T cells but did not induce any significant liver or kidney injuries.	Dexmedetomidine	35-50	CD4 antigen	Mus musculus	90-93
32174773-12	2020	Conclusion: Repetitive exposure to dexmedetomidine and propofol reduced the expression of CD4+ T cells but did not induce any significant liver or kidney injuries.	Propofol	55-63	CD4 antigen	Mus musculus	90-93
31794800-3	2020	We herein reported that the non-specific liver inflammation triggered by carbon tetrachloride (CCl4) recruited high numbers of CD4+T, CD8+T and B cells, and elevated the expression of proinflammaitory cytokines in Balb/c mice, further breaking liver tolerance and inducing autoimmune response, AIH inflammation and liver fibrosis in the presence of CYP2D6 antigen mimicry.	Carbon Tetrachloride	73-93	CD4 antigen	Mus musculus	127-130
31794800-3	2020	We herein reported that the non-specific liver inflammation triggered by carbon tetrachloride (CCl4) recruited high numbers of CD4+T, CD8+T and B cells, and elevated the expression of proinflammaitory cytokines in Balb/c mice, further breaking liver tolerance and inducing autoimmune response, AIH inflammation and liver fibrosis in the presence of CYP2D6 antigen mimicry.	Carbon Tetrachloride	95-99	CD4 antigen	Mus musculus	127-130
31874369-6	2020	In addition, iloprost-treated DCs increased OVA-specific CD4+Foxp3+ T cell differentiation from naive T cells in an IP-dependent pathway in vitro and in vivo.	Iloprost	13-21	CD4 antigen	Mus musculus	57-60
31773789-5	2020	We found that topical treatment with NG-anti-miR-210 significantly decreased the expression of miR-210 in both the skin lesions and splenic CD4+ T cells from IMQ-induced psoriasis-like mouse models and ameliorated the dermatitis in terms of the erythema, scales, acanthosis and dermal inflammatory cell infiltration in IMQ-induced mice.	ng-	37-40	CD4 antigen	Mus musculus	140-143
31773789-5	2020	We found that topical treatment with NG-anti-miR-210 significantly decreased the expression of miR-210 in both the skin lesions and splenic CD4+ T cells from IMQ-induced psoriasis-like mouse models and ameliorated the dermatitis in terms of the erythema, scales, acanthosis and dermal inflammatory cell infiltration in IMQ-induced mice.	Imiquimod	158-161	CD4 antigen	Mus musculus	140-143
31773789-5	2020	We found that topical treatment with NG-anti-miR-210 significantly decreased the expression of miR-210 in both the skin lesions and splenic CD4+ T cells from IMQ-induced psoriasis-like mouse models and ameliorated the dermatitis in terms of the erythema, scales, acanthosis and dermal inflammatory cell infiltration in IMQ-induced mice.	Imiquimod	319-322	CD4 antigen	Mus musculus	140-143
31588671-4	2020	KEY RESULTS: CD4+ T lymphocytes but not F4/80+ macrophages isolated from the lamina propria of IL-10-deficient mice with colitis express enkephalin-containing opioid peptides as assessed by cytofluorometry.	Peptides	166-174	CD4 antigen	Mus musculus	13-16
31969707-6	2020	Analysis of resting CD4+ T cells from tissues after AZD5582 treatment revealed increased SIV RNA expression in the lymph nodes of macaques and robust induction of HIV in almost all tissues analysed in humanized mice, including the lymph nodes, thymus, bone marrow, liver and lung.	N,N'-(2,2'-(hexa-2,4-diyne-1,6-diylbis(oxy))bis(2,3-dihydro-1H-indene-2,1-diyl))bis(1-(2-cyclohexyl-2-(2-(methylamino)propanamido)acetyl)pyrrolidine-2-carboxamide)	52-59	CD4 antigen	Mus musculus	20-23
31932199-8	2020	Cancer cells also over express PAD enzymes and in light of this the hypothesis that citrullinated peptides stimulate CD4+ T cell responses that would recognize these siPTM"s produced during autophagy has been investigated.	citrullinated peptides	84-106	CD4 antigen	Mus musculus	117-120
31932199-11	2020	The anti-tumour effect relied upon direct recognition of tumours by specific CD4 T cells suggesting that citrullinated peptides are attractive targets for cancer vaccines.	citrullinated peptides	105-127	CD4 antigen	Mus musculus	77-80
31746562-10	2020	Dexamethasone and the three-dose, but not the two-dose regimen, also increased levels of programmed death receptor-1 and IL-10, while reducing CD4+ CD8low cell percentage in the thymus.	Dexamethasone	0-13	CD4 antigen	Mus musculus	143-146
31917111-3	2020	demonstrate a novel mechanism through which stress drives mitochondrial fragmentation-induced xanthine accumulation in mouse CD4+ T cells, subsequently acting on oligodendrocytes to induce anxiety-like behaviors.	Xanthine	94-102	CD4 antigen	Mus musculus	125-128
31734353-7	2020	In addition, interferon-gamma-expressing CD4+ and CD8+ T cell numbers increased in the spleen and lymph nodes of mice immunized with the irradiated lactic acid-stimulated cells.	Lactic Acid	148-159	CD4 antigen	Mus musculus	41-44
31930264-0	2020	Physicochemical structure of a polyacrylic acid stabilized nanoparticle alum (nanoalum) adjuvant governs TH1 differentiation of CD4+ T cells.	carbopol 940	31-47	CD4 antigen	Mus musculus	128-131
32411785-0	2020	Erythromycin Suppresses the Cigarette Smoke Extract-Exposed Dendritic Cell-Mediated Polarization of CD4+ T Cells into Th17 Cells.	Erythromycin	0-12	CD4 antigen	Mus musculus	100-103
32411785-4	2020	Accordingly, in this study, we evaluated the effects of erythromycin (EM) on CSE-exposed DCs polarizing naive CD4+ T cells into Th17 cells.	Erythromycin	56-68	CD4 antigen	Mus musculus	110-113
32411785-4	2020	Accordingly, in this study, we evaluated the effects of erythromycin (EM) on CSE-exposed DCs polarizing naive CD4+ T cells into Th17 cells.	Erythromycin	70-72	CD4 antigen	Mus musculus	110-113
32410852-3	2020	We have previously shown that the T helper- (Th-) type 2 cytokines, Interleukin- (IL-) 4 and IL-13, mediate CD4+ T cell- or B cell-driven inflammation in the oxazolone-induced mouse model of ulcerative colitis.	Oxazolone	158-167	CD4 antigen	Mus musculus	108-111
31607752-0	2020	Shikonin attenuates hyperhomocysteinemia-induced CD4+ T cell inflammatory activation and atherosclerosis in ApoE-/- mice by metabolic suppression.	shikonin	0-8	CD4 antigen	Mus musculus	49-52
31607752-7	2020	We showed that SKN treatment markedly attenuated HHcy-accelerated atherosclerosis in ApoE-/- mice and significantly decreased inflammatory activated CD4+ T cells and proinflammatory macrophages in plaques.	shikonin	15-18	CD4 antigen	Mus musculus	149-152
31607752-8	2020	In splenic CD4+ T cells isolated from HHcy-ApoE-/- mice, SKN treatment significantly inhibited HHcy-stimulated PKM2 activity, interferon-gamma secretion and the capacity of these T cells to promote macrophage proinflammatory polarization.	shikonin	57-60	CD4 antigen	Mus musculus	11-14
31607752-9	2020	SKN treatment significantly inhibited HHcy-stimulated CD4+ T cell glycolysis and oxidative phosphorylation.	shikonin	0-3	CD4 antigen	Mus musculus	54-57
31607752-10	2020	Metabolic profiling analysis of CD4+ T cells revealed that Hcy administration significantly increased various glucose metabolites as well as lipids and acetyl-CoA carboxylase 1, which were reversed by SKN treatment.	Homocysteine	59-62	CD4 antigen	Mus musculus	32-35
31607752-10	2020	Metabolic profiling analysis of CD4+ T cells revealed that Hcy administration significantly increased various glucose metabolites as well as lipids and acetyl-CoA carboxylase 1, which were reversed by SKN treatment.	shikonin	201-204	CD4 antigen	Mus musculus	32-35
31607752-11	2020	In conclusion, our results suggest that SKN is effective to ameliorate atherosclerosis in HHcy-ApoE-/- mice and this is at least partly associated with the inhibition of SKN on CD4+ T cell inflammatory activation via PKM2-dependent metabolic suppression.	shikonin	40-43	CD4 antigen	Mus musculus	177-180
32475918-7	2020	PSP elevated the CD4+/CD8+ ratio is a dose-dependent manner and increased the levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) in the sera of Cy-treated mice.	Cyclophosphamide	168-170	CD4 antigen	Mus musculus	17-20
31678366-5	2020	Compared to controls, IMQ-treated neutropenic mice had significantly lower levels of macrophages in tissue samples (P < .05) and displayed significantly lower numbers of CD4+ T-cells (P < .05).	Imiquimod	22-25	CD4 antigen	Mus musculus	170-173
31678213-0	2020	CD4+CD25+ Tregs as dependent factor in the course of bleomycin-induced pulmonary fibrosis in mice.	Bleomycin	53-62	CD4 antigen	Mus musculus	0-3
31678213-3	2020	We here explored the relationship between peripheral blood CD4+CD25+ Tregs and the course of bleomycin-induced PF in mice.	Bleomycin	93-102	CD4 antigen	Mus musculus	59-62
31678213-7	2020	The trend of CD4+CD25+ Tregs changes was increased firstly, decreased, increased again from 7th to 28th days after bleomycin instillation, which had great relevance with alveolitis and fibrosis scores.	Bleomycin	115-124	CD4 antigen	Mus musculus	13-16
31678213-11	2020	These findings suggested that the dynamic changes of CD4+CD25+ Tregs as dependent factor might designate a different course of PF induced by bleomycin in mice, and might be a selected drug use indicator for therapy of PF.	Bleomycin	141-150	CD4 antigen	Mus musculus	53-56
32571120-9	2020	Furthermore, phloretin appeared to limit the overproliferation of splenocytes in response to DNCB stimulation, reducing the number of IFN-gamma-, IL-4-, and IL-17A-producing CD4+ T cells in the spleen back to their normal ranges.	Phloretin	13-22	CD4 antigen	Mus musculus	174-177
32571120-9	2020	Furthermore, phloretin appeared to limit the overproliferation of splenocytes in response to DNCB stimulation, reducing the number of IFN-gamma-, IL-4-, and IL-17A-producing CD4+ T cells in the spleen back to their normal ranges.	Dinitrochlorobenzene	93-97	CD4 antigen	Mus musculus	174-177
31776206-3	2020	Accordingly, effector IFN-gamma-producing CD4 and CD8 T cells are significantly decreased in the tumor microenvironment (TME) of GEM-treated mice.	gemcitabine	129-132	CD4 antigen	Mus musculus	42-45
33132244-9	2020	In mouse thyroid follicular epithelial cells co-cultured with CD4+PD-1+ and CD8+PD-1+ T lymphocytes, the cell viability, TH and TRAb levels and inflammatory cytokines level were the highest, while the TSH level and apoptosis were the lowest.	Thyrotropin	201-204	CD4 antigen	Mus musculus	62-65
31933199-8	2020	In this chapter, we detail methods used to examine in vitro effect of exogenous TNF on the proliferative expansion of Tregs in unfractionated mouse CD4+ T cells.	tregs	118-123	CD4 antigen	Mus musculus	148-151
31676364-7	2020	The percentage of CD4+IL-17 + T cells in the lungs and the concentration of interleukin (IL)-17 and IL-22 in BALF were significantly down-regulated by tangeretin.	tangeretin	151-161	CD4 antigen	Mus musculus	18-27
33268683-0	2020	[Dual Roles of alpha7 Nicotinic Acetylcholine Receptors Expressed in Immune Cells in T Cell Differentiation -alpha7 nAChRs Exert Different Actions between Antigen-presenting Cells and CD4+ T Cells].	Acetylcholine	32-45	CD4 antigen	Mus musculus	184-187
31907158-14	2019	Metformin alone did not obviously affect CD4+ cells or CD8+ cells but significantly decreased the percentage of CD4+Foxp3+ (P < 0.05); the vaccine alone significantly increased CD4+ cells and CD8+ cells (P < 0.001) and also the percentage of CD4+Foxp3+ cells (P < 0.05).	Metformin	0-9	CD4 antigen	Mus musculus	112-115
31907158-14	2019	Metformin alone did not obviously affect CD4+ cells or CD8+ cells but significantly decreased the percentage of CD4+Foxp3+ (P < 0.05); the vaccine alone significantly increased CD4+ cells and CD8+ cells (P < 0.001) and also the percentage of CD4+Foxp3+ cells (P < 0.05).	Metformin	0-9	CD4 antigen	Mus musculus	112-115
31907158-14	2019	Metformin alone did not obviously affect CD4+ cells or CD8+ cells but significantly decreased the percentage of CD4+Foxp3+ (P < 0.05); the vaccine alone significantly increased CD4+ cells and CD8+ cells (P < 0.001) and also the percentage of CD4+Foxp3+ cells (P < 0.05).	Metformin	0-9	CD4 antigen	Mus musculus	112-115
31907162-0	2019	[Kirenol relieves dextran sulfate sodium-induced ulcerative colitis in mice by inhibiting inflammatory cytokines and inducing CD4+ T lymphocyte apoptosis].	kirenol	1-8	CD4 antigen	Mus musculus	126-129
31907162-7	2019	Kirenol treatment significantly down-regulated the secretion of IFN-gamma, IL-17A, IL-6 and TNF-alpha by the MLNs lymphocytes and increased the apoptosis of lymphocytes, especially CD4+ T cells in the DSS-treated mice.	kirenol	0-7	CD4 antigen	Mus musculus	181-184
31689461-6	2019	At the molecular level, FK506-TKM significantly inhibited infiltration of CD4+ and CD8+ T lymphocytes in colon and differentiation of CD4+ T cells into Th1 and Th17 cells in colon-draining mesenteric lymph nodes via restricting dendritic cell migration from colon.	Tacrolimus	24-29	CD4 antigen	Mus musculus	74-77
31689461-6	2019	At the molecular level, FK506-TKM significantly inhibited infiltration of CD4+ and CD8+ T lymphocytes in colon and differentiation of CD4+ T cells into Th1 and Th17 cells in colon-draining mesenteric lymph nodes via restricting dendritic cell migration from colon.	Tacrolimus	24-29	CD4 antigen	Mus musculus	134-137
31564450-7	2019	Taken together, our results indicate that removal of glycans at N276/N463 and deletion of the V1/V2 region can expose the CD4-binding site and CD4-induced epitopes, but such exposure alone appears incapable of enhancing the induction of bNAbs in mice, informing that additional modification or/and immunization strategies are needed.	Polysaccharides	53-60	CD4 antigen	Mus musculus	122-125
31564450-7	2019	Taken together, our results indicate that removal of glycans at N276/N463 and deletion of the V1/V2 region can expose the CD4-binding site and CD4-induced epitopes, but such exposure alone appears incapable of enhancing the induction of bNAbs in mice, informing that additional modification or/and immunization strategies are needed.	Polysaccharides	53-60	CD4 antigen	Mus musculus	143-146
32042764-6	2019	1alpha,25(OH)2D3 treatment also resulted in an increased number of CD4+Foxp3+ regulatory T cells (Tregs) but decreased the number of CD4+IL-4+ cells.	25-hydroxyvitamin D3-bromoacetate	0-16	CD4 antigen	Mus musculus	67-70
32042764-6	2019	1alpha,25(OH)2D3 treatment also resulted in an increased number of CD4+Foxp3+ regulatory T cells (Tregs) but decreased the number of CD4+IL-4+ cells.	25-hydroxyvitamin D3-bromoacetate	0-16	CD4 antigen	Mus musculus	133-136
31407330-11	2019	Conversely, depletion of CD4+ CD25+ Tregs reversed the therapeutic effects of kaempferol on the skin lesion.	kaempferol	78-88	CD4 antigen	Mus musculus	25-28
31407330-12	2019	Kaempferol also lowered the percentage of IL-17A+ CD4+ T cells in the spleen and lymph nodes of IMQ-induced psoriatic mice.	kaempferol	0-10	CD4 antigen	Mus musculus	50-53
31407330-12	2019	Kaempferol also lowered the percentage of IL-17A+ CD4+ T cells in the spleen and lymph nodes of IMQ-induced psoriatic mice.	Imiquimod	96-99	CD4 antigen	Mus musculus	50-53
31297750-5	2019	CD4+ T cells were treated with DAPT or PI and harvested after 72 h. PKCtheta inhibition markedly attenuated pathological changes and decreased the wet to dry weight ratio of the mouse lungs.	dapt	31-35	CD4 antigen	Mus musculus	0-3
31634789-6	2019	In a mouse CIA model, CS12192 also attenuated the disease severity, which was correlated with the suppressed CD4+ T cell activation and Th17 function, as well as the reduced cytokine levels in sera and pro-inflammatory cytokine and chemokine gene expression in joint tissue.	cs12192	22-29	CD4 antigen	Mus musculus	109-112
31628154-4	2019	We find that TCR signaling regulates acetyl-CoA metabolism via AKT in murine CD4+ T cells.	Acetyl Coenzyme A	37-47	CD4 antigen	Mus musculus	77-80
31372995-5	2019	In mesenteric lymph nodes, retinoic acid (RA) released by CD103+ dendritic cells downregulated lamin A/C in CD4+ T-cells, enhancing Treg differentiation.	Tretinoin	27-40	CD4 antigen	Mus musculus	108-111
31372995-5	2019	In mesenteric lymph nodes, retinoic acid (RA) released by CD103+ dendritic cells downregulated lamin A/C in CD4+ T-cells, enhancing Treg differentiation.	Tretinoin	42-44	CD4 antigen	Mus musculus	108-111
30782087-4	2019	Numerous murine studies have shown that adoptive transfer of CD4+CD25+FoxP3+ Tregs from donors improves litter sizes in DEREG mice with depleted Tregs.	tregs	77-82	CD4 antigen	Mus musculus	61-64
31819402-0	2019	Erythromycin Prevents Elastin Peptide-Induced Emphysema and Modulates CD4+T Cell Responses in Mice.	Erythromycin	0-12	CD4 antigen	Mus musculus	70-73
31819402-13	2019	In vitro, erythromycin also limited Th17 and Th1 cell differentiation and downregulated transcript levels of Ifngamma and IL17a in the EP-stimulated CD4+T cells.	Erythromycin	10-22	CD4 antigen	Mus musculus	149-152
31819402-15	2019	Prophylactic use of erythromycin effectively ameliorated emphysema and modulated CD4+T cells responses in EP-induced lung inflammation in mice.	Erythromycin	20-32	CD4 antigen	Mus musculus	81-84
31647039-6	2019	In the 0 02 %VC and wild-type groups, dexamethasone caused a significant decrease in the cluster of differentiation (CD)4+ and CD8+ T cells among splenocytes as well as a significant decrease in IL-2, IL-12p40 and interferon-gamma protein production by splenocytes and a significant decrease in T-cell proliferation among splenocytes.	Dexamethasone	38-51	CD4 antigen	Mus musculus	116-121
31776355-7	2019	In vitro, IL-23 drove the generation of CD4+Foxp3+RORgammat+IL-17A+ cells from Treg cells.	rorgammat	50-59	CD4 antigen	Mus musculus	40-43
31776355-8	2019	Collectively, our data shows that IL-23 drives Treg plasticity by inducing a population of CD4+Foxp3+RORgammat+IL-17A+ cells that could play a role in the disease pathogenesis.	rorgammat	101-110	CD4 antigen	Mus musculus	91-94
31747595-5	2019	Antigen-specific CD4 T cells in mice with miR-181a-deficient T cells expand more and have a broader TCR repertoire with preferential expansion of high-affinity T cells than in wild-type mice.	Receptor-CD3 Complex, Antigen, T-Cell	100-103	CD4 antigen	Mus musculus	17-20
31705000-6	2019	These results suggest synergistic anti-psoriatic activity of Cal/BDP with normalization of the imbalance between regulatory CD8+ or CD4+ T cells and proinflammatory CCR6+ gammadelta T17 cells, which contributes to successful control of psoriasis by Cal-BDP combination therapy.	calcipotriene	61-64	CD4 antigen	Mus musculus	132-135
31705000-6	2019	These results suggest synergistic anti-psoriatic activity of Cal/BDP with normalization of the imbalance between regulatory CD8+ or CD4+ T cells and proinflammatory CCR6+ gammadelta T17 cells, which contributes to successful control of psoriasis by Cal-BDP combination therapy.	betamethasone-17,21-dipropionate	65-68	CD4 antigen	Mus musculus	132-135
31449782-3	2019	One of the lead compounds, an isoxazolecarboxamide designated as TRP38, efficiently converts naive CD4+ T cells to TR cells in vitro and protects mice from autoimmune colitis in vivo.	Isoxazole-3-carboxamide	30-50	CD4 antigen	Mus musculus	99-102
31393597-3	2019	To overcome this limitation, we developed a novel imiquimod-containing vaccination platform (IMI-Sol) rendering superior primary CD8+ and CD4+ T-cell responses.	Imiquimod	50-59	CD4 antigen	Mus musculus	138-141
31401712-6	2019	Using an improved mouse RUUO model, this study revealed that the mouse kidney for 3- or 7-day unilateral ureteral obstruction undergoing the RUUO surgery was still in a state of injury and fibrosis, while losartan could effectively ameliorate renal fibrosis by upregulating the expression of CD4 + CD25 + Foxp3 + regulatory T cells (Tregs) in kidney after the surgery of RUUO.	Losartan	205-213	CD4 antigen	Mus musculus	292-295
31545496-6	2019	Following the establishment of a 2,4-dinitrofluorobenzene-induced C57BL/6 mouse AD model, Th1 (CD4+IFN-gamma+) and Th2 (CD4+IL-4+) expression was analyzed in murine spleen cells via flow cytometry.	Dinitrofluorobenzene	33-57	CD4 antigen	Mus musculus	95-108
31675497-5	2019	Physical stress-induced leukotriene B4 triggers severe mitochondrial fission in CD4+ T cells, which further leads to a variety of behavioral abnormalities including anxiety, depression, and social disorders.	Leukotriene B4	24-38	CD4 antigen	Mus musculus	80-83
31675497-6	2019	Metabolomic profiles and single-cell transcriptome reveal that CD4+ T cell-derived xanthine acts on oligodendrocytes in the left amygdala via adenosine receptor A1.	Xanthine	83-91	CD4 antigen	Mus musculus	63-66
31675497-7	2019	Mitochondrial fission promotes the de novo synthesis of purine via interferon regulatory factor 1 accumulation in CD4+ T cells.	purine	56-62	CD4 antigen	Mus musculus	114-117
31653839-3	2019	Here, we compare immune repertoires of Treg-deficient and Treg-sufficient mice to find Tregs continuously constraining one-third of mature CD4+Foxp3- cells from converting to pathogenic effectors in healthy mice.	treg	39-43	CD4 antigen	Mus musculus	139-142
31653839-3	2019	Here, we compare immune repertoires of Treg-deficient and Treg-sufficient mice to find Tregs continuously constraining one-third of mature CD4+Foxp3- cells from converting to pathogenic effectors in healthy mice.	tregs	87-92	CD4 antigen	Mus musculus	139-142
31653054-3	2019	0.2% CPZ(+-PT) for 5 weeks produced oligodendrocytosis, demyelination and gliosis plus marked splenic atrophy (37%) and reduced levels of CD4 (44%) and CD8 (61%).	Cuprizone	5-8	CD4 antigen	Mus musculus	138-141
31653054-4	2019	Conversely, 0.1% CPZ(+-PT) produced a similar oligodendrocytosis, demyelination and gliosis but a smaller reduction in splenic CD4 (11%) and CD8 (14%) levels and no splenic atrophy.	Cuprizone	17-20	CD4 antigen	Mus musculus	127-130
31653054-5	2019	Long-term feeding of 0.1% CPZ(+-PT) for 12 weeks produced similar reductions in CD4 (27%) and CD8 (43%), as well as splenic atrophy (33%), as seen with 0.2% CPZ(+-PT) for 5 weeks.	Cuprizone	26-29	CD4 antigen	Mus musculus	80-83
31636084-0	2019	Homotaurine Treatment Enhances CD4+ and CD8+ Regulatory T Cell Responses and Synergizes with Low-Dose Anti-CD3 to Enhance Diabetes Remission in Type 1 Diabetic Mice.	tramiprosate	0-11	CD4 antigen	Mus musculus	31-34
31636084-6	2019	In severely diabetic NOD mice, the combination of homotaurine and low-dose anti-CD3 treatment significantly increased 1) disease remission, 2) the percentages of splenic CD4+and CD8+ regulatory T cells compared with anti-CD3 alone, and 3) the frequencies of CD4+ and CD8+ regulatory T cells in the pancreatic lymph nodes compared with homotaurine monotherapy.	tramiprosate	50-61	CD4 antigen	Mus musculus	170-173
31636084-6	2019	In severely diabetic NOD mice, the combination of homotaurine and low-dose anti-CD3 treatment significantly increased 1) disease remission, 2) the percentages of splenic CD4+and CD8+ regulatory T cells compared with anti-CD3 alone, and 3) the frequencies of CD4+ and CD8+ regulatory T cells in the pancreatic lymph nodes compared with homotaurine monotherapy.	tramiprosate	50-61	CD4 antigen	Mus musculus	258-261
31681214-10	2019	MicroRNAs (miRs) analysis of CD4+ T cells from the spleens of the PTX+TCDD treated mice revealed significant alterations in their expression and several of these miRs targeted cytokines and signaling molecules involved in inflammation.	tcdd	70-74	CD4 antigen	Mus musculus	29-32
31754392-15	2019	PET imaging in syngeneic tumor models revealed a varying maximum tumor-to-heart ratio of 89Zr-DFO-CD4 and 89Zr-DFO-CD8a across tumor types and in-between subjects that correlated with individual response to Sym021 at day 10 relative to start of therapy (p=0.0002 and p=0.0354, respectively).	Deferoxamine	94-97	CD4 antigen	Mus musculus	98-101
31754392-16	2019	The maximum 89Zr-DFO-CD4 tumor-to-heart ratio could be used to stratify mice according to Sym021 therapy response and overall survival was improved in mice with a 89Zr-DFO-CD4 ratio >9 (p=0.0018).	Deferoxamine	17-20	CD4 antigen	Mus musculus	21-24
31754392-16	2019	The maximum 89Zr-DFO-CD4 tumor-to-heart ratio could be used to stratify mice according to Sym021 therapy response and overall survival was improved in mice with a 89Zr-DFO-CD4 ratio >9 (p=0.0018).	Deferoxamine	17-20	CD4 antigen	Mus musculus	172-175
31754392-16	2019	The maximum 89Zr-DFO-CD4 tumor-to-heart ratio could be used to stratify mice according to Sym021 therapy response and overall survival was improved in mice with a 89Zr-DFO-CD4 ratio >9 (p=0.0018).	Deferoxamine	168-171	CD4 antigen	Mus musculus	21-24
31754392-16	2019	The maximum 89Zr-DFO-CD4 tumor-to-heart ratio could be used to stratify mice according to Sym021 therapy response and overall survival was improved in mice with a 89Zr-DFO-CD4 ratio >9 (p=0.0018).	Deferoxamine	168-171	CD4 antigen	Mus musculus	172-175
31681285-6	2019	Furthermore, we identified an increased expression of activation marker CD69 in brain-infiltrating neutrophils, CD4+ T and CD8+ T cells, and IFN-gamma in brain-infiltrating CD4+ T cells in db/db mice at day 7 after dMCAO.	dmcao	215-220	CD4 antigen	Mus musculus	173-176
31407808-8	2019	We found that microbial products from alcohol-fed mice significantly increased the percentage of CD38+ CD4+ (mean alcohol-fed 17.32% +- 0.683% standard deviation (SD) vs. mean pair-fed 14.2% +- 1.21% SD, p < 0.05) and CD8+ (mean alcohol-fed 20.28% +- 0.88% SD vs. mean pair-fed 12.58% +- 3.59% SD, p < 0.05) T cells.	Alcohols	38-45	CD4 antigen	Mus musculus	103-106
31407808-8	2019	We found that microbial products from alcohol-fed mice significantly increased the percentage of CD38+ CD4+ (mean alcohol-fed 17.32% +- 0.683% standard deviation (SD) vs. mean pair-fed 14.2% +- 1.21% SD, p < 0.05) and CD8+ (mean alcohol-fed 20.28% +- 0.88% SD vs. mean pair-fed 12.58% +- 3.59% SD, p < 0.05) T cells.	Alcohols	114-121	CD4 antigen	Mus musculus	103-106
31407808-8	2019	We found that microbial products from alcohol-fed mice significantly increased the percentage of CD38+ CD4+ (mean alcohol-fed 17.32% +- 0.683% standard deviation (SD) vs. mean pair-fed 14.2% +- 1.21% SD, p < 0.05) and CD8+ (mean alcohol-fed 20.28% +- 0.88% SD vs. mean pair-fed 12.58% +- 3.59% SD, p < 0.05) T cells.	Alcohols	114-121	CD4 antigen	Mus musculus	103-106
30998512-4	2019	Although the antitumor effects of CS2164 were validated in both subcutaneous and ascites HCC models in syngeneic mice, CS2164 treatment consistently modulated immune cell populations, both in the periphery and in tumor microenvironments, with upregulation of CD4 and CD8 T cells in the spleen, but downregulation of immunosuppressive populations including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages in the spleen and tumor tissues.	chiauranib	119-125	CD4 antigen	Mus musculus	259-262
31252312-5	2019	After LPS treatment 6 h, 12 h, the number of CD3+ T cells and CD4/CD8 in the mesenteric lymph nodes of ileum were reduced significantly; the levels of IFN-gamma, TNF-alpha and IL-2 were significantly decreased, and the levels of IL-6 and IL-10 were significantly increased in the ileum.	lps	6-9	CD4 antigen	Mus musculus	62-65
31421154-7	2019	In vitro, rebamipide suppressed IL-6 and IL-17 production by Th17 cells in splenic CD4+ cells from the mice.	rebamipide	10-20	CD4 antigen	Mus musculus	83-86
31422184-6	2019	The infiltration of CD4+ T cells in skin lesions and spleen was also reduced in fucoidan-treated AD mice.	fucoidan	80-88	CD4 antigen	Mus musculus	20-23
31398346-6	2019	In vitro, the glycolysis inhibitor 2-deoxy-d-glucose (2-DG) reversed T-cell dysfunction; thus, heightened metabolic activity directly controls CD4+ T-cell immunological status.	Glucose	45-52	CD4 antigen	Mus musculus	143-146
31398346-6	2019	In vitro, the glycolysis inhibitor 2-deoxy-d-glucose (2-DG) reversed T-cell dysfunction; thus, heightened metabolic activity directly controls CD4+ T-cell immunological status.	Deoxyglucose	54-58	CD4 antigen	Mus musculus	143-146
31398346-8	2019	Strikingly, these effects were abolished by preconditioning cells with 2-DG, indicating that CD4+ T-cell dysfunction partially induced by metabolic reprogramming contributes to cardiac remodeling.	Deoxyglucose	71-75	CD4 antigen	Mus musculus	93-96
31505252-8	2019	At molecular level, Ibrutinib suppressed phosphorylation of BTK in neutrophils at lower doses and ITK in CD4 + T cells at higher doses in CE-treated mice.	ibrutinib	20-29	CD4 antigen	Mus musculus	105-108
31607333-8	2019	RESULTS: After treatment for 3 and 6 moths, the percentages of Tcl, Thl cells and CD8+, Tcl/Tc2, Thl/Th2 and CD4+/CD8+ all decreased in the group of triptolide, and the percentage of CD4+, Tc2 and Th2 cells increased (P<0.05).	triptolide	149-159	CD4 antigen	Mus musculus	183-186
31182172-0	2019	Effects of prophylactic administration of glutamine on CD4+ T cell polarisation and kidney injury in mice with polymicrobial sepsis.	Glutamine	42-51	CD4 antigen	Mus musculus	55-58
31182172-1	2019	The present study investigated the effects of glutamine (GLN) pretreatment on CD4+ T cell polarisation and remote kidney injury in mice with gut-derived polymicrobial sepsis.	Glutamine	46-55	CD4 antigen	Mus musculus	78-81
31182172-1	2019	The present study investigated the effects of glutamine (GLN) pretreatment on CD4+ T cell polarisation and remote kidney injury in mice with gut-derived polymicrobial sepsis.	Glutamine	57-60	CD4 antigen	Mus musculus	78-81
31182172-7	2019	Compared with the sepsis control group, pretreatment with GLN maintained blood T and CD4+ T cells and reduced percentages of IL-4- and Foxp3-expressing CD4+ T cells.	Glutamine	58-61	CD4 antigen	Mus musculus	85-88
31182172-7	2019	Compared with the sepsis control group, pretreatment with GLN maintained blood T and CD4+ T cells and reduced percentages of IL-4- and Foxp3-expressing CD4+ T cells.	Glutamine	58-61	CD4 antigen	Mus musculus	152-155
31182172-10	2019	These findings suggest that antecedent of GLN administration elicit a more balanced blood T helper cell polarisation, sustained T cell populations, prevented splenic CD4+ T cell apoptosis and attenuated kidney injury at late phase of polymicrobial sepsis.	Glutamine	42-45	CD4 antigen	Mus musculus	166-169
31146000-2	2019	Pinellia pedatisecta Schott extract (PE) has been confirmed to suppress cervical tumor growth and modulate the antitumor CD4+T helper immunity towards Th1.	pe	37-39	CD4 antigen	Mus musculus	121-124
31511552-9	2019	The colonic transcriptional profile in steroid treated mice showed significant upregulation of a small subset of T cell associated genes, in particular C/EBPbeta, CD4, IL7R and STAT5a.	Steroids	39-46	CD4 antigen	Mus musculus	163-166
31583256-7	2019	Moreover, oral administration of sublancin increased the frequencies of CD4+ and CD8+ T cells in mesenteric lymph nodes.	sublancin	33-42	CD4 antigen	Mus musculus	72-75
31646082-7	2019	The poly-neoantigen DNA vaccine elicited T cell responses to all three neoantigens and induced functional CD8 and CD4 T cell responses to the reporter antigen ovalbumin after intradermal injection in mice.	organ-specific neoantigen	4-19	CD4 antigen	Mus musculus	114-117
31295429-5	2019	Similarly, IVV with AECD augmented significantly lymphocyte proliferation and increased the positive rates of CD4+, CD8+ and CD44+ T cells from draining lymph nodes and spleens.	aecd	20-24	CD4 antigen	Mus musculus	110-113
31070504-8	2019	Also, the effectiveness of CD4+CD25hiFoxP3+ Treg upregulation by tolDCpIL-10 was different.	toldcpil-10	65-76	CD4 antigen	Mus musculus	27-30
31070504-10	2019	DCpIL-10 may be used to induce CD4+CD25hiFoxP3+ Tregs and the regulatory potential of splenocytes.	dcpil-10	0-8	CD4 antigen	Mus musculus	31-34
30714626-0	2019	Antecedent Administration of Glutamine Benefits the Homeostasis of CD4+ T Cells and Attenuates Lung Injury in Mice With Gut-Derived Polymicrobial Sepsis.	Glutamine	29-38	CD4 antigen	Mus musculus	67-70
31014974-0	2019	2,3,7,8-Tetrachloodibenzo-p-dioxin affects the differentiation of CD4 helper T cell.	2,3,7,8-tetrachloodibenzo-p-dioxin	0-34	CD4 antigen	Mus musculus	66-69
31014974-8	2019	Our CD4 Th subset co-culture experiments showed that TCDD-induced pathobiology depended on immune cell balance, suggesting that cytokine-induced microenvironments further modulated toxic effects associated with TCDD exposure.	Polychlorinated Dibenzodioxins	53-57	CD4 antigen	Mus musculus	4-7
31254568-13	2019	Furthermore, the adoptive transfer of Treg cells that were differentiated from naive CD4 T cells by an in vitro DMSO treatment exhibited a similar effect to the in vivo DMSO treatment for the prevention of EPS formation.	Dimethyl Sulfoxide	112-116	CD4 antigen	Mus musculus	85-88
31555266-0	2019	Continuous Developmental and Early Life Trichloroethylene Exposure Promoted DNA Methylation Alterations in Polycomb Protein Binding Sites in Effector/Memory CD4+ T Cells.	Trichloroethylene	40-57	CD4 antigen	Mus musculus	157-160
31555266-1	2019	Trichloroethylene (TCE) is an industrial solvent and drinking water pollutant associated with CD4+ T cell-mediated autoimmunity.	Trichloroethylene	0-17	CD4 antigen	Mus musculus	94-97
31555266-1	2019	Trichloroethylene (TCE) is an industrial solvent and drinking water pollutant associated with CD4+ T cell-mediated autoimmunity.	Trichloroethylene	19-22	CD4 antigen	Mus musculus	94-97
31555266-1	2019	Trichloroethylene (TCE) is an industrial solvent and drinking water pollutant associated with CD4+ T cell-mediated autoimmunity.	Water	62-67	CD4 antigen	Mus musculus	94-97
31555266-14	2019	The results demonstrated that continuous developmental exposure to TCE differentially methylated binding sites of PcG proteins in effector/memory CD4+ cells.	Trichloroethylene	67-70	CD4 antigen	Mus musculus	146-149
31555266-16	2019	These results point toward a novel mechanism by which chronic developmental TCE exposure may alter terminally differentiated CD4+ T cell function in adulthood.	Trichloroethylene	76-79	CD4 antigen	Mus musculus	125-128
31475011-0	2019	The DNA Methylation Inhibitor Zebularine Controls CD4+ T Cell Mediated Intraocular Inflammation.	pyrimidin-2-one beta-ribofuranoside	30-40	CD4 antigen	Mus musculus	50-53
31475011-3	2019	Here, we investigated whether DNA methylation inhibitor zebularine can target CD4+ T cells and control intraocular inflammation.	pyrimidin-2-one beta-ribofuranoside	56-66	CD4 antigen	Mus musculus	78-81
31475011-4	2019	Our results showed that zebularine restrained the expression of inflammatory cytokines IFN-gamma and IL-17 in both human and murine CD4+ T cells in vitro.	pyrimidin-2-one beta-ribofuranoside	24-34	CD4 antigen	Mus musculus	132-135
31511826-9	2019	These data indicate that overexpression of IL-4, which constitutes the primary inducer of Th2 polarization, may cause the Th2 bias of polyclonally stimulated KSRP-/- CD4+ T cells.	th2	122-125	CD4 antigen	Mus musculus	166-169
31034952-10	2019	In ganglionic tissue of arthritic mice, CD4+ lymphocytes concentration was reduced by Bc-Wp and Bc-Cc treatment (250 mg/kg) respectively, as well IL-1beta, and TNF-alpha levels.	bc-cc	96-101	CD4 antigen	Mus musculus	40-43
31387637-11	2019	Depletion of NK cells in alpha-GalCer-treated mice showed a lower frequency of IFN-gamma-producing CD4+ and CD8+ T cells in the tumor and prevented the alpha-GalCer-induced tumor growth.	alpha-galactosylceramide	25-37	CD4 antigen	Mus musculus	99-102
31132668-13	2019	Particularly, we showed thalidomide reduced CD4+ T helper cell infiltration and downregulated Th1- and Th17-polarizing genes.	Thalidomide	24-35	CD4 antigen	Mus musculus	44-47
31218844-8	2019	rhCNB also induced the formation of CD4+ and CD8+ T cells in splenocytes from WT mice, but not from TLR4-deficient littermates.	rhcnb	0-5	CD4 antigen	Mus musculus	36-39
31129421-12	2019	Moreover, BA reduced the frequency of IL-17A-expressing CD4+ and gammadelta T cells in psoriatic mice, but did not alter CD4+FoxP3+ Treg frequency.	betulinic acid	10-12	CD4 antigen	Mus musculus	56-59
31129421-16	2019	Finally, BA inhibited T cell proliferation and IL-17A production by CD4+ T-Cells in vitro.	betulinic acid	9-11	CD4 antigen	Mus musculus	68-71
31177081-8	2019	At higher concentrations of zerumbone, the % expression of CD4+ and CD8+ in splenocytes was significantly inhibited.	zerumbone	28-37	CD4 antigen	Mus musculus	59-62
30897248-5	2019	Resveratrol treatment in mice with colitis led to an increase in CD4+ FOXP3+ and CD4+ IL-10+ T cells, and a decrease in CD4+ IFN-gamma+ and CD4+ IL-17+ T cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	65-68
30897248-5	2019	Resveratrol treatment in mice with colitis led to an increase in CD4+ FOXP3+ and CD4+ IL-10+ T cells, and a decrease in CD4+ IFN-gamma+ and CD4+ IL-17+ T cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	81-84
30897248-5	2019	Resveratrol treatment in mice with colitis led to an increase in CD4+ FOXP3+ and CD4+ IL-10+ T cells, and a decrease in CD4+ IFN-gamma+ and CD4+ IL-17+ T cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	81-84
30897248-5	2019	Resveratrol treatment in mice with colitis led to an increase in CD4+ FOXP3+ and CD4+ IL-10+ T cells, and a decrease in CD4+ IFN-gamma+ and CD4+ IL-17+ T cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	81-84
30897248-9	2019	Fecal transfer experiments confirmed the protective role of resveratrol-induced microbiota against colitis inasmuch as such recipient mice were more resistant to TNBS-colitis and exhibited polarization toward CD4+ FOXP3+ T cells and decreases in CD4+ IFN-gamma+ and CD4+ IL-17+ T cells.	Resveratrol	60-71	CD4 antigen	Mus musculus	209-212
30897248-9	2019	Fecal transfer experiments confirmed the protective role of resveratrol-induced microbiota against colitis inasmuch as such recipient mice were more resistant to TNBS-colitis and exhibited polarization toward CD4+ FOXP3+ T cells and decreases in CD4+ IFN-gamma+ and CD4+ IL-17+ T cells.	Resveratrol	60-71	CD4 antigen	Mus musculus	246-249
30897248-9	2019	Fecal transfer experiments confirmed the protective role of resveratrol-induced microbiota against colitis inasmuch as such recipient mice were more resistant to TNBS-colitis and exhibited polarization toward CD4+ FOXP3+ T cells and decreases in CD4+ IFN-gamma+ and CD4+ IL-17+ T cells.	Resveratrol	60-71	CD4 antigen	Mus musculus	246-249
31302805-5	2019	Treatment with Jeju ground water increased CD4+CD8- or CD4-CD8+ single-positive thymocytes.	jeju ground	15-26	CD4 antigen	Mus musculus	43-46
31302805-5	2019	Treatment with Jeju ground water increased CD4+CD8- or CD4-CD8+ single-positive thymocytes.	jeju ground	15-26	CD4 antigen	Mus musculus	55-58
31302805-5	2019	Treatment with Jeju ground water increased CD4+CD8- or CD4-CD8+ single-positive thymocytes.	Water	27-32	CD4 antigen	Mus musculus	43-46
31302805-5	2019	Treatment with Jeju ground water increased CD4+CD8- or CD4-CD8+ single-positive thymocytes.	Water	27-32	CD4 antigen	Mus musculus	55-58
31078116-9	2019	We found that, although PM did not significantly change the number of lung-infiltrating CD4 T cells, it significantly altered the composition of lung-infiltrating CD4 T cells, characterized by having a higher T-bet/Foxp3 ratio in the PM-treated group compared to the saline-treated group.	Sodium Chloride	267-273	CD4 antigen	Mus musculus	163-166
31078116-11	2019	The effect of PM on CD4 T cells depended on the concentration of PM and the duration of the treatment, and was independent of the PM withdrawal.	Promethium	14-16	CD4 antigen	Mus musculus	20-23
31078116-11	2019	The effect of PM on CD4 T cells depended on the concentration of PM and the duration of the treatment, and was independent of the PM withdrawal.	Promethium	65-67	CD4 antigen	Mus musculus	20-23
31229844-2	2019	The core fucosylation is dramatically up-regulated at the transition from CD4-CD8- (DN) to CD4+CD8+ (DP) in the thymic development.	dn	84-86	CD4 antigen	Mus musculus	74-77
31229844-2	2019	The core fucosylation is dramatically up-regulated at the transition from CD4-CD8- (DN) to CD4+CD8+ (DP) in the thymic development.	dp	101-103	CD4 antigen	Mus musculus	74-77
31229844-2	2019	The core fucosylation is dramatically up-regulated at the transition from CD4-CD8- (DN) to CD4+CD8+ (DP) in the thymic development.	dp	101-103	CD4 antigen	Mus musculus	91-94
31417547-7	2019	UA treatment further increased miR-10a-5p abundance in CD4+ T cells in a dose dependent fashion.	3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one	0-2	CD4 antigen	Mus musculus	55-58
31340848-0	2019	CD4+CD69+ T cells and CD4+CD25+FoxP3+ Treg cells imbalance in peripheral blood, spleen and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice.	pristane	114-122	CD4 antigen	Mus musculus	0-3
31340848-0	2019	CD4+CD69+ T cells and CD4+CD25+FoxP3+ Treg cells imbalance in peripheral blood, spleen and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice.	pristane	114-122	CD4 antigen	Mus musculus	22-25
31340848-13	2019	CONCLUSION: Increased numbers of CD4+CD69+ T cells and reduced numbers of CD4+CD25+FoxP3+ Treg cells with an altered interleukin profile suggests loss of autotolerance in pristane-induced lupus mice, which is similar to human lupus.	pristane	171-179	CD4 antigen	Mus musculus	74-77
31396305-4	2019	Methods and Results: Chronic IL-17A overexpression in T cells (CD4-IL-17Aind/+ mice) resulted in elevated reactive oxygen species in the peripheral blood and a significant vascular dysfunction compared to control mice.	Reactive Oxygen Species	106-129	CD4 antigen	Mus musculus	63-66
31396305-9	2019	We also found that the  NO/cGMP pathway was downregulated in the vasculature of the CD4-IL-17Aind/+ mice, while levels of protein tyrosine kinase 2 (PYK2), an oxidative stress-triggered process associated with T cell activation, were upregulated in the perivascular fat tissue (PVAT).	Cyclic GMP	27-31	CD4 antigen	Mus musculus	84-87
31307370-6	2019	All fimasartan-administered groups revealed significant increases of CD4+CD25+Foxp3+ regulatory T (Treg) cells with increased plasma levels of IL-10 and TGFbeta.	fimasartan	4-14	CD4 antigen	Mus musculus	69-72
31004709-8	2019	The percentage of CD4+CD25+Foxp3+T cells, the number of Th17 cells, and the expression of Foxp3 and RORC mRNA level in the high-dose rapamycin group were greater than those in the vehicle-treated group and the low-dose rapamycin group.	Sirolimus	133-142	CD4 antigen	Mus musculus	18-21
31296924-5	2019	Numbers of Tregs and IFN-gamma+, IL-13+ and IL-17A+ CD4+ T helper (Th) cells in mesenteric lymph nodes increased during chronic DSS administration and mRNA for IFN-gamma and IL-17 in the inflamed colon tissue was upregulated.	dss	128-131	CD4 antigen	Mus musculus	52-55
31288845-11	2019	Instead, SM16 treatment causes expansion of a population of CD4+CD25-Foxp3+ Treg-like cells without significantly altering the overall frequency of Treg in lymphoreplete naive and tumor-bearing mice.	SM 16	9-13	CD4 antigen	Mus musculus	60-63
31288845-12	2019	Importantly, both the CD4+CD25-Foxp3+ T cells and the CD4+CD25+Foxp3+ Tregs in mice receiving SM16 diet exhibited diminished ability to suppress naive T cell proliferation in vitro compared to Treg from mice on control diet.	tregs	70-75	CD4 antigen	Mus musculus	54-57
31288845-12	2019	Importantly, both the CD4+CD25-Foxp3+ T cells and the CD4+CD25+Foxp3+ Tregs in mice receiving SM16 diet exhibited diminished ability to suppress naive T cell proliferation in vitro compared to Treg from mice on control diet.	treg	70-74	CD4 antigen	Mus musculus	54-57
31379467-3	2019	CD4+ T cells play a pivotal role in the pathogenesis of CS-induced pulmonary disease, which has no proven curative therapy.	Cesium	56-58	CD4 antigen	Mus musculus	0-3
31270272-4	2019	As a consequence, dasatinib induces a function-off state in CD8+ and CD4+ CAR T cells that is of immediate onset and can be sustained for several days without affecting T cell viability.	Dasatinib	18-27	CD4 antigen	Mus musculus	69-72
31100343-0	2019	Amygdalin (Vitamin B17) pretreatment attenuates experimentally induced acute autoimmune hepatitis through reduction of CD4+ cell infiltration.	Amygdalin	11-22	CD4 antigen	Mus musculus	119-122
31088836-4	2019	We tested this hypothesis in an immunocompetent mouse model for ovarian cancer and found that in vivo, 5AZA-C and DFMO, either alone or in combination, significantly increased survival, decreased tumor burden, and caused recruitment of activated (IFNgamma+) CD4+ T cells, CD8+ T cells, and NK cells.	Azacitidine	103-109	CD4 antigen	Mus musculus	258-261
31088836-4	2019	We tested this hypothesis in an immunocompetent mouse model for ovarian cancer and found that in vivo, 5AZA-C and DFMO, either alone or in combination, significantly increased survival, decreased tumor burden, and caused recruitment of activated (IFNgamma+) CD4+ T cells, CD8+ T cells, and NK cells.	Eflornithine	114-118	CD4 antigen	Mus musculus	258-261
31346878-2	2019	Intraperitoneal injections of cyclophosphamide in a dose of 100 mg/kg on days 1, 3, 5, and 7 of the experiment reduced leukocyte count and the relative number of CD4+ T cells in the blood, and also depleted the cellular composition of splenic white pulp on day 10.	Cyclophosphamide	30-46	CD4 antigen	Mus musculus	162-165
31346878-4	2019	Moreover, administration of polyramyl induced marked tendency to increase in the relative number of CD4+ T cells and CD4/CD8 ratio in mice with cyclophosphamideinduced immunosuppression.	polyramyl	28-37	CD4 antigen	Mus musculus	100-103
31346878-4	2019	Moreover, administration of polyramyl induced marked tendency to increase in the relative number of CD4+ T cells and CD4/CD8 ratio in mice with cyclophosphamideinduced immunosuppression.	polyramyl	28-37	CD4 antigen	Mus musculus	117-120
31030096-7	2019	The abundance of splenic CD4 + CD25 + FOXP3 + Treg cells and the transcription factor FOXP3 were significantly increased under tangeretin treatment, either in AR mice or in naive CD4 + T-cell differentiation, followed by a concomitant reduction in Notch1/Jagged1 expression.	tangeretin	127-137	CD4 antigen	Mus musculus	25-28
31030096-7	2019	The abundance of splenic CD4 + CD25 + FOXP3 + Treg cells and the transcription factor FOXP3 were significantly increased under tangeretin treatment, either in AR mice or in naive CD4 + T-cell differentiation, followed by a concomitant reduction in Notch1/Jagged1 expression.	tangeretin	127-137	CD4 antigen	Mus musculus	179-182
31030098-7	2019	Flow cytometry was used to assess the effects of EGCG on the frequency of CD4+CD25+Foxp3+Treg cells in the splenocytes and real-time PCR method was used to measure the expression of Forkhead box P3 (Foxp3) mRNA and retinoid-related orphan receptor gammat (RORgammat) mRNA in the lung tissue.	epigallocatechin gallate	49-53	CD4 antigen	Mus musculus	74-77
31030098-8	2019	The results showed that administration of EGCG significantly decreased AHR and OVA specific IgE in the serum, increased IL-10 levels in the BALF, serum, and splenocyte culture supernatant, and the frequency of CD4+CD25+Foxp3+Treg cells in the splenocytes in asthmatic mice.	epigallocatechin gallate	42-46	CD4 antigen	Mus musculus	210-213
31030098-10	2019	These results suggested that EGCG likely ameliorated OVA-induced airway inflammation by increasing the production of IL-10, the number of CD4+CD25+Foxp3+Treg cells and expression of Foxp3 mRNA in the lung tissue, and it could be an effective agent for treating asthma.	epigallocatechin gallate	29-33	CD4 antigen	Mus musculus	138-141
31039339-6	2019	Insulin-specific CD4+ cell expansion peaked after 48 h of incubation and was in favour of Treg.	treg	90-94	CD4 antigen	Mus musculus	17-20
31177975-2	2019	ACC1 (acetyl coenzyme A carboxylase 1) is a key enzyme that has been recently found to propagate CD4+ T cell-associated inflammation by mediating de novo fatty acid synthesis; however, its role in the context of ischemic stroke remains unknown.	Fatty Acids	154-164	CD4 antigen	Mus musculus	97-100
30658013-8	2019	PGG administration decreased the content of TNF+ and IFN-gamma+ CD8 T-cells and IL-17A+ CD4+ and CD3+ CD4- CD8- cells.	beta-penta-O-galloyl-glucose	0-3	CD4 antigen	Mus musculus	88-91
30658013-8	2019	PGG administration decreased the content of TNF+ and IFN-gamma+ CD8 T-cells and IL-17A+ CD4+ and CD3+ CD4- CD8- cells.	beta-penta-O-galloyl-glucose	0-3	CD4 antigen	Mus musculus	102-105
29955175-6	2019	H6F treatment significantly reduced the T1D incidence, which was accompanied by diminished autoreactive CD8+ T cell responses to mInsB15-14, inhibited infiltration of CD8+ and CD4+ T cells in the pancreas and reduced pro-inflammatory cytokine production in pancreatic and splenic T cells in NOD.beta2mnull.HHD mice.	H6F	0-3	CD4 antigen	Mus musculus	176-179
30879681-0	2019	Inhibition of tumor growth by beta-glucans through promoting CD4+ T cell immunomodulation and neutrophil-killing in mice.	beta-Glucans	30-42	CD4 antigen	Mus musculus	61-64
30879681-4	2019	It was found that beta-glucans up-regulated CD4+ T cell level in lymphoid organs decreased by tumor-burden, indicating promotion of immunomodulation.	beta-Glucans	18-30	CD4 antigen	Mus musculus	44-47
30879681-6	2019	Furthermore, beta-glucans not only targeted to lymphoid organs and increased CD4+ T cells number, but also enhanced CD4+ T cells and neutrophils populations in tumors.	beta-Glucans	13-25	CD4 antigen	Mus musculus	77-80
30879681-6	2019	Furthermore, beta-glucans not only targeted to lymphoid organs and increased CD4+ T cells number, but also enhanced CD4+ T cells and neutrophils populations in tumors.	beta-Glucans	13-25	CD4 antigen	Mus musculus	116-119
30879681-7	2019	It was proposed that beta-glucans promoted CD4+ T cell immunomodulation and neutrophils infiltration into tumors, leading to tumor growth inhibition.	beta-Glucans	21-33	CD4 antigen	Mus musculus	43-46
30904759-11	2019	Pregnancy also enhanced the production of CD4+CD25 + T cells in response to DEP and silica exposure.	Silicon Dioxide	84-90	CD4 antigen	Mus musculus	42-45
30779332-8	2019	Fasudil-modified MNCs decreased CD4+ IFN-gamma+ and CD4+ IL-17+ T cells, increased CD4+ IL-10+ T cells, restrained M1 markers CD16/32, CCR7, IL-12, CD8a, enhanced M2 markers CD206, CD200, CD14 in spleen.	fasudil	0-7	CD4 antigen	Mus musculus	32-35
30779332-8	2019	Fasudil-modified MNCs decreased CD4+ IFN-gamma+ and CD4+ IL-17+ T cells, increased CD4+ IL-10+ T cells, restrained M1 markers CD16/32, CCR7, IL-12, CD8a, enhanced M2 markers CD206, CD200, CD14 in spleen.	fasudil	0-7	CD4 antigen	Mus musculus	52-55
30779332-8	2019	Fasudil-modified MNCs decreased CD4+ IFN-gamma+ and CD4+ IL-17+ T cells, increased CD4+ IL-10+ T cells, restrained M1 markers CD16/32, CCR7, IL-12, CD8a, enhanced M2 markers CD206, CD200, CD14 in spleen.	fasudil	0-7	CD4 antigen	Mus musculus	52-55
31136978-4	2019	CD4+ CD25+ LAP+ cells were highly expressed as part of activated Tregs, which limited CIK cell-mediated cytotoxicity and reduced the expression of the NKG2D receptor.	tregs	65-70	CD4 antigen	Mus musculus	0-3
30715796-13	2019	CONCLUSION: Survivin facilitates the development of biased Th2 polarization through promoting expression of interleukin 4 (IL-4) and impairing the AICD machinery of CD4+ T cells.	th2	59-62	CD4 antigen	Mus musculus	165-168
30889423-5	2019	Flow cytometry analysis revealed that arsenic disturbed CD4/CD8 T-cell ratio in isolated pneumonocytes and splenocytes, as well as enhanced IFN-gamma and reduced IL-4 in spleen.	Arsenic	38-45	CD4 antigen	Mus musculus	56-59
30927738-5	2019	DAZ significantly altered the relative organ weights in female B6C3F1 mice and decreased the B cell population (represented by CD3-IgM+), while the T cell populations (represented by CD3+IgM-, CD4+CD8- and CD4-CD8+) were increased.	daidzein	0-3	CD4 antigen	Mus musculus	193-196
30927738-5	2019	DAZ significantly altered the relative organ weights in female B6C3F1 mice and decreased the B cell population (represented by CD3-IgM+), while the T cell populations (represented by CD3+IgM-, CD4+CD8- and CD4-CD8+) were increased.	daidzein	0-3	CD4 antigen	Mus musculus	206-209
30654047-12	2019	CONCLUSION: Early-life undernutrition induced mechanistic target of rapamycin 1-dependent glycolysis upregulation and TH2 cytokine locus hypomethylation in CD4+ T cells, resulting in increased T-cell activation, proliferation, and TH2 skewing and further susceptibility to experimental asthma.	Sirolimus	68-77	CD4 antigen	Mus musculus	156-159
31059096-0	2019	Salmonella infection leads to severe intestinal inflammation and increased CD4+FoxP3+ Treg cells in streptozotocin-induced hyperglycemic mice.	Streptozocin	100-114	CD4 antigen	Mus musculus	75-78
31059096-7	2019	In the present study, we used streptozotocin-induced hyperglycemic mice to model T1DM and induced a Salmonella infection in the mouse model, leading to aggravated inflammation, which resulted in an elevated proportion of CD103+CD11b+ DCs and a significantly elevated proportion of CD4+FoxP3+ Tregs in the intestinal lamina propria.	Streptozocin	30-44	CD4 antigen	Mus musculus	281-284
31214160-2	2019	Here, we investigated the specific function alpha7 nAChRs on T cells and antigen presenting cells (APCs) by testing the effect of GTS-21, a selective alpha7 nAChR agonist, on differentiation of CD4+ T cells from ovalbumin (OVA)-specific TCR transgenic DO11.10 mice activated with OVA or OVA peptide323-339 (OVAp).	3-(2,4-dimethoxybenzylidene)anabaseine	130-136	CD4 antigen	Mus musculus	194-197
31214160-3	2019	GTS-21 suppressed OVA-induced antigen processing-dependent development of CD4+ regulatory T cells (Tregs) and effector T cells (Th1, Th2, and Th17).	3-(2,4-dimethoxybenzylidene)anabaseine	0-6	CD4 antigen	Mus musculus	74-77
31190768-0	2019	Long-term icariin treatment ameliorates cognitive deficits via CD4+ T cell-mediated immuno-inflammatory responses in APP/PS1 mice.	icariin	10-17	CD4 antigen	Mus musculus	63-66
30834454-0	2019	Inhibiting Sphingosine Kinase 2 Derived-sphingosine-1-phosphate Ameliorates Psoriasis-like Skin Disease via Blocking Th17 Differentiation of Naive CD4 T Lymphocytes in Mice.	sphingosine 1-phosphate	40-63	CD4 antigen	Mus musculus	147-150
30834454-6	2019	Inhibition of sphingosine kinase 2, but not sphingosine kinase 1, diminished levels of suppressor of cytokine signalling 1 and blocked T helper type 17 differentiation of naive CD4+ T cells; imiquimod-induced psoriasis-like skin symptoms were also ameliorated.	Imiquimod	191-200	CD4 antigen	Mus musculus	177-180
30548563-5	2019	Finally, in a murine model of cardiac allograft vasculopathy, depletion of donor CD4 nT-regs before organ recovery resulted in markedly accelerated heart allograft rejection and augmented host effector antibody responses.	nt-regs	85-92	CD4 antigen	Mus musculus	81-84
30615197-4	2019	Here we show that three novel small molecule IL-6 inhibitors, madindoline-5 (MDL-5), MDL-16 and MDL-101, significantly suppress IL-17 production in myelin-specific CD4 T cells in a dose-dependent manner in vitro.	madindoline A	62-73	CD4 antigen	Mus musculus	164-167
30615197-6	2019	Treatment of myelin-specific CD4 T cells with MDL-101 in vitro reduced their encephalitogenic potential following their subsequent adoptive transfer.	mdl-101	46-53	CD4 antigen	Mus musculus	29-32
31118938-4	2019	We previously demonstrated that mice bearing dopamine receptor D3 (DRD3)-deficient CD4+ T-cells are completely refractory to neuroinflammation and consequent neurodegeneration induced by the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	209-253	CD4 antigen	Mus musculus	83-86
31118938-4	2019	We previously demonstrated that mice bearing dopamine receptor D3 (DRD3)-deficient CD4+ T-cells are completely refractory to neuroinflammation and consequent neurodegeneration induced by the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	255-259	CD4 antigen	Mus musculus	83-86
31118938-10	2019	The results obtained from in vivo experiments performed in mice show that the transference of CD4+ T-cells treated ex vivo with the DRD3-selective antagonist PG01037 into MPTPp-mice resulted in a significant reduction of motor impairment, although without significant effect in neurodegeneration.	N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-enyl)-4-pyridine-2-ylbenzamide	158-165	CD4 antigen	Mus musculus	94-97
31118938-10	2019	The results obtained from in vivo experiments performed in mice show that the transference of CD4+ T-cells treated ex vivo with the DRD3-selective antagonist PG01037 into MPTPp-mice resulted in a significant reduction of motor impairment, although without significant effect in neurodegeneration.	mptpp	171-176	CD4 antigen	Mus musculus	94-97
30659606-5	2019	The effects on the major subpopulations of thymocytes based on multicolour flow cytometry studies were, first, the CD4-  CD8- double-negative (DN) cells, mainly DN2-4, were reduced with infection, LPS and Eto treatment, but not with Dex.	Etoposide	205-208	CD4 antigen	Mus musculus	115-118
30659606-5	2019	The effects on the major subpopulations of thymocytes based on multicolour flow cytometry studies were, first, the CD4-  CD8- double-negative (DN) cells, mainly DN2-4, were reduced with infection, LPS and Eto treatment, but not with Dex.	Dexamethasone	233-236	CD4 antigen	Mus musculus	115-118
30659606-7	2019	Third, treatment with LPS, Eto and Dex reduced all three subpopulations of CD4+  CD8+ double-positive (DP) thymocytes, i.e. DP1, DP2 and DP3, but the DP3 subset was relatively more resistant during infection.	Etoposide	27-30	CD4 antigen	Mus musculus	75-78
30659606-7	2019	Third, treatment with LPS, Eto and Dex reduced all three subpopulations of CD4+  CD8+ double-positive (DP) thymocytes, i.e. DP1, DP2 and DP3, but the DP3 subset was relatively more resistant during infection.	Dexamethasone	35-38	CD4 antigen	Mus musculus	75-78
30659606-8	2019	Fourth, both CD4+ and CD8+ single-positive (SP) thymocytes were lowered by Eto and Dex, but not during infection.	Etoposide	75-78	CD4 antigen	Mus musculus	13-16
30659606-8	2019	Fourth, both CD4+ and CD8+ single-positive (SP) thymocytes were lowered by Eto and Dex, but not during infection.	Dexamethasone	83-86	CD4 antigen	Mus musculus	13-16
30884992-0	2019	ECTV Abolishes the Ability of GM-BM Cells to Stimulate Allogeneic CD4 T Cells in a Mouse Strain-Independent Manner.	gm-bm	30-35	CD4 antigen	Mus musculus	66-69
30988194-4	2019	Pharmacologic inhibition of mitochondrial reactive oxygen species (mtROS) abolishes the extrusion of DNA by CD4+ T cells, reducing cytokine production in vitro and T cell priming against myelin in vivo.	Reactive Oxygen Species	42-65	CD4 antigen	Mus musculus	108-111
31105845-8	2019	Treatment of NOD mice with metformin significantly mitigated autoimmune insulitis and substantially decreased the number of pro-inflammatory IFN-gamma+ as well as IL17+ CD4 T cells in the spleens of NOD mice.	Metformin	27-36	CD4 antigen	Mus musculus	169-172
31032234-5	2019	We found that the level of PS exposure on intracellular amastigotes was modulated by CD4+ T cell and MPhi activation status in vitro and in vivo.	Phosphatidylserines	27-29	CD4 antigen	Mus musculus	85-88
30710547-2	2019	To gain better understanding of mechanisms underlying this effect, the impact of rosiglitazone (RSG), a PPAR-gamma agonist, on CD4+ effector (Teff) and Foxp3-expressing regulatory (Treg) T cells in a mouse model of allergic asthma was studied.	Rosiglitazone	81-94	CD4 antigen	Mus musculus	127-130
30710547-2	2019	To gain better understanding of mechanisms underlying this effect, the impact of rosiglitazone (RSG), a PPAR-gamma agonist, on CD4+ effector (Teff) and Foxp3-expressing regulatory (Treg) T cells in a mouse model of allergic asthma was studied.	Rosiglitazone	96-99	CD4 antigen	Mus musculus	127-130
30745361-6	2019	Our results disclosed that intraperitoneal administration of alpha-GalCer before allergen sensitization could promote the expansion and suppressive activity of lung CD4+FoxP3+ Treg cells.	alpha-galactosylceramide	61-73	CD4 antigen	Mus musculus	165-168
30988670-0	2019	Shikonin Prolongs Allograft Survival via Induction of CD4+FoxP3+ Regulatory T Cells.	shikonin	0-8	CD4 antigen	Mus musculus	54-57
30988670-9	2019	Shikonin increased the frequencies of CD4+Foxp3+ regulatory T cells (Tregs) post-transplantation and induced CD4+Foxp3+ Tregs in vitro as well.	shikonin	0-8	CD4 antigen	Mus musculus	38-41
30988670-9	2019	Shikonin increased the frequencies of CD4+Foxp3+ regulatory T cells (Tregs) post-transplantation and induced CD4+Foxp3+ Tregs in vitro as well.	shikonin	0-8	CD4 antigen	Mus musculus	109-112
30988670-15	2019	Taken together, shikonin inhibits allograft rejection via upregulating CD4+Foxp3+ Tregs.	shikonin	16-24	CD4 antigen	Mus musculus	71-74
31056969-7	2019	Exposure to four doses of DAPB increased the absolute count of immature CD4+CD8+ thymic cells as well as the percentage and absolute count of mature CD4+ and CD8+ thymocytes.	dapb	26-30	CD4 antigen	Mus musculus	72-75
31056969-7	2019	Exposure to four doses of DAPB increased the absolute count of immature CD4+CD8+ thymic cells as well as the percentage and absolute count of mature CD4+ and CD8+ thymocytes.	dapb	26-30	CD4 antigen	Mus musculus	149-152
30760618-3	2019	CD25+ FOXP3+ CD4+ T cells are increased locally within the colon of BT-11-treated mice in Citrobacter rodentium and IL-10-/- mouse models of colitis.	BT-11	68-73	CD4 antigen	Mus musculus	13-16
30760618-8	2019	Cotreatment with BT-11 and IL-2 greatly enhances the differentiation of CD25+ FOXP3+ cells from naive CD4+ T cells relative to either alone.	BT-11	17-22	CD4 antigen	Mus musculus	102-105
30826574-9	2019	RESULTS: Our data showed that fisetin and telmisartan each alone or in low-dose combination attenuated the anaphylactic manifestation, decreased blood eosinophilic count, serum OVA-specific IgE, and IL-4 levels, the intestinal total and degranulated mast cells count, and CD4+ immunohistochemical expression.	Telmisartan	42-53	CD4 antigen	Mus musculus	272-275
30984194-5	2019	The outcome of TCDD or 3-HK plus ITE treatments indicated that strong or weak AhR activation before or during T. cruzi infection was effective to regulate inflammation improving the Treg cell response and regularizing the ratio between CD4+ CD25- to Treg cells.	3-hk	23-27	CD4 antigen	Mus musculus	236-239
30984194-5	2019	The outcome of TCDD or 3-HK plus ITE treatments indicated that strong or weak AhR activation before or during T. cruzi infection was effective to regulate inflammation improving the Treg cell response and regularizing the ratio between CD4+ CD25- to Treg cells.	ite	33-36	CD4 antigen	Mus musculus	236-239
30862736-4	2019	Mice with ATF3 deficiency in CD4+ T cells (CD4 cre Atf3 fl/fl ) were much more susceptible to dextran sulfate sodium-induced colitis.	Dextran Sulfate	94-116	CD4 antigen	Mus musculus	29-32
30862736-4	2019	Mice with ATF3 deficiency in CD4+ T cells (CD4 cre Atf3 fl/fl ) were much more susceptible to dextran sulfate sodium-induced colitis.	Dextran Sulfate	94-116	CD4 antigen	Mus musculus	43-46
30509504-7	2019	Apart from this, enhanced number of immune cells i.e. CD19+ and CD4+ were also noticed in the ADF treated group.	ADF	94-97	CD4 antigen	Mus musculus	64-67
30612787-8	2019	Splenic CD4+ T cell expansion under same conditions resulted in a higher (44-45%) iTreg cell ratio that further increased (up to 50% Treg) in the presence of DX.	treg	83-87	CD4 antigen	Mus musculus	8-11
30620923-5	2019	Treatment with WPI-EGCG, in turn, decreased the levels of IgG2a and mMCP-1 in serum of mice, possibly by the modulation of Th1/Th2 response and the increase of CD4+ Foxp3+ LAP- T and IL-17A+CD4+ T (Th17) cell populations.	epigallocatechin gallate	19-23	CD4 antigen	Mus musculus	160-163
30620923-5	2019	Treatment with WPI-EGCG, in turn, decreased the levels of IgG2a and mMCP-1 in serum of mice, possibly by the modulation of Th1/Th2 response and the increase of CD4+ Foxp3+ LAP- T and IL-17A+CD4+ T (Th17) cell populations.	epigallocatechin gallate	19-23	CD4 antigen	Mus musculus	190-193
30096391-6	2019	RESULTS: We found that Blimp-1 regulates TH9 differentiation because deleting Blimp-1 increased IL-9 production in CD4+ T cells in vitro.	TH9	41-44	CD4 antigen	Mus musculus	115-118
30609280-8	2019	Thus, our results identified a potentially novel mechanism of the therapeutic action of indirubin in the treatment of ITP through regulating the homeostasis of CD4+ T cells in a PD1/PTEN/AKT signalling pathway.	indirubin	88-97	CD4 antigen	Mus musculus	160-163
30496840-10	2019	Moreover, YHQ treatment significantly increased the percentage of CD4+CD25+Foxp3+ Treg in OVA-induced allergic asthma mouse model.	yhq	10-13	CD4 antigen	Mus musculus	66-69
30496840-11	2019	CONCLUSIONS: YHQ improves the allergic asthma related symptoms via promotion of CD4+CD25+Foxp3+ Treg and suppression of Th2 responses in mouse model, suggesting YHQ can be used as a potent agent to alleviate allergic asthma related symptoms.	yhq	13-16	CD4 antigen	Mus musculus	80-83
30496840-11	2019	CONCLUSIONS: YHQ improves the allergic asthma related symptoms via promotion of CD4+CD25+Foxp3+ Treg and suppression of Th2 responses in mouse model, suggesting YHQ can be used as a potent agent to alleviate allergic asthma related symptoms.	yhq	161-164	CD4 antigen	Mus musculus	80-83
30277587-4	2019	In addition, the corresponding metabolites (short-chain fatty acids) of MF on CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) were also detected in vivo and in vitro.	Fatty Acids	56-67	CD4 antigen	Mus musculus	78-81
30277587-7	2019	Moreover, MF treatment increased the differentiation of CD4+ CD25+ Foxp3+ Tregs mainly by microbial metabolites butyrate.	Butyrates	112-120	CD4 antigen	Mus musculus	56-59
30738184-4	2019	Application of recombinant IL-16 impairs both glutamate-induced increases in intracellular Ca2+ and sEPSC frequency and amplitude in a CD4- and CD9-independent manner.	Glutamic Acid	46-55	CD4 antigen	Mus musculus	135-138
30307561-0	2019	Inhibiting Adenosine Receptor Signaling Promotes Accumulation of Effector CD4+ T Cells in the Lung Parenchyma During Severe Tuberculosis.	Adenosine	11-20	CD4 antigen	Mus musculus	74-77
30307561-6	2019	Intranasal administration of the adenosine receptor antagonist caffeine substantially enhanced the frequency and number of parenchymal CD4+ T cells as well as both CD69 expression and IFNgamma production.	Adenosine	33-42	CD4 antigen	Mus musculus	135-138
30307561-6	2019	Intranasal administration of the adenosine receptor antagonist caffeine substantially enhanced the frequency and number of parenchymal CD4+ T cells as well as both CD69 expression and IFNgamma production.	Caffeine	63-71	CD4 antigen	Mus musculus	135-138
30307561-7	2019	CONCLUSIONS: These results indicate that adenosine, which may be generated by extracellular adenosine triphosphate degradation, impairs the parenchymal CD4+ T-cell response and contributes to the development of severe tuberculosis.	Adenosine	41-50	CD4 antigen	Mus musculus	152-155
30307561-7	2019	CONCLUSIONS: These results indicate that adenosine, which may be generated by extracellular adenosine triphosphate degradation, impairs the parenchymal CD4+ T-cell response and contributes to the development of severe tuberculosis.	Adenosine	92-101	CD4 antigen	Mus musculus	152-155
30853959-3	2019	Furthermore, tumor antigen specific CD4+ T effector cells can essentially sustain anti-tumoral immune responses as shown for various tumor entities, thus suggesting that cognate interaction between tumor antigen-specific CD4+ Th1 cells and TAMs might shift the intra-tumoral M1/M2 ratio toward M1.	tams	240-244	CD4 antigen	Mus musculus	36-39
30853959-3	2019	Furthermore, tumor antigen specific CD4+ T effector cells can essentially sustain anti-tumoral immune responses as shown for various tumor entities, thus suggesting that cognate interaction between tumor antigen-specific CD4+ Th1 cells and TAMs might shift the intra-tumoral M1/M2 ratio toward M1.	tams	240-244	CD4 antigen	Mus musculus	221-224
31069134-6	2019	The modification of arginine to citrulline enhanced binding of the peptides to HLA-DP4 and induced high-frequency CD4 responses in HLA-DP4 transgenic mouse models.	Arginine	20-28	CD4 antigen	Mus musculus	114-117
31069134-6	2019	The modification of arginine to citrulline enhanced binding of the peptides to HLA-DP4 and induced high-frequency CD4 responses in HLA-DP4 transgenic mouse models.	Citrulline	32-42	CD4 antigen	Mus musculus	114-117
30906773-8	2019	Results: Oxaliplatin treatment reduced spleen size and cellularity (CD45+ cells), increased the proportion of CD4+, CD8+, and Treg cells, and elevated TNF-alpha expression.	Oxaliplatin	9-20	CD4 antigen	Mus musculus	68-71
30755715-4	2019	Our results indicate that niraparib treatment increases the activity of the type I (alpha) and type II (gamma) interferon pathways and enhances the infiltration of CD8+ cells and CD4+ cells in tumors.	niraparib	26-35	CD4 antigen	Mus musculus	179-182
30604567-6	2019	CD4+ regulatory T (Treg ) cells were refractory toward progesterone-induced cell death, in contrast to conventional CD4+ T cells, which resulted in a preferential enrichment of CD4+ Treg cells in culture.	Progesterone	55-67	CD4 antigen	Mus musculus	0-3
30503823-8	2019	These results collectively suggest that in vitro thymus-derived Treg cell expansion by alpha-GalCer treatment was caused by the proliferation of CD4+CD25+Foxp3- preTregs but not existing Treg cells.	alpha-galactosylceramide	87-99	CD4 antigen	Mus musculus	145-148
30335680-5	2019	The relevant T-cell subpopulation seems to be CD4 T cells because adoptive transfer of them but not CD8 cells into nude mice rescues both the pain and morphine analgesia phenotypes.	Morphine	151-159	CD4 antigen	Mus musculus	46-49
30700576-5	2019	The UBM scaffold created an immune microenvironment that inhibited B16-F10 melanoma tumor formation in a CD4+ T cell-dependent and macrophage-dependent manner.	UBM	4-7	CD4 antigen	Mus musculus	105-108
30682058-9	2019	recMASH2+AS15 induced MASH2-specific antibody and CD4+ responses in both mouse models.	recmash2	0-8	CD4 antigen	Mus musculus	50-53
30682058-9	2019	recMASH2+AS15 induced MASH2-specific antibody and CD4+ responses in both mouse models.	as15	9-13	CD4 antigen	Mus musculus	50-53
30733722-13	2018	Early post-transplant, improvement in the splenic and LN CD4/CD8 ratio along with fewer effector cells and high Treg levels in aHSCT recipients treated with expanded Tregs + EP11313 was detected.	tregs	166-171	CD4 antigen	Mus musculus	57-60
30733722-13	2018	Early post-transplant, improvement in the splenic and LN CD4/CD8 ratio along with fewer effector cells and high Treg levels in aHSCT recipients treated with expanded Tregs + EP11313 was detected.	ep11313	174-181	CD4 antigen	Mus musculus	57-60
30886812-0	2019	Robust Photodynamic Therapy Using 5-ALA-Incorporated Nanocomplexes Cures Metastatic Melanoma through Priming of CD4+CD8+ Double Positive T Cells.	5-amino levulinic acid	34-39	CD4 antigen	Mus musculus	112-115
30704231-6	2019	In addition, CD4(+) T cells from the spleens of mice were cultured in vitro, then stimulated with artesunate, the frequency of Th17 and Tregs in these splenocytes were evaluated by flow cytometry.	Artesunate	98-108	CD4 antigen	Mus musculus	13-16
30629626-7	2019	RESULTS: Our CS-induced COPD model exhibited an increased proinflammatory immune response (increased expression of the NF-kappaB, TNF-alpha, CD4, CD8, CD20, IL-17, and IL-6 markers) with a concomitantly decreased anti-inflammatory immune response (FOXP3, IL-10, and TGF-beta markers) compared with the control mice.	Cesium	13-15	CD4 antigen	Mus musculus	141-144
31468416-10	2019	Taurine also significantly increased the number of CD4- CD8- double negative (DN), CD4+ CD8+ double positive (DP), CD4+ single positive (CD4+) and CD8+ SP (CD8+) cells compared with the Dex + PBS group, but did not affect the CD4+/CD8+ cell ratio in thymus of Dex-induced immunoseppressive mice.	Taurine	0-7	CD4 antigen	Mus musculus	51-54
31468416-10	2019	Taurine also significantly increased the number of CD4- CD8- double negative (DN), CD4+ CD8+ double positive (DP), CD4+ single positive (CD4+) and CD8+ SP (CD8+) cells compared with the Dex + PBS group, but did not affect the CD4+/CD8+ cell ratio in thymus of Dex-induced immunoseppressive mice.	Taurine	0-7	CD4 antigen	Mus musculus	83-86
31468416-10	2019	Taurine also significantly increased the number of CD4- CD8- double negative (DN), CD4+ CD8+ double positive (DP), CD4+ single positive (CD4+) and CD8+ SP (CD8+) cells compared with the Dex + PBS group, but did not affect the CD4+/CD8+ cell ratio in thymus of Dex-induced immunoseppressive mice.	Taurine	0-7	CD4 antigen	Mus musculus	83-86
31468416-10	2019	Taurine also significantly increased the number of CD4- CD8- double negative (DN), CD4+ CD8+ double positive (DP), CD4+ single positive (CD4+) and CD8+ SP (CD8+) cells compared with the Dex + PBS group, but did not affect the CD4+/CD8+ cell ratio in thymus of Dex-induced immunoseppressive mice.	Taurine	0-7	CD4 antigen	Mus musculus	83-86
31468416-10	2019	Taurine also significantly increased the number of CD4- CD8- double negative (DN), CD4+ CD8+ double positive (DP), CD4+ single positive (CD4+) and CD8+ SP (CD8+) cells compared with the Dex + PBS group, but did not affect the CD4+/CD8+ cell ratio in thymus of Dex-induced immunoseppressive mice.	Taurine	0-7	CD4 antigen	Mus musculus	83-86
29969188-2	2019	In this study, we show that DEPTOR is expressed within CD4+ T cells, and we observed that its relative level of expression modulates differentiation as well as glucose utilization within CD4+ T effectors in vitro.	Glucose	160-167	CD4 antigen	Mus musculus	187-190
31401214-5	2019	Six hours after NH4-Ac injection, intracellular cytokine production was determined in splenic macrophages, CD4+ and CD8+ T cells.	nh4-ac	16-22	CD4 antigen	Mus musculus	107-110
31530979-8	2019	Furthermore, the results seem to imply that ASA and KET have certain potential to induce Foxp3 expression in CD25+CD8+ and CD25+CD4+ T cells, respectively.	Aspirin	44-47	CD4 antigen	Mus musculus	128-131
31530979-8	2019	Furthermore, the results seem to imply that ASA and KET have certain potential to induce Foxp3 expression in CD25+CD8+ and CD25+CD4+ T cells, respectively.	Ketoprofen	52-55	CD4 antigen	Mus musculus	128-131
30353641-5	2019	Here, we use a mouse model to demonstrate that intranasal immunization with Rv3615c induces sustained capability of adaptive CD4+ T- and B-cell responses in lung parenchyma and airway.	rv3615c	76-83	CD4 antigen	Mus musculus	125-128
30353641-6	2019	Rv3615c contains a dominant epitope of mouse CD4+ T cells, Rv3615c41-50 , and elicits CD4+ T-cell response with an effector-memory phenotype and multi-Th1-type cytokine coexpressions.	rv3615c	0-7	CD4 antigen	Mus musculus	45-48
30353641-6	2019	Rv3615c contains a dominant epitope of mouse CD4+ T cells, Rv3615c41-50 , and elicits CD4+ T-cell response with an effector-memory phenotype and multi-Th1-type cytokine coexpressions.	rv3615c	0-7	CD4 antigen	Mus musculus	86-89
31061279-0	2019	Effect of Cholecalciferol in Food Allergy Mouse Model Is Associated with Decrease of CD69+ CD4+ T Cells.	Cholecalciferol	10-25	CD4 antigen	Mus musculus	91-94
31061279-6	2019	Treatment of cholecalciferol reduced the allergic diarrhea (p&lt;0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol.	Cholecalciferol	13-28	CD4 antigen	Mus musculus	109-112
31061279-6	2019	Treatment of cholecalciferol reduced the allergic diarrhea (p&lt;0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol.	Cholecalciferol	210-225	CD4 antigen	Mus musculus	109-112
31061279-6	2019	Treatment of cholecalciferol reduced the allergic diarrhea (p&lt;0.05) with the decreasing tendency of CD69+ CD4+ T cells, suggesting that the cell population might be associated with the attenuating effect of cholecalciferol on diarrhea occurrence, although immunoglobulin E levels and cytokine productions were not significantly altered by the treatment of cholecalciferol.	Cholecalciferol	210-225	CD4 antigen	Mus musculus	109-112
31061279-8	2019	Taken together, we suggest that administration of cholecalciferol might be useful to suppress symptomatic food allergy in association with the decrease of CD69+ CD4+ T cells.	Cholecalciferol	50-65	CD4 antigen	Mus musculus	161-164
30281410-6	2019	RIPostC significantly inhibited the reduction in the percentage of CD4 T cells in the spleen and lymph node, CD8 T cells in the blood and lymph node, and natural killer T (NKT) cells in the spleen by flow cytometry analysis.	ripostc	0-7	CD4 antigen	Mus musculus	67-70
30703773-7	2019	RESULTS: We show that CD4+ T cells may influence EE-induced hippocampus plasticity via thyroid hormone signaling by regulating in the choroid plexus the expression of transthyretin, the major transporter of thyroxine (T4) to the brain parenchyma.	Thyroxine	207-216	CD4 antigen	Mus musculus	22-25
31412342-7	2019	RESULTS: OUA significantly reduced the number of CD4+ T lymphocytes in the spleen, especially regulatory T cells (Tregs).	Ouabain	9-12	CD4 antigen	Mus musculus	49-52
30096001-3	2019	CD4+ T cells isolated from DS-exposed mice were transferred to athymic recipient mice.	ds	27-29	CD4 antigen	Mus musculus	0-3
30096001-7	2019	CD4+ T cells increased in recipients of DS-exposed mice (p < 0.05) and were lower in recipients of QCT- and RES-treated mice (p < 0.05).	ds	40-42	CD4 antigen	Mus musculus	0-3
30385269-0	2019	Astragaloside IV regulates differentiation and induces apoptosis of activated CD4+ T cells in the pathogenesis of experimental autoimmune encephalomyelitis.	astragaloside A	0-16	CD4 antigen	Mus musculus	78-81
30564247-5	2018	Experiments using mouse naive CD4+ T cells showed that engagement of the TCR or CD28 with the respective cognate ligand was able to trigger a rise in fluctuating calcium mobilization levels, as shown by the frequency and average response magnitude of the reacting cells compared with basal levels occurred in unstimulated cells.	Calcium	162-169	CD4 antigen	Mus musculus	30-33
30404733-6	2018	Moreover, ARNAX + HA simultaneously induced CD8 and CD4 T cell activation.	arnax	10-15	CD4 antigen	Mus musculus	52-55
29470999-4	2018	METHODS: Isolated dendritic cells and bone marrow-derived mast cells (MCs) were used to characterize the mechanisms of action of NAD+ on CD4+ T-cell fate in vitro.	NAD	129-133	CD4 antigen	Mus musculus	137-140
29470999-5	2018	Furthermore, NAD+-mediated CD4+ T-cell differentiation was investigated in vivo by using wild-type C57BL/6, MC-/-, MHC class II-/-, Wiskott-Aldrich syndrome protein (WASP)-/-, 5C.C7 recombination-activating gene 2 (Rag2)-/-, and CD11b-DTR transgenic mice.	NAD	13-17	CD4 antigen	Mus musculus	27-30
29973080-9	2018	Moreover, HPTE-induced cell death not only resulted in selective loss of double positive thymocytes, but also loss of developing CD4 intermediate cells (post-double positive partially differentiated thymocyte population).	2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane	10-14	CD4 antigen	Mus musculus	129-132
30373851-0	2018	Increased Mitochondrial Biogenesis and Reactive Oxygen Species Production Accompany Prolonged CD4+ T Cell Activation.	Reactive Oxygen Species	39-62	CD4 antigen	Mus musculus	94-97
30373851-4	2018	We show that for 4 d following activation, mouse CD4+ T cells sustained their commitment to glycolysis facilitated by increased glucose uptake through increased expression of GLUT transporters.	Glucose	128-135	CD4 antigen	Mus musculus	49-52
30605291-0	2018	Effect of tigecycline on the production of selected cytokines and counts of murine CD4+ and CD8+ T cells - an in vitro study.	Tigecycline	10-21	CD4 antigen	Mus musculus	83-86
30605291-1	2018	Due to the unrecognized effect of tigecycline (TIG) on CD4+ and CD8+ T cells, the present study has been undertaken in order to determine whether the drug can affect these cells in respect of their counts, and the production of IFN-gamma, IL-17 (pro-inflammatory and immune-protective cytokines), IL-4 (anti-inflammatory and immune-protective cytokine), IL-10 and TGF-beta (anti-inflammatory and immune-suppressive cytokines).	Tigecycline	34-45	CD4 antigen	Mus musculus	55-58
30605291-1	2018	Due to the unrecognized effect of tigecycline (TIG) on CD4+ and CD8+ T cells, the present study has been undertaken in order to determine whether the drug can affect these cells in respect of their counts, and the production of IFN-gamma, IL-17 (pro-inflammatory and immune-protective cytokines), IL-4 (anti-inflammatory and immune-protective cytokine), IL-10 and TGF-beta (anti-inflammatory and immune-suppressive cytokines).	Tigecycline	47-50	CD4 antigen	Mus musculus	55-58
30322872-4	2018	Frequencies of CD4+ cells were significantly affected by ritonavir (CD69+ P=3E-05; CD134 P=4E-06; CD25+ P=E-07; central memory P=0.02; effector P=6E-03; effector memory P=6E-05).	Ritonavir	57-66	CD4 antigen	Mus musculus	15-18
30410049-7	2018	Working with both monophasic and relapsing-remitting mouse models of EAE, we show that oral administration of homotaurine can (1) enhance CD8+CD122+PD-1+ and CD4+Foxp3+ Treg, but not Breg, responses, (2) inhibit autoreactive Th17 and Th1 responses, and (3) effectively ameliorate ongoing disease.	tramiprosate	110-121	CD4 antigen	Mus musculus	158-161
30405245-6	2018	In vivo blockade of BH4 synthesis abrogates T-cell-mediated autoimmunity and allergic inflammation, and enhancing BH4 levels through GCH1 overexpression augments responses by CD4- and CD8-expressing T cells, increasing their antitumour activity in vivo.	sapropterin	114-117	CD4 antigen	Mus musculus	175-178
30369842-0	2018	Determination of No-Observed-Adverse-Effect Level Ammonia in White Mice Through CD4 Expression.	Ammonia	50-57	CD4 antigen	Mus musculus	80-83
30127087-0	2018	The PGI2 Analog Cicaprost Inhibits IL-33-Induced Th2 Responses, IL-2 Production, and CD25 Expression in Mouse CD4+ T Cells.	Epoprostenol	4-8	CD4 antigen	Mus musculus	110-113
30127087-0	2018	The PGI2 Analog Cicaprost Inhibits IL-33-Induced Th2 Responses, IL-2 Production, and CD25 Expression in Mouse CD4+ T Cells.	cicaprost	16-25	CD4 antigen	Mus musculus	110-113
30127087-4	2018	In this study, we investigated the effect of PGI2, a lipid mediator formed in the cyclooxygenase pathway of arachidonic acid metabolism, on naive CD4+ T cell activation, proliferation, and differentiation by IL-33.	Epoprostenol	45-49	CD4 antigen	Mus musculus	146-149
30127087-5	2018	Using wild-type and PGI2 receptor (IP) knockout mice, we found that the PGI2 analog cicaprost dose-dependently inhibited IL-33-driven IL-4, IL-5, and IL-13 production by CD4+ T cells in an IP-specific manner.	cicaprost	84-93	CD4 antigen	Mus musculus	170-173
30127087-6	2018	In addition, cicaprost inhibited IL-33-driven IL-2 production and CD25 expression by CD4+ T cells.	cicaprost	13-22	CD4 antigen	Mus musculus	85-88
30127087-8	2018	Because IL-33 is critical for Alternaria-induced type 2 responses, these data suggest that PGI2 not only inhibits IL-33-stimulated CD4+ Th2 cell responses in vitro but also suppresses IL-33-induced Th2 responses caused by protease-containing allergens in vivo.	Epoprostenol	91-95	CD4 antigen	Mus musculus	131-134
30224720-10	2018	Further confirmatory in vivo data showed that GOP-treated mice exhibited high concentrations of lymphocytes (CD3+, CD4+, CD8+) in the intestine, to rescue the irradiation-induced damage and restore baseline intestinal integrity.	Glucopine	46-49	CD4 antigen	Mus musculus	115-118
30258447-0	2018	Esculetin Ameliorates Psoriasis-Like Skin Disease in Mice by Inducing CD4+Foxp3+ Regulatory T Cells.	esculetin	0-9	CD4 antigen	Mus musculus	70-73
30258447-9	2018	Interestingly, depleting CD4+Foxp3+ Tregs largely reversed esculetin-mediated reduction in PASI scores, indicating that esculetin attenuates murine psoriasis mainly by inducing CD4+Foxp3+ Tregs.	esculetin	59-68	CD4 antigen	Mus musculus	25-28
30258447-9	2018	Interestingly, depleting CD4+Foxp3+ Tregs largely reversed esculetin-mediated reduction in PASI scores, indicating that esculetin attenuates murine psoriasis mainly by inducing CD4+Foxp3+ Tregs.	esculetin	59-68	CD4 antigen	Mus musculus	177-180
30258447-9	2018	Interestingly, depleting CD4+Foxp3+ Tregs largely reversed esculetin-mediated reduction in PASI scores, indicating that esculetin attenuates murine psoriasis mainly by inducing CD4+Foxp3+ Tregs.	esculetin	120-129	CD4 antigen	Mus musculus	25-28
30258447-9	2018	Interestingly, depleting CD4+Foxp3+ Tregs largely reversed esculetin-mediated reduction in PASI scores, indicating that esculetin attenuates murine psoriasis mainly by inducing CD4+Foxp3+ Tregs.	esculetin	120-129	CD4 antigen	Mus musculus	177-180
30233578-5	2018	Based on the therapeutic effects of the combination of metformin and 2-deoxyglucose (2DG) in lupus models that normalized the expansion of effector CD4+ T cells.	Metformin	55-64	CD4 antigen	Mus musculus	148-151
30233578-5	2018	Based on the therapeutic effects of the combination of metformin and 2-deoxyglucose (2DG) in lupus models that normalized the expansion of effector CD4+ T cells.	Deoxyglucose	69-83	CD4 antigen	Mus musculus	148-151
30233578-5	2018	Based on the therapeutic effects of the combination of metformin and 2-deoxyglucose (2DG) in lupus models that normalized the expansion of effector CD4+ T cells.	Deoxyglucose	85-88	CD4 antigen	Mus musculus	148-151
29890367-8	2018	Gal-7 enhanced the proliferation of activated CD4+ T cells in a dose- and beta-galactoside-dependent manner.	beta-galactoside	74-90	CD4 antigen	Mus musculus	46-49
30144701-0	2018	Physical exercise contributes to cisplatin-induced nephrotoxicity protection with decreased CD4+ T cells activation.	Cisplatin	33-42	CD4 antigen	Mus musculus	92-95
30166541-6	2018	Furthermore, alpinetin significantly promoted expression of miR-302 but not others, and restrained expression of DNMT-1 and methylation level of Foxp3 promoter region in CD4+ T cells and colons of colitis mice.	alpinetin	13-22	CD4 antigen	Mus musculus	170-173
30135300-2	2018	Here, we show that 5-azacytidine, a DNA methyltransferase inhibitor, targeted to either CD4 or CD8 T cells in mice with established disease using a nanolipogel delivery system dramatically ameliorates lupus-related pathology through distinct mechanisms.	Azacitidine	19-32	CD4 antigen	Mus musculus	88-91
30135300-3	2018	In vivo targeted delivery of 5-azacytidine into CD4 T cells favors the expansion and function of Foxp3+ Tregs, whereas targeted delivery to CD8 T cells enhances the cytotoxicity and restrains the expansion of pathogenic TCR-alphabeta+CD4-CD8- double-negative T cells.	Azacitidine	29-42	CD4 antigen	Mus musculus	48-51
30127782-11	2018	CD4 T cell subset analysis revealed that circulating regulatory and effector T cells counts were similarly decreased after FTY720 treatment.	Fingolimod Hydrochloride	123-129	CD4 antigen	Mus musculus	0-3
31458997-7	2018	The expression levels of CD8 and CD4 proteins in the tumor lysates of differently treated mice groups (by Western blotting) are consistent with the observed OS enhancement being a T-cell-driven process.	Osmium	157-159	CD4 antigen	Mus musculus	33-36
29923026-6	2018	Furthermore, we demonstrate that A2aR blockade with CPI-444 decreases expression of multiple checkpoint pathways, including PD-1 and LAG-3, on both CD8+ effector T cells (Teff) and FoxP3+ CD4+ regulatory T cells (Tregs).	ciforadenant	52-59	CD4 antigen	Mus musculus	188-191
30003817-5	2018	OBJECTIVE: Our objective was to induce Foxp3 + CD4+ T cells from naive CD4 + T cells isolated from C57 mice spleen in vitro using stimuli that include the short chain fatty acid sodium butyrate.	Fatty Acids, Volatile	155-177	CD4 antigen	Mus musculus	47-50
30003817-5	2018	OBJECTIVE: Our objective was to induce Foxp3 + CD4+ T cells from naive CD4 + T cells isolated from C57 mice spleen in vitro using stimuli that include the short chain fatty acid sodium butyrate.	Fatty Acids, Volatile	155-177	CD4 antigen	Mus musculus	71-74
30003817-5	2018	OBJECTIVE: Our objective was to induce Foxp3 + CD4+ T cells from naive CD4 + T cells isolated from C57 mice spleen in vitro using stimuli that include the short chain fatty acid sodium butyrate.	Butyric Acid	178-193	CD4 antigen	Mus musculus	47-50
30003817-5	2018	OBJECTIVE: Our objective was to induce Foxp3 + CD4+ T cells from naive CD4 + T cells isolated from C57 mice spleen in vitro using stimuli that include the short chain fatty acid sodium butyrate.	Butyric Acid	178-193	CD4 antigen	Mus musculus	71-74
30003817-16	2018	Sodium butyrate contributes to CD4 + Foxp3 + T cell induction in vitro and at an optimum concentration of 5 mM.	Butyric Acid	0-15	CD4 antigen	Mus musculus	31-34
28655574-5	2018	Our previous studies have shown that treatment of L. donovani infected mice with cisplatin along with herbal drugs resulted in decreased parasite load with heightened delayed type hypersensitivity responses (DTH), increased levels of IgG2a, IFN-gamma, IL-2, CD4+ cells, NK 1.1 cells over that of IgG1, IL-4, 1L-10, CD8+ and CD19 in infected mice.	Cisplatin	81-90	CD4 antigen	Mus musculus	258-261
29957340-0	2018	Cyclophosphamide-modified murine peritoneal macrophages induce CD4+ T contrasuppressor cells that protect contact sensitivity T effector cells from suppression.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	63-66
29957340-12	2018	CONCLUSIONS: Our results show that in vivo treatment with CY influences mouse peritoneal Mf to induce CD4+ Tcs cells that protect CS-effector cells from suppressive signals of Ts cells.	Cyclophosphamide	58-60	CD4 antigen	Mus musculus	102-105
29957340-12	2018	CONCLUSIONS: Our results show that in vivo treatment with CY influences mouse peritoneal Mf to induce CD4+ Tcs cells that protect CS-effector cells from suppressive signals of Ts cells.	9-ethyl-N-(3,4,5-trimethoxyphenyl)carbazole-3-sulfonamide	107-110	CD4 antigen	Mus musculus	102-105
30064486-11	2018	The number of antibody for CD3 (CD3+), CD4+, CD8+ and CD28+ cells was lower in the duloxetine groups.	Duloxetine Hydrochloride	83-93	CD4 antigen	Mus musculus	39-42
29866884-9	2018	Disruption of DNA methylation with the hypomethylating agent decitabine induced plasticity in the lung CD4+ T-cell marker phenotype.	Decitabine	61-71	CD4 antigen	Mus musculus	103-106
29781810-3	2018	have developed an HLA-B*57:01-transgenic mouse model and demonstrated that CD4+ T cells play a key role in mediating tolerance to the dramatically altered endogenous peptide repertoire induced by abacavir and postulate a known mechanism by which CD4+ T cells suppress DC maturation.	abacavir	196-204	CD4 antigen	Mus musculus	75-78
29781810-3	2018	have developed an HLA-B*57:01-transgenic mouse model and demonstrated that CD4+ T cells play a key role in mediating tolerance to the dramatically altered endogenous peptide repertoire induced by abacavir and postulate a known mechanism by which CD4+ T cells suppress DC maturation.	abacavir	196-204	CD4 antigen	Mus musculus	246-249
29617845-1	2018	Background: Small-molecule CD4-mimetic compounds (CD4mc) inhibit human immunodeficiency virus (HIV-1) entry by blocking binding to the CD4 receptor and by premature triggering of the viral envelope glycoprotein (Env) spike.	cd4mc	50-55	CD4 antigen	Mus musculus	27-30
29316256-5	2018	Tacrolimus treatment significantly altered the relative abundance of Allobaculum, Bacteroides, and Lactobacillus and CD4+ CD25hi FoxP3+ regulatory T cells in the colonic mucosa and the circulation.	Tacrolimus	0-10	CD4 antigen	Mus musculus	117-120
29753741-4	2018	Although corticosterone reportedly causes selective apoptosis of CD4+CD8+ thymocytes (CD4+CD8+DPs) in mice treated with short-term HU, the reduction of thymocyte cellularity after the 14-day HU was not selective for CD4+CD8+DPs.	Corticosterone	9-23	CD4 antigen	Mus musculus	65-68
29753741-4	2018	Although corticosterone reportedly causes selective apoptosis of CD4+CD8+ thymocytes (CD4+CD8+DPs) in mice treated with short-term HU, the reduction of thymocyte cellularity after the 14-day HU was not selective for CD4+CD8+DPs.	Corticosterone	9-23	CD4 antigen	Mus musculus	86-89
29753741-4	2018	Although corticosterone reportedly causes selective apoptosis of CD4+CD8+ thymocytes (CD4+CD8+DPs) in mice treated with short-term HU, the reduction of thymocyte cellularity after the 14-day HU was not selective for CD4+CD8+DPs.	Corticosterone	9-23	CD4 antigen	Mus musculus	86-89
29753741-4	2018	Although corticosterone reportedly causes selective apoptosis of CD4+CD8+ thymocytes (CD4+CD8+DPs) in mice treated with short-term HU, the reduction of thymocyte cellularity after the 14-day HU was not selective for CD4+CD8+DPs.	zwittergent 3-12	94-97	CD4 antigen	Mus musculus	65-68
29910732-10	2018	Administration of BLM and DNCB increased the numbers of cluster of differentiation 4 (CD4)+ T cells and CD11b+granulocyte-differentiation antigen-1 (Gr-1)+ cells among peripheral blood mononuclear cells, CD4+ cells in bronchoalveolar lavage, CD4+ and B220+CD23+ B cells in the axillary lymph node, and CD4+ cells in thymus, compared to DNCB-treated mice.	Dinitrochlorobenzene	26-30	CD4 antigen	Mus musculus	86-89
29910732-10	2018	Administration of BLM and DNCB increased the numbers of cluster of differentiation 4 (CD4)+ T cells and CD11b+granulocyte-differentiation antigen-1 (Gr-1)+ cells among peripheral blood mononuclear cells, CD4+ cells in bronchoalveolar lavage, CD4+ and B220+CD23+ B cells in the axillary lymph node, and CD4+ cells in thymus, compared to DNCB-treated mice.	Dinitrochlorobenzene	26-30	CD4 antigen	Mus musculus	204-207
29910732-10	2018	Administration of BLM and DNCB increased the numbers of cluster of differentiation 4 (CD4)+ T cells and CD11b+granulocyte-differentiation antigen-1 (Gr-1)+ cells among peripheral blood mononuclear cells, CD4+ cells in bronchoalveolar lavage, CD4+ and B220+CD23+ B cells in the axillary lymph node, and CD4+ cells in thymus, compared to DNCB-treated mice.	Dinitrochlorobenzene	26-30	CD4 antigen	Mus musculus	204-207
29732501-6	2018	Mechanistically, Hcy-activated CD4+ T cell increased the protein expression and activity of pyruvate kinase muscle isozyme 2 (PKM2), the final rate-limiting enzyme in glycolysis, via the phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin signaling pathway.	Sirolimus	243-252	CD4 antigen	Mus musculus	31-34
29732501-7	2018	Knockdown of PKM2 by small interfering RNA reduced Hcy-induced CD4+ T cell IFN-gamma secretion.	Homocysteine	51-54	CD4 antigen	Mus musculus	63-66
29732501-8	2018	Furthermore, we generated T cell-specific PKM2 knockout mice by crossing LckCre transgenic mice with PKM2fl/fl mice and observed that Hcy-induced glycolysis and oxidative phosphorylation were both diminished in PKM2-deficient CD4+ T cells with reduced glucose and lipid metabolites, and subsequently reduced IFN-gamma secretion.	Homocysteine	134-137	CD4 antigen	Mus musculus	226-229
29732501-11	2018	KEY MESSAGES: Metabolic reprogramming is crucial for Hcy-induced CD4+ T cell inflammatory activation.	Homocysteine	53-56	CD4 antigen	Mus musculus	65-68
29732501-12	2018	Hcy activates the glycolytic-lipogenic pathway in CD4+ T cells via PKM2.	Homocysteine	0-3	CD4 antigen	Mus musculus	50-53
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	Cysteine	12-15	CD4 antigen	Mus musculus	44-47
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	Cysteine	12-15	CD4 antigen	Mus musculus	128-131
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	cdb	25-28	CD4 antigen	Mus musculus	44-47
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	cdb	25-28	CD4 antigen	Mus musculus	128-131
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	Dextran Sulfate	148-170	CD4 antigen	Mus musculus	44-47
29326360-4	2018	Here, GK1.5 cys-diabody (cDb), an antimouse CD4 antibody fragment derived from the GK1.5 hybridoma, was used as a PET probe for CD4+ T cells in the dextran sulfate sodium (DSS) mouse model of IBD.	Dextran Sulfate	148-170	CD4 antigen	Mus musculus	128-131
29326360-5	2018	Methods: The DSS mouse model of IBD was validated by assessing changes in CD4+ T cells in the spleen and mesenteric lymph nodes (MLNs) using flow cytometry.	Dextran Sulfate	13-16	CD4 antigen	Mus musculus	74-77
29326360-7	2018	89Zr-labeled GK1.5 cDb was used to image distribution of CD4+ T cells in the abdominal region and lymphoid organs of mice with DSS-induced colitis.	cdb	19-22	CD4 antigen	Mus musculus	57-60
29326360-15	2018	Conclusion:89Zr-malDFO-GK1.5 cDb detected CD4+ T cells in the colons, ceca, and MLNs of colitic mice and may prove useful for further investigations of CD4+ T cells in preclinical models of IBD, with potential to guide development of antibody-based imaging in human IBD.	cdb	29-32	CD4 antigen	Mus musculus	42-45
29326360-15	2018	Conclusion:89Zr-malDFO-GK1.5 cDb detected CD4+ T cells in the colons, ceca, and MLNs of colitic mice and may prove useful for further investigations of CD4+ T cells in preclinical models of IBD, with potential to guide development of antibody-based imaging in human IBD.	cdb	29-32	CD4 antigen	Mus musculus	152-155
29881333-6	2018	Vitamin D deficiency also attenuated the structure of small intestinal villi and decreased the expression of the tight junction protein between adjacent epithelial cells and the percentages of CD4+CD25+Foxp3+Treg cell in spleen and mesenteric lymph nodes.	Vitamin D	0-9	CD4 antigen	Mus musculus	193-196
29899823-6	2018	Metformin treatment increased the number of lung CD8-effector-memory T and CD4+Foxp3+IL-10+ T cells in B16F10-transplanted mice.	Metformin	0-9	CD4 antigen	Mus musculus	75-78
29743548-6	2018	DMXAA also induced an influx of immune cells: macrophages, CD8+ cytotoxic lymphocytes, NK cells, CD4+ lymphocytes.	vadimezan	0-5	CD4 antigen	Mus musculus	97-100
29718959-9	2018	Treatment in vitro of CD4+ splenocytes from GIMAP6fl/flERT2Cre mice with 4-hydroxytamoxifen resulted in the disappearance of GIMAP6 within five days.	hydroxytamoxifen	73-91	CD4 antigen	Mus musculus	22-25
29317237-0	2018	Antitumor immunostimulatory activity of polysaccharides from Panax japonicus C. A. Mey: Roles of their effects on CD4+ T cells and tumor associated macrophages.	Polysaccharides	40-55	CD4 antigen	Mus musculus	114-117
29507085-5	2018	In addition, we found that T cell-intrinsic myeloid differentiation antigen 88 (MyD88) signaling, which occurs downstream of interleukin-1 (IL-1) and IL-18 receptors, is critical for the primed CD4 T cells to transition out of the temporary Tfh lineage.	tfh	241-244	CD4 antigen	Mus musculus	194-197
29369782-7	2018	Additionally, TAK-828F strongly inhibited Th17, Tc17 and Th1/17 cells" differentiation from naive T cells and memory CD4+ T cells at 100 nM without affecting Th1 cells" differentiation.	TAK-828F	14-22	CD4 antigen	Mus musculus	117-120
29363729-4	2018	Flow cytometric analysis indicated that the ratio of CD3+CD4+ to CD3+CD8+ T lymphocytes in the peripheral blood increased in MPTP-treated mice following treatment with EGCG, and EGCG reduced expression of inflammatory factors tumor necrosis factor-alpha and interleukin-6 in serum.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	125-129	CD4 antigen	Mus musculus	57-60
29363729-4	2018	Flow cytometric analysis indicated that the ratio of CD3+CD4+ to CD3+CD8+ T lymphocytes in the peripheral blood increased in MPTP-treated mice following treatment with EGCG, and EGCG reduced expression of inflammatory factors tumor necrosis factor-alpha and interleukin-6 in serum.	epigallocatechin gallate	168-172	CD4 antigen	Mus musculus	57-60
29363729-4	2018	Flow cytometric analysis indicated that the ratio of CD3+CD4+ to CD3+CD8+ T lymphocytes in the peripheral blood increased in MPTP-treated mice following treatment with EGCG, and EGCG reduced expression of inflammatory factors tumor necrosis factor-alpha and interleukin-6 in serum.	epigallocatechin gallate	178-182	CD4 antigen	Mus musculus	57-60
29593222-0	2018	CD4+ and CD8+ T Cells Exert Regulatory Properties During Experimental Acute Aristolochic Acid Nephropathy.	aristolochic acid I	76-93	CD4 antigen	Mus musculus	0-3
29593222-3	2018	As compared to mice injected with aristolochic acids alone, more severe acute kidney injury was observed after CD4+ or CD8+ T-cells depletion.	Aristolochic Acids	34-52	CD4 antigen	Mus musculus	111-114
29562463-0	2018	[Rapamycin affect the apoptosis of splenic CD4+CD25+ regulatory T cells of mouse severe aplastic anemia model].	Sirolimus	1-10	CD4 antigen	Mus musculus	43-46
29562463-9	2018	In the SAA group, FCM analysis showed down-expression of Foxp3 in CD4+CD25+ Tregs compared with the un-treated group.	saa	7-10	CD4 antigen	Mus musculus	66-69
29562463-11	2018	Compared with the un-treated group, increased CD4+CD25+ Tregs apoptosis [(19.84+-1.39)% vs (29.85+-2.72)%] with increased Akt phosphorylation accompanied by increased Stat3 phosphorylation was found in SAA group (P&lt;0.05, respectively).	saa	202-205	CD4 antigen	Mus musculus	46-49
29562463-12	2018	On the contrary, RAPA-treated group exhibited CD4+ CD25+ Tregs with a reduction in apoptosis rate [(22.39+-3.71)%], Akt phosphorylation and Stat3 phosphorylation compared with the SAA group (P&lt;0.05, respectively).	Sirolimus	17-21	CD4 antigen	Mus musculus	46-49
29513375-4	2018	CD4+ T-cells evidenced a pro-inflammatory phenotype characterized by increased secretion of IFNgamma and IL-17A, when exposed to high salt concentrations in vitro.	Salts	134-138	CD4 antigen	Mus musculus	0-3
29513375-10	2018	The aggravated colitis in salt-exposed animals was associated with a higher frequency of CD4+ T-cells and CD11b+ CD64+ macrophages producing TNFalpha.	Salts	26-30	CD4 antigen	Mus musculus	89-92
29513375-13	2018	However, the effects of high salt intake in vivo seem less pronounced in terms of CD4+ T-cell responses, whereas macrophage-dependent pathologies are significantly influenced.	Salts	29-33	CD4 antigen	Mus musculus	82-85
29324305-0	2018	Caveolin-mediated endocytosis of the Chlamydia M278 outer membrane peptide encapsulated in poly(lactic acid)-Poly(ethylene glycol) nanoparticles by mouse primary dendritic cells enhances specific immune effectors mediated by MHC class II and CD4+ T cells.	poly(lactide)	91-108	CD4 antigen	Mus musculus	242-245
29468499-5	2018	We investigated the effect of resveratrol treatment on TLR2, TLR3, TLR4, NF-kappaB, and inducible nitric oxide synthase (iNOS or NOS2) levels in CD4 spleen cells.	Resveratrol	30-41	CD4 antigen	Mus musculus	145-148
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	59-62
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	70-73
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	70-73
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	70-73
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	70-73
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	btbr	25-29	CD4 antigen	Mus musculus	59-62
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	btbr	25-29	CD4 antigen	Mus musculus	70-73
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	btbr	25-29	CD4 antigen	Mus musculus	70-73
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	btbr	25-29	CD4 antigen	Mus musculus	70-73
29468499-8	2018	Resveratrol treatment on BTBR mice significantly decreased CD4+TLR2+, CD4+TLR3+, CD4+TLR4+ CD4+NF-kappaB+, and CD4+iNOS+ levels in spleen cells.	btbr	25-29	CD4 antigen	Mus musculus	70-73
29676133-1	2018	This paper aimed to investigate whether psoralen inhibits the differentiation and bone resorption by regulating CD4+T cell differentiation in RANKL-induced osteoclastogenesis in RAW264.7 cells, and elucidate its mechanism for osteoporosis.	Ficusin	40-48	CD4 antigen	Mus musculus	112-115
29485127-12	2018	Moreover, the beta2-AR agonist terbutaline (Terb) inhibited CIA-induced CD4+ T cell proliferation and shift towards Th17 phenotype, and the protein kinase A (PKA) inhibitor H-89 abolished the agonist effect.	Terbutaline	31-42	CD4 antigen	Mus musculus	72-75
29485127-12	2018	Moreover, the beta2-AR agonist terbutaline (Terb) inhibited CIA-induced CD4+ T cell proliferation and shift towards Th17 phenotype, and the protein kinase A (PKA) inhibitor H-89 abolished the agonist effect.	Terbutaline	44-48	CD4 antigen	Mus musculus	72-75
29485127-12	2018	Moreover, the beta2-AR agonist terbutaline (Terb) inhibited CIA-induced CD4+ T cell proliferation and shift towards Th17 phenotype, and the protein kinase A (PKA) inhibitor H-89 abolished the agonist effect.	N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide	173-177	CD4 antigen	Mus musculus	72-75
29483570-0	2018	Protective humoral and CD4+ T cellular immune responses of Staphylococcus aureus vaccine MntC in a murine peritonitis model.	mntc	89-93	CD4 antigen	Mus musculus	23-26
29876477-3	2018	This data report describes the effect of retinoic acid (RA) and/or anti-interferon-gamma (IFNgamma) antibody supplementation on up-regulation of CD8alpha and Foxp3 in  Eed CD4+ T cells, the effect of dose or timing of TGFbeta treatment on CD4+ T cell identity of  Eed, adding further information regarding the conditions that induces CD8alpha, and mRNA expression changes of genes encoding polycomb repressive complex 2 (PRC2) subunits by TGFbeta treatment.	Tretinoin	41-54	CD4 antigen	Mus musculus	172-175
29876477-3	2018	This data report describes the effect of retinoic acid (RA) and/or anti-interferon-gamma (IFNgamma) antibody supplementation on up-regulation of CD8alpha and Foxp3 in  Eed CD4+ T cells, the effect of dose or timing of TGFbeta treatment on CD4+ T cell identity of  Eed, adding further information regarding the conditions that induces CD8alpha, and mRNA expression changes of genes encoding polycomb repressive complex 2 (PRC2) subunits by TGFbeta treatment.	Tretinoin	41-54	CD4 antigen	Mus musculus	239-242
29876477-3	2018	This data report describes the effect of retinoic acid (RA) and/or anti-interferon-gamma (IFNgamma) antibody supplementation on up-regulation of CD8alpha and Foxp3 in  Eed CD4+ T cells, the effect of dose or timing of TGFbeta treatment on CD4+ T cell identity of  Eed, adding further information regarding the conditions that induces CD8alpha, and mRNA expression changes of genes encoding polycomb repressive complex 2 (PRC2) subunits by TGFbeta treatment.	Tretinoin	56-58	CD4 antigen	Mus musculus	172-175
29876477-3	2018	This data report describes the effect of retinoic acid (RA) and/or anti-interferon-gamma (IFNgamma) antibody supplementation on up-regulation of CD8alpha and Foxp3 in  Eed CD4+ T cells, the effect of dose or timing of TGFbeta treatment on CD4+ T cell identity of  Eed, adding further information regarding the conditions that induces CD8alpha, and mRNA expression changes of genes encoding polycomb repressive complex 2 (PRC2) subunits by TGFbeta treatment.	Tretinoin	56-58	CD4 antigen	Mus musculus	239-242
28987000-7	2018	Of note, adoptive cell transfer assay showed that the pathology of colitis was more serious in carboxyfluorescein succinimidyl ester (CFSE)-labelled miR-126KD CD4+ T cell-transferred group, compared with that in the CFSE-labelled WT CD4+ T cells transferred group.	carboxyfluorescein succinimidyl ester	95-132	CD4 antigen	Mus musculus	159-162
28987000-7	2018	Of note, adoptive cell transfer assay showed that the pathology of colitis was more serious in carboxyfluorescein succinimidyl ester (CFSE)-labelled miR-126KD CD4+ T cell-transferred group, compared with that in the CFSE-labelled WT CD4+ T cells transferred group.	carboxyfluorescein succinimidyl ester	95-132	CD4 antigen	Mus musculus	233-236
29310022-6	2018	Genetic studies suggested that the altered balance between transcription factors T-bet, Runx3, and Th-POK underlies the induction of the DP-IEL-like phenotype in Eed-deficient CD4+ cells.	dp	137-139	CD4 antigen	Mus musculus	176-179
29325640-5	2018	RESULTS: Mouse CD4+ T cells expressed EGFR, and the EGFR tyrosine kinase inhibitor AG-1478 blocked in vitro T cell proliferation and Th1/Th2 cytokine production.	RTKI cpd	83-90	CD4 antigen	Mus musculus	15-18
29237780-11	2018	In conclusion, FAS in CD4 T cells regulates the early divergence of Tmem from Teff in chronic infection.	fas	15-18	CD4 antigen	Mus musculus	22-25
29312812-11	2018	Increase in immunomodulatory effects of treated NLC-Citral and Citral groups was verified from the increase in CD4/CD3 and CD8/CD3 T cell population in both NLC-citral and citral treated splenocytes.	citral	52-58	CD4 antigen	Mus musculus	111-114
29312812-11	2018	Increase in immunomodulatory effects of treated NLC-Citral and Citral groups was verified from the increase in CD4/CD3 and CD8/CD3 T cell population in both NLC-citral and citral treated splenocytes.	citral	63-69	CD4 antigen	Mus musculus	111-114
29433394-5	2018	The ethyl acetate (W-EA) fraction showed a more significant effect than the other fractions on the growth of EL-4 T cells, splenocytes, and isolated murine CD4[Formula: see text] T cells.	ethyl acetate	4-17	CD4 antigen	Mus musculus	156-159
29433394-5	2018	The ethyl acetate (W-EA) fraction showed a more significant effect than the other fractions on the growth of EL-4 T cells, splenocytes, and isolated murine CD4[Formula: see text] T cells.	w-ea	19-23	CD4 antigen	Mus musculus	156-159
29167234-4	2018	We demonstrated with chicken OVA-specific TCR-transgenic mice that the same tolerizing protocol (CD4 blockade) and the same target Ag (OVA) achieves Foxp3-dependent transplantation tolerance to OVA-expressing skin grafts, but Foxp3-independent tolerance when the Ag is provided as OVA-aluminum hydroxide.	Aluminum Hydroxide	285-303	CD4 antigen	Mus musculus	97-100
30121669-0	2018	Reduced CD4 T Lymphocytes in Lymph Nodes of the Mouse Model of Autism Induced by Valproic Acid.	Valproic Acid	81-94	CD4 antigen	Mus musculus	8-11
30121669-5	2018	We observed that the prenatal exposure to VPA induced a reduction in the numbers of CD3+CD4+ T cells in their lymph nodes when compared to the control animals.	Valproic Acid	42-45	CD4 antigen	Mus musculus	88-91
29407322-8	2018	Adoptive transfer of CD4+ splenocytes from TJ-35-exposed primary allograft recipients resulted in significant prolonged allograft survival in naive secondary recipients (MST, 63 days).	tj	43-45	CD4 antigen	Mus musculus	21-24
29407322-9	2018	Flow cytometry studies showed that the percentage of CD4+CD25+Foxp3+ cell population was increased in TJ-35-exposed CBA recipients.	tj-35	102-107	CD4 antigen	Mus musculus	53-56
29407322-10	2018	In conclusion, TJ-35-induced prolongation of fully allogeneic cardiac allografts and may generate regulatory CD4+CD25+Foxp3+ cells in our model.	tj-35	15-20	CD4 antigen	Mus musculus	109-112
29541407-0	2018	Effects of wear particles of polyether-ether-ketone and cobalt-chromium-molybdenum on CD4- and CD8-T-cell responses.	cobalt-chromium-molybdenum	56-82	CD4 antigen	Mus musculus	86-89
29281818-4	2017	Env immunization of CD4bs bnAb heavy chain rearrangement (VHDJH) knockin mice similarly induced V1V2-glycan neutralizing antibodies (nAbs), wherein the human CD4bs VH chains were replaced with mouse rearrangements bearing diversity region (D)-D fusions, creating antibodies with long, tyrosine-rich HCDR3s.	Polysaccharides	101-107	CD4 antigen	Mus musculus	20-23
29239722-0	2017	Calcium-mediated shaping of naive CD4 T-cell phenotype and function.	Calcium	0-7	CD4 antigen	Mus musculus	34-37
29239722-3	2017	To decipher the molecular mechanisms governing this process, we here focus on the TCR signaling cascade and demonstrate that a rise in intracellular calcium levels is sufficient to modulate the phenotype of mouse naive CD4 T cells and to increase their sensitivity to regulatory T-cell polarization signals, both processes relying on calcineurin activation.	Calcium	149-156	CD4 antigen	Mus musculus	219-222
29239722-5	2017	Collectively, our findings demonstrate that calcium-mediated activation of the calcineurin pathway acts as a rheostat to shape both the phenotype and effector potential of naive CD4 T cells in the steady-state.	Calcium	44-51	CD4 antigen	Mus musculus	178-181
29017923-0	2017	Lysophosphatidylserine suppresses IL-2 production in CD4 T cells through LPS3/GPR174.	lysophosphatidylserine	0-22	CD4 antigen	Mus musculus	53-56
28851628-5	2017	The highly PDE8-selective enzymatic inhibitor PF-04957325 suppresses adhesion of in vivo myelin oligodendrocyte glycoprotein (MOG) activated inflammatory CD4+ T effector (Teff) cells to brain endothelial cells under shear stress.	PF-04957325	46-57	CD4 antigen	Mus musculus	154-157
29204644-0	2017	Topical Application of Mizoribine Suppresses CD4+ T-cell-Mediated Pathogenesis in Murine Dry Eye.	mizoribine	23-33	CD4 antigen	Mus musculus	45-48
29204644-1	2017	Purpose: We investigate the effect of topical application of mizoribine (MZR) eye drops on CD4+ T-cell-mediated immunity and epithelial damage in ocular surface of dry eye disease (DED).	mizoribine	61-71	CD4 antigen	Mus musculus	91-94
29204644-1	2017	Purpose: We investigate the effect of topical application of mizoribine (MZR) eye drops on CD4+ T-cell-mediated immunity and epithelial damage in ocular surface of dry eye disease (DED).	mizoribine	73-76	CD4 antigen	Mus musculus	91-94
29032596-3	2017	Albendazole application reduces microsporidia burden in C57Bl/6 and CD4-/- mice, whereas CD8-/- mice experience only a temporary effect of the treatment.	Albendazole	0-11	CD4 antigen	Mus musculus	68-71
28899767-8	2017	Our results showed that Cr(VI) decreased the viability of CD4+ and CD8+ T cells and inhibited their activation, proliferation, cytokine release and cytolytic function.	chromium hexavalent ion	24-30	CD4 antigen	Mus musculus	58-61
29130830-4	2017	Results showed that the percentages of vaccine-induced CD8+ T cell and total CD4+ T cell responses were low among lymphocytes in the airways of VAD+VDD animals compared to controls.	vad+vdd	144-151	CD4 antigen	Mus musculus	77-80
28957452-5	2017	Furthermore, the administration of ceftriaxone, but not vancomycin, led to a significant reduction in the abundance of splenic CD4+CD25+Foxp3+ T cells.	Ceftriaxone	35-46	CD4 antigen	Mus musculus	127-130
29218051-0	2017	Sphingosine 1-Phosphate- and C-C Chemokine Receptor 2-Dependent Activation of CD4+ Plasmacytoid Dendritic Cells in the Bone Marrow Contributes to Signs of Sepsis-Induced Immunosuppression.	sphingosine 1-phosphate	0-23	CD4 antigen	Mus musculus	78-81
29218051-7	2017	Prior depletion of the CD11chiMHCII+CD4+ DCs from BMC in vitro reversed the increased IL-10 secretion of subsequently differentiating BMDC.	bmdc	134-138	CD4 antigen	Mus musculus	36-39
29201027-0	2017	l-Citrulline Metabolism in Mice Augments CD4+ T Cell Proliferation and Cytokine Production In Vitro, and Accumulation in the Mycobacteria-Infected Lung.	Citrulline	0-12	CD4 antigen	Mus musculus	41-44
29201027-5	2017	Furthermore, T cell l-citrulline metabolism is necessary for accumulation of CD4+ T cells at the site of infection, suggesting this metabolic pathway is involved during anti-mycobacterial T cell immunity in vivo.	Citrulline	20-32	CD4 antigen	Mus musculus	77-80
29021374-11	2017	Conversely, ROS were highly elevated in CD4 T cells from mice ectopically expressing PLZF.	Reactive Oxygen Species	12-15	CD4 antigen	Mus musculus	40-43
28720647-8	2017	Pretreatment with paricalcitol attenuated I/R-induced maturation of DCs (flow cytometry), CD4+ T-cell recruitment into the liver (intravital microscopy), and hepatocellular/microvascular damage (intravital microscopy, alanine aminotransferase/aspartate aminotransferase, histology).	paricalcitol	18-30	CD4 antigen	Mus musculus	90-93
28720647-8	2017	Pretreatment with paricalcitol attenuated I/R-induced maturation of DCs (flow cytometry), CD4+ T-cell recruitment into the liver (intravital microscopy), and hepatocellular/microvascular damage (intravital microscopy, alanine aminotransferase/aspartate aminotransferase, histology).	r	44-45	CD4 antigen	Mus musculus	90-93
28951199-5	2017	The proportion of annexin V positive and propidium iodide negative cells was increased in CD4 and CD8 double negative, double positive and single positive T cells from T cell-specific PAR2-null mice.	Propidium	41-57	CD4 antigen	Mus musculus	90-93
28812128-11	2017	Mice exposed to DSS alone demonstrated significantly decreased percentage of total CD4+ cells (73.1 vs. 52%, p = 0.0007), accompanied by increase of CD8+ cells (18.4 vs. 39.5%, p = 0.0001).	Dextran Sulfate	16-19	CD4 antigen	Mus musculus	83-86
28812128-12	2017	Concomitant CS exposure reversed inappropriate CD4+/CD8+ ratio both in the blood and colon and significantly increased B cell presence in the colon.	Cesium	12-14	CD4 antigen	Mus musculus	47-50
29163466-5	2017	CD4+ T-cell depletion or T-bet/IFN-gamma deficiency protects against the development of colitis induced by CS.	Cesium	107-109	CD4 antigen	Mus musculus	0-3
29163466-6	2017	Additionally, IFN-gamma-producing CD4+ T cells play a substantial role in CS-induced colitis.	Cesium	74-76	CD4 antigen	Mus musculus	34-37
28958808-10	2017	Finally, we showed that, as adjuvants, CpG-B, R848 and Poly I:C can all enhance antigen specific CD4+ T cell response, while only R848 and Poly I:C induced CD8+ cytotoxic T cells response to a CD40-targeting HIV vaccine in humanized mice, correlated with their ability to activate human mDCs but not pDCs.	Iodine	60-61	CD4 antigen	Mus musculus	97-100
28958808-10	2017	Finally, we showed that, as adjuvants, CpG-B, R848 and Poly I:C can all enhance antigen specific CD4+ T cell response, while only R848 and Poly I:C induced CD8+ cytotoxic T cells response to a CD40-targeting HIV vaccine in humanized mice, correlated with their ability to activate human mDCs but not pDCs.	Carbon	39-40	CD4 antigen	Mus musculus	97-100
29066789-5	2017	In a co-culture experiment, DCs treated with 14-dehydroergosterol induced the conversion of naive CD4-positive T cells into regulatory T cells.	(22E,24S)-24-methylcholesta-5,7,14,22-tetraen-3beta-ol	45-65	CD4 antigen	Mus musculus	98-101
28807491-6	2017	Our results showed that BTBR mice treated with SCH had increased CD4+IL-21+, CD4+IL-22+, CD4+GATA3+, and CD4+T-bet+ and decreased CD4+CTLA-4+ expression in spleen cells compared with BTBR control mice.	btbr	24-28	CD4 antigen	Mus musculus	65-68
28807491-6	2017	Our results showed that BTBR mice treated with SCH had increased CD4+IL-21+, CD4+IL-22+, CD4+GATA3+, and CD4+T-bet+ and decreased CD4+CTLA-4+ expression in spleen cells compared with BTBR control mice.	btbr	24-28	CD4 antigen	Mus musculus	77-80
28807491-6	2017	Our results showed that BTBR mice treated with SCH had increased CD4+IL-21+, CD4+IL-22+, CD4+GATA3+, and CD4+T-bet+ and decreased CD4+CTLA-4+ expression in spleen cells compared with BTBR control mice.	btbr	24-28	CD4 antigen	Mus musculus	77-80
28807491-6	2017	Our results showed that BTBR mice treated with SCH had increased CD4+IL-21+, CD4+IL-22+, CD4+GATA3+, and CD4+T-bet+ and decreased CD4+CTLA-4+ expression in spleen cells compared with BTBR control mice.	btbr	24-28	CD4 antigen	Mus musculus	77-80
28807491-6	2017	Our results showed that BTBR mice treated with SCH had increased CD4+IL-21+, CD4+IL-22+, CD4+GATA3+, and CD4+T-bet+ and decreased CD4+CTLA-4+ expression in spleen cells compared with BTBR control mice.	btbr	24-28	CD4 antigen	Mus musculus	77-80
28772190-7	2017	Furthermore, CD4+ T cells isolated from dMP-treated mice were anergic in response to disease-specific, antigen-loaded splenocytes.	dmp	40-43	CD4 antigen	Mus musculus	13-16
28646487-6	2017	The reductions of lymphocyte subsets, including CD3+, CD4+, CD8+, B cell, and natural killer cell, were observed in the TiO2 NP-treated mouse thymus.	tio2 np	120-127	CD4 antigen	Mus musculus	54-57
28912844-0	2017	Triptolide inhibits CD4+ memory T cell-mediated acute rejection and prolongs cardiac allograft survival in mice.	triptolide	0-10	CD4 antigen	Mus musculus	20-23
28912844-2	2017	Using a cluster of differentiation (CD)4+ memory T-cell transfer model, the aim of the present study was to determine the inhibitory effects of triptolide on CD4+ memory T cell-mediated acute rejection and to determine the potential underlying mechanisms.	triptolide	144-154	CD4 antigen	Mus musculus	158-161
28912844-9	2017	Therefore, the present study suggests that triptolide inhibits CD4+ memory T cell-mediated acute rejection and prolongs cardiac allograft survival in mice.	triptolide	43-53	CD4 antigen	Mus musculus	63-66
28851629-4	2017	Additionally, Gag-specific TNF-alpha secreting CD8+ and CD4+ T cells and Env-specific IL-2 secreting T cells were also elicited by mice immunized with Gag and Env constructs, respectively, as estimated by intracellular cytokine staining assay.	Glycosaminoglycans	14-17	CD4 antigen	Mus musculus	56-59
28834273-0	2017	Hollow ZnO Nanospheres Enhance Anticancer Immunity by Promoting CD4+ and CD8+ T Cell Populations In Vivo.	Zinc Oxide	7-10	CD4 antigen	Mus musculus	64-67
28834273-6	2017	HZnO nanospheres significantly improve the CD4+ and/or CD8+ T cell population in splenocytes of mice in both cancer cell challenge model and re-challenge model.	hzno	0-4	CD4 antigen	Mus musculus	43-46
28768723-4	2017	In this article, we show that Lamtor1-deficient CD4+ T cells exhibited marked reductions in proliferation, IL-2 production, mTORC1 activity, and expression of purine- and lipid-synthesis genes.	purine	159-165	CD4 antigen	Mus musculus	48-51
28502093-2	2017	We studied the role of these adaptors in the TLR4-dependent inhibition of allergic airway disease and induction of CD4+ ICOS+ T cells by nasal application of Protollin , a mucosal adjuvant composed of TLR2 and TLR4 agonists.	Protollin	158-167	CD4 antigen	Mus musculus	115-118
28502093-7	2017	Adoptive transfer of cervical lymph node cells supported a role for Protollin-induced CD4+ ICOS+ cells in the TRIF-dependent inhibition of airway hyper-responsiveness.	Protollin	68-77	CD4 antigen	Mus musculus	86-89
28502122-4	2017	In humanized mice vaccinated with either BCG or with CpG-C, a liposome-based formulation containing the M. tuberculosis antigen ESAT-6, both CD4 and CD8 T cells secreted cytokines that are known to be required for induction of protective immunity.	cpg-c	53-58	CD4 antigen	Mus musculus	141-144
28539382-2	2017	We previously found that IL-2, which is critical for Treg homeostasis, upregulates the IL-33 receptor (ST2) on CD4+ T cells, thus we hypothesized that IL-2 and IL-33 cooperate to enhance Treg function.	treg	187-191	CD4 antigen	Mus musculus	111-114
28620954-5	2017	KEY FINDINGS: Propentofylline inhibited thymocyte maturation (increase in CD4- CD8- thymocyte subset and decrease in the percentage of CD4+ CD8+ thymocytes) and modulated the lymphocyte subsets in spleen and mesenteric lymph nodes.	propentofylline	14-29	CD4 antigen	Mus musculus	74-77
28620954-5	2017	KEY FINDINGS: Propentofylline inhibited thymocyte maturation (increase in CD4- CD8- thymocyte subset and decrease in the percentage of CD4+ CD8+ thymocytes) and modulated the lymphocyte subsets in spleen and mesenteric lymph nodes.	propentofylline	14-29	CD4 antigen	Mus musculus	135-138
28864944-11	2017	This study showed rNDV-TV induced an antitumor T cell response to WEHI164 cells, and major subsets of cells involved in tumor exclusion were CD4+ and CD8+ cells, together with NKT cells.	rndv-tv	18-25	CD4 antigen	Mus musculus	141-144
28859168-4	2017	The P2X7 receptor senses extracellular ATP and induces CD4 T cell activation and death.	Adenosine Triphosphate	39-42	CD4 antigen	Mus musculus	55-58
28859168-6	2017	The P2X7 receptor was activated in CD4 T cells following the rupture of infected erythrocytes and these cells became highly responsive to ATP during acute infection.	Adenosine Triphosphate	138-141	CD4 antigen	Mus musculus	35-38
28841693-3	2017	ICR mice were subcutaneously co-administrated with V combined with different concentrations of AEAR demonstrated that 300 mug AEAR could significantly improve hemagglutination inhibition (HI) and increase IgG antibody titers in serum (P&lt;0.05) and the population of CD4+CD44+ and CD8+CD44+ (P&lt;0.05).	aear	126-130	CD4 antigen	Mus musculus	268-271
29137411-4	2017	The anti-tumor effect of PBT was lost in mice where CD4+ and CD8+ T cells were antibody depleted, implying that PBT stimulates an anti-tumor immune effect that is T-cell dependent.	(E)-2-(pent-3-en-1-yn-1-yl)thiophene	25-28	CD4 antigen	Mus musculus	52-55
28830352-6	2017	Moreover, we observed the rebalance in the populations of naive CD4+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy.	tofacitinib	106-110	CD4 antigen	Mus musculus	64-67
28830352-6	2017	Moreover, we observed the rebalance in the populations of naive CD4+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy.	tofacitinib	166-170	CD4 antigen	Mus musculus	64-67
28830352-6	2017	Moreover, we observed the rebalance in the populations of naive CD4+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy.	Dexamethasone	175-188	CD4 antigen	Mus musculus	64-67
28830352-6	2017	Moreover, we observed the rebalance in the populations of naive CD4+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy.	Dexamethasone	190-194	CD4 antigen	Mus musculus	64-67
28830352-6	2017	Moreover, we observed the rebalance in the populations of naive CD4+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy.	tofacitinib	166-170	CD4 antigen	Mus musculus	64-67
28830352-7	2017	We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3+ T cells from human patients following immunosuppressant therapy including steroid, respectively.	tofacitinib	123-127	CD4 antigen	Mus musculus	88-91
28830352-7	2017	We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3+ T cells from human patients following immunosuppressant therapy including steroid, respectively.	Dexamethasone	132-136	CD4 antigen	Mus musculus	88-91
28830352-7	2017	We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3+ T cells from human patients following immunosuppressant therapy including steroid, respectively.	Steroids	240-247	CD4 antigen	Mus musculus	88-91
28652399-7	2017	Thus, we propose that CD4+GITR+CD122+CD25-Foxp3- cells represent a Treg pre-precursor population, whose transition into Treg precursors is mediated via c-REL.	treg	67-71	CD4 antigen	Mus musculus	22-25
27966069-0	2017	ImmunoPET Imaging of Murine CD4+ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging.	Cysteine	56-59	CD4 antigen	Mus musculus	28-31
27966069-0	2017	ImmunoPET Imaging of Murine CD4+ T Cells Using Anti-CD4 Cys-Diabody: Effects of Protein Dose on T Cell Function and Imaging.	Cysteine	56-59	CD4 antigen	Mus musculus	52-55
27966069-8	2017	In vivo administration of GK1.5 cDb at the high dose of 40 mug caused a transient decrease in CD4 expression in spleen, blood, lymph nodes, and thymus, which recovered within 3 days postinjection; this effect was reduced, although not abrogated, when 2 mug was administered.	cdb	32-35	CD4 antigen	Mus musculus	94-97
27966069-10	2017	Concentrations of GK1.5 cDb in excess of 25 nM significantly inhibited CD4+ T cell proliferation and interferon-gamma production in vitro.	cdb	24-27	CD4 antigen	Mus musculus	71-74
27966069-11	2017	Overall, using low-dose GK1.5 cDb minimized biological effects on CD4+ T cells.	cdb	30-33	CD4 antigen	Mus musculus	66-69
27966069-12	2017	CONCLUSIONS: Low-dose GK1.5 cDb yields high-contrast immunoPET images with minimal effects on T cell biology in vitro and in vivo and may be a useful tool for investigating CD4+ T cells in the context of preclinical disease models.	cdb	28-31	CD4 antigen	Mus musculus	173-176
28900479-8	2017	Using ionomycin to activate CD4+ splenocytes, the results indicated that Tff1-KO CD4+ splenocytes secreted higher levels of IL-17A (p&lt;0.05 at 2 and p&lt;0.001 at 8 months) and IL-17F (p&lt;0.05 at 2 and 8 months) than Tff1-WT splenocytes.	Ionomycin	6-15	CD4 antigen	Mus musculus	28-31
28900479-8	2017	Using ionomycin to activate CD4+ splenocytes, the results indicated that Tff1-KO CD4+ splenocytes secreted higher levels of IL-17A (p&lt;0.05 at 2 and p&lt;0.001 at 8 months) and IL-17F (p&lt;0.05 at 2 and 8 months) than Tff1-WT splenocytes.	Ionomycin	6-15	CD4 antigen	Mus musculus	81-84
28729731-0	2017	Anti-asthmatic effect of pitavastatin through aerosol inhalation is associated with CD4+ CD25+ Foxp3+ T cells in an asthma mouse model.	pitavastatin	25-37	CD4 antigen	Mus musculus	84-87
28729731-6	2017	In addition, the results showed that pitavastatin inhibited OVA-induced increases in eosinophil counts and total inflammatory cell counts in bronchoalveolar lavage fluid (BALF) and increased the percentage of CD4+ CD25+ Foxp3+ Treg in the BALF of asthmatic mice.	pitavastatin	37-49	CD4 antigen	Mus musculus	209-212
28729731-8	2017	These results suggest that pitavastatin has potential as a therapy for allergic airway disease and that its effects are associated with its ability to regulate CD4+ CD25+ Foxp3+ T cell counts.	pitavastatin	27-39	CD4 antigen	Mus musculus	160-163
28442414-5	2017	Consequent to the polymer-induced immunocamouflage of the cell membrane, both CD8+ and CD4+ T cell alloproliferation were significantly inhibited in a polymer dose-dependent manner.	Polymers	18-25	CD4 antigen	Mus musculus	87-90
28442414-5	2017	Consequent to the polymer-induced immunocamouflage of the cell membrane, both CD8+ and CD4+ T cell alloproliferation were significantly inhibited in a polymer dose-dependent manner.	Polymers	151-158	CD4 antigen	Mus musculus	87-90
28715493-10	2017	In addition, D2B6F1 mice also induced a larger Th1 response than BCF1 mice and Cl-13-induced mortality in D2B6F1 mice was also dependent on CD4 T-cell-mediated IFN-gamma production.	cl-13	79-84	CD4 antigen	Mus musculus	140-143
28421266-6	2017	The results showed that iron overload could reduce the percentage of CD3+ T cells and the ratio of Th1/Th2 and Tc1/Tc2 but increase the percentage of regulatory T (Treg) cells and the ratio of CD4/CD8.	Iron	24-28	CD4 antigen	Mus musculus	193-196
28372951-4	2017	Compared with controls, allografts and recipient spleens derived from iron-overloaded recipients were characterized by a pronounced graft infiltration of CD4+ T cells (p &lt; 0.01), CD3-NKp46+ natural killer cells (p &lt; 0.05), and reduced frequencies of regulatory T cells (p &lt; 0.01).	Iron	70-74	CD4 antigen	Mus musculus	154-157
28688660-13	2017	At 24 hours after TBI, mice given TXA demonstrated lower splenic total cell counts central memory CD8, effector CD8, B cell, and increased naive CD4 cell populations.	Tranexamic Acid	34-37	CD4 antigen	Mus musculus	145-148
28947964-8	2017	Moreover, GAG increased both CD4+FoxP3+ and CD8+CD122+PD-1+ Treg numbers in both spleens and lymph nodes of NOD mice.	Glycosaminoglycans	10-13	CD4 antigen	Mus musculus	29-32
28947964-9	2017	In particular, GAG could reverse a decline in CD4+FoxP3+ Tregs resulted from CsA treatments.	Glycosaminoglycans	15-18	CD4 antigen	Mus musculus	46-49
28947964-9	2017	In particular, GAG could reverse a decline in CD4+FoxP3+ Tregs resulted from CsA treatments.	Cyclosporine	77-80	CD4 antigen	Mus musculus	46-49
28947964-12	2017	Thus, we demonstrated that GAG ameliorated autoimmune T1DM by upregulating both CD4+FoxP3+ and CD8+CD122+PD-1+ Tregs while GAG synergized with CsA to further suppress autoimmunity and T1DM by reversing the decline in CD4+FoxP3+ Tregs resulted from CsA treatments.	Glycosaminoglycans	27-30	CD4 antigen	Mus musculus	80-83
28947964-12	2017	Thus, we demonstrated that GAG ameliorated autoimmune T1DM by upregulating both CD4+FoxP3+ and CD8+CD122+PD-1+ Tregs while GAG synergized with CsA to further suppress autoimmunity and T1DM by reversing the decline in CD4+FoxP3+ Tregs resulted from CsA treatments.	Glycosaminoglycans	27-30	CD4 antigen	Mus musculus	217-220
28510418-8	2017	As compared with CT, the polymerized CT (CT-PEG) elicited significantly higher CT-specific IgG titers, higher Th1- and Th2-type cytokines and higher percentages of CD4+ IFN-gamma+ and CD4+ IL-4+ cells in BALB/c mice.	ct-peg	41-47	CD4 antigen	Mus musculus	164-167
28510418-8	2017	As compared with CT, the polymerized CT (CT-PEG) elicited significantly higher CT-specific IgG titers, higher Th1- and Th2-type cytokines and higher percentages of CD4+ IFN-gamma+ and CD4+ IL-4+ cells in BALB/c mice.	ct-peg	41-47	CD4 antigen	Mus musculus	184-187
28604806-1	2017	Prostaglandin E2 (PGE2), a major lipid mediator abundant at inflammatory sites, acts as a proinflammatory agent in models of inflammatory/autoimmune diseases by promoting CD4 Th1/Th17 differentiation.	Dinoprostone	0-16	CD4 antigen	Mus musculus	171-174
28604806-1	2017	Prostaglandin E2 (PGE2), a major lipid mediator abundant at inflammatory sites, acts as a proinflammatory agent in models of inflammatory/autoimmune diseases by promoting CD4 Th1/Th17 differentiation.	Dinoprostone	18-22	CD4 antigen	Mus musculus	171-174
28604806-4	2017	In agreement with the in vivo proinflammatory role of PGE2, here we report for the first time that PGE2 inhibits IL-27-induced differentiation and IL-10 production of murine CD4+CD49b+LAG-3+Foxp3- Tr1 cells.	Dinoprostone	99-103	CD4 antigen	Mus musculus	174-177
28604806-8	2017	The effect of PGE2 on CD4+CD49b+LAG-3+ Tr1 differentiation was not associated with either induction of Foxp3 or IL-17 production, suggesting a lack of transdifferentiation into Foxp3+ Treg or effector Th17 cells.	Dinoprostone	14-18	CD4 antigen	Mus musculus	22-25
28638225-0	2017	Sodium selenite ameliorates dextran sulfate sodium-induced chronic colitis in mice by decreasing Th1, Th17, and gammadeltaT and increasing CD4(+)CD25(+) regulatory T-cell responses.	Sodium Selenite	0-15	CD4 antigen	Mus musculus	139-142
28638225-0	2017	Sodium selenite ameliorates dextran sulfate sodium-induced chronic colitis in mice by decreasing Th1, Th17, and gammadeltaT and increasing CD4(+)CD25(+) regulatory T-cell responses.	Dextran Sulfate	28-50	CD4 antigen	Mus musculus	139-142
28638225-6	2017	RESULTS: Se significantly ameliorated the symptoms of colitis and histological injury (P &lt; 0.05 each), increasing the proportions of neutrophils and CD4+ CD25+ T cells (P &lt; 0.05 each) and decreasing the proportions of gammadeltaT cells, CD4+, CD4+CD44+, and CD4+ CD69+ T cells in LPL (P &lt; 0.05 each).	Selenium	9-11	CD4 antigen	Mus musculus	152-155
28638225-6	2017	RESULTS: Se significantly ameliorated the symptoms of colitis and histological injury (P &lt; 0.05 each), increasing the proportions of neutrophils and CD4+ CD25+ T cells (P &lt; 0.05 each) and decreasing the proportions of gammadeltaT cells, CD4+, CD4+CD44+, and CD4+ CD69+ T cells in LPL (P &lt; 0.05 each).	Selenium	9-11	CD4 antigen	Mus musculus	243-246
28638225-6	2017	RESULTS: Se significantly ameliorated the symptoms of colitis and histological injury (P &lt; 0.05 each), increasing the proportions of neutrophils and CD4+ CD25+ T cells (P &lt; 0.05 each) and decreasing the proportions of gammadeltaT cells, CD4+, CD4+CD44+, and CD4+ CD69+ T cells in LPL (P &lt; 0.05 each).	Selenium	9-11	CD4 antigen	Mus musculus	243-246
28638225-6	2017	RESULTS: Se significantly ameliorated the symptoms of colitis and histological injury (P &lt; 0.05 each), increasing the proportions of neutrophils and CD4+ CD25+ T cells (P &lt; 0.05 each) and decreasing the proportions of gammadeltaT cells, CD4+, CD4+CD44+, and CD4+ CD69+ T cells in LPL (P &lt; 0.05 each).	Selenium	9-11	CD4 antigen	Mus musculus	243-246
28638225-8	2017	CONCLUSION: These results suggest that Se protects against DSS-induced chronic colitis perhaps by increasing the number of CD4(+)CD25(+) Tregs that suppress the secretion of proinflammatory cytokines and populations of Th1, Th17, and gammadeltaT cells.	Selenium	39-41	CD4 antigen	Mus musculus	123-126
28468970-2	2017	To better understand their development and functioning in vivo, we concomitantly inactivated CD4 and CD8 genes in mice with intact MHC class I and class II molecules with the hypothesis that this would enable the development of DNT cells.	2,6-dinitrotoluene	228-231	CD4 antigen	Mus musculus	93-96
28512288-0	2017	Lactic acid bacteria-specific induction of CD4+Foxp3+T cells ameliorates shrimp tropomyosin-induced allergic response in mice via suppression of mTOR signaling.	Lactic Acid	0-11	CD4 antigen	Mus musculus	43-46
28492364-0	2017	Na+ influx via Orai1 inhibits intracellular ATP-induced mTORC2 signaling to disrupt CD4 T cell gene expression and differentiation.	Adenosine Triphosphate	44-47	CD4 antigen	Mus musculus	84-87
28492364-5	2017	Mechanistically, TCR stimulation induced rapid sodium influx in Napahyh/hyh CD4 T cells, which reduced intracellular ATP, [ATP]i. Depletion of [ATP]i inhibited mTORC2 dependent NFkappaB activation in Napahyh/hyh cells but ablation of Orai1 restored it.	Sodium	47-53	CD4 antigen	Mus musculus	76-79
28492364-5	2017	Mechanistically, TCR stimulation induced rapid sodium influx in Napahyh/hyh CD4 T cells, which reduced intracellular ATP, [ATP]i. Depletion of [ATP]i inhibited mTORC2 dependent NFkappaB activation in Napahyh/hyh cells but ablation of Orai1 restored it.	Adenosine Triphosphate	117-120	CD4 antigen	Mus musculus	76-79
28492364-5	2017	Mechanistically, TCR stimulation induced rapid sodium influx in Napahyh/hyh CD4 T cells, which reduced intracellular ATP, [ATP]i. Depletion of [ATP]i inhibited mTORC2 dependent NFkappaB activation in Napahyh/hyh cells but ablation of Orai1 restored it.	Adenosine Triphosphate	123-126	CD4 antigen	Mus musculus	76-79
28492364-5	2017	Mechanistically, TCR stimulation induced rapid sodium influx in Napahyh/hyh CD4 T cells, which reduced intracellular ATP, [ATP]i. Depletion of [ATP]i inhibited mTORC2 dependent NFkappaB activation in Napahyh/hyh cells but ablation of Orai1 restored it.	Adenosine Triphosphate	123-126	CD4 antigen	Mus musculus	76-79
28399855-13	2017	CONCLUSION: Together we can conclude that this model does feature steroid sensitive, CD4+ T cell dependent, allergen induced LAR.	Steroids	66-73	CD4 antigen	Mus musculus	85-88
28483181-0	2017	Decreased Levels of Spleen Tissue CD4+CD25+Foxp3+ Regulatory T Lymphocytes in Mice Exposed to Berberine.	Berberine	94-103	CD4 antigen	Mus musculus	34-37
28483181-1	2017	The effects of isoquinoline alkaloid berberine (BER) on spleen tissue CD4+CD25+Foxp3+ regulatory T (Treg) cells were evaluated in BALB/c mice.	Berberine	48-51	CD4 antigen	Mus musculus	70-73
28250157-2	2017	We find that using APC pretreated ex vivo with TLR agonists, polyinosinic-polycytidylic acid and CpG, to prime naive CD4 T cells in vivo, restores their ability to expand and become germinal center T follicular helpers and enhances B cell IgG Ab production.	Poly I-C	61-92	CD4 antigen	Mus musculus	117-120
28034915-4	2017	In this report, we investigated the effects of early-life Abx treatments on the pathogenicity of CD4+ T cells using an experimental T cell transfer model of IBD.	CHEMBL369125	58-61	CD4 antigen	Mus musculus	97-100
28034915-5	2017	Our results show that CD4+ T cells isolated from adult mice that had been treated with Abx during gestation and in early life induced a faster onset of IBD in Rag1-deficient mice compared with CD4+ T cells of untreated mice.	CHEMBL369125	87-90	CD4 antigen	Mus musculus	22-25
28034915-5	2017	Our results show that CD4+ T cells isolated from adult mice that had been treated with Abx during gestation and in early life induced a faster onset of IBD in Rag1-deficient mice compared with CD4+ T cells of untreated mice.	CHEMBL369125	87-90	CD4 antigen	Mus musculus	193-196
28034915-8	2017	Analysis of Abx-treated CD4+ T cell donors showed systemically elevated levels of the stress hormone corticosterone throughout life compared with untreated donors.	CHEMBL369125	12-15	CD4 antigen	Mus musculus	24-27
28034915-8	2017	Analysis of Abx-treated CD4+ T cell donors showed systemically elevated levels of the stress hormone corticosterone throughout life compared with untreated donors.	Corticosterone	101-115	CD4 antigen	Mus musculus	24-27
28034915-10	2017	Thus, our results suggest that early-life Abx treatment results in a stress response with high levels of corticosterone that influences CD4+ T cell function.	CHEMBL369125	42-45	CD4 antigen	Mus musculus	136-139
28034915-10	2017	Thus, our results suggest that early-life Abx treatment results in a stress response with high levels of corticosterone that influences CD4+ T cell function.	Corticosterone	105-119	CD4 antigen	Mus musculus	136-139
27899739-6	2017	When compared to PP Rag1-/-, vessels from PP CD4-deficient mice, which have B cells and CD8 T cells, but no CD4 cells, show increased distensibility and decreased responsiveness to ACh in a pattern similar to that seen in Rag1-/- given CD8 T cells prior to mating.	Acetylcholine	181-184	CD4 antigen	Mus musculus	45-48
28395714-6	2017	Results The levels of PFA-fixed CD3e+CD4+ T and CD3e+CD8a+ T lymphocytes from spleen tissues significantly decreased at 11 days and 16 days post collection, respectively; whereas no difference was found in the samples without PFA until 8 days and 11 days post collection, respectively.	paraform	22-25	CD4 antigen	Mus musculus	37-40
28361039-8	2017	In comparison to mice exposed to DSS or MAP only, repeated exposure of DSS-treated mice to MAP (DSS/MAP) revealed a significantly enhanced clinical score, reduction of colon length as well as severe CD4+ T cell infiltration into the colonic lamina propria.	Dextran Sulfate	71-74	CD4 antigen	Mus musculus	199-202
28361039-8	2017	In comparison to mice exposed to DSS or MAP only, repeated exposure of DSS-treated mice to MAP (DSS/MAP) revealed a significantly enhanced clinical score, reduction of colon length as well as severe CD4+ T cell infiltration into the colonic lamina propria.	Dextran Sulfate	71-74	CD4 antigen	Mus musculus	199-202
28214044-3	2017	Delivery of OVA with the TLR4 agonist monophosphoryl lipid A (MPLA) in the context of NLPs significantly enhanced the activation of both CD4+ and CD8+ T cells in vitro compared to co-administration of free OVA and MPLA.	monophosphoryl	38-52	CD4 antigen	Mus musculus	137-140
28214044-3	2017	Delivery of OVA with the TLR4 agonist monophosphoryl lipid A (MPLA) in the context of NLPs significantly enhanced the activation of both CD4+ and CD8+ T cells in vitro compared to co-administration of free OVA and MPLA.	Lipid A	53-60	CD4 antigen	Mus musculus	137-140
28214044-3	2017	Delivery of OVA with the TLR4 agonist monophosphoryl lipid A (MPLA) in the context of NLPs significantly enhanced the activation of both CD4+ and CD8+ T cells in vitro compared to co-administration of free OVA and MPLA.	monophosphoryl lipid A	62-66	CD4 antigen	Mus musculus	137-140
28257515-5	2017	Conversely, oral administration of curcumin prevented HFD-induced liver injury, metabolic alterations, intrahepatic CD4+ cell accumulation and the linoleic acid- and leptin- induced pro-inflammatory and pro-oxidant effects on mouse liver macrophages.	Curcumin	35-43	CD4 antigen	Mus musculus	116-119
28361422-2	2017	These nanocomposites stimulated the formation of CD3+CD4+CD8- and CD3+CD4-CD8+ cells from CD3-CD4-CD8- cells, the effect of argentogalactomannan was more potent.	argentogalactomannan	124-144	CD4 antigen	Mus musculus	53-56
28361422-2	2017	These nanocomposites stimulated the formation of CD3+CD4+CD8- and CD3+CD4-CD8+ cells from CD3-CD4-CD8- cells, the effect of argentogalactomannan was more potent.	argentogalactomannan	124-144	CD4 antigen	Mus musculus	70-73
28361422-2	2017	These nanocomposites stimulated the formation of CD3+CD4+CD8- and CD3+CD4-CD8+ cells from CD3-CD4-CD8- cells, the effect of argentogalactomannan was more potent.	argentogalactomannan	124-144	CD4 antigen	Mus musculus	70-73
28222146-6	2017	Immune wild-type CD4+ T cells produced high amounts of IFNgamma, induced the release of nitric oxide in R. typhi-infected macrophages and inhibited bacterial growth in vitro via IFNgamma and TNFalpha.	Nitric Oxide	88-100	CD4 antigen	Mus musculus	17-20
28220870-9	2017	The IFN-gamma/IL-4 and CD4/CD8 ratios increased, the CD4+CD25+ cells reduced on days 30 and 60 after ceftriaxone administration.	Ceftriaxone	101-112	CD4 antigen	Mus musculus	53-56
28220870-10	2017	However, after 90 days of ceftriaxone administration, the IFN-gamma/IL-4, CD4/CD8 ratios and CD4+CD25+ cells restored, which indicated a new balance of immune regulation had been formed.	Ceftriaxone	26-37	CD4 antigen	Mus musculus	74-77
28220870-10	2017	However, after 90 days of ceftriaxone administration, the IFN-gamma/IL-4, CD4/CD8 ratios and CD4+CD25+ cells restored, which indicated a new balance of immune regulation had been formed.	Ceftriaxone	26-37	CD4 antigen	Mus musculus	93-96
28212670-12	2017	Immunizing mice with rSj CP1412 induced high antibody titers, increased serum IL-4 and TGF-beta levels and splenic CD4 + CD25 + Foxp3 + T cells, downregulated serum IFN-gamma levels and alleviated the egg granuloma pathology of schistosome infection.	rsj	21-24	CD4 antigen	Mus musculus	115-118
28212670-12	2017	Immunizing mice with rSj CP1412 induced high antibody titers, increased serum IL-4 and TGF-beta levels and splenic CD4 + CD25 + Foxp3 + T cells, downregulated serum IFN-gamma levels and alleviated the egg granuloma pathology of schistosome infection.	cp1412	25-31	CD4 antigen	Mus musculus	115-118
28212670-13	2017	In vitro stimulation by rSj CP1412 significantly increased CD4 + CD25 + Foxp3 + T cell numbers in splenocytes of healthy mice.	rsj	24-27	CD4 antigen	Mus musculus	59-62
28212670-13	2017	In vitro stimulation by rSj CP1412 significantly increased CD4 + CD25 + Foxp3 + T cell numbers in splenocytes of healthy mice.	cp1412	28-34	CD4 antigen	Mus musculus	59-62
27865421-6	2017	Most importantly, the Us/o+CBD-induced CD4+CD25+ Tregs robustly suppressed responder T cell proliferation, demonstrating that the mechanism by which CBD is immunosuppressive under low-level T cell stimulation involves induction of functional Tregs.	Cannabidiol	27-30	CD4 antigen	Mus musculus	39-42
28004985-6	2017	The results suggested CY administration could promote the percentage of splenic CD8+ T cells and decrease the proportion of CD4 + CD25 + Foxp3+ Tregs in spleen.	Cyclophosphamide	22-24	CD4 antigen	Mus musculus	124-127
27838421-8	2017	(1 3)-beta-d-Glucan was shown to significantly potentiate the mouse immune responses by, among other effects, decreasing the ratio of CD4 to CD8.	(1----3)-beta-d-glucan	0-19	CD4 antigen	Mus musculus	134-137
27574736-8	2017	Tanshinol increased CD4+FoxP3+ Treg numbers in cardiac allografts, but not spleens and lymph nodes, of recipient mice by enhancing chemokine CCL22 expression in cardiac allografts, especially cardiac dendritic cells.	tanshinol	0-9	CD4 antigen	Mus musculus	20-23
27574736-12	2017	CONCLUSIONS: Tanshinol suppresses cardiac allograft rejection by recruiting CD4+FoxP3+ Tregs to the graft, whereas rapamycin does so via expanding the Tregs.	tanshinol	13-22	CD4 antigen	Mus musculus	76-79
27974559-4	2017	In contrast, the number of memory CD4 T cells was increased in rapamycin-treated mice.	Sirolimus	63-72	CD4 antigen	Mus musculus	34-37
28123720-13	2017	However, in vitamin D-treated mice, the thymus indexes, the ratios of CD4+/CD8+, secretion of IL-2 and the proliferation index of spleen T lymphocytes were significantly increased (P&lt;0.05).	Vitamin D	12-21	CD4 antigen	Mus musculus	70-73
28278498-9	2017	CONCLUSION: Our data indicate that oxygen availability can function as a local modulator of CD4+ T cell responses and thus influences tumour immune surveillance in inflammation-associated colon cancer.	Oxygen	35-41	CD4 antigen	Mus musculus	92-95
27989857-1	2017	Our study investigated poly(lactic-co-glycolic acid) (PLGA) as protein delivery vehicles encapsulate CTLA-4-antibody (anti-CTLA-4) which is essential for CD4+CD25+Treg cells suppressive function exposing superior potential for inhibiting endometriosis progress in mouse model than single anti-CTLA-4.	Polylactic Acid-Polyglycolic Acid Copolymer	23-52	CD4 antigen	Mus musculus	154-157
27867030-0	2017	Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4+CD25bri regulatory T cells.	gemcitabine	0-11	CD4 antigen	Mus musculus	102-105
27867030-4	2017	In order to overcome this unwanted suppressive factor, we found that low dose of gemcitabine could reduce the proportion of CD4+CD25bri regulatory T cells in the CIK cell culture system and significantly enhance the anti-tumor activity of CIK cells in vitro.	gemcitabine	81-92	CD4 antigen	Mus musculus	124-127
27867030-5	2017	The levels of interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta) were also reduced significantly following the depletion of CD4+CD25bri regulatory T cells in gemcitabine treated CIK cell culture system.	gemcitabine	177-188	CD4 antigen	Mus musculus	143-146
27867030-6	2017	In vivo experiment showed that low dose of gemcitabine treated CIK cells significantly suppressed tumor growth and prolonged their lifespan in tumor-bearing nude mice, with the proportion of CD4+CD25bri regulatory T cells reduced.	gemcitabine	43-54	CD4 antigen	Mus musculus	191-194
27810232-11	2017	CONCLUSION: In TPA-induced lesional skin of K14.Stat3C mice, IL-17-producing CD4+ Th17 cells, CD8+ Tc17 cells, dermal gammadelta T cells and TCR- cells probably containing ILCs all participated in skin inflammation, which is similar to human clinical psoriatic features.	Tetradecanoylphorbol Acetate	15-18	CD4 antigen	Mus musculus	77-80
27881702-0	2017	Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.	Aluminum Hydroxide	9-27	CD4 antigen	Mus musculus	79-82
27881702-0	2017	Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.	monophosphoryl	32-46	CD4 antigen	Mus musculus	79-82
27881702-0	2017	Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.	Lipid A	47-54	CD4 antigen	Mus musculus	79-82
27881702-4	2017	In contrast, Alum adjuvant effects were dependent on CD4+ T cells.	Aluminum Hydroxide	13-17	CD4 antigen	Mus musculus	53-56
29249872-2	2017	Proinflammatory cytokines such as IL-1beta, IL-6, TNF-alpha, IFN-gamma, IL-12, IL-17, and NO can be released by CD4 and CD8+ lymphocytes as well as by classically activated macrophages (CAMphis), which are important in the development of T1D.	camphis	186-193	CD4 antigen	Mus musculus	112-115
27978490-0	2017	Acute arsenic exposure induces inflammatory responses and CD4+ T cell subpopulations differentiation in spleen and thymus with the involvement of MAPK, NF-kB, and Nrf2.	Arsenic	6-13	CD4 antigen	Mus musculus	58-61
27978490-4	2017	We found that arsenic significantly decreased the spleen and thymus weights and indices, and flow cytometry revealed that arsenic decreased the relative frequency of CD4+ T cell subpopulation and the ratios of CD4/CD8 in spleen.	Arsenic	122-129	CD4 antigen	Mus musculus	166-169
27978490-4	2017	We found that arsenic significantly decreased the spleen and thymus weights and indices, and flow cytometry revealed that arsenic decreased the relative frequency of CD4+ T cell subpopulation and the ratios of CD4/CD8 in spleen.	Arsenic	122-129	CD4 antigen	Mus musculus	210-213
28736026-12	2017	In conclusion, our findings imply that yogurt containing active lactic acid bacteria could change alloimmune responses partially and induce the prolongation of cardiac allograft survival via CD4+Foxp3+ regulatory cells.	Lactic Acid	64-75	CD4 antigen	Mus musculus	191-194
27976742-6	2016	In the fetuses, decreased body weight and organ index of fetal thymus, histological changes in fetal thymus, reduced CD4SP proportion and increased fetal thymocyte apoptosis were observed in nicotine group.	Nicotine	191-199	CD4 antigen	Mus musculus	117-120
27663185-6	2016	Transcriptome analysis revealed that DHA-5-HT down-regulates LPS-induced genes, particularly those involved in generating a CD4+ Th17 response.	dehydroacetic acid	37-40	CD4 antigen	Mus musculus	124-127
27771254-3	2016	CD4+ T-cell deficient MHC-II KO mice showed smaller histologically determined infarct size (34.5+-4.7% in MHCII KO versus 59.4+-4.9% in wildtype (WT)) and better preserved ejection fraction determined by magnetic resonance tomography (56.9+-2.8% in MHC II KO versus 39.0+-4.2% in WT).	mhc ii	249-255	CD4 antigen	Mus musculus	0-3
27564970-17	2016	The same results were found when CD4 + CD25- T-cells were co-cultured with Treg in the NS group.	treg	75-79	CD4 antigen	Mus musculus	33-36
27887569-0	2016	Immune modulation of CD4+CD25+ regulatory T cells by zoledronic acid.	Zoledronic Acid	53-68	CD4 antigen	Mus musculus	21-24
27765364-9	2016	Phyllanthin at 100mg/kg caused a significant reduction in the percentage expression of CD4+ and CD8+ in splenocytes and the inhibition was comparable to that of cyclosporin A at 50mg/kg.	phyllanthin	0-11	CD4 antigen	Mus musculus	87-90
27582100-4	2016	Serum creatinine, blood urea nitrogen (BUN) level, and renal tubular injury score were significantly increased in CD4creIKK2f/f (CD4xIKK2Delta) and CD4creNEMOf/f (CD4xNEMODelta) mice compared with CD4cre mice after IRI induction.	Creatinine	6-16	CD4 antigen	Mus musculus	114-117
27582100-4	2016	Serum creatinine, blood urea nitrogen (BUN) level, and renal tubular injury score were significantly increased in CD4creIKK2f/f (CD4xIKK2Delta) and CD4creNEMOf/f (CD4xNEMODelta) mice compared with CD4cre mice after IRI induction.	Urea	24-28	CD4 antigen	Mus musculus	114-117
27582100-4	2016	Serum creatinine, blood urea nitrogen (BUN) level, and renal tubular injury score were significantly increased in CD4creIKK2f/f (CD4xIKK2Delta) and CD4creNEMOf/f (CD4xNEMODelta) mice compared with CD4cre mice after IRI induction.	Nitrogen	29-37	CD4 antigen	Mus musculus	114-117
27694496-7	2016	Furthermore, PLN CD4+ T cells isolated from anti-CD4 versus control Ab-treated animals displayed increased in vitro chemotaxis to chemoattractants such as sphingosine-1-phosphate and CXCL12.	sphingosine 1-phosphate	155-178	CD4 antigen	Mus musculus	17-20
27694496-7	2016	Furthermore, PLN CD4+ T cells isolated from anti-CD4 versus control Ab-treated animals displayed increased in vitro chemotaxis to chemoattractants such as sphingosine-1-phosphate and CXCL12.	sphingosine 1-phosphate	155-178	CD4 antigen	Mus musculus	49-52
27424318-7	2016	Beneficial immunological effects were also observed: niclosamide decreased the production of effector memory CD4 and CD8 T cells, T-cell infiltration of the skin and visceral organs, and decreased productions of IL-4 and IL-13, and autoimmune B-cell activation.	Niclosamide	53-64	CD4 antigen	Mus musculus	109-112
27817787-0	2016	[Effect of montelukast sodium intervention on airway remodeling and percentage of Th17 cells/CD4+CD25+ regulatory T cells in asthmatic mice].	montelukast	11-29	CD4 antigen	Mus musculus	93-96
27817787-1	2016	OBJECTIVE: To study the dynamic changes in the percentage of Th17 cells/CD4+CD25+ regulatory T cells after intervention with montelukast sodium, a leukotriene receptor antagonist, in asthmatic mice and the association between them.	montelukast	125-143	CD4 antigen	Mus musculus	72-75
27817787-10	2016	Compared with the blank group, the asthma group and the montelukast sodium group had significant increases in Th17 cells (positively correlated with airway remodeling) and significant reductions in CD4+CD25+ regulatory T cells (negatively correlated to airway remodeling) at all time points (P&lt;0.05).	montelukast	56-74	CD4 antigen	Mus musculus	198-201
27817787-11	2016	At 8 weeks of intervention, the montelukast sodium group had a significant reduction in the number of Th17 cells and a significant increase in the number of CD4+CD25+ regulatory T cells compared with the asthma group (P&lt;0.05).	montelukast	32-50	CD4 antigen	Mus musculus	157-160
27448502-0	2016	Stephanthraniline A suppressed CD4(+) T cell-mediated immunological hepatitis through impairing PKCtheta function.	stephanthraniline A	0-19	CD4 antigen	Mus musculus	31-34
27448502-3	2016	The results showed that pretreatment with STA significantly attenuated concanavalin A (Con A)-induced hepatitis and reduced CD4(+) T cells activation and aggregation in hepatic tissue in mice.	stephanthraniline A	42-45	CD4 antigen	Mus musculus	124-127
27448502-8	2016	Collectively, the present study indicated that STA could protect against CD4(+) T cell-mediated immunological hepatitis in mice through PKCtheta and its downstream NFAT, NFkappaB and MAPK signaling cascades.	stephanthraniline A	47-50	CD4 antigen	Mus musculus	73-76
27448502-9	2016	These results highlight the potential of STA as an effective leading compound for use in the treatment of CD4(+) T cell-mediated inflammatory and autoimmune diseases.	stephanthraniline A	41-44	CD4 antigen	Mus musculus	106-109
27638864-5	2016	In addition to genetic deficiency, treatment of wt mice with the Asm inhibitor amitriptyline recapitulated the phenotype of Asm-deficient mice because it also increased the frequency of Tregs among CD4+ T cells.	Amitriptyline	79-92	CD4 antigen	Mus musculus	198-201
27721488-3	2016	Using a cynomolgus macaque model of vaginal challenge with SHIV162P3, we report that mCD4.1-PS1, formulated into a hydroxyethyl-cellulose gel provides 83% protection (5/6 animals).	hydroxyethylcellulose	115-137	CD4 antigen	Mus musculus	85-89
27784989-6	2016	Moringin pretreatment normalizes the aberrant Wnt-beta-catenin pathway, resulting in GSK3beta inhibition and beta-catenin upregulation, which regulates T-cell activation (CD4 and FoxP3), suppresses the main inflammatory mediators (IL-1beta, IL-6, and COX2), through activation of PPARgamma.	moringin	0-8	CD4 antigen	Mus musculus	171-174
27609767-7	2016	Intriguingly, Scd1KO CD4+CD25- T cells display augmented inflammatory cytokine profile and cellular membrane fluidity with a concomitant increase in proinflammatory saturated fatty acids, which we postulate to potentially underlie their augmented colitogenic potential.	Fatty Acids	165-186	CD4 antigen	Mus musculus	21-24
27440860-5	2016	Sorafenib induces differentiation of BMCs into suppressive dendritic cells that inhibit autologous T-cell proliferation and stimulate CD4(+) T cells to express increased IL-1beta, IL-2, IL-4, IL-10, IFN-gamma and TNF-alpha, and reduced levels of IL-6 and CD25, which indicates that sorafenib-induced dendritic cells represent a distinct cellular subset with unique properties.	Sorafenib	0-9	CD4 antigen	Mus musculus	134-137
27494685-6	2016	The ratio of CD4(+)CD25(+)CD127dim/CD4(+) of the kappa-carrageenan+TNBS groups was significantly lower than that of the TNBS group.	Trinitrobenzenesulfonic Acid	67-71	CD4 antigen	Mus musculus	13-16
27494685-6	2016	The ratio of CD4(+)CD25(+)CD127dim/CD4(+) of the kappa-carrageenan+TNBS groups was significantly lower than that of the TNBS group.	Trinitrobenzenesulfonic Acid	67-71	CD4 antigen	Mus musculus	35-38
27494685-6	2016	The ratio of CD4(+)CD25(+)CD127dim/CD4(+) of the kappa-carrageenan+TNBS groups was significantly lower than that of the TNBS group.	Trinitrobenzenesulfonic Acid	120-124	CD4 antigen	Mus musculus	13-16
27449383-10	2016	In addition to decreasing keratinocyte hyper-proliferation and restoring their terminal differentiation, AZM treatment decreased the accumulation of DCs as well as CD4, CD8 T cells and IL-17 producing cells in psoriatic skin lesions.	Azithromycin	105-108	CD4 antigen	Mus musculus	164-167
27549171-7	2016	Administration of DHEA in symptomatic mice induced regulatory CD4(+) T cells that were suppressive in an IL-10-dependent manner.	Dehydroepiandrosterone	18-22	CD4 antigen	Mus musculus	62-65
27549171-8	2016	Expression of the estrogen receptor beta by CD4(+) T cells was necessary for DHEA-mediated EAE amelioration, as well as for direct downregulation of Th17 responses.	Dehydroepiandrosterone	77-81	CD4 antigen	Mus musculus	44-47
27608299-6	2016	AG126 treatment significantly attenuated the severity of AIA and caused a substantial reduction in the percentage of CD2+, CD3+, CD4+, CD8+, CD23+, CD80+, CD86+ CD122+, CD195+, TCRbeta+, and GITR+ cells in whole blood.	AG 127	0-5	CD4 antigen	Mus musculus	129-132
27608299-7	2016	Moreover, administration of AG126 under arthritis-inducing conditions resulted in suppression of IL-17A+, IFN-gamma+, CD4+ and CD25+ populations while causing an increase in the Foxp3+, CD4+Foxp3+, and CD25+Foxp3+ Treg populations in the spleen.	AG 127	28-33	CD4 antigen	Mus musculus	118-121
27608299-7	2016	Moreover, administration of AG126 under arthritis-inducing conditions resulted in suppression of IL-17A+, IFN-gamma+, CD4+ and CD25+ populations while causing an increase in the Foxp3+, CD4+Foxp3+, and CD25+Foxp3+ Treg populations in the spleen.	AG 127	28-33	CD4 antigen	Mus musculus	186-189
27464762-0	2016	DHEA prevents bone loss by suppressing the expansion of CD4(+) T cells and TNFa production in the OVX-mouse model for postmenopausal osteoporosis.	Dehydroepiandrosterone	0-4	CD4 antigen	Mus musculus	56-59
27464762-5	2016	DHEA also suppressed an OVX-induced increase in CD4(+) T cell subsets and TNF-alpha production.	Dehydroepiandrosterone	0-4	CD4 antigen	Mus musculus	48-51
27464762-5	2016	DHEA also suppressed an OVX-induced increase in CD4(+) T cell subsets and TNF-alpha production.	ovx	24-27	CD4 antigen	Mus musculus	48-51
27464762-8	2016	In conclusion, DHEA may prevent bone loss by suppressing the OVX-induced expansion of CD4(+) T cells and TNF-alpha production in mice, independent of E2.	Dehydroepiandrosterone	15-19	CD4 antigen	Mus musculus	86-89
27621627-0	2016	Defect density in multiwalled carbon nanotubes influences ovalbumin adsorption and promotes macrophage activation and CD4(+) T-cell proliferation.	Carbon	30-36	CD4 antigen	Mus musculus	118-121
27083148-6	2016	In TCRdelta(-/-) mice, pulmonary IL-17A(+) CD4(+) Tau cells expanded at days 7 and 14 after bleomycin exposure.	Bleomycin	92-101	CD4 antigen	Mus musculus	43-46
27504712-0	2016	MAP4K4 deficiency in CD4(+) T cells aggravates lung damage induced by ozone-oxidized black carbon particles.	Carbon	91-97	CD4 antigen	Mus musculus	21-24
27263829-9	2016	There was retention of CD4(+) cells in the spleen after use of DHEA, along with augmented frequency of CD4(+)IL-4(+) cells, decreased CD4(+)IFN-gamma(+) in spleen and constrained CD4(+)IL-17(+) population in the mesenteric lymph nodes.	Dehydroepiandrosterone	63-67	CD4 antigen	Mus musculus	23-26
27236299-3	2016	We have previously demonstrated the effect of PF on DCs stimulated with 1-chloro-2,4-dinitrobenze (DNCB) and naive CD4(+)CD45RA(+) T cells for Th17 cell differentiation.	peoniflorin	46-48	CD4 antigen	Mus musculus	115-118
27236299-8	2016	When mice CD4(+)CD45 RA(+) T cells were co-cultured with PF-treated DCs stimulated with/without DNCB, the gene expression of the Th17 cell markers such as retinoic acid-related orphan nuclear hormone receptor gammat (RORgammat), IL-17A, and IL-23R decreased, in accordance with the less secretions of IL-17 and IL-23 in vitro and in vivo.	peoniflorin	57-59	CD4 antigen	Mus musculus	10-13
27236299-8	2016	When mice CD4(+)CD45 RA(+) T cells were co-cultured with PF-treated DCs stimulated with/without DNCB, the gene expression of the Th17 cell markers such as retinoic acid-related orphan nuclear hormone receptor gammat (RORgammat), IL-17A, and IL-23R decreased, in accordance with the less secretions of IL-17 and IL-23 in vitro and in vivo.	Tretinoin	155-168	CD4 antigen	Mus musculus	10-13
26682527-0	2016	Long-term exposure to high levels of decabrominated diphenyl ether inhibits CD4 T-cell functions in C57Bl/6 mice.	phenyl ether	52-66	CD4 antigen	Mus musculus	76-79
26682527-2	2016	This study applies our previous animal model simulating occupational exposure to BDE-209 to investigate its potential adverse effects on CD4 T cells.	decabromobiphenyl ether	81-88	CD4 antigen	Mus musculus	137-140
26682527-7	2016	BDE-209 exposure in vitro also suppressed the reactivity of CD4 T cells at concentrations of 0.01, 0.1, 1 and 10 muM.	decabromobiphenyl ether	0-7	CD4 antigen	Mus musculus	60-63
26682527-8	2016	Furthermore, we observed weaker antigen-specific CD4 T-cell responses to Listeria monocytogenes infection in the mice exposed to BDE-209, suggesting decreased resistance to exogenous pathogens.	decabromobiphenyl ether	129-136	CD4 antigen	Mus musculus	49-52
27456482-0	2016	Prostaglandin I2 Suppresses Proinflammatory Chemokine Expression, CD4 T Cell Activation, and STAT6-Independent Allergic Lung Inflammation.	Epoprostenol	0-16	CD4 antigen	Mus musculus	66-69
27456482-7	2016	We also showed that the PGI2 analogue cicaprost inhibited CD4 T cell proliferation and IL-5 and IL-13 expression in vitro, and IP deficiency diminished the stimulatory effect of indomethacin on STAT6-independent IL-5 and IL-13 responses in vivo.	cicaprost	38-47	CD4 antigen	Mus musculus	58-61
27456482-8	2016	The inhibitory effects of PGI2 and the IP signaling pathway on CD4 T cell activation, inflammatory chemokine production, and allergic sensitization and airway inflammation suggest that PGI2 and its analogue iloprost, both Food and Drug Administration-approved drugs, may be useful in treating allergic diseases and asthma.	Iloprost	207-215	CD4 antigen	Mus musculus	63-66
27474077-0	2016	NADPH Oxidase-Derived Superoxide Provides a Third Signal for CD4 T Cell Effector Responses.	Superoxides	22-32	CD4 antigen	Mus musculus	61-64
27561877-0	2016	Baicalein induces CD4(+)Foxp3(+) T cells and enhances intestinal barrier function in a mouse model of food allergy.	baicalein	0-9	CD4 antigen	Mus musculus	18-21
27217214-7	2016	Treatment with CGS significantly suppressed specific lymphocyte proliferation, reduced infiltration of CD4(+) T lymphocytes, and attenuated the expression of inflammatory cytokines, which in turn inhibited the EAE progression.	2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine	15-18	CD4 antigen	Mus musculus	103-106
27481131-5	2016	Using a tamoxifen-dependent conditional Blimp-1 knockout mixed bone marrow chimera as well as an adoptive transfer approach, we show that CD4 T cell-intrinsic deletion of Blimp-1 reversed CD8 T cell dysfunction and resulted in improved pathogen control.	Tamoxifen	8-17	CD4 antigen	Mus musculus	138-141
27402696-1	2016	The vitamin A metabolite all-trans retinoic acid (ATRA) induces a gut-homing phenotype in activated CD4(+) conventional T cells (Tconv) by upregulating the integrin alpha4beta7 and the chemokine receptor CCR9.	Vitamin A	4-13	CD4 antigen	Mus musculus	100-103
27402696-1	2016	The vitamin A metabolite all-trans retinoic acid (ATRA) induces a gut-homing phenotype in activated CD4(+) conventional T cells (Tconv) by upregulating the integrin alpha4beta7 and the chemokine receptor CCR9.	Tretinoin	35-48	CD4 antigen	Mus musculus	100-103
27402696-1	2016	The vitamin A metabolite all-trans retinoic acid (ATRA) induces a gut-homing phenotype in activated CD4(+) conventional T cells (Tconv) by upregulating the integrin alpha4beta7 and the chemokine receptor CCR9.	Tretinoin	50-54	CD4 antigen	Mus musculus	100-103
27460423-6	2016	CPS-II also significantly increased the expression of CD4(+) and CD8(+) splenic T lymphocytes, which were suppressed by CTX in peripheral blood.	cps-ii	0-6	CD4 antigen	Mus musculus	54-57
27439875-3	2016	In mice lacking CRBN, CD4(+) T cells show increased activation and IL-2 production on T-cell receptor stimulation, ultimately resulting in increased potassium flux and calcium-mediated signaling.	Potassium	149-158	CD4 antigen	Mus musculus	22-25
27439875-3	2016	In mice lacking CRBN, CD4(+) T cells show increased activation and IL-2 production on T-cell receptor stimulation, ultimately resulting in increased potassium flux and calcium-mediated signaling.	Calcium	168-175	CD4 antigen	Mus musculus	22-25
27365404-8	2016	Adoptive transfer of Axl(-/-) CD4(+) T cells was protective in a later phase of deoxycorticosterone-acetate and salt hypertension.	Desoxycorticosterone Acetate	80-107	CD4 antigen	Mus musculus	30-33
27106589-4	2016	In the thymus, an increase of CD4+ and a decrease of CD8+ T-cells were observed after oral administration of BanLec.	banlec	109-115	CD4 antigen	Mus musculus	30-33
26744488-4	2016	In this study, cell tracking experiments with CD4-Cre mT/mG reporter mice revealed robust infiltration of T lymphocytes into the kidney after cisplatin injection.	Cisplatin	142-151	CD4 antigen	Mus musculus	46-49
26661207-4	2016	We show that magnetic resonance imaging (MRI) or Xenogen imaging combined with labeling of SPIO-Molday ION Rhodamine-B (MIRB) can be used to monitor the dynamics of CD4(+) T cells in a passive transfer model.	xenogen	49-56	CD4 antigen	Mus musculus	165-168
26661207-4	2016	We show that magnetic resonance imaging (MRI) or Xenogen imaging combined with labeling of SPIO-Molday ION Rhodamine-B (MIRB) can be used to monitor the dynamics of CD4(+) T cells in a passive transfer model.	rhodamine B	107-118	CD4 antigen	Mus musculus	165-168
26661207-5	2016	MIRB-labeled CD4(+) T cells can be longitudinally visualized in the mouse brain and peripheral organs such as the spleen and liver after cerebral ischemia.	mirb	0-4	CD4 antigen	Mus musculus	13-16
27335499-6	2016	In fact, a transient treatment with a specific CD73 inhibitor (adenosine 5"-alpha,beta-methylene-diphosphate) enhanced the microbicidal M1 subset predominance, diminished IL-4- and IL-10-producing CD4(+) T cells, promoted a proinflammatory cytokine milieu, and reduced parasite load within the myocardium during the acute phase.	alpha,beta-methyleneadenosine 5'-diphosphate	63-108	CD4 antigen	Mus musculus	197-200
27295346-0	2016	Recombinant IL-33 prolongs leflunomide-mediated graft survival by reducing IFN-gamma and expanding CD4(+)Foxp3(+) T cells in concordant heart transplantation.	Leflunomide	27-38	CD4 antigen	Mus musculus	99-102
26041399-13	2016	RESULTS: Compared with mice treated with CA + RA, CA + TA, or CA alone, the mice treated with CA + RA + TA showed (1) significantly smaller tumor weight and tumor volume; (2) significantly longer tumor latency; (3) significantly lower tumor incidence; and (4) significantly increased percentage of CD4(+) and CD8(+) in spleen and increased activities of NK and CTL.	ca + ra + ta	94-106	CD4 antigen	Mus musculus	298-301
27418244-8	2016	RESULTS The inhalation of ketamine 25 or 50 mg/mL markedly suppressed OVA-induced airway hyper-responsiveness and airway inflammation, significantly increased the percentage of CD4+CD25+ T cells, and significantly decreased OVA-induced up-regulation of TGF-beta1 and the EMT.	Ketamine	26-34	CD4 antigen	Mus musculus	177-180
27226368-3	2016	CD4(+) T cells were required for the induction of IgG antibody responses to the split vaccine and the effects of alum adjuvant.	alum adjuvant	113-126	CD4 antigen	Mus musculus	0-3
27377819-7	2016	AZA-treated mice had also lower counts of CD4(+)Tconvs and CD8(+) T cells from day +21 to day +35 after transplantation, as well as a lower proportion of CD4(+)Tconvs expressing the Ki67 antigen on day +21 demonstrating an anti-proliferating effect of the drug on T cells.	Azacitidine	0-3	CD4 antigen	Mus musculus	42-45
27377819-7	2016	AZA-treated mice had also lower counts of CD4(+)Tconvs and CD8(+) T cells from day +21 to day +35 after transplantation, as well as a lower proportion of CD4(+)Tconvs expressing the Ki67 antigen on day +21 demonstrating an anti-proliferating effect of the drug on T cells.	Azacitidine	0-3	CD4 antigen	Mus musculus	154-157
27013083-8	2016	Meanwhile, the effect of daphnetin on the activity of dendritic cells (DCs) was evaluated, as assessed by DCs" capability to express surface markers, secrete cytokines, and activate naive CD4(+) T cells.	daphnetin	25-34	CD4 antigen	Mus musculus	188-191
27013083-9	2016	Furthermore, we explored the molecular mechanisms whereby DAPH regulated DCs" activity and thereby CD4(+) T cell responses.	4,5-dianilinophthalimide	58-62	CD4 antigen	Mus musculus	99-102
27533940-6	2016	Co-culture of CD4(+) T lymphocyte and peritoneal macrophage 7 days after melatonin administration to young and aged mice significantly increased APRIL mRNA, suggesting induction or maintenance of T lymphocyte responses.	Melatonin	73-82	CD4 antigen	Mus musculus	14-17
27216637-9	2016	There was also a significant and dose-responsive increase in the number of activated CD44 (+) CD4 (+) and CD8 (+) T-cells and CD86 (+) B-cells and dendritic cells following exposure to all concentrations of DDAC.	didecyldimethylammonium	207-211	CD4 antigen	Mus musculus	85-88
27191183-2	2016	The hollow structure of mesoporous silica nanospheres significantly promote cellular uptake of a model cancer antigen by macrophage-like cells in vitro, improve anti-cancer immunity, CD4(+) and CD8(+) T cell populations in splenocytes of mice in vivo.	Silicon Dioxide	35-41	CD4 antigen	Mus musculus	183-186
27622052-6	2016	This should result in an increase in Tregs, but paradoxically our data illustrate that PEG-rIL-10 treatment of mice reduces intratumoral FoxP3(+)CD4(+) T cells in an IDO-independent manner.	peg-ril-10	87-97	CD4 antigen	Mus musculus	145-148
27622052-7	2016	Additional investigation indicates that PEG-rIL-10 inhibits TGFbeta/IL-2-dependent in vitro polarization of FoxP3(+)CD4(+) Tregs and potentiates IFNgamma(+)T-bet(+)CD4(+) T cells.	peg-ril-10	40-50	CD4 antigen	Mus musculus	116-119
27622052-7	2016	Additional investigation indicates that PEG-rIL-10 inhibits TGFbeta/IL-2-dependent in vitro polarization of FoxP3(+)CD4(+) Tregs and potentiates IFNgamma(+)T-bet(+)CD4(+) T cells.	peg-ril-10	40-50	CD4 antigen	Mus musculus	164-167
27622052-8	2016	These data suggest that rather than acting as an immunosuppressant, PEG-rIL-10 may counteract the FoxP3(+)CD4(+) Treg suppressive milieu in tumor-bearing mice and humans, thereby further facilitating PEG-rIL-10"s potent antitumor immunity.	peg-ril-10	68-78	CD4 antigen	Mus musculus	106-109
27347005-6	2016	Activity tests showed that Se-CEPS improved the immune organ index, serum cytokine content, and CD8(+) and CD4(+) T lymphocyte ratio in colon cancer CT26 tumor-bearing mice, thereby inhibiting tumor growth.	se-ceps	27-34	CD4 antigen	Mus musculus	107-110
27251638-3	2016	CD4(+) T helper cells are poised to be influenced by MT transduced zinc signaling because they produce intracellular reactive oxygen species following activation through the T cell receptor and are sensitive to small changes in intracellular [Zn(2+)].	Reactive Oxygen Species	117-140	CD4 antigen	Mus musculus	0-3
27251638-3	2016	CD4(+) T helper cells are poised to be influenced by MT transduced zinc signaling because they produce intracellular reactive oxygen species following activation through the T cell receptor and are sensitive to small changes in intracellular [Zn(2+)].	Zinc	243-249	CD4 antigen	Mus musculus	0-3
27383160-2	2016	Fluoxetine produced an immunostimulatory effect manifested in an increase in the relative and absolute number of IgM antibody-producing cells in the spleen and index of immunoreactivity (CD4/CD8).	Fluoxetine	0-10	CD4 antigen	Mus musculus	187-190
26154776-0	2016	Fructooligosaccharides exert intestinal anti-inflammatory activity in the CD4+ CD62L+ T cell transfer model of colitis in C57BL/6J mice.	fructooligosaccharide	0-22	CD4 antigen	Mus musculus	74-77
27183595-5	2016	The data are consistent with a compact assembly in which CD4 is proximal to CD3deltaepsilon, CD3zetazeta resides behind the TCR, and CD3gammaepsilon is offset from CD3deltaepsilon.	cd3deltaepsilon	76-91	CD4 antigen	Mus musculus	57-60
27109448-0	2016	CD4+ T cell responses in Balb/c mice with food allergy induced by trinitrobenzene sulfonic acid and ovalbumin.	Trinitrobenzenesulfonic Acid	66-95	CD4 antigen	Mus musculus	0-3
26900758-7	2016	Furthermore, the number of CD4(+) CD25(+) FoxP3(+) regulatory T (Treg) cells was significantly increased by treatment with 4-MH (40 mg/kg).	4-methylhistamine	123-127	CD4 antigen	Mus musculus	27-30
26704363-6	2016	Likewise, CD4(+) T-cells lacking HDAC5 convert poorly to Tregs under appropriately polarizing conditions.	tregs	57-62	CD4 antigen	Mus musculus	10-13
27059596-2	2016	Thus, we predicted that injection of clodronate-containing liposomes (CLs), which selectively deplete cells efficient in phagocytosis, would inhibit murine CD4(+) T cell-dependent IgG responses to Ags expressed by intact bacteria but not isolated soluble Ags.	Clodronic Acid	37-47	CD4 antigen	Mus musculus	156-159
27059596-2	2016	Thus, we predicted that injection of clodronate-containing liposomes (CLs), which selectively deplete cells efficient in phagocytosis, would inhibit murine CD4(+) T cell-dependent IgG responses to Ags expressed by intact bacteria but not isolated soluble Ags.	calusterone	70-73	CD4 antigen	Mus musculus	156-159
27076682-3	2016	In this article, we demonstrate that chemokines, which bind CCR5 and CXCR4, especially SDF-1alpha/CXCL12, result in a transient opening (peak at 5 min) of Panx1 channels found on CD4(+) T lymphocytes, which induces ATP secretion, focal adhesion kinase phosphorylation, cell polarization, and subsequent migration.	Adenosine Triphosphate	215-218	CD4 antigen	Mus musculus	179-182
27148737-0	2016	Estradiol Enhances CD4+ T-Cell Anti-Viral Immunity by Priming Vaginal DCs to Induce Th17 Responses via an IL-1-Dependent Pathway.	Estradiol	0-9	CD4 antigen	Mus musculus	19-22
27092578-0	2016	Chronic exposure to water pollutant trichloroethylene increased epigenetic drift in CD4(+) T cells.	Trichloroethylene	36-53	CD4 antigen	Mus musculus	84-87
27092578-1	2016	AIM: Autoimmune disease and CD4(+) T-cell alterations are induced in mice exposed to the water pollutant trichloroethylene (TCE).	Trichloroethylene	105-122	CD4 antigen	Mus musculus	28-31
27092578-1	2016	AIM: Autoimmune disease and CD4(+) T-cell alterations are induced in mice exposed to the water pollutant trichloroethylene (TCE).	Trichloroethylene	124-127	CD4 antigen	Mus musculus	28-31
27092578-4	2016	RESULTS: A probabilistic model calculated from multiple genes showed that TCE decreased methylation control in CD4(+) T cells.	Trichloroethylene	74-77	CD4 antigen	Mus musculus	111-114
27131971-12	2016	Administered MICCop migrated to various organs leading to an increased infiltration of the spleen and the central nervous system with CD4(+)CD25(+)FoxP3(+) cells displaying a suppressive cytokine profile and inhibiting T-cell responses.	miccop	13-19	CD4 antigen	Mus musculus	134-137
26822306-6	2016	In fact, the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has been shown to attenuate EAE pathogenesis by affecting CD4(+ )T and regulatory T (Treg) cells in an AHR-dependent manner.	Polychlorinated Dibenzodioxins	39-74	CD4 antigen	Mus musculus	140-143
26822306-6	2016	In fact, the environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has been shown to attenuate EAE pathogenesis by affecting CD4(+ )T and regulatory T (Treg) cells in an AHR-dependent manner.	Polychlorinated Dibenzodioxins	76-80	CD4 antigen	Mus musculus	140-143
27134645-14	2016	CONCLUSION: LZ-SMS treatment led to significant increases in the percentages of CD4(+)CD25(+)Foxp3(+) Treg and IL-10(+) Breg cells, together with a reduction in the plasma concentrations of several inflammatory cytokines and the down-regulated expression of the corresponding cytokine related genes in SLE mice.	lz-sms	12-18	CD4 antigen	Mus musculus	80-83
26921788-0	2016	Environmentally relevant concentrations of arsenite and monomethylarsonous acid inhibit IL-7/STAT5 cytokine signaling pathways in mouse CD3+CD4-CD8- double negative thymus cells.	arsenite	43-51	CD4 antigen	Mus musculus	140-143
26921788-0	2016	Environmentally relevant concentrations of arsenite and monomethylarsonous acid inhibit IL-7/STAT5 cytokine signaling pathways in mouse CD3+CD4-CD8- double negative thymus cells.	monomethylarsonous acid	56-79	CD4 antigen	Mus musculus	140-143
26660519-11	2016	Consistent with direct inhibition of T cells, ibrutinib inhibited Th17 differentiation of murine CD4(+)T cells in vitro Finally, in the bone marrow microenvironment, we found that ibrutinib disaggregated the interactions of macrophages and CLL cells, inhibited secretion of CXCL13, and decreased the chemoattraction of CLL cells.	ibrutinib	46-55	CD4 antigen	Mus musculus	97-100
26854575-6	2016	After resveratrol-treatment (15 mg/kg body weight), the function of peritoneal macrophages was enhanced and the CD4+ cells were increased in peripheral blood.	Resveratrol	6-17	CD4 antigen	Mus musculus	112-115
26874324-5	2016	In addition, we found that acarbose reduced infiltration of CD3(+) T cells and GR-1(+) neutrophils in lesional skin and also reduced the percentage of IL-17-producing CD4(+) T cells (Th17) and IL-17- and IL-22-producing gammadelta T cells in the spleen.	Acarbose	27-35	CD4 antigen	Mus musculus	167-170
26620676-2	2016	The aim of the study was to determine whether CD4 T cell knockout protects against AKI and cancer in a clinically relevant model of low-dose cisplatin-induced AKI in mice with cancer.	Cisplatin	141-150	CD4 antigen	Mus musculus	46-49
26620676-6	2016	Tumor size was double, and cisplatin had an impaired therapeutic effect on the tumors in CD4 -/- vs. wild-type mice.	Cisplatin	27-36	CD4 antigen	Mus musculus	89-92
26620676-7	2016	Mice depleted of CD4 T cells using the GK1.5 antibody were not protected against AKI and had larger tumors and lesser response to cisplatin.	Cisplatin	130-139	CD4 antigen	Mus musculus	17-20
26620676-8	2016	In summary, in a clinically relevant model of cisplatin-induced AKI in mice with cancer, (1) CD4 -/- mice were not protected against AKI; (2) ERK, p38, CXCL1, and TNF-alpha, known mediators of AKI, and interstitial fibrosis were increased in CD4 -/- kidneys; and (3) CD4 -/- mice had faster tumor growth and an impaired therapeutic effect of cisplatin on the tumors.	Cisplatin	46-55	CD4 antigen	Mus musculus	93-96
26620676-13	2016	CD4 -/- mice had an impaired therapeutic effect of cisplatin on the tumors.	Cisplatin	51-60	CD4 antigen	Mus musculus	0-3
26982734-4	2016	Inhibiting cholesterol esterification in T cells by genetic ablation or pharmacological inhibition of ACAT1, a key cholesterol esterification enzyme, led to potentiated effector function and enhanced proliferation of CD8(+) but not CD4(+) T cells.	Cholesterol	11-22	CD4 antigen	Mus musculus	232-235
27015810-6	2016	RESULTS: Intragastric administration of kappa-carrageenan to BALB/c mice prior to the induction of oxazolone colitis resulted in an aggravation of body weight loss, a decrease in the survival ratio, aggravation of colonic inflammation, and decrease in the ratio of CD4 + CD25+/CD4+.	Carrageenan	40-57	CD4 antigen	Mus musculus	265-268
27015810-6	2016	RESULTS: Intragastric administration of kappa-carrageenan to BALB/c mice prior to the induction of oxazolone colitis resulted in an aggravation of body weight loss, a decrease in the survival ratio, aggravation of colonic inflammation, and decrease in the ratio of CD4 + CD25+/CD4+.	Carrageenan	40-57	CD4 antigen	Mus musculus	277-280
26868187-0	2016	IkappaB kinase beta inhibitor, IMD-0354, prevents allergic asthma in a mouse model through inhibition of CD4(+) effector T cell responses in the lung-draining mediastinal lymph nodes.	N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide	31-39	CD4 antigen	Mus musculus	105-108
27471620-6	2016	Finally, LPS/ibrutinib-treated DCs promoted higher rates of CD4(+) T cell proliferation and cytokine production compared to LPS only stimulated DCs.	ibrutinib	13-22	CD4 antigen	Mus musculus	60-63
27471620-7	2016	Taken together, our results indicate that ibrutinib enhances the maturation and activation of DCs to promote CD4(+) T cell activation which could be exploited for the development of DC-based cancer therapies.	ibrutinib	42-51	CD4 antigen	Mus musculus	109-112
26267553-5	2016	The percentages of CD4(+) and CD8(+) T cells that decreased with the fluoride administration were confirmed by flow cytometry.	Fluorides	69-77	CD4 antigen	Mus musculus	19-22
26267553-8	2016	Our findings suggest that the administration of high concentrations of fluoride to mice induces a decrease in CD4(+) and CD8(+) thymus T cells by harming TECs leading to the dysfunction of the thymus by altering the expression of T cell function-related genes and immunoregulatory cytokine production.	Fluorides	71-79	CD4 antigen	Mus musculus	110-113
26927553-0	2016	[Tubacin promotes Foxp3 expression and suppressive function of mouse CD4+;CD25+; regulatory T cells].	tubacin	1-8	CD4 antigen	Mus musculus	69-72
26927553-6	2016	The tubacin induced CD4(+) CD25(+) Foxp3(high) Tregs significantly inhibited syngeneic CD4(+) CD25(-) T cell activation.	tubacin	4-11	CD4 antigen	Mus musculus	20-23
26927553-6	2016	The tubacin induced CD4(+) CD25(+) Foxp3(high) Tregs significantly inhibited syngeneic CD4(+) CD25(-) T cell activation.	tubacin	4-11	CD4 antigen	Mus musculus	87-90
26927553-7	2016	CONCLUSION: Tubacin can upregulate Foxp3 expression of CD4(+) CD25(+) Tregs and enhances their cellular immunosuppressive capability.	tubacin	12-19	CD4 antigen	Mus musculus	55-58
27236895-0	2016	[Effect of Coixenolide on Foxp3+ CD4+ CD25+ Regulatory T Cells in Collagen-induced Arthritis Mice].	Coixenolide	11-22	CD4 antigen	Mus musculus	33-36
27236895-1	2016	OBJECTIVE: To study the effect of coixenolide on Foxp3+ CD4+ CD25+ regulatory T cells (Treg) in collagen induced arthritis (CIA) mice, and to explore its possible mechanism for treating rheumatiol arthritis.	Coixenolide	34-45	CD4 antigen	Mus musculus	56-59
27236895-11	2016	Foxp3+ CD4+ CD25+ Treg levels obviously increased more in the coixenolide control group than in the model control group (P &lt; 0.01).	Coixenolide	62-73	CD4 antigen	Mus musculus	7-10
27236895-12	2016	CONCLUSION: Coixenolide could up-regulate Foxp3+ CD4+ CD25+ Treg ratios in CIA mice, which might play certain immunoregulation roles in the incidence of CIA.	Coixenolide	12-23	CD4 antigen	Mus musculus	49-52
26728458-6	2016	NAADP was shown to evoke functionally relevant Ca(2+) signals in both naive CD4 and naive CD8 T cells.	NAADP	0-5	CD4 antigen	Mus musculus	76-79
26901413-0	2016	IL-17 Induction by ArtinM is Due to Stimulation of IL-23 and IL-1 Release and/or Interaction with CD3 in CD4+ T Cells.	artinm	19-25	CD4 antigen	Mus musculus	105-108
26901413-9	2016	Therefore, we investigated whether ArtinM exerts a direct effect on CD4+ T cells in promoting IL-17 production.	artinm	35-41	CD4 antigen	Mus musculus	68-71
26901413-10	2016	Indeed, spleen cell suspensions depleted of CD4+ T cells responded to ArtinM with very low levels of IL-17 release.	artinm	70-76	CD4 antigen	Mus musculus	44-47
26901413-11	2016	Likewise, isolated CD4+ T cells under ArtinM stimulus augmented the expression of TGF-beta mRNA and released high levels of IL-17.	artinm	38-44	CD4 antigen	Mus musculus	19-22
26901413-13	2016	We verified that ArtinM increased the IL-17 production significantly, a response that was inhibited when the CD4+ T cells were pre-incubated with anti-CD3 antibody.	artinm	17-23	CD4 antigen	Mus musculus	109-112
26901413-14	2016	In conclusion, ArtinM stimulates the production of IL-17 by CD4+ T cells in two major ways: (I) through the induction of IL-23 and IL-1 by APCs and (II) through the direct interaction with CD3 on the CD4+ T cells.	artinm	15-21	CD4 antigen	Mus musculus	60-63
26901413-14	2016	In conclusion, ArtinM stimulates the production of IL-17 by CD4+ T cells in two major ways: (I) through the induction of IL-23 and IL-1 by APCs and (II) through the direct interaction with CD3 on the CD4+ T cells.	artinm	15-21	CD4 antigen	Mus musculus	200-203
26879055-6	2016	Notably, the antiserum only had significant protective role against similar bacteria, while adoptive transfer of lymphocytes significantly controlled the spread of the virulent heterologous serogroup PAO-6 infection, and the protective role could be reversed by CD4 rather than CD8 antibody.	pao-6	200-205	CD4 antigen	Mus musculus	262-265
26604037-9	2016	CD4 and CD8 T cells and B cells in atherosclerotic lesions were decreased in DPPE-PEG350-treated mice.	dppe-peg350	77-88	CD4 antigen	Mus musculus	0-3
26838738-11	2016	Real-time PCR results showed that TGF-beta and MCP-1 had no significant changes, at the same time, CD4(+) T cells associated cytokines were partially regulated by pioglitazone pretreatment.	Pioglitazone	163-175	CD4 antigen	Mus musculus	99-102
26746143-2	2016	Exosomes (EXs) secreted from dendritic cells (DCs) can activate T cells in tumor models; however, whether DEXs (DC-EXs) can mediate CD4(+) T cell activation and improve wound healing post-MI remains unknown.	dexs	106-110	CD4 antigen	Mus musculus	132-135
26746143-2	2016	Exosomes (EXs) secreted from dendritic cells (DCs) can activate T cells in tumor models; however, whether DEXs (DC-EXs) can mediate CD4(+) T cell activation and improve wound healing post-MI remains unknown.	dc-exs	112-118	CD4 antigen	Mus musculus	132-135
26746143-3	2016	This study sought to determine whether DEXs mediate CD4(+) T cell activation and improve cardiac function post-MI in mice.	dexs	39-43	CD4 antigen	Mus musculus	52-55
26746143-9	2016	Confocal imaging and flow cytometry revealed that MI-DEXs exhibited higher uptake by splenic CD4(+) T cells than the control- and negative-DEXs, and this increase was correlated with significantly greater increases in the expression of chemokines and the inflammatory cytokines IFN-gamma and TNF by the CD4(+) T cells in vitro and in vivo.	dexs	53-57	CD4 antigen	Mus musculus	93-96
26746143-9	2016	Confocal imaging and flow cytometry revealed that MI-DEXs exhibited higher uptake by splenic CD4(+) T cells than the control- and negative-DEXs, and this increase was correlated with significantly greater increases in the expression of chemokines and the inflammatory cytokines IFN-gamma and TNF by the CD4(+) T cells in vitro and in vivo.	dexs	53-57	CD4 antigen	Mus musculus	303-306
26746143-11	2016	These results suggest that DEXs could mediate the activation of CD4(+) T cells through an endocrine mechanism and improve cardiac function post-MI.	dexs	27-31	CD4 antigen	Mus musculus	64-67
26657721-6	2016	The results showed that peptides containing 63-77 and 96-110 induced significant antigen-specific CD4(+) T-cells proliferation response in vivo.	Peptides	24-32	CD4 antigen	Mus musculus	98-101
26499876-3	2016	Supplementation with quercetin suppressed the increase in the number of macrophages, the decrease in the ratio of CD4(+) to CD8(+) T cells in EAT, and the elevation of plasma leptin and tumor necrosis factor alpha levels in mice fed the Western diet.	Quercetin	21-30	CD4 antigen	Mus musculus	114-117
26902275-8	2016	FITC-labeled human anti-mouse CD4 monoclonal antibody and PE-labeled human anti-mouse interleukin-4 (IL-4) monoclonal antibody were added to the other part of cell suspension to mark Th2.	Fluorescein-5-isothiocyanate	0-4	CD4 antigen	Mus musculus	30-33
26869766-0	2016	Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(-)CD69(+) subset proliferation.	18alpha,20beta-hydroxy-11-oxo-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranurosyl-alpha-D-glucopyranosiduronate magnesium tetrahydrate	63-91	CD4 antigen	Mus musculus	114-117
26763872-5	2016	In contrast, temporarily immunosuppressed allogeneic mice, following cessation of tacrolimus injection displayed diminished progression of the teratocarcinoma, accompanied by an accumulation of CD4/CD8-positive T cells, and finally achieved complete elimination of the teratocarcinoma.	Tacrolimus	82-92	CD4 antigen	Mus musculus	194-197
26571309-0	2016	A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs.	glucopyranosyl lipid-A	38-41	CD4 antigen	Mus musculus	52-55
26476105-0	2016	n-3 polyunsaturated fatty acids suppress CD4(+) T cell proliferation by altering phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] organization.	Fatty Acids, Omega-3	0-31	CD4 antigen	Mus musculus	41-44
26476105-0	2016	n-3 polyunsaturated fatty acids suppress CD4(+) T cell proliferation by altering phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] organization.	Phosphatidylinositol 4,5-Diphosphate	81-120	CD4 antigen	Mus musculus	41-44
26476105-0	2016	n-3 polyunsaturated fatty acids suppress CD4(+) T cell proliferation by altering phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] organization.	pi(4,5)p2	122-131	CD4 antigen	Mus musculus	41-44
26476105-2	2016	We have previously demonstrated that n-3 PUFA decrease the amount of phosphatidylinositol-(4,5)-bisphosphate, [PI(4,5)P2], in CD4(+) T cells, leading to suppressed actin remodeling upon activation.	Fatty Acids, Omega-3	37-45	CD4 antigen	Mus musculus	126-129
26476105-2	2016	We have previously demonstrated that n-3 PUFA decrease the amount of phosphatidylinositol-(4,5)-bisphosphate, [PI(4,5)P2], in CD4(+) T cells, leading to suppressed actin remodeling upon activation.	Phosphatidylinositol 4,5-Diphosphate	69-108	CD4 antigen	Mus musculus	126-129
26476105-2	2016	We have previously demonstrated that n-3 PUFA decrease the amount of phosphatidylinositol-(4,5)-bisphosphate, [PI(4,5)P2], in CD4(+) T cells, leading to suppressed actin remodeling upon activation.	pi(4,5)p2	111-120	CD4 antigen	Mus musculus	126-129
26476105-5	2016	CD4(+) T cells enriched in n-3 PUFA also exhibited a depleted plasma membrane non-raft PI(4,5)P2 pool as detected by decreased co-clustering of Src(N15), a non-raft marker, and PH(PLC-delta), a PI(4,5)P2 reporter.	pi(4,5)p2	87-96	CD4 antigen	Mus musculus	0-3
26476105-6	2016	Incubation with exogenous PI(4,5)P2 rescued the effects on the non-raft PI(4,5)P2 pool, and reversed the suppression of T cell proliferation in CD4(+) T cells enriched with n-3 PUFA.	pi(4,5)p2	26-35	CD4 antigen	Mus musculus	144-147
26476105-7	2016	Furthermore, CD4(+) T cells isolated from mice fed a 4% docosahexaenoic acid (DHA)-enriched diet exhibited a decrease in the non-raft pool of PI(4,5)P2, and exogenous PI(4,5)P2 reversed the suppression of T cell proliferation.	Docosahexaenoic Acids	56-76	CD4 antigen	Mus musculus	13-16
26476105-7	2016	Furthermore, CD4(+) T cells isolated from mice fed a 4% docosahexaenoic acid (DHA)-enriched diet exhibited a decrease in the non-raft pool of PI(4,5)P2, and exogenous PI(4,5)P2 reversed the suppression of T cell proliferation.	Docosahexaenoic Acids	78-81	CD4 antigen	Mus musculus	13-16
26476105-7	2016	Furthermore, CD4(+) T cells isolated from mice fed a 4% docosahexaenoic acid (DHA)-enriched diet exhibited a decrease in the non-raft pool of PI(4,5)P2, and exogenous PI(4,5)P2 reversed the suppression of T cell proliferation.	pi(4,5)p2	142-151	CD4 antigen	Mus musculus	13-16
26476105-7	2016	Furthermore, CD4(+) T cells isolated from mice fed a 4% docosahexaenoic acid (DHA)-enriched diet exhibited a decrease in the non-raft pool of PI(4,5)P2, and exogenous PI(4,5)P2 reversed the suppression of T cell proliferation.	pi(4,5)p2	167-176	CD4 antigen	Mus musculus	13-16
27537353-6	2016	Additionally, the percentage of CD4+ T lymphocytes, CD8+ T lymphocytes and NK cells was increased in tumor-bearing mice following PTA administration.	pta	130-133	CD4 antigen	Mus musculus	32-35
27140596-8	2016	In the present study, LY294002 resulted in a moderate reduction in absolute CD4(+) cell numbers and a significant decrease in the absolute numbers of CD8(+) cells.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	22-30	CD4 antigen	Mus musculus	76-79
27140596-9	2016	Consequently, LY294002 increased the CD4(+)/CD8(+) ratio compared with peptide treatment alone.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	14-22	CD4 antigen	Mus musculus	37-40
26202376-0	2016	Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.	Naltrexone	34-44	CD4 antigen	Mus musculus	91-94
26262583-6	2016	CD4(+) helper and CD8(+) cytotoxic T lymphocytes were essential for the antitumor effect generated by Meso-VAX combined with AAV-IL-12.	meso-vax	102-110	CD4 antigen	Mus musculus	0-3
26051593-4	2016	In addition, we show that autocrine PGE2 signaling through EP receptors is essential for optimal CD4(+) T-cell activation in vitro and in vivo, and for T helper 1 (Th1) and regulatory T cell differentiation.	Dinoprostone	36-40	CD4 antigen	Mus musculus	97-100
26608911-1	2016	We have previously shown that CD4(+) T cells from B6.Sle1Sle2.Sle3 lupus mice and patients present a high cellular metabolism, and a treatment combining 2-deoxy-D-glucose, which inhibits glucose metabolism, and metformin, which inhibits oxygen consumption, normalized lupus T cell functions in vitro and reverted disease in mice.	Deoxyglucose	153-170	CD4 antigen	Mus musculus	30-33
26608911-1	2016	We have previously shown that CD4(+) T cells from B6.Sle1Sle2.Sle3 lupus mice and patients present a high cellular metabolism, and a treatment combining 2-deoxy-D-glucose, which inhibits glucose metabolism, and metformin, which inhibits oxygen consumption, normalized lupus T cell functions in vitro and reverted disease in mice.	Glucose	163-170	CD4 antigen	Mus musculus	30-33
26608911-1	2016	We have previously shown that CD4(+) T cells from B6.Sle1Sle2.Sle3 lupus mice and patients present a high cellular metabolism, and a treatment combining 2-deoxy-D-glucose, which inhibits glucose metabolism, and metformin, which inhibits oxygen consumption, normalized lupus T cell functions in vitro and reverted disease in mice.	Metformin	211-220	CD4 antigen	Mus musculus	30-33
26608911-1	2016	We have previously shown that CD4(+) T cells from B6.Sle1Sle2.Sle3 lupus mice and patients present a high cellular metabolism, and a treatment combining 2-deoxy-D-glucose, which inhibits glucose metabolism, and metformin, which inhibits oxygen consumption, normalized lupus T cell functions in vitro and reverted disease in mice.	Oxygen	237-243	CD4 antigen	Mus musculus	30-33
26763430-6	2016	BOT-4-one inhibited the differentiation of CD4(+) T-cell subsets by regulating the expression and production of T-cell lineage-specific master transcription factors and cytokines and activating the signal transducer and activator of transcription proteins.	2-cyclohexylimino-6-methyl-6,7-dihydro-5H-benzo(1,3)oxathiol-4-one	0-9	CD4 antigen	Mus musculus	43-46
26763430-9	2016	Our study demonstrated that BOT-4-one ameliorates inflammatory skin diseases by suppressing the pathogenic CD4(+) T cell differentiation and overall immune responses.	2-cyclohexylimino-6-methyl-6,7-dihydro-5H-benzo(1,3)oxathiol-4-one	28-37	CD4 antigen	Mus musculus	107-110
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Docosahexaenoic Acids	61-64	CD4 antigen	Mus musculus	33-36
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Eicosapentaenoic Acid	65-68	CD4 antigen	Mus musculus	33-36
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Tacrolimus	74-79	CD4 antigen	Mus musculus	33-36
27644556-6	2016	Secretion of IL-13 and IL-17A in CD4(+) T cells was lower in DHA/EPA- and FK506-treated mice than in mice treated with FK506 alone.	Tacrolimus	119-124	CD4 antigen	Mus musculus	33-36
27872515-0	2016	Therapeutic Treatment of Arthritic Mice with 15-Deoxy Delta12,14-Prostaglandin J2 (15d-PGJ2) Ameliorates Disease through the Suppression of Th17 Cells and the Induction of CD4+CD25-FOXP3+ Cells.	14-prostaglandin j2	62-81	CD4 antigen	Mus musculus	172-175
27872515-0	2016	Therapeutic Treatment of Arthritic Mice with 15-Deoxy Delta12,14-Prostaglandin J2 (15d-PGJ2) Ameliorates Disease through the Suppression of Th17 Cells and the Induction of CD4+CD25-FOXP3+ Cells.	15-deoxy-delta(12,14)-prostaglandin J2	83-91	CD4 antigen	Mus musculus	172-175
27872515-7	2016	The specific and polyclonal CD4+ Th17 cell responses were limited during the addition of prostaglandin to cell culture.	Prostaglandins	89-102	CD4 antigen	Mus musculus	28-31
27069316-1	2016	CD4(+) T cells play an important role in regulating silica-induced inflammation and fibrosis.	Silicon Dioxide	52-58	CD4 antigen	Mus musculus	0-3
26129650-0	2016	Metal-specific CD4+ T-cell responses induced by beryllium exposure in HLA-DP2 transgenic mice.	Metals	0-5	CD4 antigen	Mus musculus	15-18
26129650-0	2016	Metal-specific CD4+ T-cell responses induced by beryllium exposure in HLA-DP2 transgenic mice.	Beryllium	48-57	CD4 antigen	Mus musculus	15-18
26129650-1	2016	Chronic beryllium disease (CBD) is a granulomatous lung disorder that is associated with the accumulation of beryllium (Be)-specific CD4(+) T cells into the lung.	Beryllium	8-17	CD4 antigen	Mus musculus	133-136
26129650-1	2016	Chronic beryllium disease (CBD) is a granulomatous lung disorder that is associated with the accumulation of beryllium (Be)-specific CD4(+) T cells into the lung.	Beryllium	109-118	CD4 antigen	Mus musculus	133-136
26129650-1	2016	Chronic beryllium disease (CBD) is a granulomatous lung disorder that is associated with the accumulation of beryllium (Be)-specific CD4(+) T cells into the lung.	Beryllium	120-122	CD4 antigen	Mus musculus	133-136
26129650-4	2016	Here we characterized the T-cell receptor (TCR) repertoire of Be-responsive CD4(+) T cells derived from the lungs of Be oxide-exposed HLA-DP2 Tg mice.	beryllium oxide	117-125	CD4 antigen	Mus musculus	76-79
26129650-6	2016	We delineated mimotopes that bind to HLA-DP2 and form a complex recognized by Be-specific CD4(+) T cells in the absence of Be.	Beryllium	78-80	CD4 antigen	Mus musculus	90-93
26729097-5	2015	Furthermore, following insulin stimulation, Aire cells decreased the number of CD4+ IFN-gamma+ T cells in both STZ-T1D and WT mouse-derived splenocytes and reduced the expression levels of TCR signaling molecules (Ca(2+) and p-ERK) in CD4+ T cells.	Streptozocin	111-114	CD4 antigen	Mus musculus	79-82
26782505-7	2015	Sirolimus-treated CD4+ T cell TGF-beta secretion increased 2.5X over control levels (P &lt; 0.01), but that of the cyclosporine group decreased marginally (P &gt; 0.05).	Sirolimus	0-9	CD4 antigen	Mus musculus	18-21
26782505-8	2015	The CD4+ cell proportion decreased significantly (41.25 vs 69.22%, P &lt; 0.01) and slightly (65.21 vs 69.22, P &gt; 0.05) in the cyclosporine and sirolimus groups, respectively.	Cyclosporine	130-142	CD4 antigen	Mus musculus	4-7
26782505-8	2015	The CD4+ cell proportion decreased significantly (41.25 vs 69.22%, P &lt; 0.01) and slightly (65.21 vs 69.22, P &gt; 0.05) in the cyclosporine and sirolimus groups, respectively.	Sirolimus	147-156	CD4 antigen	Mus musculus	4-7
26782505-10	2015	Overall, sirolimus promoted CD4+ CD25+ Treg cell proliferation and growth in vitro, whereas cyclosporin A inhibited proliferation.	Sirolimus	9-18	CD4 antigen	Mus musculus	28-31
26782505-11	2015	Sirolimus might promote CD4+ CD25+ FoxP3+ regulatory T cell proliferation by inducing TGF-beta secretion in vivo.	Sirolimus	0-9	CD4 antigen	Mus musculus	24-27
26691857-5	2015	Moreover, chronic liver injury by carbon tetrachloride in Ccr6-/- mice was associated with enhanced inflammation and fibrosis, altered macrophage recruitment, enhanced CD4+ cells and a reduction in Th17 (CD4+IL17+) and mature dendritic (MHCII+CD11c+) cells recruitment.	Carbon Tetrachloride	34-54	CD4 antigen	Mus musculus	168-171
26691857-5	2015	Moreover, chronic liver injury by carbon tetrachloride in Ccr6-/- mice was associated with enhanced inflammation and fibrosis, altered macrophage recruitment, enhanced CD4+ cells and a reduction in Th17 (CD4+IL17+) and mature dendritic (MHCII+CD11c+) cells recruitment.	Carbon Tetrachloride	34-54	CD4 antigen	Mus musculus	204-207
26631690-4	2015	When poly(I:C) was used to produce exosomes together with ovalbumin (OVA), the resulting Dexo vaccine strongly stimulated OVA-specific CD8(+) and CD4(+) T cells to proliferate and acquire effector functions.	dexo	89-93	CD4 antigen	Mus musculus	146-149
26386311-5	2015	Colonic epithelium from control and DSS-treated TNFR1-/- mice showed intense AnxA1 expression and AnxA1+ CD4+ and CD8+ T cells were more frequent in TNFR1-/- animals, suggesting an extra supply of AnxA1.	Dextran Sulfate	36-39	CD4 antigen	Mus musculus	105-108
26781792-14	2015	DHEA treatment can increase selective T lymphocyte infiltration in mice, resulting in a decline in the CD4+ T lymphocyte population and an upregulation of the CD8+ T lymphocyte population in ovarian tissue, thus regulating the balance of CD4+/CD8+ T cells.	Dehydroepiandrosterone	0-4	CD4 antigen	Mus musculus	103-106
26781792-14	2015	DHEA treatment can increase selective T lymphocyte infiltration in mice, resulting in a decline in the CD4+ T lymphocyte population and an upregulation of the CD8+ T lymphocyte population in ovarian tissue, thus regulating the balance of CD4+/CD8+ T cells.	Dehydroepiandrosterone	0-4	CD4 antigen	Mus musculus	238-241
26351281-6	2015	Further characterization confirmed that administration of glycyrrhizic acid to L. donovani-infected BALB/c mice results in an impairment of the generation of MDSCs and a reciprocal organ-specific proliferation of IFN-gamma- and IL-10-expressing CD4(+) and CD8(+) T cells.	Glycyrrhizic Acid	58-75	CD4 antigen	Mus musculus	245-248
26474695-12	2015	In vitro, high salt could up-regulate Th17 cells of CD4(+) T cells.	Salts	15-19	CD4 antigen	Mus musculus	52-55
26474695-13	2015	The effects of high salt treatment on CD4(+) T cells were reversed by SGK1 inhibitor.	Salts	20-24	CD4 antigen	Mus musculus	38-41
26491197-5	2015	Treatment of male CD4(+) T cells with the PPARalpha agonist fenofibrate induced the recruitment of PPARalpha and the nuclear receptor-interacting protein, nuclear receptor corepressor 1, to specific cis-regulatory elements in the Ifng locus.	Fenofibrate	60-71	CD4 antigen	Mus musculus	18-21
26423555-0	2015	Identification of CD4+ T-cell epitopes on iron-regulated surface determinant B of Staphylococcus aureus.	Iron	42-46	CD4 antigen	Mus musculus	18-21
26423555-1	2015	Iron-regulated surface determinant B (IsdB) of Staphylococcus aureus (S. aureus) is a highly conserved surface protein that can induce protective CD4(+) T-cell immune response.	Iron	0-4	CD4 antigen	Mus musculus	146-149
26453752-6	2015	Furthermore, our results showed that bvPLA2 directly bound to CD206 on dendritic cells and consequently promoted the secretion of PGE2, which resulted in Treg differentiation via PGE2 (EP2) receptor signaling in Foxp3(-)CD4(+) T cells.	Dinoprostone	130-134	CD4 antigen	Mus musculus	220-223
26559484-6	2015	Potential antigen-presenting cells (APC) ingesting myelin were characterized by flow cytometry and their ability to activate SR T cells tested by co-culture with carboxyfluorescein succinimidyl ester (CFSE)-labeled myelin-specific CD4 T cells.	carboxyfluorescein succinimidyl ester	162-199	CD4 antigen	Mus musculus	231-234
26447613-0	2015	CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.	Lenalidomide	37-49	CD4 antigen	Mus musculus	0-3
26447613-4	2015	Depletion of CD4+ T cells, but not NK cells, B cells, or CD8+ T cells, deprived lenalidomide of its therapeutic effects on 5TGM1-bearing immunocompetent mice.	Lenalidomide	80-92	CD4 antigen	Mus musculus	13-16
26447613-5	2015	Lenalidomide significantly increased the numbers of IFN-gamma-secreting CD4+ and CD8+ T cells but had no effects on NK cells and B cells in this mouse model.	Lenalidomide	0-12	CD4 antigen	Mus musculus	72-75
26447613-8	2015	The CD4+ T cell subset may play a critical role in the lenalidomide-mediated anti-myeloma immune response in vivo.	Lenalidomide	55-67	CD4 antigen	Mus musculus	4-7
26456588-9	2015	Prednisone treatment also significantly decreased the elevated percentages of plasma cells and plasma cell precursors, decreased the percentages of activated T cells, and increased the frequency of CD4(+)CD62L(+) cells, demonstrated that decreased anti-nuclear antibodies and improvements in lupus symptoms were associated with decreased plasma cells.	Prednisone	0-10	CD4 antigen	Mus musculus	198-201
26417913-7	2015	Glycogen clearance was clearly enhanced by treatment with a nondepleting anti-CD4 monoclonal antibody (anti-CD4 mAb) along with muscle-specific GAA expression in cardiac muscle, but that treatment was not effective in skeletal muscle.	Glycogen	0-8	CD4 antigen	Mus musculus	78-81
26417913-7	2015	Glycogen clearance was clearly enhanced by treatment with a nondepleting anti-CD4 monoclonal antibody (anti-CD4 mAb) along with muscle-specific GAA expression in cardiac muscle, but that treatment was not effective in skeletal muscle.	Glycogen	0-8	CD4 antigen	Mus musculus	108-111
25899567-6	2015	Functionally, RA increased DC induction of CD4(+) T-cell IL-10, while reducing CD4(+) T-cell IL-4 and IL-13, revealing a previously unidentified role for RA in regulating the ability of alternatively activated DCs to influence Th2 polarization.	Tretinoin	14-16	CD4 antigen	Mus musculus	43-46
25899567-6	2015	Functionally, RA increased DC induction of CD4(+) T-cell IL-10, while reducing CD4(+) T-cell IL-4 and IL-13, revealing a previously unidentified role for RA in regulating the ability of alternatively activated DCs to influence Th2 polarization.	Tretinoin	14-16	CD4 antigen	Mus musculus	79-82
26099025-8	2015	Aspartame inhibited infiltration of inflammatory cells including eosinophils, mast cells, and CD4(+) T cells, and suppressed the expression of cytokines including IL-4 and IFN-gamma, and total serum IgE levels.	Aspartame	0-9	CD4 antigen	Mus musculus	94-97
25760420-5	2015	Beryllium enhanced classical dendritic cell (cDC) migration from the lung to draining lymph nodes (LNs) in an IL-1R-independent manner, and the accumulation of activated cDCs in the LN was associated with increased priming of CD4(+) T cells.	Beryllium	0-9	CD4 antigen	Mus musculus	226-229
25760420-7	2015	The adjuvant effects of beryllium on CD4(+) T-cell priming were similar in wild-type, IL-1R-, caspase-1-, TLR2-, TLR4-, TLR7-, and TLR9-deficient mice.	Beryllium	24-33	CD4 antigen	Mus musculus	37-40
26297915-5	2015	We observed that Ara-LAM-treated infected BALB/c mice showed a strong host-protective Th1 immune response due to reduced IL-10 and TGF-beta production, along with marked decrease in CD4(+) CD25(+) Foxp3(+) GITR(+) CTLA4(+) regulatory T cell (Treg) generation and activation.	ara-lam	17-24	CD4 antigen	Mus musculus	182-185
26086746-0	2015	Dexamethasone suppresses allergic rhinitis and amplifies CD4(+) Foxp3(+) regulatory T cells in vitro.	Dexamethasone	0-13	CD4 antigen	Mus musculus	57-60
26086746-5	2015	Further, CD4(+) CD25(-) T cells from the spleens were cultured in presence of DEX.	Dexamethasone	78-81	CD4 antigen	Mus musculus	9-12
26086746-6	2015	The effects of DEX on CD4(+) Foxp3(+) T cells were then assessed in vivo as well as in vitro.	Dexamethasone	15-18	CD4 antigen	Mus musculus	22-25
26086746-11	2015	In vivo, DEX treatment significantly decreased the number of CD4(+) Foxp3(+) T cells.	Dexamethasone	9-12	CD4 antigen	Mus musculus	61-64
26086746-13	2015	Furthermore, the number of late stage apoptotic CD4(+) T cells was also significantly increased upon exposure to DEX.	Dexamethasone	113-116	CD4 antigen	Mus musculus	48-51
25864619-5	2015	Interestingly, CD4(+)Foxp3(+) regulatory T cells were markedly increased in the spleens of atRA-treated mice.	Tretinoin	91-95	CD4 antigen	Mus musculus	15-18
26108182-8	2015	We found that subpopulations of CD4(+) cells (Th1 and Tregs) were differentially expanded in MPTP mice, which could be regulated by inhibition of calpain with the potent inhibitor calpeptin.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	93-97	CD4 antigen	Mus musculus	32-35
26004193-0	2015	Vitamin A supplementation leads to increases in regulatory CD4+Foxp3+LAP+ T cells in mice.	Vitamin A	0-9	CD4 antigen	Mus musculus	59-62
26004193-5	2015	Conversely, supplemented mice showed higher frequencies of CD4+Foxp3+LAP+ regulatory T cells in gut lymphoid tissues and spleen, suggesting that vitamin A supplementation in the diet may be beneficial in pathologic situations such as inflammatory bowel diseases.	Vitamin A	145-154	CD4 antigen	Mus musculus	59-62
26330173-3	2015	In addition, isogarcinol alleviated the abnormal activation of CD4 T cells and decreased the expression of inflammatory genes and cytokines in the kidneys and peritoneal macrophages.	isogarcinol	13-24	CD4 antigen	Mus musculus	63-66
26330173-4	2015	The mechanism of action of isogarcinol is associated with downregulation of CD4 T cells and inflammatory effects.	isogarcinol	27-38	CD4 antigen	Mus musculus	76-79
26116901-0	2015	High-dose cyclophosphamide induces specific tumor immunity with concomitant recruitment of LAMP1/CD107a-expressing CD4-positive T cells into tumor sites.	Cyclophosphamide	10-26	CD4 antigen	Mus musculus	115-118
26403780-6	2015	RESULTS: Among three DAMPs tested, HSP70 and CRT mediate a key role in SK-TCL-induced DC immunity for both CD4(+) and CD8(+) T cell proliferations in vitro.	Triclosan	74-77	CD4 antigen	Mus musculus	107-110
26298324-0	2015	Vitamin D and estrogen synergy in Vdr-expressing CD4(+) T cells is essential to induce Helios(+)FoxP3(+) T cells and prevent autoimmune demyelinating disease.	Vitamin D	0-9	CD4 antigen	Mus musculus	49-52
26298324-12	2015	Thus, CD4(+) T cells have a cooperative amplification loop involving E2 and calcitriol that promotes CD4(+)Helios(+)FoxP3(+) Treg cell development and is disrupted when the D3 pathway is impaired.	Calcitriol	76-86	CD4 antigen	Mus musculus	6-9
26298324-12	2015	Thus, CD4(+) T cells have a cooperative amplification loop involving E2 and calcitriol that promotes CD4(+)Helios(+)FoxP3(+) Treg cell development and is disrupted when the D3 pathway is impaired.	Calcitriol	76-86	CD4 antigen	Mus musculus	101-104
26370562-10	2015	In CIA mice, ThiaMet-G significantly aggravated the severity of arthritis clinically and histologically, and it also increased CD4 + IFN-gamma + T cells and CD4 + IL-17+ T cells.	thiamet	13-20	CD4 antigen	Mus musculus	127-130
26370562-10	2015	In CIA mice, ThiaMet-G significantly aggravated the severity of arthritis clinically and histologically, and it also increased CD4 + IFN-gamma + T cells and CD4 + IL-17+ T cells.	thiamet	13-20	CD4 antigen	Mus musculus	157-160
26010396-7	2015	These findings suggest that arginine-methylation of RUNX1 in the RTAMR-motif is dispensable for the development of definitive haematopoiesis and for steady-state platelet production, however this modification affects the role of RUNX1 in the maintenance of the peripheral CD4(+) T-cell population.	Arginine	28-36	CD4 antigen	Mus musculus	272-275
25724441-9	2015	Mice that received high and medium dose of PA-MSHA had significantly higher serum levels of IFN-gamma and TNF-alpha (days 21 and 28), and higher levels of CD4(+) /CD8(+) cells (days 21 and 28).	Protactinium	43-45	CD4 antigen	Mus musculus	155-158
26153538-6	2015	When these HSC-like cells were transplanted into irradiated immunodeficient mice and they were supplied with a dox-containing water, CD4/8 double negative T cells were detected in their thymi.	Doxycycline	111-114	CD4 antigen	Mus musculus	133-136
26153538-6	2015	When these HSC-like cells were transplanted into irradiated immunodeficient mice and they were supplied with a dox-containing water, CD4/8 double negative T cells were detected in their thymi.	Water	126-131	CD4 antigen	Mus musculus	133-136
26379666-0	2015	Characterization of the Antigen-Specific CD4(+) T Cell Response Induced by Prime-Boost Strategies with CAF01 and CpG Adjuvants Administered by the Intranasal and Subcutaneous Routes.	caf01	103-108	CD4 antigen	Mus musculus	41-44
26379666-5	2015	Subcutaneous (SC) priming with H56 and CAF01 followed by nasal boosting with H56 and CpG showed the greater expansion of CD4(+) tetramer-positive T cells in the spleen and lungs compared to all the other homologous and heterologous prime-boost combinations.	caf01	39-44	CD4 antigen	Mus musculus	121-124
26154582-8	2015	Mice treated with AQ and anti-CTLA4 had a significant increase in percentage of hepatic CD4, CD8, Th17, and Treg cells after 10 weeks of AQ treatment, as well as significantly decreased NK cells.	Amodiaquine	18-20	CD4 antigen	Mus musculus	88-91
26268402-7	2015	We observed that ES-treated BMDC co-cultured with DO11.10 transgenic CD4(+) T cells induced the generation of CD4(+)CD25(+)Foxp3(+) T cells.	Einsteinium	17-19	CD4 antigen	Mus musculus	69-72
26268402-7	2015	We observed that ES-treated BMDC co-cultured with DO11.10 transgenic CD4(+) T cells induced the generation of CD4(+)CD25(+)Foxp3(+) T cells.	Einsteinium	17-19	CD4 antigen	Mus musculus	110-113
26268402-7	2015	We observed that ES-treated BMDC co-cultured with DO11.10 transgenic CD4(+) T cells induced the generation of CD4(+)CD25(+)Foxp3(+) T cells.	bmdc	28-32	CD4 antigen	Mus musculus	69-72
26268402-7	2015	We observed that ES-treated BMDC co-cultured with DO11.10 transgenic CD4(+) T cells induced the generation of CD4(+)CD25(+)Foxp3(+) T cells.	bmdc	28-32	CD4 antigen	Mus musculus	110-113
26168493-10	2015	Moreover, the CD4(+)/CD8(+) ratio of splenic T-cells increased by IP-PA1 administration.	ip-pa1	66-72	CD4 antigen	Mus musculus	14-17
26165613-4	2015	We adoptively transferred CD4(+) T cells treated in vitro with oxidants hydrogen peroxide or nitric oxide or the demethylating agent 5-azacytidine into syngeneic mice and studied the development and severity of lupus in the recipients.	Hydrogen Peroxide	72-89	CD4 antigen	Mus musculus	26-29
26165613-4	2015	We adoptively transferred CD4(+) T cells treated in vitro with oxidants hydrogen peroxide or nitric oxide or the demethylating agent 5-azacytidine into syngeneic mice and studied the development and severity of lupus in the recipients.	Nitric Oxide	93-105	CD4 antigen	Mus musculus	26-29
26130503-7	2015	In terms of the in vivo effect of EtxB on CD4 and CD8 T cell responses in mice, the interaction of EtxB directly with DC was demonstrated following conditional depletion of CD11c(+) DC.	etxb	34-38	CD4 antigen	Mus musculus	42-45
26130503-7	2015	In terms of the in vivo effect of EtxB on CD4 and CD8 T cell responses in mice, the interaction of EtxB directly with DC was demonstrated following conditional depletion of CD11c(+) DC.	etxb	99-103	CD4 antigen	Mus musculus	42-45
26002824-12	2015	Praziquantel (PZQ) treatment could partially restore the frequency of CD28(+) T cell of CD4(+) T cells and CD38(+) T cell of CD8(+)/CD4(+) T cells in the spleen and CD38(+) T cell in the thymus.	Praziquantel	0-12	CD4 antigen	Mus musculus	88-91
26002824-12	2015	Praziquantel (PZQ) treatment could partially restore the frequency of CD28(+) T cell of CD4(+) T cells and CD38(+) T cell of CD8(+)/CD4(+) T cells in the spleen and CD38(+) T cell in the thymus.	Praziquantel	0-12	CD4 antigen	Mus musculus	132-135
26002824-12	2015	Praziquantel (PZQ) treatment could partially restore the frequency of CD28(+) T cell of CD4(+) T cells and CD38(+) T cell of CD8(+)/CD4(+) T cells in the spleen and CD38(+) T cell in the thymus.	Praziquantel	14-17	CD4 antigen	Mus musculus	88-91
26002824-12	2015	Praziquantel (PZQ) treatment could partially restore the frequency of CD28(+) T cell of CD4(+) T cells and CD38(+) T cell of CD8(+)/CD4(+) T cells in the spleen and CD38(+) T cell in the thymus.	Praziquantel	14-17	CD4 antigen	Mus musculus	132-135
25867817-7	2015	Flow cytometry results showed that the proportion of CD4(+) and CD8(+) T cells was significantly reduced, and the number of T regulatory cells increased in the spleen and lymph nodes in the iPSC-MSCs combined with the rapamycin group compared with the rapamycin-alone group.	Sirolimus	218-227	CD4 antigen	Mus musculus	53-56
26157038-3	2015	For example, CD4 and CD8 have been difficult to detect using IHC on formalin-fixed and paraffin-embedded mouse tissue, prompting alternative methods.	Formaldehyde	68-76	CD4 antigen	Mus musculus	13-16
26041539-5	2015	Cyclophosphamide (CPA) treatment depleted lymphocytes more efficiently than other cytotoxic agents; however, the percentage of CD4(+)CD25(+) Foxp3(+) Tregs was significantly increased in CPA-treated lymphopenic mice.	Cyclophosphamide	187-190	CD4 antigen	Mus musculus	127-130
26056253-6	2015	Peritoneal CD49d(high)CD4(+) T cells were more resistant to irradiation and more sensitive to NAD-induced cell death than CD49d(low)CD4(+) T cells.	NAD	94-97	CD4 antigen	Mus musculus	11-14
26056253-6	2015	Peritoneal CD49d(high)CD4(+) T cells were more resistant to irradiation and more sensitive to NAD-induced cell death than CD49d(low)CD4(+) T cells.	NAD	94-97	CD4 antigen	Mus musculus	22-25
26169874-14	2015	In ex vivo studies, PARP inhibition by olaparib or PARP-1 gene knockout markedly reduced CD3/CD28-stimulated gata-3 and il4 expression in Th2-skewed CD4(+) T cells while causing a moderate elevation in t-bet and ifn-gamma expression in Th1-skewed CD4(+) T cells.	olaparib	39-47	CD4 antigen	Mus musculus	149-152
33434976-5	2015	In mice, d-amino acid peptide nanofibers displaying OVA elicited stronger antibody responses, equivalent levels of CD4+ T cell responses, and long-term antigen-presentation in vivo compared to l-amino acid nanofibers.	d-amino acid peptide	9-29	CD4 antigen	Mus musculus	115-118
26161262-9	2015	Enzymatic digestion used to isolate eBM did, however, have a detrimental effect on detecting the expression of the human HSC-antigens CD4, CD90 and CD93, whereas CD34, CD38, CD133 and HLA-DR were unaffected.	2-Iodo-N-isopropylbenzamide	36-39	CD4 antigen	Mus musculus	134-137
25808405-0	2015	Kaempferol Promotes Transplant Tolerance by Sustaining CD4+FoxP3+ Regulatory T Cells in the Presence of Calcineurin Inhibitor.	kaempferol	0-10	CD4 antigen	Mus musculus	55-58
25808405-8	2015	Kaempferol increased CD4+FoxP3+ Tregs both in transplanted mice and in vitro, likely by suppressing DC maturation and their IL-6 expression.	kaempferol	0-10	CD4 antigen	Mus musculus	21-24
25808405-11	2015	Administering IL-6 abrogated allograft tolerance induced by kaempferol and cyclosporine via diminishing CD4+FoxP3+ Tregs.	Cyclosporine	75-87	CD4 antigen	Mus musculus	104-107
25888329-9	2015	In KPC mice given gemcitabine and a CD40 agonist, CD4(+) and CD8(+) T cells infiltrated subcutaneous tumors, but only CD4(+) T cells infiltrated spontaneous pancreatic tumors (not CD8(+) T cells).	gemcitabine	18-29	CD4 antigen	Mus musculus	50-53
25680514-6	2015	The DEX (CRCL-GL261)-DCs were found to promote cell proliferation and cytotoxic T lymphocyte (CTL) activity of CD4(+) and CD8(+) T cells in vitro compared with DEX (GL261)-DCs, which were loaded with DEXs derived from DCs loaded with GL261 tumor cell lysates.	dex	4-7	CD4 antigen	Mus musculus	111-114
25680514-6	2015	The DEX (CRCL-GL261)-DCs were found to promote cell proliferation and cytotoxic T lymphocyte (CTL) activity of CD4(+) and CD8(+) T cells in vitro compared with DEX (GL261)-DCs, which were loaded with DEXs derived from DCs loaded with GL261 tumor cell lysates.	crcl	9-13	CD4 antigen	Mus musculus	111-114
25680514-6	2015	The DEX (CRCL-GL261)-DCs were found to promote cell proliferation and cytotoxic T lymphocyte (CTL) activity of CD4(+) and CD8(+) T cells in vitro compared with DEX (GL261)-DCs, which were loaded with DEXs derived from DCs loaded with GL261 tumor cell lysates.	gl261	14-19	CD4 antigen	Mus musculus	111-114
25680514-10	2015	Moreover, depletion of CD4(+) and CD8(+) T cells significantly impaired the anti-tumor effect of DEX (CRCL-GL261)-DCs.	dex	97-100	CD4 antigen	Mus musculus	23-26
25680514-10	2015	Moreover, depletion of CD4(+) and CD8(+) T cells significantly impaired the anti-tumor effect of DEX (CRCL-GL261)-DCs.	crcl-gl261	102-112	CD4 antigen	Mus musculus	23-26
26052942-10	2015	The clathrin-specific inhibitor chlorpromazine blocked endothelial chemokine internalization and CD4(+) T-cell transmigration in vitro as well as migration of CD4(+) T cells into the inflamed liver in vivo.	Chlorpromazine	32-46	CD4 antigen	Mus musculus	97-100
26052942-10	2015	The clathrin-specific inhibitor chlorpromazine blocked endothelial chemokine internalization and CD4(+) T-cell transmigration in vitro as well as migration of CD4(+) T cells into the inflamed liver in vivo.	Chlorpromazine	32-46	CD4 antigen	Mus musculus	159-162
26052942-11	2015	Moreover, hepatic accumulation of CXCR3(+) CD4(+) T cells during T cell-mediated hepatitis was strongly reduced after administration of chlorpromazine.	Chlorpromazine	136-150	CD4 antigen	Mus musculus	43-46
26053248-0	2015	Thymic Atrophy and Apoptosis of CD4+CD8+ Thymocytes in the Cuprizone Model of Multiple Sclerosis.	Cuprizone	59-68	CD4 antigen	Mus musculus	32-35
26053248-4	2015	Fluorescent microscopy and flow-cytometric analyses of thymi from cuprizone- and vehicle-treated mice indicated that eradication of the cluster of the differentiation-4 (CD4)-CD8 double-positive T-cell subset was behind the substantial cell loss.	Cuprizone	66-75	CD4 antigen	Mus musculus	170-173
26026087-8	2015	Vaccination with TRAMP-H6 alone and TRAMP-H11 combined with docetaxel augmented tumor infiltration by activated CD8(+) and CD4(+) T-cells and attracted higher number of activated, mature DCs infiltrating tumors.	Docetaxel	60-69	CD4 antigen	Mus musculus	123-126
25801950-5	2015	Direct intrathymic labeling showed that AMD3100 selectively mobilizes naive thymic CD4(+) and CD8(+) T cells to blood.	plerixafor	40-47	CD4 antigen	Mus musculus	83-86
25613226-6	2015	Flow cytometry test demonstrated that icariin or DEX administration resulted in a significant percentage reduction in CD4+RORgammat+ T cells and elevation of CD4+Foxp3+ T cells in BALF.	icariin	38-45	CD4 antigen	Mus musculus	118-121
25613226-6	2015	Flow cytometry test demonstrated that icariin or DEX administration resulted in a significant percentage reduction in CD4+RORgammat+ T cells and elevation of CD4+Foxp3+ T cells in BALF.	icariin	38-45	CD4 antigen	Mus musculus	158-161
25613226-6	2015	Flow cytometry test demonstrated that icariin or DEX administration resulted in a significant percentage reduction in CD4+RORgammat+ T cells and elevation of CD4+Foxp3+ T cells in BALF.	Dextromethorphan	49-52	CD4 antigen	Mus musculus	118-121
25613226-6	2015	Flow cytometry test demonstrated that icariin or DEX administration resulted in a significant percentage reduction in CD4+RORgammat+ T cells and elevation of CD4+Foxp3+ T cells in BALF.	Dextromethorphan	49-52	CD4 antigen	Mus musculus	158-161
25613226-10	2015	qPCR analysis revealed that icariin and DEX resulted in a notable decrease in RORgammat and increase in Foxp3 mRNA expression in isolated spleen CD4+ T cell.	icariin	28-35	CD4 antigen	Mus musculus	145-148
25613226-10	2015	qPCR analysis revealed that icariin and DEX resulted in a notable decrease in RORgammat and increase in Foxp3 mRNA expression in isolated spleen CD4+ T cell.	Dextromethorphan	40-43	CD4 antigen	Mus musculus	145-148
25929804-4	2015	2,4,6-Trinitrophenyl hapten (TNP) - Keyhole Limpet Hemocyanin (KLH)-primed B cells cocultured with OVA-primed CD4(+) T cells from OVA-immunized VSIG4 KO mice in the presence of TNP-OVA showed enhanced isotype switching to IgG subclasses compared to those cocultured with cells isolated from OVA-immunized wild-type (WT) mice.	2,4,6-trinitrophenyl hapten	0-27	CD4 antigen	Mus musculus	110-113
25929804-4	2015	2,4,6-Trinitrophenyl hapten (TNP) - Keyhole Limpet Hemocyanin (KLH)-primed B cells cocultured with OVA-primed CD4(+) T cells from OVA-immunized VSIG4 KO mice in the presence of TNP-OVA showed enhanced isotype switching to IgG subclasses compared to those cocultured with cells isolated from OVA-immunized wild-type (WT) mice.	IP3K Inhibitor	29-32	CD4 antigen	Mus musculus	110-113
25975579-4	2015	However, osthole administration significantly elevated the proportion and number of the splenic CD8(+) T cells, the proportion of CD4(+) T and CD8(+) T cells in tumor tissues, and the levels of IL-2 and TNF-alpha in the serum of HCC tumor-bearing mice.	osthol	9-16	CD4 antigen	Mus musculus	130-133
25975579-5	2015	Our results suggested that osthole could promote the activation of the tumor-infiltrating CD4(+) T and CD8(+) T cells, and elevate the proportion of CD4(+) and CD8(+) effector T cells.	osthol	27-34	CD4 antigen	Mus musculus	90-93
25975579-5	2015	Our results suggested that osthole could promote the activation of the tumor-infiltrating CD4(+) T and CD8(+) T cells, and elevate the proportion of CD4(+) and CD8(+) effector T cells.	osthol	27-34	CD4 antigen	Mus musculus	149-152
25975579-6	2015	Osthole treatment also significantly decreased the proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells in the spleen.	osthol	0-7	CD4 antigen	Mus musculus	65-68
25370454-6	2015	Furthermore, metformin inhibited de novo generation of Th1 and Th17 cells from naive CD4(+) cells.	Metformin	13-22	CD4 antigen	Mus musculus	85-88
25370454-9	2015	Notably, metformin led to a reduction in glucose transporter Glut1 expression, resulting in less glucose uptake, which is critical to regulate CD4(+) T cell fate.	Metformin	9-18	CD4 antigen	Mus musculus	143-146
25370454-9	2015	Notably, metformin led to a reduction in glucose transporter Glut1 expression, resulting in less glucose uptake, which is critical to regulate CD4(+) T cell fate.	Glucose	41-48	CD4 antigen	Mus musculus	143-146
25962107-11	2015	FM administration maintained an increased antitumor response associated to CD8 lymphocytes, and also increased CD4 lymphocytes that can be involved in the modulation of the immune response.	Fermium	0-2	CD4 antigen	Mus musculus	111-114
25405323-3	2015	Therefore, the aim of this study was to examine whether DHA suppresses allergic reactions and upregulates the generation of CD4(+)Foxp3(+) T cells.	Docosahexaenoic Acids	56-59	CD4 antigen	Mus musculus	124-127
25405323-5	2015	Here, we show that administration of DHA upregulates the generation of TGF-beta-dependent CD4(+) forkhead box protein 3 (Foxp3(+)) Tregs.	Docosahexaenoic Acids	37-40	CD4 antigen	Mus musculus	90-93
25405323-7	2015	The differentiation of Foxp3(+) Tregs into CD4(+) T cells was directly mediated by DHA-M2 macrophages, which deactivated effector macrophages and inhibited CD4(+) T-cell proliferation.	Docosahexaenoic Acids	83-86	CD4 antigen	Mus musculus	43-46
25405323-7	2015	The differentiation of Foxp3(+) Tregs into CD4(+) T cells was directly mediated by DHA-M2 macrophages, which deactivated effector macrophages and inhibited CD4(+) T-cell proliferation.	Docosahexaenoic Acids	83-86	CD4 antigen	Mus musculus	156-159
25877924-6	2015	Analysis of chimeric mice indicated that the increased sensitivity to DSS was due to the lack of Fyn kinase in hematopoietic, but not stromal, cells, in accordance with Fyn(+) T cell increases in WT mice exposed to DSS and Fyn KO mice having a reduced number of CD4(+)Foxp3(+) cells in baseline or colitic conditions and a reduced capacity to induce Foxp3 expression in vitro.	dss	70-73	CD4 antigen	Mus musculus	262-265
25980325-8	2015	Additionally, O-1966 treatment caused a dose-related decrease in the expression of CD4 in MLR cultures from wild-type, but not CB2R k/o, mice.	1-(4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl)-3-methylcyclohexanol	14-20	CD4 antigen	Mus musculus	83-86
26030277-4	2015	It also attenuated the DSS-dependent increase in inflammatory cytokine production and decreased interferon-gamma (IFN-gamma)-producing CD4(+) Th1 cell numbers in the colon.	dss	23-26	CD4 antigen	Mus musculus	135-138
25770929-4	2015	It was observed that topical administration of tacrolimus significantly accelerated the tumor promotion events in dimethylbenz(a)anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA) promoted two-stage mouse skin carcinogenesis, which were accompanied by reduced CD4(+)/CD8(+) ratio of lymph nodes and serum IL-2 level.	Tacrolimus	47-57	CD4 antigen	Mus musculus	284-287
25770929-4	2015	It was observed that topical administration of tacrolimus significantly accelerated the tumor promotion events in dimethylbenz(a)anthracene (DMBA)-initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA) promoted two-stage mouse skin carcinogenesis, which were accompanied by reduced CD4(+)/CD8(+) ratio of lymph nodes and serum IL-2 level.	6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene	141-145	CD4 antigen	Mus musculus	284-287
25787078-4	2015	Administration of agents to deplete macrophages (liposome-clodronate and Clophosome-A(TM)) or T cells (anti-CD4 antibody and FTY720) could suppress PSL-induced thermal hyperalgesia and tactile allodynia.	Disulfuric acid	148-151	CD4 antigen	Mus musculus	108-111
26191196-0	2015	Cytoprotective effects of high dose of alpha-galactosylceramide against activation-induced CD4+ T and CD8+ T cell death as an adjuvant.	alpha-galactosylceramide	39-63	CD4 antigen	Mus musculus	91-94
26191196-1	2015	OBJECTIVE: To investigate the cytoprotective effects of high dose of alpha-galactosylceramide (alpha-GC) on the activation-induced CD4+ T and CD8+ T cell death.	alpha-galactosylceramide	69-93	CD4 antigen	Mus musculus	131-134
26191196-1	2015	OBJECTIVE: To investigate the cytoprotective effects of high dose of alpha-galactosylceramide (alpha-GC) on the activation-induced CD4+ T and CD8+ T cell death.	alpha-galactosylceramide	95-103	CD4 antigen	Mus musculus	131-134
26191196-9	2015	CONCLUSIONS: high dose of alpha-GC could be used as an adjuvant for inhibiting activation-induced CD4+ T and CD8+ T cell death.	alpha-galactosylceramide	26-34	CD4 antigen	Mus musculus	98-101
25714796-6	2015	CsA reduced the proportion of CD4(+) T cells and the level of IFN-gamma.	Cyclosporine	0-3	CD4 antigen	Mus musculus	30-33
25625352-13	2015	BSYQF and DEX treatment resulted in an obvious elevation in CD4(+)Foxp3(+) T cells in BALF and spleen (p&lt;0.05).	bsyqf	0-5	CD4 antigen	Mus musculus	60-63
25625352-13	2015	BSYQF and DEX treatment resulted in an obvious elevation in CD4(+)Foxp3(+) T cells in BALF and spleen (p&lt;0.05).	Dextromethorphan	10-13	CD4 antigen	Mus musculus	60-63
25576766-8	2015	The number of total splenocytes and T cells and both the number and the proportion of CD4+ IFN-gamma+ and CD8+ IFN-gamma+ T cells in the spleen were significantly reduced in SA-treated NOD mice compared with controls.	sodium arsenite	174-176	CD4 antigen	Mus musculus	86-89
25347992-6	2015	These findings reveal that bacterial polysaccharides link the microbiota with the peripheral immune system by activating CD4(+)Foxp3(-) T cells upon exposure in the gut, and they facilitate resistance to unnecessary inflammatory responses via the production of IL-10.	Polysaccharides	37-52	CD4 antigen	Mus musculus	121-124
25676533-4	2015	Piceatannol treatment inhibited surface expression of CD4 and CD8 T cell activation markers CD25 and CD69, reduced production of cytokines IFNgamma, IL-2, and IL-17, and suppressed proliferation of activated T cells.	3,3',4,5'-tetrahydroxystilbene	0-11	CD4 antigen	Mus musculus	54-57
25676533-5	2015	Moreover, piceatannol treatment significantly inhibited differentiation of CD4(+)CD25(-)CD62L(+) naive CD4 T cells into Th1, Th2, and Th17 cells, presumably due to inhibition of TcR signaling through p-Erk, p-Akt, and p-p38.	3,3',4,5'-tetrahydroxystilbene	10-21	CD4 antigen	Mus musculus	75-78
25676533-5	2015	Moreover, piceatannol treatment significantly inhibited differentiation of CD4(+)CD25(-)CD62L(+) naive CD4 T cells into Th1, Th2, and Th17 cells, presumably due to inhibition of TcR signaling through p-Erk, p-Akt, and p-p38.	3,3',4,5'-tetrahydroxystilbene	10-21	CD4 antigen	Mus musculus	103-106
25687198-3	2015	Herein, we found that distinct CD4(+) T cell subsets but not CD8(+) T cells modulated APAP-induced liver injury in mice.	Acetaminophen	86-90	CD4 antigen	Mus musculus	31-34
25687198-4	2015	After APAP challenge, more CD62L(low)CD44(hi)CD4(+) T cells appeared in the liver, accompanied by increased IFN-gamma.	Acetaminophen	6-10	CD4 antigen	Mus musculus	37-40
25861418-10	2015	Compared to mice treated with 5-FU, mice treated with AHCC plus 5-FU had higher thymus index, percentages of CD3(+), CD4(+), and NK cells (P &lt; 0.01), and ratio of CD4(+)/CD8(+) (P &lt; 0.01) in peripheral blood.	Fluorouracil	64-68	CD4 antigen	Mus musculus	117-120
25861418-10	2015	Compared to mice treated with 5-FU, mice treated with AHCC plus 5-FU had higher thymus index, percentages of CD3(+), CD4(+), and NK cells (P &lt; 0.01), and ratio of CD4(+)/CD8(+) (P &lt; 0.01) in peripheral blood.	Fluorouracil	64-68	CD4 antigen	Mus musculus	166-169
25742430-0	2015	Nicotine ameliorates experimental severe acute pancreatitis via enhancing immunoregulation of CD4+ CD25+ regulatory T cells.	Nicotine	0-8	CD4 antigen	Mus musculus	94-97
25742430-10	2015	Moreover, nicotine up-regulated the number and suppressive capacity of CD4 CD25 Treg via inducing the expression of immunoregulatory molecules and transforming growth factor beta1 elevation.	Nicotine	10-18	CD4 antigen	Mus musculus	71-74
25645543-7	2015	Furthermore, spermidine suppressed mast cell degranulation and production of interferon-gamma by activated CD4(+) T cells in AD-like skin lesions.	Spermidine	13-23	CD4 antigen	Mus musculus	107-110
25891732-10	2015	RESULTS: Thalidomide significantly decreased the proliferation of CD4(+) Teffs in a dose-dependent manner (P &lt; .01).	Thalidomide	9-20	CD4 antigen	Mus musculus	66-69
25891732-11	2015	In contrast, conversion to CD4(+)FoxP3(+) Tregs tended to increase by thalidomide treatment, although the increase was not statistically significant.	Thalidomide	70-81	CD4 antigen	Mus musculus	27-30
25891732-12	2015	CONCLUSION: These findings suggest that thalidomide may have an immune modulatory effect by selectively suppressing CD4(+) Teff proliferation.	Thalidomide	40-51	CD4 antigen	Mus musculus	116-119
25595736-3	2015	Here, we showed that induction of PF4/heparin-specific antibodies by PF4/heparin complexes was markedly impaired in mice depleted of CD4 T cells by anti-CD4 antibodies.	Heparin	38-45	CD4 antigen	Mus musculus	133-136
25595736-3	2015	Here, we showed that induction of PF4/heparin-specific antibodies by PF4/heparin complexes was markedly impaired in mice depleted of CD4 T cells by anti-CD4 antibodies.	Heparin	38-45	CD4 antigen	Mus musculus	153-156
24770553-6	2015	The percentage of CD4(+)CXCR3(+)Tbet(+)IL-10(+) and CD4(+)CD69(+)CD25(-) regulatory T cells was reduced.	tbet	32-36	CD4 antigen	Mus musculus	18-21
25747889-16	2015	The ratio of CD4(+)CD25(+) Treg significantly decreased and CD4(+) T cell increased in BLTA and 5-FU group (P&lt;0.01).	Fluorouracil	96-100	CD4 antigen	Mus musculus	13-16
25747889-16	2015	The ratio of CD4(+)CD25(+) Treg significantly decreased and CD4(+) T cell increased in BLTA and 5-FU group (P&lt;0.01).	Fluorouracil	96-100	CD4 antigen	Mus musculus	60-63
25682002-6	2015	The docking results demonstrated that piperine has good binding affinity towards CD4 and CD8 receptors.	piperine	38-46	CD4 antigen	Mus musculus	81-84
25641586-5	2015	Moreover, miR-155-mediated control of HO-1 expression in CD4(+) T cells was shown to sustain in vivo antigen-specific expansion and IL-2 production.	mir-155	10-17	CD4 antigen	Mus musculus	57-60
24814297-8	2015	Repeated exposure to silica-coated TiO2 ENMs induced also pulmonary inflammation: inflammatory cells infiltrated in peribronchial and perivascular areas of the lungs, neutrophils were found in BAL fluids, and the number of CD3 and CD4 positive T cells increased significantly.	Silicon Dioxide	21-27	CD4 antigen	Mus musculus	231-234
24814297-8	2015	Repeated exposure to silica-coated TiO2 ENMs induced also pulmonary inflammation: inflammatory cells infiltrated in peribronchial and perivascular areas of the lungs, neutrophils were found in BAL fluids, and the number of CD3 and CD4 positive T cells increased significantly.	titanium dioxide	35-39	CD4 antigen	Mus musculus	231-234
25540199-0	2015	Polysaccharide A from the capsule of Bacteroides fragilis induces clonal CD4+ T cell expansion.	polysaccharide a	0-16	CD4 antigen	Mus musculus	73-76
25540199-2	2015	Published findings further demonstrate that polysaccharide A (PSA) from the capsule of Bacteroides fragilis is a potent activator of CD4(+) T cells and that these T cells have important biological functions, especially in the maintenance of immunological homeostasis.	polysaccharide a	44-60	CD4 antigen	Mus musculus	133-136
25540199-7	2015	These data support a model in which PSA, and possibly other T cell-dependent polysaccharide antigens, elicits a clonal and therefore specific CD4(+) T cell response often characterized by pairing dual-charged CDR3 loop sequences with dual-charged PSA.	Polysaccharides	77-91	CD4 antigen	Mus musculus	142-145
25560408-0	2015	Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells.	Melphalan	17-26	CD4 antigen	Mus musculus	96-99
25595785-9	2015	Amelioration of AD progression by cyclosporin A treatment was well correlated with downregulation of IL-31 expressions in CD4(+) T cells and total ear residual cells.	Cyclosporine	34-47	CD4 antigen	Mus musculus	122-125
25679777-4	2015	Immunization of BALB/c mice with the recombinant mAb in the presence of polyriboinosinic: polyribocytidylic acid (poly (I:C)) specifically enhanced the number of IFN-gamma producing cells and CD4+ T cell proliferation when compared to mice immunized with a mAb without receptor affinity or with the non-targeted ASP-2 protein.	Poly C	90-112	CD4 antigen	Mus musculus	192-195
25673763-6	2015	Metformin also restored the defective interleukin-2 (IL-2) production by TC CD4(+) T cells.	Metformin	0-9	CD4 antigen	Mus musculus	76-79
25685964-2	2015	This study aimed to determine the effect of prolonged treatment with angiotensin II (Ang II) on atherosclerosis and the effect of valsartan on the activity of CD4(+) T lymphocyte subsets.	Valsartan	130-139	CD4 antigen	Mus musculus	159-162
25685964-4	2015	In contrast, valsartan treatment efficiently reversed the imbalance in CD4(+) T lymphocyte activity, ameliorated atherosclerosis and elicited a stable plaque phenotype in addition to controlling blood pressure.	Valsartan	13-22	CD4 antigen	Mus musculus	71-74
25973010-0	2015	BTLA associates with increased Foxp3 expression in CD4(+) T cells in dextran sulfate sodium-induced colitis.	Dextran Sulfate	69-91	CD4 antigen	Mus musculus	51-54
25973010-5	2015	The frequency of Foxp3-expressing cells in BTLA+ CD4(+) T cell from lamina propria mononuclear cells (LPMCs) was much higher in DSS-treated mice than that in controls.	lpmcs	102-107	CD4 antigen	Mus musculus	49-52
25973010-6	2015	Similarly, the proportion of IL-17+ cells in BTLA+ CD4(+) T cells from LPMCs in DSS-treated mice is much higher than that in controls, while no perceptible difference for the proportion of IFN-gamma+ cells in BTLA+ CD4(+) T cells was noted between DSS-treated mice and controls.	lpmcs	71-76	CD4 antigen	Mus musculus	51-54
25315497-3	2015	Administration of polyI:C/d-GalN increased the number of CD4(+)Foxp3(+) Tregs in the liver.	Poly I	18-23	CD4 antigen	Mus musculus	57-60
25315497-10	2015	CONCLUSION: CD4(+)Foxp3(+) Tregs modify innate immune responses in polyI:C/d-GalN-induced fulminant hepatitis via producing TGF-beta and enhancing IL-10 secretion by Kupffer cells.	Poly I	67-72	CD4 antigen	Mus musculus	12-15
25452304-4	2015	In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival.	Cyclosporine	3-6	CD4 antigen	Mus musculus	225-228
25452304-4	2015	In CsA-treated allograft recipient mice, CD11b(+) Gr1(+) myeloid-derived suppressor cells (MDSCs) were functional suppressive immune modulators that resulted in fewer gamma interferon (IFN-gamma)-producing CD8(+) T cells and CD4(+) T cells (T(H)1 T helper cells) and more interleukin 4 (IL-4)-producing CD4(+) T cells (T(H2)) and prolonged allogeneic skin graft survival.	Cyclosporine	3-6	CD4 antigen	Mus musculus	303-306
25433234-4	2015	In this study we have examined the impact of in vitro atrazine exposure on the activation, proliferation, and effector cytokine production by primary murine CD4(+) T lymphocytes.	Atrazine	54-62	CD4 antigen	Mus musculus	157-160
25433234-5	2015	We found that atrazine exposure significantly inhibited CD4(+) T cell proliferation and accumulation as well as the expression of the activation markers CD25 and CD69 in a dose-dependent manner.	Atrazine	14-22	CD4 antigen	Mus musculus	56-59
25433234-8	2015	Consistent with these findings, atrazine exposure during T cell activation resulted in a 2- to 5-fold increase in the frequency of Foxp3(+) CD4(+) T cells.	Atrazine	32-40	CD4 antigen	Mus musculus	140-143
25574091-16	2015	The proliferation cycles of CD4(+) T cells from mice with DSS-induced colitis appeared as five cycles, which was more than in the control and treated groups.	dss	58-61	CD4 antigen	Mus musculus	28-31
25110149-6	2015	PGE2, which acts on prostaglandin E receptor subtype 4 (EP4), upregulated the expression of receptor activator for NF-kappaB ligand (RANKL) in CD4(+) T cells and mediated the increase in Treg cells in bone marrow.	Dinoprostone	0-4	CD4 antigen	Mus musculus	143-146
25925287-0	2015	Chloroquine Inhibits Ca(2+) Signaling in Murine CD4(+) Thymocytes.	Chloroquine	0-11	CD4 antigen	Mus musculus	48-51
25925287-3	2015	METHODS: In this study, CD4(+) T cells were isolated from the thymus, and the calcium content of CD4(+) thymocytes was measured using fura-2 AM and a TILL imaging system.	Calcium	78-85	CD4 antigen	Mus musculus	97-100
25925287-4	2015	Pyrazole-3 (Pyr3), thapsigargin (TG), and caffeine were used to assess the effects of chloroquine on the intracellular Ca(2+) content of CD4(+) T cells.	Chloroquine	86-97	CD4 antigen	Mus musculus	137-140
25925287-5	2015	RESULTS: In murine CD4(+) thymocytes, chloroquine decreased the TG-triggered intracellular Ca(2+) increase in a dose-dependent manner.	Chloroquine	38-49	CD4 antigen	Mus musculus	19-22
25925287-5	2015	RESULTS: In murine CD4(+) thymocytes, chloroquine decreased the TG-triggered intracellular Ca(2+) increase in a dose-dependent manner.	Thapsigargin	64-66	CD4 antigen	Mus musculus	19-22
25925287-12	2015	CONCLUSION: These data indicate that chloroquine inhibits the elevation of intracellular Ca(2+) in thymic CD4(+) T cells by inhibiting IP3 receptor-mediated Ca(2+) release from intracellular stores and TRPC3 channel-mediated and/or STIM/Orai channel-mediated Ca(2+) influx.	Chloroquine	37-48	CD4 antigen	Mus musculus	106-109
25287052-3	2015	Fasudil inhibited expression of CCL20 on T cells and migration of T cells, decreased CD4(+) IFN-gamma(+) and CD4(+) IL-17(+) T cells, but increased CD4(+) IL-10(+) and CD4(+) TGF-beta(+) T cells.	fasudil	0-7	CD4 antigen	Mus musculus	85-88
25287052-3	2015	Fasudil inhibited expression of CCL20 on T cells and migration of T cells, decreased CD4(+) IFN-gamma(+) and CD4(+) IL-17(+) T cells, but increased CD4(+) IL-10(+) and CD4(+) TGF-beta(+) T cells.	fasudil	0-7	CD4 antigen	Mus musculus	109-112
25287052-3	2015	Fasudil inhibited expression of CCL20 on T cells and migration of T cells, decreased CD4(+) IFN-gamma(+) and CD4(+) IL-17(+) T cells, but increased CD4(+) IL-10(+) and CD4(+) TGF-beta(+) T cells.	fasudil	0-7	CD4 antigen	Mus musculus	109-112
25287052-3	2015	Fasudil inhibited expression of CCL20 on T cells and migration of T cells, decreased CD4(+) IFN-gamma(+) and CD4(+) IL-17(+) T cells, but increased CD4(+) IL-10(+) and CD4(+) TGF-beta(+) T cells.	fasudil	0-7	CD4 antigen	Mus musculus	109-112
25918545-7	2015	Dex + Rh1 significantly decreased the ratio of CD4+/CD8+ splenic lymphocytes compared with control.	dex + rh1	0-9	CD4 antigen	Mus musculus	47-50
25918545-8	2015	Con A-induced CD4+ splenic lymphocytes proliferation was increased in Dex-treated mice and was inhibited in Dex + Rh1-treated mice.	Dexamethasone	70-73	CD4 antigen	Mus musculus	14-17
25918545-11	2015	In conclusion, our data suggest that Rh1 may enhance the effect of Dex in the treatment of MRL/lpr mice through regulating CD4+ T cells activation and Th1/Th2 balance.	Dexamethasone	67-70	CD4 antigen	Mus musculus	123-126
25257859-8	2015	However, the CD4(+) T cell response, as monitored by IFN-gamma, was significantly increased in mice given polyI:C+MmSVN2B.	Poly I-C	106-113	CD4 antigen	Mus musculus	13-16
25257859-11	2015	These results suggest that activated, self-reactive CD4(+) helper T cells proliferate in MmSVN2B+polyI:C immunization and contribute to Th1 polarization followed by antibody production, but hardly participate in CTL induction.	Poly I-C	97-104	CD4 antigen	Mus musculus	52-55
26181650-4	2015	The data showed that TBMS1 inhibited ConA-induced T lymphocyte proliferation, decreased the ratio of CD4(+)/CD8(+), suppressed IL-2, IFN-gamma, IL-4 and IL-6 production and mRNA expression, down-regulate activation of NF-kappaB, NFAT2 and AP-1 signal transduction pathways in vitro.	tubeimoside I	21-26	CD4 antigen	Mus musculus	101-104
25461918-6	2015	In mice infected with 1x10(6) parasites, only (S)-propranolol caused a reduction of footpad swelling (p&lt;0.05, weeks 11-12), without effects on parasite burden, or in the percentage of IFN-gamma-immunopositive CD4(+) or CD8(+) T lymphocytes.	Propranolol	46-61	CD4 antigen	Mus musculus	212-215
25479726-8	2015	Meanwhile, paeoniflorin pretreatment decreased CD4(+), CD8(+) and NKT cell infiltration in the liver.	peoniflorin	11-23	CD4 antigen	Mus musculus	47-50
25479726-11	2015	These results suggest that paeoniflorin pretreatment protects mice against Con A-induced liver injury via inhibition of several inflammatory mediators and, at least in part, by suppressing CD4(+), CD8(+) and NKT cell infiltration in liver.	peoniflorin	27-39	CD4 antigen	Mus musculus	189-192
25456971-7	2015	Mechanistically, we show a critical involvement for oxysterols in recruiting leukocytes into inflamed tissues and propose that 7alpha,25-OHC preferentially promotes the migration of activated CD44(+)CD4(+) T cells by binding the G protein-coupled receptor called Epstein-Barr virus induced gene 2 (EBI2).	7alpha	127-133	CD4 antigen	Mus musculus	192-195
25456971-7	2015	Mechanistically, we show a critical involvement for oxysterols in recruiting leukocytes into inflamed tissues and propose that 7alpha,25-OHC preferentially promotes the migration of activated CD44(+)CD4(+) T cells by binding the G protein-coupled receptor called Epstein-Barr virus induced gene 2 (EBI2).	25-hydroxycholesterol	134-140	CD4 antigen	Mus musculus	192-195
25437876-7	2015	This alteration in the CD4+ T cell populations was mediated in part through ROS, as N-acetyl cysteine (NAC) treatment restored Th17 cell generation.	ros	76-79	CD4 antigen	Mus musculus	23-26
25437876-7	2015	This alteration in the CD4+ T cell populations was mediated in part through ROS, as N-acetyl cysteine (NAC) treatment restored Th17 cell generation.	Acetylcysteine	84-101	CD4 antigen	Mus musculus	23-26
25437876-7	2015	This alteration in the CD4+ T cell populations was mediated in part through ROS, as N-acetyl cysteine (NAC) treatment restored Th17 cell generation.	Acetylcysteine	103-106	CD4 antigen	Mus musculus	23-26
25274854-3	2015	Mice treated with oseltamivir plus fenofibrate exhibited the longest mean survival time, the largest reduction of viral titre in lung tissue, the highest levels of CD4(+) and CD8(+) T-lymphocytes, and the greatest decrease in pulmonary inflammation.	Oseltamivir	18-29	CD4 antigen	Mus musculus	164-167
25274854-3	2015	Mice treated with oseltamivir plus fenofibrate exhibited the longest mean survival time, the largest reduction of viral titre in lung tissue, the highest levels of CD4(+) and CD8(+) T-lymphocytes, and the greatest decrease in pulmonary inflammation.	Fenofibrate	35-46	CD4 antigen	Mus musculus	164-167
26269136-2	2015	A preliminary investigation showed that an isoxazole derivative R-13 (3,5-dimethyl-isoxazole[5,4-e]8H-triazepin-4-one) hydrochloride, given in a single oral dose to normal mice, induced significant increases in the content of CD4(+) cells in the spleens and lymph nodes.	Isoxazoles	43-52	CD4 antigen	Mus musculus	226-229
26269136-2	2015	A preliminary investigation showed that an isoxazole derivative R-13 (3,5-dimethyl-isoxazole[5,4-e]8H-triazepin-4-one) hydrochloride, given in a single oral dose to normal mice, induced significant increases in the content of CD4(+) cells in the spleens and lymph nodes.	r-13 (3,5-dimethyl-isoxazole[5,4-e]8h-triazepin-4-one) hydrochloride	64-132	CD4 antigen	Mus musculus	226-229
26063978-4	2015	In this paper, we present that atorvastatin could upregulate the expression of GARP and TGF-beta in CD4+ T cells and increase the numbers of CD4+LAP+ and CD4+Foxp3+ regulatory T cells in ApoE-/- mice.	Atorvastatin	31-43	CD4 antigen	Mus musculus	100-103
26063978-4	2015	In this paper, we present that atorvastatin could upregulate the expression of GARP and TGF-beta in CD4+ T cells and increase the numbers of CD4+LAP+ and CD4+Foxp3+ regulatory T cells in ApoE-/- mice.	Atorvastatin	31-43	CD4 antigen	Mus musculus	141-144
26063978-4	2015	In this paper, we present that atorvastatin could upregulate the expression of GARP and TGF-beta in CD4+ T cells and increase the numbers of CD4+LAP+ and CD4+Foxp3+ regulatory T cells in ApoE-/- mice.	Atorvastatin	31-43	CD4 antigen	Mus musculus	141-144
24800755-5	2015	Pargyline reduced the percentage of IFN-gamma-producing CD4+ cells and the CD4+IFN-gamma+/CD4+IL-4+ cell ratio, although it did not alter the proportion of IL-4-producing CD4+ cells.	Pargyline	0-9	CD4 antigen	Mus musculus	75-88
25565816-6	2015	Immunizing mice with H53 encapsulated into polyanhydride nanoparticles induced high neutralizing antibody titers and enhanced CD4(+) T cell recall responses in mice.	Polyanhydrides	43-56	CD4 antigen	Mus musculus	126-129
25722879-1	2014	BACKGROUND: In clinical studies, the findings on sulfur mustard (SM) toxicity for CD3(+)CD4(+) and CD3(+)CD8(+) T lymphocyte subsets are contradictory.	Mustard Gas	49-63	CD4 antigen	Mus musculus	88-91
25722879-1	2014	BACKGROUND: In clinical studies, the findings on sulfur mustard (SM) toxicity for CD3(+)CD4(+) and CD3(+)CD8(+) T lymphocyte subsets are contradictory.	Mustard Gas	65-67	CD4 antigen	Mus musculus	88-91
25278453-0	2014	iNOS expression in CD4+ T cells limits Treg induction by repressing TGFbeta1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.	treg	39-43	CD4 antigen	Mus musculus	19-22
25446921-3	2014	The present study was designed to investigate the immunological and molecular mechanisms by which SPA0355 modulates cluster of differentiation of (CD4)(+) T-cell-mediated immune responses in allergic airway inflammation.	SPA0355	98-105	CD4 antigen	Mus musculus	147-150
25446921-4	2014	In vitro studies have shown that SPA0355 suppresses CD4(+) T-cell activation, proliferation, and differentiation via modulation of T-cell receptor (TCR) signal transduction and cytokine-induced Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling.	SPA0355	33-40	CD4 antigen	Mus musculus	52-55
25565837-8	2014	The CD4(+)/CD8(+) ratio, a marker for matured T-cells was slightly reduced, which implies the alteration of immune status induced by ZnO NPs.	Zinc Oxide	133-136	CD4 antigen	Mus musculus	4-7
25378595-3	2014	In this study, we exploited gammaHV68 infection of mice to enhance our understanding of the CD4 T cell response during gamma-herpesvirus infection.	gammahv68	28-37	CD4 antigen	Mus musculus	92-95
25395320-9	2014	MPA-DMBA-induced tumors contained a higher percentage of FOXP3(+) CD4(+) T-cells (p &lt; 0.01) and MDSC (p &lt; 0.001) compared with the other models.	6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene	4-8	CD4 antigen	Mus musculus	66-69
24944101-9	2014	The DNMT antagonist 5-aza-2"-deoxycytidine (5-Aza) induced increased Foxp3 expression in mature CD4(+) T cells.	Decitabine	20-42	CD4 antigen	Mus musculus	96-99
24944101-9	2014	The DNMT antagonist 5-aza-2"-deoxycytidine (5-Aza) induced increased Foxp3 expression in mature CD4(+) T cells.	Decitabine	44-49	CD4 antigen	Mus musculus	96-99
25281414-9	2014	Flavonoid treated mice exhibited decreased activation of splenic CD4+ cells (STAT4 phosphorylation and IFNgamma expression) and reduced plasma cytokine levels.	Flavonoids	0-9	CD4 antigen	Mus musculus	65-68
25489855-4	2014	In the T cell priming assay, cell proliferation was analyzed by flow cytometry following co-culture of DCs from both groups of mice with carboxyfluorescein succinimidyl ester (CFSE) - labeled CD4(+) T cells of OTII transgenic mice.	carboxyfluorescein succinimidyl ester	137-174	CD4 antigen	Mus musculus	192-195
25291010-7	2014	RESULTS: BBL was characterized, and its supplementation in situ led to significant decrease in paw edema, tissue myeloperoxidase activity, NO level, serum TNFalpha level and CINC 1 level as well as decrease in splenic CD4(+)/CD8(+) ratios and increase in level of Treg cells.	N-Carbobenzyloxy-L-alanine	9-12	CD4 antigen	Mus musculus	218-221
25218598-6	2014	In addition, neochromine S5 downregulated the expression of CD25 and CD69 and the production of inflammatory cytokines, including TNFalpha, IFNgamma and IL-2, improved ear swelling in mice with contact hypersensitivity, reduced CD4(+) T cells infiltration, and increased apoptosis of isolated T lymphocytes from peripheral lymph nodes.	neochromine	13-24	CD4 antigen	Mus musculus	228-231
25051576-7	2014	Reciprocal adoptive transfers were used to define whether modifications in CD4+ T-cell responses resulted from direct effects of developmental TCDD exposure on CD4+ T cells.	Polychlorinated Dibenzodioxins	143-147	CD4 antigen	Mus musculus	160-163
25051576-12	2014	CONCLUSIONS: Maternal exposure to TCDD resulted in durable changes in the responsive capacity and differentiation of CD4+ T cells in adult C57BL/6 mice.	Polychlorinated Dibenzodioxins	34-38	CD4 antigen	Mus musculus	117-120
25086399-7	2014	The outperformance of DOTAP-cholesterol-DOPE liposomes+CpG-ODN was found to be attributed to its capability in induction of both CD8+ and CD4+ responses.	1,2-dioleoyloxy-3-(trimethylammonium)propane	22-27	CD4 antigen	Mus musculus	138-141
25086399-7	2014	The outperformance of DOTAP-cholesterol-DOPE liposomes+CpG-ODN was found to be attributed to its capability in induction of both CD8+ and CD4+ responses.	Cholesterol	28-39	CD4 antigen	Mus musculus	138-141
25259750-9	2014	In response to a sodium/volume challenge, wild-type and CD4(-/-) mice infused with angiotensin II retained water and sodium, whereas CD8(-/-) mice did not.	Sodium	17-23	CD4 antigen	Mus musculus	56-59
25259750-9	2014	In response to a sodium/volume challenge, wild-type and CD4(-/-) mice infused with angiotensin II retained water and sodium, whereas CD8(-/-) mice did not.	Water	107-112	CD4 antigen	Mus musculus	56-59
25259750-9	2014	In response to a sodium/volume challenge, wild-type and CD4(-/-) mice infused with angiotensin II retained water and sodium, whereas CD8(-/-) mice did not.	Sodium	117-123	CD4 antigen	Mus musculus	56-59
25124713-0	2014	Non-eosinophilic airway hyper-reactivity in mice, induced by IFN-gamma producing CD4(+) and CD8(+) lung T cells, is responsive to steroid treatment.	Steroids	130-137	CD4 antigen	Mus musculus	81-84
25290058-0	2014	NAD+ protects against EAE by regulating CD4+ T-cell differentiation.	NAD	0-4	CD4 antigen	Mus musculus	40-43
25290058-2	2014	Here we show that nicotinamide adenine dinucleotide (NAD(+)) blocks experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, by inducing immune homeostasis through CD4(+)IFNgamma(+)IL-10(+) T cells and reverses disease progression by restoring tissue integrity via remyelination and neuroregeneration.	NAD	18-51	CD4 antigen	Mus musculus	177-180
25290058-2	2014	Here we show that nicotinamide adenine dinucleotide (NAD(+)) blocks experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, by inducing immune homeostasis through CD4(+)IFNgamma(+)IL-10(+) T cells and reverses disease progression by restoring tissue integrity via remyelination and neuroregeneration.	NAD	53-59	CD4 antigen	Mus musculus	177-180
25290058-3	2014	We show that NAD(+) regulates CD4(+) T-cell differentiation through tryptophan hydroxylase-1 (Tph1), independently of well-established transcription factors.	NAD	13-19	CD4 antigen	Mus musculus	30-33
25290058-4	2014	In the presence of NAD(+), the frequency of T-bet(-/-) CD4(+)IFNgamma(+) T cells was twofold higher than wild-type CD4(+) T cells cultured in conventional T helper 1 polarizing conditions.	NAD	19-25	CD4 antigen	Mus musculus	55-58
25290058-4	2014	In the presence of NAD(+), the frequency of T-bet(-/-) CD4(+)IFNgamma(+) T cells was twofold higher than wild-type CD4(+) T cells cultured in conventional T helper 1 polarizing conditions.	NAD	19-25	CD4 antigen	Mus musculus	115-118
25290058-5	2014	Our findings unravel a new pathway orchestrating CD4(+) T-cell differentiation and demonstrate that NAD(+) may serve as a powerful therapeutic agent for the treatment of autoimmune and other diseases.	NAD	100-106	CD4 antigen	Mus musculus	49-52
25279459-11	2014	However, paricalcitol treatment increased the number of CD4+ and CD8+ Treg cells in vivo.	paricalcitol	9-21	CD4 antigen	Mus musculus	56-59
25151997-4	2014	Of note, EGTE treatment decreased the production antigen-specific IgE via increased the proportion of CD4+ CD25+ regulatory T lymphocytes in the spleen, suggesting that EGTE may play a role in regulating the allergic response.	egte	9-13	CD4 antigen	Mus musculus	102-105
25151997-4	2014	Of note, EGTE treatment decreased the production antigen-specific IgE via increased the proportion of CD4+ CD25+ regulatory T lymphocytes in the spleen, suggesting that EGTE may play a role in regulating the allergic response.	egte	169-173	CD4 antigen	Mus musculus	102-105
25139358-0	2014	Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice.	Cyclophosphamide	75-91	CD4 antigen	Mus musculus	6-9
25213768-8	2014	Flow cytometry showed that simvastatin treatment significantly reduced the percentage of pulmonary CD4(+) cells and the CD4(+)/CD8(+) T-cell ratio (P&lt;0.05).	Simvastatin	27-38	CD4 antigen	Mus musculus	99-102
25213768-8	2014	Flow cytometry showed that simvastatin treatment significantly reduced the percentage of pulmonary CD4(+) cells and the CD4(+)/CD8(+) T-cell ratio (P&lt;0.05).	Simvastatin	27-38	CD4 antigen	Mus musculus	120-123
25077421-0	2014	Protection promoted by pGP3 or pGP4 against Chlamydia muridarum is mediated by CD4(+) cells in C57BL/6N mice.	pgp3	23-27	CD4 antigen	Mus musculus	79-82
25077421-0	2014	Protection promoted by pGP3 or pGP4 against Chlamydia muridarum is mediated by CD4(+) cells in C57BL/6N mice.	pgp4	31-35	CD4 antigen	Mus musculus	79-82
24806609-8	2014	Immune cell surface markers (CD4, CD8, CD19, MHC-II) and cytokine levels were also found to be highly up-regulated in the splenocytes of mice subjected to particulate glucan administration.	Glucans	167-173	CD4 antigen	Mus musculus	29-32
25156660-2	2014	The effects of resveratrol (trans-3,5,4"-trihydroxystilbene) that can protect T lymphocytes in various disease conditions on the HFD-induced apoptosis of CD4(+) CD25(+) CD127(low/-) regulatory T cells (Tregs) were studied, and the possible mechanism was postulated.	Resveratrol	15-26	CD4 antigen	Mus musculus	154-157
25156660-2	2014	The effects of resveratrol (trans-3,5,4"-trihydroxystilbene) that can protect T lymphocytes in various disease conditions on the HFD-induced apoptosis of CD4(+) CD25(+) CD127(low/-) regulatory T cells (Tregs) were studied, and the possible mechanism was postulated.	trans-3,5,4"-trihydroxystilbene	28-59	CD4 antigen	Mus musculus	154-157
25104614-6	2014	Early Dex treatment starting from 1 day postinfection caused atrophy and enhanced apoptosis in lymphoid organs to decrease the numbers of lymphocytes (CD4(+) T cells, CD8(+) T cells, and CD19(+) B cells) and to increase viral loads in infected tissues of mice.	Dexamethasone	6-9	CD4 antigen	Mus musculus	151-154
24968155-3	2014	The ability of LCP vaccines to activate antigen-specific CD8(+) and/or CD4(+) T cell responses was tested using compounds that contained two or four copies of OVA257-264 and/or OVA323-339 peptides conjugated to LCP, which are recognised by OTI (CD8(+) specific) and OTII (CD4(+) specific) T cells, respectively.	Perchloric Acid	15-18	CD4 antigen	Mus musculus	71-74
25109392-4	2014	Finally, in vivo treatment with rIL-17A inhibited local CD4(+)CD25(+)Foxp3(+) T regulatory cells as well as Th2 cytokines without affecting IL-9 in the lung.	ril-17a	32-39	CD4 antigen	Mus musculus	56-59
24547942-4	2014	In this study we have taken advantage of our ability to induce autoimmune cholangitis with 2-octynoic acid, a common component of cosmetics, conjugated to bovine serum albumin (2-OA-BSA), and studied the natural history of pathology in mice genetically deleted for CD4 or CD8 following immunization with 2-OA-BSA in the presence or absence of alpha-galactosylceramide (alpha-GalCer).	2-octynoic acid	91-106	CD4 antigen	Mus musculus	265-268
24547942-6	2014	We report herein that CD4 and CD8 knock-out mice immunized with 2-OA-BSA/PBS or 2-OA-BSA/alpha-GalCer develop anti-mitochondrial antibodies (AMAs), portal infiltrates and fibrosis.	Lead	73-76	CD4 antigen	Mus musculus	22-25
24749746-1	2014	While murine CD4(+) CD39(+) regulatory T cells (T(reg)) co-express CD73 and hydrolyze exogenous (e) adenosine triphosphate (ATP) to immunosuppressive adenosine (ADO), surface co-expression of CD73 on human circulating CD4(+) CD39(+) T(reg) is rare.	Adenosine Triphosphate	100-122	CD4 antigen	Mus musculus	13-16
24749746-1	2014	While murine CD4(+) CD39(+) regulatory T cells (T(reg)) co-express CD73 and hydrolyze exogenous (e) adenosine triphosphate (ATP) to immunosuppressive adenosine (ADO), surface co-expression of CD73 on human circulating CD4(+) CD39(+) T(reg) is rare.	Adenosine Triphosphate	124-127	CD4 antigen	Mus musculus	13-16
24749746-1	2014	While murine CD4(+) CD39(+) regulatory T cells (T(reg)) co-express CD73 and hydrolyze exogenous (e) adenosine triphosphate (ATP) to immunosuppressive adenosine (ADO), surface co-expression of CD73 on human circulating CD4(+) CD39(+) T(reg) is rare.	Adenosine	100-109	CD4 antigen	Mus musculus	13-16
24749746-1	2014	While murine CD4(+) CD39(+) regulatory T cells (T(reg)) co-express CD73 and hydrolyze exogenous (e) adenosine triphosphate (ATP) to immunosuppressive adenosine (ADO), surface co-expression of CD73 on human circulating CD4(+) CD39(+) T(reg) is rare.	Adenosine	161-164	CD4 antigen	Mus musculus	13-16
24773049-6	2014	Moreover, pretreatment with GANRA-5 significantly (p &lt; 0.01) enhanced the cellular immune response, which was characterized by higher peritoneal macrophage as well as splenocyte survival, and a higher ratio of CD4(+)/CD8(+) T lymphocytes.	ganra-5	28-35	CD4 antigen	Mus musculus	213-216
24953123-6	2014	Oddly, only when the selenium was given with the toxin could the effects on the CD3(+) and CD4(+) cells be altered.	Selenium	21-29	CD4 antigen	Mus musculus	91-94
24964870-3	2014	The data showed that alpinetin markedly suppressed ConA-induced murine splenocyte proliferation, Th1/Th2 cytokines production, CD4(+) T-cell populations and ratio of CD4(+)/CD8(+).	alpinetin	21-30	CD4 antigen	Mus musculus	127-130
24964870-3	2014	The data showed that alpinetin markedly suppressed ConA-induced murine splenocyte proliferation, Th1/Th2 cytokines production, CD4(+) T-cell populations and ratio of CD4(+)/CD8(+).	alpinetin	21-30	CD4 antigen	Mus musculus	166-169
24944284-3	2014	Previously, we demonstrated that n-3 (omega-3) polyunsaturated fatty acids (PUFAs) reduce CD4(+) T-cell activation and differentiation into pathogenic Th17 cells by 25-30%.	n-3 (omega-3) polyunsaturated fatty acids	33-74	CD4 antigen	Mus musculus	90-93
24944284-3	2014	Previously, we demonstrated that n-3 (omega-3) polyunsaturated fatty acids (PUFAs) reduce CD4(+) T-cell activation and differentiation into pathogenic Th17 cells by 25-30%.	Fatty Acids, Unsaturated	76-81	CD4 antigen	Mus musculus	90-93
24812660-4	2014	Furthermore, resveratrol decreased the fasting blood glucose and fasting plasma insulin and increased the CD3(+)CD4(+)/CD3(+)CD8(+) subsets percentages and the regulatory T cells (Tregs) production after 13 and 26 weeks of feeding.	Resveratrol	13-24	CD4 antigen	Mus musculus	112-115
24958858-4	2014	Interrogation of mechanism showed that testosterone regulates T-helper 1 (Th1) differentiation by inhibiting IL-12-induced Stat4 phosphorylation: in murine models, we determined that androgen receptor binds a conserved region within the phosphatase, Ptpn1, and consequent up-regulation of Ptpn1 then inhibits IL-12 signaling in CD4 T cells.	Testosterone	39-51	CD4 antigen	Mus musculus	328-331
24780756-7	2014	In mice with advanced lymphoma, adoptive transfer (AT) of tumor-specific CD4(+) T cells following cyclophosphamide treatment (CTX+CD4 AT) provoked a robust initial antitumor immune response, but also resulted in enhanced expansion of monocytic myeloid cells.	Cyclophosphamide	98-114	CD4 antigen	Mus musculus	73-76
24780756-7	2014	In mice with advanced lymphoma, adoptive transfer (AT) of tumor-specific CD4(+) T cells following cyclophosphamide treatment (CTX+CD4 AT) provoked a robust initial antitumor immune response, but also resulted in enhanced expansion of monocytic myeloid cells.	Cyclophosphamide	98-114	CD4 antigen	Mus musculus	130-133
24611843-1	2014	SEW2871, a selective sphingosine-1-phosphate type 1 receptor (S1P1) agonist, has been shown to be effective in protecting kidneys against ischaemia-reperfusion injury by reducing CD4(+) T cell infiltration in mice.	SEW2871	0-7	CD4 antigen	Mus musculus	179-182
24769016-8	2014	PHMG-P also decreased the total cell number and the CD4(+)/CD8(+) cell ratio in the thymus, with the histopathological examination indicating severe reduction of cortex and medulla.	polyhexamethyleneguanidine	0-6	CD4 antigen	Mus musculus	52-55
24698552-1	2014	Vitamin C has been found to stimulate dendritic cells (DCs) to secrete more IL-12 and thereby drive naive CD4(+) T cells to differentiate into Th1 cells.	Ascorbic Acid	0-9	CD4 antigen	Mus musculus	106-109
24836681-0	2014	Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation and inhibit collagen-induced arthritis in mice.	Tacrolimus	40-50	CD4 antigen	Mus musculus	60-63
24836681-14	2014	CONCLUSIONS: tDCs modified by tacrolimus suppressed CD4(+) T cell proliferation and inhibited collagen-induced arthritis.	Tacrolimus	30-40	CD4 antigen	Mus musculus	52-55
25120275-9	2014	The proportion of CD4 lymphocytes in the blood of aged tempol-treated mice was partially increased in comparison to aged control mice.	tempol	55-61	CD4 antigen	Mus musculus	18-21
24555985-6	2014	Injection of CS in mice for 4-5 days expands B cells in the spleen and results in a marked increase of CD138(+) cells in the spleen that is dependent on BTK but independent of CD4(+) T cells.	Cesium	13-15	CD4 antigen	Mus musculus	176-179
24879795-4	2014	In ISAT, activated CD4+ T cells specific for T4p2553 are detected before the disease onset in thyroid-draining cervical lymph nodes only in mice placed on an iodide-rich diet and not in age-matched controls.	Iodides	158-164	CD4 antigen	Mus musculus	19-22
24899497-1	2014	The immunosuppressant dexamethasone was shown to preferentially deplete CD4+ effector T cells while sparing regulatory T cells (Tregs) in vivo.	Dexamethasone	22-35	CD4 antigen	Mus musculus	72-75
24817032-6	2014	Resveratrol treatment dramatically reversed the effects of DSS on the numbers of specific inflammatory CD4(+) T cells, CD8(+) T cells, B cells, natural killer T cells, and myeloid-derived suppressor cells in mesenteric lymph nodes.	Resveratrol	0-11	CD4 antigen	Mus musculus	103-106
24817032-6	2014	Resveratrol treatment dramatically reversed the effects of DSS on the numbers of specific inflammatory CD4(+) T cells, CD8(+) T cells, B cells, natural killer T cells, and myeloid-derived suppressor cells in mesenteric lymph nodes.	dss	59-62	CD4 antigen	Mus musculus	103-106
24789784-4	2014	In this report, we characterized the CD8 T cell response to gammaHV68 in major histocompatibility complex (MHC) class II(-/-) mice, which lack CD4 T cells, or after antibody-mediated depletion of CD4 T cells.	gammahv68	60-69	CD4 antigen	Mus musculus	143-146
24789784-4	2014	In this report, we characterized the CD8 T cell response to gammaHV68 in major histocompatibility complex (MHC) class II(-/-) mice, which lack CD4 T cells, or after antibody-mediated depletion of CD4 T cells.	gammahv68	60-69	CD4 antigen	Mus musculus	196-199
24820417-2	2014	Conditional inactivation of F-box protein Fbw7 in mouse T-cell development resulted in reduced thymic CD4 single-positive (SP) and splenic CD4(+) and CD8(+) cell proportions.	sp	123-125	CD4 antigen	Mus musculus	102-105
25052609-3	2014	With treatment of 3-BrPA at different concentrations (0-200 mumol/L), lymphocyte proliferation capacity was detected by the CCK-8 method, the expression of CD3, CD4, and CD8 by flow cytometry, and the concentrations of cytokine interleukin (IL)-4 and interferon (IFN)-gamma in the supernatant by ELISA.	bromopyruvate	18-24	CD4 antigen	Mus musculus	161-164
24877765-8	2014	The CD4+ T cells induced by CAF09 were mainly of an effector-memory-like phenotype and the CD8+ T cells were highly cytotoxic.	caf09	28-33	CD4 antigen	Mus musculus	4-7
24837764-8	2014	CD4(+) T-cell responses were optimally induced when using TLR9- and TLR3-ligand-adjuvants or CAF09.	caf09	93-98	CD4 antigen	Mus musculus	0-3
24249003-0	2014	Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	90-93
24249003-3	2014	Treatment of DBA/2 mice bearing P815 mastocytoma with cyclophosphamide induced rejection and long-term protection in a CD4- and CD8-dependent manner.	Cyclophosphamide	54-70	CD4 antigen	Mus musculus	119-122
24912188-3	2014	As opposed to WT mice, BeO-exposed HLA-DP2 Tg mice developed mononuclear infiltrates in a peribronchovascular distribution that were composed of CD4(+) T cells and included regulatory T (Treg) cells.	beryllium oxide	23-26	CD4 antigen	Mus musculus	145-148
24912188-4	2014	Beryllium-responsive, HLA-DP2-restricted CD4(+) T cells expressing IFN-gamma and IL-2 were present in BeO-exposed HLA-DP2 Tg mice and not in WT mice.	Beryllium	0-9	CD4 antigen	Mus musculus	41-44
24550187-6	2014	Moreover, vitamin D3 treatment decreased interferon-gamma-positive CD8(+) T cells and increased CD4(+)(CD25(+))FoxP3(+) T cells in pancreatic draining lymph nodes.	Cholecalciferol	10-20	CD4 antigen	Mus musculus	96-99
24623063-3	2014	In this study, we immunized mice with isonicotinic acid (INA)-modified proteins and Freund"s adjuvant, which led to mild experimental autoimmune hepatitis (EAH) with an increase in cells staining positive for F4/80, CD11b, CD8, CD4, CD45R, and KI67.	Isonicotinic Acids	38-55	CD4 antigen	Mus musculus	228-231
24440384-6	2014	When we examine CD4 subsets we also find a shift towards Th1 and cytotoxic CD4 (ThCTL) responses.	thctl	80-85	CD4 antigen	Mus musculus	16-19
24440384-6	2014	When we examine CD4 subsets we also find a shift towards Th1 and cytotoxic CD4 (ThCTL) responses.	thctl	80-85	CD4 antigen	Mus musculus	75-78
24704625-9	2014	Furthermore, CD4(+) T cell infiltration as well as the differentiation of Th1 (CD4(+)IFN-gamma(+)) and Th17 (CD4(+)IL17A(+)) subset were inhibited by andrographolide sulfonate.	andrographolide sulfonate	150-175	CD4 antigen	Mus musculus	13-16
24704625-9	2014	Furthermore, CD4(+) T cell infiltration as well as the differentiation of Th1 (CD4(+)IFN-gamma(+)) and Th17 (CD4(+)IL17A(+)) subset were inhibited by andrographolide sulfonate.	andrographolide sulfonate	150-175	CD4 antigen	Mus musculus	79-82
24704625-9	2014	Furthermore, CD4(+) T cell infiltration as well as the differentiation of Th1 (CD4(+)IFN-gamma(+)) and Th17 (CD4(+)IL17A(+)) subset were inhibited by andrographolide sulfonate.	andrographolide sulfonate	150-175	CD4 antigen	Mus musculus	79-82
24511136-8	2014	Furthermore, aggravation of NTN was reversible in the absence of Th17 responses, as shown in CD4(Cre)xStat3(fl/fl) mice lacking both Treg17 and Th17 cells, suggesting that Th17 cells are indeed the major target of Treg17 cells.	ISONICOTINAMIDINE	28-31	CD4 antigen	Mus musculus	93-96
24992758-8	2014	Serum levels of TNF-alpha, IL-2, and IFN-gamma, frequencies of CD4 + and CD8+ T cells in the spleen, and splenic NK and CTL activities were also significantly increased in mice treated with 5-FU+PL or 5-FU+PTM compared with mice treated with 5-FU alone (P &lt; 0.05).	Fluorouracil	190-194	CD4 antigen	Mus musculus	63-66
24690150-4	2014	Mice receiving pVAX/TgMIC8 alone developed a strong humoral responses and Th1 type cellular immune responses, and showed an increase of CD4+ and CD8+ T cells compared with all the controls.	pvax	15-19	CD4 antigen	Mus musculus	136-139
24690150-4	2014	Mice receiving pVAX/TgMIC8 alone developed a strong humoral responses and Th1 type cellular immune responses, and showed an increase of CD4+ and CD8+ T cells compared with all the controls.	tgmic8	20-26	CD4 antigen	Mus musculus	136-139
24583006-8	2014	Immunization of mice with a synthetic nicotine nanoparticle vaccine containing TpD showed that the peptide was required for robust antibody production and resulted in a long term CD4 memory T cell recall response.	Nicotine	38-46	CD4 antigen	Mus musculus	179-182
24674776-0	2014	Upregulation of KCa3.1 K(+) channel in mesenteric lymph node CD4(+) T lymphocytes from a mouse model of dextran sodium sulfate-induced inflammatory bowel disease.	dextran sodium sulfate	104-126	CD4 antigen	Mus musculus	61-64
24440144-0	2014	The sympathetic nervous system modulates CD4(+)Foxp3(+) regulatory T cells via noradrenaline-dependent apoptosis in a murine model of lymphoproliferative disease.	Norepinephrine	79-92	CD4 antigen	Mus musculus	41-44
24515893-5	2014	While total lymphocytes (including isolated CD4(+) T cells) exhibit Ae1 expression and Na(+) -HCO3 (-) co-transport with acidifying potential, CD8(+) T cells lack these acid-loading mechanisms.	Sodium Bicarbonate	87-98	CD4 antigen	Mus musculus	44-47
24343820-1	2014	Sphingosine 1-phosphate (S1P) and S1P receptor 1 (S1P1) play an important role in the egress of mature CD4 or CD8 single-positive (SP) thymocytes from the thymus.	sphingosine 1-phosphate	0-23	CD4 antigen	Mus musculus	103-106
24656780-8	2014	Gallium nitrate inhibited the increase of CD4(+) T cell populations (p&lt;0.05) and also inhibited the type II collagen-specific IgG2a-isotype autoantibodies (p&lt;0.05).	gallium nitrate	0-15	CD4 antigen	Mus musculus	42-45
24618260-7	2014	CD4+ and CD8+ T cells subtypes were detected by flow cytometry with FITC-labelled antimouse CD4 and PE antimouse CD8 staining.	Fluorescein-5-isothiocyanate	68-72	CD4 antigen	Mus musculus	0-3
24618260-13	2014	Finally, we found that H(2) could regulate the polarization of CD4+ T cells and the level of related cytokines.	Hydrogen	23-27	CD4 antigen	Mus musculus	63-66
24231259-8	2014	We also demonstrate that virus-specific effector and memory CD4 T cells formed independently of Tbet and STAT4, although a slight reduction in the number of antigen-specific CD4 T cells was apparent in mice lacking both transcription factors.	tbet	96-100	CD4 antigen	Mus musculus	60-63
24714355-7	2014	In this context, lung tumor-derived pDCs obtained from mice treated with doxorubicin had higher levels of MHC I and MHC II that well correlated with the higher proliferation rate of CD4 and CD8 T cells, compared with PBS mice.	Doxorubicin	73-84	CD4 antigen	Mus musculus	182-185
24849419-0	2014	Peptidic HIV-1 fusion inhibitor VIR576 as a potential dual- functional microbicide inhibits antigen-specific CD4(+) T-cell activation.	vir576	32-38	CD4 antigen	Mus musculus	109-112
24849419-6	2014	CONCLUSIONS: Given the high susceptibility of activated CD4(+) T cells in the mucosa to HIV-1 infection, the inhibitory effects of VIR576 on both HIV entry into the target cells and CD4(+) T-cell activation suggest the potential of VIR576 as a microbicide for prevention of sexual transmission of HIV.	vir576	131-137	CD4 antigen	Mus musculus	182-185
24889233-4	2014	Nine new CD4(+) T cell epitopes were identified, 3 encoded by gag, 1 by pol, and 5 by env.	Glycosaminoglycans	62-65	CD4 antigen	Mus musculus	9-12
24627473-8	2014	Further mutagenesis narrowed this endocytosis-controlling region to four residues conforming to a YXXPhi (where X is any amino acid and Phi is Val, Leu, or Ile) endocytic motif that, when transferred to CD4, resulted in its internalization from the cell surface.	Leucine	148-151	CD4 antigen	Mus musculus	203-206
24687160-6	2014	Corticosterone levels were negatively associated with the numbers of CD19(+) (r(2) = 0.43, p = 0.0017), CD4(+) (r(2) = 0.28, p = 0.0154) and CD8(+) cells (r(2) = 0.20, p = 0.0503).	Corticosterone	0-14	CD4 antigen	Mus musculus	104-107
24613838-6	2014	In a coculture system, murine bone marrow-derived DCs pretreated with astilbin resulted in an enhanced production of CD4(+)CD25(+)Foxp3(+) T cells.	astilbin	70-78	CD4 antigen	Mus musculus	117-120
24558202-5	2014	DTA-1-induced anaphylaxis requires GITR, CD4(+) T cells, B cells, and interleukin-4.	dta-1	0-5	CD4 antigen	Mus musculus	41-44
24705413-5	2014	Secondly, we demonstrated that DH-PS expanded mouse splenocytes in vivo including CD4(+) T cells, CD8(+) T cells, B cells, NK cells, NKT cells, monocytes/macrophages, granulocytes and regulatory T cells.	dh-ps	31-36	CD4 antigen	Mus musculus	82-85
24702146-6	2014	RESULTS: Mice that received an infusion of isogeneic CD4+CD25+ regulatory T cells had significantly greater mean median survival time, greater degree of chimerism, decreased levels of cytokines (monokine induced by interferon-gamma, interleukin 6, interleukin 10, and regulated upon activation, normal T cell expressed and secreted protein), and decreased lymphocytic infiltration than did mice that received phosphate-buffered saline alone.	Phosphate-Buffered Saline	409-434	CD4 antigen	Mus musculus	53-56
24361466-1	2014	BACKGROUND &amp; AIMS: CD4(+) T cells specific for dietary gluten and interleukin 15 (IL15) contribute to the pathogenesis of celiac disease.	Adenosine Monophosphate	12-15	CD4 antigen	Mus musculus	23-26
24552830-6	2014	In vitro assays demonstrate that CD4 T cells treated with novobiocin produced significantly less TNF-alpha measured by intracellular cytokine staining and by enzyme-linked immunosorbent assay.	Novobiocin	58-68	CD4 antigen	Mus musculus	33-36
24965394-7	2014	CD4(+) and CD8(+) T- lymphocytes subpopulations increased, while the ratio of CD4(+)/ CD8(+) decreased in after madecassic acid administration.	madecassic acid	112-127	CD4 antigen	Mus musculus	78-81
23937474-6	2014	A marked decrease in the total number of thymocytes and the proportion of thymic CD4(+)CD8(+) cells was observed in the 25 mg ANE/kg-treated mice, whereas the proportion of CD4 and CD8 single positive and CD4(-)CD8(-) cells was significantly increased.	ane	126-129	CD4 antigen	Mus musculus	81-84
24646699-6	2014	The populations of CD4 and CD8 T cells were higher and splenic lymphocyte-mediated cytotoxicity towards B16 melanoma was significantly increased in PSB603-treated mice.	PSB603	148-154	CD4 antigen	Mus musculus	19-22
24868871-7	2014	The suppressive function of CD4CD25+ Tregs in association with the proliferative activity of CD4+CD25 effector T cells (Teffs) and the feeder function of CD4 antigen-presenting cells (APCs) were analyzed by carboxyfluorescein succinimidyl ester-dilution assay.	carboxyfluorescein succinimidyl ester	207-244	CD4 antigen	Mus musculus	28-31
24662726-0	2014	Tremella Polysaccharides attenuated sepsis through inhibiting abnormal CD4+CD25(high) regulatory T cells in mice.	tremella polysaccharides	0-24	CD4 antigen	Mus musculus	71-74
24580056-10	2014	CD4-positive staining was seen in the bladder submucosa and lamina propria of all methoxetamine-treated mice and muscle-layer of two methoxetamine-treated mice; these changes were not seen in the control mice.	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone	82-95	CD4 antigen	Mus musculus	0-3
24580056-10	2014	CD4-positive staining was seen in the bladder submucosa and lamina propria of all methoxetamine-treated mice and muscle-layer of two methoxetamine-treated mice; these changes were not seen in the control mice.	2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone	133-146	CD4 antigen	Mus musculus	0-3
24444892-1	2014	The study was designed to investigate the immune-modulatory effects of triptolide (TP) on CD4(+) T cell responses during liver injury.	triptolide	71-81	CD4 antigen	Mus musculus	90-93
24444892-1	2014	The study was designed to investigate the immune-modulatory effects of triptolide (TP) on CD4(+) T cell responses during liver injury.	triptolide	83-85	CD4 antigen	Mus musculus	90-93
24366217-0	2014	Increased expression of herpesvirus entry mediator in 1,25-dihydroxyvitamin D3-treated mouse bone marrow-derived dendritic cells promotes the generation of CD4+CD25+Foxp3+ regulatory T cells.	Calcitriol	54-78	CD4 antigen	Mus musculus	156-159
24366217-6	2014	The capability of 1,25(OH)2D3-treated DCs to induce CD4+CD25+Foxp3+ Treg and the stimulation of allogeneic CD4+ T-cell proliferation in mixed lymphocyte reaction (MLR) was studied.	Calcitriol	18-29	CD4 antigen	Mus musculus	52-55
24366217-11	2014	Together with this pattern of cytokines, 1,25(OH)2D3-treated DCs exhibited low allogeneic CD4+ T-cell stimulatory activity and a higher number of CD4+CD25+Foxp3+ cells in the MLR cultures but not in the activated control DCs.	Calcitriol	41-52	CD4 antigen	Mus musculus	90-93
24366217-11	2014	Together with this pattern of cytokines, 1,25(OH)2D3-treated DCs exhibited low allogeneic CD4+ T-cell stimulatory activity and a higher number of CD4+CD25+Foxp3+ cells in the MLR cultures but not in the activated control DCs.	Calcitriol	41-52	CD4 antigen	Mus musculus	146-149
24785276-15	2014	Real-time RT-PCR revealed that the expression of CD4, CD8 and CD11c mRNAs was increased in tumors treated with DIP compared with that of the saline group at all time points.	Sodium Chloride	141-147	CD4 antigen	Mus musculus	49-52
24453250-5	2014	Primary virus-specific CD4(+) Th1 cells were generated in B cell-depleted mice; however, there was a decrease in the CD4(+)Ly6C(lo)Tbet(+) memory precursor population and a corresponding 4-fold reduction in CD4(+) memory cell number.	tbet	131-135	CD4 antigen	Mus musculus	117-120
24453250-5	2014	Primary virus-specific CD4(+) Th1 cells were generated in B cell-depleted mice; however, there was a decrease in the CD4(+)Ly6C(lo)Tbet(+) memory precursor population and a corresponding 4-fold reduction in CD4(+) memory cell number.	tbet	131-135	CD4 antigen	Mus musculus	117-120
24592261-10	2014	In the post-DP compartment, 91.7% undergo death by negative selection, 4.7% become CD4 SP, and 3.6% become CD8 SP.	dp	12-14	CD4 antigen	Mus musculus	83-86
24592261-12	2014	Approximately 46.3% of CD4 SP and 27% of CD8 SP thymocytes divide before dying or exiting the thymus.	sp	27-29	CD4 antigen	Mus musculus	23-26
24398778-11	2014	Importantly, we found that FGFR inhibition by PD173074 reduced myeloid-derived suppressor cells (MDSCs) in the blood, spleens and tumors, accompanied by the increased infiltration of CD4(+) and CD8(+) T cells in the spleens and tumors.	PD 173074	46-54	CD4 antigen	Mus musculus	183-186
24075232-10	2014	PGE2 decreased cytokine production and inhibited signal transducer and activator of transcription 6 phosphorylation by CD3/CD28-stimulated CD4(+) T cells.	Dinoprostone	0-4	CD4 antigen	Mus musculus	139-142
23682557-9	2014	Moreover, the potent inhibitor of IDO1, 1-methyl-l-tryptophan, attenuated the conversion of CD4 + CD25- T cells into CD4 + CD25+ FoxP3 + T cells.	1-Methyl-L-tryptophan	40-61	CD4 antigen	Mus musculus	92-95
23682557-9	2014	Moreover, the potent inhibitor of IDO1, 1-methyl-l-tryptophan, attenuated the conversion of CD4 + CD25- T cells into CD4 + CD25+ FoxP3 + T cells.	1-Methyl-L-tryptophan	40-61	CD4 antigen	Mus musculus	117-120
23807119-7	2014	Among that, the frequency of CD4(+)CD25(+) T cells was significant lower in SCID mice with MG-thymus.	mg-thymus	91-100	CD4 antigen	Mus musculus	29-32
24180344-11	2014	The CD4(+) lymphocyte numbers in the IE spaces were significantly lower in both PTX groups than in the control group.	Paclitaxel	80-83	CD4 antigen	Mus musculus	4-7
23962659-0	2014	Dietary fish oil and DHA down-regulate antigen-activated CD4+ T-cells while promoting the formation of liquid-ordered mesodomains.	dehydroacetic acid	21-24	CD4 antigen	Mus musculus	57-60
23962659-1	2014	We have demonstrated previously that n-3 PUFA endogenously produced by fat-1 transgenic mice regulate CD4+ T-cell function by affecting the formation of lipid rafts, liquid-ordered mesodomains in the plasma membrane.	Fatty Acids, Omega-3	37-45	CD4 antigen	Mus musculus	102-105
24416230-0	2014	Effects of dietary glutamine on the homeostasis of CD4+ T cells in mice with dextran sulfate sodium-induced acute colitis.	Glutamine	19-28	CD4 antigen	Mus musculus	51-54
24595607-7	2014	We found that tularinum-induced CD4(+) T-cells increased TNF-alpha and IFN-gamma synthesis and expression of CD69 only in group mice with high degree of post immunization protection against F. tularensis Schu challenge.	tularinum	14-23	CD4 antigen	Mus musculus	32-35
24696780-2	2014	We have shown that continuous exposure of MRL+/+ mice to trichloroethylene (TCE) from gestational day (GD) 0 to postnatal day (PND) 49 alters several aspects of CD4(+) T cell function.	Trichloroethylene	57-74	CD4 antigen	Mus musculus	161-164
24696780-2	2014	We have shown that continuous exposure of MRL+/+ mice to trichloroethylene (TCE) from gestational day (GD) 0 to postnatal day (PND) 49 alters several aspects of CD4(+) T cell function.	Trichloroethylene	76-79	CD4 antigen	Mus musculus	161-164
24696780-9	2014	In contrast, expansion of memory/activation cell subset of peripheral CD4(+) T cells were only found in mice exposed to TCE during early life.	Trichloroethylene	120-123	CD4 antigen	Mus musculus	70-73
25036122-0	2014	Attenuation of migration properties of CD4+ T cells from aged mice correlates with decrease in chemokine receptor expression, response to retinoic acid, and RALDH expression compared to young mice.	Tretinoin	138-151	CD4 antigen	Mus musculus	39-42
25036122-4	2014	Upon addition of retinoic acid (RA), CD4(+) T cells from aged mice showed decreased CCR9 expression level compared to young mice and the migration ability of CD4(+) T cells from aged mice toward CCL25 was attenuated compared to young mice.	Tretinoin	17-30	CD4 antigen	Mus musculus	37-40
25036122-4	2014	Upon addition of retinoic acid (RA), CD4(+) T cells from aged mice showed decreased CCR9 expression level compared to young mice and the migration ability of CD4(+) T cells from aged mice toward CCL25 was attenuated compared to young mice.	Tretinoin	17-30	CD4 antigen	Mus musculus	158-161
25036122-4	2014	Upon addition of retinoic acid (RA), CD4(+) T cells from aged mice showed decreased CCR9 expression level compared to young mice and the migration ability of CD4(+) T cells from aged mice toward CCL25 was attenuated compared to young mice.	Tretinoin	32-34	CD4 antigen	Mus musculus	37-40
25036122-4	2014	Upon addition of retinoic acid (RA), CD4(+) T cells from aged mice showed decreased CCR9 expression level compared to young mice and the migration ability of CD4(+) T cells from aged mice toward CCL25 was attenuated compared to young mice.	Tretinoin	32-34	CD4 antigen	Mus musculus	158-161
24197130-6	2014	Importantly, the frequency of CD4(+) and CD8(+) T lymphocytes and consequently the effector lymphocytes or natural killer (NK) to suppressive MDSC ratios were significantly increased following doxorubicin treatment of tumor-bearing mice.	Doxorubicin	193-204	CD4 antigen	Mus musculus	30-33
24642893-9	2014	Importantly, through the AZD4547 treatment, the CD4(+) and CD8(+) T-cells were significantly increased in tumor and spleens.	AZD4547	25-32	CD4 antigen	Mus musculus	48-51
24105651-6	2014	Importantly, the in vivo inhibition of JNK signaling with SP600125 protected C57BL/6 CD4(+) CD8(+) thymocytes from depletion via multiple mechanisms as follows: lower intracellular ROS, inflammatory cytokines, Bax and caspase 3 activity, increase in Bcl-xL amounts, and prevention of the loss in mitochondrial membrane potential.	pyrazolanthrone	58-66	CD4 antigen	Mus musculus	85-88
24105651-6	2014	Importantly, the in vivo inhibition of JNK signaling with SP600125 protected C57BL/6 CD4(+) CD8(+) thymocytes from depletion via multiple mechanisms as follows: lower intracellular ROS, inflammatory cytokines, Bax and caspase 3 activity, increase in Bcl-xL amounts, and prevention of the loss in mitochondrial membrane potential.	ros	181-184	CD4 antigen	Mus musculus	85-88
25024726-7	2014	In dexamethasone-induced immunosuppressed mice, NNAV restored the concentration of serum IgG and IgM, while decreasing the percentage of CD4 and CD8 T-cell subsets.	Dexamethasone	3-16	CD4 antigen	Mus musculus	137-140
24055279-1	2014	BACKGROUND &amp; AIMS: A dysregulated response of CD4(+) T cells against the microbiota contributes to the development of inflammatory bowel disease.	Adenosine Monophosphate	12-15	CD4 antigen	Mus musculus	50-53
24055279-8	2014	RESULTS: In mice with T cell- or dextran sulfate sodium-induced colitis, colitogenic CD4(+) T cells (T-helper 1 and Th17 cells) accumulated in the inflamed intestine and expressed a high level of endogenous opioids.	Dextran Sulfate	33-55	CD4 antigen	Mus musculus	85-88
23813495-7	2014	In vitro, differentiation of CD4(+) naive T cells into Th17 lymphocytes was decreased by the CB2 agonist, JWH-133, and was associated with reduced Th17 marker messenger RNA expression and IL-17 production, without modification of IL-22 release.	(4-methyl-1-naphthyl)-(1-pentylindol-3-yl)methanone	106-109	CD4 antigen	Mus musculus	29-32
24993442-0	2014	Epicutaneous immunization with TNP-Ig and Zymosan induces TCRalphabeta+ CD4+ contrasuppressor cells that reverse skin-induced suppression via IL-17A.	Zymosan	42-49	CD4 antigen	Mus musculus	72-75
23884312-5	2014	A significant increase of CD4+ CD25+-activated T cells (P&lt;0.01) and elevated serum IgE levels (P&lt;0.05) in KO mice indicated more the development of FITC sensitization than an irritative reaction.	Fluorescein-5-isothiocyanate	154-158	CD4 antigen	Mus musculus	26-29
25242406-10	2014	Moreover, CXCL10 mRNA attenuated by dexmedetomidine in liver may result in the lower level of CD4(+) T cells infiltration in liver.	Dexmedetomidine	36-51	CD4 antigen	Mus musculus	94-97
24808635-8	2014	Salidroside altered the distribution of CD4(+) and CD8(+) T lymphocyte in the liver and spleen through regulating CXCL-10 and decreased the severity of liver injuries.	rhodioloside	0-11	CD4 antigen	Mus musculus	40-43
24891765-0	2014	Hesperidin inhibits inflammatory response induced by Aeromonas hydrophila infection and alters CD4+/CD8+ T cell ratio.	Hesperidin	0-10	CD4 antigen	Mus musculus	95-98
24891765-9	2014	CONCLUSION: Present data indicated that HES has a potential role in the suppression of inflammatory response induced by A. hydrophila toxins through downmodulation of ROS production and CD14 and adhesion molecules expression, as well as increase of CD4(+)/CD8(+) cell ratio.	Hesperidin	40-43	CD4 antigen	Mus musculus	249-252
24140555-4	2014	In mice with two different genetic backgrounds, the pharmacologic inhibition of HO activity with zinc-protoporphyrin IX (ZnPPIX) induced enhanced myocarditis and reduced parasitaemia, which was accompanied by an amplified production of nitric oxide and increased influx of CD4(+), CD8(+) and IFN-gamma(+) cells to the myocardium in comparison with the control group.	protoporphyrin IX	102-119	CD4 antigen	Mus musculus	273-276
24140555-4	2014	In mice with two different genetic backgrounds, the pharmacologic inhibition of HO activity with zinc-protoporphyrin IX (ZnPPIX) induced enhanced myocarditis and reduced parasitaemia, which was accompanied by an amplified production of nitric oxide and increased influx of CD4(+), CD8(+) and IFN-gamma(+) cells to the myocardium in comparison with the control group.	zinc protoporphyrin	121-127	CD4 antigen	Mus musculus	273-276
24140555-5	2014	Conversely, treatment with haemin (an activator of HO) lead to a decreased number of intracardiac CD4(+) (but not CD8(+)) cells compared to the control group.	Hemin	27-33	CD4 antigen	Mus musculus	98-101
24107512-5	2014	In the circulation, spleen, bone marrow, and thymus, we find that nicotine promotes an increase in CD3(+)CD4(+) cells via its activation of the alpha4 nAChR and regulation of G protein subunit o, G protein regulated-inducer of neurite outgrowth, and CDC42 signaling within T cells.	Nicotine	66-74	CD4 antigen	Mus musculus	105-108
24226770-6	2013	Among short-chain fatty acids, butyrate induced the differentiation of Treg cells in vitro and in vivo, and ameliorated the development of colitis induced by adoptive transfer of CD4(+) CD45RB(hi) T cells in Rag1(-/-) mice.	Butyrates	31-39	CD4 antigen	Mus musculus	179-182
24339889-5	2013	A DEX-based nanovaccine containing OVA and lipopolysaccharide (LPS) as a DC stimulus induced strong OVA peptide-specific CD4(+) and CD8(+) T cell proliferation both in vitro and upon systemic application in mice, as well as a robust OVA-specific humoral immune response (IgG1&gt;IgG2a) in vivo.	Dextrans	2-5	CD4 antigen	Mus musculus	121-124
24339889-5	2013	A DEX-based nanovaccine containing OVA and lipopolysaccharide (LPS) as a DC stimulus induced strong OVA peptide-specific CD4(+) and CD8(+) T cell proliferation both in vitro and upon systemic application in mice, as well as a robust OVA-specific humoral immune response (IgG1&gt;IgG2a) in vivo.	based nanovaccine	6-23	CD4 antigen	Mus musculus	121-124
24339889-5	2013	A DEX-based nanovaccine containing OVA and lipopolysaccharide (LPS) as a DC stimulus induced strong OVA peptide-specific CD4(+) and CD8(+) T cell proliferation both in vitro and upon systemic application in mice, as well as a robust OVA-specific humoral immune response (IgG1&gt;IgG2a) in vivo.	ova	35-38	CD4 antigen	Mus musculus	121-124
24339889-5	2013	A DEX-based nanovaccine containing OVA and lipopolysaccharide (LPS) as a DC stimulus induced strong OVA peptide-specific CD4(+) and CD8(+) T cell proliferation both in vitro and upon systemic application in mice, as well as a robust OVA-specific humoral immune response (IgG1&gt;IgG2a) in vivo.	ova	100-103	CD4 antigen	Mus musculus	121-124
24218229-8	2013	Se-Met supplementation helped to maintain the CD4/CD8 ratio of lymphocytes in the spleen, although it increased the proportion of B cells.	se-met	0-6	CD4 antigen	Mus musculus	46-49
24048955-3	2013	In this study, we analyzed the relationship between tyrosine phosphorylation and the co-stimulatory function of CD28 in murine primary CD4(+) T cells.	Tyrosine	52-60	CD4 antigen	Mus musculus	135-138
24201080-8	2013	Reduction in the number of thymocytes was observed in mice treated for 8days, and CD4+CD8+ cells were more sensitive to apoptosis induced by oridonin.	oridonin	141-149	CD4 antigen	Mus musculus	82-85
23494705-0	2013	Arsenic trioxide alleviates airway hyperresponsiveness and promotes apoptosis of CD4+ T lymphocytes: evidence for involvement of the ER stress-CHOP pathway.	Arsenic Trioxide	0-16	CD4 antigen	Mus musculus	81-84
23494705-12	2013	Furthermore, arsenic trioxide treatment promoted apoptosis of CD4+T cells in vivo and in vitro.	Arsenic Trioxide	13-29	CD4 antigen	Mus musculus	62-65
23494705-13	2013	When CD4+T cells were cultured with arsenic trioxide for 5 h at a concentration of 5 muM, the expression of GRP78 and CHOP was increased.	Arsenic Trioxide	36-52	CD4 antigen	Mus musculus	5-8
23494705-14	2013	Treatment of CD4+T cells with CHOP siRNA, provided partial resistance to arsenic trioxide-induced apoptosis of CD4+T cells CONCLUSIONS: These data demonstrated that arsenic trioxide can reduce the severity of asthma attacks and induce the apoptosis of CD4+ T cell which the ER stress-CHOP pathway involved.	Arsenic Trioxide	73-89	CD4 antigen	Mus musculus	13-16
23494705-14	2013	Treatment of CD4+T cells with CHOP siRNA, provided partial resistance to arsenic trioxide-induced apoptosis of CD4+T cells CONCLUSIONS: These data demonstrated that arsenic trioxide can reduce the severity of asthma attacks and induce the apoptosis of CD4+ T cell which the ER stress-CHOP pathway involved.	Arsenic Trioxide	73-89	CD4 antigen	Mus musculus	111-114
23494705-14	2013	Treatment of CD4+T cells with CHOP siRNA, provided partial resistance to arsenic trioxide-induced apoptosis of CD4+T cells CONCLUSIONS: These data demonstrated that arsenic trioxide can reduce the severity of asthma attacks and induce the apoptosis of CD4+ T cell which the ER stress-CHOP pathway involved.	Arsenic Trioxide	73-89	CD4 antigen	Mus musculus	111-114
23494705-14	2013	Treatment of CD4+T cells with CHOP siRNA, provided partial resistance to arsenic trioxide-induced apoptosis of CD4+T cells CONCLUSIONS: These data demonstrated that arsenic trioxide can reduce the severity of asthma attacks and induce the apoptosis of CD4+ T cell which the ER stress-CHOP pathway involved.	Arsenic Trioxide	165-181	CD4 antigen	Mus musculus	13-16
23494705-14	2013	Treatment of CD4+T cells with CHOP siRNA, provided partial resistance to arsenic trioxide-induced apoptosis of CD4+T cells CONCLUSIONS: These data demonstrated that arsenic trioxide can reduce the severity of asthma attacks and induce the apoptosis of CD4+ T cell which the ER stress-CHOP pathway involved.	Arsenic Trioxide	165-181	CD4 antigen	Mus musculus	111-114
23494705-14	2013	Treatment of CD4+T cells with CHOP siRNA, provided partial resistance to arsenic trioxide-induced apoptosis of CD4+T cells CONCLUSIONS: These data demonstrated that arsenic trioxide can reduce the severity of asthma attacks and induce the apoptosis of CD4+ T cell which the ER stress-CHOP pathway involved.	Arsenic Trioxide	165-181	CD4 antigen	Mus musculus	111-114
23983225-4	2013	TSP-1KO mice subjected to DS had less corneal barrier disruption, reduced loss of PAS+ GC, and decreased CD4(+) T cell infiltration in the conjunctiva.	Deuterium	26-28	CD4 antigen	Mus musculus	105-108
23911424-4	2013	In this work we showed that chronic application of sildenafil in healthy mice leads to opposite gender-dependent effects on NK cells, subpopulations of CD4(+) and CD8(+) T cells, activated conventional T cells, and to a decrease in Gr-1(+)CD11b(+) immature myeloid cells.	Sildenafil Citrate	51-61	CD4 antigen	Mus musculus	152-155
23911424-6	2013	Ex vivo cultivation of isolated splenocytes with sildenafil results in an increase in CD4(+) T cells and a concomitant decrease in B cells and central memory CD8(+) T cells.	Sildenafil Citrate	49-59	CD4 antigen	Mus musculus	86-89
24103733-4	2013	RESULTS: We showed that IL-35 and decitabine stimulated the proliferation of CD4(+)CD25(+) Tregs and suppressed CD8(+) T cell proliferation in an allogenic mixed lymphocyte culture in vitro.	Decitabine	34-44	CD4 antigen	Mus musculus	77-80
24103733-6	2013	CONCLUSIONS: The possible mechanism through which IL-35 and decitabine treatment increased the survival of graft tissues is to enhance the proliferation of CD4(+)CD25(+) Treg cells and suppress the generation and function of effector T cells.	Decitabine	60-70	CD4 antigen	Mus musculus	156-159
24260551-0	2013	Roscovitine suppresses CD4+ T cells and T cell-mediated experimental uveitis.	Roscovitine	0-11	CD4 antigen	Mus musculus	23-26
24260551-5	2013	Thus, we sought to test the immunosuppressive effect of roscovitine, a potent CdK2 inhibitor, on CD4+ T cell activation, proliferation, and function.	Roscovitine	56-67	CD4 antigen	Mus musculus	97-100
24260551-13	2013	Roscovitine treatment blocked activated CD4+ cells from entering S phase.	Roscovitine	0-11	CD4 antigen	Mus musculus	40-43
24260551-14	2013	In addition, roscovitine not only reduced the viability of CD4+ lymphocytes but also suppressed T cell activation and cytokine production.	Roscovitine	13-24	CD4 antigen	Mus musculus	59-62
23999542-1	2013	We have previously reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in marijuana, suppresses CD40 ligand (CD40L) expression by activated mouse CD4(+) T cells.	Dronabinol	33-62	CD4 antigen	Mus musculus	138-141
23999542-1	2013	We have previously reported that Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the main psychoactive cannabinoid in marijuana, suppresses CD40 ligand (CD40L) expression by activated mouse CD4(+) T cells.	Dronabinol	64-76	CD4 antigen	Mus musculus	138-141
23999542-4	2013	Pretreatment with Delta(9)-THC attenuated CD40L expression in human CD4(+) T cells activated by anti-CD3/CD28 at both the protein and mRNA level, as determined by flow cytometry and quantitative real-time PCR, respectively.	Dronabinol	18-30	CD4 antigen	Mus musculus	42-45
24265670-7	2013	Rapamycin induced a general decrease in muscle of CD4 and CD8 T cells in lymphoid tissues, but spared B cells.	Sirolimus	0-9	CD4 antigen	Mus musculus	50-53
24270218-6	2013	Our results demonstrated that a significant decrease in the level of IL-4 and increase in the IFN-gamma in the animals treated with salvigenin and significant decreased in the level of splenic CD4+CD25+Foxp3+ T regulatory cells.	salvigenin	132-142	CD4 antigen	Mus musculus	193-196
24100390-8	2013	These results suggest that ROS may be involved in promoting the functional maturation of CD4(+) SPs and thymic medullary microenvironment contributes to the pro-oxidant shift of SP thymocytes.	Reactive Oxygen Species	27-30	CD4 antigen	Mus musculus	89-92
24100390-8	2013	These results suggest that ROS may be involved in promoting the functional maturation of CD4(+) SPs and thymic medullary microenvironment contributes to the pro-oxidant shift of SP thymocytes.	sp	96-98	CD4 antigen	Mus musculus	89-92
23954198-2	2013	Based on in vitro assay, 6-O-palmitoyl Agnuside (AG-3) was further taken up for detailed in vivo activity and found to significantly enhance the production of anti OVA IgG titer, neutralizing antibody (IgG1 and IgG2a) titer as well as soluble mediators of a Th1 (IL-2, IFN-gamma)/Th2 response (IL-4) and proliferation of T lymphocyte subsets (CD4/CD8) and co stimulatory molecules CD80/CD86.	6-o-palmitoyl agnuside	25-47	CD4 antigen	Mus musculus	343-346
24058174-8	2013	CD4(+) T cells from CRA-immunized and challenged abr(-/-) mice contained elevated levels of activated GTP-bound Rac compared with wild-type controls.	Guanosine Triphosphate	102-105	CD4 antigen	Mus musculus	0-3
24078700-3	2013	In this study, we demonstrate that aging increases TORC2 signaling in murine CD4 T cells, a change blocked by long-term exposure to rapamycin, suggesting that functional defects may be the result of enhanced TORC2 function.	Sirolimus	132-141	CD4 antigen	Mus musculus	77-80
24339053-0	2013	Locally instilled tumor necrosis factor alpha antisense oligonucleotide contributes to inhibition of TH 2-driven pulmonary fibrosis via induced CD4+ CD25+ Foxp3+ regulatory T cells.	Oligonucleotides	56-71	CD4 antigen	Mus musculus	144-147
24090996-0	2013	Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.	Cyclophosphamide	80-96	CD4 antigen	Mus musculus	43-46
24090996-0	2013	Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.	Sirolimus	101-110	CD4 antigen	Mus musculus	43-46
24090996-9	2013	Rapamycin treatment selectively arrested more CD8(+)CD4(+) T-ALL cells at G0 phase of cell cycle.	Sirolimus	0-9	CD4 antigen	Mus musculus	52-55
24204874-11	2013	We propose that the sialyl motif of Tc Muc is able to interact with sialic acid-binding Ig-like lectins (Siglecs) on CD4(+) T cells, which may allow the parasite to modulate the immune system.	N-Acetylneuraminic Acid	68-79	CD4 antigen	Mus musculus	117-120
23933131-5	2013	In addition, naringenin significantly suppressed production of interferon-gamma (IFN-gamma) by activated CD4(+) T cells and serum IgE level.	naringenin	13-23	CD4 antigen	Mus musculus	105-108
23933131-6	2013	Furthermore, naringenin reduced DNFB-induced infiltration of eosinophils, mast cells, CD4(+) T cells, and CD8(+) T cells in skin lesions.	naringenin	13-23	CD4 antigen	Mus musculus	86-89
23933131-6	2013	Furthermore, naringenin reduced DNFB-induced infiltration of eosinophils, mast cells, CD4(+) T cells, and CD8(+) T cells in skin lesions.	Dinitrofluorobenzene	32-36	CD4 antigen	Mus musculus	86-89
23933131-7	2013	SIGNIFICANCE: Naringenin may suppress the development of AD-like skin lesions in DNFB-treated NC/Nga mice by reducing IFN-gamma production of activated CD4(+) T cells, serum IgE levels and infiltration of immune cells to skin lesion.	naringenin	14-24	CD4 antigen	Mus musculus	152-155
23933131-7	2013	SIGNIFICANCE: Naringenin may suppress the development of AD-like skin lesions in DNFB-treated NC/Nga mice by reducing IFN-gamma production of activated CD4(+) T cells, serum IgE levels and infiltration of immune cells to skin lesion.	Dinitrofluorobenzene	81-85	CD4 antigen	Mus musculus	152-155
24052129-8	2013	Interestingly, the increased DCOVA-P30-induced CTL responses are mainly contributed by enhanced CD4(+) T-cell-stimulated CTL proliferation.	dcova-p30	29-38	CD4 antigen	Mus musculus	96-99
23850945-4	2013	The results showed that 2,3-DCP markedly inhibited ConA-induced splenocyte proliferation, Th1 and Th2 cytokine production, CD4(+) T cell populations, and the ratio of CD4(+)/CD8(+) T cells and cell cycle arrest in vitro.	2,3-dichloro-1-propanol	24-31	CD4 antigen	Mus musculus	123-126
23850945-4	2013	The results showed that 2,3-DCP markedly inhibited ConA-induced splenocyte proliferation, Th1 and Th2 cytokine production, CD4(+) T cell populations, and the ratio of CD4(+)/CD8(+) T cells and cell cycle arrest in vitro.	2,3-dichloro-1-propanol	24-31	CD4 antigen	Mus musculus	167-170
23897609-2	2013	The study was also aimed at understanding the potential of immunization with PhtD and PhtE in eliciting qualitative CD4 T cell memory responses and protection against pneumococcal NP colonization in mice.	phte	86-90	CD4 antigen	Mus musculus	116-119
23905628-6	2013	Meanwhile, CD4(+) /CD25(+) regulatory T cells more significantly increase in NZB/W F1 mice receiving cystamine than in those mice receiving PBS, accompanied by significantly reduced IL-6/phosphorylated STAT-3 expression.	Cystamine	101-110	CD4 antigen	Mus musculus	11-14
23905628-7	2013	The above findings suggest the beneficial effects of cystamine in terms of increasing antioxidant activities and CD4(+) /CD25(+) regulatory T cells in lupus-prone mice by suppressing IL-6/STAT3 signalling.	Cystamine	53-62	CD4 antigen	Mus musculus	113-116
23980207-4	2013	We found in this study that the RXR agonists, PA024 and tributyltin, augmented the ability of all-trans-RA or the RAR agonist Am80 to enhance CD4(+)CD25(-) T cells to acquire Foxp3 expression and suppressive function.	pa024	46-51	CD4 antigen	Mus musculus	142-145
23722874-1	2013	We have recently reported that CD4(+) T cells synthesize and secrete catecholamines that facilitate a shift of T helper 1 (Th1)/Th2 balance toward Th2 polarization.	Catecholamines	69-83	CD4 antigen	Mus musculus	31-34
24066030-4	2013	The in vivo depletion of CD4(+) T cells one day before tumor challenge resulted in compromised vaccine efficacy in both TC-1 (25%) and 3LL (12.5%) tumor models.	TC 1	120-124	CD4 antigen	Mus musculus	25-28
23642129-7	2013	Bleomycin induced an equal increase in CD4(+)/CD25(+)/FoxP3(+) Treg populations in WT and GzmB(-/-) mice.	Bleomycin	0-9	CD4 antigen	Mus musculus	39-42
23233133-4	2013	We have found that CD8(+) T cells express very high levels of o-series gangliosides, but on the other hand, CD4(+) T cells preferably express a-series gangliosides.	a-series gangliosides	142-163	CD4 antigen	Mus musculus	108-111
23233133-5	2013	In the TCR-dependent activation, CD4(+) T cells selectively require a-series gangliosides, but CD8(+) T cells do require only o-series gangliosides but not a-series gangliosides.	Gangliosides	77-89	CD4 antigen	Mus musculus	33-36
23233133-7	2013	These findings imply that the distinct expression pattern of ganglioside species in CD4(+) and CD8(+) T cells define the immune function of each T cell subset.	Gangliosides	61-72	CD4 antigen	Mus musculus	84-87
23663075-9	2013	Cyclophosphamide treatment led to a significantly lower percentage of apoptotic CD4(+) , CD8(+) and CD4(+) CD25(+) T cells in SPCs from NOD.GzmB(-/-) mice than those from wt-NOD mice.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	80-83
23663075-9	2013	Cyclophosphamide treatment led to a significantly lower percentage of apoptotic CD4(+) , CD8(+) and CD4(+) CD25(+) T cells in SPCs from NOD.GzmB(-/-) mice than those from wt-NOD mice.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	100-103
23667148-2	2013	The calcium release-activated calcium (CRAC/ORAI) channels, which act upstream of calcineurin, are essential for calcium entry and CD4(+) T-cell activation.	Calcium	4-11	CD4 antigen	Mus musculus	131-134
23904160-5	2013	When Ad5-ID93 is administered in a prime-boost strategy with ID93/GLA-SE, both CD4(+) and CD8(+) T cells are generated and provide protection against M. tuberculosis.	gamma-Linolenic Acid	66-69	CD4 antigen	Mus musculus	79-82
23455655-7	2013	DTPP-based PDT cell lysate vaccination had a significant inhibitory effect on tumor growth based on increased CD4(+)/CD8(+) ratios, NK cell percentages, elevated serum IFN-gamma and IL-1 levels, and lymphocyte aggregation at the edge of tumors.	DTPP	0-4	CD4 antigen	Mus musculus	110-113
24013775-11	2013	Copper lowering was also associated with a CD4(+) T cell infiltrate.	Copper	0-6	CD4 antigen	Mus musculus	43-46
23991089-0	2013	The retinoic acid-metabolizing enzyme Cyp26b1 regulates CD4 T cell differentiation and function.	Tretinoin	4-17	CD4 antigen	Mus musculus	56-59
23991087-4	2013	We found that CD4(+) T cells that were co-stimulated and polarized with TGF-beta and IL-4 in the presence or absence of rapamycin each yielded effector cells of Th9 phenotype that secreted increased IL-9 and expressed a transcription factor profile characteristic of both Th9 and Th2 cells (high GATA-3/low T-bet).	Sirolimus	120-129	CD4 antigen	Mus musculus	14-17
23991087-5	2013	Augmentation of T cell replete allografts with manufactured rapamycin resistant Th9 cells markedly reduced both CD4(+) and CD8(+) T cell engraftment and strongly inhibited allo-specific T cell secretion of IFN-gamma.	Sirolimus	60-69	CD4 antigen	Mus musculus	112-115
23791694-5	2013	The population of CD19(+) and CD11c(+) cells in the spleen and mesenteric lymph node (MLN) and of F4/80(+) cells in the spleen was significantly decreased in DON-treated mice, whereas the level of CD8(+) and CD4(+)CD25(+)Foxp3(+) cells in the spleen and CD4(+) T cells in MLN was significantly increased.	deoxynivalenol	158-161	CD4 antigen	Mus musculus	208-211
23791694-5	2013	The population of CD19(+) and CD11c(+) cells in the spleen and mesenteric lymph node (MLN) and of F4/80(+) cells in the spleen was significantly decreased in DON-treated mice, whereas the level of CD8(+) and CD4(+)CD25(+)Foxp3(+) cells in the spleen and CD4(+) T cells in MLN was significantly increased.	deoxynivalenol	158-161	CD4 antigen	Mus musculus	254-257
23880180-7	2013	In aortic arches, however, cromolyn treatment significantly reduced lesion contents of Mac-3(+) macrophages, CD4(+) T cells, activated MCs, and lesion cell proliferation.	Cromolyn Sodium	27-35	CD4 antigen	Mus musculus	109-112
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	31-40	CD4 antigen	Mus musculus	85-88
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	31-40	CD4 antigen	Mus musculus	195-198
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	211-220	CD4 antigen	Mus musculus	85-88
23480027-9	2013	Supporting the hypothesis that sirolimus directly affects the functional activity of CD4+ CD25+ Treg cells, we observed a remarkable enhancement of FoxP3 expression in colon tissues and isolated CD4+ T cells of sirolimus-treated mice.	Sirolimus	211-220	CD4 antigen	Mus musculus	195-198
23480027-10	2013	Simultaneously, sirolimus treatment led to a significant reduction in the number of CD4+ IL-17A+ T cells in the mesenteric lymph node cells as well as IL-17A production in mesenteric lymph node cells.	Sirolimus	16-25	CD4 antigen	Mus musculus	84-87
23663055-8	2013	3, 4-DAA also induced CD4(+) CD25(+) T cells expression (5.88 +- 2.1 vs 11.03 +- 2.93, P &lt; 0.05) in mice MLNs.	N-(3',4'-dimethoxycinnamonyl)anthranilic acid	0-8	CD4 antigen	Mus musculus	22-25
23663055-14	2013	CONCLUSION: 3, 4-DAA can alleviate the severity of colitis through inhibiting Th1 cells response, promoting Th2 cytokines expression and inducing CD4(+) CD25(+) T cells expression.	N-(3',4'-dimethoxycinnamonyl)anthranilic acid	12-20	CD4 antigen	Mus musculus	146-149
23632310-0	2013	Immunoregulatory effects of glycyrrhizic acid exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4(+)CD25(+)Foxp3+ regulatory T cells in ovalbumin-sensitized mice.	Glycyrrhizic Acid	28-45	CD4 antigen	Mus musculus	131-134
23936123-6	2013	While OVA-directed, CD4+ Foxp3+ regulatory T cells could be detected in the spleens of both OVA-treated control and DSS mice, OVA-reactive, CD4+ Foxp3-T cells were only found in the OVA and DSS-treated mice.	dss	116-119	CD4 antigen	Mus musculus	20-23
23636127-7	2013	These therapeutic effects were ablated in both CD4(+)- and CD8(+)-depleted mice and nude mouse systems, indicating that the therapeutic effect of miR-124 depends on the presence of a T-cell-mediated antitumor immune response.	mir-124	146-153	CD4 antigen	Mus musculus	47-50
23649092-5	2013	We initially demonstrated that intact Staphylococcus aureus elicits murine CD4(+) T cell-dependent (poly)glycerolphosphate-specific IgM and IgG responses in vivo.	polyglycerolphosphate	99-122	CD4 antigen	Mus musculus	75-78
23837973-0	2013	[Effect of resveratrol on the activation of murine CD4(+);T lymphocytes].	Resveratrol	11-22	CD4 antigen	Mus musculus	51-54
23837973-1	2013	OBJECTIVE: To study the effect of resveratrol on murine CD4(+);T lymphocyte activation.	Resveratrol	34-45	CD4 antigen	Mus musculus	56-59
23837973-4	2013	RESULTS: Resveratrol (&gt;=10 mmol/L) significantly decreased CD69 levels on CD4(+);T lymphocytes activated with anti-CD3 in a dose-dependent manner (P&lt;0.01).	Resveratrol	9-20	CD4 antigen	Mus musculus	77-80
23837973-5	2013	In addition, resveratrol (&gt;=20 mmol/L) decreased CD69 levels on CD4(+);T lymphocytes activated with ConA, and anti-CD3/anti-CD28 in a dose-dependent manner (P&lt;0.05).	Resveratrol	13-24	CD4 antigen	Mus musculus	67-70
23837973-6	2013	When concentrations &gt;=10 mmol/L, resveratrol depressed CD71 expression on ConA stimulated CD4(+);T lymphocytes (P&lt;0.05), and resveratrol (&gt;=20 mmol/L) decreased CD71 levels on anti-CD3 and anti-CD3/anti-CD28 stimulated CD4(+);T lymphocytes (P&lt;0.05), all in a dose-dependent manner.	Resveratrol	36-47	CD4 antigen	Mus musculus	93-96
23837973-6	2013	When concentrations &gt;=10 mmol/L, resveratrol depressed CD71 expression on ConA stimulated CD4(+);T lymphocytes (P&lt;0.05), and resveratrol (&gt;=20 mmol/L) decreased CD71 levels on anti-CD3 and anti-CD3/anti-CD28 stimulated CD4(+);T lymphocytes (P&lt;0.05), all in a dose-dependent manner.	Resveratrol	36-47	CD4 antigen	Mus musculus	228-231
23837973-7	2013	CONCLUSION: Resveratrol inhibits the activation of murine CD4(+);T lymphocytes in a dosedependent manner.	Resveratrol	12-23	CD4 antigen	Mus musculus	58-61
23805274-2	2013	Previously, we have shown that GA therapy of MS induces CD8(+) T cell responses that can potentially suppress pathogenic CD4(+) T cell responses.	Glatiramer Acetate	31-33	CD4 antigen	Mus musculus	121-124
23805274-6	2013	GA-induced regulatory myeloid cells, previously shown to activate CD4(+) regulatory T cells in an antigen-independent manner, required CD8(+) T cells for disease suppression in vivo.	Glatiramer Acetate	0-2	CD4 antigen	Mus musculus	66-69
23861729-5	2013	Ovalbumin-specific CD4(+) DO11.10 and OT-II T cells that had been stimulated with their cognate antigen in the presence of OvALT-2 or OvNLT-1 displayed reduced DNA synthesis quantified by (3)H-thymidine incorporation and reduced cell division quantified by CFSE dilution.	Thymidine	193-202	CD4 antigen	Mus musculus	19-22
23840617-7	2013	The IFN-gamma-expressing CD4(+) splenocytes and IFN-gamma-expressing lymph node cells were dramatically decreased in curcumin-treated mice.	Curcumin	117-125	CD4 antigen	Mus musculus	25-28
23840617-8	2013	In contrast, CD4(+)Foxp3(+) splenocytes were increased in the curcumin-treated acute GVHD animals.	Curcumin	62-70	CD4 antigen	Mus musculus	13-16
23840617-9	2013	Flow cytometric analysis revealed that animals transplanted with curcumin-treated allogeneic splenocytes showed increased populations of CD4(+) regulatory T cells (Tregs) as well as CD8(+) Treg cells, compared to animals administered vehicle-treated splenocytes.	Curcumin	65-73	CD4 antigen	Mus musculus	137-140
23840617-13	2013	Curcumin exerted in vivo preventive effects on acute GVHD by reciprocal regulation of T helper 1 (Th1) and Treg (both CD4(+) and CD8(+) Treg) cell lineages as well as B cell homeostasis.	Curcumin	0-8	CD4 antigen	Mus musculus	118-121
23776480-6	2013	In vivo CD69(-/-) CD4 T cells accumulate in the intestine in higher numbers than B6 CD4 T cells as observed in competitive homing assay, dextran sodium sulphate (DSS)-induced colitis and antigen-specific transfer colitis.	dextran sodium sulphate	137-160	CD4 antigen	Mus musculus	18-21
23674757-8	2013	CD4(+) lymph node cells from IRBP-immunized WT mice transferred EAU to naive wild-type (WT) and miR-155(-/-) mice, while miR-155(-/-) IRBP-specific T cells did not.	Water	64-67	CD4 antigen	Mus musculus	0-3
23478034-2	2013	We have previously shown strong CD8(+) T cell responses to antigen conjugated to NPs via a disulfide link, and here we investigated the extent to which antigen incorporated within oxidatively-sensitive PSs could induce CD4(+) or CD8(+) T cell responses.	pss	202-205	CD4 antigen	Mus musculus	219-222
23478034-5	2013	Antigen-loaded PSs induced enhanced frequencies of antigen-specific CD4(+) T cells in the spleen, lymph nodes and lungs as compared to the NP formulation, whereas antigen-conjugated NPs induced stronger CD8(+) T cell responses.	pss	15-18	CD4 antigen	Mus musculus	68-71
23519969-7	2013	Moreover, in vivo stimulation of naive OT-II CD4(+) T cells with OVA leads to increase of pre-cDCs and cDCs in draining lymph nodes of Flt3L(-/-) mice in a partially Flt3L-dependent manner.	Chenodeoxycholate 3-sulphate	94-98	CD4 antigen	Mus musculus	45-48
23519969-7	2013	Moreover, in vivo stimulation of naive OT-II CD4(+) T cells with OVA leads to increase of pre-cDCs and cDCs in draining lymph nodes of Flt3L(-/-) mice in a partially Flt3L-dependent manner.	Chenodeoxycholate 3-sulphate	103-107	CD4 antigen	Mus musculus	45-48
23519987-0	2013	A crucial role for retinoic acid in the development of Notch-dependent murine splenic CD8- CD4- and CD4+ dendritic cells.	Tretinoin	19-32	CD4 antigen	Mus musculus	91-94
23519987-0	2013	A crucial role for retinoic acid in the development of Notch-dependent murine splenic CD8- CD4- and CD4+ dendritic cells.	Tretinoin	19-32	CD4 antigen	Mus musculus	100-103
23519987-3	2013	We observed that CD8(-) CD4(-) (double negative (DN)) and CD4(+) DCs, but not CD8(+) DCs, express vitamin A regulated genes.	Vitamin A	98-107	CD4 antigen	Mus musculus	24-27
23519987-3	2013	We observed that CD8(-) CD4(-) (double negative (DN)) and CD4(+) DCs, but not CD8(+) DCs, express vitamin A regulated genes.	Vitamin A	98-107	CD4 antigen	Mus musculus	58-61
23519987-5	2013	We detected a specific reduction of CD4(+) and DN DCs in the spleens of mice fed a vitamin A-deficient diet, while pre-DC numbers in both spleen and bone marrow were not affected.	Vitamin A	83-92	CD4 antigen	Mus musculus	36-39
23519987-6	2013	Vitamin A was specifically necessary for the development of RelB(high) , Notch-dependent CD4(+) , and DN DCs.	Vitamin A	0-9	CD4 antigen	Mus musculus	89-92
23347132-5	2013	In antigen-specific and allogeneic T-cell culture experiments, the TF on DEX-treated DC provided a signal through PAR-2, which contributed to the reduced ability of these cells to stimulate CD4(+) T-cell proliferation and cytokine production.	Dexamethasone	73-76	CD4 antigen	Mus musculus	190-193
23619554-2	2013	In vitro, farrerol markedly suppressed concanavalin A (ConA)-induced lymphocyte proliferation, Th1 and Th2 cytokine production, cluster of differentiation 4-positive (CD4(+)) T cell populations, and the ratio of CD4(+)/cluster of differentiation 8-positive (CD8(+)) T cells.	farrerol	10-18	CD4 antigen	Mus musculus	167-170
23619554-2	2013	In vitro, farrerol markedly suppressed concanavalin A (ConA)-induced lymphocyte proliferation, Th1 and Th2 cytokine production, cluster of differentiation 4-positive (CD4(+)) T cell populations, and the ratio of CD4(+)/cluster of differentiation 8-positive (CD8(+)) T cells.	farrerol	10-18	CD4 antigen	Mus musculus	212-215
23636056-4	2013	DNMAML blocked GVHD induced by either CD4(+) or CD8(+) T cells.	dnmaml	0-6	CD4 antigen	Mus musculus	38-41
23360710-6	2013	The CQ-mediated inhibition of the clinical course of EAE was accompanied by suppression of demyelination and reduced infiltration by encephalitogenic immune cells including CD4, CD8, CD20 and F4/80 positive cells.	Clioquinol	4-6	CD4 antigen	Mus musculus	173-176
23557855-3	2013	We further observed the effect of specific inhibitor of PI3K(LY294002) and specific inhibitor of Notch(DAPT) on the proliferation of such CD4(+) T lymphocytes.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	61-69	CD4 antigen	Mus musculus	138-141
23557855-3	2013	We further observed the effect of specific inhibitor of PI3K(LY294002) and specific inhibitor of Notch(DAPT) on the proliferation of such CD4(+) T lymphocytes.	dapt	103-107	CD4 antigen	Mus musculus	138-141
23557855-5	2013	Both LY294002 and DAPT inhibit the proliferation of CD4(+) T lymphocytes in a time- and dose-dependent manner.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	5-13	CD4 antigen	Mus musculus	52-55
23557855-5	2013	Both LY294002 and DAPT inhibit the proliferation of CD4(+) T lymphocytes in a time- and dose-dependent manner.	dapt	18-22	CD4 antigen	Mus musculus	52-55
23454555-11	2013	TACI-Ig and Methotrexate also reduced CD4(+)CD69(+) T cell, rhTNFR:Fc had no effects on the T cell subset.	Methotrexate	12-24	CD4 antigen	Mus musculus	38-41
23589621-8	2013	Furthermore, RAG1 knockout mice, which are devoid of T cells and are resistant to MPTP-induced neurodegeneration, become susceptible to MPTP-induced loss of dopaminergic neurons when reconstituted with WT CD4(+) T cells but not when transferred with D3R-deficient CD4(+) T cells.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	136-140	CD4 antigen	Mus musculus	205-208
23589621-8	2013	Furthermore, RAG1 knockout mice, which are devoid of T cells and are resistant to MPTP-induced neurodegeneration, become susceptible to MPTP-induced loss of dopaminergic neurons when reconstituted with WT CD4(+) T cells but not when transferred with D3R-deficient CD4(+) T cells.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	136-140	CD4 antigen	Mus musculus	264-267
23589621-10	2013	These findings indicate that D3R expressed on CD4(+) T cells plays a fundamental role in the physiopathology of MPTP-induced PD in a mouse model.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	112-116	CD4 antigen	Mus musculus	46-49
23682316-3	2013	Here we show that CD4(+) DCs highly express EBI2 and migrate to its oxysterol ligand, 7alpha,25-OHC.	Oxysterols	68-77	CD4 antigen	Mus musculus	18-21
23588375-6	2013	M-T413 is a monoclonal CD4 antibody, which inhibits T cell proliferation.	Direct Red 79	2-6	CD4 antigen	Mus musculus	23-26
23395695-8	2013	Adoptive transfer of T cells revealed that transfer of either CD8(+) or CD4(+) cells from silymarin-treated, UVB-exposed donors resulted in enhancement of the CHS response.	Silymarin	90-99	CD4 antigen	Mus musculus	72-75
23395695-9	2013	Cell culture study showed enhanced secretion of IL-2 and IFNgamma by CD8(+) T cells, and reduced secretion of Th2 cytokines by CD4(+) T cells, obtained from silymarin-treated UVB-exposed mice.	Silymarin	157-166	CD4 antigen	Mus musculus	127-130
23395695-10	2013	These data suggest that DNA repair-dependent functional activation of DCs, a reduction in CD4(+) regulatory T-cell activity, and stimulation of CD8(+) effector T cells contribute to silymarin-mediated inhibition of UVB-induced immunosuppression.	Silymarin	182-191	CD4 antigen	Mus musculus	90-93
23514739-0	2013	Antisense oligonucleotide treatment enhances the recovery of acute lung injury through IL-10-secreting M2-like macrophage-induced expansion of CD4+ regulatory T cells.	Oligonucleotides	10-25	CD4 antigen	Mus musculus	143-146
23474022-5	2013	Furthermore, the two lipidated tripeptides enhanced the CD4, CD8, CD3 and CD19 cell populations as well as CD4/CD8 derived IL-2, IL-4, IFN-gamma and TNF-alpha in whole blood of treated mice.	tripeptides	31-42	CD4 antigen	Mus musculus	56-59
23474022-5	2013	Furthermore, the two lipidated tripeptides enhanced the CD4, CD8, CD3 and CD19 cell populations as well as CD4/CD8 derived IL-2, IL-4, IFN-gamma and TNF-alpha in whole blood of treated mice.	tripeptides	31-42	CD4 antigen	Mus musculus	107-110
23313662-7	2013	In case of spleen, ROS generation and mitochondrial trans-membrane potential changes promotes intrinsic pathway of apoptosis that was p53 independent, ultimately leads to decrease in CD4(+) T cell population and increase in CD8(+) T cell population.	ros	19-22	CD4 antigen	Mus musculus	183-186
23313662-9	2013	Due to copper treatment, thymic CD4(+) T cell population decreased and CD8(+) T cell population was increased or proliferated.	Copper	7-13	CD4 antigen	Mus musculus	32-35
23518712-3	2013	In experimental autoimmune encephalomyelitis, the therapeutic administration of laquinimod beginning during the recovery of SJL mice, prevented further relapses as expected and strongly reduced infiltration of CD4+ and CD8+ T cells in the central nervous system.	laquinimod	80-90	CD4 antigen	Mus musculus	210-213
23770716-5	2013	CPT-11 could also inhibit alloresponses of memory T cells, while decreasing the proportion of CD4(+) memory T cells in the spleen of the recipients and significantly reducing serum alloantibody levels.	Irinotecan	0-6	CD4 antigen	Mus musculus	94-97
23186527-11	2013	Importantly, the number of CD4(+) CD8(+) thymocytes is significantly higher in Ifngamma(-/-) mice treated with RU486 along with lower caspase-3 activity and mitochondrial damage.	Mifepristone	111-116	CD4 antigen	Mus musculus	27-30
23447566-0	2013	Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells.	aluminum adjuvant	33-50	CD4 antigen	Mus musculus	116-119
23401586-5	2013	Conversely, mature naive CD4 cells have a lower sensitivity to retinoic acid, resulting in increased IFN-gamma production and subsequent IFN-gamma-mediated silencing of Foxp3 expression.	Tretinoin	63-76	CD4 antigen	Mus musculus	25-28
23408835-6	2013	The microRNA miR-181a, which enhances activation-induced calcium flux in murine thymocytes, was expressed at significantly higher levels in CB naive CD4(+) T cells compared with adult cells.	Calcium	57-64	CD4 antigen	Mus musculus	149-152
23261674-7	2013	Low-dose alcohol administration reversed the immune response, decreasing inflammatory responses and the increment of adaptive immunity mainly related to CD4(+) T cells, but not CD8(+) T cells, to normal background levels.	Alcohols	9-16	CD4 antigen	Mus musculus	153-156
23232294-3	2013	We investigated the immunodominant CD4(+) T-cell response to neuraminyllactose-binding hemagglutinin (HpaA), which is a conserved, H pylori-specific colonization factor that is being investigated as an antigen for vaccination strategies.	N-acetylneuraminoyllactose	61-78	CD4 antigen	Mus musculus	35-38
23232294-8	2013	CONCLUSIONS: The HLA-DRB1*1501-restricted immunodominant CD4(+) T-cell response to HpaA(88-100) is associated with reduced risk of severe gastric diseases.	hpaa	83-87	CD4 antigen	Mus musculus	57-60
23318147-8	2013	We further investigated whether RASV can modulate immunosuppressive Treg cells, and CD4(+)CD25(+) Foxp3(+) Tregs was significantly reduced in RASV-treated mice.	rasv	32-36	CD4 antigen	Mus musculus	84-87
23319738-5	2013	AC accumulation in GCs led to augmented Ab-forming cell, GC, and IgG2 Ab responses in Mer(-/-) mice, which were sustained for at least 80 d. Enhanced responses in Mer(-/-) mice were due to increased activation and proliferation of B cells and CD4(+) Th cells, including follicular helper T cells, which resulted in high titers of anti-nuclear Abs in Mer(-/-) mice compared with wild-type controls.	Charcoal	0-2	CD4 antigen	Mus musculus	243-246
22864396-8	2013	Combination therapy with Rosiglitazone and Gemcitabine modulated T cell populations by enhancing circulating CD8(+) T cells and intra-tumoral CD4(+) and CD8(+) T cells while limiting T regulatory cells.	Rosiglitazone	25-38	CD4 antigen	Mus musculus	142-145
22864396-8	2013	Combination therapy with Rosiglitazone and Gemcitabine modulated T cell populations by enhancing circulating CD8(+) T cells and intra-tumoral CD4(+) and CD8(+) T cells while limiting T regulatory cells.	gemcitabine	43-54	CD4 antigen	Mus musculus	142-145
22769982-0	2013	Pretreatment of rapamycin before allogenic corneal transplant promotes graft survival through increasing CD4(+)CD25(+)Foxp3(+) regulatory T cells.	Sirolimus	16-25	CD4 antigen	Mus musculus	105-108
22769982-10	2013	CONCLUSIONS: Pretreatment with rapamycin for 14 days before an allogenic corneal transplant enhances the percentage of CD4(+)CD25(+)Foxp3(+)Treg cells in peripheral blood, draining lymph nodes, and grafts, thereby inhibiting graft rejection.	Sirolimus	31-40	CD4 antigen	Mus musculus	119-122
22975588-8	2013	Moreover, flow cytometric analysis indicated the prominent inhibition of CD4, CD8 and CD19 cell populations in the spleen of mice treated with the variable doses of Lawsonone (1), with the maximum inhibition at the lowest dose (0.1muM).	lawsonone	165-174	CD4 antigen	Mus musculus	73-76
23080082-6	2013	The ratio of CD4+Foxp3- and CD4+Foxp3+ fractions within the proliferating CD4+ pool progressively changed from 74:26 in control animals to 59:41 eleven days after irradiation, demonstrating a more dynamic increase in the proliferation and regeneration of the Treg pool.	treg	259-263	CD4 antigen	Mus musculus	13-16
23261361-3	2013	OBJECTIVE: The study was designed to evaluate the effects of TCA on cytokine secretion, such as TNF-alpha and IL-1beta and on the ratio of CD4(+)/CD8(+), which is beneficial for understanding the mechanism of TCA on immunoregulation preliminarily, and also will benefit our further research.	Taurocholic Acid	209-212	CD4 antigen	Mus musculus	139-142
23261361-7	2013	TCA (0.25g/kg, 0.125g/kg) could recover the suppressed expressions of TNF-alpha and IL-1beta and increase the ratio of CD4(+)/CD8(+).	Taurocholic Acid	0-3	CD4 antigen	Mus musculus	119-122
23261361-10	2013	CONCLUSION: The function of immunoregulation of TCA may be accomplished through modulating the gene and protein expressions of TNF-alpha and IL-1beta and elevating CD4(+)/CD8(+) T-cell ratio.	Taurocholic Acid	48-51	CD4 antigen	Mus musculus	164-167
23352844-13	2013	Collectively, our findings suggest that combination treatment of Glu and low-dose CsA leads to the therapeutic effects in Df-induced AD-like skin lesion in NC/Nga mice through inhibition of IgE, inflammatory cellular infiltrate, and recovery of skin barrier function via a mechanism that may inhibition of Th2-mediated immune responses, in part, increment of CD4(+)CD25(+) Treg cells.	Glucosamine	65-68	CD4 antigen	Mus musculus	359-362
23352844-13	2013	Collectively, our findings suggest that combination treatment of Glu and low-dose CsA leads to the therapeutic effects in Df-induced AD-like skin lesion in NC/Nga mice through inhibition of IgE, inflammatory cellular infiltrate, and recovery of skin barrier function via a mechanism that may inhibition of Th2-mediated immune responses, in part, increment of CD4(+)CD25(+) Treg cells.	Cyclosporine	82-85	CD4 antigen	Mus musculus	359-362
23264660-11	2013	These results suggest that CS exposure initiates an Ag-specific response that leads to pulmonary destruction and inflammation that involves both CD8(+) and CD4(+) T cells.	Cesium	27-29	CD4 antigen	Mus musculus	156-159
23142275-11	2013	Taken together, our data suggest that the prevailing Th2 immune response in BALB/c mice may be responsible for the resistance to MLD-STZ diabetes and that ST2 gene deletion reveals the role of highly cyclophosphamide sensitive CD4+Foxp3+ regulatory T cells in the pancreatic lymph nodes in diabetes modulation.	Cyclophosphamide	200-216	CD4 antigen	Mus musculus	227-230
23248265-8	2013	Finally, we demonstrated that the administration of N(omega)-hydroxy-L-arginine at the peritumor site significantly enhanced CD4(+) T cell responses and inhibited tumor growth.	N(omega)-hydroxyarginine	52-79	CD4 antigen	Mus musculus	125-128
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	8-11	CD4 antigen	Mus musculus	22-25
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	8-11	CD4 antigen	Mus musculus	55-58
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	8-11	CD4 antigen	Mus musculus	55-58
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	8-11	CD4 antigen	Mus musculus	55-58
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	8-11	CD4 antigen	Mus musculus	55-58
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	8-11	CD4 antigen	Mus musculus	55-58
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	85-88	CD4 antigen	Mus musculus	22-25
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	85-88	CD4 antigen	Mus musculus	55-58
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	85-88	CD4 antigen	Mus musculus	55-58
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	85-88	CD4 antigen	Mus musculus	55-58
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	85-88	CD4 antigen	Mus musculus	55-58
23293358-5	2013	Using a tet-sensitive Cd4 allele harboring a removable Cd4 silencer, we found that a tet-controlled repressor recapitulated the phenotype of Cd4-deficient mice, inhibited Cd4 expression in a reversible and dose-dependent manner, and could surprisingly replace the Cd4 silencer to induce irreversible Cd4 silencing in CD8 cells, thus suggesting the Cd4 silencer is not the (only) determinant of heterochromatin formation.	Tetracycline	85-88	CD4 antigen	Mus musculus	55-58
23293358-6	2013	In contrast, a tet-controlled activator reversibly disrupted Cd4 silencing in CD8 cells.	Tetracycline	15-18	CD4 antigen	Mus musculus	61-64
23123796-15	2013	The analysis of lymphocyte T subsets demonstrated that both investigated fractions and MTX caused a partial or complete normalization in the percentage and the absolute number of CD4(-)CD8(-) thymocytes (immature, double-negative cells), and increased the percentage of CD8(+) T cells in peripheral lymphoid organs of mice with CIA.	Methotrexate	87-90	CD4 antigen	Mus musculus	179-182
23123796-16	2013	Moreover, an increase in the percentage of CD4(+) thymic cells was observed after treatment with fraction B or MTX.	Methotrexate	111-114	CD4 antigen	Mus musculus	43-46
23710206-4	2013	This resulted in specific elimination of CD4+CD25hiFoxp3+ Treg within brain-infiltrating lymphocytes and complete protection against subsequent orthotopic GL261 tumor challenge.	gl261	155-160	CD4 antigen	Mus musculus	41-44
23002042-6	2013	Finally, we confirmed the role of CD4(+)  T cells in dextran sulfate sodium induced colitis progression, and clarified that GA-induced CD8(+)  T cells exerted their therapeutic effects on colitis by targeting pathogenic CD4(+)  T cells.	Glatiramer Acetate	124-126	CD4 antigen	Mus musculus	34-37
23002042-6	2013	Finally, we confirmed the role of CD4(+)  T cells in dextran sulfate sodium induced colitis progression, and clarified that GA-induced CD8(+)  T cells exerted their therapeutic effects on colitis by targeting pathogenic CD4(+)  T cells.	Glatiramer Acetate	124-126	CD4 antigen	Mus musculus	220-223
23864893-4	2013	In addition, the expression of CTLA-4 and IL-10 was induced in LZ-8-treated CD4(+) T cells.	lz-8	63-67	CD4 antigen	Mus musculus	76-79
23864893-6	2013	The suppressive activity of LZ-8 was confirmed using a murine model of DSS-induced colitis; the disease was alleviated by the adoptive transfer of LZ-8-treated CD4(+) T cells.	lz-8	28-32	CD4 antigen	Mus musculus	160-163
23864893-6	2013	The suppressive activity of LZ-8 was confirmed using a murine model of DSS-induced colitis; the disease was alleviated by the adoptive transfer of LZ-8-treated CD4(+) T cells.	lz-8	147-151	CD4 antigen	Mus musculus	160-163
23476708-0	2013	Bee Venom Mitigates Cisplatin-Induced Nephrotoxicity by Regulating CD4(+)CD25(+)Foxp3(+) Regulatory T Cells in Mice.	Cisplatin	20-29	CD4 antigen	Mus musculus	67-70
23802174-1	2013	The aim of this study was to evaluate and determine the potential mechanisms of As2O3 in accelerated rejection mediated by alloreactive CD4+ memory T cells.	Arsenic Trioxide	80-85	CD4 antigen	Mus musculus	136-139
23802174-3	2013	As a result, As2O3 could reduce the proliferation of allo-primed CD4+ memory T cells in vitro in MLR and the baseline rate of proliferation was restored by the addition of exogenous IL-2.	Arsenic Trioxide	13-18	CD4 antigen	Mus musculus	65-68
23802174-7	2013	These results indicate the potential of As2O3 as a novel immunosuppressant targeting CD4+ memory T cells.	Arsenic Trioxide	40-45	CD4 antigen	Mus musculus	85-88
22968996-0	2013	The role of dendritic cells in the generation of CD4(+) CD25(HI) Foxp3(+) T cells induced by amino acid copolymers.	amino acid copolymers	93-114	CD4 antigen	Mus musculus	49-52
23665931-4	2013	The influence seems to result from inhibition of the thymocyte development, because increased and decreased populations of the CD4- CD8- double-negative and CD4+ CD8+ double-positive thymocytes were observed in the o-phenylphenol-administered mice, respectively.	2-phenylphenol	215-229	CD4 antigen	Mus musculus	127-130
23665931-4	2013	The influence seems to result from inhibition of the thymocyte development, because increased and decreased populations of the CD4- CD8- double-negative and CD4+ CD8+ double-positive thymocytes were observed in the o-phenylphenol-administered mice, respectively.	2-phenylphenol	215-229	CD4 antigen	Mus musculus	157-160
23577203-7	2013	Importantly, our data indicated that CD4(+)CD25(-)Nrp1(+) T cell transfer augments the accumulation of Tregs in the recipient, and creates conditions that favored induction of hyporesponsiveness of the T effector cells.	tregs	103-108	CD4 antigen	Mus musculus	37-40
23418431-4	2013	Fasudil mainly inhibited CD4(+)IL-17(+) T cells in early treatment, but also elevated CD4(+)IL-10(+) regulatory T cells and IL-10 production in late treatment.	fasudil	0-7	CD4 antigen	Mus musculus	25-28
23418431-4	2013	Fasudil mainly inhibited CD4(+)IL-17(+) T cells in early treatment, but also elevated CD4(+)IL-10(+) regulatory T cells and IL-10 production in late treatment.	fasudil	0-7	CD4 antigen	Mus musculus	86-89
23349887-9	2013	In protocol 1, both rapamycin and dexamethasone suppressed goblet cells and total CD4(+) T cells including activated, effector, and regulatory T cells in the lung tissue, with no effect on AHR or total inflammatory cell numbers in the bronchoalveolar lavage fluid.	Sirolimus	20-29	CD4 antigen	Mus musculus	82-85
23349887-9	2013	In protocol 1, both rapamycin and dexamethasone suppressed goblet cells and total CD4(+) T cells including activated, effector, and regulatory T cells in the lung tissue, with no effect on AHR or total inflammatory cell numbers in the bronchoalveolar lavage fluid.	Dexamethasone	34-47	CD4 antigen	Mus musculus	82-85
23326313-1	2013	Gamma-interferon-inducible lysosomal thiol reductase (GILT) is known to reduce disulfide bonds present in proteins internalized by antigen presenting cells, facilitating optimal processing and presentation of peptides on Major Histocompatibility Complex class II molecules, as well as the subsequent activation of CD4-positive T lymphocytes.	Disulfides	79-88	CD4 antigen	Mus musculus	314-317
22767872-5	2013	The number of spleen CD4(+) T lymphocytes decreased with simazine exposure, while CD8(+) T cells remained unchanged.	Simazine	57-65	CD4 antigen	Mus musculus	21-24
23253693-10	2012	Immunohistochemical analysis revealed reduced numbers of infiltrating leukocytes and CD4+ cells in the CNS of the sevoflurane-treated mice, as well as reduced glial cell activation.	Sevoflurane	114-125	CD4 antigen	Mus musculus	85-88
23169344-9	2012	Both CD4(+) and CD8(+) T cells were involved in the anti-neuroblastoma responses induced by YB-1 immunization combined with Treg depletion.	treg	124-128	CD4 antigen	Mus musculus	5-8
23198878-0	2012	Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo.	Tetradecanoylphorbol Acetate	47-50	CD4 antigen	Mus musculus	7-10
23198878-0	2012	Murine CD4+CD25- cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo.	Ionomycin	51-60	CD4 antigen	Mus musculus	7-10
23198878-5	2012	METHODS: Using phorbol myristate acetate (PMA)/ionomycin and anti-CD3 activation of CD4+CD25- cells we generated in vitro functional CD4+CD25- iTreg (TregPMA) cells.	Tetradecanoylphorbol Acetate	15-40	CD4 antigen	Mus musculus	133-136
23198878-5	2012	METHODS: Using phorbol myristate acetate (PMA)/ionomycin and anti-CD3 activation of CD4+CD25- cells we generated in vitro functional CD4+CD25- iTreg (TregPMA) cells.	Tetradecanoylphorbol Acetate	42-45	CD4 antigen	Mus musculus	133-136
23198878-5	2012	METHODS: Using phorbol myristate acetate (PMA)/ionomycin and anti-CD3 activation of CD4+CD25- cells we generated in vitro functional CD4+CD25- iTreg (TregPMA) cells.	Ionomycin	47-56	CD4 antigen	Mus musculus	133-136
22890814-0	2012	Nitric oxide inhibits the accumulation of CD4+CD44hiTbet+CD69lo T cells in mycobacterial infection.	Nitric Oxide	0-12	CD4 antigen	Mus musculus	42-45
22890814-3	2012	Examination of the T-cell phenotype in M. avium infected mice demonstrated that CD4(+)CD44(hi) effector T cells expressing the Th1 transcriptional regulator T-bet (T-bet(+)) were specifically reduced by the presence of nitric oxide.	Nitric Oxide	219-231	CD4 antigen	Mus musculus	80-83
22887772-7	2012	To study molecular mechanisms of peripheral CD4-T-cell differentiation in vivo and in vitro we generated transgenic mice expressing a tamoxifen inducible Cre recombinase (CreER(T2) ) under the control of the CD4 gene promoter.	Tamoxifen	134-143	CD4 antigen	Mus musculus	208-211
22940540-1	2012	The aims of this study were to elucidate the immunomodulatory effects of glycyrrhizin (GL) on CD4(+)T cell responses during liver fibrogenesis.	Glycyrrhizic Acid	73-85	CD4 antigen	Mus musculus	94-97
22940540-1	2012	The aims of this study were to elucidate the immunomodulatory effects of glycyrrhizin (GL) on CD4(+)T cell responses during liver fibrogenesis.	Glycyrrhizic Acid	87-89	CD4 antigen	Mus musculus	94-97
22940540-6	2012	GL at a concentration of 10 or 100 mug/mL was respectively incubated with ConA-stimulated splenic CD4(+)T cells in vitro, and JNK inhibitor (SP600125), ERK inhibitor (U0126), p38 inhibitor (SB203580) or PI3K/AKT inhibitor (LY29400225) was added during the incubation.	Glycyrrhizic Acid	0-2	CD4 antigen	Mus musculus	98-101
22940540-7	2012	Notably, GL not only inhibited ConA-induced proliferation of splenic CD4(+)T cells but also enhanced the mRNAs of IFN-gamma and IL-10 in these cells.	Glycyrrhizic Acid	9-11	CD4 antigen	Mus musculus	69-72
22940540-8	2012	Be similar to the effects of GL, SP600125, U0126 and LY29400225, however not SB203580, also inhibited ConA-induced CD4(+)T cell proliferation, indicating the involvement of JNK, ERK and PI3K/AKT in this process.	pyrazolanthrone	33-41	CD4 antigen	Mus musculus	115-118
22940540-8	2012	Be similar to the effects of GL, SP600125, U0126 and LY29400225, however not SB203580, also inhibited ConA-induced CD4(+)T cell proliferation, indicating the involvement of JNK, ERK and PI3K/AKT in this process.	U 0126	43-48	CD4 antigen	Mus musculus	115-118
22940540-8	2012	Be similar to the effects of GL, SP600125, U0126 and LY29400225, however not SB203580, also inhibited ConA-induced CD4(+)T cell proliferation, indicating the involvement of JNK, ERK and PI3K/AKT in this process.	ly29400225	53-63	CD4 antigen	Mus musculus	115-118
22940540-10	2012	Collectively, GL might alleviate liver injury and fibrosis progression via regulation of CD4(+)T cell response in JNK, ERK and PI3K/AKT-dependent pathways.	Glycyrrhizic Acid	14-16	CD4 antigen	Mus musculus	89-92
22951188-6	2012	Furthermore, RvE1 reduced DNFB-induced infiltration of eosinophils, mast cells, CD4(+) T cells, and CD8(+) T cells in skin lesions.	Dinitrofluorobenzene	26-30	CD4 antigen	Mus musculus	80-83
22951188-7	2012	Therefore, RvE1 may suppress the development of AD-like skin lesions in DNFB-treated NC/Nga mice by reducing IL-4 and IFN-gamma of activated CD4(+) T cells and serum IgE levels and infiltration of immune cells to skin lesion.	Dinitrofluorobenzene	72-76	CD4 antigen	Mus musculus	141-144
23105140-1	2012	CD1d-dependent NKT cells represent a heterogeneous family of effector T cells including CD4(+)CD8(-) and CD4(-)CD8(-) subsets that respond to glycolipid Ags with rapid and potent cytokine production.	Glycolipids	142-152	CD4 antigen	Mus musculus	88-91
23105140-1	2012	CD1d-dependent NKT cells represent a heterogeneous family of effector T cells including CD4(+)CD8(-) and CD4(-)CD8(-) subsets that respond to glycolipid Ags with rapid and potent cytokine production.	Glycolipids	142-152	CD4 antigen	Mus musculus	105-108
22851303-0	2012	Differential modulation by delta9-tetrahydrocannabinol ( 9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells.	Dronabinol	27-54	CD4 antigen	Mus musculus	68-71
22851303-0	2012	Differential modulation by delta9-tetrahydrocannabinol ( 9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cells.	( 9)-thc	55-63	CD4 antigen	Mus musculus	68-71
22851303-4	2012	Time course studies demonstrated that peak surface expression of CD40L by CD4(+) T cells after anti-CD3/CD28 or phorbol ester plus calcium ionophore (PMA/Io) occurred 8 h post activation.	Phorbol Esters	112-125	CD4 antigen	Mus musculus	65-68
22851303-4	2012	Time course studies demonstrated that peak surface expression of CD40L by CD4(+) T cells after anti-CD3/CD28 or phorbol ester plus calcium ionophore (PMA/Io) occurred 8 h post activation.	Calcium	131-138	CD4 antigen	Mus musculus	65-68
22851303-8	2012	Additionally,  (9)-THC also attenuated anti-CD3/CD28-induced CD40L expression on CD4(+) T cells derived from CB1(-/-)/CB2(-/-) mice.	(9)-thc	15-22	CD4 antigen	Mus musculus	61-64
21789506-5	2012	Furthermore, viability in CD4(+) and CD8(+) cells was reduced in a concentration-dependent manner with Delta(9)-THC, independent of CB(1) and CB(2), but no effect of Delta(9)-THC on proliferation was observed, suggesting that Delta(9)-THC decreases the number of T cells initially activated.	Dronabinol	103-115	CD4 antigen	Mus musculus	26-29
21789506-6	2012	Delta(9)-THC increased expression of the activation markers, CD69 in CD8(+) cells and CD25 in CD4(+) cells in a concentration-dependent manner in cells derived from WT and CB(1)                                   (-/-)CB(2)                                   (-/-) mice.	Dronabinol	0-12	CD4 antigen	Mus musculus	94-97
21789506-7	2012	Furthermore, Delta(9)-THC synergized with the calcium ionophore, ionomycin, to increase CD69 expression on both CD4(+) and CD8(+) cells.	Dronabinol	13-25	CD4 antigen	Mus musculus	112-115
21789506-7	2012	Furthermore, Delta(9)-THC synergized with the calcium ionophore, ionomycin, to increase CD69 expression on both CD4(+) and CD8(+) cells.	Calcium	46-53	CD4 antigen	Mus musculus	112-115
21789506-7	2012	Furthermore, Delta(9)-THC synergized with the calcium ionophore, ionomycin, to increase CD69 expression on both CD4(+) and CD8(+) cells.	Ionomycin	65-74	CD4 antigen	Mus musculus	112-115
23196974-0	2012	Isolation of carbohydrate-specific CD4(+) T cell clones from mice after stimulation by two model glycoconjugate vaccines.	Carbohydrates	13-25	CD4 antigen	Mus musculus	35-38
23196974-4	2012	Upon immunization of mice with GBSIII-OVA, carbohydrate epitopes are presented to and recognized by CD4(+) T cells.	Carbohydrates	43-55	CD4 antigen	Mus musculus	100-103
23196974-5	2012	Subsequently, polysaccharide-recognizing CD4(+) T cells are expanded in vitro by stimulating splenic CD4(+) T cells with GBSIII-TT.	Polysaccharides	14-28	CD4 antigen	Mus musculus	41-44
23196974-5	2012	Subsequently, polysaccharide-recognizing CD4(+) T cells are expanded in vitro by stimulating splenic CD4(+) T cells with GBSIII-TT.	Polysaccharides	14-28	CD4 antigen	Mus musculus	101-104
23088857-4	2012	Prenatal Cd exposure caused an increase in the percent of CD4(-)CD8(-)CD44(+)CD25(-) (DN1) thymocytes in both sexes and a decrease in the percent of CD4(-)CD8(-)CD44(-)CD25(+) (DN3) thymocytes in females.	Cadmium	9-11	CD4 antigen	Mus musculus	58-61
23088857-4	2012	Prenatal Cd exposure caused an increase in the percent of CD4(-)CD8(-)CD44(+)CD25(-) (DN1) thymocytes in both sexes and a decrease in the percent of CD4(-)CD8(-)CD44(-)CD25(+) (DN3) thymocytes in females.	Cadmium	9-11	CD4 antigen	Mus musculus	70-73
23041608-7	2012	TCDD treatment decreased the number of CD4-CD8-, CD4+CD8+, CD4+CD8- and CD4-CD8+ precursor T cells, but not the number of thymic CD4+CD25+Foxp3+ Treg cells.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	39-42
23041608-7	2012	TCDD treatment decreased the number of CD4-CD8-, CD4+CD8+, CD4+CD8- and CD4-CD8+ precursor T cells, but not the number of thymic CD4+CD25+Foxp3+ Treg cells.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	49-52
23041608-7	2012	TCDD treatment decreased the number of CD4-CD8-, CD4+CD8+, CD4+CD8- and CD4-CD8+ precursor T cells, but not the number of thymic CD4+CD25+Foxp3+ Treg cells.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	49-52
23041608-7	2012	TCDD treatment decreased the number of CD4-CD8-, CD4+CD8+, CD4+CD8- and CD4-CD8+ precursor T cells, but not the number of thymic CD4+CD25+Foxp3+ Treg cells.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	49-52
23041608-7	2012	TCDD treatment decreased the number of CD4-CD8-, CD4+CD8+, CD4+CD8- and CD4-CD8+ precursor T cells, but not the number of thymic CD4+CD25+Foxp3+ Treg cells.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	49-52
23041608-8	2012	TCDD treatment increased the number of splenic CD4+CD25+Foxp3+ Treg cells and decreased Th1, Th2 and cytotoxic T cells in the spleen.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	47-50
23041608-10	2012	In MLN, TCDD treatment suppressed the increase of the number of CD4+CD25+Foxp3+ Treg cells, Th1, Th2 and cytotoxic T cells induced by peanut sensitization.	Polychlorinated Dibenzodioxins	8-12	CD4 antigen	Mus musculus	64-67
23041608-11	2012	Together, TCDD treatment preserves thymic CD4+CD25+Foxp3+ Treg cells and decreases peripheral T helper and cytotoxic T cells.	Polychlorinated Dibenzodioxins	10-14	CD4 antigen	Mus musculus	42-45
23041608-12	2012	This effect of TCDD may contribute to the increased influence of CD4+CD25+Foxp3+ Treg cells on immune mediated responses and to the understanding of how AhR activation modulates immune mediated diseases, including food allergy.	Polychlorinated Dibenzodioxins	15-19	CD4 antigen	Mus musculus	65-68
22902832-6	2012	Furthermore, the protective effect of fusaruside was attributable to a novel regulatory mechanism through down-regulating STAT1 activation and T-bet expression in liver CD4(+) T cells and up-regulating STAT3 activation and Bcl-X(L) expression in hepatocytes.	fusaruside	38-48	CD4 antigen	Mus musculus	169-172
22933401-6	2012	The OVA-NP-induced tolerance was transferable from donor to naive recipient mice via adoptive spleen cell transfer and was mediated by CD4(+)CD25(+) T cells.	ova-np	4-10	CD4 antigen	Mus musculus	135-138
22884509-0	2012	Resveratrol analog, HS-1793 enhance anti-tumor immunity by reducing the CD4+CD25+ regulatory T cells in FM3A tumor bearing mice.	Resveratrol	0-11	CD4 antigen	Mus musculus	72-75
22884510-7	2012	These results indicate that ZM5 (N-{4-(2-Azepan-1-yl)-but-2-yn-1-yl}isoindoline-1,3-dione) enhances TGF-beta production from CD4+CD25+ve cells independent of protein kinase C activation and suggest that all ZM compounds suppress TNF-alpha from monocytes/macrophage cells.	zm5	28-31	CD4 antigen	Mus musculus	125-128
22884510-7	2012	These results indicate that ZM5 (N-{4-(2-Azepan-1-yl)-but-2-yn-1-yl}isoindoline-1,3-dione) enhances TGF-beta production from CD4+CD25+ve cells independent of protein kinase C activation and suggest that all ZM compounds suppress TNF-alpha from monocytes/macrophage cells.	n-{4-(2-azepan-1-yl)-but-2-yn-1-yl}isoindoline-1,3-dione	33-89	CD4 antigen	Mus musculus	125-128
22891289-6	2012	Suppression of iTreg differentiation from naive CD4(+) cells by gr-MDSC occurs early in the polarization process, requires inhibition of early T cell activation, and depends on ROS and IDO but does not require arginase 1, iNOS, NO, cystine/cysteine depletion, PD-1 and PD-L1 signaling, or COX-2.	ros	177-180	CD4 antigen	Mus musculus	48-51
22402368-0	2012	Differential regulation of CD4(+) T helper cell responses by curcumin in experimental autoimmune encephalomyelitis.	Curcumin	61-69	CD4 antigen	Mus musculus	27-30
22402368-8	2012	The inhibition of EAE by curcumin was also associated with an up-regulation of IL-10, peroxisome proliferator activated receptor gamma and CD4(+)CD25(+-)Foxp3(+) Treg cells in the CNS and lymphoid organs.	Curcumin	25-33	CD4 antigen	Mus musculus	139-142
22402368-9	2012	These findings highlight that curcumin differentially regulates CD4(+) T helper cell responses in EAE.	Curcumin	30-38	CD4 antigen	Mus musculus	64-67
23243588-5	2012	Moreover, both Cd4(-/-) and Cd8(-/-) mice as well as mice depleted of NK cells manifested a significant impaired ability to control tumor growth following LC administration.	Leu-Cys	155-157	CD4 antigen	Mus musculus	15-18
22724664-0	2012	n-Butyrate anergized effector CD4+ T cells independent of regulatory T cell generation or activity.	Butyrates	0-10	CD4 antigen	Mus musculus	30-33
22724664-4	2012	To assess if HDAC inhibitor n-butyrate induces anergy independent of the generation or expansion of FoxP3(+) T(reg) cells in vitro, we examine n-butyrate-treated murine CD4(+) T cells for anergy induction and FoxP3(+) T(reg) activity.	Butyrates	143-153	CD4 antigen	Mus musculus	169-172
23012474-6	2012	Conversely, the early lineages of B and T cells declined in the marrow and thymus with particularly large losses observed among pre-B and pre-T cells with heightened levels of apoptosis noted among CD4(+)CD8(+) thymocytes from DSS-treated mice.	dss	227-230	CD4 antigen	Mus musculus	198-201
23093039-16	2012	Our lab has developed the HY(cd4) model, in which the transgenic HY TCRalpha is conditionally expressed at the DP stage, allowing negative selection to occur during the DP to SP transition as occurs in wildtype mice(10).	dp	111-113	CD4 antigen	Mus musculus	29-32
23093039-16	2012	Our lab has developed the HY(cd4) model, in which the transgenic HY TCRalpha is conditionally expressed at the DP stage, allowing negative selection to occur during the DP to SP transition as occurs in wildtype mice(10).	sp	175-177	CD4 antigen	Mus musculus	29-32
23814701-8	2012	Dietary ABA significantly increased the percentages of MLN CD4+IL-10+ T cells, and blood CD4+CD25+FoxP3+ T cells and CD8+IL-10+ T cells.	Abscisic Acid	8-11	CD4 antigen	Mus musculus	59-62
23814701-8	2012	Dietary ABA significantly increased the percentages of MLN CD4+IL-10+ T cells, and blood CD4+CD25+FoxP3+ T cells and CD8+IL-10+ T cells.	Abscisic Acid	8-11	CD4 antigen	Mus musculus	89-92
22908333-6	2012	Adoptive transfer of cervical LN CD4+ICOS+, but not CD4+ICOS-, cells inhibited BPEx-induced airway hyperresponsiveness and bronchoalveolar lavage eosinophilia.	bpex	79-83	CD4 antigen	Mus musculus	33-36
22946091-6	2012	The accumulation of macrophages and expression of CD4(+) and CD8(+) cells in the lesions were decreased by the treatment of the drugs, of which carvedilol was the most effective.	Carvedilol	144-154	CD4 antigen	Mus musculus	50-53
22971531-5	2012	After injected with halofuginone, we observed a decrease in the number of CD4(+) interleukin  (IL)-17(+) cells and a parallel increase in that of CD4(+) interferon (IFN)-gamma(+) cells in peripheral blood.	halofuginone	20-32	CD4 antigen	Mus musculus	74-77
22971531-5	2012	After injected with halofuginone, we observed a decrease in the number of CD4(+) interleukin  (IL)-17(+) cells and a parallel increase in that of CD4(+) interferon (IFN)-gamma(+) cells in peripheral blood.	halofuginone	20-32	CD4 antigen	Mus musculus	146-149
22749847-0	2012	Curcumin inhibits suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.	Curcumin	0-8	CD4 antigen	Mus musculus	62-65
22749847-4	2012	In the present study, curcumin inhibition of the suppressive activity of CD4(+)CD25(+) regulatory T cells appears to be dependent on three categories: inhibiting cell-cell contact by down-regulation of CTLA-4, suppressing inhibitory cytokine secretion and decreasing the ability to consume IL-2 and/or suppress IL-2 production.	Curcumin	22-30	CD4 antigen	Mus musculus	73-76
22935591-6	2012	RESULTS: Depletion of CD4(+)CD25(+)FOXP3(+) Treg cells during tolerance induction completely abolishes the development of LZT, resulting in a pronounced contact hypersensitivity response.	N~2~-{[(1s)-6-Methoxy-3-Oxo-2,3-Dihydro-1h-Inden-1-Yl]acetyl}-N-{(1s)-1-[(4-Methylbenzyl)carbamoyl]-3-Phenylpropyl}-L-Threoninamide	122-125	CD4 antigen	Mus musculus	22-25
23024640-2	2012	This vaccine protects cortisone acetate (CA)-immunosuppressed mice from invasive pulmonary aspergillosis via CD4(+) T cell mediators.	Cortisone	22-39	CD4 antigen	Mus musculus	109-112
22626443-4	2012	LPS abrogated EAMG resistance in CD4-/- mice by increasing high-affinity anti-AChR IgG2b in sera and enhancing immune complex deposition in muscle.	eamg	14-18	CD4 antigen	Mus musculus	33-36
22873687-13	2012	The absolute numbers of CD4+ T cells, DCs and macrophages were significantly higher in allicin-treated mice.	allicin	87-94	CD4 antigen	Mus musculus	24-27
22888330-2	2012	The suppressive effects of TCDD occur early during CD4(+) T-cell differentiation in the absence of effects on proliferation and have recently been associated with the induction of AhR-dependent regulatory T-cells (Treg).	Polychlorinated Dibenzodioxins	27-31	CD4 antigen	Mus musculus	51-54
22888330-3	2012	Since AhR functions as a ligand-activated transcription factor, changes in gene expression induced by TCDD during the early stages of CD4(+) T-cell differentiation are likely to reflect fundamental mechanisms of AhR action.	Polychlorinated Dibenzodioxins	102-106	CD4 antigen	Mus musculus	134-137
22774982-6	2012	These differences in the T cell compartment were not antigen-specific, as ovalbumin/complete Freund"s adjuvant (OVA/CFA) or CFA immunization elicited the same differences in CD4(+) T cells and T(regs) between A.SW and B10.S mice.	3-chloro-4-fluoroaniline	116-119	CD4 antigen	Mus musculus	174-177
22487925-9	2012	Moreover, CD4(+)CD25(+) cells from wild-type NOD mice suppressed and delayed the onset of diabetes compared with those from Cxcr3                            (                               -/-                            ) NOD mice in a cyclophosphamide-induced diabetes model system.	Cyclophosphamide	236-252	CD4 antigen	Mus musculus	10-13
22730534-9	2012	In contrast, transfer of CD4(+)CD25(+)Foxp3(+) T cells could correct the defect after denileukin diftitox treatment.	diftitox	97-105	CD4 antigen	Mus musculus	25-28
22712636-5	2012	An increase in CD4(+)CD25(+) T cells was observed both in splenic cells from mice injected with rSj16 and the cells pretreated with rSj16, respectively.	rsj16	96-101	CD4 antigen	Mus musculus	15-18
22712636-5	2012	An increase in CD4(+)CD25(+) T cells was observed both in splenic cells from mice injected with rSj16 and the cells pretreated with rSj16, respectively.	rsj16	132-137	CD4 antigen	Mus musculus	15-18
22712636-7	2012	Additionally, rSj16-treated bone marrow dendritic cells (BMDCs) demonstrate an immature phenotype and play a role in the conversion of CD4(+)CD25(-) T cells into suppressive CD4(+)CD25(+) regulatory T cells.	rsj16	14-19	CD4 antigen	Mus musculus	135-138
22712636-7	2012	Additionally, rSj16-treated bone marrow dendritic cells (BMDCs) demonstrate an immature phenotype and play a role in the conversion of CD4(+)CD25(-) T cells into suppressive CD4(+)CD25(+) regulatory T cells.	rsj16	14-19	CD4 antigen	Mus musculus	174-177
22613676-8	2012	In contrast to RPM and FTY720, MMF, LEF, CsA, and Cy markedly decreased the levels of Ag-specific CD4(+)KJ1-26(+)CD25(+)Foxp3(+) Tregs during immune response.	Cyclosporine	41-44	CD4 antigen	Mus musculus	98-101
22613676-10	2012	The stronger inhibiting effects of MMF, LEF, CsA and Cy on CD4(+)CD25(+)Foxp3(+) Tregs than on T effectors may block the host immune tolerance potentiality.	Cyclosporine	45-48	CD4 antigen	Mus musculus	59-62
22613676-10	2012	The stronger inhibiting effects of MMF, LEF, CsA and Cy on CD4(+)CD25(+)Foxp3(+) Tregs than on T effectors may block the host immune tolerance potentiality.	Cyclophosphamide	53-55	CD4 antigen	Mus musculus	59-62
22696440-5	2012	Interestingly, Foxp3(+) regulatory T cells were markedly increased and IL-17-producing CD4(+) T cells (Th17 cells) were decreased in the spleens of ATRA-treated mice.	Tretinoin	148-152	CD4 antigen	Mus musculus	87-90
22696440-6	2012	In vitro treatment with ATRA induced the expression of Foxp3 and repressed the IL-17 expression in the CD4(+) T cells in mice.	Tretinoin	24-28	CD4 antigen	Mus musculus	103-106
22588256-0	2012	A novel, orally active alpha 4 integrin antagonist, AJM300 prevents the development of experimental colitis induced by adoptive transfer of IL-10 deficient CD4(+) T cells in mice.	AJM300	52-58	CD4 antigen	Mus musculus	156-159
22231228-9	2012	Adoptive transfer of CD4+CD25+ T cells from altered HA308-317 peptide-treated mice resulted in greater suppressive capacity in ameliorating CIA severity than did adoptive transfer of CD4+CD25+ T cells from wild HA308-317 peptide-treated, wild CII263-272 peptide-treated, or irrelevant peptide-treated mice.	cii263	243-249	CD4 antigen	Mus musculus	21-24
22728763-5	2012	Here, we show that the JAK3 inhibitor 4-(4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) suppresses proliferation of short-term cultured NOD CD4(+) T cells through induction of apoptosis, while promoting survival of a particular population of long-term cultured cells.	WHI P131	38-89	CD4 antigen	Mus musculus	153-156
22728763-5	2012	Here, we show that the JAK3 inhibitor 4-(4"-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) suppresses proliferation of short-term cultured NOD CD4(+) T cells through induction of apoptosis, while promoting survival of a particular population of long-term cultured cells.	WHI P131	91-99	CD4 antigen	Mus musculus	153-156
22626517-6	2012	Cyclophosphamide-immunosuppressed mice have greatly reduced amounts of CD8(+), CD4(+) and CD3(+) T cells and CD19(+) B cells.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	79-82
22626517-8	2012	Mice treated with ciclosporin, which is both antiparasitic and immunosuppressive, have a milder, chronic, non-lethal infection and showed a significant reduction only in CD3(+) and CD4(+) T cell numbers.	Cyclosporine	18-29	CD4 antigen	Mus musculus	181-184
22622238-5	2012	NPr-4-S-CAP-associated host immunity was studied using a B16F1 mouse melanoma model through the application of CD4- and CD8-specific antibodies and tetramer assay.	npr-4-s	0-7	CD4 antigen	Mus musculus	111-114
22109893-0	2012	Connecting liver and gut: murine liver sinusoidal endothelium induces gut tropism of CD4+ T cells via retinoic acid.	Tretinoin	102-115	CD4 antigen	Mus musculus	85-88
21792901-5	2012	6-Gingerol treatment of tumor-bearing mice caused massive infiltration of CD4 and CD8 T-cells and B220(+)  B-cells, but reduced the number of CD4(+) Foxp3(+)  regulatory T-cells.	gingerol	0-10	CD4 antigen	Mus musculus	74-77
21792901-5	2012	6-Gingerol treatment of tumor-bearing mice caused massive infiltration of CD4 and CD8 T-cells and B220(+)  B-cells, but reduced the number of CD4(+) Foxp3(+)  regulatory T-cells.	gingerol	0-10	CD4 antigen	Mus musculus	142-145
22434859-8	2012	Finally, we showed that the sodium salt of IQ-1 had favorable pharmacokinetics and inhibited the ovalbumin-induced CD4(+) T-cell immune response in a murine delayed-type hypersensitivity model in vivo.	sodium salt	28-39	CD4 antigen	Mus musculus	115-118
22521604-11	2012	CD4(+)FoxP3(+)CD25(+) (nTreg) cell percentages were increased in the spleen and thymus in all Cd-exposed offspring except in the female spleen where a decrease was seen.	Cadmium	94-96	CD4 antigen	Mus musculus	0-3
22640559-12	2012	Three exceptional LAINefdd-infected mice that lost CD4+ T cells received 600,000 TCIU.	lainefdd	18-26	CD4 antigen	Mus musculus	51-54
22331300-9	2012	Intriguingly, we found that RSV suppressed the differentiation of CD4(+) T lymphocytes to IL-17A-positive T(H)17 cells.	Resveratrol	28-31	CD4 antigen	Mus musculus	66-69
22491256-3	2012	Therefore, we tested whether CD4(+) and pDCs, activated cells that produce high levels of reactive oxygen species, could be killed by arsenic trioxide (As(2)O(3)), a chemotherapeutic drug used in the treatment of acute promyelocytic leukemia.	Arsenic Trioxide	134-150	CD4 antigen	Mus musculus	29-32
22491256-3	2012	Therefore, we tested whether CD4(+) and pDCs, activated cells that produce high levels of reactive oxygen species, could be killed by arsenic trioxide (As(2)O(3)), a chemotherapeutic drug used in the treatment of acute promyelocytic leukemia.	Arsenic Trioxide	152-162	CD4 antigen	Mus musculus	29-32
22429962-8	2012	Administration of CLF-1/CLC to both uninjured and bleomycin-injured mice led to the pulmonary accumulation of CD4(+) T cells.	Bleomycin	50-59	CD4 antigen	Mus musculus	110-113
22020772-4	2012	Here, we show that peripheral B cell levels decreased in nude mice fed the Se -  or Se++ diet and the CD4(+) T cell levels increased in mice fed the Se++ diet.	Selenium	149-153	CD4 antigen	Mus musculus	102-105
22020772-5	2012	During the PC-3 cell tumorigenesis, dietary Se status did not affect peripheral CD4(+) or CD8(+) T cells in nude mice whereas mice fed with the Se++ diet appeared to exhibit greater peripheral CD25(+)CD4(+) T cells on day 9.	Selenium	144-148	CD4 antigen	Mus musculus	200-203
22522606-12	2012	But CD4(+) T cells also decreased in spleen cells of tumor-bearing mice by alone 5-FU treated, splenic NK cell and CTL activity also degraded, while CD4(+) T cells and splenic NK cell and CTL activity significantly increased by BLTA treated.	Fluorouracil	81-85	CD4 antigen	Mus musculus	4-7
22522606-13	2012	BLTA in combination with 5-FU could also enhance the ratio of CD4(+) T cells and splenic NK cell and CTL activity.	Fluorouracil	25-29	CD4 antigen	Mus musculus	62-65
22522606-14	2012	CONCLUSION: The present study suggested that BLTA in combination with 5-FU could enhance antitumor effect, with inhibiting TIM-3/TIM-3L pathway, cutting down immunosuppressive activity of CD4(+)CD25(+) T(reg) and enhancing cell-mediated immunity.	blta	45-49	CD4 antigen	Mus musculus	188-191
22522606-14	2012	CONCLUSION: The present study suggested that BLTA in combination with 5-FU could enhance antitumor effect, with inhibiting TIM-3/TIM-3L pathway, cutting down immunosuppressive activity of CD4(+)CD25(+) T(reg) and enhancing cell-mediated immunity.	Fluorouracil	70-74	CD4 antigen	Mus musculus	188-191
22543833-7	2012	17-DMAG increased CD8(+) T cells, reduced double-negative T cells, decreased the CD4/CD8 ratio and reduced follicular B cells.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	0-7	CD4 antigen	Mus musculus	81-84
22776176-5	2012	Treatment with TSA could improve mice corneal allograft survival by promoting the proportions and allosuppressive function of CD4+ CD25+ regulatory T cells.	trichostatin A	15-18	CD4 antigen	Mus musculus	126-129
22776176-6	2012	Our findings suggest that the use of TSA allows the beneficial pharmacological effect on CD4+ CD25- T activation in vitro and enhancement of Foxp3+ Treg cells in vivo.	trichostatin A	37-40	CD4 antigen	Mus musculus	89-92
22551544-7	2012	RESULTS: Treatment of mice with BiLu resulted in a dosedependent transient decrease in CD3+ T cells (both CD4+ and CD8+) that returned to the normal range within 48 h. Catumaxomab physiologically activated T cells in vitro (increased CD69 expression) and induced cytokine release (TNFalpha, IFNgamma).	bilu	32-36	CD4 antigen	Mus musculus	106-109
22345277-5	2012	CD4+ T cells from SMS1(-/-) mice showed severe deficiency of membrane SM and several profound defects compared with wild-type controls as follows: (i) cellular proliferation and production of IL-2 and IFN-gamma by co-cross-linking of CD3 and CD4; (ii) tyrosine phosphorylation of LAT and its association with ZAP-70; (iii) clustering and co-localization of TCR with lipid rafts.	Tyrosine	252-260	CD4 antigen	Mus musculus	0-3
22189844-4	2012	Pretreatment of mice with the naturally occurring sphingosine N,N-dimethylsphingosine (DMS) was found to increase both tissue-infiltrating T effectors (Teffs, CD4(+)Foxp3(-)) and Tregs (CD4(+)Foxp3(+)) in the early phase of bilateral renal ischemia/reperfusion injury.	sphingosine n,n-dimethylsphingosine	50-85	CD4 antigen	Mus musculus	159-162
22189844-4	2012	Pretreatment of mice with the naturally occurring sphingosine N,N-dimethylsphingosine (DMS) was found to increase both tissue-infiltrating T effectors (Teffs, CD4(+)Foxp3(-)) and Tregs (CD4(+)Foxp3(+)) in the early phase of bilateral renal ischemia/reperfusion injury.	sphingosine n,n-dimethylsphingosine	50-85	CD4 antigen	Mus musculus	186-189
22189844-4	2012	Pretreatment of mice with the naturally occurring sphingosine N,N-dimethylsphingosine (DMS) was found to increase both tissue-infiltrating T effectors (Teffs, CD4(+)Foxp3(-)) and Tregs (CD4(+)Foxp3(+)) in the early phase of bilateral renal ischemia/reperfusion injury.	N,N-dimethylsphingosine	87-90	CD4 antigen	Mus musculus	159-162
22189844-4	2012	Pretreatment of mice with the naturally occurring sphingosine N,N-dimethylsphingosine (DMS) was found to increase both tissue-infiltrating T effectors (Teffs, CD4(+)Foxp3(-)) and Tregs (CD4(+)Foxp3(+)) in the early phase of bilateral renal ischemia/reperfusion injury.	N,N-dimethylsphingosine	87-90	CD4 antigen	Mus musculus	186-189
22404374-0	2012	Low-dose clarithromycin therapy modulates CD4(+)  T-cell responses in a mouse model of chronic Pseudomonas aeruginosa lung infection.	Clarithromycin	9-23	CD4 antigen	Mus musculus	42-45
22404374-3	2012	As CD4(+) T cells play an important role in the initiation of immune responses to infectious microorganisms, we aimed to investigate the effects of low-dose CAM on CD4(+) T-cell responses.	Clarithromycin	157-160	CD4 antigen	Mus musculus	164-167
22407948-0	2012	Epigenetic alterations may regulate temporary reversal of CD4(+) T cell activation caused by trichloroethylene exposure.	Trichloroethylene	93-110	CD4 antigen	Mus musculus	58-61
22407948-1	2012	Previous studies have shown that short-term (4 weeks) or chronic (32 weeks) exposure to trichloroethylene (TCE) in drinking water of female MRL+/+ mice generated CD4(+) T cells that secreted increased levels of interferon (IFN)-gamma and expressed an activated (CD44(hi)CD62L(lo)) phenotype.	Trichloroethylene	88-105	CD4 antigen	Mus musculus	162-165
22407948-1	2012	Previous studies have shown that short-term (4 weeks) or chronic (32 weeks) exposure to trichloroethylene (TCE) in drinking water of female MRL+/+ mice generated CD4(+) T cells that secreted increased levels of interferon (IFN)-gamma and expressed an activated (CD44(hi)CD62L(lo)) phenotype.	Trichloroethylene	107-110	CD4 antigen	Mus musculus	162-165
22407948-1	2012	Previous studies have shown that short-term (4 weeks) or chronic (32 weeks) exposure to trichloroethylene (TCE) in drinking water of female MRL+/+ mice generated CD4(+) T cells that secreted increased levels of interferon (IFN)-gamma and expressed an activated (CD44(hi)CD62L(lo)) phenotype.	Drinking Water	115-129	CD4 antigen	Mus musculus	162-165
22407948-2	2012	In contrast, the current study of subchronic TCE exposure showed that midway in the disease process both of these parameters of CD4(+) T cell activation were reversed.	Trichloroethylene	45-48	CD4 antigen	Mus musculus	128-131
22407948-4	2012	The decrease in CD4(+) T cell production of IFN-gamma following subchronic TCE exposure could not be attributed to skewing toward a Th2 or Th17 phenotype or to an increase in Treg cells.	Trichloroethylene	75-78	CD4 antigen	Mus musculus	16-19
22407948-7	2012	CD4(+) T cells from a second study in which MRL+/+ mice were treated for 17 weeks with TCE showed a similar increase in Iap and decrease in Cdkn1a.	Trichloroethylene	87-90	CD4 antigen	Mus musculus	0-3
22407948-8	2012	In addition, DNA collected from the CD4(+) T cells in the second study showed TCE-decreased global DNA methylation.	Trichloroethylene	78-81	CD4 antigen	Mus musculus	36-39
22407948-9	2012	Thus, these results described the biphasic nature of TCE-induced alterations in CD4(+) T cell function and suggested that these changes represented potentially reversible alterations in epigenetic processes.	Trichloroethylene	53-56	CD4 antigen	Mus musculus	80-83
22564626-6	2012	Moreover, secondary CBA recipients of whole splenocytes and CD4(+) cells from primary danazol-treated (4 mg/kg/d) CBA recipients at 30 days after transplantation displayed prolonged allograft survival (MSTs, 29 and 60 days, respectively).	Danazol	86-93	CD4 antigen	Mus musculus	60-63
22564626-9	2012	Flow cytometry studies showed an increased CD4(+)CD25(+)Foxp3(+) cell population among splenocytes from danazol-treated mice.	Danazol	104-111	CD4 antigen	Mus musculus	43-46
22564626-10	2012	In conclusion, danazol induced prolonged cardiac allograft survival and generation of regulatory CD4(+) cells.	Danazol	15-22	CD4 antigen	Mus musculus	97-100
22564628-10	2012	Flow cytometry studies showed increased CD4(+)CD25(+)Foxp3(+) regulatory cells in transplant recipients given ACH.	Acetylcholine	110-113	CD4 antigen	Mus musculus	40-43
22564628-11	2012	In conclusion, ACH, 1 component of TJ-117, as well as TJ-117 induced hyporesponsiveness to fully allogeneic cardiac allografts with generation of CD4(+)CD25(+)Foxp3(+) regulatory cells.	Acetylcholine	15-18	CD4 antigen	Mus musculus	146-149
22566972-7	2012	Finally, in mice with cyclophosphamide induced lymphopenia, the administration of P3 mAb accelerated the recovery of both CD4(+) and CD8(+) T cells.	Cyclophosphamide	22-38	CD4 antigen	Mus musculus	122-125
22288521-4	2012	Further studies revealed that the homing of the CD4(+)CD25(+) regulatory T cells to the NALT is dependent not only on the L-selectin-sulfated glycan interaction but also on P-selectin glycoprotein ligand-1 and CD44.	Polysaccharides	142-148	CD4 antigen	Mus musculus	48-51
22250985-0	2012	n-3 polyunsaturated fatty acids suppress phosphatidylinositol 4,5-bisphosphate-dependent actin remodelling during CD4+ T-cell activation.	Fatty Acids, Omega-3	0-31	CD4 antigen	Mus musculus	114-117
22250985-0	2012	n-3 polyunsaturated fatty acids suppress phosphatidylinositol 4,5-bisphosphate-dependent actin remodelling during CD4+ T-cell activation.	Phosphatidylinositol 4,5-Diphosphate	41-78	CD4 antigen	Mus musculus	114-117
22250985-3	2012	CD4+ T-cells isolated from Fat-1 transgenic mice (membranes enriched in n-3 PUFA) exhibited a 50% decrease in PtdIns(4,5)P2.	Phosphatidylinositol 4,5-Diphosphate	110-123	CD4 antigen	Mus musculus	0-3
22250985-4	2012	Upon activation by plate-bound anti-CD3/anti-CD28 or PMA/ionomycin, Fat-1 CD4+ T-cells failed to metabolize PtdIns(4,5)P2.	Tetradecanoylphorbol Acetate	53-56	CD4 antigen	Mus musculus	74-77
22250985-4	2012	Upon activation by plate-bound anti-CD3/anti-CD28 or PMA/ionomycin, Fat-1 CD4+ T-cells failed to metabolize PtdIns(4,5)P2.	Ionomycin	57-66	CD4 antigen	Mus musculus	74-77
22250985-8	2012	Collectively, these data demonstrate that n-3 PUFA, such as DHA, alter PtdIns(4,5)P2 in CD4+ T-cells, thereby suppressing the recruitment of WASP to the immunological synapse, and impairing actin remodelling in CD4+ T-cells.	Docosahexaenoic Acids	60-63	CD4 antigen	Mus musculus	88-91
22250985-8	2012	Collectively, these data demonstrate that n-3 PUFA, such as DHA, alter PtdIns(4,5)P2 in CD4+ T-cells, thereby suppressing the recruitment of WASP to the immunological synapse, and impairing actin remodelling in CD4+ T-cells.	Docosahexaenoic Acids	60-63	CD4 antigen	Mus musculus	211-214
22250985-8	2012	Collectively, these data demonstrate that n-3 PUFA, such as DHA, alter PtdIns(4,5)P2 in CD4+ T-cells, thereby suppressing the recruitment of WASP to the immunological synapse, and impairing actin remodelling in CD4+ T-cells.	Phosphatidylinositol 4,5-Diphosphate	71-84	CD4 antigen	Mus musculus	88-91
22250985-8	2012	Collectively, these data demonstrate that n-3 PUFA, such as DHA, alter PtdIns(4,5)P2 in CD4+ T-cells, thereby suppressing the recruitment of WASP to the immunological synapse, and impairing actin remodelling in CD4+ T-cells.	Phosphatidylinositol 4,5-Diphosphate	71-84	CD4 antigen	Mus musculus	211-214
22178962-7	2012	In fact, LHVS exacerbated a CD4(+)-T cell-dependent model of GVHD similar to chronic GVHD.	LHVS	9-13	CD4 antigen	Mus musculus	28-31
22136142-4	2012	We have recently demonstrated, in murine mercury-induced autoimmunity (mHgIA), that an accumulation of CD44(high) Daf(low) CD4(+) T cells is associated with the development of autoimmunity.	Mercury	41-48	CD4 antigen	Mus musculus	103-106
21871023-4	2012	RESULTS: In CD4(+) T cells, RBV selectively downmodulates the expression of inducible costimulator (ICOS), a ligand for B7-H2 on dendritic cells, which mainly differentiates Th0 into Th2 cells.	Ribavirin	28-31	CD4 antigen	Mus musculus	12-15
22189601-4	2012	CD4(+) T cells were cultured in the presence of rapamycin for three 7-day rounds of stimulation.	Sirolimus	48-57	CD4 antigen	Mus musculus	0-3
22189601-9	2012	With rapamycin, stimulated CD4(+) T cells expanded eightfold in 3 weeks in vitro, and the proportion of Tregs increased to about 40%.	Sirolimus	5-14	CD4 antigen	Mus musculus	27-30
22189601-12	2012	CONCLUSIONS: We demonstrated, for the first time, that CD4(+) T cells expanded with rapamycin in vitro suppressed colitis.	Sirolimus	84-93	CD4 antigen	Mus musculus	55-58
22379034-7	2012	Deficiency of D5R on the surface of DCs impaired LPS-induced IL-23 and IL-12 production and consequently attenuated the activation and proliferation of Ag-specific CD4(+) T cells.	d5r	14-17	CD4 antigen	Mus musculus	164-167
22133647-0	2012	Acceleration of neutrophil precursors" maturation and immunostimulation of CD3+, CD4+ lymphocytes by stanozolol in mice.	Stanozolol	101-111	CD4 antigen	Mus musculus	81-84
22133647-7	2012	The flow cytometry analysis of lymphocyte subpopulations (CD3(+) and CD4(+)) revealed immunoenhancing response of stanozolol at optimum physiological dose, however, it is immunosuppressive at supraphysiologic level.	Stanozolol	114-124	CD4 antigen	Mus musculus	69-72
22370159-5	2012	Studies using SHIP-1 shRNA, knockout mice and decoy inhibitors further indicate that CD4-mediated inhibition of TCR-mediated T cell activation is SHIP-1 and Dok-1/2 dependent, and involves SHIP-1 hydrolysis of Phosphatidylinositol 3,4,5-trisphosophate (PI(3,4,5)P3) needed for TCR signaling.	phosphatidylinositol 3,4,5-trisphosophate	210-251	CD4 antigen	Mus musculus	85-88
22370159-5	2012	Studies using SHIP-1 shRNA, knockout mice and decoy inhibitors further indicate that CD4-mediated inhibition of TCR-mediated T cell activation is SHIP-1 and Dok-1/2 dependent, and involves SHIP-1 hydrolysis of Phosphatidylinositol 3,4,5-trisphosophate (PI(3,4,5)P3) needed for TCR signaling.	phosphoinositide-3,4,5-triphosphate	253-264	CD4 antigen	Mus musculus	85-88
22247254-5	2012	Monocyte/macrophages, dendritic cells, granulocytes, natural killer cells, and CD4 T cells significantly infiltrated the LCA as early as 4 days.	Lithocholic Acid	121-124	CD4 antigen	Mus musculus	79-82
22144105-7	2012	Dorsomorphin efficiently suppressed IL-2 production even at low doses in mouse CD4(+)  T cells, suggesting that the BMP-Smad signalling physiologically regulates IL-2 transcription in these cells.	dorsomorphin	0-12	CD4 antigen	Mus musculus	79-82
22248986-5	2012	The results indicated that specific antibody and the increased percentage of CD4(+) T lymphocyte were found in vaccinated BALB/c mice with rADF, when compared with adjuvant or PBS groups.	radf	139-143	CD4 antigen	Mus musculus	77-80
22155173-1	2012	BACKGROUND &amp; AIMS: The glucocorticoid-induced tumor necrosis factor receptor family-related protein (GITR; also called TNFRSF18 or CD357) regulates the T cell-mediated immune response and is present on surfaces of regulatory T (Treg) cells and activated CD4(+) T cells.	Adenosine Monophosphate	12-15	CD4 antigen	Mus musculus	258-261
22118797-6	2012	We found that both ATP and NAD induce a dose-dependent decrease on the Treg CD4+ CD25+ population.	Adenosine Triphosphate	19-22	CD4 antigen	Mus musculus	76-79
22118797-6	2012	We found that both ATP and NAD induce a dose-dependent decrease on the Treg CD4+ CD25+ population.	NAD	27-30	CD4 antigen	Mus musculus	76-79
22291189-11	2012	In addition, Reg-DCs(CBA)-treated mice had higher Foxp3(+)CD4(+)CD25(+) and IL-10-producing regulatory T cell frequencies in MLNs.	cba	21-24	CD4 antigen	Mus musculus	58-61
22323768-0	2012	Epigallocatechin-3-gallate inhibits expression of receptors for T cell regulatory cytokines and their downstream signaling in mouse CD4+ T cells.	epigallocatechin gallate	0-26	CD4 antigen	Mus musculus	132-135
22323768-3	2012	We found that EGCG inhibited anti-CD3/CD28-induced proliferation of naive CD4(+) T cells from C57BL/6 mice.	epigallocatechin gallate	14-18	CD4 antigen	Mus musculus	74-77
22239184-0	2012	Danazol induces prolonged survival of fully allogeneic cardiac grafts and maintains the generation of regulatory CD4(+)  cells in mice.	Danazol	0-7	CD4 antigen	Mus musculus	113-116
22239184-6	2012	Moreover, secondary CBA recipients given whole splenocytes or CD4(+) cells from primary danazol-treated (4mg/kg/day) CBA recipients 30days after transplantation had prolonged allograft survival (MSTs, 29 and 60days, respectively).	Danazol	88-95	CD4 antigen	Mus musculus	62-65
22239184-9	2012	Flow cytometry showed an increased CD4(+) CD25(+) Foxp3(+) cell population in splenocytes from danazol-treated mice.	Danazol	95-102	CD4 antigen	Mus musculus	35-38
22239184-10	2012	Danazol prolongs cardiac allograft survival and generates regulatory CD4(+) cells.	Danazol	0-7	CD4 antigen	Mus musculus	69-72
22249078-0	2012	CpG oligonucleotides induce the differentiation of CD4(+)Th17 cells by triggering plasmacytoid dendritic cells in adoptively cell transfer immunotherapy.	Oligonucleotides	4-20	CD4 antigen	Mus musculus	51-54
22308377-0	2012	CD4 and CD8 T cells require different membrane gangliosides for activation.	Gangliosides	47-59	CD4 antigen	Mus musculus	0-3
22308377-3	2012	While investigating T-cell activation in ganglioside-deficient mice, we observed that CD4(+) and CD8(+) T cells required different ganglioside subsets for activation.	Gangliosides	41-52	CD4 antigen	Mus musculus	86-89
22308377-3	2012	While investigating T-cell activation in ganglioside-deficient mice, we observed that CD4(+) and CD8(+) T cells required different ganglioside subsets for activation.	Gangliosides	131-142	CD4 antigen	Mus musculus	86-89
22308377-4	2012	Activation of CD4(+) T cells from GM3 synthase-null mice, deficient in GM3-derived gangliosides, is severely compromised, whereas CD8(+) T-cell activation is normal.	gm3-derived gangliosides	71-95	CD4 antigen	Mus musculus	14-17
22308377-8	2012	Distinct expression patterns of ganglioside species in CD4(+) T and CD8(+) T cells, perhaps in uniquely functional lipid rafts, define immune functions in each T-cell subset.	Gangliosides	32-43	CD4 antigen	Mus musculus	55-58
21383770-7	2012	Diabetogenic CD4(+) T cells transferred disease to NODscid.IL2Rgamma(-/-) mice lacking NK cells, indicating that NK cells do not contribute to beta-cell death in vitro or in vivo.	nodscid	51-58	CD4 antigen	Mus musculus	13-16
22009715-9	2012	RESULTS: DSS colitis increases CD4+ T cells in colonic tissue and induces Th1 (interferon gamma [IFN-gamma], tumor necrosis factor [TNF]) and Th17 (interleukin [IL]-17, IL-22) cytokines.	dss	9-12	CD4 antigen	Mus musculus	31-34
22306900-6	2012	RM-9/mIL-7-vaccinated mice, depleted for CD3, CD4, CD8, or NK1.1, all showed shortened host survival times with regard to the nondepleted vaccinated mice group.	N(1)-methyl-2-lysergic acid diethylamide	5-8	CD4 antigen	Mus musculus	46-49
22020144-15	2012	EGCG-induced shifts in CD4(+) T cell subsets in EAE mice are accompanied by the corresponding changes in their regulator molecules.	epigallocatechin gallate	0-4	CD4 antigen	Mus musculus	23-26
22079836-7	2012	The two vitamin D dependent cell types are the iNKT cells and CD4/CD8alphaalpha intraepithelial lymphocytes (IEL).	Vitamin D	8-17	CD4 antigen	Mus musculus	62-65
22667143-3	2012	The immunocompromised mice model was established by intraperitoneal injection cyclophosphamide to detected the content of IL-2, IL-6 in serum, CD4+, CD8+ in the peripheral blood by ELISA and flow cytometry, respectively.	Cyclophosphamide	78-94	CD4 antigen	Mus musculus	143-146
21351096-5	2012	The number of recipient CD4+ CD25+ Foxp3+ Tregs significantly decreased 3 days after an intraperitoneal injection of cyclophosphamide in C3H/HeN mice that had been injected with spleen cells and BMC of donor AKR/J mice, compared with the number of CD4+ CD25+ Foxp3- T cells.	Cyclophosphamide	117-133	CD4 antigen	Mus musculus	24-27
21351096-5	2012	The number of recipient CD4+ CD25+ Foxp3+ Tregs significantly decreased 3 days after an intraperitoneal injection of cyclophosphamide in C3H/HeN mice that had been injected with spleen cells and BMC of donor AKR/J mice, compared with the number of CD4+ CD25+ Foxp3- T cells.	Cyclophosphamide	117-133	CD4 antigen	Mus musculus	248-251
21950267-10	2012	There was significant increase in the percentage of CD4+FOXP3+ and CD4+CD25+ cells in the SP group, indicating the significant role of Tregs in immune regulation.	sp	90-92	CD4 antigen	Mus musculus	52-55
21950267-10	2012	There was significant increase in the percentage of CD4+FOXP3+ and CD4+CD25+ cells in the SP group, indicating the significant role of Tregs in immune regulation.	sp	90-92	CD4 antigen	Mus musculus	67-70
21905017-9	2012	Criss-cross experiments with CD4+ T cells and splenic DCs showed a significant reduction in IL-17 production by CII-reactive CD4+ T cells in T-bet-Tg mice, even upon coculture with DCs from B6 mice, indicating dysfunction of IL-17-producing CD4+ T cells.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	112-115	CD4 antigen	Mus musculus	29-32
21905017-9	2012	Criss-cross experiments with CD4+ T cells and splenic DCs showed a significant reduction in IL-17 production by CII-reactive CD4+ T cells in T-bet-Tg mice, even upon coculture with DCs from B6 mice, indicating dysfunction of IL-17-producing CD4+ T cells.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	112-115	CD4 antigen	Mus musculus	125-128
21905017-9	2012	Criss-cross experiments with CD4+ T cells and splenic DCs showed a significant reduction in IL-17 production by CII-reactive CD4+ T cells in T-bet-Tg mice, even upon coculture with DCs from B6 mice, indicating dysfunction of IL-17-producing CD4+ T cells.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	112-115	CD4 antigen	Mus musculus	125-128
22062590-9	2012	CONCLUSION: Poly-IgM treatment reduced aortic and accelerated carotid atherosclerosis in apoE-/- mice in association with increased anti-oxLDL IgG titers, and reduced number and proliferative function of splenic CD4(+) T cells.	poly	12-16	CD4 antigen	Mus musculus	212-215
22507872-2	2012	We have shown previously that M. tuberculosis cell wall glycolipids, including mannose capped lipoarabinomannan (ManLAM), directly inhibit polyclonal murine CD4(+) T cell activation by blocking ZAP-70 phosphorylation.	Glycolipids	56-67	CD4 antigen	Mus musculus	157-160
22507872-2	2012	We have shown previously that M. tuberculosis cell wall glycolipids, including mannose capped lipoarabinomannan (ManLAM), directly inhibit polyclonal murine CD4(+) T cell activation by blocking ZAP-70 phosphorylation.	Mannose	79-86	CD4 antigen	Mus musculus	157-160
22507872-2	2012	We have shown previously that M. tuberculosis cell wall glycolipids, including mannose capped lipoarabinomannan (ManLAM), directly inhibit polyclonal murine CD4(+) T cell activation by blocking ZAP-70 phosphorylation.	lipoarabinomannan	94-111	CD4 antigen	Mus musculus	157-160
22507872-2	2012	We have shown previously that M. tuberculosis cell wall glycolipids, including mannose capped lipoarabinomannan (ManLAM), directly inhibit polyclonal murine CD4(+) T cell activation by blocking ZAP-70 phosphorylation.	manlam	113-119	CD4 antigen	Mus musculus	157-160
21983870-0	2012	Alterations of peripheral CD4+CD25+Foxp3+ T regulatory cells in mice with STZ-induced diabetes.	Streptozocin	74-77	CD4 antigen	Mus musculus	26-29
21983870-9	2012	In an in vitro assay in which Tregs were induced from CD4+CD25- T cells by transforming growth factor (TGF)-beta, high glucose enhanced the efficiency of CD4+CD25+Foxp3+ inducible Tregs (iTregs) induction.	Glucose	119-126	CD4 antigen	Mus musculus	54-57
21983870-9	2012	In an in vitro assay in which Tregs were induced from CD4+CD25- T cells by transforming growth factor (TGF)-beta, high glucose enhanced the efficiency of CD4+CD25+Foxp3+ inducible Tregs (iTregs) induction.	Glucose	119-126	CD4 antigen	Mus musculus	154-157
22028728-8	2012	Polymerized Collagen and methotrexate/polymerized collagen but not methotrexate alone induces downregulation of CD4(+)/IL17A(+) T cells and upregulation of Tregs and CD4(+)/IFN-gamma(+) T cells.	Methotrexate	25-37	CD4 antigen	Mus musculus	112-115
22028728-8	2012	Polymerized Collagen and methotrexate/polymerized collagen but not methotrexate alone induces downregulation of CD4(+)/IL17A(+) T cells and upregulation of Tregs and CD4(+)/IFN-gamma(+) T cells.	Methotrexate	25-37	CD4 antigen	Mus musculus	166-169
22811750-8	2012	Flow cytometry studies showed that the CD4(+)CD25(+)Foxp3(+) regulatory cell population was increased in transplant recipients given ACH.	Acetylcholine	133-136	CD4 antigen	Mus musculus	39-42
22811750-10	2012	In conclusion, ACH, one component of TJ-117, as well as TJ-117 induced hyporesponsiveness to fully allogeneic cardiac allografts and may generate CD4(+)CD25(+)Foxp3(+) regulatory cells.	Acetylcholine	15-18	CD4 antigen	Mus musculus	146-149
22116001-2	2012	Retinoic acid (RA) enhances induction of CD4(+) Tregs in the presence of TGFbeta.	Tretinoin	0-13	CD4 antigen	Mus musculus	41-44
22116001-2	2012	Retinoic acid (RA) enhances induction of CD4(+) Tregs in the presence of TGFbeta.	Tretinoin	15-17	CD4 antigen	Mus musculus	41-44
22467029-9	2012	In OVA-immunized mice, TCE (3 mg/l) significantly expanded CD3(+), CD8(+) and CD4(+) cell populations, however the effect at the lower concentration was significant only in the CD8(+) populations, whereas TCE had no effect on these cells population in non-immunized mice.	Trichloroethylene	23-26	CD4 antigen	Mus musculus	78-81
22774468-5	2012	The diisocyanate-inducedsensitization, is associated with the recruitment of CD4 T lymphocytes to the lungs and the production of Th2-type cytokines, including IL-4, IL-5 and IL-13.	4,4'-diphenylmethane diisocyanate	4-16	CD4 antigen	Mus musculus	77-80
22933069-6	2012	Mice receiving CD4+ T cells demethylated by a variety of agents including procainamide and hydralazine develop a lupus-like disease.	Procainamide	74-86	CD4 antigen	Mus musculus	15-18
22933069-6	2012	Mice receiving CD4+ T cells demethylated by a variety of agents including procainamide and hydralazine develop a lupus-like disease.	Hydralazine	91-102	CD4 antigen	Mus musculus	15-18
23300712-4	2012	We demonstrate here that conventional SP CD4+ thymocytes bearing autoreactive TCRs drive a homeostatic process that fine-tunes medullary plasticity in adult mice by governing the expansion and patterning of the medulla.	sp	38-40	CD4 antigen	Mus musculus	41-44
23227154-6	2012	CD4 and CD8 T cell subsets were affected by methamphetamine, both showing a reduction in antigen-experienced subsets.	Methamphetamine	44-59	CD4 antigen	Mus musculus	0-3
23166651-4	2012	In this study, we showed that dendritic cells (DCs) that phagocytose apoptotic T cells acquire inhibitory function (named DCapos) toward CD4(+) and CD8(+) T cells.	dcapos	122-128	CD4 antigen	Mus musculus	137-140
23110086-0	2012	Age-dependent changes in the sphingolipid composition of mouse CD4+ T cell membranes and immune synapses implicate glucosylceramides in age-related T cell dysfunction.	Sphingolipids	29-41	CD4 antigen	Mus musculus	63-66
23110086-0	2012	Age-dependent changes in the sphingolipid composition of mouse CD4+ T cell membranes and immune synapses implicate glucosylceramides in age-related T cell dysfunction.	Glucosylceramides	115-132	CD4 antigen	Mus musculus	63-66
23110086-3	2012	Broadly, increased amounts of sphingomyelins, dihydrosphingomyelins and ceramides were found in aged CD4(+) T cells.	Sphingomyelins	30-44	CD4 antigen	Mus musculus	101-104
23110086-3	2012	Broadly, increased amounts of sphingomyelins, dihydrosphingomyelins and ceramides were found in aged CD4(+) T cells.	dihydrosphingomyelins	46-67	CD4 antigen	Mus musculus	101-104
23110086-3	2012	Broadly, increased amounts of sphingomyelins, dihydrosphingomyelins and ceramides were found in aged CD4(+) T cells.	Ceramides	72-81	CD4 antigen	Mus musculus	101-104
23110086-5	2012	This change was balanced by less dramatic increases in the molar fractions of sphingomyelins and dihydrosphingomyelins in aged CD4(+) T cells.	Sphingomyelins	78-92	CD4 antigen	Mus musculus	127-130
23110086-5	2012	This change was balanced by less dramatic increases in the molar fractions of sphingomyelins and dihydrosphingomyelins in aged CD4(+) T cells.	dihydrosphingomyelins	97-118	CD4 antigen	Mus musculus	127-130
23110086-6	2012	In vitro, the direct or enzymatic enhancement of ceramide levels decreased CD4(+) T cell proliferation without regard for the age of the responding T cells.	Ceramides	49-57	CD4 antigen	Mus musculus	75-78
23110086-8	2012	These results suggest that reductions in glucosylceramide abundance contribute to age-related impairments in CD4(+) T cell function.	Glucosylceramides	41-57	CD4 antigen	Mus musculus	109-112
23029447-2	2012	Previous work showed that IL-12 reversed Treg-mediated suppression of CD4(+)Foxp3(-) T cell (Tconv) proliferation.	treg	41-45	CD4 antigen	Mus musculus	70-73
22916101-4	2012	The CD4+ T cell recipient mice developed partial contact hypersensitivity responses to oxazolone.	Oxazolone	87-96	CD4 antigen	Mus musculus	4-7
22916101-8	2012	These data show that CD4+ T cells mediate contact hypersensitivity to oxazolone, but CD8+ T cells contribute with the most potent effector mechanisms.	Oxazolone	70-79	CD4 antigen	Mus musculus	21-24
22927977-4	2012	CONCLUSION/SIGNIFICANCE: This study shows that the developmental dynamics of DN iNKT cells in DP(dim) are very rapid and that it takes less than 1 day to down-regulate CD4 and CD8 and become DN.	dp	94-96	CD4 antigen	Mus musculus	168-171
22723880-5	2012	Antigen stimulation or CD3/CD28 polyclonal stimulation of membrane cholesterol-enriched, resting CD4 T-cells followed a path of Th1 differentiation, which was more vigorous in the presence of increased IL-12 secretion by APCs enriched in membrane cholesterol.	Cholesterol	67-78	CD4 antigen	Mus musculus	97-100
22723880-5	2012	Antigen stimulation or CD3/CD28 polyclonal stimulation of membrane cholesterol-enriched, resting CD4 T-cells followed a path of Th1 differentiation, which was more vigorous in the presence of increased IL-12 secretion by APCs enriched in membrane cholesterol.	Cholesterol	247-258	CD4 antigen	Mus musculus	97-100
22723880-7	2012	However, membrane cholesterol enrichment in CD4(+)Foxp3(+) T-reg cells did not alter their suppressogenic function.	Cholesterol	18-29	CD4 antigen	Mus musculus	44-47
22723880-8	2012	These findings revealed a differential regulatory effect of membrane cholesterol on the function of CD4 T-cell subsets.	Cholesterol	69-80	CD4 antigen	Mus musculus	100-103
22723935-6	2012	The loss of the T memory response following TBI was associated with a relative increase of CD4+CD25+ Foxp3+ expressing T regs, as compared to the CD8+ T effector cells requisite for skin graft rejection.	tbi	44-47	CD4 antigen	Mus musculus	91-94
22540016-0	2012	The effect of enzymatically polymerised polyphenols on CD4 binding and cytokine production in murine splenocytes.	Polyphenols	40-51	CD4 antigen	Mus musculus	55-58
22540016-8	2012	In addition, the anti-CD4 neutralised monoclonal antibody (mAb) inhibited polymerised polyphenol-induced IFN-gamma and GM-CSF secretion.	Polyphenols	86-96	CD4 antigen	Mus musculus	22-25
22540016-9	2012	Moreover, polymerised polyphenols bound directly to a recombinant CD4 protein, and FACS analysis confirmed that interaction occurs between polymerised polyphenols and CD4 molecules expressed on the cell surface.	Polyphenols	22-33	CD4 antigen	Mus musculus	66-69
22540016-9	2012	Moreover, polymerised polyphenols bound directly to a recombinant CD4 protein, and FACS analysis confirmed that interaction occurs between polymerised polyphenols and CD4 molecules expressed on the cell surface.	Polyphenols	22-33	CD4 antigen	Mus musculus	167-170
22540016-9	2012	Moreover, polymerised polyphenols bound directly to a recombinant CD4 protein, and FACS analysis confirmed that interaction occurs between polymerised polyphenols and CD4 molecules expressed on the cell surface.	Polyphenols	151-162	CD4 antigen	Mus musculus	66-69
22540016-9	2012	Moreover, polymerised polyphenols bound directly to a recombinant CD4 protein, and FACS analysis confirmed that interaction occurs between polymerised polyphenols and CD4 molecules expressed on the cell surface.	Polyphenols	151-162	CD4 antigen	Mus musculus	167-170
22479648-5	2012	Specifically, bortezomib-treated mice showed significantly decreased numbers of CD4(+) and CD8(+) T cells in the colon and mesenteric lymph nodes.	Bortezomib	14-24	CD4 antigen	Mus musculus	80-83
22479648-7	2012	Furthermore, cytoplasmic IFN-gamma production by CD4(+) and CD8(+) T cells in mesenteric lymph nodes was substantially decreased by bortezomib treatment.	Bortezomib	132-142	CD4 antigen	Mus musculus	49-52
22348129-8	2012	A mixed lymphocyte reaction showed that mutant BMDC only induced a weak Th1 immune response but stimulated increased Th2 cytokine production from allogeneic naive CD4(+) T cells.	bmdc	47-51	CD4 antigen	Mus musculus	163-166
22359647-10	2012	Analysis of Treg subsets revealed a Cy-sensitive CD4(+)Foxp3(+)CD25(low) tumor-seeking migratory phenotype, characteristic of effector/memory Tregs, and capable of high avidity T cell suppression.	Cyclophosphamide	36-38	CD4 antigen	Mus musculus	49-52
22962636-3	2012	Here we showed that retinoic acid and transforming growth factor-beta1 promoted the differentiation of CD8alphaalpha T cells from CD4 T cells in a Runx3-dependent manner.	Tretinoin	20-33	CD4 antigen	Mus musculus	130-133
21896286-4	2011	The protective effect observed is associated with a decreased activation of peripheral CD4+ and CD8+ T lymphocytes and a decrease in the intensity of the Th1 and Th17 autoimmune response to IRBP in pristane-treated mice compared to control mice, as evidenced by the decreased production of IFNgamma and IL17 by IRBP-specific lymphocytes from lymph nodes draining the site of immunization and by the increased production of anti-IRBP IgG1 over IgG2a.	pristane	198-206	CD4 antigen	Mus musculus	87-90
21711135-5	2011	The results indicated that co-administration of salidroside with OVA significantly enhanced the ConA-, LPS-, and OVA-induced splenocyte proliferation, produced more IL-2, IL-4, IFN-gamma, and IgG, IgG1, and IgG2b antibody levels, and increased the percentage of CD4(+), CD8(+) lymphocyte subsets than OVA alone.	rhodioloside	48-59	CD4 antigen	Mus musculus	262-265
22039014-6	2011	Moreover, mesenteric lymph node non-T cells obtained from mice that were orally treated with CoA led allogeneic naive CD4(+) T cells to differentiate into T(h)2.	Coenzyme A	93-96	CD4 antigen	Mus musculus	118-121
21952987-3	2011	Splenocytes of infected mice (C3H/HeN) responded to Tc-antigenic stimulus by more than a two-fold increase in NADPH oxidase (NOX) activity, ROS generation, cytokine production (IFN-gamma &gt; IL-4 &gt; TNFalpha &gt; IL1-beta  IL6), and predominant expansion of CD4(+) and CD8(+) T cells.	Technetium	52-54	CD4 antigen	Mus musculus	261-264
22018827-8	2011	In addition, DHEA-androgenisation induced the activation of CD4(+) cells both in vivo and in vitro, and their expression of the respective ligands for VCAM-1 and ICAM-1, VLA-4 and LFA-1, as assessed in vitro.	Dehydroepiandrosterone	13-17	CD4 antigen	Mus musculus	60-63
21695461-6	2011	The reduced severity of hepatitis in curcumin pretreated mice correlated with decrease in numbers of liver CD4(+) T cells but not CD8(+) T cells by immunohistochemical analysis.	Curcumin	37-45	CD4 antigen	Mus musculus	107-110
22082615-4	2011	In both models, DeltafbpA mutant induced a stronger response of T-bet(+)CD4 T cells, which correlated with an increased expansion of IFN-gamma(+)CD4 T cells in vivo and in vitro.	deltafbpa	16-25	CD4 antigen	Mus musculus	72-75
22082615-4	2011	In both models, DeltafbpA mutant induced a stronger response of T-bet(+)CD4 T cells, which correlated with an increased expansion of IFN-gamma(+)CD4 T cells in vivo and in vitro.	deltafbpa	16-25	CD4 antigen	Mus musculus	145-148
22082615-8	2011	DeltafbpA vaccinated mice showed a rapid and stronger expansion of CD4(+)CXCR3(+) IFN-gamma(+) T cells in the lungs of Mtb challenged mice, compared to those which had BCG vaccine.	deltafbpa	0-9	CD4 antigen	Mus musculus	67-70
22379819-0	2011	[Effects of Schistosoma 22.6 kDa/26 GST molecule mixed with Sepharose 4B beads on induction of CD4+CD25+ regulatory T cells].	Sepharose	60-72	CD4 antigen	Mus musculus	95-98
22379819-9	2011	Meanwhile, the proportions of regulatory T cells were (17.0 +/- 80.57)% and (30.14 +/- 3.62)% when the CD4+ T cells were co-cultured with dendritic cells pulsed with Sepharose 4B beads mixed rSj22.6/26GST and OVA, respectively.	Sepharose	166-178	CD4 antigen	Mus musculus	103-106
22101769-4	2011	In conjunction with a carrier protein-derived peptide, this carbohydrate epitope binds major histocompatibility class II (MHCII) and stimulates carbohydrate-specific CD4(+) T cell clones to produce interleukins 2 and 4-cytokines essential for providing T cell help to antibody-producing B cells.	Carbohydrates	60-72	CD4 antigen	Mus musculus	166-169
22101769-4	2011	In conjunction with a carrier protein-derived peptide, this carbohydrate epitope binds major histocompatibility class II (MHCII) and stimulates carbohydrate-specific CD4(+) T cell clones to produce interleukins 2 and 4-cytokines essential for providing T cell help to antibody-producing B cells.	Carbohydrates	144-156	CD4 antigen	Mus musculus	166-169
22101769-6	2011	Our discovery of how glycoconjugates are processed resulting in presentation of carbohydrate epitopes that stimulate CD4(+) T cells has key implications for glycoconjugate vaccine design that could result in greatly enhanced vaccine efficacy.	Carbohydrates	80-92	CD4 antigen	Mus musculus	117-120
22001857-12	2011	The effect of TC on differentiation of CD4(+)CD25(+) Foxp3(+)Treg cells was examined by flow cytometry.	Technetium	14-16	CD4 antigen	Mus musculus	39-42
22001857-17	2011	TC also induced the generation of CD4(+)CD25(+) Treg cells with a Treg phenotype Foxp3.	Technetium	0-2	CD4 antigen	Mus musculus	34-37
21347662-0	2011	Depletion of CD4+CD25+Foxp3+ regulatory T cells with anti-CD25 antibody may exacerbate the 1,3-beta-glucan-induced lung inflammatory response in mice.	beta-1,3-glucan	91-106	CD4 antigen	Mus musculus	13-16
21862617-0	2011	Induction of autoimmune thyroiditis by depletion of CD4+CD25+ regulatory T cells in thyroiditis-resistant IL-17, but not interferon-gamma receptor, knockout nonobese diabetic-H2h4 mice.	h2h4	175-179	CD4 antigen	Mus musculus	52-55
21807124-5	2011	Proliferating CD4+ T cells from control and RRMS subjects, cultured with or without IL-2, decreased in response to 75 muM deferiprone, although the extent of decreased proliferation of CD4+ T cells from RRMS subjects was less than for control subjects.	Deferiprone	122-133	CD4 antigen	Mus musculus	14-17
21807124-7	2011	CD4+CD25+ and CD8+CD25+ cells from control subjects, cultured with or without IL-2, declined in 75 muM deferiprone, but the decrease was smaller than for the CD4+ and CD8+ proliferative responses.	Deferiprone	103-114	CD4 antigen	Mus musculus	0-3
21824530-0	2011	Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo.	Artemether	45-55	CD4 antigen	Mus musculus	82-85
22036898-7	2011	In the absence of the MR, antigen-specific CD4(+) cells are Th1 biased, suggesting that ligation of the MR by glycosylated E/S material released by schistosome larvae modulates the production of CD4(+) cell specific IFNgamma.	Sulfur	125-126	CD4 antigen	Mus musculus	43-46
22036898-7	2011	In the absence of the MR, antigen-specific CD4(+) cells are Th1 biased, suggesting that ligation of the MR by glycosylated E/S material released by schistosome larvae modulates the production of CD4(+) cell specific IFNgamma.	Sulfur	125-126	CD4 antigen	Mus musculus	195-198
21949094-6	2011	In contrast, administration of recombinant IL-33 (rIL-33) exacerbated cisplatin-induced AKI, measured by an increase in CD4 T cell infiltration, serum creatinine, ATN, and apoptosis; this did not occur in CD4-deficient mice, suggesting that CD4 T cells mediate the injurious effect of IL-33.	Cisplatin	70-79	CD4 antigen	Mus musculus	205-208
21949094-7	2011	Wildtype mice that received cisplatin and rIL-33 also had higher levels of the proinflammatory chemokine CXCL1, which CD T cells produce, in the kidney compared with CD4-deficient mice.	Cisplatin	28-37	CD4 antigen	Mus musculus	166-169
21949026-7	2011	Finally, Treg depletion in C57BL/6 transgenic APPPS1 mice, a mouse model of AD, results in enhanced vaccine-induced CD4(+) T cell responses in AD compared with wild-type animals.	treg	9-13	CD4 antigen	Mus musculus	116-119
21918192-8	2011	Splenocytes from CD4-depleted IFN-gamma KO mice produce significantly less IL-17 compared with splenocytes from isotype-treated IFN-gamma KO animals in response to TAs.	tas	164-167	CD4 antigen	Mus musculus	17-20
21918192-10	2011	In this model we propose that, in the absence of IFN-gamma, CD4(+) T cells produce IL-17 in response to TAs, which increases CTL activity that mediates tumor rejection; however, this does not occur in the eye.	tas	104-107	CD4 antigen	Mus musculus	60-63
21843497-7	2011	Adoptive transfer of CD4(+) T cells from donors subjected to DS increased corneal epithelial apoptosis via activation of caspase-8 in recipients, similar to that in the donor mice.	ds	61-63	CD4 antigen	Mus musculus	21-24
21864492-6	2011	CD11b(+)Gr-1(+) cells from lung of doxycycline-treated bitransgenic mice strongly inhibited proliferation and function of wild-type CD4(+) T cells in vitro.	Doxycycline	35-46	CD4 antigen	Mus musculus	132-135
20820943-0	2011	Dynamic changes of CD4+CD25 + regulatory T cells in NOD.H-2h4 mice with iodine-induced autoimmune thyroiditis.	Iodine	72-78	CD4 antigen	Mus musculus	19-22
20820943-2	2011	We investigated the dynamic changes of CD4(+)CD25(+) regulatory T cells in NOD.H-2(h4) mice with iodine-induced autoimmune thyroiditis (AIT), and explore potential immune mechanism of AIT induced by iodine.	Iodine	97-103	CD4 antigen	Mus musculus	39-42
20820943-2	2011	We investigated the dynamic changes of CD4(+)CD25(+) regulatory T cells in NOD.H-2(h4) mice with iodine-induced autoimmune thyroiditis (AIT), and explore potential immune mechanism of AIT induced by iodine.	Iodine	199-205	CD4 antigen	Mus musculus	39-42
20820943-7	2011	These data suggest that CD4(+)CD25(+) regulatory T cells may be involved in the pathogenesis and development of AIT induced by iodine.	Iodine	127-133	CD4 antigen	Mus musculus	24-27
21770045-1	2011	Levels of anti-inflammatory extracellular adenosine are controlled by the sequential action of the ectonucleotidases CD39 and CD73, whose expression in CD4(+)  T cells has been associated with natural regulatory T cells (nTregs).	Adenosine	42-51	CD4 antigen	Mus musculus	152-155
21770045-2	2011	We here show that CD73 expression on activated murine CD4(+)  T cells is induced by TGF-beta independently of Foxp3 expression, operates at the transcriptional level and translates into gain of functional capacity to generate adenosine.	Adenosine	226-235	CD4 antigen	Mus musculus	54-57
21770045-3	2011	In the presence of AMP, CD73 induced by TGF-beta generates adenosine able to suppress proliferation of activated CD4(+)  T cells in vitro.	Adenosine Monophosphate	19-22	CD4 antigen	Mus musculus	113-116
21770045-3	2011	In the presence of AMP, CD73 induced by TGF-beta generates adenosine able to suppress proliferation of activated CD4(+)  T cells in vitro.	Adenosine	59-68	CD4 antigen	Mus musculus	113-116
21773974-4	2011	We show that all mature mouse B-cell subsets, including follicular (FO), marginal zone (MZ), B1a, and B1b cells, as well as CD4(+)  and CD8(+)  T cells produce Camp mRNA and mCRAMP protein.	Cyclic AMP	160-164	CD4 antigen	Mus musculus	124-127
20730501-5	2011	RSV reversed surface phenotypes of old mice to that of young mice by maintaining the CD4+ and CD8+ population in splenocytes as well as reducing CD8+CD44+ (CD8M) cells in the aged.	Resveratrol	0-3	CD4 antigen	Mus musculus	85-88
20730501-6	2011	RSV also enhanced the CD4+CD25+ population in old mice.	Resveratrol	0-3	CD4 antigen	Mus musculus	22-25
21763264-2	2011	We hypothesized that if FLIP were overexpressed on lymphocytes, CD4(+) effector cells would be protected from Fas-mediated apoptosis, and resolution would be delayed.	ammonium ferrous sulfate	110-113	CD4 antigen	Mus musculus	64-67
21817104-5	2011	EPA treatment significantly regressed atherosclerosis (-22.7%, P&lt;0.05) and decreased the content of macrophages, CD4(+) T cells, and dendritic cells (DCs) in atherosclerotic lesions, though only changing the chow never induced the regression.	Eicosapentaenoic Acid	0-3	CD4 antigen	Mus musculus	116-119
21626029-8	2011	Analysis of tumor infiltrating lymphocytes (TILs) on day 12 post-tumor challenge revealed that mice treated with Ad5-OVA + CpG IT possessed a significantly reduced percentage of regulatory T lymphocytes (Tregs) within the CD4+ lymphocyte population, compared with TILs isolated from mice treated with Ad5-OVA only.	ad5-ova	113-120	CD4 antigen	Mus musculus	222-225
21851214-10	2011	Furthermore, the ratio of CD4(+)/CD8(+) T lymphocytes was significantly increased from 0.69 to 2.29 by treatment with DGVL.	dgvl	118-122	CD4 antigen	Mus musculus	26-29
21504802-7	2011	In addition, intraperitoneal administered RA at 10 or 50 mg/kg significantly inhibited the infiltrations of CD4(+) T, CD8(+) T, and mast cells into DNFB-induced skin lesions in NC/Nga mice.	rosmarinic acid	42-44	CD4 antigen	Mus musculus	108-111
21891823-10	2011	PD98059 decreased IL-17 production and expression in CD4+ T lymphocytes in a murine asthma model (p &lt; 0.05).	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-7	CD4 antigen	Mus musculus	53-56
21784975-0	2011	Cytokine-induced alterations of alpha7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17- versus Th2-mediated colitis.	Nicotine	113-121	CD4 antigen	Mus musculus	69-72
21784975-7	2011	TCR stimulation of naive CD4(+)CD62L(+) T cells in the presence of nicotine upregulated expression of Foxp3.	Nicotine	67-75	CD4 antigen	Mus musculus	25-28
21784975-8	2011	In marked contrast, nicotine worsened TNBS colitis, and this was associated with increased Th17 cells among colonic CD4 T cells.	Nicotine	20-28	CD4 antigen	Mus musculus	116-119
21784975-10	2011	The dichotomous action of nicotine resulted from the up- and downregulation of anti-inflammatory alpha7 nAChR on colonic CD4 T cells induced by cytokines characteristic of the inflammatory milieu in oxazolone (IL-4) and TNBS (IL-12) colitis, respectively.	Nicotine	26-34	CD4 antigen	Mus musculus	121-124
21784975-10	2011	The dichotomous action of nicotine resulted from the up- and downregulation of anti-inflammatory alpha7 nAChR on colonic CD4 T cells induced by cytokines characteristic of the inflammatory milieu in oxazolone (IL-4) and TNBS (IL-12) colitis, respectively.	Oxazolone	199-208	CD4 antigen	Mus musculus	121-124
21109419-9	2011	Additionally, ABA improved colon histopathology, reduced blood F4/80(+)CD11b(+) monocytes, increased the percentage of CD4(+) T cells expressing the inhibitory molecule cytotoxic T lymphocyte antigen 4 in blood and enhanced the number of T(reg) cells in the mesenteric lymph nodes and colons of PPARgamma-expressing but not T cell-specific PPARgamma null mice.	Abscisic Acid	14-17	CD4 antigen	Mus musculus	119-122
21508181-14	2011	The IG-PQQ-PN group had significantly greater PP lymphocyte number and PP CD4+ cell numbers than the IG-STD-PN group.	pqq-pn	7-13	CD4 antigen	Mus musculus	74-77
21593451-6	2011	Treatment of stimulated CD4(+) T-cells with adenosine (25 muM) potently reduced IFN-gamma release which is mediated by adenosine A2a receptors (A2aR).	Adenosine	44-53	CD4 antigen	Mus musculus	24-27
21593451-10	2011	In summary, CD73-derived adenosine tonically inhibits active NF-kappaB in CD4(+) T-cells, thereby modulating the release of a broad spectrum of proinflammatory cytokines and chemokines.	Adenosine	25-34	CD4 antigen	Mus musculus	74-77
21624364-5	2011	Our data also demonstrated that the percentage of CD4(+)CD25(+) regulatory T cells (Tregs) was significantly decreased in the spleens of mice immunized with pEGFP-Sj26GST plus CIM.	Cimetidine	176-179	CD4 antigen	Mus musculus	50-53
21221123-6	2011	Chronic ethanol consumption downregulates the number of F4/80(+) cells expressing MHC-I and -II and decreases CD4(+) T-cell activation in wild-type mice.	Ethanol	8-15	CD4 antigen	Mus musculus	110-113
21870425-0	2011	Inhibition of subcutaneous growth of Ehrlich ascites carcinoma (EAC) tumor by post-immunization with EAC-cell gangliosides and its anti-idiotype antibody in relation to tumor angiogenesis, apoptosis, cell cycle and infiltration of CD4+, CD8+ lymphocytes, NK cells, suppressor cells and APC-cells in tumor.	eac-cell gangliosides	101-122	CD4 antigen	Mus musculus	231-234
21870426-8	2011	Cell-surface beta2AR of CD4+ T lymphocytes decreased (15.27%) after terbutaline treatment, but recovered after beta-arrestin 2 RNAi down-modulation.	Terbutaline	68-79	CD4 antigen	Mus musculus	24-27
21697289-3	2011	Vitamin D-deficient CD4(+) T cells also overproduced IL-17 in vitro and 1,25 dihydroxyvitamin D(3) inhibited the development of T(h)17 cells in CD4(+) T-cell cultures.	Vitamin D	0-9	CD4 antigen	Mus musculus	20-23
21697289-3	2011	Vitamin D-deficient CD4(+) T cells also overproduced IL-17 in vitro and 1,25 dihydroxyvitamin D(3) inhibited the development of T(h)17 cells in CD4(+) T-cell cultures.	Vitamin D	0-9	CD4 antigen	Mus musculus	144-147
21697289-3	2011	Vitamin D-deficient CD4(+) T cells also overproduced IL-17 in vitro and 1,25 dihydroxyvitamin D(3) inhibited the development of T(h)17 cells in CD4(+) T-cell cultures.	1,25-dihydroxyvitamin D	72-95	CD4 antigen	Mus musculus	144-147
21697460-6	2011	Adoptively transferred CD4(+)CD25(-) T cells were converted into Treg within the liver after BDL.	treg	65-69	CD4 antigen	Mus musculus	23-26
21690296-0	2011	c-Abl-mediated tyrosine phosphorylation of the T-bet DNA-binding domain regulates CD4+ T-cell differentiation and allergic lung inflammation.	Tyrosine	15-23	CD4 antigen	Mus musculus	82-85
21690296-9	2011	Therefore, c-Abl catalyzes tyrosine phosphorylation of the DNA-binding domain of T-bet to regulate CD4(+) T cell differentiation.	Tyrosine	27-35	CD4 antigen	Mus musculus	99-102
21270773-6	2011	Studies further demonstrated that CD4(+) T cells induced bladder inflammation in URO-OVA mice depleted of CD8(+) T cells or deficient in the recombinase activating gene-1 (Rag-1(-/-)).	uro-ova	81-88	CD4 antigen	Mus musculus	34-37
21822803-8	2011	To ensure the safety of the method, the employment of thymidine kinase gene made it possible to eliminate these transgenic CD4(+) T cells following ganciclovir treatment.	Ganciclovir	148-159	CD4 antigen	Mus musculus	123-126
21375556-6	2011	OT-II CD4(+) T cells also ignored OVA in the periphery of Tyr-OVA mice, albeit being potently reactive to vaccination.	tyr-ova	58-65	CD4 antigen	Mus musculus	6-9
21375556-7	2011	OVA challenge in single transgenic Tyr-OVA mice confirmed the existence of OVA-reactive CD4(+) T cells with the induction of efficient T helper cells for antibody production and anti-tumour T cell response.	tyr-ova	35-42	CD4 antigen	Mus musculus	88-91
21543518-8	2011	Tumors treated with TLR4 agonist-absorbed GVAX showed increased infiltrating CD4 and CD8 T cells as well as increased numbers of CD86(+) cells in the tumor tissue.	gvax	42-46	CD4 antigen	Mus musculus	77-80
21593380-2	2011	Previously implicated as an anti-inflammatory mediator in CD4(+) T cell regulation, we report that adenosine acts via dendritic cell (DC) A(2B) adenosine receptor (A(2B)AR) to promote the development of Th17 cells.	Adenosine	99-108	CD4 antigen	Mus musculus	58-61
21593380-3	2011	Mouse naive CD4(+) T cells cocultured with DCs in the presence of adenosine or the stable adenosine mimetic 5"-(N-ethylcarboximado) adenosine resulted in the differentiation of IL-17- and IL-22-secreting cells and elevation of mRNA that encode signature Th17-associated molecules, such as IL-23R and RORgammat.	Adenosine	66-75	CD4 antigen	Mus musculus	12-15
21593380-3	2011	Mouse naive CD4(+) T cells cocultured with DCs in the presence of adenosine or the stable adenosine mimetic 5"-(N-ethylcarboximado) adenosine resulted in the differentiation of IL-17- and IL-22-secreting cells and elevation of mRNA that encode signature Th17-associated molecules, such as IL-23R and RORgammat.	Adenosine	90-99	CD4 antigen	Mus musculus	12-15
21593380-3	2011	Mouse naive CD4(+) T cells cocultured with DCs in the presence of adenosine or the stable adenosine mimetic 5"-(N-ethylcarboximado) adenosine resulted in the differentiation of IL-17- and IL-22-secreting cells and elevation of mRNA that encode signature Th17-associated molecules, such as IL-23R and RORgammat.	5"-(n-ethylcarboximado) adenosine	108-141	CD4 antigen	Mus musculus	12-15
21255222-6	2011	Furthermore, the significantly lower numbers of CD4(+) CD25(+) regulatory T cells in AQP4-deficient mice compared to WT mice, perhaps resulting from impaired thymic generation, may be responsible for the uncontrolled microglial inflammatory responses and subsequent severe loss of DNs in the substantia nigra pars compacta in the MPTP-induced PD model.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	330-334	CD4 antigen	Mus musculus	48-51
21469117-0	2011	Selective effects of NF-kappaB1 deficiency in CD4+ T cells on Th2 and TFh induction by alum-precipitated protein vaccines.	tfh	70-73	CD4 antigen	Mus musculus	46-49
21376048-1	2011	BACKGROUND &amp; AIMS: Regulatory T (Treg) cells (CD4+ CD25high FoxP3+) regulate mucosal tolerance; their adoptive transfer prevents or reduces symptoms of colitis in mouse models of inflammatory bowel disease.	Adenosine Monophosphate	12-15	CD4 antigen	Mus musculus	50-53
21518963-2	2011	Tacrolimus treatment of mice for 1 week dose-dependently decreased splenic CD4(+)/FoxP3(+) (regulatory T cells), increased splenic CD4(+)/IL-17(+) (T-helper 17) cells, and caused endothelial dysfunction and hypertension.	Tacrolimus	0-10	CD4 antigen	Mus musculus	75-78
21518963-2	2011	Tacrolimus treatment of mice for 1 week dose-dependently decreased splenic CD4(+)/FoxP3(+) (regulatory T cells), increased splenic CD4(+)/IL-17(+) (T-helper 17) cells, and caused endothelial dysfunction and hypertension.	Tacrolimus	0-10	CD4 antigen	Mus musculus	131-134
21388431-4	2011	These professional antigen-presenting cells endocytose and process TSA to display antigenic peptides on their MHC class II molecules for indirect cancer cell recognition by CD4(+) T cells.	trichostatin A	67-70	CD4 antigen	Mus musculus	173-176
21388431-9	2011	Second, TSA secretion results in stronger activation of naive tumour-specific CD4(+) T cells in lymph nodes.	trichostatin A	8-11	CD4 antigen	Mus musculus	78-81
21388431-13	2011	Therefore, we propose that CD4(+) T cells that recognize secreted TSA may be superior for immunotherapy by T cell transfer, because the local extracellular antigen concentration will be higher for secreted TSA.	trichostatin A	66-69	CD4 antigen	Mus musculus	27-30
21388431-14	2011	Thus, it is anticipated that secreted TSA will be more readily detected in vivo by transferred CD4(+) T cells, resulting in more efficient tumour eradication.	trichostatin A	38-41	CD4 antigen	Mus musculus	95-98
22164498-9	2011	The inhibition of CD4+CD25+ Tregs of the B16F10/ESA-injected mice decreased markedly on Day 4 (50.03%) and Day 6 (50%) compared with those in the control (75.03% and 78.14%) post-ESA injection, there were significant difference (both P values &lt; 0.05).	esa	48-51	CD4 antigen	Mus musculus	18-21
21292993-0	2011	Accumulation of CD4+ T cells in the colon of CsA-treated mice following myeloablative conditioning and bone marrow transplantation.	Cyclosporine	45-48	CD4 antigen	Mus musculus	16-19
21292993-5	2011	Time-course studies revealed a significant increase in migration of CD4(+) T cells into the colon during CsA therapy, as well as significantly elevated mRNA levels of TNF-alpha, proinflammatory chemokines, and cell adhesion molecules in colonic tissue of CsA-treated animals compared with BMT controls, as early as day 14 post-BMT.	Cyclosporine	105-108	CD4 antigen	Mus musculus	68-71
21292993-6	2011	Homing studies revealed a greater migration of labeled CD4(+) T cells into the gut of CsA-treated mice at day 21 post-BMT than control animals via CsA-induced upregulation of mucosal addressin cell adhesion molecule.	Cyclosporine	86-89	CD4 antigen	Mus musculus	55-58
21292993-6	2011	Homing studies revealed a greater migration of labeled CD4(+) T cells into the gut of CsA-treated mice at day 21 post-BMT than control animals via CsA-induced upregulation of mucosal addressin cell adhesion molecule.	Cyclosporine	147-150	CD4 antigen	Mus musculus	55-58
21292993-7	2011	This study demonstrates that, during the 21 days of immunosuppressive therapy, functional mechanisms are in place that result in increased homing of CD4(+) T effector cells to colons of CsA-treated mice.	Cyclosporine	186-189	CD4 antigen	Mus musculus	149-152
21416626-0	2011	Role of CD4+ CD25+ regulatory T cells in melatonin-mediated inhibition of murine gastric cancer cell growth in vivo and in vitro.	Melatonin	41-50	CD4 antigen	Mus musculus	8-11
21416626-10	2011	In conclusion, the antigastric cancer effect of melatonin is associated with downregulation of CD4(+) CD25(+) Tregs and its Foxp3 expression in the tumor tissue.	Melatonin	48-57	CD4 antigen	Mus musculus	95-98
21130889-4	2011	Relative to single-agent regimens, combination regimens with pentostatin and cyclophosphamide (PC) and with fludarabine and cyclophosphamide (FC) worked synergistically to deplete host CD4(+) and CD8(+) T cells.	Cyclophosphamide	77-93	CD4 antigen	Mus musculus	185-188
21130889-4	2011	Relative to single-agent regimens, combination regimens with pentostatin and cyclophosphamide (PC) and with fludarabine and cyclophosphamide (FC) worked synergistically to deplete host CD4(+) and CD8(+) T cells.	fludarabine	108-119	CD4 antigen	Mus musculus	185-188
21130889-4	2011	Relative to single-agent regimens, combination regimens with pentostatin and cyclophosphamide (PC) and with fludarabine and cyclophosphamide (FC) worked synergistically to deplete host CD4(+) and CD8(+) T cells.	Cyclophosphamide	124-140	CD4 antigen	Mus musculus	185-188
21130889-4	2011	Relative to single-agent regimens, combination regimens with pentostatin and cyclophosphamide (PC) and with fludarabine and cyclophosphamide (FC) worked synergistically to deplete host CD4(+) and CD8(+) T cells.	Fc(alpha) receptor	142-144	CD4 antigen	Mus musculus	185-188
21244371-0	2011	Inhibitor of PI3Kgamma ameliorates TNBS-induced colitis in mice by affecting the functional activity of CD4+CD25+FoxP3+ regulatory T cells.	Trinitrobenzenesulfonic Acid	35-39	CD4 antigen	Mus musculus	104-107
21244371-10	2011	In addition, a significant increase in CD25 and FoxP3 expression was found in isolated lamina propria CD4+ T cells of AS605240-treated mice.	5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione	118-126	CD4 antigen	Mus musculus	102-105
21244371-12	2011	CONCLUSIONS AND IMPLICATIONS: These results suggest that AS605240 protects mice against TNBS-induced colitis by inhibiting multiple inflammatory components through the NF-kappaB pathway while simultaneously inducing an increase in the functional activity of CD4+CD25+ Treg.	5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione	57-65	CD4 antigen	Mus musculus	258-261
21074892-12	2011	Liver CD4 and NKT cells significantly increased after GC treatment suggesting liver involvement.	gallocatechol	54-56	CD4 antigen	Mus musculus	6-9
21283109-0	2011	Antibody responses to glycolipid-borne carbohydrates require CD4+ T cells but not CD1 or NKT cells.	Glycolipids	22-32	CD4 antigen	Mus musculus	61-64
21283109-0	2011	Antibody responses to glycolipid-borne carbohydrates require CD4+ T cells but not CD1 or NKT cells.	Carbohydrates	39-52	CD4 antigen	Mus musculus	61-64
21283109-5	2011	These studies showed that CD4(+) T cells were required to generate antibodies to the carbohydrates expressed on glycolipids, and unexpectedly, these antibody responses were CD1d and NKT cell independent.	Carbohydrates	85-98	CD4 antigen	Mus musculus	26-29
21283109-5	2011	These studies showed that CD4(+) T cells were required to generate antibodies to the carbohydrates expressed on glycolipids, and unexpectedly, these antibody responses were CD1d and NKT cell independent.	Glycolipids	112-123	CD4 antigen	Mus musculus	26-29
21084064-1	2011	3G11 is a sialylated carbohydrate epitope of the disialoganglioside molecule expressed on mouse CD4(+) T cells.	Carbohydrates	21-33	CD4 antigen	Mus musculus	96-99
21084064-1	2011	3G11 is a sialylated carbohydrate epitope of the disialoganglioside molecule expressed on mouse CD4(+) T cells.	sialogangliosides	49-67	CD4 antigen	Mus musculus	96-99
21163250-7	2011	Taken together, our data demonstrated that supCD28mAb targets CD4+Foxp3+Treg cells expansion in vivo, maintains and enhances their regulatory functions, to reduce the damage of colon in dextran sulfate sodium (DSS)-induced mouse colitis by secreting a large amount of IL-10.	Dextran Sulfate	186-208	CD4 antigen	Mus musculus	62-65
21163250-7	2011	Taken together, our data demonstrated that supCD28mAb targets CD4+Foxp3+Treg cells expansion in vivo, maintains and enhances their regulatory functions, to reduce the damage of colon in dextran sulfate sodium (DSS)-induced mouse colitis by secreting a large amount of IL-10.	Dextran Sulfate	210-213	CD4 antigen	Mus musculus	62-65
21402768-4	2011	Clodronate-induced depletion of the alveolar macrophage population resulted in increased numbers of dendritic cells (DCs) and CD4(+) cells in bronchoalveolar lavage (BAL) fluid and was associated with significantly increased mortality by 18 h following S. aureus inoculation but had no effect on bacterial load or polymorphonuclear leukocyte (PMN) numbers in the lung.	Clodronic Acid	0-10	CD4 antigen	Mus musculus	126-129
21430224-6	2011	The lung parenchyma of WT mice was infiltrated with inflammatory neutrophils, CD11b(hi)CD103(-) DCs, and activated CD4(+) T cells after CS exposure.	Cesium	136-138	CD4 antigen	Mus musculus	115-118
21434774-6	2011	The percentages of CD4(+) and CD8(+) lymphocytes in the 50 mg/kg of body weight hesperidin group tended to increase compared with the normal group.	Hesperidin	80-90	CD4 antigen	Mus musculus	19-22
21212175-0	2011	3-hydroxykynurenine suppresses CD4+ T-cell proliferation, induces T-regulatory-cell development, and prolongs corneal allograft survival.	3-hydroxykynurenine	0-19	CD4 antigen	Mus musculus	31-34
21443863-2	2011	Here we show that micromolar concentrations of curcumin inhibited DNA synthesis by mouse CD4(+) T-lymphocytes, as well as interleukin-2 (IL-2) and CD25 (alpha chain of the high affinity IL-2 receptor) expression in response to antibody-mediated cross-linking of CD3 and CD28.	Curcumin	47-55	CD4 antigen	Mus musculus	89-92
21443863-6	2011	In line with the inhibitory action of curcumin on IL-2R signaling, pretreatment of CD4(+)CD25(+) regulatory T-cells with curcumin downregulated suppressor function, as well as forkhead box p3 (Foxp3) expression.	Curcumin	38-46	CD4 antigen	Mus musculus	83-86
21443863-6	2011	In line with the inhibitory action of curcumin on IL-2R signaling, pretreatment of CD4(+)CD25(+) regulatory T-cells with curcumin downregulated suppressor function, as well as forkhead box p3 (Foxp3) expression.	Curcumin	121-129	CD4 antigen	Mus musculus	83-86
21338678-3	2011	In a 14-month experiment, we showed that TB vaccine-induced CD4 T cell responses were heterogenous.	Terbium	41-43	CD4 antigen	Mus musculus	60-63
21220536-10	2011	PC-SA-PM showed an immunomodulatory effect on CD4(+) and CD8(+) T cells for gamma interferon (IFN-gamma) production and downregulated disease-associated interleukin-10 (IL-10) and transforming growth factor beta (TGF-beta) to almost negligible levels.	pc-sa-pm	0-8	CD4 antigen	Mus musculus	46-49
21272929-6	2011	Wild-type mice treated with blocking antibodies against CD4 and IL-17 showed markedly lower TDI-induced airway hyperresponsiveness.	Toluene 2,4-Diisocyanate	92-95	CD4 antigen	Mus musculus	56-59
21339368-4	2011	In adult mice, RepliVAX WN induced robust and long-lasting CD4(+) and CD8(+) T cell and Ab (B cell) responses against natural WNV epitopes, similar to those elicited by primary WNV infection.	replivax wn	15-26	CD4 antigen	Mus musculus	59-62
21389872-6	2011	Aldara treatment was associated with a reduction in the number CD4(+)Foxp3(+) regulatory T cells in the blood and brain tumor site.	Imiquimod	0-6	CD4 antigen	Mus musculus	63-66
21389872-7	2011	Mice treated with Aldara exhibited a generalized lymphopenia in the blood amidst an increase in brain tumor infiltrating CD4(+) and CD8(+) T cells and dendritic cells.	Imiquimod	18-24	CD4 antigen	Mus musculus	121-124
21392113-7	2011	Mice receiving CD4(+) CD25(+) cells from mice vaccinated with PDT-induced apoptotic MPhi showed smaller lesions 3 weeks after infection and lower parasitic burdens than mice that received Tregs from mice of thaw-frozen necrotic MPhi or PBS groups.	pbs	236-239	CD4 antigen	Mus musculus	15-18
21483778-7	2011	Higher numbers of CD3+CD49b+ NKT cells were found in spleen and liver of the alcohol treated compared to the control mice (p&lt;0.05), whereas the amount of CD4+Foxp3+ regulator T cells did not differ.	Alcohols	77-84	CD4 antigen	Mus musculus	22-25
21223350-0	2011	CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4.	Paclitaxel	43-53	CD4 antigen	Mus musculus	0-3
21223350-3	2011	Here, we demonstrated that PTX not only decreased the percentage of CD4+Foxp3+ regulatory T (Treg) cells both in vitro and in vivo but also impaired cell viability and cytokine production of Treg cells rather than CD4+Foxp3- effector T (Teff) cells.	Paclitaxel	27-30	CD4 antigen	Mus musculus	68-71
21307293-3	2011	We have previously shown an autocrine/paracrine release of dopamine by dendritic cells (DCs) during Ag presentation to naive CD4(+) T cells and found efficacious results of a D1-like receptor antagonist SCH-23390 in the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis and in the NOD mouse model of type I diabetes, with inhibition of Th17 response.	Dopamine	59-67	CD4 antigen	Mus musculus	125-128
20660719-8	2011	Intestinal colonization with segmented filamentous bacteria (SFB) is known to promote IL-17 production in the gut; here, we show that SFBs also induced IL-17A-producing CD4(+) T cells (Th17) in the CNS.	N-succinimidyl 8-((4'-fluorobenzyl)amino)suberate	134-138	CD4 antigen	Mus musculus	169-172
21234656-2	2011	Chronic alcohol consumption increases IFN-gamma producing NK, NKT, CD4(+), and CD8(+) T cells.	Alcohols	8-15	CD4 antigen	Mus musculus	67-70
21306399-5	2011	Excretory-secretory (ES) antigen of the nematode prevented Dex-induced apoptosis in CD4-positive T cells with CD4(+) CD25(-) and CD4(+) CD25(High) phenotype by Bcl-2 protein expression.	dex	59-62	CD4 antigen	Mus musculus	84-87
21306399-5	2011	Excretory-secretory (ES) antigen of the nematode prevented Dex-induced apoptosis in CD4-positive T cells with CD4(+) CD25(-) and CD4(+) CD25(High) phenotype by Bcl-2 protein expression.	dex	59-62	CD4 antigen	Mus musculus	110-113
21306399-5	2011	Excretory-secretory (ES) antigen of the nematode prevented Dex-induced apoptosis in CD4-positive T cells with CD4(+) CD25(-) and CD4(+) CD25(High) phenotype by Bcl-2 protein expression.	dex	59-62	CD4 antigen	Mus musculus	110-113
21242523-12	2011	Furthermore, we found a significantly higher number of CD4(+)CD25(+)Foxp3(+) T cells (regulatory T cells [Tregs]) in PBS- and OVA-treated STAT6(-/-) mouse lungs compared with that in WT animals suggesting that STAT6 limits both naturally occurring and Ag-induced Tregs.	Lead	117-120	CD4 antigen	Mus musculus	55-58
20348207-9	2011	Flow cytometry of bronchoalveolar lavage (BAL) demonstrated CD4(+) T-cell responses against sodA peptide in the sodA-sensitized mice only.	soda peptide	92-104	CD4 antigen	Mus musculus	60-63
21245731-10	2011	In mixed cell cultures with CD3-positive T cells, midazolam-treated DCs showed less propensity to stimulate the proliferation of CD3-positive T cells and the secretion of interferon-gamma from CD4-positive T cells.	Midazolam	50-59	CD4 antigen	Mus musculus	193-196
21075976-0	2011	Proanthocyanidins inhibit UV-induced immunosuppression through IL-12-dependent stimulation of CD8+ effector T cells and inactivation of CD4+ T cells.	Proanthocyanidins	0-17	CD4 antigen	Mus musculus	136-139
21075976-6	2011	Naive mice that received CD4(+) suppressor T cells from GSP-treated, UVB-exposed mice could mount a CHS response after sensitization and subsequent challenge with DNFB.	Dinitrofluorobenzene	163-167	CD4 antigen	Mus musculus	25-28
21123117-7	2011	The number of CD4(+)Foxp3(+) cells was higher in pancreatic lymph nodes of heme-exposed IVIG treated mice.	Heme	75-79	CD4 antigen	Mus musculus	14-17
21145253-6	2011	This is evidenced by our finding that pretreatment with BAPTA/AM, an intracellular Ca(2+) chelator, significantly attenuated the proliferation of hsBAFF-stimulated CD4(+) T lymphocytes.	1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid	56-61	CD4 antigen	Mus musculus	164-167
21145253-7	2011	Subsequently, we revealed that hsBAFF-stimulated CD4(+) T cell proliferation was markedly suppressed after pretreatment with EGTA, an extracellular Ca(2+) chelator, or with 2-APB, an inhibitor of Ca(2+) influx through CRAC channels, respectively, suggesting that extracellular Ca(2+) influx due to hsBAFF is closely associated with [Ca(2+)](i) elevation contributing to CD4(+) T cell proliferation.	Egtazic Acid	125-129	CD4 antigen	Mus musculus	49-52
21145253-7	2011	Subsequently, we revealed that hsBAFF-stimulated CD4(+) T cell proliferation was markedly suppressed after pretreatment with EGTA, an extracellular Ca(2+) chelator, or with 2-APB, an inhibitor of Ca(2+) influx through CRAC channels, respectively, suggesting that extracellular Ca(2+) influx due to hsBAFF is closely associated with [Ca(2+)](i) elevation contributing to CD4(+) T cell proliferation.	2-aminoethoxydiphenyl borate	173-178	CD4 antigen	Mus musculus	49-52
20882053-9	2011	Moreover, cyclophosphamide reduced the infiltration of inflammatory cells, including total leukocytes, lymphocytes, CD4+ and CD8+T cells.	Cyclophosphamide	10-26	CD4 antigen	Mus musculus	116-119
21178009-8	2011	In addition, we observed that tolerance to NIMA K(b) was abrogated via depletion of CD4(+) but not CD8(+) T cells and could be transferred to naive nonexposed mice via adoptive transfer of CD4(+)CD25(high) T cell expressing Foxp3 isolated from NIMA mice.	nima k	43-49	CD4 antigen	Mus musculus	84-87
21178009-8	2011	In addition, we observed that tolerance to NIMA K(b) was abrogated via depletion of CD4(+) but not CD8(+) T cells and could be transferred to naive nonexposed mice via adoptive transfer of CD4(+)CD25(high) T cell expressing Foxp3 isolated from NIMA mice.	nima k	43-49	CD4 antigen	Mus musculus	189-192
21097750-13	2011	Additionally, TCDD-BMDCs increased the generation of CD4(+) CD25(+) FoxP3(+) Tregs in vitro in an IDO-dependent fashion.	Polychlorinated Dibenzodioxins	14-18	CD4 antigen	Mus musculus	53-56
21070856-5	2011	Poly I:C-induced a marked pulmonary T cell response in allogeneic HCT mice as compared to syngeneic HCT, with increased CD4+ cells in the lung fluid and tissue.	Poly I-C	0-8	CD4 antigen	Mus musculus	120-123
21070856-8	2011	In vivo, poly I:C exposure was associated with an early increase in pulmonary monocyte recruitment and activation as well as a decrease in CD4+FOXP3+ regulatory T cells in allogeneic mice as compared to syngeneic.	Poly I-C	9-17	CD4 antigen	Mus musculus	139-142
21073952-0	2011	Adoptive transfer of DNT cells induces long-term cardiac allograft survival and augments recipient CD4(+)Foxp3(+) Treg cell accumulation.	2,6-dinitrotoluene	21-24	CD4 antigen	Mus musculus	99-102
21073952-5	2011	Furthermore adoptive transfer DNT cells augmented CD4+Foxp3+ Treg cells accumulation in transplant recipients while depletion of CD4(+) Treg cells by anti-CD25 inhibited the effect of DNT cells on long-term graft survival (48+-12 days vs. 101+-31 days, p&lt;0.001).	2,6-dinitrotoluene	30-33	CD4 antigen	Mus musculus	50-53
21073952-5	2011	Furthermore adoptive transfer DNT cells augmented CD4+Foxp3+ Treg cells accumulation in transplant recipients while depletion of CD4(+) Treg cells by anti-CD25 inhibited the effect of DNT cells on long-term graft survival (48+-12 days vs. 101+-31 days, p&lt;0.001).	2,6-dinitrotoluene	184-187	CD4 antigen	Mus musculus	129-132
21073952-6	2011	In conclusion, DNT cells combined with short-term immunosuppression can prolong allograft survival, which may be through the accumulation of CD4(+)Foxp3(+) Treg cells in the recipient.	2,6-dinitrotoluene	15-18	CD4 antigen	Mus musculus	141-144
21253614-13	2011	CONCLUSIONS/SIGNIFICANCE: We present evidence that NADPH oxidase derived ROS plays a role in the direct Treg mediated suppression of CD4+ effector T cells in a process that is blocked by thiol-containing antioxidants, NADPH oxidase inhibitors or a lack of Ncf1 expression in Tregs and Teffs.	ros	73-76	CD4 antigen	Mus musculus	133-136
21253614-13	2011	CONCLUSIONS/SIGNIFICANCE: We present evidence that NADPH oxidase derived ROS plays a role in the direct Treg mediated suppression of CD4+ effector T cells in a process that is blocked by thiol-containing antioxidants, NADPH oxidase inhibitors or a lack of Ncf1 expression in Tregs and Teffs.	Sulfhydryl Compounds	187-192	CD4 antigen	Mus musculus	133-136
22312332-6	2011	Molecular dynamics simulations indicate that the mCD4-peptide stably interacts with gp120 via an intermolecular beta-sheet, while an important salt-bridge formed by a C-terminal lysine is lost.	Lysine	178-184	CD4 antigen	Mus musculus	49-53
20118221-1	2011	Indoleamine 2,3-dioxygenase (IDO) suppresses the functions of CD4(+) T cells through its ability to metabolize the essential amino acid tryptophan.	essential amino acid tryptophan	115-146	CD4 antigen	Mus musculus	62-65
20118221-4	2011	Upon inhalation of formalin-fixed Aspergillus fumigatus hyphal antigens, the overexpression of IDO from airway epithelial cells of these mice reduced the number of CD4(+) T cells within the inflamed lung and impaired the capacity of antigen-specific splenic CD4(+) effector T cells to secrete the cytokines IL-4, IL-5, IL-13, and IFN-gamma.	Formaldehyde	19-27	CD4 antigen	Mus musculus	164-167
21389605-3	2011	The percentage of CD4(+)CD25(+) cells was increased in DO11.10 mice orally given OVA, but this increase of CD4(+)CD25(+) cells were suppressed in L. lactis-fed DO11.10 mice.	ova	81-84	CD4 antigen	Mus musculus	18-21
21636079-0	2011	Increased expression of mGITRL on D2SC/1 cells by particulate beta-glucan impairs the suppressive effect of CD4+CD25+ regulatory T cells and enhances the effector T cell proliferation.	beta-Glucans	62-73	CD4 antigen	Mus musculus	108-111
21696712-4	2011	The findings show that combination treatment with desloratadine and nortriptyline decreases the mean clinical score, disease relapse frequency, and number of CD4(+) T cells infiltrating into the CNS.	desloratadine	50-63	CD4 antigen	Mus musculus	158-161
21696712-4	2011	The findings show that combination treatment with desloratadine and nortriptyline decreases the mean clinical score, disease relapse frequency, and number of CD4(+) T cells infiltrating into the CNS.	Nortriptyline	68-81	CD4 antigen	Mus musculus	158-161
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	desloratadine	51-64	CD4 antigen	Mus musculus	148-151
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	desloratadine	51-64	CD4 antigen	Mus musculus	291-294
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	Nortriptyline	69-82	CD4 antigen	Mus musculus	148-151
21696712-7	2011	The data also show that combination treatment with desloratadine and nortriptyline inhibits the production of IFN-gamma and IL-17 produced by naive CD4(+) T cells activated in the presence of Th1 cell- and Th17 cell-promoting conditions, while increasing the level of IL-4 produced by naive CD4(+) T cells activated in the presence of Th2 cell-promoting conditions.	Nortriptyline	69-82	CD4 antigen	Mus musculus	291-294
21808653-7	2011	Intravenous administration of EEA increased the number of CD4(+) T cells in spleen and tumor necrosis factor (TNF)-alpha in serum of DTH mice.	N-{3-[3-(3'-Chlorobiphenyl-4-Yl)isoxazol-5-Yl]propanoyl}-L-Alpha-Glutamyl-L-Alpha-Glutamyl-Amide	30-33	CD4 antigen	Mus musculus	58-61
20008077-5	2011	In addition, poly I:C led to evident alternations in neuroendocrine and immune systems of mice, such as reduced spontaneous activity and learning ability, declined serum level of corticosterone, increased weight indexes and T lymphocyte numbers in thymuses and spleens, and increased CD4(+)/CD8(+) ratio but decreased proliferation ability of T lymphocytes in spleens.	Poly I-C	13-21	CD4 antigen	Mus musculus	284-287
21747891-3	2011	We found that chronic morphine-induced decrease of splenic T lymphocyte proliferation and IL-2 production can be significantly raised by 2 Hz EA, and the fluctuation of CD4(+)/CD8(+) ratio was also run to the baseline level by the EA.	Morphine	22-30	CD4 antigen	Mus musculus	169-172
20514074-4	2011	Macrophages of mice injected with CD4(+)CD25(+) Treg cells displayed a remarkably enhanced phagocytosis of chicken red blood cells, and arginase activity together with an increased interleukin-10 (IL-10) production, whereas they showed a decreased antigen-presenting ability and nitric oxide production.	Nitric Oxide	279-291	CD4 antigen	Mus musculus	34-37
20971187-7	2011	Concanavalin A (ConA) activation of CD4(+) and CD8(+) T cells, which were purified from mouse spleen following depletion of endogenous 5-HT, was enhanced by a selective 5-HT2AR agonist, (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI).	(R)-DOI	186-235	CD4 antigen	Mus musculus	36-39
20937010-0	2011	MK615, a prospective anti-proliferative agent, enhances CD4/CD8 ratio after exposure to irradiation.	mk615	0-5	CD4 antigen	Mus musculus	56-59
22034573-0	2011	Thioperamide induces CD4 CD25 Foxp3 regulatory T lymphocytes in the lung mucosa of allergic mice through its action on dendritic cells.	thioperamide	0-12	CD4 antigen	Mus musculus	21-24
21131418-9	2011	Th2 skewing was accelerated in the culture of WT CD4 T cells stimulated with Ags and LPS-activated Bcl6-KO BM-derived DCs, which produced more IL-6 and less IL-12 than did WT DCs; the addition of anti-IL-6 Abs to the culture partially abrogated the Th2 skewing.	Silver	77-80	CD4 antigen	Mus musculus	49-52
20884652-2	2011	This study uses a TCR transgenic T cell adoptive transfer approach and in vivo Treg depletion to determine specifically the in vivo influence of Tregs on antigen-driven CD4 T cell reactivity following burn injury in mice.	tregs	145-150	CD4 antigen	Mus musculus	169-172
20884652-4	2011	In contrast, CD4 T cell expansion and reactivity were suppressed significantly in injured Treg-replete mice.	treg	90-94	CD4 antigen	Mus musculus	13-16
20941602-5	2011	We present a detailed protocol demonstrating that polyclonal activation of conventional CD4(+) T cells in the presence of IL-2, TGFbeta, and all trans retinoic acid induces &gt;90% conversion of these T cells to Foxp3-expressing iTregs as well as promotes a three- to fourfold increase in proliferation following a 4-day incubation period in vitro.	Tretinoin	151-164	CD4 antigen	Mus musculus	88-91
20702533-0	2011	CD4+ CD25+ regulatory T cells partially mediate the beneficial effects of FTY720, a sphingosine-1-phosphate analogue, during ischaemia/reperfusion-induced acute kidney injury.	sphingosine 1-phosphate	84-107	CD4 antigen	Mus musculus	0-3
22206014-3	2011	We set out to delineate the essential signaling pathways by which the RNA-like IRMs, resiquimod (R-848) and polyinosinic:polycytidylic acid (poly I:C), augment CD4+ T-helper 1 (Th1) responses.	Poly I-C	108-139	CD4 antigen	Mus musculus	160-163
22216357-2	2011	To address the question whether T cells themselves harbor a functional clock driving circadian rhythms of immune function, we analyzed clock gene expression by qPCR in unstimulated CD4+ T cells and immune responses of PMA/ionomycin stimulated CD4+ T cells by FACS analysis purified from blood of healthy subjects at different time points throughout the day.	Ionomycin	222-231	CD4 antigen	Mus musculus	243-246
22145029-0	2011	NADPH oxidase-2 derived ROS dictates murine DC cytokine-mediated cell fate decisions during CD4 T helper-cell commitment.	Reactive Oxygen Species	24-27	CD4 antigen	Mus musculus	92-95
22194977-5	2011	METHODOLOGY/PRINCIPAL FINDINGS: DS was induced by subcutaneous injection of scopolamine and exposure to a drafty low humidity environment in CD4-DNTGFbetaRII and wild-type (WT) mice, aged 14 weeks, for 5 days.	ds	32-34	CD4 antigen	Mus musculus	141-144
22066016-5	2011	In contrast, in response to alpha-galactosylceramide (alpha-GalCer), CD4(-) and CD4(+) cDC differentially activate invariant Natural Killer T (iNKT) cells, a population of lipid-reactive non-conventional T lymphocytes.	alpha-galactosylceramide	28-52	CD4 antigen	Mus musculus	69-72
22066016-5	2011	In contrast, in response to alpha-galactosylceramide (alpha-GalCer), CD4(-) and CD4(+) cDC differentially activate invariant Natural Killer T (iNKT) cells, a population of lipid-reactive non-conventional T lymphocytes.	alpha-galactosylceramide	28-52	CD4 antigen	Mus musculus	80-83
22066016-5	2011	In contrast, in response to alpha-galactosylceramide (alpha-GalCer), CD4(-) and CD4(+) cDC differentially activate invariant Natural Killer T (iNKT) cells, a population of lipid-reactive non-conventional T lymphocytes.	alpha-galactosylceramide	54-66	CD4 antigen	Mus musculus	69-72
21966503-8	2011	Notably, oral treatment with GABA significantly increased the frequency of CD4(+)Foxp3(+) Tregs in mice.	gamma-Aminobutyric Acid	29-33	CD4 antigen	Mus musculus	75-78
21931768-1	2011	BACKGROUND: It has been documented all-trans retinoic acid (atRA) promotes the development of TGF-beta-induced CD4(+)Foxp3(+) regulatory T cells (iTreg) that play a vital role in the prevention of autoimmune responses, however, molecular mechanisms involved remain elusive.	Tretinoin	45-58	CD4 antigen	Mus musculus	111-114
21931768-1	2011	BACKGROUND: It has been documented all-trans retinoic acid (atRA) promotes the development of TGF-beta-induced CD4(+)Foxp3(+) regulatory T cells (iTreg) that play a vital role in the prevention of autoimmune responses, however, molecular mechanisms involved remain elusive.	Tretinoin	60-64	CD4 antigen	Mus musculus	111-114
21931768-3	2011	METHODOLOGY/PRINCIPAL FINDINGS: Addition of atRA to naive CD4(+)CD25(-) cells stimulated with anti-CD3/CD28 antibodies in the presence of TGF-beta not only increased Foxp3(+) iTreg differentiation, but maintained Foxp3 expression through apoptosis inhibition.	Tretinoin	44-48	CD4 antigen	Mus musculus	58-61
21931768-6	2011	atRA did not significantly affect the phosphorylation levels of Smad2/3 and still promoted iTreg differentiation in CD4(+) cells isolated from Smad3 KO and Smad2 conditional KO mice.	Tretinoin	0-4	CD4 antigen	Mus musculus	116-119
21698274-0	2011	Astragalus polysaccharides attenuate postburn sepsis via inhibiting negative immunoregulation of CD4+ CD25(high) T cells.	Polysaccharides	11-26	CD4 antigen	Mus musculus	97-100
21731677-0	2011	Daidzein prevents the increase in CD4+CD28null T cells and B lymphopoesis in ovariectomized mice: a key mechanism for anti-osteoclastogenic effect.	daidzein	0-8	CD4 antigen	Mus musculus	34-37
21721401-5	2011	Florfenicol increased the percentage of CD4CD8- thymocytes and the absolute number of CD4+ and CD8+ thymocytes on day 7.	florfenicol	0-11	CD4 antigen	Mus musculus	40-43
21721401-6	2011	The increased percentage and absolute number of CD3+, CD4+ and CD8+ lymphocytes in mesenteric lymph nodes and decreased percentage of lymphocytes B were also observed 24 hours from the last administration of florfenicol.	florfenicol	208-219	CD4 antigen	Mus musculus	54-57
21957733-5	2011	Five and ten exposures to bestatin (10, 1 and 0.1 mg/kg) increased the absolute count of both immature CD4+CD8+ and CD4-CD8- thymic cells.	ubenimex	26-34	CD4 antigen	Mus musculus	103-106
21957733-5	2011	Five and ten exposures to bestatin (10, 1 and 0.1 mg/kg) increased the absolute count of both immature CD4+CD8+ and CD4-CD8- thymic cells.	ubenimex	26-34	CD4 antigen	Mus musculus	116-119
21957733-6	2011	Moreover, both a single and multiple administration of bestatin (1 and 0.1 mg/kg) decreased the percentage and absolute count of CD3+ splenocytes and mesenteric lymph node cells with corresponding decreases in the percentage and absolute count of CD4+ and CD8+ cells.	ubenimex	55-63	CD4 antigen	Mus musculus	247-250
20688035-1	2010	The acylated analogs of picroside-II were synthesized and tested for immune-adjuvant activity in the presence of weak antigen ovalbumin found to stimulate anti-OVA IgG titer, neutralizing antibody (IgG1 and IgG2a) titer as well as the production of soluble mediators of a Th1 response (IL-2 and IFN-gamma) and Th2 response (IL-4) and proliferation of T lymphocytes sub-sets (CD4/CD8).	picroside II	24-36	CD4 antigen	Mus musculus	375-378
20869956-7	2010	Mice receiving UA or metformin supplementation had increased CD4(+)CD8(+) subpopulations in the thymus compared to the untreated diabetic mice.	ursolic acid	15-17	CD4 antigen	Mus musculus	61-64
20869956-7	2010	Mice receiving UA or metformin supplementation had increased CD4(+)CD8(+) subpopulations in the thymus compared to the untreated diabetic mice.	Metformin	21-30	CD4 antigen	Mus musculus	61-64
20869956-8	2010	Concanavalin A-stimulated splenic T-lymphocyte proliferation and single-positive (CD4(+) and CD8(+)) subpopulations were significantly higher in the UA-supplemented diabetic groups than in the untreated diabetic group, but lipopolysaccharide-stimulated B-lymphocyte proliferation and the CD19(+) subpopulation were not significantly different among the groups.	ursolic acid	149-151	CD4 antigen	Mus musculus	82-85
20869956-9	2010	In the STZ/NA-induced diabetic mice, metformin increased the splenic T-lymphocyte CD4(+) and CD8(+) cell numbers without any change in T-lymphocyte proliferation.	Metformin	37-46	CD4 antigen	Mus musculus	82-85
21108691-4	2010	The ratio of spleen interferon-gamma(+) CD4(+) /IL-4(+) CD4(+) cells was higher in the mice administered the KT-11-supplemented diet compared to that in mice administered the control or L. rhamnosus GG-supplemented diet.	kt-11	109-114	CD4 antigen	Mus musculus	20-46
20930170-3	2010	Oral calcitriol administration decreased atherosclerotic lesions, macrophage accumulation, and CD4(+) T-cell infiltration at the aortic sinus, when compared with the corresponding observations in control mice.	Calcitriol	5-15	CD4 antigen	Mus musculus	95-98
20735407-6	2010	Shikonin-treated BM-DCs were poor stimulators of CD4(+) T lymphocyte and induced lower levels of interleukin (IL)-4, IL-5, IL-13 and tumour necrosis factor (TNF)-alpha release by responding T-cells.	shikonin	0-8	CD4 antigen	Mus musculus	49-52
20236740-10	2010	ABA also increased CD4(+) and CD8(+) T-lymphocytes in blood and MLN and regulatory T cells in blood.	Abscisic Acid	0-3	CD4 antigen	Mus musculus	19-22
20980632-4	2010	In vivo administration of CpG, polyinosinic-polycytidylic acid, and Pam(3)CSK(4) in combination with Ag resulted in the increased expression of costimulatory molecules and MHC class II by DCs, increased serum levels of the inflammatory cytokines IL-6 and RANTES, and increased cognate CD4 T cell responses in young and aged mice.	Poly I-C	31-62	CD4 antigen	Mus musculus	285-288
21048105-0	2010	Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells.	methyl gallate	0-14	CD4 antigen	Mus musculus	88-91
21048105-4	2010	Methyl gallate inhibited Treg cell-suppressive effects on effector CD4(+) T cells and Treg migration toward tumor environment.	methyl gallate	0-14	CD4 antigen	Mus musculus	67-70
21048105-9	2010	In addition, in tumor-bearing Treg-depleted mice, tumor growth and the survival rates were not changed by methyl gallate treatment, strongly suggesting that the main therapeutic target of methyl gallate in tumor suppression was related to modulation of the CD4(+)CD25(+) Treg cell functions.	methyl gallate	188-202	CD4 antigen	Mus musculus	257-260
21048105-10	2010	In the spleen of tumor-bearing mice, methyl gallate treatment induced a significant decrease in the CD4(+)CD25(+)Foxp3(high) Treg cell population.	methyl gallate	37-51	CD4 antigen	Mus musculus	100-103
20843956-0	2010	Stimulation of alpha7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.	Nicotine	58-66	CD4 antigen	Mus musculus	121-124
20843956-4	2010	We found that CD4(+)CD25(+) Tregs from naive C57BL/6J mice positively expressed alpha7 nAChR, and its activation by nicotine enhanced the suppressive capacity of Tregs.	Nicotine	116-124	CD4 antigen	Mus musculus	14-17
20843956-6	2010	In the supernatants of CD4(+)CD25(+) Tregs/CD4(+)CD25(-) T-cell cocultures, we observed a decrease in the concentration of IL-2 in nicotine-stimulated groups, but nicotine stimulation had no effect on the ratio of IL-4/interferon (IFN)-gamma, which partially represented T-cell polarization.	Nicotine	131-139	CD4 antigen	Mus musculus	23-26
20843956-6	2010	In the supernatants of CD4(+)CD25(+) Tregs/CD4(+)CD25(-) T-cell cocultures, we observed a decrease in the concentration of IL-2 in nicotine-stimulated groups, but nicotine stimulation had no effect on the ratio of IL-4/interferon (IFN)-gamma, which partially represented T-cell polarization.	Nicotine	131-139	CD4 antigen	Mus musculus	43-46
20843956-6	2010	In the supernatants of CD4(+)CD25(+) Tregs/CD4(+)CD25(-) T-cell cocultures, we observed a decrease in the concentration of IL-2 in nicotine-stimulated groups, but nicotine stimulation had no effect on the ratio of IL-4/interferon (IFN)-gamma, which partially represented T-cell polarization.	Nicotine	163-171	CD4 antigen	Mus musculus	23-26
20843956-6	2010	In the supernatants of CD4(+)CD25(+) Tregs/CD4(+)CD25(-) T-cell cocultures, we observed a decrease in the concentration of IL-2 in nicotine-stimulated groups, but nicotine stimulation had no effect on the ratio of IL-4/interferon (IFN)-gamma, which partially represented T-cell polarization.	Nicotine	163-171	CD4 antigen	Mus musculus	43-46
21113099-4	2010	Flow cytometry revealed that BA increased the percentage of CD4(+) cells in thymus as well as the percentage of CD19(+) and the ratios of CD4(+)/CD8(+) in spleen.	betulinic acid	29-31	CD4 antigen	Mus musculus	60-63
21113099-4	2010	Flow cytometry revealed that BA increased the percentage of CD4(+) cells in thymus as well as the percentage of CD19(+) and the ratios of CD4(+)/CD8(+) in spleen.	betulinic acid	29-31	CD4 antigen	Mus musculus	138-141
20463654-0	2010	CD4+CD25+ regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice.	Cisplatin	39-48	CD4 antigen	Mus musculus	0-3
20463654-3	2010	In this study, we determined whether CD4+CD25+ Treg cells had protective effects against cisplatin-induced acute renal injury in nu/nu mice that lack mature T cells.	Cisplatin	89-98	CD4 antigen	Mus musculus	37-40
20463654-6	2010	Infusion of CD4+CD25+Treg cells into wild-type Balb/c mice reduced serum blood urea nitrogen and creatinine levels equivalent to those in nu/nu mice and extended their survival time after cisplatin injection.	Urea	79-83	CD4 antigen	Mus musculus	12-15
20463654-6	2010	Infusion of CD4+CD25+Treg cells into wild-type Balb/c mice reduced serum blood urea nitrogen and creatinine levels equivalent to those in nu/nu mice and extended their survival time after cisplatin injection.	Nitrogen	84-92	CD4 antigen	Mus musculus	12-15
20463654-6	2010	Infusion of CD4+CD25+Treg cells into wild-type Balb/c mice reduced serum blood urea nitrogen and creatinine levels equivalent to those in nu/nu mice and extended their survival time after cisplatin injection.	Creatinine	97-107	CD4 antigen	Mus musculus	12-15
20463654-6	2010	Infusion of CD4+CD25+Treg cells into wild-type Balb/c mice reduced serum blood urea nitrogen and creatinine levels equivalent to those in nu/nu mice and extended their survival time after cisplatin injection.	Cisplatin	188-197	CD4 antigen	Mus musculus	12-15
20463654-7	2010	In contrast, depletion of CD4+CD25+ Treg cells in wild-type mice exacerbated kidney injury after cisplatin administration.	Cisplatin	97-106	CD4 antigen	Mus musculus	26-29
20463654-9	2010	Our results suggest that CD4+CD25+ Treg cells directly affect cisplatin nephrotoxicity and their modulation represents an additional treatment strategy.	Cisplatin	62-71	CD4 antigen	Mus musculus	25-28
20887202-4	2010	METHODS: They examined the phenotype of murine CD4(+) CD25(-) T cells activated in the presence of ethanol-fixed RPE cell layers as fixation preserves membrane structure while preventing the secretion of soluble factors.	Ethanol	99-106	CD4 antigen	Mus musculus	47-50
21172136-5	2010	RESULTS: The levels of CD4+ CD25+ T subsets in peripheral blood and intestinal mucosa in the 250 IU/g vitamin A group were significantly higher than those in the 4 IU/g vitamin A group (P&lt;0.05).	Vitamin A	102-111	CD4 antigen	Mus musculus	23-26
21172136-5	2010	RESULTS: The levels of CD4+ CD25+ T subsets in peripheral blood and intestinal mucosa in the 250 IU/g vitamin A group were significantly higher than those in the 4 IU/g vitamin A group (P&lt;0.05).	Vitamin A	169-178	CD4 antigen	Mus musculus	23-26
21172136-7	2010	CONCLUSIONS: vitamin A may promote the development of CD4+ CD25+ T lymphocytes in peripheral blood and small intestine.	Vitamin A	13-22	CD4 antigen	Mus musculus	54-57
20682853-4	2010	We also found that SIRPalpha is required intrinsically within cDCs or DC precursors for the homeostasis of splenic CD4+ cDCs.	chenodeoxycholate sulfate conjugate	62-66	CD4 antigen	Mus musculus	115-118
20682853-4	2010	We also found that SIRPalpha is required intrinsically within cDCs or DC precursors for the homeostasis of splenic CD4+ cDCs.	chenodeoxycholate sulfate conjugate	120-124	CD4 antigen	Mus musculus	115-118
21072213-0	2010	CD4+CD25+Foxp3+ regulatory T cells depletion may attenuate the development of silica-induced lung fibrosis in mice.	Silicon Dioxide	78-84	CD4 antigen	Mus musculus	0-3
20977632-1	2010	We have shown that CD39 and CD73 are coexpressed on the surface of murine CD4+ Foxp3+ regulatory T cells (Treg) and generate extracellular adenosine, contributing to Treg immunosuppressive activity.	Adenosine	139-148	CD4 antigen	Mus musculus	74-77
20844003-3	2010	Additionally, 17beta-estradiol (E2) is able to initiate immune suppression through CD4(+)CD25(+) Treg cells during early pregnancy.	Estradiol	14-30	CD4 antigen	Mus musculus	83-86
20561084-10	2010	The CD11c(+) cells from the SDLN of mice treated with topical 1,25(OH)(2)D(3) expressed increased levels of indoleamine 2,3-dioxygenase messenger RNA, a molecule by which topical 1,25(OH)(2)D(3) may enhance the ability of DC to control the suppressive function of CD4(+) CD25(+) cells.	indolamine	108-119	CD4 antigen	Mus musculus	264-267
20728597-0	2010	Rapid burst of H2O2 by plant growth regulators increases intracellular Ca2+ amounts and modulates CD4+ T cell activation.	Hydrogen Peroxide	15-19	CD4 antigen	Mus musculus	98-101
20728597-2	2010	Three molecules that regulate plant growth and differentiation, but not their structurally similar analogs, were identified to enhance primary mouse CD4(+) T cell activation in conjunction with soluble anti-CD3 stimulation: Indoleacetic acid (natural plant auxin), 1-Napthaleneacetic acid (synthetic plant auxin) and 2,4-Dichlorophenoxyacetic acid (synthetic plant auxin and herbicide).	indoleacetic acid	224-241	CD4 antigen	Mus musculus	149-152
20728597-7	2010	Interestingly, maximal IL-2 production and CD4(+) T cell cycle progression are observed upon activation with soluble anti-CD3 and phorbol 12-myristate 13-acetate (PMA), a phorbol ester.	Tetradecanoylphorbol Acetate	130-161	CD4 antigen	Mus musculus	43-46
20728597-7	2010	Interestingly, maximal IL-2 production and CD4(+) T cell cycle progression are observed upon activation with soluble anti-CD3 and phorbol 12-myristate 13-acetate (PMA), a phorbol ester.	Tetradecanoylphorbol Acetate	163-166	CD4 antigen	Mus musculus	43-46
20728597-7	2010	Interestingly, maximal IL-2 production and CD4(+) T cell cycle progression are observed upon activation with soluble anti-CD3 and phorbol 12-myristate 13-acetate (PMA), a phorbol ester.	Phorbol Esters	171-184	CD4 antigen	Mus musculus	43-46
20881191-6	2010	Accordingly, CD4(+) T cells treated with the combination of all-trans-RA and tributyltin migrated into the small intestine upon adoptive transfer much more efficiently than did those treated with all-trans-RA alone.	tributyltin	77-88	CD4 antigen	Mus musculus	13-16
20869773-3	2010	Here we show that, although purified naive cells are highly susceptible to Treg generation, total CD4(+) T-cell populations from different mouse strains display significantly different sensitivities to TGF-beta/ATRA-induced Treg conversion.	Tretinoin	211-215	CD4 antigen	Mus musculus	98-101
20869773-3	2010	Here we show that, although purified naive cells are highly susceptible to Treg generation, total CD4(+) T-cell populations from different mouse strains display significantly different sensitivities to TGF-beta/ATRA-induced Treg conversion.	treg	224-228	CD4 antigen	Mus musculus	98-101
21328972-12	2010	(2) New Compound Codonopsis Pilosula (NCCP), Xiang Qi Polysaccharide (XQP) and NCCP + XQP could significantly increase the number of peripheral blood CD3+, CD4+ and spleen CD4+, but had no significant influence on the number of spleen CD8+.	Polysaccharides	54-68	CD4 antigen	Mus musculus	156-159
21328972-12	2010	(2) New Compound Codonopsis Pilosula (NCCP), Xiang Qi Polysaccharide (XQP) and NCCP + XQP could significantly increase the number of peripheral blood CD3+, CD4+ and spleen CD4+, but had no significant influence on the number of spleen CD8+.	Polysaccharides	54-68	CD4 antigen	Mus musculus	172-175
20798218-11	2010	DFO consumption was associated with decreased CD8(+) cell frequency and diminished CD69 expression on CD4(+) and CD8(+) T-cell populations.	dfo	0-3	CD4 antigen	Mus musculus	102-105
20798218-12	2010	Mice consuming DFO also exhibited higher FoxP3(+) CD25(+) CD4(+) T regulatory cell frequency, FoxP3 expression, and altered L-selectin expression during infection.	dfo	15-18	CD4 antigen	Mus musculus	58-61
21042564-12	2010	Treatment with pBTLA led to a decreased infiltration of CD4(+) T cells into infected corneas, and diminished Th1 responses in murine corneas, draining lymph nodes, and splenocytes.	pbtla	15-20	CD4 antigen	Mus musculus	56-59
20949105-0	2010	The zwitterionic cell wall teichoic acid of Staphylococcus aureus provokes skin abscesses in mice by a novel CD4+ T-cell-dependent mechanism.	Teichoic Acids	27-40	CD4 antigen	Mus musculus	109-112
20949105-1	2010	Zwitterionic polysaccharide (ZPS) components of the bacterial cell envelope have been shown to exert a major histocompatibility complex (MHC) II-dependent activation of CD4+ T cells, which in turn can modulate the outcome and progression of infections in animal models.	zwitterionic polysaccharide	0-27	CD4 antigen	Mus musculus	169-172
20949105-1	2010	Zwitterionic polysaccharide (ZPS) components of the bacterial cell envelope have been shown to exert a major histocompatibility complex (MHC) II-dependent activation of CD4+ T cells, which in turn can modulate the outcome and progression of infections in animal models.	1,1-cyclobutane dicarboxylate	29-32	CD4 antigen	Mus musculus	169-172
20949105-10	2010	CD4-/- mice similarly injected with WTA failed to develop abscesses.	5'-O-[(S)-ethoxy(hydroxy)phosphoryl]adenosine	36-39	CD4 antigen	Mus musculus	0-3
20599940-4	2010	This occurs at the transition from a double positive (DP) to a single positive (SP) phenotype, resulting in higher numbers of CD4 and CD8 SP cells, and to a lesser extent at the transition from double negative (DN) to DP cells.	dp	54-56	CD4 antigen	Mus musculus	126-129
20599940-4	2010	This occurs at the transition from a double positive (DP) to a single positive (SP) phenotype, resulting in higher numbers of CD4 and CD8 SP cells, and to a lesser extent at the transition from double negative (DN) to DP cells.	sp	80-82	CD4 antigen	Mus musculus	126-129
19897529-3	2010	Zwitterionic polysaccharides (ZPSs) represent a novel class of immunomodulatory bacterial antigens that stimulate CD4+ T-cells in a major histocompatibility complex (MHC) class II-dependent manner.	zwitterionic polysaccharides	0-28	CD4 antigen	Mus musculus	114-117
19897529-3	2010	Zwitterionic polysaccharides (ZPSs) represent a novel class of immunomodulatory bacterial antigens that stimulate CD4+ T-cells in a major histocompatibility complex (MHC) class II-dependent manner.	zpss	30-34	CD4 antigen	Mus musculus	114-117
20679513-0	2010	Targeting ganglioside epitope 3G11 on the surface of CD4+ T cells suppresses EAE by altering the Treg/Th17 cell balance.	Gangliosides	10-21	CD4 antigen	Mus musculus	53-56
20679513-1	2010	Loss of expression of the 3G11 epitope, present on disialoceramide that is predominantly found on CD4(+) T cells, has been associated with a regulatory T cell (Treg) phenotype and tolerance induction in experimental autoimmune encephalomyelitis (EAE).	disialoceramide	51-66	CD4 antigen	Mus musculus	98-101
20728595-8	2010	Furthermore, IL-4 production by CD4+ T cells from the lymph nodes of DNFB-treated NC/Nga mice was significantly inhibited by TSA, although levels of IFN-gamma were not.	Dinitrofluorobenzene	69-73	CD4 antigen	Mus musculus	32-35
20728595-8	2010	Furthermore, IL-4 production by CD4+ T cells from the lymph nodes of DNFB-treated NC/Nga mice was significantly inhibited by TSA, although levels of IFN-gamma were not.	trichostatin A	125-128	CD4 antigen	Mus musculus	32-35
20574434-0	2010	Gene regulation by 1,25-dihydroxyvitamin D3 in CD4+CD25+ cells is enabled by IL-2.	Calcitriol	19-43	CD4 antigen	Mus musculus	47-50
20574434-2	2010	Topically applied 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) enhances the immunoregulatory ability of CD4+CD25+ T cells residing in the skin-draining lymph nodes (SDLNs) of mice.	1,25-dihydroxyvitamin D	18-41	CD4 antigen	Mus musculus	104-107
20574434-4	2010	CD4+CD25+ cells isolated from the SDLNs of BALB/c mice, 24 and 96  hours after topical treatment with 1,25(OH)(2)D(3), consistently expressed increased IL-2 mRNA levels and also secreted enhanced quantities of IL-2 after ex vivo stimulation with phorbol 12-myristate 13-acetate and ionomycin.	Tetradecanoylphorbol Acetate	246-277	CD4 antigen	Mus musculus	0-3
20574434-4	2010	CD4+CD25+ cells isolated from the SDLNs of BALB/c mice, 24 and 96  hours after topical treatment with 1,25(OH)(2)D(3), consistently expressed increased IL-2 mRNA levels and also secreted enhanced quantities of IL-2 after ex vivo stimulation with phorbol 12-myristate 13-acetate and ionomycin.	Ionomycin	282-291	CD4 antigen	Mus musculus	0-3
20801101-0	2010	Deacetylase inhibitor trichostatin A down-regulates Foxp3 expression and reduces CD4+CD25+ regulatory T cells.	trichostatin A	22-36	CD4 antigen	Mus musculus	81-84
20801101-3	2010	Lysine deacetylase inhibitor trichostatin A (TSA) is reported to up-regulate Foxp3 expression and increase the generation of CD4+CD25+ Treg cells in vivo.	trichostatin A	29-43	CD4 antigen	Mus musculus	125-128
20801101-3	2010	Lysine deacetylase inhibitor trichostatin A (TSA) is reported to up-regulate Foxp3 expression and increase the generation of CD4+CD25+ Treg cells in vivo.	trichostatin A	45-48	CD4 antigen	Mus musculus	125-128
20801101-6	2010	Furthermore, administration of TSA significantly impaired the expression of Foxp3 and reduced the number of CD4+CD25+Foxp3+ Treg cells in C57BL/6J mice.	trichostatin A	31-34	CD4 antigen	Mus musculus	108-111
20702612-8	2010	Docetaxel-pretreated MDSCs cocultured with OT-II splenocytes in the presence of OVA(323-339) showed OT-II-specific CD4 activation and expansion in vitro.	Docetaxel	0-9	CD4 antigen	Mus musculus	115-118
20634434-1	2010	The murine model of cyclosporine A (CsA)-induced syngeneic graft-versus-host disease (SGVHD) is a bone marrow (BM) transplantation model that develops chronic colon inflammation identical to other murine models of CD4(+) T cell-mediated colitis.	Cyclosporine	20-34	CD4 antigen	Mus musculus	214-217
20634434-1	2010	The murine model of cyclosporine A (CsA)-induced syngeneic graft-versus-host disease (SGVHD) is a bone marrow (BM) transplantation model that develops chronic colon inflammation identical to other murine models of CD4(+) T cell-mediated colitis.	Cyclosporine	36-39	CD4 antigen	Mus musculus	214-217
20490489-14	2010	A synergistic effect of ES on the infiltration of CD4 (P &lt; 0.001) and CD49b cells (P &lt; 0.01) was also observed over the effect of IL-2.	Einsteinium	24-26	CD4 antigen	Mus musculus	50-53
20490489-15	2010	Here, we show that ES led to an increase in CD4 T helper cells as well as cytotoxic lymphocytes, such as NK cells and CD8 cells, within tumors of IL-2 treated mice.	Einsteinium	19-21	CD4 antigen	Mus musculus	44-47
20580249-5	2010	CR had no mitogenic effects on un-stimulated CD4(+) T cells, however, it increased the CD4(+) T cell population.	Chromium	0-2	CD4 antigen	Mus musculus	87-90
20705624-8	2010	Furthermore, flow cytometry analysis showed a significant increase in the number of CD4 and CD8 T-cells (P = .001) in the spleens of FS-grafted mice.	phenylalanylserine	133-135	CD4 antigen	Mus musculus	84-87
20808846-9	2010	Sulfasalazine accelerated the onset of the CD4(+) T cell-dependent alveolar macrophage phagocytic response in PcP-IRIS mice, resulting in enhanced fungal clearance.	Sulfasalazine	0-13	CD4 antigen	Mus musculus	43-46
20621800-1	2010	3G11, a sialylated carbohydrate epitope on the disialoganglioside molecule, is expressed predominantly on the surface of mouse CD4(+) T cells.	sialogangliosides	47-65	CD4 antigen	Mus musculus	127-130
20698600-0	2010	Novel streptavidin-functionalized silicon nanowire arrays for CD4+ T lymphocyte separation.	Silicon	34-41	CD4 antigen	Mus musculus	62-65
20698600-3	2010	Our system employed the specific high-affinity binding features of streptavidin (STR)-functionalized SiNW with biotin-labeled CD4(+) T lymphocytes.	Biotin	111-117	CD4 antigen	Mus musculus	126-129
20371613-4	2010	Our results showed that the selective A(2A) receptor agonist CGS21680 (EC(50)=15.2-32.6 nM) rescued mouse CD4(+) hybridomas and human Jurkat cells from AICD and that this effect was reversed by the selective A(2A) receptor antagonist ZM241385 (EC(50)=2.3 nM).	2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine	61-69	CD4 antigen	Mus musculus	106-109
20423734-0	2010	Selective depletion of splenic CD4 dendritic cells in mice treated with immunomodulatory quinoline-3-carboxamide ABR-215757.	quinoline-3-carboxamide	89-112	CD4 antigen	Mus musculus	31-34
20624644-4	2010	RESULTS: 2,4-Dinitrofluorobenzene immunization induced a population of CD4(+)CD25(+) Treg cells that controlled CD8(+) T-cell effector responses in a hapten-specific manner in vivo.	Dinitrofluorobenzene	9-33	CD4 antigen	Mus musculus	71-74
20534878-4	2010	To determine the mechanisms for this effect of EGCG, we stimulated purified mouse T cells with anti-CD3/CD28 in the presence of EGCG (2.5-15 micromol/L) and found that EGCG dose-dependently inhibited cell division and cell cycle progression and this effect of EGCG was more pronounced in CD4(+) than in CD8(+) T cells.	epigallocatechin gallate	47-51	CD4 antigen	Mus musculus	288-291
20534878-10	2010	CD4(+) cells are more responsive to EGCG than CD8(+) cells.	epigallocatechin gallate	36-40	CD4 antigen	Mus musculus	0-3
20534878-11	2010	Future studies should determine the effect of EGCG on CD4(+) cell subsets to assess its application in T cell-mediated autoimmune diseases.	epigallocatechin gallate	46-50	CD4 antigen	Mus musculus	54-57
20644342-3	2010	A lectin from Amaranthus leucocarpus seeds (ALL) is specific for glycoprotein structures containing galactose-N-acetylgalactosamine and is able to bind to human and murine CD4(+) T cells, however, its effect on activation remains unclear.	galactose-n-acetylgalactosamine	100-131	CD4 antigen	Mus musculus	172-175
20361943-5	2010	Obaculactone significantly enhanced the percentage of CD4(+)CD25(+)Foxp3(+) Treg cells in the CD4(+) splenocytes without any effect on their inhibitory function.	limonin	0-12	CD4 antigen	Mus musculus	54-57
20361943-5	2010	Obaculactone significantly enhanced the percentage of CD4(+)CD25(+)Foxp3(+) Treg cells in the CD4(+) splenocytes without any effect on their inhibitory function.	limonin	0-12	CD4 antigen	Mus musculus	94-97
20368408-0	2010	Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.	Sitagliptin Phosphate	0-11	CD4 antigen	Mus musculus	93-96
20368408-0	2010	Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.	Sitagliptin Phosphate	13-19	CD4 antigen	Mus musculus	93-96
20368408-1	2010	OBJECTIVE: Treatment of NOD mice with the dipeptidyl peptidase-IV (DPP-IV) inhibitor sitagliptin preserved islet transplants through a pathway involving modulation of splenic CD4(+) T-cell migration.	Sitagliptin Phosphate	85-96	CD4 antigen	Mus musculus	175-178
20368408-2	2010	In the current study, effects of sitagliptin on migration of additional subsets of CD4(+) T-cells were examined and underlying molecular mechanisms were further defined.	Sitagliptin Phosphate	33-44	CD4 antigen	Mus musculus	83-86
20368408-3	2010	RESEARCH DESIGN AND METHODS: Effects of sitagliptin on migration of NOD mouse splenic, thymic, and lymph node CD4(+) T-cells were determined.	Sitagliptin Phosphate	40-51	CD4 antigen	Mus musculus	110-113
20368408-4	2010	Signaling modules involved in DPP-IV-, Sitagliptin- and incretin-mediated modulation of CD4(+) T-cell migration were studied using Western blot and Rac1 and nuclear factor-kappaB (NF-kappaB) activity assays.	Sitagliptin Phosphate	39-50	CD4 antigen	Mus musculus	88-91
20368408-5	2010	RESULTS: Migration of splenic and lymph node CD4(+) T-cells of diabetic NOD mice was reduced by sitagliptin treatment.	Sitagliptin Phosphate	96-107	CD4 antigen	Mus musculus	45-48
20368408-7	2010	Sitagliptin abolished sDPP-IV effects on splenic CD4(+) T-cell migration, whereas incretins decreased migration of lymph node, but not splenic, CD4(+) T-cells.	Sitagliptin Phosphate	0-11	CD4 antigen	Mus musculus	49-52
20368408-8	2010	Splenic CD4(+) T-cells demonstrating increased in vitro migration in response to sDPP-IV and lymph node CD4(+) T-cells that were nonresponsive to incretins selectively infiltrated islets of NOD mice, after injection.	(2,5-dioxopyrrolidin-1-yl) diphenyl phosphate	81-85	CD4 antigen	Mus musculus	8-11
20368408-9	2010	Sitagliptin decreases migration of splenic CD4(+) T-cells through a pathway involving Rac1/vasodilator-stimulated phosphoprotein, whereas its inhibitory effects on the migration of lymph node CD4(+) T-cells involve incretin-activation of the NF-kappaB pathway.	Sitagliptin Phosphate	0-11	CD4 antigen	Mus musculus	43-46
20368408-9	2010	Sitagliptin decreases migration of splenic CD4(+) T-cells through a pathway involving Rac1/vasodilator-stimulated phosphoprotein, whereas its inhibitory effects on the migration of lymph node CD4(+) T-cells involve incretin-activation of the NF-kappaB pathway.	Sitagliptin Phosphate	0-11	CD4 antigen	Mus musculus	192-195
20444936-13	2010	In conclusion, NVP-DPP728 treatment can reverse new-onset diabetes in NOD mice by reducing insulitis, increasing CD4(+)CD25(+)FoxP3(+) regulatory T cells, and stimulating beta-cell replication.	dpp728	19-25	CD4 antigen	Mus musculus	113-116
20452188-5	2010	Posaconazole was more effective than benznidazole in controlling spleen enlargement and unspecific splenocyte proliferation in the early acute phase, but allowed higher levels of activation of CD4(+) and CD8(+) T-cells in the late acute phase when the adaptive immune response takes control of the infection.	posaconazole	0-12	CD4 antigen	Mus musculus	193-196
20418448-5	2010	Specifically, bortezomib-treated mice showed significantly decreased numbers of CD4(+) and CD8(+) T cells in the challenged skin and draining lymph nodes.	Bortezomib	14-24	CD4 antigen	Mus musculus	80-83
20418448-6	2010	Cytoplasmic IFN-gamma production by CD4(+) and CD8(+) T cells in the draining lymph nodes was decreased substantially by bortezomib treatment.	Bortezomib	121-131	CD4 antigen	Mus musculus	36-39
20211255-9	2010	Finally, topical 1,25(OH)2D3 also enhanced the number and suppressive activity of CD4+CD25+ regulatory T cells in the lymphatic tissue draining skin.	Calcitriol	17-28	CD4 antigen	Mus musculus	82-85
20806494-12	2010	In vivo, immunization of Sepharose 4B coupling rSj22.6/26GST increased the number of CD4+CD25+ T cells.	Sepharose	25-37	CD4 antigen	Mus musculus	85-88
20806494-12	2010	In vivo, immunization of Sepharose 4B coupling rSj22.6/26GST increased the number of CD4+CD25+ T cells.	rsj22	47-52	CD4 antigen	Mus musculus	85-88
20806494-13	2010	CD4+CD25+ T cells separated from Sepharose 4B coupling rSj22.6/26GST immunized mice had stronger inhibitory ability (cpm 1 420 +/- 335), compared with that of mice immunized with soluble antigen (cpm 3 558 +/- 147).	Sepharose	33-42	CD4 antigen	Mus musculus	0-3
20806494-14	2010	CONCLUSION: In contrast to the Freund"s adjuvant emulsified antigen, immunization with Sepharose 4B coupling rSj22.6/26GST increases the number of CD4+CD25+ T cells, which showed stronger inhibition on the CD4+ CD25- T cell proliferation, and the mechanism of which may be involved in DCs maturation.	Sepharose	87-99	CD4 antigen	Mus musculus	147-150
20806494-14	2010	CONCLUSION: In contrast to the Freund"s adjuvant emulsified antigen, immunization with Sepharose 4B coupling rSj22.6/26GST increases the number of CD4+CD25+ T cells, which showed stronger inhibition on the CD4+ CD25- T cell proliferation, and the mechanism of which may be involved in DCs maturation.	Sepharose	87-99	CD4 antigen	Mus musculus	206-209
20455559-7	2010	Furthermore, the proportion of CD4(+) CD103(+) T cells in Peyer"s patches of mice fed a carotenoid-rich diet was significantly lower than in control mice.	Carotenoids	88-98	CD4 antigen	Mus musculus	31-34
20574522-4	2010	The C-terminal end of the resulting CD4-CD8 chimeric peptide was coupled to a tumor carbohydrate B-cell epitope, based on a regioselectively addressable functionalized templates (RAFT), made of four alpha-GalNAc molecules.	Acetylgalactosamine	199-211	CD4 antigen	Mus musculus	36-39
20488788-4	2010	PUVA induced the Th2 pathway and IL-10-producing CD4+CD25+Foxp3+Tregs with disease-suppressive activity that was abolished by anti-CTLA4 mAb treatment.	puva	0-4	CD4 antigen	Mus musculus	49-52
20438120-4	2010	Immunoprecipitation and IMAC purification of tyrosine-phosphorylated peptides, combined with a stable-isotope iTRAQ labeling, enabled us to identify and quantify over 77 phosphorylation events in 54 different proteins downstream of TCR stimulation of primary CD4(+) T cells.	Tyrosine	45-53	CD4 antigen	Mus musculus	259-262
20059575-0	2010	1,25-dihydroxyvitamin D3 enhances the ability of transferred CD4+ CD25+ cells to modulate T helper type 2-driven asthmatic responses.	Calcitriol	0-24	CD4 antigen	Mus musculus	61-64
20375261-0	2010	Dietary selenium modulates activation and differentiation of CD4+ T cells in mice through a mechanism involving cellular free thiols.	Selenium	8-16	CD4 antigen	Mus musculus	61-64
20375261-0	2010	Dietary selenium modulates activation and differentiation of CD4+ T cells in mice through a mechanism involving cellular free thiols.	Sulfhydryl Compounds	126-132	CD4 antigen	Mus musculus	61-64
20375261-8	2010	Addition of exogenous free thiols eliminated differences in CD4(+) T cell activation among the dietary groups.	Sulfhydryl Compounds	27-33	CD4 antigen	Mus musculus	60-63
20375261-9	2010	Overall, these data suggest that dietary Se levels modulate free thiol levels and specific signaling events during CD4(+) T cell activation, which influence their proliferation and differentiation.	Selenium	41-43	CD4 antigen	Mus musculus	115-118
20631884-5	2010	Multiple clusters, indicating proliferation, were observed in ginsan-treated spleen cells and, carboxyfluorescein succinimidyl ester and surface marker staining assay revealed that ginsan promoted proliferation from CD19(+) B cells rather than CD4(+) or CD8(+) T cells.	ginsan	181-187	CD4 antigen	Mus musculus	244-247
20445103-4	2010	We induced TGF-beta-dependent CD4(+) latency-associated peptide (LAP)-positive Tregs by oral administration of anti-CD3 antibody plus beta-glucosylceramide.	beta-glucosylceramide	134-155	CD4 antigen	Mus musculus	30-33
20385879-6	2010	This feature was apparently due to a strong and selective downmodulation of MHC class II expression on the tumor cells surface, a phenomenon that could be reverted by the demethylating agent 5-aza-2"-deoxycytidine, thus leading to restoration of lymphoblastoid cell line recognition and killing by CD4(+) T cells, as well as to a more pronounced therapeutic activity.	Decitabine	191-213	CD4 antigen	Mus musculus	298-301
20156533-7	2010	Both CD4(+) and CD8(+) subsets of T cells were activated and the TFA-specific responses were detected not only in the spleen but also in the liver of mice immunized with mouse serum albumin adducts of TFA (TFA-MSA) plus the combined CD40/TLR agonist.	Trifluoroacetic Acid	65-68	CD4 antigen	Mus musculus	5-8
20156533-7	2010	Both CD4(+) and CD8(+) subsets of T cells were activated and the TFA-specific responses were detected not only in the spleen but also in the liver of mice immunized with mouse serum albumin adducts of TFA (TFA-MSA) plus the combined CD40/TLR agonist.	Trifluoroacetic Acid	201-204	CD4 antigen	Mus musculus	5-8
20156533-7	2010	Both CD4(+) and CD8(+) subsets of T cells were activated and the TFA-specific responses were detected not only in the spleen but also in the liver of mice immunized with mouse serum albumin adducts of TFA (TFA-MSA) plus the combined CD40/TLR agonist.	Trifluoroacetic Acid	201-204	CD4 antigen	Mus musculus	5-8
20056147-0	2010	Silymarin suppress CD4+ T cell activation and proliferation: effects on NF-kappaB activity and IL-2 production.	Silymarin	0-9	CD4 antigen	Mus musculus	19-22
20056147-2	2010	In this study, the in vitro immunomodulatory activity of silymarin was investigated using CD4+ splenocytes from C57/Bl6 mice.	Silymarin	57-66	CD4 antigen	Mus musculus	90-93
20056147-3	2010	Proliferation assay revealed that silymarin, at 50 microM concentration, significantly inhibited CD4+ cells proliferation.	Silymarin	34-43	CD4 antigen	Mus musculus	97-100
20056147-6	2010	Moreover, silymarin inhibited p65/NF-kappaB phosphorylation in CD4+ T cell.	Silymarin	10-19	CD4 antigen	Mus musculus	63-66
20403575-7	2010	We are the first group using CB-SC to correct functional defects of CD4(+)CD62L(+) Tregs, leading to a reversal of overt diabetes in an autoimmune-caused diabetic NOD mouse model.	cb-sc	29-34	CD4 antigen	Mus musculus	68-71
20403575-8	2010	Notably, treatment with CB-SC-modulated CD4(+)CD62L(+) Tregs (mCD4CD62L Tregs) simultaneously can overcome the autoimmunity via systemic and local immune modulations and the shortage of insulin-producing cells via stimulating the beta-cell regeneration.	cb-sc	24-29	CD4 antigen	Mus musculus	62-66
20497692-9	2010	A total of 1 x 10(5) carboxyfluorescein succinimidyl ester (CFSE)-labeled naive CD4(+)CD25(-) T cells/well from C57BL/6 mice were cocultured with DBA/2 or C3H maturation of dendritic cells (mDCs) (0.25 x 10(5)/well) in 96-well round-bottom plates for 6 days.	carboxyfluorescein succinimidyl ester	21-58	CD4 antigen	Mus musculus	80-83
20131272-7	2010	Carvacrol administration also increased the number of CD4+CD25+FoxP3+ T cells, systemically in the spleen and locally in the joint, and almost completely suppressed proteoglycan-induced experimental arthritis.	carvacrol	0-9	CD4 antigen	Mus musculus	54-57
20084083-4	2010	Further study showed that high doses of alpha-GC directly enhance the Th17 and Th1 response by activation of CD4(+)CD44(+) memory T cells through phosphorylation of STAT3 and activation of NF-kappaB.	alpha-galactosylceramide	40-48	CD4 antigen	Mus musculus	109-112
20102411-1	2010	Histone deacetylase inhibitor n-butyrate induced proliferative unresponsiveness in antigen-stimulated murine CD4(+) T cells.	Butyrates	30-40	CD4 antigen	Mus musculus	109-112
20102411-9	2010	The n-butyrate-induced p21(Cip1)-mediated inhibition of JNK and c-jun represents a novel potential mechanism by which proliferative unresponsiveness was maintained in CD4(+) T cells.	Butyrates	4-14	CD4 antigen	Mus musculus	167-170
20060322-6	2010	RESULTS: Compared with recipients treated with control Ab plus PBS, allografts treated with anti-CCR5 Ab and cyclosporine showed significantly prolonged survival (p &lt; 0.001), markedly decreased CD4+ and CD8+ T cells (p &lt; 0.005), and increased frequency of CD4+CD25+Foxp3+ regulatory cells (23.98% +/- 1.55% vs 6.30% +/- 0.57%, p &lt; 0.005).	Cyclosporine	109-121	CD4 antigen	Mus musculus	197-200
20060322-6	2010	RESULTS: Compared with recipients treated with control Ab plus PBS, allografts treated with anti-CCR5 Ab and cyclosporine showed significantly prolonged survival (p &lt; 0.001), markedly decreased CD4+ and CD8+ T cells (p &lt; 0.005), and increased frequency of CD4+CD25+Foxp3+ regulatory cells (23.98% +/- 1.55% vs 6.30% +/- 0.57%, p &lt; 0.005).	Cyclosporine	109-121	CD4 antigen	Mus musculus	262-265
20181888-5	2010	We found that melatonin protects human and murine CD4(+) T cells from apoptosis by inhibiting CD95 ligand mRNA and protein upregulation in response to TCR/CD3 stimulation.	Melatonin	14-23	CD4 antigen	Mus musculus	50-53
20208003-5	2010	In addition, our data show that purified CD4 T cells isolated from gammaHV68-latently infected mice have the capacity to inhibit gammaHV68 reactivation from latency.	gammahv68	67-76	CD4 antigen	Mus musculus	41-44
20208003-5	2010	In addition, our data show that purified CD4 T cells isolated from gammaHV68-latently infected mice have the capacity to inhibit gammaHV68 reactivation from latency.	gammahv68	129-138	CD4 antigen	Mus musculus	41-44
20138670-9	2010	The measurement of splenic CD4(+)CD25(+)Foxp3(+) T lymphocytes indicated that Tehranolide significantly (p&lt;0.05) decreased the number of these lymphocytes.	tehranolide	78-89	CD4 antigen	Mus musculus	27-30
20149931-1	2010	Rapamycin is an oral immunosuppressant drug previously reported to efficiently induce naturally occurring CD4(+)CD25(+)FoxP3(+) regulatory T ((n)T(reg)) cells re-establishing long-term immune self-tolerance in autoimmune diseases.	Sirolimus	0-9	CD4 antigen	Mus musculus	106-109
20332428-1	2010	To investigate the temporal regulation of the commitment of immature thymocytes to either the CD4(+) or the CD8(+) lineage in the thymus, we developed a transgenic mouse that expressed a tetracycline-inducible gene encoding the tyrosine kinase zeta chain-associated protein kinase of 70 kD (Zap70), which restored development in Zap70(-/-) thymocytes arrested at the preselection, CD4(+)CD8(+) double-positive (DP) stage.	Tetracycline	187-199	CD4 antigen	Mus musculus	94-97
20332428-1	2010	To investigate the temporal regulation of the commitment of immature thymocytes to either the CD4(+) or the CD8(+) lineage in the thymus, we developed a transgenic mouse that expressed a tetracycline-inducible gene encoding the tyrosine kinase zeta chain-associated protein kinase of 70 kD (Zap70), which restored development in Zap70(-/-) thymocytes arrested at the preselection, CD4(+)CD8(+) double-positive (DP) stage.	Tetracycline	187-199	CD4 antigen	Mus musculus	381-384
20142362-6	2010	The CTA1R7K-OVA-DD-induced tolerance was strong, long-lasting, and impaired the ability of adoptively transferred naive peptide-specific CD4(+) T cells to respond to Ag-challenge, irrespective if this was given i.p or i.n.	ova-dd	12-18	CD4 antigen	Mus musculus	137-140
20142362-10	2010	Thus, for the first time, we can provide unequivocal proof that ADP-ribosylation can control the outcome of mucosal Ag exposure from tolerance to an enhanced effector CD4(+) T cell response.	Adenosine Diphosphate	64-67	CD4 antigen	Mus musculus	167-170
20035147-0	2010	Naringenin chalcone suppresses allergic asthma by inhibiting the type-2 function of CD4 T cells.	naringenin chalcone	0-19	CD4 antigen	Mus musculus	84-87
20035147-7	2010	RESULTS: Eosinophilic airway inflammation, airway hyperreactivity and Th2 cytokine production from CD4 T cells were significantly suppressed in mice that were treated with naringenin chalcone.	naringenin chalcone	172-191	CD4 antigen	Mus musculus	99-102
20035147-9	2010	CONCLUSIONS: The results of this study suggest that naringenin chalcone suppresses asthmatic symptoms by inhibiting Th2 cytokine production from CD4 T cells.	naringenin chalcone	52-71	CD4 antigen	Mus musculus	145-148
19448155-9	2010	Flt3-L significantly decreased CD62-L, but increased inducible costimulatory molecule and Foxp3 mRNA expression in the CD4(+)CD25(+) T cells isolated from lungs of Flt3-L-treated, CRA-sensitized mice compared to CRA-sensitized mice without Flt3-L treatment and PBS control group.	cra	180-183	CD4 antigen	Mus musculus	119-122
20140010-3	2010	In this study, by analyzing the immune patterns of lymphocytes, we found that the percentage and absolute number of CD4(+)CD25(+)Foxp3(+) regulatory T cells are markedly decreased in naive mice following treatment with LTBI.	ltbi	219-223	CD4 antigen	Mus musculus	116-119
20102290-0	2010	The role of CD4+ T cells in the induction of contact hypersensitivity to mercury in a murine model.	Mercury	73-80	CD4 antigen	Mus musculus	12-15
20102290-2	2010	OBJECTIVE: The aim of the present study was to assess the role of CD4+ T cells in mercury-induced CH in mice.	Mercury	82-89	CD4 antigen	Mus musculus	66-69
20102290-5	2010	The next experiments were to transfer nonsensitized CD4+ T cells to group A of the recipients, whereas mercury-sensitized CD4+ T cells were transferred to groups B and C. Groups A and B were ear-challenged with mercury, whereas group C was ear-challenged with chromium.	Mercury	103-110	CD4 antigen	Mus musculus	122-125
20102290-8	2010	Furthermore, mercury-sensitized CD4+ T cells could transfer the induction of CH only in the recipients that were challenged with mercury, but not those that were challenged with chromium.	Mercury	13-20	CD4 antigen	Mus musculus	32-35
20102290-8	2010	Furthermore, mercury-sensitized CD4+ T cells could transfer the induction of CH only in the recipients that were challenged with mercury, but not those that were challenged with chromium.	Mercury	129-136	CD4 antigen	Mus musculus	32-35
20102290-9	2010	CONCLUSION: The results of the present study suggest that mercury-induced CH may be mediated by mercury-specific CD4+ T cells.	Mercury	58-65	CD4 antigen	Mus musculus	113-116
20102290-9	2010	CONCLUSION: The results of the present study suggest that mercury-induced CH may be mediated by mercury-specific CD4+ T cells.	Mercury	96-103	CD4 antigen	Mus musculus	113-116
19940103-5	2010	After resveratrol treatment, the percentage of CD4(+) T cells in mesenteric lymph nodes (MLN) of colitis mice was restored to normal levels, and there was a decrease in these cells in the colon lamina propria (LP).	Resveratrol	6-17	CD4 antigen	Mus musculus	47-50
20117839-3	2010	Agilent Mouse Whole Genome microarrays were hybridized with fluorescently labeled total RNA isolated from resting CD4 T cells cultured +/-10(-7)M VIP for 5h or PMA/ionomycin activated CD4 T cells cultured +/-10(-7)M VIP for 5h.	Tetradecanoylphorbol Acetate	160-163	CD4 antigen	Mus musculus	184-187
20117839-3	2010	Agilent Mouse Whole Genome microarrays were hybridized with fluorescently labeled total RNA isolated from resting CD4 T cells cultured +/-10(-7)M VIP for 5h or PMA/ionomycin activated CD4 T cells cultured +/-10(-7)M VIP for 5h.	Ionomycin	164-173	CD4 antigen	Mus musculus	184-187
20117839-6	2010	In the PMA/ionomycin activated CD4 T cells, 326 gene expression levels were changed by VIP, ranging from 2.94 to -1.66-fold.	Ionomycin	11-20	CD4 antigen	Mus musculus	31-34
20083650-4	2010	Of several founder lines, Foxp3.LuciDTR-4 mice displayed approximately 95% Treg depletion following injection of DT, resulting in activation of conventional CD4(+) T cells, probably due to lack of control by Tregs.	Thymidine	36-38	CD4 antigen	Mus musculus	157-160
20145550-5	2010	Treatment of tumor-bearing mice with SU5416 blocked the development of endothelial cells that are suppressive to CD4 and CD8 T-cell functions.	Semaxinib	37-43	CD4 antigen	Mus musculus	113-116
20081544-13	2010	Flow cytometry analysis revealed that hemin markedly expanded the CD4 + CD25 + Foxp3+ Treg population.	Hemin	38-43	CD4 antigen	Mus musculus	66-69
19755159-4	2010	This study was conducted to investigate the inhibiting capability of RAPA or FK-506 against transferred alloreactive CD4(+) Tm cells in a mouse cardiac transplant model.	Tacrolimus	77-83	CD4 antigen	Mus musculus	117-120
19965687-0	2010	DNA vaccination with all-trans retinoic acid treatment induces long-term survival and elicits specific immune responses requiring CD4+ and CD8+ T-cell activation in an acute promyelocytic leukemia mouse model.	Tretinoin	31-44	CD4 antigen	Mus musculus	130-133
19698701-5	2010	The therapeutic effect of cirsilineol was attributable to a novel regulatory mechanism with selective inhibiting IFN-gamma signaling in colonic lamina propria CD4(+) T cells, which was mediated through down-regulating STAT1 activation and T-bet expression.	cirsilineol	26-37	CD4 antigen	Mus musculus	159-162
19818801-10	2010	Prenatal Cd exposure increased the number of CD4(+) cells and a subpopulation of double-negative cells (DN; CD4(-)CD8(-)), DN4 (CD44(-)CD25(-)).	Cadmium	9-11	CD4 antigen	Mus musculus	45-48
19818801-10	2010	Prenatal Cd exposure increased the number of CD4(+) cells and a subpopulation of double-negative cells (DN; CD4(-)CD8(-)), DN4 (CD44(-)CD25(-)).	Cadmium	9-11	CD4 antigen	Mus musculus	108-111
21249305-0	2010	Cyclosporin A-treated dendritic cells may affect the outcome of organ transplantation by decreasing CD4+CD25+ regulatory T cell proliferation.	Cyclosporine	0-13	CD4 antigen	Mus musculus	100-103
19854435-0	2010	The ACE inhibitors enalapril and captopril modulate cytokine responses in Balb/c and C57Bl/6 normal mice and increase CD4(+)CD103(+)CD25(negative) splenic T cell numbers.	Enalapril	19-28	CD4 antigen	Mus musculus	118-121
19854435-0	2010	The ACE inhibitors enalapril and captopril modulate cytokine responses in Balb/c and C57Bl/6 normal mice and increase CD4(+)CD103(+)CD25(negative) splenic T cell numbers.	Captopril	33-42	CD4 antigen	Mus musculus	118-121
19854435-8	2010	Furthermore, CD4(+)CD103(+) presented increased IL-10 production after enalapril treatment.	Enalapril	71-80	CD4 antigen	Mus musculus	13-16
19854435-10	2010	Besides, enhanced IL-2 and IL-10 levels correlates with increased CD4(+)CD103(+)CD25(negative) T cells numbers in spleens from enalapril-treated mice.	Enalapril	127-136	CD4 antigen	Mus musculus	66-69
20042183-6	2010	DAB(389)IL-2 also significantly reduced the number of CD4(+), CD8(+), CD25(+), TCRgammadelta(+) phenotype and CD11b(+) macrophages/microglia within spinal cord lesions.	diazobenzenesulfonic acid	0-3	CD4 antigen	Mus musculus	54-57
20042183-7	2010	These data strongly suggest that DAB(389)IL-2 specifically targeted myelin protein-activated CD4(+) T cells and strengthens the argument for the use of DAB(389)IL-2 in treatment strategies for MS.	diazobenzenesulfonic acid	33-36	CD4 antigen	Mus musculus	93-96
20832059-6	2010	We show that vitamin A-depleted animals have increased polymorphonuclear neutrophils, lymphoid DCs, and memory CD8(+) T cells and decreased CD4(+) T lymphocytes.	Vitamin A	13-22	CD4 antigen	Mus musculus	140-143
19889936-5	2010	TMZ chemotherapy increased tumor antigen cross-priming from tumor cells, leading to cross-priming of tumor antigen-specific CD4(+) T cells and CD8(+) T cells.	Temozolomide	0-3	CD4 antigen	Mus musculus	124-127
20453397-0	2010	Selenium upregulates CD4(+)CD25(+) regulatory T cells in iodine-induced autoimmune thyroiditis model of NOD.H-2(h4) mice.	Selenium	0-8	CD4 antigen	Mus musculus	21-24
20453397-0	2010	Selenium upregulates CD4(+)CD25(+) regulatory T cells in iodine-induced autoimmune thyroiditis model of NOD.H-2(h4) mice.	Iodine	57-63	CD4 antigen	Mus musculus	21-24
20453397-3	2010	We investigated the effects of Se treatment on CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) in a iodine-induced autoimmune thyroiditis model.	Selenium	31-33	CD4 antigen	Mus musculus	47-50
20453397-11	2010	Se supplementation may restore normal levels of CD4(+)CD25(+) T cells by up-regulating the expression of Foxp3 mRNA in mice with AIT.	Selenium	0-2	CD4 antigen	Mus musculus	48-51
20484930-8	2010	The Rag-2(-/-) mice transfused with the CD4+ splenic cells from the Ni-Ti alloy sensitized GATA-3 Tg mice showed a significantly more pronounced ear swelling response than the control mice.	ni-ti alloy	68-79	CD4 antigen	Mus musculus	40-43
22084591-3	2010	Its suppressive effects are mostly mediated by dendritic cells (DCs) and involve tryptophan deprivation and/or production of kynurenines, which act on IDO-negative DCs as well as CD4(+) and CD8(+) T cells.	Kynurenine	125-136	CD4 antigen	Mus musculus	179-182
19696173-5	2010	Proliferation of CD4(+)CD25(-) T cells was measured using a modified MTT assay.	monooxyethylene trimethylolpropane tristearate	69-72	CD4 antigen	Mus musculus	17-20
19696173-11	2010	Transfer of CD4(+)CD25(+) Treg cells obtained from EAU mice was able to suppress EAU induction by IRBP(161-180) that was not observed after transfer of cells from mice that had received CFA alone, suggesting antigen specificity of the Treg response.	Water	51-54	CD4 antigen	Mus musculus	12-15
19696173-11	2010	Transfer of CD4(+)CD25(+) Treg cells obtained from EAU mice was able to suppress EAU induction by IRBP(161-180) that was not observed after transfer of cells from mice that had received CFA alone, suggesting antigen specificity of the Treg response.	3-chloro-4-fluoroaniline	186-189	CD4 antigen	Mus musculus	12-15
20625506-4	2010	We found that beta-glu6 promoted the recruitment and maturation of dendritic cells, enhanced the activation of CD8(+) and CD4(+) T cells and increased the number of specific CD8(+)/IFN-gamma(+) T cells in lymphoid and nonlymphoid tissues in mice immunized by pB144.	beta-glu6	14-23	CD4 antigen	Mus musculus	122-125
19591245-1	2010	L-glutathione capped highly fluorescent CdTe quantum dots (QDs) were prepared by an aqueous approach and used as fluorescent labels to link albumin bovine serum (BSA) and rat anti-mouse CD4, which was expressed on mouse T-lymphocyte and mouse spleen tissue.	Glutathione	0-13	CD4 antigen	Mus musculus	186-189
19591245-1	2010	L-glutathione capped highly fluorescent CdTe quantum dots (QDs) were prepared by an aqueous approach and used as fluorescent labels to link albumin bovine serum (BSA) and rat anti-mouse CD4, which was expressed on mouse T-lymphocyte and mouse spleen tissue.	cadmium telluride	40-44	CD4 antigen	Mus musculus	186-189
19591245-3	2010	Both CdTe-BSA and CdTe-CD4 conjugates showed an enhancement of fluorescence intensity over that of bare CdTe QDs.	cadmium telluride	18-22	CD4 antigen	Mus musculus	23-26
19591245-3	2010	Both CdTe-BSA and CdTe-CD4 conjugates showed an enhancement of fluorescence intensity over that of bare CdTe QDs.	cadmium telluride	18-22	CD4 antigen	Mus musculus	23-26
19591245-4	2010	The experimental result of gel electrophoresis confirmed the successful conjugation of CdTe-BSA and CdTe-CD4.	cadmium telluride	100-104	CD4 antigen	Mus musculus	105-108
19591245-5	2010	The fluorescent microscopic images of CdTe-CD4 labeled mouse T-lymphocyte cells and mouse spleen tissue were compared with that obtained from fluorescein isothiocyanate labeling.	cadmium telluride	38-42	CD4 antigen	Mus musculus	43-46
21188276-0	2010	Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration.	Ivabradine	0-10	CD4 antigen	Mus musculus	37-40
21188276-6	2010	The effect of ivabradine on CD4-positive lymphocyte migration was mediated through an early inhibition of chemokine-induced PI-3 kinase activity as determined by PI-3 kinase activity assays.	Ivabradine	14-24	CD4 antigen	Mus musculus	28-31
21188276-9	2010	CONCLUSION: Ivabradine inhibits chemokine-induced migration of CD4-positive lymphocytes.	Ivabradine	12-22	CD4 antigen	Mus musculus	63-66
19893030-7	2009	Cellular analyses indicated that chronic exposure to PCN profoundly increased the lung population of recruited macrophages, CD4(+) T cells, and neutrophils responsible for the secretion of these cytokines.	Pyocyanine	53-56	CD4 antigen	Mus musculus	124-127
19418018-0	2009	Resistance to activation-induced cell death and elevated FLIPL expression of CD4+ T cells in a polyI:C-induced primary biliary cirrhosis mouse model.	Poly I-C	95-102	CD4 antigen	Mus musculus	77-80
19418018-2	2009	We established a PBC animal model by injecting C57BL/6 mice with polyI:C to study activation-induced cell death (AICD) in CD4+ T lymphocytes and changes of apoptosis-associated molecules as a first step to understand the immune tolerance of PBC mice.	Poly I-C	65-72	CD4 antigen	Mus musculus	122-125
19051282-5	2009	In the spleen, all doses of PFOA decreased CD8(+) lymphocytes; CD4(+) lymphocytes were increased by 50 and 250 ppm of PFOA.	perfluorooctanoic acid	118-122	CD4 antigen	Mus musculus	63-66
19741155-3	2009	More severe HP was observed in CD4(+)CD25(+) T(reg) cell-depleted mice than in control mice in terms of histological alterations, inflammatory cell numbers in BALF, and the serum level of SR-specific IgG, which were restored by the adoptive transfer of CD4(+)CD25(+) T(reg) cells.	histidylproline	12-14	CD4 antigen	Mus musculus	31-34
19741155-3	2009	More severe HP was observed in CD4(+)CD25(+) T(reg) cell-depleted mice than in control mice in terms of histological alterations, inflammatory cell numbers in BALF, and the serum level of SR-specific IgG, which were restored by the adoptive transfer of CD4(+)CD25(+) T(reg) cells.	histidylproline	12-14	CD4 antigen	Mus musculus	253-256
19917689-6	2009	We compared responses from recipients that were transiently depleted of CD4(+) cells (that develop CR and express intragraft TGFbeta) with responses from mice that received anti-CD40L mAb therapy (that do not develop CR and do not express intragraft TGFbeta).	Chromium	99-101	CD4 antigen	Mus musculus	72-75
19917705-4	2009	In the mouse vascularized cardiac allograft model, transient depletion of CD4(+) cells promotes graft survival but leads to CR, which is associated with intragraft TGFbeta expression.	Chromium	124-126	CD4 antigen	Mus musculus	74-77
19841877-3	2009	During T-cell activation in vitro, a DNA demethylation agent 5-Aza-2"-deoxycytydine (DAC) can induce Foxp3 expression in CD4(+)CD25(-) Foxp3(-) cells via altering methylation status of a conserved element in the 5"-untranslated region of the Foxp3 gene.	5-aza-2"-deoxycytydine	61-83	CD4 antigen	Mus musculus	121-124
19818504-9	2009	Thus, we conclude that glycan modification of antigens and targeting to DC-SIGN enhance both CD4 and CD8 T cell responses.	Polysaccharides	23-29	CD4 antigen	Mus musculus	93-96
19846875-11	2009	In vivo, administration of nicotine (2 mg/kg s.c.) suppressed the severity of CD4(+) T cell-mediated disease experimental autoimmune encephalomyelitis.	Nicotine	27-35	CD4 antigen	Mus musculus	78-81
19595724-5	2009	This approach results in an efficient (&gt;50%) incorporation of siRNA into lipoplexes, which when incorporated with Ni-NTA(3)-DTDA and engrafted with a His-tagged form of murine CD4 can target siRNA to murine A20 B cells, in vitro.	(3)-dtda	123-131	CD4 antigen	Mus musculus	179-182
19881301-3	2009	In this study, we showed that 7,8,4"-trihydroxyflavone (T-412) significantly decreased IL-4 production both in phorbol 12-myristate 13-acetate (PMA) and ionomycin (PI)-activated EL-4 T cells and concanavalin A (ConA)-activated murine CD4(+) T cells in a dose- and time-dependent manner.	norwogonin	30-54	CD4 antigen	Mus musculus	234-237
19881301-3	2009	In this study, we showed that 7,8,4"-trihydroxyflavone (T-412) significantly decreased IL-4 production both in phorbol 12-myristate 13-acetate (PMA) and ionomycin (PI)-activated EL-4 T cells and concanavalin A (ConA)-activated murine CD4(+) T cells in a dose- and time-dependent manner.	t-412	56-61	CD4 antigen	Mus musculus	234-237
19839007-7	2009	These curcumin-treated DC induced differentiation of naive CD4(+) T cells into Treg resembling Treg in the intestine, including both CD4(+)CD25(+) Foxp3(+) Treg and IL-10-producing Tr1 cells.	Curcumin	6-14	CD4 antigen	Mus musculus	59-62
19839007-7	2009	These curcumin-treated DC induced differentiation of naive CD4(+) T cells into Treg resembling Treg in the intestine, including both CD4(+)CD25(+) Foxp3(+) Treg and IL-10-producing Tr1 cells.	Curcumin	6-14	CD4 antigen	Mus musculus	133-136
19706340-0	2009	Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice.	Naloxone	0-8	CD4 antigen	Mus musculus	61-64
19706340-5	2009	Our findings showed that co-administration of gp96 and naloxone has resulted in a significant reduction in CD4+CD25+Foxp3+ regulatory T cells in the spleen.	Naloxone	55-63	CD4 antigen	Mus musculus	107-110
19843933-3	2009	The defect of CD4(+) T cells in MHC class II-deficient (Abeta(degrees/degrees)) mice allowed priming of 2,4-dinitrobenzene sulfonic acid-specific IFN-gamma-producing CD8 colitogenic effectors and development of colitis in the otherwise resistant C57BL/6 strain.	2,4-dinitrobenzenesulfonic acid	104-136	CD4 antigen	Mus musculus	14-17
19817972-5	2009	Furthermore, interleukin (IL)-4 and interferon (IFN)-gamma secretion by activated CD4(+) T cells from the draining lymph nodes of DNFB-treated NC/Nga mice were significantly inhibited by melatonin, and total IgE levels in serum were reduced.	Dinitrofluorobenzene	130-134	CD4 antigen	Mus musculus	82-85
19817972-5	2009	Furthermore, interleukin (IL)-4 and interferon (IFN)-gamma secretion by activated CD4(+) T cells from the draining lymph nodes of DNFB-treated NC/Nga mice were significantly inhibited by melatonin, and total IgE levels in serum were reduced.	Melatonin	187-196	CD4 antigen	Mus musculus	82-85
19817972-6	2009	Our findings suggest that melatonin suppresses the development of AD-like dermatitis in DNFB-treated NC/Nga mice by reducing total IgE in serum, and IL-4 and IFN-gamma production by activated CD4(+) T cells.	Melatonin	26-35	CD4 antigen	Mus musculus	192-195
19817972-6	2009	Our findings suggest that melatonin suppresses the development of AD-like dermatitis in DNFB-treated NC/Nga mice by reducing total IgE in serum, and IL-4 and IFN-gamma production by activated CD4(+) T cells.	Dinitrofluorobenzene	88-92	CD4 antigen	Mus musculus	192-195
19740990-5	2009	Long-term treatment of these mice with DOX also led to loss, apoptosis, and activation of CD4+ T cells, this latter phenotype being observed even with low levels of Nef.	Doxycycline	39-42	CD4 antigen	Mus musculus	90-93
19901657-0	2009	Effect of hypertonic saline resuscitation on CD4+CD25+ regulatory T cells and gammadelta T cells after hemorrhagic shock and resuscitation in relation to apoptosis and iNOS.	Sodium Chloride	21-27	CD4 antigen	Mus musculus	45-48
19211146-7	2009	However, administration of ATRA to NOD mice in which the proportion and function of CD4(+)Foxp3(+) Treg cells was abrogated by cyclophosphamide (CY), failed to permit progression to T1D.	Tretinoin	27-31	CD4 antigen	Mus musculus	84-87
19356801-4	2009	We show that low dose cyclophosphamide (CY) sensitive CD4(+)CD25(+)FoxP3(+) Treg cell-dependent mechanisms can be demonstrated in C57Bl/6 mice susceptible to MLD-STZ diabetes induction.	Cyclophosphamide	22-38	CD4 antigen	Mus musculus	54-57
19356801-4	2009	We show that low dose cyclophosphamide (CY) sensitive CD4(+)CD25(+)FoxP3(+) Treg cell-dependent mechanisms can be demonstrated in C57Bl/6 mice susceptible to MLD-STZ diabetes induction.	Cyclophosphamide	40-42	CD4 antigen	Mus musculus	54-57
20137305-0	2009	[Combination of dexamethasone with IL-2 selectively induces the expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft versus host disease.].	Dexamethasone	16-29	CD4 antigen	Mus musculus	77-80
20137305-6	2009	RESULTS: Administration of Dex and IL-2 markedly expanded functional CD4(+)CD25(+)FOXP3(+) Treg cells in murine spleen, the number of which in treated group was (24.2 +/- 7.6)% while in control group was (4.0 +/- 0.8)% (P = 0.01).	Dexamethasone	27-30	CD4 antigen	Mus musculus	69-72
20137305-9	2009	CONCLUSION: Costimulation with Dex and IL-2 can selectively expand the functional CD4(+)CD25(+)FOXP3(+) Treg in vivo, which can suppress acute GVHD.	Dexamethasone	31-34	CD4 antigen	Mus musculus	82-85
19698774-7	2009	By FACS, we found that treatment with EAE (200 mg kg(-1)) resulted in an immature statement of DCs and stimulated the differentiation of CD4(+)CD25(+)Tregs.	EAE	38-41	CD4 antigen	Mus musculus	137-140
19698774-10	2009	CONCLUSIONS: The anti-allograft rejection effect of EAE by enhancing CD4(+)CD25(+)Tregs differentiation and sustaining DCs immaturation makes EAE to be a possible choice for treating autoimmune diseases in a way of inducing a stable immunological tolerance state.	EAE	52-55	CD4 antigen	Mus musculus	69-72
19698774-10	2009	CONCLUSIONS: The anti-allograft rejection effect of EAE by enhancing CD4(+)CD25(+)Tregs differentiation and sustaining DCs immaturation makes EAE to be a possible choice for treating autoimmune diseases in a way of inducing a stable immunological tolerance state.	EAE	142-145	CD4 antigen	Mus musculus	69-72
19675224-2	2009	When ovalbumin was coupled to liposomes made by using unsaturated fatty acids, it was found to be presented not only to CD4(+) T cells but also to CD8(+) T cells and induced cytotoxic T lymphocytes (CTLs) which effectively eradicated the tumor from mice.	Fatty Acids, Unsaturated	54-77	CD4 antigen	Mus musculus	120-123
19602431-6	2009	In CD4-CD8- double-negative (DN) thymocytes of aged mice, which showed the highest levels of DSBs, there was a modest increase in levels of the DNA repair protein MRE11, but not of either Ku70, another DNA repair protein, or the cell cycle checkpoint protein p53.	dsbs	93-97	CD4 antigen	Mus musculus	3-6
19577564-7	2009	In addition, VPA treatment increased both the suppressive function of CD4(+)CD25(+) Tregs (p&lt;0.04) and the numbers of CD25(+)FOXP3(+) Tregs in vivo.	Valproic Acid	13-16	CD4 antigen	Mus musculus	70-73
19651854-0	2009	Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4+ T-cell activation by interfering with proximal T-cell-receptor signaling.	Glycolipids	37-48	CD4 antigen	Mus musculus	66-69
19651854-9	2009	ZAP-70 phosphorylation was decreased in the presence of M. tuberculosis glycolipids, indicating that M. tuberculosis glycolipids directly inhibited CD4(+) T-cell activation by interfering with proximal T-cell-receptor signaling.	[n-(benzyloxycarbonyl)amino](4-amidinophenyl)methane-phosphonate	0-3	CD4 antigen	Mus musculus	148-151
19762394-8	2009	Also, TCDD group had significantly lower thymic and splenic weights, decreased percentages of CD4(+)CD8(+) thymocytes and splenic CD4(+) T cells, increased percentage of splenic B220(+)sIgM(+) B cells and higher serum interferon gamma concentration.	Polychlorinated Dibenzodioxins	6-10	CD4 antigen	Mus musculus	94-97
19762394-8	2009	Also, TCDD group had significantly lower thymic and splenic weights, decreased percentages of CD4(+)CD8(+) thymocytes and splenic CD4(+) T cells, increased percentage of splenic B220(+)sIgM(+) B cells and higher serum interferon gamma concentration.	Polychlorinated Dibenzodioxins	6-10	CD4 antigen	Mus musculus	130-133
19796023-9	2009	At the higher dose, atorvastatin also led to a significant reduction in apoptosis of splenic CD4(+) T lymphocytes.	Atorvastatin	20-32	CD4 antigen	Mus musculus	93-96
20073223-10	2009	CONCLUSION: THH could prevent GVHD in mice after allogeneic bone marrow transplantation, and prolong their survival time, the mechanism is possibly related with its immunosuppressive effect in raising CD4(+)CD25(+) T cells and promoting the Foxp3 mRNA expression.	5-methyltetrahydrofolate	12-15	CD4 antigen	Mus musculus	201-204
19774076-7	2009	The enhanced protection appears to be dependent upon the prior development of inducible bronchus-associated lymphoid tissue (iBALT) in the lung in response to the PCN treatment and to be mediated through CD4+ T cell and B cell dependent mechanisms.	PREGNENOLONE CARBONITRILE	163-166	CD4 antigen	Mus musculus	204-207
19727527-5	2009	Results showed that short-term simultaneous administration of Dex and IL-2 markedly expanded functional suppressive CD4(+)CD25(+)FOXP3(+) T cells in the murine spleen.	Dextromethorphan	62-65	CD4 antigen	Mus musculus	116-119
19727527-8	2009	This study demonstrated that co-stimulation with Dex and IL-2 selectively expanded functional CD4(+)CD25(+)FOXP3(+) T cells in vivo, and that grafts from donors pre-treated with Dex and IL-2 led to longer survival time and greater suppression of GVHD after allogeneic transplantation.	Dextromethorphan	49-52	CD4 antigen	Mus musculus	94-97
19571233-6	2009	The esophageal CD4(+)CD45RB(high) effector T cells in allergen-challenged mice increased compared with saline-challenged mice (65.4 +/- 3.6 x 10(3) to 44.8 +/- 4.2 x 10(3)), whereas CD4(+)CD45RB(low) mostly regulatory T cells decreased in allergen-challenged mice compared with saline-challenged mice (5.8 +/- 0.9 x 10(3) from 10.2 +/- 1.7 x 10(3)).	Sodium Chloride	278-284	CD4 antigen	Mus musculus	15-18
19571233-6	2009	The esophageal CD4(+)CD45RB(high) effector T cells in allergen-challenged mice increased compared with saline-challenged mice (65.4 +/- 3.6 x 10(3) to 44.8 +/- 4.2 x 10(3)), whereas CD4(+)CD45RB(low) mostly regulatory T cells decreased in allergen-challenged mice compared with saline-challenged mice (5.8 +/- 0.9 x 10(3) from 10.2 +/- 1.7 x 10(3)).	Sodium Chloride	278-284	CD4 antigen	Mus musculus	21-24
19571233-8	2009	Additionally, a significantly reduced interleukin (IL)-2 production by CD4(+)CD45RB(low) cells in allergen-challenged mice compared with saline-challenged mice was observed.	Sodium Chloride	137-143	CD4 antigen	Mus musculus	71-74
19191902-7	2009	At the same time, rBCG induced a CD4(+) CD25(+) Foxp3(+) T-cell subtype that could suppress the proliferation of Th2 effector cells in vitro in an antigen-specific manner.	rbcg	18-22	CD4 antigen	Mus musculus	33-36
19546196-0	2009	Oligoclonal CD4+ T cells promote host memory immune responses to Zwitterionic polysaccharide of Streptococcus pneumoniae.	Polysaccharides	78-92	CD4 antigen	Mus musculus	12-15
19546196-1	2009	Zwitterionic polysaccharides of the normal flora bacteria represent a novel class of antigens in that they correct systemic CD4(+) T-cell deficiencies and direct lymphoid organogenesis during colonization of the host.	zwitterionic polysaccharides	0-28	CD4 antigen	Mus musculus	124-127
19546196-2	2009	Presentation of these polysaccharides to CD4(+) T cells depends on major histocompatibility complex class II- and DM-dependent retrograde transport from lysosomes to the cell surface.	Polysaccharides	22-37	CD4 antigen	Mus musculus	41-44
19546196-4	2009	Using the zwitterionic capsular polysaccharide Sp1 of Streptococcus pneumoniae, a transient member of the bacterial flora, in an experimental mouse model of cellular immunity, we demonstrated the accumulation of TH1- and TH17-polarized CD4(+) CD44(high) CD62(low) CD25(-) memory T cells.	Polysaccharides	32-46	CD4 antigen	Mus musculus	236-239
19546196-4	2009	Using the zwitterionic capsular polysaccharide Sp1 of Streptococcus pneumoniae, a transient member of the bacterial flora, in an experimental mouse model of cellular immunity, we demonstrated the accumulation of TH1- and TH17-polarized CD4(+) CD44(high) CD62(low) CD25(-) memory T cells.	boron nitride	47-50	CD4 antigen	Mus musculus	236-239
19546196-6	2009	CD4(+) T cells stimulated with polysaccharide in vitro and in vivo showed a nonrestricted pattern for the T-cell receptor (TCR) beta-chain variable region, as demonstrated by semiquantitative reverse transcription-PCR and flow cytometry.	Polysaccharides	31-45	CD4 antigen	Mus musculus	0-3
19546196-7	2009	Clonotype mapping of in vivo and in vitro polysaccharide-activated CD4(+) T cells revealed clonotypic TCR transcripts.	Polysaccharides	42-56	CD4 antigen	Mus musculus	67-70
19546196-8	2009	Taken together, the data show the induction of clonal expansion of CD4(+) T cells by polysaccharides of commensal bacteria.	Polysaccharides	85-100	CD4 antigen	Mus musculus	67-70
19740328-4	2009	Using double-staining and tracking of proliferation of purified and carboxyflourescein succinimidyl ester (CFSE)-labelled mouse T-cell subpopulations we demonstrated that CD4(+) CD25(+) Foxp3(+) iTregs develop upon alloantigenic stimulation in the presence of TGF-beta exclusively from CD4(+) CD25(-) Foxp3(-) precursors.	carboxyflourescein succinimidyl ester	68-105	CD4 antigen	Mus musculus	171-174
19678760-6	2009	Significant changes in the CD4/CD8 subsets in the thymus and spleen among mercury-exposed male and female mice were not observed.	Mercury	74-81	CD4 antigen	Mus musculus	27-30
19678760-7	2009	However, there was a significant reduction in splenic CD4(+)CD25(+) cells in mercury-exposed female, but not in male, mice.	Mercury	77-84	CD4 antigen	Mus musculus	54-57
19703012-11	2009	A direct impact of high-dose EtOH administration in the activation status of splenic CD4(+) T cells was observed.	Ethanol	29-33	CD4 antigen	Mus musculus	85-88
19703012-12	2009	Together, our results demonstrated that short-term high-dose EtOH administration has differential impact on APC populations, downregulating splenic macrophages and DC activity but up-regulating B lymphocyte function as APC, and ultimately yielding a micro-environment that led to increased activation of CD4(+) T cells.	Ethanol	61-65	CD4 antigen	Mus musculus	304-307
19682930-2	2009	Here we show that equipping postthymic CD4(+) T cells with LATY136F molecules or rendering them deficient in LAT molecules triggers a lymphoproliferative disorder dependent on prior TCR engagement.	laty136f	59-67	CD4 antigen	Mus musculus	39-42
19682930-4	2009	Unexpectedly, in CD4(+) T cells recently deprived of LAT, the proximal triggering module of the TCR induced a spectrum of protein tyrosine phosphorylation that largely overlapped the one observed in the presence of LAT.	Tyrosine	130-138	CD4 antigen	Mus musculus	17-20
19667934-5	2009	RESULTS: Pirfenidone was found to inhibit the responder frequency of TCR-stimulated CD4 cell total proliferation in vitro and in vivo, whereas both CD4 and CD8 proliferation index were reduced by pirfenidone.	pirfenidone	9-20	CD4 antigen	Mus musculus	84-87
19667934-5	2009	RESULTS: Pirfenidone was found to inhibit the responder frequency of TCR-stimulated CD4 cell total proliferation in vitro and in vivo, whereas both CD4 and CD8 proliferation index were reduced by pirfenidone.	pirfenidone	196-207	CD4 antigen	Mus musculus	148-151
19326358-7	2009	Capsaicin-induced depletion of nociceptive afferent nerves prior to CD4(+)CD25(-) T-cell transfer completely inhibited the development of colitis.	Capsaicin	0-9	CD4 antigen	Mus musculus	68-71
19584680-8	2009	The beneficial effect of adenosine was also observed for BALB/c islet allografts when alloimmune rejection was prevented by anti-CD4 antibody.	Adenosine	25-34	CD4 antigen	Mus musculus	129-132
19582154-8	2009	Syngeneic NA-BMCs protected 83% of mice from death (n = 8, CD4(+) donor chimerism of 5.8+/-2.4% [day 40], P&lt;.001).	na-bmcs	10-17	CD4 antigen	Mus musculus	59-62
19564349-1	2009	Relative to several other toll-like receptor (TLR) agonists, we found polyinosinic:polycytidylic acid (poly IC) to be the most effective adjuvant for Th1 CD4(+) T cell responses to a dendritic cell (DC)-targeted HIV gag protein vaccine in mice.	Poly C	83-101	CD4 antigen	Mus musculus	154-157
19564349-1	2009	Relative to several other toll-like receptor (TLR) agonists, we found polyinosinic:polycytidylic acid (poly IC) to be the most effective adjuvant for Th1 CD4(+) T cell responses to a dendritic cell (DC)-targeted HIV gag protein vaccine in mice.	Poly I-C	103-110	CD4 antigen	Mus musculus	154-157
19290021-8	2009	To address the molecular mechanism, we found that after TCR stimulation, CD4(+) T cells from PKO mice display an increased intracellular calcium flux and subsequently enhance activation of transcription factor NFAT1.	Calcium	137-144	CD4 antigen	Mus musculus	73-76
20174617-2	2009	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), the most potent AHR ligand, induces adaptive CD4+CD25+ Tregs during an acute graft-versus-host (GvH) response and prevents the generation of allospecific cytotoxic T lymphocytes.	Polychlorinated Dibenzodioxins	0-35	CD4 antigen	Mus musculus	89-92
20174617-2	2009	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), the most potent AHR ligand, induces adaptive CD4+CD25+ Tregs during an acute graft-versus-host (GvH) response and prevents the generation of allospecific cytotoxic T lymphocytes.	Polychlorinated Dibenzodioxins	37-41	CD4 antigen	Mus musculus	89-92
20174617-4	2009	In this study, we show that chronic treatment of NOD mice with TCDD potently suppresses the development of autoimmune Type 1 diabetes in parallel with greatly reduced pancreatic islet insulitis and an expanded population of CD4+CD25+Foxp3+ cells in the pancreatic lymph nodes.	Polychlorinated Dibenzodioxins	63-67	CD4 antigen	Mus musculus	224-227
19715998-3	2009	The aim of this study was to establish if RA synergizing with TGF-beta induced antigen specific CD4(+) CD25(high) Foxp3(+) Treg portraying gut homing receptors.	Tretinoin	42-44	CD4 antigen	Mus musculus	96-99
19529765-4	2009	CD4/10.4 and CD8/10.4 T cells displayed marked differences in terms of expansion and contraction in a mouse TB model.	Terbium	108-110	CD4 antigen	Mus musculus	0-3
19378946-6	2009	Furthermore, Dj-dioscorins enhanced proliferation of CD4(+), CD8(+), and Tim3(+) (Th1) cells in spleen and CD19(+) cells in both spleen and thymus.	dj-dioscorins	13-26	CD4 antigen	Mus musculus	53-56
19446580-10	2009	GSPE significantly reduced hydrogen peroxide production by anti-CD3-monoclonal-antibody-stimulated CD4+ splenocytes.	Hydrogen Peroxide	27-44	CD4 antigen	Mus musculus	99-102
19459813-7	2009	Adoptive transfer of whole, CD4(+) and CD4(+)CD25(+) splenocytes from EPA-treated recipients induced indefinite survival in secondary recipients.	Eicosapentaenoic Acid	70-73	CD4 antigen	Mus musculus	28-31
19459813-7	2009	Adoptive transfer of whole, CD4(+) and CD4(+)CD25(+) splenocytes from EPA-treated recipients induced indefinite survival in secondary recipients.	Eicosapentaenoic Acid	70-73	CD4 antigen	Mus musculus	39-42
19428326-3	2009	In the present study, we found that fraxinellone, a small natural compound isolated from the root bark of Dictamnus dasycarpus, selectively facilitated apoptosis of concanavalin A (Con A)-activated CD4(+) T cells rather than those non-activated, by disrupting the mitochondrial transmembrane potential, decreasing the ratio of Bcl-2/Bax, and increasing cytochrome c release from the mitochondria to the cytosol.	fraxinellone	36-48	CD4 antigen	Mus musculus	198-201
19428326-6	2009	Consistent with the in vitro results, fraxinellone dramatically induced apoptosis of activated peripheral CD4(+) T cells in vivo, consequently resulting in less CD4(+) T-cell activation and infiltration to the liver.	fraxinellone	38-50	CD4 antigen	Mus musculus	106-109
19428326-6	2009	Consistent with the in vitro results, fraxinellone dramatically induced apoptosis of activated peripheral CD4(+) T cells in vivo, consequently resulting in less CD4(+) T-cell activation and infiltration to the liver.	fraxinellone	38-50	CD4 antigen	Mus musculus	161-164
19427686-0	2009	CD4+CD25+ regulatory T cells suppress contact hypersensitivity reactions through a CD39, adenosine-dependent mechanism.	Adenosine	89-98	CD4 antigen	Mus musculus	0-3
19403707-2	2009	Here, we evaluated the effect of in vitro supplementation with 46 mumol/L of vitamin E on T cell receptor-proximal signaling events of CD4(+) T cells from young (4-6 mo) and old (22-26 mo) C57BL mice.	Vitamin E	77-86	CD4 antigen	Mus musculus	135-138
19403707-3	2009	Aged murine CD4(+) T cells stimulated via CD3 and CD28, tyrosine 191 of the adaptor protein Linker for Activation of T cells (LAT), was hypo-phosphorylated.	Tyrosine	56-64	CD4 antigen	Mus musculus	12-15
19545742-2	2009	We treated splenic CD4(+)/CD25(-) naive T cells from BALB/c mice with the DNA-methyltransferase inhibitor 5-aza-2"-deoxycytidine (5AzaD) or the histone protein deacetylase (HDAC) inhibitor Trichostatin A (TSA), and measured the effects on the expression of FOXP3, which encodes a transcription factor (FOXP3) that regulates T(reg) development.	Decitabine	106-128	CD4 antigen	Mus musculus	19-22
19200812-2	2009	We document a decrease of CD4+ cells in peripheral blood and spleen after immunization with the human CD4-p28 immunogenic peptide of transgenic mice expressing human CD4, human HLA class II and mouse class II I-A(q) (HLA-DR4-huCD4-I-A(q+)); however, no decrease of CD4 cells was found in transgenic HLA-DR4-huCD4-I-A(q-) mice or in control C57BL/6 and DBA immunized mice.	1,2,5,6-dibenzanthracene	352-355	CD4 antigen	Mus musculus	102-105
19414758-4	2009	Immunization through calcipotriol-treated skin induces CD4(+)CD25(+) regulatory T cells (Treg) that prevent subsequent Ag-specific CD8(+) T cell proliferation and IFN-gamma production.	calcipotriene	21-33	CD4 antigen	Mus musculus	55-58
19414758-10	2009	The in vivo expansion of Ag-specific Treg with the topical application of the vitamin D analog calcipotriol followed by transcutaneous immunization is a simple method to augment functional Ag-specific CD4(+)CD25(+)Foxp3(+) Treg populations and mimics Ag-specific UV-induced tolerance.	Vitamin D	78-87	CD4 antigen	Mus musculus	201-204
19414758-10	2009	The in vivo expansion of Ag-specific Treg with the topical application of the vitamin D analog calcipotriol followed by transcutaneous immunization is a simple method to augment functional Ag-specific CD4(+)CD25(+)Foxp3(+) Treg populations and mimics Ag-specific UV-induced tolerance.	calcipotriene	95-107	CD4 antigen	Mus musculus	201-204
19366577-0	2009	CD4(+) T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA.	cbpa	127-131	CD4 antigen	Mus musculus	0-3
19366577-5	2009	The anti-infection activity and production of hyperimmune antibodies induced by mucosal immunization with ClpP and CbpA could be abrogated by the depletion of CD4(+) T lymphocytes.	cbpa	115-119	CD4 antigen	Mus musculus	159-162
19188932-0	2009	Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes.	Glatiramer Acetate	59-77	CD4 antigen	Mus musculus	13-16
19204734-0	2009	Injection of bleomycin in newborn mice induces autoimmune sialitis that is transferred by CD4 T cells.	Bleomycin	13-22	CD4 antigen	Mus musculus	90-93
19539558-0	2009	Combined therapy of CD4(+)CD25(+) regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice.	Sirolimus	67-76	CD4 antigen	Mus musculus	20-23
19539558-7	2009	Even though the cell numbers of CD4(+) T cells were found to decrease in sirolimus-treated mice, sirolimus selectively enhanced the numbers of CD4(+)CD25(+) cells and increased the expression of Foxp3 in spleens and lymph nodes, respectively, in recipients.	Sirolimus	73-82	CD4 antigen	Mus musculus	32-35
19539558-7	2009	Even though the cell numbers of CD4(+) T cells were found to decrease in sirolimus-treated mice, sirolimus selectively enhanced the numbers of CD4(+)CD25(+) cells and increased the expression of Foxp3 in spleens and lymph nodes, respectively, in recipients.	Sirolimus	97-106	CD4 antigen	Mus musculus	143-146
19136706-11	2009	LN cell proliferative responses against hIRBP-p and the number of CD44(high)CD4(+) T cells were remarkably reduced in telmisartan-treated mice.	Telmisartan	118-129	CD4 antigen	Mus musculus	66-69
19380818-7	2009	In addition, administration of poly(I:C), which is an innate immune agonist, to TMEV-infected mice during the innate immune response resulted in decreased myelin-specific CD4(+) T cell responses and reduced demyelinating disease.	Poly I-C	31-39	CD4 antigen	Mus musculus	171-174
19321585-0	2009	Dietary curcumin and limonin suppress CD4+ T-cell proliferation and interleukin-2 production in mice.	Curcumin	8-16	CD4 antigen	Mus musculus	38-41
19321585-6	2009	CD4(+) T-cell proliferation in response to either mitogenic anti-CD3/28 monoclonal antibodies (mAb) or antigenic stimulation by OVA was also suppressed (P &lt; 0.05) by Cur as assessed by carboxyfluorescein succinimidyl ester staining.	carboxyfluorescein succinimidyl ester	188-225	CD4 antigen	Mus musculus	0-3
19318495-6	2009	Treatment of mice with low-dose cyclophosphamide or anti-CD25 antibody to deplete regulatory T cells unmasked latent T-cell antitumor activity; the number of activated CD8(+) T cells in tumors increased and B16/3L86 tumors were completely rejected in a CD8(+) and CD4(+) T-cell-dependent fashion.	Cyclophosphamide	32-48	CD4 antigen	Mus musculus	264-267
19342637-4	2009	In vitro, calcitriol directly suppressed IL-17 induction in purified naive CD4(+) T cells without inhibiting Th17 lineage commitment, as reflected by unaltered RORgammat, STAT3, and FoxP3 expression.	Calcitriol	10-20	CD4 antigen	Mus musculus	75-78
19342637-5	2009	In contrast, in vivo treatment with calcitriol of mice challenged for EAU impaired commitment to the Th17 lineage, as judged by reduction of both RORgammat and IL-17 in CD4(+) T cells.	Calcitriol	36-46	CD4 antigen	Mus musculus	169-172
19342637-7	2009	Finally, supernatants of calcitriol-conditioned bone marrow-derived DC had reduced ability to support Th17 polarization of naive CD4(+) T cells in vitro and in vivo.	Calcitriol	25-35	CD4 antigen	Mus musculus	129-132
19342637-8	2009	Thus, calcitriol appears to suppress autoimmunity by inhibiting the Th17 response at several levels, including the ability of DC to support priming of Th17 cells, the ability of CD4(+) T cells to commit to the Th17 lineage, and the ability of committed Th17 T cells to produce IL-17.	Calcitriol	6-16	CD4 antigen	Mus musculus	178-181
18989352-4	2009	We showed that the combination of vaccination with high-dose cyclophosphamide was able to skew the response toward the target antigen and enhanced both the quantity and quality of antigen-specific CD8+ and CD4+ T-cell responses in tumor-bearing mice, which resulted in the inhibition of tumor growth.	Cyclophosphamide	61-77	CD4 antigen	Mus musculus	206-209
19189863-7	2009	Meanwhile, apoptosis of CD4(+) T cell in spleens of mice pretreated with lentinan was significantly reduced.	Lentinan	73-81	CD4 antigen	Mus musculus	24-27
19228878-3	2009	This report shows that T cell-deficient BALB/c nude mice reconstituted with naive unfractionated T cells are specifically tolerized to DBA/2 skin grafts by DST and anti-CD4 mAb treatment, whereas those transferred with T cell suspensions depleted of all Foxp3(+)CD25(+)CD4(+) natural regulatory T cells (Tregs) are not.	1,2,5,6-dibenzanthracene	135-138	CD4 antigen	Mus musculus	169-172
19193795-9	2009	In BCG-immune mice the resistance to VV infection and VV-induced CD4 T-cell IFN-gamma production were ablated by cyclosporine A, which inhibits signaling through the T-cell receptor.	Cyclosporine	113-127	CD4 antigen	Mus musculus	65-68
19264469-2	2009	Here, we examined the effects of LTB4 and PGE2 on the differentiation of immunosuppressive CD4+CD25+Foxp3+ T regulatory cells (Treg) and pro-inflammatory IL-17-producing cells (Th17) from murine naive CD4+ T cells.	Dinoprostone	42-46	CD4 antigen	Mus musculus	91-94
19575969-16	2009	J2 and CsA groups only showed a small number of CD4(+) and CD8(+) T-lymphocytes in the grafts.	Cyclosporine	7-10	CD4 antigen	Mus musculus	48-51
19323907-9	2009	After pretreatment with H-GLS before sialoadenitis onset, the ratio of CD4(+)/CD8(+) T lymphocyte and the serum IgG levels of NOD mice decreased significantly (P &lt; 0.05).	h-gls	24-29	CD4 antigen	Mus musculus	71-74
19567068-9	2009	The percentage of CD4+CD25+Foxp3+ T cells in the CD4+ T cells cultured with 1, 25 (OH)(2)D(3)-treated DCs was (22.49% +/- 0.56%), significantly higher than that of the a PBS control group [(6.67% +/- 0.60%), P &lt; 0.01].	Lead	170-173	CD4 antigen	Mus musculus	18-21
19567068-9	2009	The percentage of CD4+CD25+Foxp3+ T cells in the CD4+ T cells cultured with 1, 25 (OH)(2)D(3)-treated DCs was (22.49% +/- 0.56%), significantly higher than that of the a PBS control group [(6.67% +/- 0.60%), P &lt; 0.01].	Lead	170-173	CD4 antigen	Mus musculus	49-52
19567068-12	2009	The percentage of CD4+CD25+Foxp3+ T cells in the spleens of the 1, 25 (OH)(2)D(3)-treated DC group was (14.69% +/- 1.14%), significantly higher than that of the PBS-treated DC group [(2.38% +/- 0.14%, P &lt; 0.01).	Lead	161-164	CD4 antigen	Mus musculus	18-21
18710402-3	2009	CD4(+) T cells were activated with phorbol 12-myristate 13-acetate (PMA) and different concentrations of a Ca(2+) ionophore, Ionomycin (I), or a sarcoplasmic Ca(2+) ATPase inhibitor, Thapsigargin (TG).	Tetradecanoylphorbol Acetate	35-66	CD4 antigen	Mus musculus	0-3
18710402-3	2009	CD4(+) T cells were activated with phorbol 12-myristate 13-acetate (PMA) and different concentrations of a Ca(2+) ionophore, Ionomycin (I), or a sarcoplasmic Ca(2+) ATPase inhibitor, Thapsigargin (TG).	Tetradecanoylphorbol Acetate	68-71	CD4 antigen	Mus musculus	0-3
19302141-2	2009	We here demonstrate that treatment with 17beta-oestradiol (E(2)) in C57BL/6 mice boosted the expression of programmed death 1 (PD-1), a negative regulator of immune responses, in the CD4(+) FoxP3(+) regulatory T (Treg) cell compartment in a dose-dependent manner that correlated with the efficiency of EAE protection.	Estradiol	40-57	CD4 antigen	Mus musculus	183-186
19157794-0	2009	Skin application of ketoprofen systemically suppresses contact hypersensitivity by inducing CD4(+) CD25(+) regulatory T cells.	Ketoprofen	20-30	CD4 antigen	Mus musculus	92-95
19088177-9	2009	Interestingly, depletion of endogenous CD8(+) but not CD4(+) T cells restored the ability of naive CD4(+) T cells to undergo HP, increasing the number of CD4(+) T cells with memory but not activation markers.	Hematoporphyrins	125-127	CD4 antigen	Mus musculus	99-102
19088177-9	2009	Interestingly, depletion of endogenous CD8(+) but not CD4(+) T cells restored the ability of naive CD4(+) T cells to undergo HP, increasing the number of CD4(+) T cells with memory but not activation markers.	Hematoporphyrins	125-127	CD4 antigen	Mus musculus	99-102
19234156-5	2009	GMME1 administration to experimental autoimmune encephalomyelitis mice suppresses symptomatic disease and correlates with decreased levels of inflammatory cytokines including IL-17, MOG-specific Ab titers, and blockade of CD4 and CD8 T cell infiltration in spinal cords.	gmme1	0-5	CD4 antigen	Mus musculus	222-225
19234198-7	2009	Furthermore, we show that CD4 T cells isolated after RSV challenge of vacvG-immunized gld mice exhibit enhanced expression of Annexin V and caspase 3/7 indicating that FasL is important for either the survival or the expansion of virus-specific secondary effector CD4 T cells.	vacvg	70-75	CD4 antigen	Mus musculus	26-29
19234198-7	2009	Furthermore, we show that CD4 T cells isolated after RSV challenge of vacvG-immunized gld mice exhibit enhanced expression of Annexin V and caspase 3/7 indicating that FasL is important for either the survival or the expansion of virus-specific secondary effector CD4 T cells.	vacvg	70-75	CD4 antigen	Mus musculus	264-267
19146957-0	2009	The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice.	Aspirin	106-113	CD4 antigen	Mus musculus	51-54
19146957-4	2009	The frequency, phenotype and immunosuppressive function of CD4(+)CD25(+)Foxp3(+) Treg cells were detected in BALB/c mice treated with low or high doses of ASA for 4 weeks.	Aspirin	155-158	CD4 antigen	Mus musculus	59-62
19146957-5	2009	ASA significantly decreased the percentage and number of CD4(+) T cells in the periphery, while ASA remarkably increased the percentage of CD4(+)CD25(+)Foxp3(+) Treg cells in CD4(+)T cells.	Aspirin	0-3	CD4 antigen	Mus musculus	57-60
19146957-5	2009	ASA significantly decreased the percentage and number of CD4(+) T cells in the periphery, while ASA remarkably increased the percentage of CD4(+)CD25(+)Foxp3(+) Treg cells in CD4(+)T cells.	Aspirin	96-99	CD4 antigen	Mus musculus	139-142
19146957-5	2009	ASA significantly decreased the percentage and number of CD4(+) T cells in the periphery, while ASA remarkably increased the percentage of CD4(+)CD25(+)Foxp3(+) Treg cells in CD4(+)T cells.	Aspirin	96-99	CD4 antigen	Mus musculus	139-142
19146957-6	2009	The total cell numbers of thymocytes were significantly decreased in ASA-treated mice, but the number of CD4(+) CD25(+)Fxop3(+) cells and its ratio in CD4(+)CD8(-) thymocytes were markedly enhanced in the thymi of ASA-treated mice.	Aspirin	214-217	CD4 antigen	Mus musculus	105-108
19146957-8	2009	CD4(+)CD25(+) Treg cells in ASA-treated mice exhibited unimpaired immunosuppressive function on CD4(+)CD25(-) T effector cells.	Aspirin	28-31	CD4 antigen	Mus musculus	0-3
19146957-9	2009	ASA significantly enhanced the frequency of functional CD4(+)CD25(+)Foxp3(+) Treg cells in mice in a therapeutic dose range.	Aspirin	0-3	CD4 antigen	Mus musculus	55-58
19101620-4	2009	RESULTS: Oral administration of ASMq was found to increase the thymus and spleen indices, lymphocytes proliferation induced by Con A and LPS, the percentage of CD4(+) in thymus, spleen and peripheral blood and restore the CD4(+)/CD8(+) ratio.	asmq	32-36	CD4 antigen	Mus musculus	160-163
19101620-4	2009	RESULTS: Oral administration of ASMq was found to increase the thymus and spleen indices, lymphocytes proliferation induced by Con A and LPS, the percentage of CD4(+) in thymus, spleen and peripheral blood and restore the CD4(+)/CD8(+) ratio.	asmq	32-36	CD4 antigen	Mus musculus	222-225
19302742-5	2009	RESULTS: In peripheral blood, the SA group had significantly lower CCR3 expression (P &lt; 0.01) and higher CCR5 and CXCR3 expression (P &lt; 0.01) on CD4(+) T cells than did the NP group.	2-chloro-10-(4'(N-beta-hydroxyethyl)piperazinyl-1')acetylphenothiazine	34-36	CD4 antigen	Mus musculus	151-154
19302742-7	2009	In spleen, the SA group expressed significantly lower CCR3 expression (P &lt; 0.01) and higher CCR5 and CXCR3 expression (P &lt; 0.05) on CD4(+) T cells than did the NP group.	2-chloro-10-(4'(N-beta-hydroxyethyl)piperazinyl-1')acetylphenothiazine	15-17	CD4 antigen	Mus musculus	138-141
19302742-9	2009	In thymus, the SA group had significantly lower CCR3 expression (P &lt; 0.05) and higher CXCR3 expression (P &lt; 0.05) on CD4(+) T cells than the NP group, with no significant difference in CCR5 expression (P &gt; 0.05).	2-chloro-10-(4'(N-beta-hydroxyethyl)piperazinyl-1')acetylphenothiazine	15-17	CD4 antigen	Mus musculus	123-126
19056158-0	2009	Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.	Dasatinib	0-9	CD4 antigen	Mus musculus	61-64
19056158-3	2009	The purpose of this study was to evaluate the inhibitory action of dasatinib on antigen-specific CD8(+) and CD4(+) T-cell function, as well as natural killer (NK) cell cytotoxicity.	Dasatinib	67-76	CD4 antigen	Mus musculus	108-111
19056158-7	2009	RESULTS: Dasatinib inhibited antigen-specific proliferation of murine CD4(+) and CD8(+) transgenic T cells in vitro and in vivo.	Dasatinib	9-18	CD4 antigen	Mus musculus	70-73
19236233-6	2009	K57 substitution with a glycine in sCD38p impaired its ability to inhibit syncytia formation in MT-2/H9(IIIB) cell cocultures and gp120 binding to CD4 in a mouse T cell line expressing human but not mouse CD4.	Glycine	24-31	CD4 antigen	Mus musculus	147-150
19236233-6	2009	K57 substitution with a glycine in sCD38p impaired its ability to inhibit syncytia formation in MT-2/H9(IIIB) cell cocultures and gp120 binding to CD4 in a mouse T cell line expressing human but not mouse CD4.	Glycine	24-31	CD4 antigen	Mus musculus	205-208
19027047-6	2009	Furthermore, non-specific and antigen-specific stimulation of CD8+ T cells by phorbol myristate acetate and MHC class I peptide-pulsed splenocytes, respectively, modulated TLR expression in purified CD4+ and CD8+ T cells.	Tetradecanoylphorbol Acetate	78-103	CD4 antigen	Mus musculus	199-202
19507278-13	2009	Our findings demonstrated that preventive administration of PHC protected beta cells from apoptosis in type 1 diabetes induced by STZ, and the underlying mechanism may be involved in suppressing CD4(+) T cells reaction, reducing inflammatory cells infiltration and protecting beta cell apoptosis in pancreatic islet.	Propoxur	60-63	CD4 antigen	Mus musculus	195-198
19938223-9	2009	FACS assay showed that icariin dramatically decreased the percentage of CD4+ and CD8+ cells in bone marrow and CD19+ cells in blood on day 8.	icariin	23-30	CD4 antigen	Mus musculus	72-75
19001113-0	2009	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.	posaconazole	109-121	CD4 antigen	Mus musculus	11-14
19001113-0	2009	Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection.	benzonidazole	126-138	CD4 antigen	Mus musculus	11-14
19001113-3	2009	CD4(+)-T-lymphocyte-knockout (KO) mice infected with T. cruzi and treated with BZ or POS controlled parasitemia during treatment, although circulating parasites reappeared after drug pressure cessation, leading to only a 6% survival rate and no cure.	benzonidazole	79-81	CD4 antigen	Mus musculus	0-3
18984738-7	2009	Depletion of CD4(+)CD25(+) Treg cells impaired the inhibitory effect of ATRA on islet-infiltrating T-cells and blocked its protective effect on diabetes.	Tretinoin	72-76	CD4 antigen	Mus musculus	13-16
18984738-8	2009	Therefore, ATRA treatment induced Treg cell-dependent immune tolerance by suppressing both CD4(+) and CD8(+) Teff cells while promoting Treg cell expansion.	Tretinoin	11-15	CD4 antigen	Mus musculus	91-94
19234960-0	2009	Role of CD4(+) T cells in the modulation of neurotrophin production in mice exposed to low-level toluene.	Toluene	97-104	CD4 antigen	Mus musculus	8-11
19234960-5	2009	These findings suggest that the CD4(+) T cells may be involved in the toluene-induced modulation of neurotrophin production.	Toluene	70-77	CD4 antigen	Mus musculus	32-35
18992850-3	2009	Flow cytometric analysis revealed that ASB16165 suppressed induction of activated CD4+ as well as CD8+ T cells in MLR.	1-cyclohexyl-N-(6-(4-hydroxy-1-piperidinyl)-3-pyridinyl)-3-methyl-1H-thieno(2,3-c)pyrazole-5-carboxamide	39-47	CD4 antigen	Mus musculus	82-85
18992850-4	2009	In cell division analyses using 5-carboxyfluorescein diacetate succinimide ester (CFSE), ASB16165 was shown to markedly inhibit proliferation of CD4+ and CD8+ T cells.	1-cyclohexyl-N-(6-(4-hydroxy-1-piperidinyl)-3-pyridinyl)-3-methyl-1H-thieno(2,3-c)pyrazole-5-carboxamide	89-97	CD4 antigen	Mus musculus	145-148
19104149-6	2009	Importantly, similar attenuation of MPTP-induced dopaminergic cell death was seen in mice lacking CD4 as well as in Rag1-/- mice reconstituted with FasL-deficient splenocytes.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	36-40	CD4 antigen	Mus musculus	98-101
19109143-5	2009	We show an essential requirement for FoxN1 in the initial development of cTEC from bipotent progenitors, and demonstrate a stage-specific requirement for CD4(-)8(-) thymocytes in later stages of cTEC development.	ctec	195-199	CD4 antigen	Mus musculus	154-157
18820175-6	2009	In contrast to CD4+ responses, three methods of in vitro antigen presentation indicated that the primary response of CD8+ T cells to several different epitopes was reduced significantly in mice chronically fed ethanol.	Ethanol	210-217	CD4 antigen	Mus musculus	15-18
19340309-8	2009	Taken together these results indicate an involvement of CD4(+) T-cells in J8-DT-mediated protection possibly via an ability to maintain antibody levels.	Thymidine	77-79	CD4 antigen	Mus musculus	56-59
19156219-6	2009	Correspondingly, treatment with CB-SC-modulated CD4(+)CD62L(+) Tregs (mCD4CD62L Tregs) resulted in a marked reduction of insulitis, restored Th1/Th2 cytokine balance in blood, and induced apoptosis of infiltrated leukocytes in pancreatic islets.	cb-sc	32-37	CD4 antigen	Mus musculus	70-74
19340966-2	2009	Cyclophosphan (CP) administered to mice four times with 24 hours intervals decreased levels of T-, B-, T-regulatory (T-reg CD4/CD25/Foxp3) lymphocytes, increased quantity of cells expressing early activation marker CD25 (assessment after 4 hours).	Cyclophosphamide	0-13	CD4 antigen	Mus musculus	123-126
19050241-2	2008	To investigate these issues, we mutated a serine phosphorylation site (S408) in the cytoplasmic tail of murine CD4.	Serine	42-48	CD4 antigen	Mus musculus	111-114
19050241-2	2008	To investigate these issues, we mutated a serine phosphorylation site (S408) in the cytoplasmic tail of murine CD4.	Farnesylacetone	71-75	CD4 antigen	Mus musculus	111-114
19050241-3	2008	Preventing phosphorylation of S408 did not block CD4 recruitment to the IS; rather, it blocked the ability of CD4 to leave the IS.	Farnesylacetone	30-34	CD4 antigen	Mus musculus	110-113
19050249-7	2008	Zymosan treatment induced suppression of T1D was associated with an increase in the L-selectin(high) T cell frequencies and enhanced suppressor function of CD4(+)CD25(+) T regulatory cells.	Zymosan	0-7	CD4 antigen	Mus musculus	156-159
19050249-8	2008	Further, activation by anti-CD3-Ab induced larger amounts of TGF-beta1 and/or IL-10 production by CD4(+)CD25(+) and CD4(+)CD25(-) T cells from zymosan-treated mice.	Zymosan	143-150	CD4 antigen	Mus musculus	98-101
19050249-8	2008	Further, activation by anti-CD3-Ab induced larger amounts of TGF-beta1 and/or IL-10 production by CD4(+)CD25(+) and CD4(+)CD25(-) T cells from zymosan-treated mice.	Zymosan	143-150	CD4 antigen	Mus musculus	116-119
18838247-2	2008	EAU is induced in B10.RIII mice by immunization with RBP-3 161-180 peptide and intraperitoneal pertussis toxin and is mediated by CD4(+) T cells that generate a clinically monophasic disease peaking approximately 2 weeks post-immunization.	Water	0-3	CD4 antigen	Mus musculus	130-133
18977126-0	2008	fat-1 transgene expression prevents cell culture-induced loss of membrane n-3 fatty acids in activated CD4+ T-cells.	Fatty Acids, Omega-3	74-89	CD4 antigen	Mus musculus	103-106
18977126-8	2008	Carboxyfluorescein succinidyl ester (CFSE) -labeled CD4+ T-cells from fat-1/SAF vs. WT/SAF mice stimulated with anti-CD3 and anti-CD28 for 3d, exhibited a reduced (P&lt;0.05) number of cell divisions.	carboxyfluorescein succinidyl ester	0-35	CD4 antigen	Mus musculus	52-55
18977126-9	2008	We conclude that fat-1-containing CD4+ T-cells express a physiologically relevant, n-3 PUFA enriched, membrane fatty acid composition which is resistant to conventional cell culture-induced depletion.	Fatty Acids, Omega-3	83-91	CD4 antigen	Mus musculus	34-37
18977126-9	2008	We conclude that fat-1-containing CD4+ T-cells express a physiologically relevant, n-3 PUFA enriched, membrane fatty acid composition which is resistant to conventional cell culture-induced depletion.	Fatty Acids	111-121	CD4 antigen	Mus musculus	34-37
19068204-5	2008	RESULTS: In vivo, the mean survival time of recipients with islets and antigen-specific CD4(+)CD25(+) Treg cells were (34.57+/-17.15) days, whereas transplanted islets without Treg treatment survived (10.6+/-1.82) days in control mice.	treg	102-106	CD4 antigen	Mus musculus	88-91
19134256-19	2008	CONCLUSION: The conditioned immune response models established by both noise and SAC as CS and budesonide and salbutamol as UCS can downregulate nAChRalpha7 on CD4(+)T lymphocytes, regulate the function of CD4(+)T lymphocytes, and achieve the same therapeutic efficacy in treatment of asthma.	Cesium	88-90	CD4 antigen	Mus musculus	160-163
19134256-19	2008	CONCLUSION: The conditioned immune response models established by both noise and SAC as CS and budesonide and salbutamol as UCS can downregulate nAChRalpha7 on CD4(+)T lymphocytes, regulate the function of CD4(+)T lymphocytes, and achieve the same therapeutic efficacy in treatment of asthma.	Budesonide	95-105	CD4 antigen	Mus musculus	160-163
19134256-19	2008	CONCLUSION: The conditioned immune response models established by both noise and SAC as CS and budesonide and salbutamol as UCS can downregulate nAChRalpha7 on CD4(+)T lymphocytes, regulate the function of CD4(+)T lymphocytes, and achieve the same therapeutic efficacy in treatment of asthma.	Budesonide	95-105	CD4 antigen	Mus musculus	206-209
19134256-19	2008	CONCLUSION: The conditioned immune response models established by both noise and SAC as CS and budesonide and salbutamol as UCS can downregulate nAChRalpha7 on CD4(+)T lymphocytes, regulate the function of CD4(+)T lymphocytes, and achieve the same therapeutic efficacy in treatment of asthma.	Albuterol	110-120	CD4 antigen	Mus musculus	160-163
19134256-19	2008	CONCLUSION: The conditioned immune response models established by both noise and SAC as CS and budesonide and salbutamol as UCS can downregulate nAChRalpha7 on CD4(+)T lymphocytes, regulate the function of CD4(+)T lymphocytes, and achieve the same therapeutic efficacy in treatment of asthma.	Albuterol	110-120	CD4 antigen	Mus musculus	206-209
19141973-0	2008	[Effect of suppressive oligodeoxynucleotides on the functional differentiation in CD4(+) Th1 lymphocytes in mice in vitro].	Oligodeoxyribonucleotides	23-44	CD4 antigen	Mus musculus	82-85
19141973-1	2008	OBJECTIVE: To explore the effect of suppressive oligodeoxynucleotides (Sup ODN) on the Th1 differentiation of CD4(+)T splenetic lymphocytes in mice.	Oligodeoxyribonucleotides	48-69	CD4 antigen	Mus musculus	110-113
19004789-4	2008	The MP CD4(+) and CD8(+) T cells produced IFNgamma upon PMA/ionomycin stimulation, thus showing innate-like function.	Ionomycin	60-69	CD4 antigen	Mus musculus	7-10
18981115-0	2008	Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.	Imatinib Mesylate	0-17	CD4 antigen	Mus musculus	27-30
18981115-4	2008	In the current study, we have investigated the influence of imatinib mesylate on CD4(+)CD25(+)FoxP3(+) regulatory T cells (Treg), a critical population of lymphocytes that contributes to peripheral tolerance.	Imatinib Mesylate	60-77	CD4 antigen	Mus musculus	81-84
18765239-7	2008	RESULTS: Both ethanol and AT1002 induced persistent latency-associated peptide-positive CD4(+) regulatory T cells that, as shown in adoptive transfer studies, render mice resistant to the induction of TNBS colitis.	Ethanol	14-21	CD4 antigen	Mus musculus	88-91
18765239-7	2008	RESULTS: Both ethanol and AT1002 induced persistent latency-associated peptide-positive CD4(+) regulatory T cells that, as shown in adoptive transfer studies, render mice resistant to the induction of TNBS colitis.	AT1002	26-32	CD4 antigen	Mus musculus	88-91
18941214-0	2008	n-3 polyunsaturated fatty acids suppress the localization and activation of signaling proteins at the immunological synapse in murine CD4+ T cells by affecting lipid raft formation.	Fatty Acids, Omega-3	0-31	CD4 antigen	Mus musculus	134-137
18941214-2	2008	Using CD4(+) T cells from wild-type control and fat-1 transgenic mice (enriched in n-3 PUFA), we show that membrane raft accumulation assessed by Laurdan (6-dodecanoyl-2-dimethyl aminonaphthalene) labeling was enhanced in fat-1 cells following immunological synapse (IS) formation by CD3-specific Ab expressing hybridoma cells.	Nitrogen	3-4	CD4 antigen	Mus musculus	6-9
18941214-2	2008	Using CD4(+) T cells from wild-type control and fat-1 transgenic mice (enriched in n-3 PUFA), we show that membrane raft accumulation assessed by Laurdan (6-dodecanoyl-2-dimethyl aminonaphthalene) labeling was enhanced in fat-1 cells following immunological synapse (IS) formation by CD3-specific Ab expressing hybridoma cells.	6-dodecanoyl-2-dimethyl aminonaphthalene	155-195	CD4 antigen	Mus musculus	6-9
18832748-5	2008	Adoptive transfer of carboxyfluorescein diacetate, succinimidyl ester (CFSE)-labeled naive CD4(+) T cells in LDLR(-/-) recipients and subsequent immunization demonstrated effective priming of naive T cells in hypercholesterolemic mice.	carboxyfluoresceindiacetate	21-49	CD4 antigen	Mus musculus	91-94
18832748-5	2008	Adoptive transfer of carboxyfluorescein diacetate, succinimidyl ester (CFSE)-labeled naive CD4(+) T cells in LDLR(-/-) recipients and subsequent immunization demonstrated effective priming of naive T cells in hypercholesterolemic mice.	succinimidyl ester	51-69	CD4 antigen	Mus musculus	91-94
18835195-5	2008	B cell-specific Fas-deficient mice also showed an accumulation of IgG1(+) memory B cells expressing high amounts of CD80 and the expansion of CD28-expressing CD4(+) Th cells.	ammonium ferrous sulfate	16-19	CD4 antigen	Mus musculus	158-161
18855977-0	2008	Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma.	benzo[a]	101-109	CD4 antigen	Mus musculus	13-16
18855977-0	2008	Depletion of CD4(+)CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a]pyrene-induced forestomach carcinoma.	pyrene	109-115	CD4 antigen	Mus musculus	13-16
18833297-8	2008	This interference was signal sequence-dependent since replacing the signal peptide with that of CD4 or murine HC rendered human HCs resistant to rh178.	rh178	145-150	CD4 antigen	Mus musculus	96-99
18649937-3	2008	These nanocrystals were further tested for their ability to bind CD4+ T lymphocytes, bound to biotin-labeled anti-CD4 mAbs, isolated from the spleen of C57BL/6 mice.	Biotin	94-100	CD4 antigen	Mus musculus	65-68
18649937-3	2008	These nanocrystals were further tested for their ability to bind CD4+ T lymphocytes, bound to biotin-labeled anti-CD4 mAbs, isolated from the spleen of C57BL/6 mice.	Biotin	94-100	CD4 antigen	Mus musculus	114-117
18649083-6	2008	Additionally, proliferation of carboxyfluorescein diacetate succinimidylester-labelled CD4(+) T cells cocultured with gammadelta T cells was analysed by flow cytometry.	5-(6)-carboxyfluorescein diacetate succinimidyl ester	31-77	CD4 antigen	Mus musculus	87-90
18802066-8	2008	injection of PLP(139-151)-pulsed, ethylcarbodiimide-fixed APCs (PLP(139-151)-SP) inhibited the development of clinical disease concomitant with increased production of IL-10 and conversion of Foxp3(+) Tregs from CD4(+)CD25(-) progenitors.	ethylcarbodiimide	34-51	CD4 antigen	Mus musculus	212-215
18802086-6	2008	Importantly, memory CD4 T cells generated from aged BMPC exhibit potent cognate helper function for humoral responses, which are critical for effective immunization.	Dimethylol-p-kresol	52-56	CD4 antigen	Mus musculus	20-23
18782267-4	2008	Here, we found that triptolide significantly inhibited the generation of Th17 cells from murine splenocytes and purified CD4(+) T cells in a dose-dependent manner.	triptolide	20-30	CD4 antigen	Mus musculus	121-124
18791453-2	2008	We hypothesized that Kupffer cells activate CD4+ T-cells in the postischemic liver, by the release of free oxygen radicals and cytokines.	free oxygen radicals	102-122	CD4 antigen	Mus musculus	44-47
18791453-9	2008	CONCLUSION: Kupffer cells trigger recruitment of CD4+ T-cells in the postischemic liver by the release of reactive oxygen species, IL-6, and TNF-alpha.	Reactive Oxygen Species	106-129	CD4 antigen	Mus musculus	49-52
18769544-6	2008	Pressurized oxygen therapy reduced peripheral parasitemia, expression of TNF-alpha, IFN-gamma and IL-10 mRNA levels and percentage of gammadelta and alphabeta CD4(+) and CD8(+) T lymphocytes sequestered in mice brains, thus resulting in a reduction of blood-brain barrier (BBB) dysfunction and hypothermia.	Oxygen	12-18	CD4 antigen	Mus musculus	159-162
18493168-0	2008	Depletion of thymus-derived CD4+CD25+ T cells abrogates the suppressive effects of alpha-galactosylceramide treatment on experimental allergic conjunctivitis.	alpha-galactosylceramide	83-107	CD4 antigen	Mus musculus	28-31
18493168-1	2008	BACKGROUND: We showed previously that alpha-galactosylceramide (alpha-GalCer) treatment elevated splenic CD4+CD25+Foxp3+ T-cell numbers and suppressed the development of experimental allergic conjunctivitis (EC).	alpha-galactosylceramide	38-62	CD4 antigen	Mus musculus	105-108
18493168-1	2008	BACKGROUND: We showed previously that alpha-galactosylceramide (alpha-GalCer) treatment elevated splenic CD4+CD25+Foxp3+ T-cell numbers and suppressed the development of experimental allergic conjunctivitis (EC).	alpha-galactosylceramide	64-76	CD4 antigen	Mus musculus	105-108
18795166-3	2008	RESULTS: ApoE(-/-) mice exposed to inhaled asbestos fibers had approximately 3-fold larger atherosclerotic lesions than did TiO(2)-exposed ApoE(-/-) mice or asbestos-exposed ApoE(-/-)/CD4(-/-) double-knockout (DKO) mice.	Asbestos	43-51	CD4 antigen	Mus musculus	184-187
18469197-9	2008	Although EtxB treatment of in vitro cocultures of T cells and Mphis increased IL-10 production, EtxB treatment in vivo increased the proportion and number of IL-17-producing CD4(+) cells infiltrating the eye.	etxb	96-100	CD4 antigen	Mus musculus	174-177
18650065-8	2008	Spleen size and the percentage of CD4+CD69+ cells were decreased, with an increase in CD4+CD25+ T cells in the TSA-treated mice.	trichostatin A	111-114	CD4 antigen	Mus musculus	86-89
18463970-6	2008	It is interesting to note that in vivo treatment with 15d-PGJ2 or curcumin results in a significant decrease in TLR4 and TLR9 expression in CD4(+) and CD8(+) T cells in association with the amelioration of EAE.	15-deoxyprostaglandin J2	54-62	CD4 antigen	Mus musculus	140-143
18463970-6	2008	It is interesting to note that in vivo treatment with 15d-PGJ2 or curcumin results in a significant decrease in TLR4 and TLR9 expression in CD4(+) and CD8(+) T cells in association with the amelioration of EAE.	Curcumin	66-74	CD4 antigen	Mus musculus	140-143
18539902-9	2008	These results indicate that decreased toxicity and increased efficacy of bortezomib in murine allo-BMT can be achieved by removal of CD4(+) T cells from the graft or by inhibiting TNFalpha.	Bortezomib	73-83	CD4 antigen	Mus musculus	133-136
18550851-3	2008	In vivo VAG539 treatment results in increased frequency of splenic CD4(+) T cells expressing CD25 and Foxp3, markers associated with regulatory T (Tr) cells, and in vitro VAF347 treatment of splenic CD4(+) T cells improved CD4(+)CD25(+)Foxp3(+) T-cell survival.	vag539	8-14	CD4 antigen	Mus musculus	67-70
18550851-3	2008	In vivo VAG539 treatment results in increased frequency of splenic CD4(+) T cells expressing CD25 and Foxp3, markers associated with regulatory T (Tr) cells, and in vitro VAF347 treatment of splenic CD4(+) T cells improved CD4(+)CD25(+)Foxp3(+) T-cell survival.	vag539	8-14	CD4 antigen	Mus musculus	199-202
18550851-3	2008	In vivo VAG539 treatment results in increased frequency of splenic CD4(+) T cells expressing CD25 and Foxp3, markers associated with regulatory T (Tr) cells, and in vitro VAF347 treatment of splenic CD4(+) T cells improved CD4(+)CD25(+)Foxp3(+) T-cell survival.	vag539	8-14	CD4 antigen	Mus musculus	199-202
18684927-0	2008	Functional characterization and gene expression analysis of CD4+ CD25+ regulatory T cells generated in mice treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin.	Polychlorinated Dibenzodioxins	121-156	CD4 antigen	Mus musculus	60-63
18684927-2	2008	Mice exposed to TCDD during an acute B6-into-B6D2F1 graft-vs-host response do not develop disease, and recently this has been shown to correlate with the generation of CD4(+) T cells that express CD25 and demonstrate in vitro suppressive function.	Polychlorinated Dibenzodioxins	16-20	CD4 antigen	Mus musculus	168-171
18684927-5	2008	We found that TCDD-CD4(+) cells actively proliferate in response to various stimuli but suppress IL-2 production and the proliferation of effector T cells.	Polychlorinated Dibenzodioxins	14-18	CD4 antigen	Mus musculus	19-22
18684927-6	2008	Like natural T-regs, TCDD-CD4(+) cells do not produce IL-2 and their suppressive function is contact dependent but abrogated by costimulation through glucocorticoid-induced TNFR (GITR).	Polychlorinated Dibenzodioxins	21-25	CD4 antigen	Mus musculus	26-29
18684927-8	2008	Several genes were significantly up-regulated in TCDD-CD4(+) cells including TGF-beta3, Blimp-1, and granzyme B, as well as genes associated with the IL12-Rb2 signaling pathway.	Polychlorinated Dibenzodioxins	49-53	CD4 antigen	Mus musculus	54-57
18684927-10	2008	Only 2% of TCDD-CD4(+) cells express Foxp3, suggesting that the AhR does not rely on Foxp3 for suppressive activity.	Polychlorinated Dibenzodioxins	11-15	CD4 antigen	Mus musculus	16-19
18684927-11	2008	The generation of CD4(+) cells with regulatory function mediated through activation of the AhR by TCDD may represent a novel pathway for the induction of T-regs.	Polychlorinated Dibenzodioxins	98-102	CD4 antigen	Mus musculus	18-21
18668589-10	2008	Culture of CD4+CD25+ cells with norepinephrine (10(-5)M) for 24 hours before transfer worsened the arthritis.	Norepinephrine	32-46	CD4 antigen	Mus musculus	11-14
18496852-8	2008	Expert analysis, SUG and FDG identified regions in the data that showed activation of CD4+ and CD8+ lymphocytes with anti-CD3 treatment.	N(2)-succinyl-L-arginine	17-20	CD4 antigen	Mus musculus	86-89
18463686-0	2008	Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice.	Doxorubicin	45-56	CD4 antigen	Mus musculus	15-18
18463686-4	2008	In contrast, pretreatment with doxorubicin enhanced the PADRE-specific CD4+ T-cell immune responses generated by Ii-PADRE DNA vaccination.	Doxorubicin	31-42	CD4 antigen	Mus musculus	71-74
18641331-11	2008	Interestingly, CD4(+)T cells isolated from mercury-treated hemopexin-null mice show reduced IFN-gamma-dependent STAT1 phosphorylation compared with that of wild-type mice.	Mercury	43-50	CD4 antigen	Mus musculus	15-18
18656798-9	2008	Tacrolimus prophylaxis was associated with inhibition of recruitment of CD4+, CD8+ and interleukin-2R+ inflammatory cells into the allografts, suggesting a central role for interleukin-2 in the development of OAD.	Tacrolimus	0-10	CD4 antigen	Mus musculus	72-75
18704301-9	2008	It is concluded that the treatment with anti-CD4 McAb could prevent the activation of T cells, reverse the abnormal secretion of cytokines and the imbalance between Th1/Th2 cell subsets and abnormal production of autoantibody against ADP/ATP carrier, and eventually avoid myocardial injuries.	Adenosine Diphosphate	234-237	CD4 antigen	Mus musculus	45-48
18704301-9	2008	It is concluded that the treatment with anti-CD4 McAb could prevent the activation of T cells, reverse the abnormal secretion of cytokines and the imbalance between Th1/Th2 cell subsets and abnormal production of autoantibody against ADP/ATP carrier, and eventually avoid myocardial injuries.	Adenosine Triphosphate	238-241	CD4 antigen	Mus musculus	45-48
18601933-0	2008	Leukotriene B4 is essential for selective eosinophil recruitment following allergen challenge of CD4+ cells in a model of chronic eosinophilic inflammation.	Leukotriene B4	0-14	CD4 antigen	Mus musculus	97-100
18157673-9	2008	CONCLUSION: Our study suggests that immunization with peptides mimicking GD2 ganglioside inhibits tumor growth through antibody and/or CD4-positive T cell-mediated mechanisms.	ganglioside, GD2	73-88	CD4 antigen	Mus musculus	135-138
18340641-11	2008	Analysis of mucosal lymphocyte subsets suggested pentostatin reduced numbers of effector CD4+ CD69+ T cells, while sparing CD4+ CD62L+ T cells.	Pentostatin	49-60	CD4 antigen	Mus musculus	89-92
18856067-7	2008	Moreover, coreceptor CD4 dominates CDS, because the response of transfectants CD4+CD8+ is blocked by antibodies to CD4 and MHC Class II Ab molecule but not to coreceptor CD8.	Cadmium	35-38	CD4 antigen	Mus musculus	78-81
18856067-7	2008	Moreover, coreceptor CD4 dominates CDS, because the response of transfectants CD4+CD8+ is blocked by antibodies to CD4 and MHC Class II Ab molecule but not to coreceptor CD8.	Cadmium	35-38	CD4 antigen	Mus musculus	78-81
19160959-5	2008	The inhibitory role of the CD4+CD25+ T cells was assessed by [3H] thymidine incorporation method and the cytokines in the cultural supernatant were detected by ELISA.	Tritium	62-64	CD4 antigen	Mus musculus	27-30
19160959-5	2008	The inhibitory role of the CD4+CD25+ T cells was assessed by [3H] thymidine incorporation method and the cytokines in the cultural supernatant were detected by ELISA.	Thymidine	66-75	CD4 antigen	Mus musculus	27-30
18408127-4	2008	The impaired EDV and increased superoxide generation induced by HC were significantly blunted in severe combined immunodeficient (SCID) mice and CD4+ T lymphocyte-deficient mice.	Superoxides	31-41	CD4 antigen	Mus musculus	145-148
18408127-8	2008	These findings implicate the immune system in the early endothelial cell dysfunction associated with hypercholesterolemia and are consistent with a mechanism of impaired EDV that is mediated by CD4+ T cells and IFN-gamma, acting through the generation of superoxide from vascular NAD(P)H oxidase.	Superoxides	255-265	CD4 antigen	Mus musculus	194-197
18200517-10	2008	Secretion of IL-4 and IL-5 by CD4(+) lymphocytes of BALB/c mice but not SJL/J mice was significantly augmented by ConA and reduced to control levels by curcumin.	Curcumin	152-160	CD4 antigen	Mus musculus	30-33
18347032-6	2008	Stimulation of CD4(+) T cells by LFn fusion proteins does not require PA but is enhanced by PA in vitro.	Protactinium	92-94	CD4 antigen	Mus musculus	15-18
18381351-9	2008	Enhanced activation of STAT1, a higher ratio of CD4(+)IFN-gamma(+) T cells and a lower frequency of Foxp3(+) regulatory T (Treg) cells, were observed in the colon of DSS-treated SOCS-1(+/-) mice compared with DSS-treated WT mice.	Dextran Sulfate	166-169	CD4 antigen	Mus musculus	48-51
18433816-0	2008	Reduction of myeloid suppressor cell derived nitric oxide provides a mechanistic basis of lead enhancement of alloreactive CD4(+) T cell proliferation.	Nitric Oxide	45-57	CD4 antigen	Mus musculus	123-126
18420312-1	2008	We compared murine T-cell responses to synthetic lipopeptide vaccines in which the TLR2 ligand Pam(2)Cys was attached to co-linear CD4+ and CD8+ T-cell epitopes of ovalbumin (OVA) in a linear or branched configuration.	(2)cys	98-104	CD4 antigen	Mus musculus	131-134
18483278-0	2008	Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis.	7,12-dimethylbenz	47-64	CD4 antigen	Mus musculus	22-25
18483278-0	2008	Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis.	anthracene	67-77	CD4 antigen	Mus musculus	22-25
18483278-5	2008	CD4(+) T cells from DMBA contact-sensitized mice preferentially produced interleukin 4 (IL-4), IL-10, and IL-17; CD8(+) T cells, on the other hand, secreted IFN-gamma.	9,10-Dimethyl-1,2-benzanthracene	20-24	CD4 antigen	Mus musculus	0-3
18465023-0	2008	Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in prevention of autoimmune diabetes in non-obese diabetic mice treated with alpha-galactosylceramide.	alpha-galactosylceramide	145-169	CD4 antigen	Mus musculus	39-42
18465023-4	2008	We show that treatment with alpha-galactosylceramide increases the size of the CD4+CD25+ Treg cell compartment in NOD mice, and augments the expression of forkhead/winged helix transcription factor and the potency of CD4+CD25+ Treg cells to inhibit proliferation of CD4+CD25- T cells.	alpha-galactosylceramide	28-52	CD4 antigen	Mus musculus	79-82
18465023-4	2008	We show that treatment with alpha-galactosylceramide increases the size of the CD4+CD25+ Treg cell compartment in NOD mice, and augments the expression of forkhead/winged helix transcription factor and the potency of CD4+CD25+ Treg cells to inhibit proliferation of CD4+CD25- T cells.	alpha-galactosylceramide	28-52	CD4 antigen	Mus musculus	217-220
18465023-4	2008	We show that treatment with alpha-galactosylceramide increases the size of the CD4+CD25+ Treg cell compartment in NOD mice, and augments the expression of forkhead/winged helix transcription factor and the potency of CD4+CD25+ Treg cells to inhibit proliferation of CD4+CD25- T cells.	alpha-galactosylceramide	28-52	CD4 antigen	Mus musculus	217-220
18465023-5	2008	Our data indicate that NKT cells and CD4+CD25+ Treg cells might cooperate in the prevention of autoimmune diabetes in NOD mice treated with alpha-galactosylceramide.	alpha-galactosylceramide	140-164	CD4 antigen	Mus musculus	37-40
18303055-7	2008	On the other hand, quantitative analysis of cellular infiltration in the central nervous system (CNS) on day 9 of active immunization EAE showed that the CD4+ cell number in the CNS isolated from GM2/GD2-/- mice was significantly less than that from wild-type mice.	gm2	196-199	CD4 antigen	Mus musculus	154-157
18408722-0	2008	The proline-rich sequence of CD3epsilon controls T cell antigen receptor expression on and signaling potency in preselection CD4+CD8+ thymocytes.	Proline	4-11	CD4 antigen	Mus musculus	125-128
18431243-3	2008	RESULTS: In an alloimmune response model, transfer of nondiabetic CD4, but not CD8 T cells, elicited pancreas allograft rejection in streptozotocin (STZ)-induced diabetic NOD/scid mice.	Streptozocin	133-147	CD4 antigen	Mus musculus	66-69
18431243-3	2008	RESULTS: In an alloimmune response model, transfer of nondiabetic CD4, but not CD8 T cells, elicited pancreas allograft rejection in streptozotocin (STZ)-induced diabetic NOD/scid mice.	Streptozocin	149-152	CD4 antigen	Mus musculus	66-69
18414636-10	2008	The percentages of CD4(+)CD25(+) cells were decreased in mice exposed to BPA either prenatally or in adulthood.	bisphenol A	73-76	CD4 antigen	Mus musculus	19-22
18267128-0	2008	Lipid peroxidation-derived aldehyde-protein adducts contribute to trichloroethene-mediated autoimmunity via activation of CD4+ T cells.	Aldehydes	27-35	CD4 antigen	Mus musculus	122-125
18267128-0	2008	Lipid peroxidation-derived aldehyde-protein adducts contribute to trichloroethene-mediated autoimmunity via activation of CD4+ T cells.	Trichloroethylene	66-81	CD4 antigen	Mus musculus	122-125
18267128-6	2008	Furthermore, stimulation of cultured splenic lymphocytes from both control and TCE-treated mice with MDA-adducted mouse serum albumin (MDA-MSA) or HNE-MSA for 72 h showed significant proliferation of CD4+ T cells in TCE-treated mice as analyzed by flow cytometry.	Trichloroethylene	79-82	CD4 antigen	Mus musculus	200-203
18267128-6	2008	Furthermore, stimulation of cultured splenic lymphocytes from both control and TCE-treated mice with MDA-adducted mouse serum albumin (MDA-MSA) or HNE-MSA for 72 h showed significant proliferation of CD4+ T cells in TCE-treated mice as analyzed by flow cytometry.	Trichloroethylene	216-219	CD4 antigen	Mus musculus	200-203
18328445-0	2008	Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells.	Resveratrol	0-11	CD4 antigen	Mus musculus	53-56
18328445-4	2008	In the present study, CD4+CD25+ cell population among CD4+ cells was inhibited ex vivo by resveratrol treatment in a dose-dependent manner.	Resveratrol	90-101	CD4 antigen	Mus musculus	22-25
18328445-4	2008	In the present study, CD4+CD25+ cell population among CD4+ cells was inhibited ex vivo by resveratrol treatment in a dose-dependent manner.	Resveratrol	90-101	CD4 antigen	Mus musculus	54-57
18328445-5	2008	FoxP3+ expressing cells among CD4+CD25+ population were significantly reduced after resveratrol treatment ex vivo in intracellular FACS analysis.	Resveratrol	84-95	CD4 antigen	Mus musculus	30-33
18328445-6	2008	Single intraperitoneal administration of 4 mg/kg resveratrol suppressed the CD4+CD25+ cell population among CD4+ cells and downregulated secretion of TGF-beta, an immunosuppressive cytokine, measured from the spleens of tumor-bearing mice.	Resveratrol	49-60	CD4 antigen	Mus musculus	76-79
18328445-6	2008	Single intraperitoneal administration of 4 mg/kg resveratrol suppressed the CD4+CD25+ cell population among CD4+ cells and downregulated secretion of TGF-beta, an immunosuppressive cytokine, measured from the spleens of tumor-bearing mice.	Resveratrol	49-60	CD4 antigen	Mus musculus	108-111
18328445-8	2008	Taken together, these results suggest that resveratrol has a suppressive role on CD4+CD25+ cell population and makes peritumoral microenvironment unfavorable to tumor in tumor-bearing mice.	Resveratrol	43-54	CD4 antigen	Mus musculus	81-84
18395551-9	2008	Adoptive transfer of DEX-treated effector memory CD8+ T cells into ovalbumin-sensitized and ovalbumin-challenged CD8-/- mice resulted in significant increases in AHR, allergic inflammation, goblet cell metaplasia, and numbers of both CD8+ and CD4+ T cells in the bronchoalveolar lavage fluid and lungs.	Dexamethasone	21-24	CD4 antigen	Mus musculus	243-246
18354225-10	2008	Furthermore, there was a significant reduction in the PG-specific CD4(+) T cell recall response as well as significantly fewer PG-specific CD4(+) T cells producing IFN-gamma and IL-17, but not IL-4.	pg	54-56	CD4 antigen	Mus musculus	66-69
18354225-10	2008	Furthermore, there was a significant reduction in the PG-specific CD4(+) T cell recall response as well as significantly fewer PG-specific CD4(+) T cells producing IFN-gamma and IL-17, but not IL-4.	pg	127-129	CD4 antigen	Mus musculus	139-142
18194666-0	2008	Combined insulin B:9-23 self-peptide and polyinosinic-polycytidylic acid accelerate insulitis but inhibit development of diabetes by increasing the proportion of CD4+Foxp3+ regulatory T cells in the islets in non-obese diabetic mice.	Poly I-C	41-72	CD4 antigen	Mus musculus	162-165
18292539-6	2008	Importantly, reduction of complex N-glycans on MA782 tumor cells by Mgat5-shRNA resulted in significantly increased proliferation and CD45 surface expression of CD4+ T cells.	n-glycans	34-43	CD4 antigen	Mus musculus	134-137
18470679-6	2008	Levels of CD4 and CD8 proteins in tumors were higher in the pHSVtk/GCV group than in the control group.	Ganciclovir	67-70	CD4 antigen	Mus musculus	10-13
18208456-0	2008	The immunosuppressive effects of phthalocyanine photodynamic therapy in mice are mediated by CD4+ and CD8+ T cells and can be adoptively transferred to naive recipients.	phthalocyanine	33-47	CD4 antigen	Mus musculus	93-96
18078970-6	2008	In transgenic mice, 3 to 6 weeks of oral AC-PS administration increased the proportion of CD4(+) T cells and B cells within the spleen.	ac-ps	41-46	CD4 antigen	Mus musculus	90-93
18637590-4	2008	It indicates that the combination of Fructus psoraleae and dihydroartemisinin is effective to mice cryptosporidiosis probably through upregulating serum IFN-gamma, proportion of CD4+ and CD3+ T cells and NO concentration in intestine.	artenimol	59-77	CD4 antigen	Mus musculus	178-181
18258343-3	2008	RTS,S/AS01B-induced high specific antibody titers and increased the frequency of mouse CD4(+) and CD8(+) T cells expressing IFN-gamma, and of monkey CD4(+) T cells expressing IL-2 and/or IFN-gamma and/or TNF-alpha upon stimulation with vaccine antigens.	as01b	6-11	CD4 antigen	Mus musculus	87-90
18258343-3	2008	RTS,S/AS01B-induced high specific antibody titers and increased the frequency of mouse CD4(+) and CD8(+) T cells expressing IFN-gamma, and of monkey CD4(+) T cells expressing IL-2 and/or IFN-gamma and/or TNF-alpha upon stimulation with vaccine antigens.	as01b	6-11	CD4 antigen	Mus musculus	149-152
17900858-5	2008	The main findings were that: (1) chronic restraint-stress reduced the i-IEl population in the small intestine; (2) adrenalectomy, treatment with RU-486 and chemical sympathectomy decreased the number of gammadelta, CD4+ and CD8+ T cells in non-stressed groups; (3) dexamethasone reduced the number of gammadelta and CD8+ T cells, and (4) epinephrine reduced the number of gammadelta, CD4+ and CD8+ T cells.	Mifepristone	145-151	CD4 antigen	Mus musculus	215-218
17900858-5	2008	The main findings were that: (1) chronic restraint-stress reduced the i-IEl population in the small intestine; (2) adrenalectomy, treatment with RU-486 and chemical sympathectomy decreased the number of gammadelta, CD4+ and CD8+ T cells in non-stressed groups; (3) dexamethasone reduced the number of gammadelta and CD8+ T cells, and (4) epinephrine reduced the number of gammadelta, CD4+ and CD8+ T cells.	Mifepristone	145-151	CD4 antigen	Mus musculus	384-387
17900858-5	2008	The main findings were that: (1) chronic restraint-stress reduced the i-IEl population in the small intestine; (2) adrenalectomy, treatment with RU-486 and chemical sympathectomy decreased the number of gammadelta, CD4+ and CD8+ T cells in non-stressed groups; (3) dexamethasone reduced the number of gammadelta and CD8+ T cells, and (4) epinephrine reduced the number of gammadelta, CD4+ and CD8+ T cells.	gammadelta	203-213	CD4 antigen	Mus musculus	215-218
17900858-5	2008	The main findings were that: (1) chronic restraint-stress reduced the i-IEl population in the small intestine; (2) adrenalectomy, treatment with RU-486 and chemical sympathectomy decreased the number of gammadelta, CD4+ and CD8+ T cells in non-stressed groups; (3) dexamethasone reduced the number of gammadelta and CD8+ T cells, and (4) epinephrine reduced the number of gammadelta, CD4+ and CD8+ T cells.	gammadelta	203-213	CD4 antigen	Mus musculus	384-387
17654501-6	2008	We also found that the estrogen receptor (ER) exist in the CD4+CD25- T cells and the conversion of CD4+CD25- T cells into CD4+CD25+ T cells stimulated by E2 could be inhibited by ICI182,780, a specific inhibitor of ER(s).	ici182	179-185	CD4 antigen	Mus musculus	59-62
17654501-6	2008	We also found that the estrogen receptor (ER) exist in the CD4+CD25- T cells and the conversion of CD4+CD25- T cells into CD4+CD25+ T cells stimulated by E2 could be inhibited by ICI182,780, a specific inhibitor of ER(s).	ici182	179-185	CD4 antigen	Mus musculus	99-102
17654501-6	2008	We also found that the estrogen receptor (ER) exist in the CD4+CD25- T cells and the conversion of CD4+CD25- T cells into CD4+CD25+ T cells stimulated by E2 could be inhibited by ICI182,780, a specific inhibitor of ER(s).	ici182	179-185	CD4 antigen	Mus musculus	99-102
18203901-9	2008	Consumption of AlaGln did not lessen the effects of asparaginase in bone marrow or thymus but mitigated cellular losses in the CD4+, CD8+, and CD11b+ populations in spleen.	alanylglutamine	15-21	CD4 antigen	Mus musculus	127-130
18683721-5	2008	The suppressive activity of CD4+ CD25+ Treg to CD4+ CD25- T cells was analyzed by MTT test.	monooxyethylene trimethylolpropane tristearate	82-85	CD4 antigen	Mus musculus	28-31
18186095-4	2008	In vitro data are presented that demonstrate that carbohydrate modification of OVA leads to a 50-fold enhancement of presentation of antigenic peptide to CD4(+) T cells.	Carbohydrates	50-62	CD4 antigen	Mus musculus	154-157
18466643-2	2008	A new report in the previous issue of Arthritis Research &amp; Therapy supports this idea by demonstrating that indoleamine 2,3-dioxygenase-expressing dendritic cells in Peyer"s patches from orally tolerized mice suppress T-cell responses via the generation of CD4+CD25+ regulatory T cells.	Adenosine Monophosphate	58-61	CD4 antigen	Mus musculus	261-264
18466643-2	2008	A new report in the previous issue of Arthritis Research &amp; Therapy supports this idea by demonstrating that indoleamine 2,3-dioxygenase-expressing dendritic cells in Peyer"s patches from orally tolerized mice suppress T-cell responses via the generation of CD4+CD25+ regulatory T cells.	indolamine	112-123	CD4 antigen	Mus musculus	261-264
18024466-3	2008	Monitoring the fate of CFSE-labeled ovalbumin peptide-specific TCR transgenic CD4(+) T cells revealed that immunization with M-OVA(323-339) induced normal clonal expansion, recirculation and CD62L expression of antigen-specific T cells in vivo.	m-ova	125-130	CD4 antigen	Mus musculus	78-81
17719275-5	2008	This SPI2 carrier molecule is sufficient to induce a concomitant p60-specific CD4 and CD8 T-cell response in Salmonella-vaccinated mice.	spi2	5-9	CD4 antigen	Mus musculus	78-81
17911179-8	2008	Finally, in competitive reaggregation thymic organ cultures, CCR9(-/-) preselection DP thymocytes were disadvantaged significantly in their ability to generate CD4 single-positive (SP) thymocytes, a finding that correlated with a reduced ability to form TCR-MHC-dependent conjugates with thymic epithelial cells.	dp	84-86	CD4 antigen	Mus musculus	160-163
18369925-2	2008	Mice that are chronically exposed to 20% (w/v) ethanol in water develop immunodeficiency and have T cells with abnormal activation profiles, reduced total numbers, increased CD4/CD8 ratios, and an increased memory/naive phenotype ratio.	Ethanol	47-54	CD4 antigen	Mus musculus	174-177
17604837-8	2008	Triggering the CD3/TCR complex together with co-stimulation applied by rVCAM-1 or rICAM-1 induced the generation of CD4+ single positive (SP) thymocytes from CD4+CD8+ DP thymocytes whereas either signal alone did not result in generation of CD4+ SP thymocytes.	sp	138-140	CD4 antigen	Mus musculus	116-119
17604837-8	2008	Triggering the CD3/TCR complex together with co-stimulation applied by rVCAM-1 or rICAM-1 induced the generation of CD4+ single positive (SP) thymocytes from CD4+CD8+ DP thymocytes whereas either signal alone did not result in generation of CD4+ SP thymocytes.	sp	138-140	CD4 antigen	Mus musculus	158-161
17604837-8	2008	Triggering the CD3/TCR complex together with co-stimulation applied by rVCAM-1 or rICAM-1 induced the generation of CD4+ single positive (SP) thymocytes from CD4+CD8+ DP thymocytes whereas either signal alone did not result in generation of CD4+ SP thymocytes.	sp	138-140	CD4 antigen	Mus musculus	158-161
17604837-8	2008	Triggering the CD3/TCR complex together with co-stimulation applied by rVCAM-1 or rICAM-1 induced the generation of CD4+ single positive (SP) thymocytes from CD4+CD8+ DP thymocytes whereas either signal alone did not result in generation of CD4+ SP thymocytes.	sp	246-248	CD4 antigen	Mus musculus	116-119
18974870-8	2008	Flow cytometric analysis showed 15-22% enhancement of CD8+ and CD4+ T cell populations when immunized with the PPE41 or PE25/PPE41 complex as compared to a marginal increase (8-10%) in the mice immunized with the PE25 protein.	ppe41	111-116	CD4 antigen	Mus musculus	63-66
18974870-8	2008	Flow cytometric analysis showed 15-22% enhancement of CD8+ and CD4+ T cell populations when immunized with the PPE41 or PE25/PPE41 complex as compared to a marginal increase (8-10%) in the mice immunized with the PE25 protein.	pe25	120-124	CD4 antigen	Mus musculus	63-66
19205364-9	2008	Results of clinical studies indicate that phenytoin, carbamazepine, and valproate, show immunosuppressive activity, inhibit protein synthesis in lymphocytes, decrease CD4+/CD8+ ratio, decrease IgA, and induce changes in IgG and IgM plasma levels.	Phenytoin	42-51	CD4 antigen	Mus musculus	167-170
19205364-9	2008	Results of clinical studies indicate that phenytoin, carbamazepine, and valproate, show immunosuppressive activity, inhibit protein synthesis in lymphocytes, decrease CD4+/CD8+ ratio, decrease IgA, and induce changes in IgG and IgM plasma levels.	Carbamazepine	53-66	CD4 antigen	Mus musculus	167-170
19205364-9	2008	Results of clinical studies indicate that phenytoin, carbamazepine, and valproate, show immunosuppressive activity, inhibit protein synthesis in lymphocytes, decrease CD4+/CD8+ ratio, decrease IgA, and induce changes in IgG and IgM plasma levels.	Valproic Acid	72-81	CD4 antigen	Mus musculus	167-170
17693926-7	2008	The combined depletion of CD4(+) T and NK cells resulted in improved survival and decreased cytokine production compared with mice possessing a full lymphocyte complement, especially when CD4(+) T and NK cell-deficient mice were treated with imipenem.	Imipenem	242-250	CD4 antigen	Mus musculus	26-29
17983375-10	2007	Finally, serum IL-5 and Bronchoalveolar lavage fluid eotaxin-2 levels were abolished in allergen exposed CD4-/- mice to levels seen in saline exposed WT mice.	Sodium Chloride	135-141	CD4 antigen	Mus musculus	105-108
18056471-4	2007	In adoptive transfer studies using an erbB2(+) lung metastasis model, complete survival of mice was observed when transduced Th1, Th2, or Thi CD4(+) cells were transferred in combination with an equivalent number of transduced CD8(+) T cells.	2-acetyl-4(5)-tetrahydroxybutylimidazole	138-141	CD4 antigen	Mus musculus	142-145
18025180-6	2007	Moreover, CD4(+) effector T cells play a crucial role in mediating DTA-1-induced immune activation and expansion of CD8(+), NK, and B cells in the tumor-draining lymph nodes.	dta-1	67-72	CD4 antigen	Mus musculus	10-13
18025205-6	2007	We demonstrated that CD28 activation in CD4(+)CD25(-) T lymphocytes leads to STAT3 Tyr(705) phosphorylation in an Lck-dependent manner.	Tyrosine	83-86	CD4 antigen	Mus musculus	40-43
18049114-10	2007	Adoptive transfer of splenocytes and CD4 cells from ranitidine-treated allograft recipients induced significant prolongation of allograft survival in naive secondary recipients (MST, 71 and &gt;100 days, respectively).	Ranitidine	52-62	CD4 antigen	Mus musculus	37-40
18049114-13	2007	CONCLUSION: In our model, ranitidine treatment induced significantly prolonged survival of fully allogeneic cardiac grafts, generated CD4 regulatory cells, and indefinite survival when combined with FK506 (0.1 mg/kg/day).	Ranitidine	26-36	CD4 antigen	Mus musculus	134-137
17690255-4	2007	As early as 24 hours after sepsis, CD4(+) T cells proliferated poorly to T-cell receptor stimulation, despite normal responses to phorbol myristate acetate and ionomycin, and possessed decreased levels of CD3zeta.	Tetradecanoylphorbol Acetate	130-155	CD4 antigen	Mus musculus	35-38
17690255-4	2007	As early as 24 hours after sepsis, CD4(+) T cells proliferated poorly to T-cell receptor stimulation, despite normal responses to phorbol myristate acetate and ionomycin, and possessed decreased levels of CD3zeta.	Ionomycin	160-169	CD4 antigen	Mus musculus	35-38
17982065-9	2007	Rejector and acceptor NIMA(d)-exposed mice had reduced T effector responses and increased Foxp3(+) T(R) cells (CD4(+)CD25(+)Foxp3(+) T(R)) in spleen and lymph nodes compared with controls.	nima	22-26	CD4 antigen	Mus musculus	111-114
17982075-6	2007	T cells conjugated to unpulsed B cells exhibited capping of CD4 and microclusters of the TCR zeta-chain, but only the CD4 enrichment was cholesterol dependent.	Cholesterol	137-148	CD4 antigen	Mus musculus	118-121
17904293-9	2007	Circulating CD3 and CD4 lymphocytes remained depressed by 85-90% while on dexamethasone and for 7 days after discontinuing dexamethasone.	Dexamethasone	123-136	CD4 antigen	Mus musculus	20-23
17904293-12	2007	Fourteen days post-dexamethasone treatment, which was 8 days after oocyst shedding had ceased, the CD8 counts per 5000 events were only 1.6% below controls, while the CD3 and CD4 counts were still depressed by 66%.	Dexamethasone	19-32	CD4 antigen	Mus musculus	175-178
17947673-6	2007	In vitro, using naive CD4(+) cells from TRIF-deficient mice, tryptophan metabolites were capable of inducing the Foxp3-encoding gene transcriptionally and suppressing the gene encoding RORgammat, Th17 lineage specification factor.	Tryptophan	61-71	CD4 antigen	Mus musculus	22-25
17947695-0	2007	Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma.	prostaglandin i2-ip	0-19	CD4 antigen	Mus musculus	98-101
17947695-7	2007	However, the prostanoid strongly inhibited CCL17-induced chemotaxis of CD4(+) Th2 but not Th1 cells.	Prostaglandins	13-23	CD4 antigen	Mus musculus	71-74
17947695-10	2007	Our results identify PGI(2)-IP as an important pathway for inhibiting allergic pulmonary inflammation by controlling recruitment of CD4(+) Th2 cells into the inflammatory site.	pgi(2)-ip	21-30	CD4 antigen	Mus musculus	132-135
17947703-0	2007	Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes.	Calcitriol	18-42	CD4 antigen	Mus musculus	80-83
17639287-4	2007	In the present study, we observed the cell levels, phenotypes, and immunoregulatory function of CD4(+)CD25(+)Treg cells in indirubin-treated mice.	indirubin	123-132	CD4 antigen	Mus musculus	96-99
17639287-5	2007	Treatment with indirubin significantly enhanced the ratios of CD4(+)CD25(+)Treg cells or CD4(+)CD25(+)Foxp3(+)Treg cells to CD4(+)T cells in peripheral blood, lymph nodes, and spleens (P &lt; 0.01 compared with control mice).	indirubin	15-24	CD4 antigen	Mus musculus	62-65
17639287-5	2007	Treatment with indirubin significantly enhanced the ratios of CD4(+)CD25(+)Treg cells or CD4(+)CD25(+)Foxp3(+)Treg cells to CD4(+)T cells in peripheral blood, lymph nodes, and spleens (P &lt; 0.01 compared with control mice).	indirubin	15-24	CD4 antigen	Mus musculus	89-92
17639287-5	2007	Treatment with indirubin significantly enhanced the ratios of CD4(+)CD25(+)Treg cells or CD4(+)CD25(+)Foxp3(+)Treg cells to CD4(+)T cells in peripheral blood, lymph nodes, and spleens (P &lt; 0.01 compared with control mice).	indirubin	15-24	CD4 antigen	Mus musculus	89-92
17639287-7	2007	Furthermore, splenic CD4(+)CD25(+)Treg cells in indirubin-treated mice showed immunosuppressive ability on the immune response of T effector cells to alloantigens or mitogen as efficiently as the control CD4(+)CD25(+)Treg cells in vitro.	indirubin	48-57	CD4 antigen	Mus musculus	21-24
17639287-7	2007	Furthermore, splenic CD4(+)CD25(+)Treg cells in indirubin-treated mice showed immunosuppressive ability on the immune response of T effector cells to alloantigens or mitogen as efficiently as the control CD4(+)CD25(+)Treg cells in vitro.	indirubin	48-57	CD4 antigen	Mus musculus	204-207
17639287-9	2007	The selectively enhanced CD4(+)CD25(+)Treg cell levels by indirubin made host to be more favorable for immune tolerance induction, which opened one possibility for indirubin to treat autoimmune diseases.	indirubin	58-67	CD4 antigen	Mus musculus	25-28
17850646-10	2007	CD11c+ DC derived from ethanol consuming BALB/c mice show diminished ability to support IFN-gamma responses by purified CD4+ T cells derived from DO11.10 or DO11.10Rag2-/- mice.	Ethanol	23-30	CD4 antigen	Mus musculus	120-123
17850646-13	2007	Data show that cocultures containing purified CD4+ T DO11.10 cells and APC derived from alcohol-consuming mice show decreased IL-6, IL-12, IL-17A, and IFN-gamma and increased IL-13 cytokine production in response to OVA stimulation.	Alcohols	88-95	CD4 antigen	Mus musculus	46-49
17704653-8	2007	Finally, using nonimmunodeficient mice, we observed an in-vivo decrease of CD4-positive T-cells and mature B-cell lymphocytes after imatinib administration.	Imatinib Mesylate	132-140	CD4 antigen	Mus musculus	75-78
17632037-0	2007	CD4(+)CD25(+) regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis.	Glatiramer Acetate	74-92	CD4 antigen	Mus musculus	0-3
17883721-12	2007	The transfer of CD4+ T cells from mesenteric lymph nodes of OVA-sensitized and OVA-challenged mice triggered airway hyperreactivity and eosinophilic airway inflammation in recipients aerosol challenged with OVA, but not with PBS.	pbs	225-228	CD4 antigen	Mus musculus	16-19
17823980-4	2007	Overexpression of c-Maf results in increased susceptibility of CD4 cells to apoptosis induced by multiple stimuli, including growth factor withdrawal, dexamethasone, irradiation, and TCR engagement.	Dexamethasone	151-164	CD4 antigen	Mus musculus	63-66
17853408-6	2007	Transfection of L-selectin was sufficient for K562 cells to acquire sulfatide-induced CXCR4 up-regulation, while analysis of L-selectin knockout mice revealed that this response was critically L-selectin dependent only for CD4(+) T cells, suggesting an alternative pathway in CD8(+) T cells and B cells.	Sulfoglycosphingolipids	68-77	CD4 antigen	Mus musculus	223-226
17850585-5	2007	Fas-mediated death of resting CD4(+) and CD8(+) T cells was mainly caspase dependent but could only partly be blocked by FLIP(L) overexpression.	ammonium ferrous sulfate	0-3	CD4 antigen	Mus musculus	30-33
17875988-0	2007	Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40.	Nitric Oxide	0-12	CD4 antigen	Mus musculus	21-24
17875988-0	2007	Nitric oxide induces CD4+CD25+ Foxp3 regulatory T cells from CD4+CD25 T cells via p53, IL-2, and OX40.	Nitric Oxide	0-12	CD4 antigen	Mus musculus	61-64
17875988-4	2007	Here we report a previously unrecognized subset of CD4(+)CD25(+) Tregs derived from CD4(+)CD25(-) T cells induced by nitric oxide (NO).	Nitric Oxide	117-129	CD4 antigen	Mus musculus	51-54
17875988-4	2007	Here we report a previously unrecognized subset of CD4(+)CD25(+) Tregs derived from CD4(+)CD25(-) T cells induced by nitric oxide (NO).	Nitric Oxide	117-129	CD4 antigen	Mus musculus	84-87
17875988-9	2007	NO-Tregs also were induced in vivo in SCID mice adoptively transferred with CD4(+)CD25(-) T cells in the presence of LPS and IFNgamma, and the induction was completely inhibited by N(G)-monomethyl-L-arginine, a pan NO synthase inhibitor.	omega-N-Methylarginine	181-207	CD4 antigen	Mus musculus	76-79
17785809-2	2007	We found that the major vitamin A metabolite all-trans-retinoic acid induces histone acetylation at the FoxP3 gene promoter and expression of the FoxP3 protein in CD4+ T cells.	Vitamin A	24-33	CD4 antigen	Mus musculus	163-166
17785809-2	2007	We found that the major vitamin A metabolite all-trans-retinoic acid induces histone acetylation at the FoxP3 gene promoter and expression of the FoxP3 protein in CD4+ T cells.	Tretinoin	45-68	CD4 antigen	Mus musculus	163-166
17875775-6	2007	Significant inhibition of tumor growth in mice treated with low-dose paclitaxel plus intratumoral dendritic cell vaccine, associated with increased tumor infiltration by CD4(+) and CD8(+) T cells and elevated tumor-specific IFN-gamma production by draining lymph node cells, was revealed.	Paclitaxel	69-79	CD4 antigen	Mus musculus	170-173
17643252-5	2007	Treatment of DCs with PS liposomes also suppressed DNCB induced CD4 + T cell proliferation and IFN-gamma production.	Dinitrochlorobenzene	51-55	CD4 antigen	Mus musculus	64-67
17643252-7	2007	Furthermore, PS-treated DCs enhance the ratio of CD4(+) CD25(high)Foxp3(+) T cells to CD4(+) T cells and PD-1 expression on CD4(+) T cells.	Phosphatidylserines	13-15	CD4 antigen	Mus musculus	86-89
17643252-7	2007	Furthermore, PS-treated DCs enhance the ratio of CD4(+) CD25(high)Foxp3(+) T cells to CD4(+) T cells and PD-1 expression on CD4(+) T cells.	Phosphatidylserines	13-15	CD4 antigen	Mus musculus	86-89
17719247-7	2007	We propose that high wild-type CD45 expression is necessary to dephosphorylate p56(lck) pTyr-394, suppressing CD4 T+ cell lineage commitment and hyperactivity.	Phosphotyrosine	88-92	CD4 antigen	Mus musculus	31-34
17826032-0	2007	CD4+CD25+ naturally occurring regulatory T cells and not lymphopenia play a role in the pathogenesis of iodide-induced autoimmune thyroiditis in NOD-H2h4 mice.	Iodides	104-110	CD4 antigen	Mus musculus	0-3
17826032-0	2007	CD4+CD25+ naturally occurring regulatory T cells and not lymphopenia play a role in the pathogenesis of iodide-induced autoimmune thyroiditis in NOD-H2h4 mice.	h2h4	149-153	CD4 antigen	Mus musculus	0-3
17709493-0	2007	Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses.	Polyglactin 910	0-23	CD4 antigen	Mus musculus	179-182
17709493-0	2007	Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses.	CPG-oligonucleotide	92-111	CD4 antigen	Mus musculus	179-182
17709493-7	2007	Furthermore, s.c. immunization with tPrP and CpG-ODN co-encapsulated in biodegradable polylactide-coglycolide microspheres (PLGA-MS) enhanced CD4 T cell responses and, more prominent, the induction of CD8 T cells.	poly(lactide)	86-97	CD4 antigen	Mus musculus	142-145
17709493-7	2007	Furthermore, s.c. immunization with tPrP and CpG-ODN co-encapsulated in biodegradable polylactide-coglycolide microspheres (PLGA-MS) enhanced CD4 T cell responses and, more prominent, the induction of CD8 T cells.	coglycolide	98-109	CD4 antigen	Mus musculus	142-145
17610959-6	2007	Culturing CD8alpha(+) DCs with CD4(+) T cells significantly increased the proliferative response of CD4(+) T cells in the presence of CII.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	134-137	CD4 antigen	Mus musculus	31-34
17610959-6	2007	Culturing CD8alpha(+) DCs with CD4(+) T cells significantly increased the proliferative response of CD4(+) T cells in the presence of CII.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	134-137	CD4 antigen	Mus musculus	100-103
17383204-0	2007	Sinomenine inhibits primary CD4+ T-cell proliferation via apoptosis.	sinomenine	0-10	CD4 antigen	Mus musculus	28-31
17383204-3	2007	In this study, we investigated the possible immunosuppressive effect of sinomenine on CD4(+) T cells and its underlying mechanism.	sinomenine	72-82	CD4 antigen	Mus musculus	86-89
17383204-4	2007	Our data demonstrated that sinomenine remarkably suppressed the proliferation of CD4(+) T cells, blocked the cell cycle progression from G0/G1 phase to S plusG2/M phases.	sinomenine	27-37	CD4 antigen	Mus musculus	81-84
17383204-5	2007	Finally, the immunosuppressive activity elicited by sinomenine in CD4(+) primary lymphocytes was found to be largely accounted for by caspase 3-dependent cells apoptosis.	sinomenine	52-62	CD4 antigen	Mus musculus	66-69
17490400-7	2007	Importantly, co-injection of the induced CD4(+) CD25(+) T cells with 5,6-carboxy-succinimidyl-fluorescence-ester (CFSE)-labelled naive CD4(+) T cells (responder cells) into BALB/c recipient mice reduced proliferation and differentiation of the responder cells in response to challenge with OVA(323-339) peptide plus adjuvant.	succinimidyl	81-93	CD4 antigen	Mus musculus	135-138
17671140-13	2007	The percentage of CD4(+)CD25(+) T cells and Foxp3(+) T cells (T regulatory cells) was increased or reduced, respectively, in lymph nodes from tumor-bearing animals treated with the combination of MS-275 and IL-2 as compared with control and single agents.	entinostat	196-202	CD4 antigen	Mus musculus	18-21
17762268-9	2007	CONCLUSION: These results suggest that dexamethasone may play an important role in the regulation of allergic reactions by at least two mechanisms; one by suppressing allergic sensitization through decrease of CD4+ T cells and increase of TGF-beta, and the other by suppressing late allergic reactions through the inhibition of proliferation and chemotaxis of inflammatory cells such as eosinophils.	Dexamethasone	39-52	CD4 antigen	Mus musculus	210-213
17540342-3	2007	In this study, we incubated CMFDA-labeled ovalbumin (OVA)-pulsed DC2.4 (DC2.4(OVA)) cells with Dil-labeled OT II CD4(+) T cells and analyzed the potential bidirectional molecule transfer.	5-chloromethylfluorescein	28-33	CD4 antigen	Mus musculus	113-116
17559172-5	2007	Furthermore, we showed that TCV significantly inhibited Ag-specific CD4 and CD8 T cell proliferation and decreased Ag-specific IFN-gamma production by CD4 T cells in mice undergoing TCV, and blocking of B7 on the surface of vaccinating T cells reduced this inhibition on Ag-specific CD4 and CD8 T cell proliferation, more significantly on Ag-specific CD4 T cell proliferation.	Trichloroethylene	28-31	CD4 antigen	Mus musculus	68-71
17559172-5	2007	Furthermore, we showed that TCV significantly inhibited Ag-specific CD4 and CD8 T cell proliferation and decreased Ag-specific IFN-gamma production by CD4 T cells in mice undergoing TCV, and blocking of B7 on the surface of vaccinating T cells reduced this inhibition on Ag-specific CD4 and CD8 T cell proliferation, more significantly on Ag-specific CD4 T cell proliferation.	Trichloroethylene	28-31	CD4 antigen	Mus musculus	151-154
17559172-5	2007	Furthermore, we showed that TCV significantly inhibited Ag-specific CD4 and CD8 T cell proliferation and decreased Ag-specific IFN-gamma production by CD4 T cells in mice undergoing TCV, and blocking of B7 on the surface of vaccinating T cells reduced this inhibition on Ag-specific CD4 and CD8 T cell proliferation, more significantly on Ag-specific CD4 T cell proliferation.	Trichloroethylene	28-31	CD4 antigen	Mus musculus	151-154
17559172-5	2007	Furthermore, we showed that TCV significantly inhibited Ag-specific CD4 and CD8 T cell proliferation and decreased Ag-specific IFN-gamma production by CD4 T cells in mice undergoing TCV, and blocking of B7 on the surface of vaccinating T cells reduced this inhibition on Ag-specific CD4 and CD8 T cell proliferation, more significantly on Ag-specific CD4 T cell proliferation.	Trichloroethylene	28-31	CD4 antigen	Mus musculus	151-154
17303597-0	2007	CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection.	Serotonin	84-103	CD4 antigen	Mus musculus	0-3
17603790-0	2007	Inducible gene expression with the Tet-on system in CD4+ T cells and thymocytes of mice.	tetramethylenedisulfotetramine	35-38	CD4 antigen	Mus musculus	52-55
17603790-5	2007	Reporter transgene expression in mice expressing these constructs is highly specific for CD4+ cells, is strictly dependent on the tetracycline derivative doxycycline, and can be regulated by up to five logs depending on the doxycycline concentration.	Tetracycline	130-142	CD4 antigen	Mus musculus	89-92
17603790-5	2007	Reporter transgene expression in mice expressing these constructs is highly specific for CD4+ cells, is strictly dependent on the tetracycline derivative doxycycline, and can be regulated by up to five logs depending on the doxycycline concentration.	Doxycycline	154-165	CD4 antigen	Mus musculus	89-92
17603790-5	2007	Reporter transgene expression in mice expressing these constructs is highly specific for CD4+ cells, is strictly dependent on the tetracycline derivative doxycycline, and can be regulated by up to five logs depending on the doxycycline concentration.	Doxycycline	224-235	CD4 antigen	Mus musculus	89-92
17587345-3	2007	Repeated intradermal administration of the GMP-produced vaccine using a novel needle-free jet injection device (Biojector) induced robust CD4 and CD8 T-cell responses in mice, and did not result in any vaccine-related toxicity.	guanosine 5'-monophosphorothioate	43-46	CD4 antigen	Mus musculus	138-141
17317051-4	2007	We have shown that both polymers are able to upregulate expression of CD69 on B cells and CD4+ T-lymphocytes, with alginate as the least potent stimulus.	Polymers	24-32	CD4 antigen	Mus musculus	90-93
17530719-9	2007	In B10.S mice exposed to mercury, the production of interleukin-4 (IL-4), but not that of IL-2 or interferon-gamma, in the spleen was associated with CD44(high),Daf1(low),CD4+ T cells.	Mercury	25-32	CD4 antigen	Mus musculus	150-153
17284532-0	2007	Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.	TES	78-81	CD4 antigen	Mus musculus	55-58
17493961-2	2007	Here, we show that in the perivascular spaces (PVS) of mice surrounding large blood vessels, CD117-positive hematopoietic progenitor cells, CD4 single-positive (SP) and CD8SP T cells are located.	sp	161-163	CD4 antigen	Mus musculus	140-143
17187395-0	2007	Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.	monophosphoryl	115-129	CD4 antigen	Mus musculus	34-37
17187395-0	2007	Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.	Lipid A	130-137	CD4 antigen	Mus musculus	34-37
17187395-0	2007	Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles.	Polylactic Acid-Polyglycolic Acid Copolymer	141-174	CD4 antigen	Mus musculus	34-37
17187395-1	2007	The purpose of this research was to investigate the use of biodegradable poly(D,L-lactic-co-glycolic acid) nanoparticles (PLGA-NP) as a vaccine delivery system to codeliver antigen, ovalbumin (OVA) along with monophosphoryl lipid A (MPLA) as adjuvant for induction of potent CD4(+) and CD8(+) T cell responses.	Polylactic Acid-Polyglycolic Acid Copolymer	73-106	CD4 antigen	Mus musculus	275-278
17363918-4	2007	Decreases in systemic CD4+ but not CD8+ T cells significantly increased and prolonged the acute UVB-induced cutaneous inflammatory response, as measured by neutrophil influx, myeloperoxidase activity, and prostaglandin E2 levels.	Dinoprostone	205-221	CD4 antigen	Mus musculus	22-25
17363918-7	2007	Furthermore, topical treatment with the anti-inflammatory drug celecoxib significantly decreased tumor numbers in both CD4-replete and CD4-depleted mice.	Celecoxib	63-72	CD4 antigen	Mus musculus	119-122
17363918-7	2007	Furthermore, topical treatment with the anti-inflammatory drug celecoxib significantly decreased tumor numbers in both CD4-replete and CD4-depleted mice.	Celecoxib	63-72	CD4 antigen	Mus musculus	135-138
17523950-6	2007	Further, inhibition of ERK1,2 by its inhibitor, U0126, in dual APL-induced CD4(+)CD25(+) cells, abrogated their ability to suppress interferon (IFN)-gamma secretion by lymph node (LN) cells of mice that were immunized with the myasthenogenic peptide.	U 0126	48-53	CD4 antigen	Mus musculus	75-78
17475841-6	2007	These data suggest that CD8 blockade promotes responsiveness to nontolerizing Ags in tolerant mice by inhibiting CD4+ T cell apoptosis.	Silver	78-81	CD4 antigen	Mus musculus	113-116
17229932-6	2007	CsA administration enhanced Th2 and reduced Th1 cytokine production at the materno-fetal interface, and it expanded peripheral CD4(+)CD25(+) FOXP3(+) regulatory T cells in abortion-prone matings, implying development of Th2 bias and regulatory T cells.	Cyclosporine	0-3	CD4 antigen	Mus musculus	127-130
17351648-0	2007	Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells.	Sirolimus	0-9	CD4 antigen	Mus musculus	86-89
17351648-6	2007	Here we demonstrate in a mouse model that in contrast to rapamycin, cyclosporine compromises not only the thymic generation of CD4(+)CD25(+)FoxP3(+) T cells but also their homeostatic behavior in peripheral immune compartments.	Cyclosporine	68-80	CD4 antigen	Mus musculus	127-130
17351648-8	2007	Prolonged rapamycin treatment allowed for thymic generation of CD4(+)FoxP3(+) T cells, whereas treatment with cyclosporine led to a reduced generation of these cells.	Sirolimus	10-19	CD4 antigen	Mus musculus	63-66
17351648-9	2007	In conclusion, cyclosporine and rapamycin differentially affect homeostasis of CD4(+)FoxP3(+) T(REG) in vivo.	Cyclosporine	15-27	CD4 antigen	Mus musculus	79-82
17351648-9	2007	In conclusion, cyclosporine and rapamycin differentially affect homeostasis of CD4(+)FoxP3(+) T(REG) in vivo.	Sirolimus	32-41	CD4 antigen	Mus musculus	79-82
17430547-6	2007	Similarly, phorbol myristate acetate (PMA)- and ionomycin-stimulated intracellular cytokine expression of IL-4, IL-5, and GM-CSF in splenic CD4(+) T cells was inversely correlated with serum CRI and directly correlated with spleen size.	Tetradecanoylphorbol Acetate	11-36	CD4 antigen	Mus musculus	140-143
17430547-6	2007	Similarly, phorbol myristate acetate (PMA)- and ionomycin-stimulated intracellular cytokine expression of IL-4, IL-5, and GM-CSF in splenic CD4(+) T cells was inversely correlated with serum CRI and directly correlated with spleen size.	Tetradecanoylphorbol Acetate	38-41	CD4 antigen	Mus musculus	140-143
17430547-6	2007	Similarly, phorbol myristate acetate (PMA)- and ionomycin-stimulated intracellular cytokine expression of IL-4, IL-5, and GM-CSF in splenic CD4(+) T cells was inversely correlated with serum CRI and directly correlated with spleen size.	Ionomycin	48-57	CD4 antigen	Mus musculus	140-143
17892128-6	2007	The proliferation and suppressive function of the CD4+ CD25+ T cells coming from tumor-bearing mice was measured by [3H]-thymidines incorporation experiment in vitro, and then effect of CD4+ CD25+ T cells originated from hepatocellular carcinoma-bearing mice on tumor growth was observed in vivo.	Tritium	117-119	CD4 antigen	Mus musculus	50-53
17892128-6	2007	The proliferation and suppressive function of the CD4+ CD25+ T cells coming from tumor-bearing mice was measured by [3H]-thymidines incorporation experiment in vitro, and then effect of CD4+ CD25+ T cells originated from hepatocellular carcinoma-bearing mice on tumor growth was observed in vivo.	Thymidine	121-131	CD4 antigen	Mus musculus	50-53
17337447-2	2007	Exposure to TCDD induces acute thymocyte cell loss, which occurs concomitantly with proliferation arrest and premature emigration of triple negative (TN; CD4(-), CD8(-), CD3(-)) T cell progenitors.	Polychlorinated Dibenzodioxins	12-16	CD4 antigen	Mus musculus	154-157
17337447-7	2007	Administration of a 100 microg/kg dose of TCDD results in a approximately 15-fold induction of KLF2 as early as the TN2 (CD44(+), CD25(+)) stage of development and immediately precedes acute cell loss in the TN3, TN4, and double positive (CD4(+), CD8(+)) cell stages.	Polychlorinated Dibenzodioxins	42-46	CD4 antigen	Mus musculus	121-124
17009048-8	2007	Arsenite also decreased early activation (surface CD69+ expression) in both CD4+ and CD8+, and decreased total CD8+ count without significantly affecting CD4+, supporting that the cellular immune response mediated by cytotoxic T cells is an arsenic target.	arsenite	0-8	CD4 antigen	Mus musculus	76-79
17430355-7	2007	However, CD4+CD25+ T cell depletion during long-term exposure to PE alone did not result in allergic sensitization.	pe	65-67	CD4 antigen	Mus musculus	9-12
17220309-6	2007	Passive vaccination with PPS3-TT-induced sera from Wt, CD4(-/-), CD8(-/-), and sIgM(-/-) mice protected naive Wt mice from death due to pulmonary challenge; however, CD8(-/-) mice were not protected by sera from Wt or CD8(-/-) mice.	pps3-tt	25-32	CD4 antigen	Mus musculus	55-58
17220309-7	2007	Our findings suggest that PPS-based vaccines can be effective in the setting of CD4 T-cell deficiency but that CD8 T cells could be required for vaccine-mediated protection against pulmonary challenge with serotype 3 pneumococcus.	pps	26-29	CD4 antigen	Mus musculus	80-83
17497276-3	2007	Compared with the immunization with CpG ODN, the immunization with CS-CpG ODN gene carrier was more efficient in up-regulating the percentage of CD4(+)T cells and the ratio of CD4(+)/CD8(+) of mice.	Cesium	67-69	CD4 antigen	Mus musculus	145-148
17497276-3	2007	Compared with the immunization with CpG ODN, the immunization with CS-CpG ODN gene carrier was more efficient in up-regulating the percentage of CD4(+)T cells and the ratio of CD4(+)/CD8(+) of mice.	Cesium	67-69	CD4 antigen	Mus musculus	176-179
18958721-1	2007	Trichloroethylene (TCE) is a widespread environmental toxicant known to promote CD4(+) T-lymphocyte activation, IFNgamma production, and autoimmunity in adult MRL(+/+) mice.	Trichloroethylene	0-17	CD4 antigen	Mus musculus	80-83
18958721-1	2007	Trichloroethylene (TCE) is a widespread environmental toxicant known to promote CD4(+) T-lymphocyte activation, IFNgamma production, and autoimmunity in adult MRL(+/+) mice.	Trichloroethylene	19-22	CD4 antigen	Mus musculus	80-83
18958721-2	2007	Because developing tissues may be more sensitive to toxicant exposure, it was hypothesized that continuous TCE exposure beginning at conception might induce even more pronounced CD4(+) T-lymphocyte effects and exacerbate the development of autoimmunity in MRL(+/+) mice.	Trichloroethylene	107-110	CD4 antigen	Mus musculus	178-181
18958721-5	2007	TCE exposure altered the number of thymocyte subsets, and reduced the capacity of the most immature CD4-/CD8- thymocytes to undergo apoptosis in vitro.	Trichloroethylene	0-3	CD4 antigen	Mus musculus	100-103
17331841-5	2007	The cell numbers of CD4(+) and CD4(+)CD25(+)Treg cell subsets were markedly decreased in rapa-treated mice as reported.	Sirolimus	89-93	CD4 antigen	Mus musculus	20-23
17331841-5	2007	The cell numbers of CD4(+) and CD4(+)CD25(+)Treg cell subsets were markedly decreased in rapa-treated mice as reported.	Sirolimus	89-93	CD4 antigen	Mus musculus	31-34
17331841-7	2007	Furthermore, splenic CD4(+)CD25(+)Treg cells in rapa-treated mice showed immunosuppressive ability on the immune response of T effector cells to alloantigens or mitogen as efficiently as the control CD4(+)CD25(+)Treg cells in vitro and in vivo.	Sirolimus	48-52	CD4 antigen	Mus musculus	21-24
17331841-7	2007	Furthermore, splenic CD4(+)CD25(+)Treg cells in rapa-treated mice showed immunosuppressive ability on the immune response of T effector cells to alloantigens or mitogen as efficiently as the control CD4(+)CD25(+)Treg cells in vitro and in vivo.	Sirolimus	48-52	CD4 antigen	Mus musculus	199-202
17339438-0	2007	Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3.	sphingosine 1-phosphate	52-75	CD4 antigen	Mus musculus	13-16
17339450-4	2007	Quantitative studies of the CD4(high) populations in transgenic mice following immunization with Talpha146-162 revealed a diminished expansion of cells expressing the canonical TCRBV6 but not other TCRBV gene segments when compared with nontransgenic littermates.	talpha146	97-106	CD4 antigen	Mus musculus	28-31
17339450-5	2007	In addition, CD4(high) cells from transgenic mice were functionally hyporesponsive to Talpha146-162 in terms of proliferation and cytokine secretion regardless of TCRBV gene segment use.	talpha146	86-95	CD4 antigen	Mus musculus	13-16
17302906-0	2007	Depletion of CD4+CD25+ regulatory T cells exacerbates sodium iodide-induced experimental autoimmune thyroiditis in human leucocyte antigen DR3 (DRB1*0301) transgenic class II-knock-out non-obese diabetic mice.	Sodium Iodide	54-67	CD4 antigen	Mus musculus	13-16
17328786-4	2007	In vivo studies in C57BL/6 mice showed that injection of DNA encoding ovalbumin (OVA) complexed to oxidized or reduced mannan-poly-L-lysine induced CD8 and CD4 T-cell responses as well as antibody responses leading to protection of mice from OVA+ tumours.	Mannans	119-125	CD4 antigen	Mus musculus	156-159
17328786-4	2007	In vivo studies in C57BL/6 mice showed that injection of DNA encoding ovalbumin (OVA) complexed to oxidized or reduced mannan-poly-L-lysine induced CD8 and CD4 T-cell responses as well as antibody responses leading to protection of mice from OVA+ tumours.	Lysine	126-139	CD4 antigen	Mus musculus	156-159
17092505-8	2007	Moreover, DNBS-induced colitis in CD4-/- mice (wasting, tissue damage, elevated myeloperoxidase) was not reduced by H. diminuta infection, whereas time-matched infected CD4+ C57Bl/6 mice had significantly less DNBS-induced inflammation.	2,4-dinitrofluorobenzene sulfonic acid	10-14	CD4 antigen	Mus musculus	34-37
17135575-0	2007	Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells.	Epoprostenol	0-16	CD4 antigen	Mus musculus	77-80
17135575-1	2007	An anti-inflammatory effect of PGI(2) has been suggested by increased inflammation in mice that are deficient in the PGI(2) receptor (IP) or in respiratory syncytial viral- or OVA-induced CD4 T cell-associated responses.	Epoprostenol	31-37	CD4 antigen	Mus musculus	188-191
17135575-2	2007	To determine the mechanism of the anti-inflammatory effect, we hypothesized that PGI(2) analogs inhibit CD4 T cell effector cytokine production.	Epoprostenol	81-87	CD4 antigen	Mus musculus	104-107
17135575-6	2007	Pretreatment of the CD4 T cells with 8-bromoadenosine-3",5"-cyclic monophosphorothioate, Rp-isomer, to inhibit a key signaling molecule in the cAMP pathway, protein kinase A (PKA), attenuated the suppressive effect of PGI(2) analogs significantly, suggesting that PKA, in part, mediates the inhibition of the cytokine production.	8-bromoadenosine-3',5'-cyclic monophosphorothioate	37-87	CD4 antigen	Mus musculus	20-23
17135575-6	2007	Pretreatment of the CD4 T cells with 8-bromoadenosine-3",5"-cyclic monophosphorothioate, Rp-isomer, to inhibit a key signaling molecule in the cAMP pathway, protein kinase A (PKA), attenuated the suppressive effect of PGI(2) analogs significantly, suggesting that PKA, in part, mediates the inhibition of the cytokine production.	Cyclic AMP	143-147	CD4 antigen	Mus musculus	20-23
17135575-6	2007	Pretreatment of the CD4 T cells with 8-bromoadenosine-3",5"-cyclic monophosphorothioate, Rp-isomer, to inhibit a key signaling molecule in the cAMP pathway, protein kinase A (PKA), attenuated the suppressive effect of PGI(2) analogs significantly, suggesting that PKA, in part, mediates the inhibition of the cytokine production.	Epoprostenol	218-224	CD4 antigen	Mus musculus	20-23
17135575-7	2007	These data indicate that PGI(2) analogs have an immune-suppressive effect on previously activated and differentiated CD4 T cells in vitro and suggest that PGI(2) may have a similar function in vivo.	Epoprostenol	25-31	CD4 antigen	Mus musculus	117-120
17256743-11	2007	Finally, cellular immune therapy with CD4+CD25+ cells prevented ConA-induced liver injury, with higher protection by Treg from ConA-tolerized mice.	treg	117-121	CD4 antigen	Mus musculus	38-41
17076705-5	2007	Transfer of highly enriched double-negative TCR-alphabeta(+) T cells from mc(2)6030-immunized CD4(-/-) mice into naive CD4(-/-) mice resulted in significant protection against an aerosol tuberculosis challenge.	mc(2)6030	74-83	CD4 antigen	Mus musculus	94-97
17076705-5	2007	Transfer of highly enriched double-negative TCR-alphabeta(+) T cells from mc(2)6030-immunized CD4(-/-) mice into naive CD4(-/-) mice resulted in significant protection against an aerosol tuberculosis challenge.	mc(2)6030	74-83	CD4 antigen	Mus musculus	119-122
17101665-9	2007	Intracellular staining of cells isolated from FMP011/AS01B-immunized BALB/c mice indicated that CD4(+) cells, but not CD8(+) cells, were the main IFN-gamma-producing splenocyte.	as01b	53-58	CD4 antigen	Mus musculus	96-99
17237392-0	2007	Age-associated decline in effective immune synapse formation of CD4(+) T cells is reversed by vitamin E supplementation.	Vitamin E	94-103	CD4 antigen	Mus musculus	64-67
17237392-7	2007	Vitamin E increased the percentage of old CD4(+) T cells capable of forming an effective immune synapse.	Vitamin E	0-9	CD4 antigen	Mus musculus	42-45
17237392-10	2007	These data show, for the first time, that vitamin E significantly improves age-related early T cell signaling events in naive CD4(+) T cells.	Vitamin E	42-51	CD4 antigen	Mus musculus	126-129
17471165-0	2007	CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope.	Poly I-C	86-95	CD4 antigen	Mus musculus	0-3
17196666-0	2007	CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson"s disease.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	81-125	CD4 antigen	Mus musculus	0-3
16908068-5	2007	The results suggested that, the CD4(+)/CD8(+) ratio decreased over time in piglets inoculated with phosphate buffer saline (PBS) alone, however, it was stable in CpG ODN-inoculated piglets; the use of CpG ODN can prevent effectively the reduction of the proportion of CD4(+) T lymphocytes.	phosphate buffer saline	99-122	CD4 antigen	Mus musculus	32-35
16908068-5	2007	The results suggested that, the CD4(+)/CD8(+) ratio decreased over time in piglets inoculated with phosphate buffer saline (PBS) alone, however, it was stable in CpG ODN-inoculated piglets; the use of CpG ODN can prevent effectively the reduction of the proportion of CD4(+) T lymphocytes.	pbs	124-127	CD4 antigen	Mus musculus	32-35
17077186-5	2007	In addition, TCAH appeared to modulate the CD4(+) T-cell subset by promoting the expression of an activated/effector (i.e., CD62L(lo)) phenotype with an increased capacity to secrete the proinflammatory cytokine interferon-gamma.	Chloral Hydrate	13-17	CD4 antigen	Mus musculus	43-46
17202352-6	2007	Modulating redox balance led to decreased Ag-specific T cell proliferation and IFN-gamma synthesis by diminishing ROS production in the APC, which affected TNF-alpha levels produced by CD4(+) T cells and impairing effector function.	Reactive Oxygen Species	114-117	CD4 antigen	Mus musculus	185-188
16943228-7	2007	CONCLUSION: These findings show that natural CD4+CD25+ regulatory T cells possess the ability to inhibit activation of IRBP-reactive T cells that have been already sensitised in vivo, and adoptive transfer of these cells ameliorates EAU even in the effector phase.	Water	233-236	CD4 antigen	Mus musculus	45-48
17593662-3	2007	During development in the thymus, rare CD4+ CD8+ (DP) cortical thymocytes that successfully rearrange the semi-invariant TCR are directed to the Valpha14i NKT cell lineage via interactions with CD d-associated endogenous glycolipids expressed by other DP thymocytes.	NPPA protein, human	194-198	CD4 antigen	Mus musculus	39-42
18309632-3	2007	In old mice after epithalamin injections the season differences between the amount of Mac-1+-cells restored, CD4+-cells amplitude diminished, the amount of CFC-GM increased in spring and CFC-F diminished in autumn.	epithalamin	18-29	CD4 antigen	Mus musculus	109-112
18309632-6	2007	After melatonin injections to adult mice in winter the amount of CD4+-cells increased; the ratio CFC-GM and CFC-F changed because of increase of stromal fibroblasts.	Melatonin	6-15	CD4 antigen	Mus musculus	65-68
17182564-5	2007	B6.TC DCs also induce a higher level of proliferation in CD4(+) T cells than B6 DCs, and B6.TC DCs block the suppressive activity of Treg.	Technetium	3-5	CD4 antigen	Mus musculus	57-60
17963048-8	2007	CD4+ and CD8+ T-cell showed increased reactivity (tyrosine phosphorylation, CD69 expression, and proliferation) in AD, while APP x PS1 transgenic mice displayed hyporeactive CD8+ T-cells after TCR ligation.	Tyrosine	50-58	CD4 antigen	Mus musculus	0-3
17142730-3	2006	We recently reported that rapamycin allows in vitro expansion of murine CD4+CD25+FoxP3+ Tregs, which preserve their suppressive function.	Sirolimus	26-35	CD4 antigen	Mus musculus	72-75
17142748-2	2006	Administration of Elocalcitol, at normocalcemic doses, for 2 wk in already established EAP significantly inhibits the intraprostatic cell infiltrate, leading to a profound reduction in the number of CD4(+) and CD8(+) T cells, B cells, macrophages, dendritic cells, and I-A(g7)-positive cells.	BXL628	18-29	CD4 antigen	Mus musculus	199-202
17142748-6	2006	Finally, CD4(+) splenic T cells from Elocalcitol-treated NOD mice show decreased ability, upon adoptive transfer into NOD.SCID recipients, to induce autoimmune prostatitis, paralleled by a reduced capacity to produce IFN-gamma in response to prostate steroid-binding protein.	BXL628	37-48	CD4 antigen	Mus musculus	9-12
17142748-6	2006	Finally, CD4(+) splenic T cells from Elocalcitol-treated NOD mice show decreased ability, upon adoptive transfer into NOD.SCID recipients, to induce autoimmune prostatitis, paralleled by a reduced capacity to produce IFN-gamma in response to prostate steroid-binding protein.	Steroids	251-258	CD4 antigen	Mus musculus	9-12
17164721-10	2006	Furthermore, CsA markedly impaired the immunosuppressive function of CD4CD25Treg cells.	Cyclosporine	13-16	CD4 antigen	Mus musculus	69-72
17164721-11	2006	CONCLUSIONS: CsA significantly impaired the development and function of CD4CD25Treg cells.	Cyclosporine	13-16	CD4 antigen	Mus musculus	72-75
17143954-14	2006	CONCLUSION: The immune regulation of CD4+ and CD8+ cells in Peyer"s patch and suppression of TNF-alpha levels in enteric homogenates may partially explain the effect of HXZQ on improvement of BSD.	hxzq	169-173	CD4 antigen	Mus musculus	37-40
17112417-12	2006	LLDT-8 markedly blocked the cell division of CD4 and CD8 T cells after ConA stimulation.	5alpha-Hydroxytriptolide	0-6	CD4 antigen	Mus musculus	45-48
17087945-9	2006	S boulardii induces an accumulation of IFN-gamma-producing T-helper 1 cells within the mesenteric lymph nodes correlated with a diminution of CD4(+) T-cell number and IFN-gamma production by CD4+ T cells within the colon.	boulardii	2-11	CD4 antigen	Mus musculus	142-145
17087945-9	2006	S boulardii induces an accumulation of IFN-gamma-producing T-helper 1 cells within the mesenteric lymph nodes correlated with a diminution of CD4(+) T-cell number and IFN-gamma production by CD4+ T cells within the colon.	boulardii	2-11	CD4 antigen	Mus musculus	191-194
17015458-2	2006	We have found that intranasal immunization with recombinant chlamydial protease-like activity factor (CPAF) induces CD4(+) T-cell- and gamma interferon (IFN-gamma)-dependent protective immunity against murine genital chlamydial infection, thus making CPAF a viable vaccine candidate for further characterization.	1-O-hexadecyl-2-N-methylcarbamol -sn-glycerol-3-phosphocholine	102-106	CD4 antigen	Mus musculus	116-119
17082588-4	2006	The CD4+ T cells were found to reject the transplanted tumor cells very efficiently under conditions in which the CTLs were removed either genetically, or via the action of anti-CD8 Ab in mice that had been immunized with tumor extracts and alpha-galactosylceramide.	alpha-galactosylceramide	241-265	CD4 antigen	Mus musculus	4-7
17082591-0	2006	T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5"-adenosine monophosphate to adenosine.	Adenosine Monophosphate	114-140	CD4 antigen	Mus musculus	36-39
17082591-0	2006	T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5"-adenosine monophosphate to adenosine.	Adenosine Monophosphate	114-140	CD4 antigen	Mus musculus	88-91
17082591-0	2006	T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5"-adenosine monophosphate to adenosine.	Adenosine	117-126	CD4 antigen	Mus musculus	36-39
17082591-0	2006	T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5"-adenosine monophosphate to adenosine.	Adenosine	117-126	CD4 antigen	Mus musculus	88-91
17212088-6	2006	Furthermore, the tumor cytotoxicity of the LNT-treated group was also significantly reduced by a treatment of splenocytes with anti-CD8 antibody and its complement and with an anti-CD4 and its complement in the effector phase and the induction phase, respectively.	Lentinan	43-46	CD4 antigen	Mus musculus	181-184
16979121-4	2006	When we compared ability to inhibit CD4(+) T cell proliferation in response to IL-2 stimulation, Trichostatin A was the most potent with 100% inhibition using 100 nM Trichostatin A, while 1 muM of HDAC III, Oxamflatin and Scriptaid and 1 mM of n-butyrate were required for this effect.	trichostatin A	97-111	CD4 antigen	Mus musculus	36-39
16979121-6	2006	Finally, Trichostatin A (0.05 mM) was shown to induce anergy in OT-II ovalbumin-specific naive CD4(+) T-cells.	trichostatin A	9-23	CD4 antigen	Mus musculus	95-98
16979121-7	2006	We concluded that Trichostatin A was the most potent HDAI with regard to inhibition of histone deacetylation and the ability to induce antigen-specific anergy in both cloned and naive CD4(+) T cells.	trichostatin A	18-32	CD4 antigen	Mus musculus	184-187
17047058-9	2006	Furthermore, increased infiltrating CD4(+) and CD8(+) T cells and necrosis within tumors were found in mice receiving combination therapy of Ad-hTERT-CD and etoposide compared with those treated with either treatment alone.	Etoposide	157-166	CD4 antigen	Mus musculus	36-39
16919835-4	2006	The results suggested that, the CD4(+)/CD8(+) ratio decreased significantly in weaned piglets inoculated with phosphate buffer saline (PBS) alone, however, it was stable in CpG ODN-inoculated piglets.	phosphate buffer saline	110-133	CD4 antigen	Mus musculus	32-35
16919835-4	2006	The results suggested that, the CD4(+)/CD8(+) ratio decreased significantly in weaned piglets inoculated with phosphate buffer saline (PBS) alone, however, it was stable in CpG ODN-inoculated piglets.	pbs	135-138	CD4 antigen	Mus musculus	32-35
16945426-3	2006	Aluminum hydroxide (Alum) was used to immunize B6 mice to the TAChR and prime CD4+ T and B cells secreting Th2 cytokines.	Aluminum Hydroxide	0-18	CD4 antigen	Mus musculus	78-81
16945426-3	2006	Aluminum hydroxide (Alum) was used to immunize B6 mice to the TAChR and prime CD4+ T and B cells secreting Th2 cytokines.	Aluminum Hydroxide	0-4	CD4 antigen	Mus musculus	78-81
17096891-5	2006	The numbers of CD3(+), CD4(+), CD8(+), CD11a(+), CD18(+) lymphocytes in skin and lung decreased markedly by GTT, GTT + CsA and CsA + MTX treatments.	gtt	108-111	CD4 antigen	Mus musculus	23-26
17096891-5	2006	The numbers of CD3(+), CD4(+), CD8(+), CD11a(+), CD18(+) lymphocytes in skin and lung decreased markedly by GTT, GTT + CsA and CsA + MTX treatments.	gtt	113-116	CD4 antigen	Mus musculus	23-26
17096891-5	2006	The numbers of CD3(+), CD4(+), CD8(+), CD11a(+), CD18(+) lymphocytes in skin and lung decreased markedly by GTT, GTT + CsA and CsA + MTX treatments.	Cyclosporine	127-130	CD4 antigen	Mus musculus	23-26
17060024-8	2006	We propose that the proliferation of T-cells was significantly inhibited in anti-CD4 treated mice and CD4+ T-cells may play a critical role in ADP/ATP carrier caused mouse DCM.	Adenosine Diphosphate	143-146	CD4 antigen	Mus musculus	81-84
17060024-8	2006	We propose that the proliferation of T-cells was significantly inhibited in anti-CD4 treated mice and CD4+ T-cells may play a critical role in ADP/ATP carrier caused mouse DCM.	Adenosine Diphosphate	143-146	CD4 antigen	Mus musculus	102-105
17060024-8	2006	We propose that the proliferation of T-cells was significantly inhibited in anti-CD4 treated mice and CD4+ T-cells may play a critical role in ADP/ATP carrier caused mouse DCM.	Adenosine Triphosphate	147-150	CD4 antigen	Mus musculus	81-84
17060024-8	2006	We propose that the proliferation of T-cells was significantly inhibited in anti-CD4 treated mice and CD4+ T-cells may play a critical role in ADP/ATP carrier caused mouse DCM.	Adenosine Triphosphate	147-150	CD4 antigen	Mus musculus	102-105
16846835-4	2006	Treatment with ERalpha-selective agonist propyl pyrazole triol (PPT) caused thymic atrophy and significant changes in thymic CD4/CD8 phenotypic profile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	41-62	CD4 antigen	Mus musculus	125-128
16846835-4	2006	Treatment with ERalpha-selective agonist propyl pyrazole triol (PPT) caused thymic atrophy and significant changes in thymic CD4/CD8 phenotypic profile.	4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol	64-67	CD4 antigen	Mus musculus	125-128
16969058-5	2006	The percentages of CD4+ and CD8 alpha + T cells in the Toxo/Dexa-treated mice were significantly reduced 2 weeks after dexamethasone treatment.	Dexamethasone	119-132	CD4 antigen	Mus musculus	19-22
16887993-2	2006	In the present study, Ag presentation of liposome-coupled OVA was investigated in vitro, and it was found that OVA coupled to liposomes made using unsaturated fatty acid was presented to both CD4+ and CD8+ T cells, whereas OVA coupled to liposomes made using saturated fatty acid was presented only to CD4+ T cells.	Fatty Acids, Unsaturated	147-169	CD4 antigen	Mus musculus	192-195
16887993-2	2006	In the present study, Ag presentation of liposome-coupled OVA was investigated in vitro, and it was found that OVA coupled to liposomes made using unsaturated fatty acid was presented to both CD4+ and CD8+ T cells, whereas OVA coupled to liposomes made using saturated fatty acid was presented only to CD4+ T cells.	Fatty Acids	149-169	CD4 antigen	Mus musculus	192-195
16888005-0	2006	Activation of murine CD4+ and CD8+ T lymphocytes leads to dramatic remodeling of N-linked glycans.	n-linked glycans	81-97	CD4 antigen	Mus musculus	21-24
16888005-3	2006	Surprisingly, the major change observed in activated CD4 and CD8 T cells was a dramatic reduction of sialylated biantennary N-glycans carrying the terminal NeuGcalpha2-6Gal sequence, and a corresponding increase in glycans carrying the Galalpha1-3Gal sequence.	n-glycans	124-133	CD4 antigen	Mus musculus	53-56
16888005-3	2006	Surprisingly, the major change observed in activated CD4 and CD8 T cells was a dramatic reduction of sialylated biantennary N-glycans carrying the terminal NeuGcalpha2-6Gal sequence, and a corresponding increase in glycans carrying the Galalpha1-3Gal sequence.	Polysaccharides	126-133	CD4 antigen	Mus musculus	53-56
17116296-5	2006	The protective effects of CPAF vaccination against genital chlamydial challenge were abrogated by anti-CD4 neutralizing antibody treatment.	1-O-hexadecyl-2-N-methylcarbamol -sn-glycerol-3-phosphocholine	26-30	CD4 antigen	Mus musculus	103-106
17116296-7	2006	Therefore, CPAF mediated anti-chlamydial immunity is highly dependent upon antigen-specific CD4(+) T cells.	1-O-hexadecyl-2-N-methylcarbamol -sn-glycerol-3-phosphocholine	11-15	CD4 antigen	Mus musculus	92-95
16841298-5	2006	We show in this study that short-term simultaneous administration of Dex and IL-2 markedly expanded functional suppressive Foxp3(+)CD4(+)CD25(+) T cells in murine peripheral lymphoid tissues.	Dexamethasone	69-72	CD4 antigen	Mus musculus	131-134
16899582-6	2006	Blockade of glucocorticoid receptors with the glucocorticoid antagonist RU486, starting on day 10 after infection, partially reversed the thymic atrophy and decreased the number of CD4(+)CD8(+) thymocytes without affecting parasitemia and the number of inflammatory foci in the heart.	Mifepristone	72-77	CD4 antigen	Mus musculus	181-184
16854782-0	2006	Ozone exposure impairs antigen-specific immunity but activates IL-7-induced proliferation of CD4-CD8- thymocytes in BALB/c mice.	Ozone	0-5	CD4 antigen	Mus musculus	93-96
16854782-7	2006	It was also found that O3 exposure dramatically enhanced the proliferation of CD4-CD8- thymocytes stimulated by recombinant mouse interleukin-7 (rmIL-7), which is usually observed during the mammal aging process.	Ozone	23-25	CD4 antigen	Mus musculus	78-81
16835866-4	2006	In addition, alloxan induced a notable increase in the expression of CD8+ lymphocytes to form a dramatic decrease in CD4+/CD8+ ratio (while CD4+ was unchanged).	Alloxan	13-20	CD4 antigen	Mus musculus	117-120
16699168-8	2006	Exposure to CS increased the number of macrophages, neutrophils, lymphocytes (B cells and activated CD4- and CD8-positive T cells), and activity of MMP-2 and -9 in the bronchoalveolar lavage fluid (BALF).	Cesium	12-14	CD4 antigen	Mus musculus	100-103
16624819-11	2006	Furthermore, we showed that the percentages of CD4(+) cells, CD8(+) cells, and CD4(+)CD25(+) cells in the splenocytes of mice fed with CS are significantly higher than those of the control.	Chondroitin Sulfates	135-137	CD4 antigen	Mus musculus	47-50
16624819-11	2006	Furthermore, we showed that the percentages of CD4(+) cells, CD8(+) cells, and CD4(+)CD25(+) cells in the splenocytes of mice fed with CS are significantly higher than those of the control.	Chondroitin Sulfates	135-137	CD4 antigen	Mus musculus	79-82
16799332-8	2006	Docetaxel induced a mild lymphodepletion in mice, both CD4 and CD8 subsets were reduced in LN and spleens.	Docetaxel	0-9	CD4 antigen	Mus musculus	55-58
16799332-9	2006	Interestingly, docetaxel also diminished the number of memory CD8+ T cells (CD122+) and possible CD4+ CD25+ Foxp3+ natural Treg cells.	Docetaxel	15-24	CD4 antigen	Mus musculus	97-100
16798043-0	2006	Identification of a cross-reactive HLA-DRB1*0301-restricted CD4 T cell response directed against cholesterol-binding cytolysins from two different pathogens.	Cholesterol	97-108	CD4 antigen	Mus musculus	60-63
16786137-1	2006	It is known that, besides its direct cytotoxic effect as an alkylating chemotherapeutic agent, cyclophosphamide also has immuno-modulatory effects, such as depletion of CD4+CD25+ regulatory T cells.	Cyclophosphamide	95-111	CD4 antigen	Mus musculus	169-172
16786137-4	2006	Cyclophosphamide (20 mg/kg) decreased the numbers of splenocytes, CD4+ and CD8+ T cells by approximately 50%, while a decline in CD4+CD25+ T cell number was more profound, leading to the remarkably lower ratios of CD4+CD25+ T cells to CD4+ T cells.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	66-69
16786137-5	2006	In contrast, 200 mg/kg cyclophosphamide severely decreased the numbers of all the T cell subsets by &gt; 90% although the decreased ratios of CD4+CD25+ T cells to CD4+ T cells were still observed.	Cyclophosphamide	23-39	CD4 antigen	Mus musculus	142-145
16786137-5	2006	In contrast, 200 mg/kg cyclophosphamide severely decreased the numbers of all the T cell subsets by &gt; 90% although the decreased ratios of CD4+CD25+ T cells to CD4+ T cells were still observed.	Cyclophosphamide	23-39	CD4 antigen	Mus musculus	163-166
16786137-10	2006	Our data show that low-dose cyclophosphamide selectively depletes CD4+CD25+ T cells, leading to enhanced anti-tumor effects against pre-existing tumors, while the anti-tumor effect of high-dose cyclophosphamide is solely attributed to its direct cytotoxicity.	Cyclophosphamide	28-44	CD4 antigen	Mus musculus	66-69
16786137-10	2006	Our data show that low-dose cyclophosphamide selectively depletes CD4+CD25+ T cells, leading to enhanced anti-tumor effects against pre-existing tumors, while the anti-tumor effect of high-dose cyclophosphamide is solely attributed to its direct cytotoxicity.	Cyclophosphamide	194-210	CD4 antigen	Mus musculus	66-69
16412592-6	2006	In addition, rutaecarpine administered mice exhibited reduced splenic cellularity, decreased numbers of total T cells, CD4(+) cells, CD8(+) cells, and B cells in spleen.	rutecarpine	13-25	CD4 antigen	Mus musculus	119-122
16412592-8	2006	The number of CD4(+)IL-2(+) cells was reduced significantly following administration of mice with rutaecarpine.	rutecarpine	98-110	CD4 antigen	Mus musculus	14-17
16480776-7	2006	Human, monkey and mouse CD4 have the cystein and the disulfide bond, but pig, cat, whale and dog CD4, like that of the bat, lacked the cystein.	Disulfides	53-62	CD4 antigen	Mus musculus	24-27
16689863-8	2006	Examination of macrophages and T cells from peripheral lymph nodes of control and LNFPIII-treated fsn/fsn mice showed that glycan treatment reduced the numbers of Gr1(+)F4/80(+) macrophages and the numbers of CD8(+) T cells, restoring the numbers of these two cell populations as well as the CD4 : CD8 ratio to near normal levels.	Polysaccharides	123-129	CD4 antigen	Mus musculus	292-295
16670285-9	2006	After administration of highly polymerized procyanidins, there was a decrease in both dendritic and CD4(+) T cells.	Proanthocyanidins	43-55	CD4 antigen	Mus musculus	100-103
16651623-9	2006	Concomitantly, CD4 and CD8 cells of the UCP2-deficient mice showed increased production of reactive oxygen species.	Reactive Oxygen Species	91-114	CD4 antigen	Mus musculus	15-18
16783460-1	2006	To investigate type II collagen (CII)-specific CD4+ T cell receptors involving in Collagen-induced arthritis (CIA) in DBA/1J mice as a model of rheumatoid arthritis in humans, TCR Vbeta usage in draining lymph nodes (dLNs) was assessed by flow cytometric analysis at 3, 5, and 8 weeks after bovine CII immunizations.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	33-36	CD4 antigen	Mus musculus	47-50
16783460-4	2006	In addition, CII-reactive response was observed when CD4+ Vbeta3+ T cells were added to a non-responding T cell population.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	13-16	CD4 antigen	Mus musculus	53-56
16585551-3	2006	We found that intranasal vaccination of NOD mice with plasmid DNA encoding mouse proinsulin II-induced CD4+ T(reg) that suppressed diabetes development, both after adoptive cotransfer with "diabetogenic" spleen cells and after transfer into NOD mice given cyclophosphamide to accelerate diabetes onset.	Cyclophosphamide	256-272	CD4 antigen	Mus musculus	103-106
16208470-4	2006	The present work demonstrates, for the first time, the capacity of NGcGM3 ganglioside to down-modulate CD4 expression in murine and human T lymphocytes, especially in non-activated T cells.	ngcgm3 ganglioside	67-85	CD4 antigen	Mus musculus	103-106
16208470-5	2006	Thirty and tenfold reductions in CD4 expression were induced by purified NGcGM3 ganglioside in murine and human T lymphocytes, respectively.	ngcgm3 ganglioside	73-91	CD4 antigen	Mus musculus	33-36
16415170-0	2006	H2 complex controls CD4/CD8 ratio, recurrent responsiveness to repeated stimulations, and resistance to activation-induced apoptosis during T cell response to mycobacterial antigens.	Hydrogen	0-2	CD4 antigen	Mus musculus	20-23
16547229-6	2006	The results suggest that DS exposes shared epitopes in the cornea, conjunctiva, and LG that induce pathogenic CD4(+) T cells that produce LKC, which under normal circumstances is restrained by CD4(+)CD25(+)forkhead/winged helix transcription factor(+) regulatory T cells.	ds	25-27	CD4 antigen	Mus musculus	110-113
16547229-6	2006	The results suggest that DS exposes shared epitopes in the cornea, conjunctiva, and LG that induce pathogenic CD4(+) T cells that produce LKC, which under normal circumstances is restrained by CD4(+)CD25(+)forkhead/winged helix transcription factor(+) regulatory T cells.	ds	25-27	CD4 antigen	Mus musculus	193-196
16481417-7	2006	T cell levels significantly increased in kidneys of WT mice after cisplatin administration as early as at 1 h, peaked at 12 h, and declined by 24 h. CD4- and, to a lesser degree, CD8-deficient mice were relatively protected from cisplatin-induced mortality and renal dysfunction compared with WT mice.	Cisplatin	66-75	CD4 antigen	Mus musculus	149-152
16493027-3	2006	Cyclophosphamide could 1) abolish the suppressive function of CD4+CD25+Foxp3+ regulatory T cells, 2) markedly enhance the magnitude of secondary but not primary CTL responses induced by DEX vaccines, 3) synergize with DEX in therapy but not prophylaxis tumor models.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	62-65
16493027-3	2006	Cyclophosphamide could 1) abolish the suppressive function of CD4+CD25+Foxp3+ regulatory T cells, 2) markedly enhance the magnitude of secondary but not primary CTL responses induced by DEX vaccines, 3) synergize with DEX in therapy but not prophylaxis tumor models.	dex	186-189	CD4 antigen	Mus musculus	62-65
16493027-4	2006	Therefore, therapeutic vaccines such as DEX aimed at boosting tumor-primed effector T cells could benefit procedures that minimize the effects of CD4+CD25+ regulatory T cells.	dex	40-43	CD4 antigen	Mus musculus	146-149
16514202-7	2006	Using flow cytometry assays we found that the treatment with DHEA diminished the percentage of the CD4 + T lymphocyte population and increased the percentage of the CD8 + T lymphocyte population from both ovarian tissue and retroperitoneal lymph nodes.	Dehydroepiandrosterone	61-65	CD4 antigen	Mus musculus	99-102
16514202-8	2006	However, when metformin was administered together with DHEA, the percentages of CD4 + and CD8 + T lymphocyte populations from both ovarian tissue and retroperitoneal lymph nodes were similar to those observed in controls.	Metformin	14-23	CD4 antigen	Mus musculus	80-83
16514202-8	2006	However, when metformin was administered together with DHEA, the percentages of CD4 + and CD8 + T lymphocyte populations from both ovarian tissue and retroperitoneal lymph nodes were similar to those observed in controls.	Dehydroepiandrosterone	55-59	CD4 antigen	Mus musculus	80-83
16425136-0	2006	Vigorous hepatitis C virus-specific CD4+ and CD8+ T cell responses induced by protein immunization in the presence of Montanide ISA720 plus synthetic oligodeoxynucleotides containing immunostimulatory cytosine-guanine dinucleotide motifs.	mannide monooleate	118-134	CD4 antigen	Mus musculus	36-39
16290121-0	2006	Amelioration of experimental colitis by Copaxone is associated with class-II-restricted CD4 immune blocking.	Glatiramer Acetate	40-48	CD4 antigen	Mus musculus	88-91
16290121-10	2006	CD4 subsets significantly decreased following Copaxone administration as compared to naive mice (P = 0.05).	Glatiramer Acetate	46-54	CD4 antigen	Mus musculus	0-3
16290121-15	2006	CONCLUSIONS: Copaxone had class-II-restricted anti-inflammatory effect in our animal colitis model associated with CD4/NK/NKT/TH1/TH2 suppression.	Glatiramer Acetate	13-21	CD4 antigen	Mus musculus	115-118
16399633-2	2006	The characteristic features of TCDD-induced thymic changes include reductions in the number of the thymocytes and in the ratio of CD4 to CD8 T cells in the thymus.	Polychlorinated Dibenzodioxins	31-35	CD4 antigen	Mus musculus	130-133
16760124-6	2006	Zinc salt fixation preserved processing-sensitive murine cell markers (CD4, CD8 and CD54) and improved the intensity of immunolabeling for CD45, F4/80 and CD3.	zinc salt	0-9	CD4 antigen	Mus musculus	71-74
16393663-0	2006	In vitro immune toxicity of depleted uranium: effects on murine macrophages, CD4+ T cells, and gene expression profiles.	Uranium	37-44	CD4 antigen	Mus musculus	77-80
16409124-8	2006	When tested in vivo, either in CD4 knockout mice or in a hemophilic mouse model, the heparin-purified hybrid vector showed &gt;10-fold higher activity than similarly purified AAV2.	Heparin	85-92	CD4 antigen	Mus musculus	31-34
16365447-0	2006	CD4+ T lymphocytes expressing CD40 ligand help the IgM antibody response to soluble pneumococcal polysaccharides via an intermediate cell type.	Polysaccharides	97-112	CD4 antigen	Mus musculus	0-3
16365447-11	2006	In conclusion, we provide evidence that CD4+ T lymphocytes expressing CD40L stimulate the Ab response to soluble caps-PS by interacting with CD40-expressing non-B cells.	caps-ps	113-120	CD4 antigen	Mus musculus	40-43
16221546-0	2006	Dietary eicosapentaenoic acid modulates CTLA-4 expression in murine CD4+ T-cells.	Eicosapentaenoic Acid	8-29	CD4 antigen	Mus musculus	68-71
16221546-1	2006	We have demonstrated that downregulation of proliferation by CD4(+) T-cells in mice fed n-3 PUFA diets is dependent on the involvement of CD28.	Fatty Acids, Unsaturated	92-96	CD4 antigen	Mus musculus	61-64
16221546-4	2006	The proliferation of splenic CD4(+) T-cells was suppressed by DHA and EPA following stimulation with anti-CD3 and anti-CD28.	Docosahexaenoic Acids	62-65	CD4 antigen	Mus musculus	29-32
16221546-4	2006	The proliferation of splenic CD4(+) T-cells was suppressed by DHA and EPA following stimulation with anti-CD3 and anti-CD28.	Eicosapentaenoic Acid	70-73	CD4 antigen	Mus musculus	29-32
16221546-7	2006	Therefore, we conclude that dietary EPA may suppress CD4(+) T-cell activation by enhancing the downregulatory co-receptor CTLA-4, while not altering the levels of CD28.	Eicosapentaenoic Acid	36-39	CD4 antigen	Mus musculus	53-56
16378103-13	2005	At the concentrations of 0.2-12.8 mg/L or 3.2-12.8 mg/L, Gl-BSP demonstrated more significant activity in increasing the percentage of the CD4(+) or CD8(+) subset than Gl-SP.	gl-bsp	57-63	CD4 antigen	Mus musculus	139-142
16378103-14	2005	At the concentrations of 0.2-0.8 mg/L, the ratio of the CD4(+) and CD8(+) subset in the Gl-BSP treated group was higher than that of the Gl-SP treated group.	gl-bsp	88-94	CD4 antigen	Mus musculus	56-59
16285009-3	2005	In this study, we demonstrate that LT induces in mice a rapid increase in the levels of circulating corticosterone, resulting in a dramatic induction of cell death of immature CD4+CD8+, B220+IgM- and IgM+IgD- T and B cell progenitors, respectively.	Leu-Thr	35-37	CD4 antigen	Mus musculus	176-179
16285009-3	2005	In this study, we demonstrate that LT induces in mice a rapid increase in the levels of circulating corticosterone, resulting in a dramatic induction of cell death of immature CD4+CD8+, B220+IgM- and IgM+IgD- T and B cell progenitors, respectively.	Corticosterone	100-114	CD4 antigen	Mus musculus	176-179
16306767-15	2005	Splenic CD4 lymphocytes decreased in the sham+TNBS and Adex+TNBS groups as compared with control groups (Adex and naive).	Trinitrobenzenesulfonic Acid	46-50	CD4 antigen	Mus musculus	8-11
16306767-15	2005	Splenic CD4 lymphocytes decreased in the sham+TNBS and Adex+TNBS groups as compared with control groups (Adex and naive).	Trinitrobenzenesulfonic Acid	60-64	CD4 antigen	Mus musculus	8-11
16306767-16	2005	The CD8/CD4 ratio was significantly higher in the Adex+TNBS compared with the sham+TNBS group.	Trinitrobenzenesulfonic Acid	55-59	CD4 antigen	Mus musculus	8-11
16306767-16	2005	The CD8/CD4 ratio was significantly higher in the Adex+TNBS compared with the sham+TNBS group.	Trinitrobenzenesulfonic Acid	83-87	CD4 antigen	Mus musculus	8-11
16297148-7	2005	In contrast, female PBS-mice had significantly lower percentages of regulatory CD4(+)/CD25(+) T cells than males (females 4.2+/-0.2% vs. males 5.3+/-0.1% of CD4(+) T cells, P&lt;0.05).	Lead	20-23	CD4 antigen	Mus musculus	79-82
16297148-7	2005	In contrast, female PBS-mice had significantly lower percentages of regulatory CD4(+)/CD25(+) T cells than males (females 4.2+/-0.2% vs. males 5.3+/-0.1% of CD4(+) T cells, P&lt;0.05).	Lead	20-23	CD4 antigen	Mus musculus	157-160
16282061-7	2005	The levels of CD3, CD4, CD4/CD8, IgG, IgM in 5-FU group were lower (P&lt;0.05), while those in the three Shengmai Injection combined with 5-FU groups were higher than those in the control group (P&lt;0.05).	Fluorouracil	45-49	CD4 antigen	Mus musculus	19-22
16282061-7	2005	The levels of CD3, CD4, CD4/CD8, IgG, IgM in 5-FU group were lower (P&lt;0.05), while those in the three Shengmai Injection combined with 5-FU groups were higher than those in the control group (P&lt;0.05).	Fluorouracil	45-49	CD4 antigen	Mus musculus	24-27
16210602-3	2005	Although chronic morphine administration has been shown to selectively promote Th2 development in unpurified T cell populations, the direct effects of chronic morphine on Th cell skewing and cytokine production by CD4(+) T cells have not been elucidated.	Morphine	159-167	CD4 antigen	Mus musculus	214-217
16210602-8	2005	Furthermore, morphine enhanced the mRNA expression of Fas, FasL and TRAIL and promoted Fas-mediated AICD of CD4(+) T cells.	Morphine	13-21	CD4 antigen	Mus musculus	108-111
16210602-9	2005	Additionally, blockade of Fas/FasL interaction by anti-FasL inhibited the morphine-induced production of IL-4 and IL-13 and AICD of CD4(+) T cells.	Morphine	74-82	CD4 antigen	Mus musculus	132-135
16210648-4	2005	We assessed the contribution of these glycans to the development of colitis induced by CD4(+)CD45RB(high) T cell transfer to Rag1(-/-) mice.	Polysaccharides	38-45	CD4 antigen	Mus musculus	87-90
16405934-2	2005	Following stimulation with phorbol 12-myristate 13-acetate and ionomycin, anti-CD3/CD28, antigen-specific peptide, or allogeneic cells, both CD4 and CD8 T cells expressed the transgene within 24h in a manner that was consistent with cellular activation markers.	Tetradecanoylphorbol Acetate	27-58	CD4 antigen	Mus musculus	141-144
16405934-2	2005	Following stimulation with phorbol 12-myristate 13-acetate and ionomycin, anti-CD3/CD28, antigen-specific peptide, or allogeneic cells, both CD4 and CD8 T cells expressed the transgene within 24h in a manner that was consistent with cellular activation markers.	Ionomycin	63-72	CD4 antigen	Mus musculus	141-144
16214535-10	2005	Secondary CBA recipients given CD4+ splenocytes from primary CBA recipients treated with NS-398 also had indefinite survival of C57BL/10 hearts (median survival time, &gt;60 days).	N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	89-95	CD4 antigen	Mus musculus	31-34
16223671-4	2005	Using CD4(-/-) and CD8(-/-) mice, we established that CyA immunosuppression at this dose was only effective at preventing allograft vasculopathy in mice lacking CD8(+) T cells.	Cyclosporine	54-57	CD4 antigen	Mus musculus	6-9
16223671-11	2005	We interpret these data to suggest that in the face of CyA immunosuppression CD4(+) T cell effector function is ablated while CD8(+) T cell function remains partially intact.	Cyclosporine	55-58	CD4 antigen	Mus musculus	77-80
16116196-0	2005	High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors.	NAD	78-111	CD4 antigen	Mus musculus	20-23
16116196-0	2005	High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors.	Adenosine Triphosphate	116-119	CD4 antigen	Mus musculus	20-23
16116196-2	2005	In this study we demonstrate that micromolar concentrations of the common cell metabolite NAD induce death in murine forkhead/winged helix transcription factor gene-expressing CD4+CD25+ regulatory T cells with high efficiency and within minutes.	NAD	90-93	CD4 antigen	Mus musculus	176-179
16116196-6	2005	Injection of NAD or benzoylbenzoyl-ATP causes preferential induction of a cell death signal in CD4+CD25+ cells.	NAD	13-16	CD4 antigen	Mus musculus	95-98
16116196-6	2005	Injection of NAD or benzoylbenzoyl-ATP causes preferential induction of a cell death signal in CD4+CD25+ cells.	3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate	20-38	CD4 antigen	Mus musculus	95-98
15947025-12	2005	The specific downregulation of the CD4 coreceptor transcript by genistein was consistent with the decline of CD4+ thymocytes in genistein-treated mice in our previous study.	Genistein	64-73	CD4 antigen	Mus musculus	35-38
15947025-12	2005	The specific downregulation of the CD4 coreceptor transcript by genistein was consistent with the decline of CD4+ thymocytes in genistein-treated mice in our previous study.	Genistein	64-73	CD4 antigen	Mus musculus	109-112
15927321-4	2005	An increase in the LLO-specific response of both CD8(+) and CD4(+) T cells could be detected following the addition of dimethyldioctadecylammonium bromide (DDA), although the generation of this response was not dependent upon LLO pore formation, suggesting that DDA might change the presentation pathway of LLO leading to activation of the CD8(+) T cells.	dimethyldioctadecylammonium	119-154	CD4 antigen	Mus musculus	60-63
15927321-4	2005	An increase in the LLO-specific response of both CD8(+) and CD4(+) T cells could be detected following the addition of dimethyldioctadecylammonium bromide (DDA), although the generation of this response was not dependent upon LLO pore formation, suggesting that DDA might change the presentation pathway of LLO leading to activation of the CD8(+) T cells.	dimethyldioctadecylammonium	156-159	CD4 antigen	Mus musculus	60-63
15964028-3	2005	Administration of THC alone, in the absence of HIV, decreased CD4 counts and the CD4:CD8 ratio.	Dronabinol	18-21	CD4 antigen	Mus musculus	62-65
15964028-3	2005	Administration of THC alone, in the absence of HIV, decreased CD4 counts and the CD4:CD8 ratio.	Dronabinol	18-21	CD4 antigen	Mus musculus	81-84
16000332-0	2005	A glycoprotein endopeptidase enhances calcium influx and cytokine production by CD4+ T cells of old and young mice.	Calcium	38-45	CD4 antigen	Mus musculus	80-83
15899580-0	2005	Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	76-79
15899580-4	2005	METHOD: We examined Cy-treated CD25(+) CD4(+) T cells by flow cytometer and by inhibition assay on proliferation of CD25(-) CD4(+) T cells.	Cyclophosphamide	20-22	CD4 antigen	Mus musculus	39-42
15899580-4	2005	METHOD: We examined Cy-treated CD25(+) CD4(+) T cells by flow cytometer and by inhibition assay on proliferation of CD25(-) CD4(+) T cells.	Cyclophosphamide	20-22	CD4 antigen	Mus musculus	124-127
15899580-5	2005	RESULTS: Cy treatment remarkably reduced the number and percentage of CD25(+) CD4(+) T cells in the spleen and lymph nodes 3 and 5 days later.	Cyclophosphamide	9-11	CD4 antigen	Mus musculus	78-81
15899580-7	2005	Furthermore, transfer of CD25(+) CD4(+) T cells from untreated mice resulted in a significant decrease (p &lt; 0.05) of the CH reactions enhanced by Cy treatment.	Cyclophosphamide	149-151	CD4 antigen	Mus musculus	33-36
15899580-8	2005	CONCLUSION: These results indicate that enhancement of the CH reactions to TNCB by Cy treatment is attributed to the decrease in the number, percentage and the function of CD25(+) CD4(+) regulatory T cells.	Picryl Chloride	75-79	CD4 antigen	Mus musculus	180-183
15899580-8	2005	CONCLUSION: These results indicate that enhancement of the CH reactions to TNCB by Cy treatment is attributed to the decrease in the number, percentage and the function of CD25(+) CD4(+) regulatory T cells.	Cyclophosphamide	83-85	CD4 antigen	Mus musculus	180-183
16083070-8	2005	Immunized mice with homogenate treated with iridoid mixture showed a significant increase (P &lt; 0.05) in CD4+T thymocytes, a non significant increase in CD8+T thymocytes, a significant increase (P &lt; 0.05) in CD4+T lymphocytes (MLNC) and a non significant increase in CD8+ T- and B-lymphocytes (MLNC) compared with mice immunized with untreated homogenate or non-injected normal mice.	Iridoids	44-51	CD4 antigen	Mus musculus	107-110
16083070-8	2005	Immunized mice with homogenate treated with iridoid mixture showed a significant increase (P &lt; 0.05) in CD4+T thymocytes, a non significant increase in CD8+T thymocytes, a significant increase (P &lt; 0.05) in CD4+T lymphocytes (MLNC) and a non significant increase in CD8+ T- and B-lymphocytes (MLNC) compared with mice immunized with untreated homogenate or non-injected normal mice.	Iridoids	44-51	CD4 antigen	Mus musculus	213-216
15961135-6	2005	We show here that virus-specific CD4 T cells require IFNgamma for their anti-viral function in both acute and latent gammaHV68 infection.	gammahv68	117-126	CD4 antigen	Mus musculus	33-36
15908443-5	2005	IL-27-mediated tyrosine phosphorylation of STAT1 was also enhanced in WSX-1 Tg CD4(+) T cells, but STAT3 activation was normal.	Tyrosine	15-23	CD4 antigen	Mus musculus	79-82
15788440-6	2005	The enhanced CD4(+) T cell death with a suppressive dose of Con A is dependent on excess H(2)O(2) and nitric oxide but is independent of Fas and caspase activity.	Water	89-95	CD4 antigen	Mus musculus	13-16
15788440-6	2005	The enhanced CD4(+) T cell death with a suppressive dose of Con A is dependent on excess H(2)O(2) and nitric oxide but is independent of Fas and caspase activity.	Nitric Oxide	102-114	CD4 antigen	Mus musculus	13-16
15788440-7	2005	It is surprising that the increased proliferation of CD4(+) T cells with a suppressive dose of Con A on blocking CTLA4-CD80/CD86 interactions is largely interleukin (IL)-2-independent but is cyclosporine A-sensitive.	Cyclosporine	191-205	CD4 antigen	Mus musculus	53-56
15963362-8	2005	While the CD8+ cytokine response appeared non-specific, the cytokine response elicited in the lungs by CD4+ cells to Len/17-ca-inoculation was greater than that induced by Len/47-ca, or AA/ca.	17-ca	121-126	CD4 antigen	Mus musculus	103-106
15961541-1	2005	We examined the role of CD4+CD25+ regulatory T cells in the development of 3-methylcholanthrene (MCA)-induced tumors.	Methylcholanthrene	75-95	CD4 antigen	Mus musculus	24-27
15961541-1	2005	We examined the role of CD4+CD25+ regulatory T cells in the development of 3-methylcholanthrene (MCA)-induced tumors.	Methylcholanthrene	97-100	CD4 antigen	Mus musculus	24-27
15746082-0	2005	Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.	Sirolimus	0-9	CD4 antigen	Mus musculus	30-33
15944258-5	2005	Tetrahydro-4-aminobiopterin also reduced activation of CD4(+) T cells isolated from mice overexpressing an OVA-specific TCR by OVA-loaded murine bone marrow-derived dendritic cells, thus indicating that its effect on MHC class II expression is involved in attenuating T cell activation.	tetrahydro-4-aminobiopterin	0-27	CD4 antigen	Mus musculus	55-58
15944260-7	2005	The transfer of syngeneic CD4 T cells at the time of initiation of cGVH did not correct these B cell abnormalities; however, if CD4 T cells were transferred during the development and maturation of B cells, then the B cells from CD4KO mice acquire the ability to respond in cGVH.	cgvh	67-71	CD4 antigen	Mus musculus	26-29
15944263-2	2005	Immunization with OVA, poly(I:C), and anti-4-1BB generated a population of SIINFEKL-specific CD8 T regulatory cells that profoundly inhibited peptide-responding CD4 T cells from cellular division.	poly	23-27	CD4 antigen	Mus musculus	161-164
15958544-2	2005	It has been previously shown that cyclophosphamide augments the efficacy of antitumor immune responses by depleting CD4+ CD25+ T regulatory cells and increasing both T-lymphocyte proliferation and T memory cells.	Cyclophosphamide	34-50	CD4 antigen	Mus musculus	116-119
15958566-0	2005	Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.	Dinoprostone	23-39	CD4 antigen	Mus musculus	84-87
15921778-9	2005	By an unchanged infiltration with CD3-T-lymphocytes, carvedilol showed a representative reduction in CD4-T-lymphocytes.	Carvedilol	53-63	CD4 antigen	Mus musculus	101-104
15905592-6	2005	Prior adoptive transfer of the same CD4(+)CD25(+) Treg cells into CBA/J hosts suppressed Tg-induced EAT.	Thioguanine	89-91	CD4 antigen	Mus musculus	36-39
15883172-7	2005	Cyclophosphamide seemed to inhibit regulatory T (T reg) cells by selectively depleting the cycling population of CD4(+)CD25(+) T cells in neu-N mice.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	113-116
15879088-0	2005	CD4+CD25+ regulatory T cells attenuate the phosphatidylinositol 3-kinase/Akt pathway in antigen-primed immature CD8+ CTLs during functional maturation.	Phosphatidylinositols	43-63	CD4 antigen	Mus musculus	0-3
15851684-6	2005	It was evident that in vitro treatment and administration with COP-I significantly raised the level of Foxp3 expression in CD4+ T cells and promoted conversion of CD4+CD25+ regulatory T cells in wild-type B6 mice but not in IFN-gamma knockout mice.	cop-i	63-68	CD4 antigen	Mus musculus	123-126
15851684-6	2005	It was evident that in vitro treatment and administration with COP-I significantly raised the level of Foxp3 expression in CD4+ T cells and promoted conversion of CD4+CD25+ regulatory T cells in wild-type B6 mice but not in IFN-gamma knockout mice.	cop-i	63-68	CD4 antigen	Mus musculus	163-166
15855522-0	2005	Benznidazole therapy in Trypanosoma cruzi-infected mice blocks thymic involution and apoptosis of CD4+CD8+ double-positive thymocytes.	benzonidazole	0-12	CD4 antigen	Mus musculus	98-101
15855522-7	2005	The thymocyte loss related to the depletion of double-positive CD4(+)CD8(+) thymocytes was clearly prevented, corroborating the idea that the mechanism responsible for the prevention of thymus involution is related to the decrease of apoptosis rate in this subset after benznidazole treatment.	benzonidazole	270-282	CD4 antigen	Mus musculus	63-66
16083869-1	2005	CD4+ T cell proliferation depends on the balance between NO and extra-cellular superoxide (O2-).	Superoxides	79-89	CD4 antigen	Mus musculus	0-3
16083869-1	2005	CD4+ T cell proliferation depends on the balance between NO and extra-cellular superoxide (O2-).	Superoxides	91-93	CD4 antigen	Mus musculus	0-3
15897137-0	2005	[Effect of koumine on proliferation of murine CD4+ T cells purified by magnetic-activated cell sorting in vitro].	koumine	11-18	CD4 antigen	Mus musculus	46-49
15897137-9	2005	Koumine significantly inhibits the proliferation of murine CD4+ T cells due to its immunosuppressive effect and inhibition of IL-2 secretion.	koumine	0-7	CD4 antigen	Mus musculus	59-62
15788479-5	2005	Treg injection induced a dramatic decrease of glomerular damage as well as a marked decrease of CD4+ T cell, CD8+ T cell, and macrophage infiltration.	treg	0-4	CD4 antigen	Mus musculus	96-99
15792999-2	2005	Intrathymic precursor transfer experiments and the identification of CD4(+)8+ double-positive (DP), V alpha 14J alpha 18 natural T (iNKT) cells suggest that commitment to this lineage might occur at the DP stage.	dp	95-97	CD4 antigen	Mus musculus	69-72
15804283-8	2005	Most importantly, when EL4 cells were incubated in the presence of the MRP1 inhibitors indomethacin and MK 571 for 6 days, they started to express CD4 and CD8 molecules on their surface, producing double-positive cells and CD8 single-positive cells.	Indomethacin	87-99	CD4 antigen	Mus musculus	147-150
15804283-8	2005	Most importantly, when EL4 cells were incubated in the presence of the MRP1 inhibitors indomethacin and MK 571 for 6 days, they started to express CD4 and CD8 molecules on their surface, producing double-positive cells and CD8 single-positive cells.	verlukast	104-110	CD4 antigen	Mus musculus	147-150
15753207-4	2005	CD4(+)CD25(+) T reg cells from the thymus of dnTbetaRII mice retain the ability to inhibit colitis, suggesting that T cell responsiveness to TGF-beta is not required for the development or peripheral function of thymic-derived T reg cells.	dntbetarii	45-55	CD4 antigen	Mus musculus	0-3
15731032-4	2005	PhoP/PhoQ, a regulon controlling Salmonella virulence and remodeling of LPS to resist innate immunity, coordinately represses production of surface-exposed antigens recognized by CD4+ T cells and TLRs.	PHOP	0-4	CD4 antigen	Mus musculus	179-182
15731032-4	2005	PhoP/PhoQ, a regulon controlling Salmonella virulence and remodeling of LPS to resist innate immunity, coordinately represses production of surface-exposed antigens recognized by CD4+ T cells and TLRs.	phoq	5-9	CD4 antigen	Mus musculus	179-182
15728482-7	2005	Stimulation with anti-CD3 mAb induced transiently greater thymidine incorporation in IL-16-deficient CD4(+) T cells than wild-type controls, but there was no difference in cell survival or in the CFSE dilution profiles.	Thymidine	58-67	CD4 antigen	Mus musculus	101-104
15728527-11	2005	Depletion of CD4(+)CD25(+) regulatory T cells offset the suppression of H2E-mediated thyroiditis by H2A.	h2e	72-75	CD4 antigen	Mus musculus	13-16
15737197-4	2005	Here, we show that CD4-/- mice develop a normal delayed-type hypersensitivity response to protein antigen, which is mediated by major histocompatibility molecules class II-restricted CD4-CD8- T cells, but a decreased CHS response to 2,4-dinitro-fluorobenezene.	2,4-dinitro-fluorobenezene	233-259	CD4 antigen	Mus musculus	19-22
15654818-0	2005	Dietary n-3 polyunsaturated fatty acids suppress splenic CD4(+) T cell function in interleukin (IL)-10(-/-) mice.	Fatty Acids, Omega-3	8-39	CD4 antigen	Mus musculus	57-60
15654818-1	2005	Our laboratory has demonstrated that down-regulation of proliferation and cytokine synthesis by CD4(+) T cells in mice fed diets rich in n-3 polyunsaturated fatty acids (PUFA) is highly dependent on the involvement of the co-stimulatory molecule, CD28.	Fatty Acids, Omega-3	137-168	CD4 antigen	Mus musculus	96-99
15654818-1	2005	Our laboratory has demonstrated that down-regulation of proliferation and cytokine synthesis by CD4(+) T cells in mice fed diets rich in n-3 polyunsaturated fatty acids (PUFA) is highly dependent on the involvement of the co-stimulatory molecule, CD28.	Fatty Acids, Unsaturated	170-174	CD4 antigen	Mus musculus	96-99
15542542-10	2005	Even with an activated phenotype, 10 days post-burn injury, CD4+ naive T cells significantly increased spontaneous apoptosis, detected by using a fluorescent DNA-binding agent 7-amino-actinomycin D.	7-aminoactinomycin D	176-197	CD4 antigen	Mus musculus	60-63
15634910-6	2005	CD4(+) T cells isolated from aged donors (&gt;16 mo) had increased 11beta-HSD1 protein and an elevated capacity to convert cortisone to cortisol.	Cortisone	123-132	CD4 antigen	Mus musculus	0-3
15634910-6	2005	CD4(+) T cells isolated from aged donors (&gt;16 mo) had increased 11beta-HSD1 protein and an elevated capacity to convert cortisone to cortisol.	Hydrocortisone	136-144	CD4 antigen	Mus musculus	0-3
15588915-0	2005	Exposure of mice to the nitroso metabolite of sulfamethoxazole stimulates interleukin 5 production by CD4+ T-cells.	nitroso	24-31	CD4 antigen	Mus musculus	102-105
15588915-0	2005	Exposure of mice to the nitroso metabolite of sulfamethoxazole stimulates interleukin 5 production by CD4+ T-cells.	Sulfamethoxazole	46-62	CD4 antigen	Mus musculus	102-105
15588915-12	2005	Depletion of CD4(+) or CD8(+) T-cells from SMX-NO stimulated lymph node cells revealed that CD4(+) T-cells were the major source of IL-5.	4-nitrososulfamethoxazole	43-49	CD4 antigen	Mus musculus	13-16
15588915-13	2005	In conclusion, the data presented indicates that subcutaneous administration to mice of SMX-NO, but not the parent drug, stimulated the secretion of high levels of IL-5 from activated CD4(+) T-cells, which is consistent with the clinical profile of the drug.	4-nitrososulfamethoxazole	88-94	CD4 antigen	Mus musculus	184-187
15659321-3	2005	SST, wogonin-7-O-glucuronoside (a major SST ingredient), and wogonin (an intestinal metabolite of wogonin-7-O-glucuronoside) increased CD4/CD8 ratio via a decrease of CD8+ T-cell counts with no effect on CD4+ T-cell counts.	wogonin-7-o-glucuronoside	5-30	CD4 antigen	Mus musculus	135-138
15659321-3	2005	SST, wogonin-7-O-glucuronoside (a major SST ingredient), and wogonin (an intestinal metabolite of wogonin-7-O-glucuronoside) increased CD4/CD8 ratio via a decrease of CD8+ T-cell counts with no effect on CD4+ T-cell counts.	wogonin-7-o-glucuronoside	5-30	CD4 antigen	Mus musculus	204-207
15659321-3	2005	SST, wogonin-7-O-glucuronoside (a major SST ingredient), and wogonin (an intestinal metabolite of wogonin-7-O-glucuronoside) increased CD4/CD8 ratio via a decrease of CD8+ T-cell counts with no effect on CD4+ T-cell counts.	wogonin	5-12	CD4 antigen	Mus musculus	135-138
15659321-3	2005	SST, wogonin-7-O-glucuronoside (a major SST ingredient), and wogonin (an intestinal metabolite of wogonin-7-O-glucuronoside) increased CD4/CD8 ratio via a decrease of CD8+ T-cell counts with no effect on CD4+ T-cell counts.	wogonin	5-12	CD4 antigen	Mus musculus	204-207
15659321-3	2005	SST, wogonin-7-O-glucuronoside (a major SST ingredient), and wogonin (an intestinal metabolite of wogonin-7-O-glucuronoside) increased CD4/CD8 ratio via a decrease of CD8+ T-cell counts with no effect on CD4+ T-cell counts.	wogonin-7-o-glucuronoside	98-123	CD4 antigen	Mus musculus	135-138
15659321-6	2005	These findings suggest that SST may modulate the CD4/CD8 ratio via the selective inhibition of CD8+ T-cell proliferation by the SST ingredient wogonin-7-O-glucuronoside or its metabolite wogonin.	wogonin-7-o-glucuronoside	143-168	CD4 antigen	Mus musculus	49-52
15649272-11	2005	TSA also reduced infiltration of CD4+ and inflammatory cells and mucus occlusions in lung tissue, and decreased the concentrations of IL-4, IL-5, and IgE in BALF.	trichostatin A	0-3	CD4 antigen	Mus musculus	33-36
15692785-8	2005	Immunohistochemical analysis revealed a significant increase of both F4/80+ macrophages and CD4+ T cells in the inflamed mucosa in DSS-fed MyD88(-/-) mice compared to DSS-fed WT mice.	Dextran Sulfate	131-134	CD4 antigen	Mus musculus	92-95
15753183-0	2004	Vitamin E supplementation reverses the age-associated decrease in effective immune synapse formation in CD4+ T cells.	Vitamin E	0-9	CD4 antigen	Mus musculus	104-107
15753183-3	2004	On the basis of our previous research with vitamin E (VE), we hypothesized that VE supplementation of old CD4(+) T cells enhances effective immune synapse formation through increased translocation of signaling proteins.	Vitamin E	43-52	CD4 antigen	Mus musculus	106-109
15557147-0	2004	"Pruning" of alloreactive CD4+ T cells using 5- (and 6-)carboxyfluorescein diacetate succinimidyl ester prolongs skin allograft survival.	5- (and 6-)carboxyfluorescein diacetate succinimidyl ester	45-103	CD4 antigen	Mus musculus	26-29
15596227-8	2004	Therefore, while ovarian controls showed equivalent expression of CD4+ and CD8+ T cell subsets, injection of DHEA yielded a selective ovarian T cell infiltration as demonstrated by enhanced CD8+ and diminished CD4+ T lymphocyte expression.	Dehydroepiandrosterone	109-113	CD4 antigen	Mus musculus	210-213
15577330-0	2004	Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.	Tyrosine	72-75	CD4 antigen	Mus musculus	104-107
15528345-5	2004	In vivo, CyaA induces strong and specific Th1 CD4(+) and CD8(+) T cell responses against, respectively, the MalE(100-114) and OVA(257-264) epitopes.	cyaa	9-13	CD4 antigen	Mus musculus	46-49
15498030-14	2004	Overall, following DHEA application in WT mice, an alteration in the cellular immune response was characterized by a reduction in the percentage counts of CD4(+), CD8(+) and NK cells.	Dehydroepiandrosterone	19-23	CD4 antigen	Mus musculus	155-158
15501392-0	2004	Activation and attenuation of apoptosis of CD4+ T cells following in vivo exposure to two common environmental toxicants, trichloroacetaldehyde hydrate and trichloroacetic acid.	Chloral Hydrate	122-151	CD4 antigen	Mus musculus	43-46
15501392-0	2004	Activation and attenuation of apoptosis of CD4+ T cells following in vivo exposure to two common environmental toxicants, trichloroacetaldehyde hydrate and trichloroacetic acid.	Trichloroacetic Acid	156-176	CD4 antigen	Mus musculus	43-46
15501392-1	2004	Exposure to occupationally relevant concentrations of the environmental pollutant, trichloroethylene (TCE), in the drinking water of autoimmune-prone MRL+/+ mice has been shown to promote the generation of lupus and autoimmune hepatitis in association with the activation of Interferon-gamma (IFN-gamma)-producing CD4+ T cells.	Trichloroethylene	83-100	CD4 antigen	Mus musculus	314-317
15501392-1	2004	Exposure to occupationally relevant concentrations of the environmental pollutant, trichloroethylene (TCE), in the drinking water of autoimmune-prone MRL+/+ mice has been shown to promote the generation of lupus and autoimmune hepatitis in association with the activation of Interferon-gamma (IFN-gamma)-producing CD4+ T cells.	Trichloroethylene	102-105	CD4 antigen	Mus musculus	314-317
15501392-4	2004	CD4+ T cells from TCAH and TCA-treated MRL+/+ mice, unlike CD4+ T cells from control mice, demonstrated functional and phenotypic signs of activation, as evidenced by increased IFN-gamma production in association with the increased percentage of CD62L(lo) CD4+ T cells.	Trichloroacetic Acid	18-21	CD4 antigen	Mus musculus	0-3
15501392-5	2004	Interestingly, it was also found that the CD4+ T cells from the TCAH and TCA-treated mice showed a decreased susceptibility to the activation-induced cell death (AICD) form of apoptosis following re-stimulation in vitro.	Trichloroacetic Acid	64-67	CD4 antigen	Mus musculus	42-45
15501392-6	2004	By demonstrating that TCAH and TCA can activate CD4+ T cells and inhibit their apoptosis following in vivo exposure represents a mechanism by which environmental toxicants may induce or accelerate the development of autoimmune disease.	Chloral Hydrate	22-26	CD4 antigen	Mus musculus	48-51
15501392-6	2004	By demonstrating that TCAH and TCA can activate CD4+ T cells and inhibit their apoptosis following in vivo exposure represents a mechanism by which environmental toxicants may induce or accelerate the development of autoimmune disease.	Trichloroacetic Acid	22-25	CD4 antigen	Mus musculus	48-51
15313434-12	2004	Finally, exposure to WDDD decreased both the percentage and absolute number of regulatory CD4(+)CD25(+) T cells in the spleen, which was consistent with a significant increase in interferon-gamma (IFN-gamma) production from Con A-stimulated splenocytes.	wddd	21-25	CD4 antigen	Mus musculus	90-93
15356168-8	2004	The animals treated with SAHA had decreased spleen size and a concomitant decrease in CD4-CD8- (double-negative) T cells compared with controls.	Vorinostat	25-29	CD4 antigen	Mus musculus	86-89
15383175-7	2004	Administration of anti-CD4 or anti-CD8 antibodies suppressed growth of MH134-pCXN2-eotaxin cells compared with control antibodies, suggesting that T cells may interfere with immunity against MH134.	mh134	71-76	CD4 antigen	Mus musculus	23-26
15362034-7	2004	The therapeutic efficacy of CLA also was examined by using the CD4 + CD45RB hi transfer colitis model.	Linoleic Acids, Conjugated	28-31	CD4 antigen	Mus musculus	63-66
15362034-10	2004	Clinically, CLA ameliorated DSS- and CD4 + -induced colitis.	Linoleic Acids, Conjugated	12-15	CD4 antigen	Mus musculus	37-40
15322178-0	2004	Fas-mediated inhibition of CD4+ T cell priming results in dominance of type 1 CD8+ T cells in the immune response to the contact sensitizer trinitrophenyl.	ammonium ferrous sulfate	0-3	CD4 antigen	Mus musculus	27-30
15336689-6	2004	Prednisolone reduced macrophages (-59%, -57%), CD4(+) T-cells (-50%, -60%), CD8(+) T-cells (-58%, -48%), and eosinophils (-36%, -25%) in quadriceps and soleus muscles, respectively.	Prednisolone	0-12	CD4 antigen	Mus musculus	47-50
15197777-9	2004	CD4(+) T cells, but not CD8(+) T cells, from inoculated mice produced IFN-gamma by incubation with DC/MIH-2.	mih-2	102-107	CD4 antigen	Mus musculus	0-3
15284386-0	2004	Dietary polyunsaturated fatty acids modulate in vivo, antigen-driven CD4+ T-cell proliferation in mice.	Fatty Acids, Unsaturated	8-35	CD4 antigen	Mus musculus	69-72
15205027-9	2004	Alterations were detected in thymic and splenic CD4/8 subpopulations, and proliferative responses of bone marrow progenitor cells were enhanced in mice exposed to 2000 mg/kg/d of JP-8.	JP-8	179-183	CD4 antigen	Mus musculus	48-51
15240692-0	2004	Oral tolerance to nickel requires CD4+ invariant NKT cells for the infectious spread of tolerance and the induction of specific regulatory T cells.	Nickel	18-24	CD4 antigen	Mus musculus	34-37
15240692-9	2004	We conclude that CD4(+) iNKT cells are required for the induction of oral nickel tolerance and, in particular, for the infectious spread of tolerance from APCs to T cells.	Nickel	74-80	CD4 antigen	Mus musculus	17-20
14975940-7	2004	The reduced lung fibrotic response to silica in IL-10-/- mice was accompanied by a marked recruitment of TH1 CD4+ lymphocytes.	Silicon Dioxide	38-44	CD4 antigen	Mus musculus	109-112
14975940-8	2004	However, treatment with anti-CD4 antibodies reduced silica-induced lung fibrosis in both IL-10-/- and IL-10+/+ mice, suggesting that this T cell population actually contributes to the extension of the fibrotic lesions in a manner that is independent of IL-10.	Silicon Dioxide	52-58	CD4 antigen	Mus musculus	29-32
15215094-4	2004	In CEL-1000-treated and protected mice, high levels of gamma interferon (IFN-gamma) in serum and elevated frequencies of hepatic and splenic CD4+ IFN-gamma-positive T cells were detected 24 h after administration of an additional dose of CEL-1000.	cel-1000	3-11	CD4 antigen	Mus musculus	141-144
15215094-6	2004	Our data establish that the protection induced by CEL-1000 is dependent on IFN-gamma and is partially dependent on CD4+ T cells but is independent of CD8+ T cells, NK cells, and IL-12 at the effector phase and does not induce a detectable antibody response.	cel-1000	50-58	CD4 antigen	Mus musculus	115-118
15207780-2	2004	Vaccination with OVA-CT-pulsed DC concurrently induced strong CTL in vitro activity and anti-E.G7 tumor protection in vivo in WT, NK-depleted and CD4-deficient mice as well as in IL-12-/- and IFN-gamma-/- mice but not in CD8-deficient mice.	ova-ct	17-23	CD4 antigen	Mus musculus	146-149
15210777-6	2004	However, blockade or genetic absence of CD28/CD154 costimulatory molecules rendered CD4(+) T cell-mediated rejection sensitive to rapamycin, and long term skin allograft survival can be readily induced by rapamycin in the absence of CD28/CD154 signals (&gt;100 days).	Sirolimus	130-139	CD4 antigen	Mus musculus	84-87
15291406-10	2004	CONCLUSIONS: One percent ARG supplementation of TPN does not improve GALT cell number or mucosal IgA level but benefits to increase CD4+ cell percentages in GALT.	Arginine	25-28	CD4 antigen	Mus musculus	132-135
15238080-1	2004	Citrullination (deimination is an enzymatic, posttranslational conversion of arginine residues to citrulline residues) of joint-associated self-proteins may be a possible mechanism in the induction of autoimmune CD4 T-cell responses in rheumatoid arthritis.	Arginine	77-85	CD4 antigen	Mus musculus	212-215
15238080-1	2004	Citrullination (deimination is an enzymatic, posttranslational conversion of arginine residues to citrulline residues) of joint-associated self-proteins may be a possible mechanism in the induction of autoimmune CD4 T-cell responses in rheumatoid arthritis.	Citrulline	98-108	CD4 antigen	Mus musculus	212-215
15147420-6	2004	Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset.	Cyclosporine	79-82	CD4 antigen	Mus musculus	120-123
15147420-6	2004	Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset.	Cyclosporine	79-82	CD4 antigen	Mus musculus	238-241
15147420-6	2004	Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset.	Cyclosporine	79-82	CD4 antigen	Mus musculus	120-123
15147420-6	2004	Analysis of the T-cell recovery in ASCT- and ASCT/CsA-treated mice showed that CsA induced an increase in the number of CD4+ 25+ T cells, suggesting that the lack of GVHD in ASCT/CsA treated-mice could be related to the expansion of this CD4 T-cell subset.	Cyclosporine	79-82	CD4 antigen	Mus musculus	238-241
15147343-11	2004	The frequencies of CD4(+)CD25(+) regulatory T cells in the spleen were significantly decreased in neonatal thymectomized mice administered with poly I:C compared to PBS-treated neonatal thymectomized mice (P &lt; 0.01).	Poly I	144-151	CD4 antigen	Mus musculus	19-22
15147343-11	2004	The frequencies of CD4(+)CD25(+) regulatory T cells in the spleen were significantly decreased in neonatal thymectomized mice administered with poly I:C compared to PBS-treated neonatal thymectomized mice (P &lt; 0.01).	pbs	165-168	CD4 antigen	Mus musculus	19-22
15084513-0	2004	Physiological sphingosine 1-phosphate requirement for optimal activity of mouse CD4+ regulatory T Cells.	sphingosine 1-phosphate	14-37	CD4 antigen	Mus musculus	80-83
15084513-3	2004	CD4+25+ T cell suppression of 3H-thymidine uptake and IL-2 generation by CD4+25- T cells stimulated with anti-T cell receptor antibodies without S1P was enhanced significantly by S1P at normal blood and lymph concentrations.	3h-thymidine	30-42	CD4 antigen	Mus musculus	0-3
15273668-0	2004	CD4+ T cells tumor specific response exists in L615 leukemia mice: adoptive transfer in combination with cyclophosphamide.	Cyclophosphamide	105-121	CD4 antigen	Mus musculus	0-3
15273668-11	2004	These CD4+ T cells can cure leukemia mice upon adoptive transfer in combination with cyclophosphamide pretreatment.	Cyclophosphamide	85-101	CD4 antigen	Mus musculus	6-9
15146310-5	2004	TCDD treatment caused significant thymic atrophy in pregnant mice as early as 48 h after exposure, but this effect was apparent in virgin mice only after 72 h. TCDD treatment also caused more marked alterations in thymic T-cell subpopulations of pregnant mice when compared to the virgin mice, with a decrease in the percentage of double-positive T cells and an increase in the percentage of single-positive (sP CD4(+) or sP CD8(+)) and double-negative T cells.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	412-415
15146310-5	2004	TCDD treatment caused significant thymic atrophy in pregnant mice as early as 48 h after exposure, but this effect was apparent in virgin mice only after 72 h. TCDD treatment also caused more marked alterations in thymic T-cell subpopulations of pregnant mice when compared to the virgin mice, with a decrease in the percentage of double-positive T cells and an increase in the percentage of single-positive (sP CD4(+) or sP CD8(+)) and double-negative T cells.	Polychlorinated Dibenzodioxins	160-164	CD4 antigen	Mus musculus	412-415
15455131-2	2004	Epithalamin, Epithalon, and melatonin appreciably increased the titer of thymic serum factor in the supernatant of thymus stroma cultures from mice of different age and increased the percentage of CD4+ cells in the bone marrow suspension from old animals in vitro.	epithalamin	0-11	CD4 antigen	Mus musculus	197-200
15455131-2	2004	Epithalamin, Epithalon, and melatonin appreciably increased the titer of thymic serum factor in the supernatant of thymus stroma cultures from mice of different age and increased the percentage of CD4+ cells in the bone marrow suspension from old animals in vitro.	Melatonin	28-37	CD4 antigen	Mus musculus	197-200
15082586-5	2004	CD4 T cells cocultured with CEC were CD25lo and CD45RBlo and remained in the G1 phase of the cell cycle.	cec	28-31	CD4 antigen	Mus musculus	0-3
15102763-5	2004	The alcohol-consuming mice had significantly higher lung organism burdens than the control mice, and the CD4(+)- and CD8(+)-lymphocyte responses to pulmonary infection with M. tuberculosis were blunted in the alcohol group.	Alcohols	209-216	CD4 antigen	Mus musculus	105-108
15102763-6	2004	Lymphocyte proliferation and production of gamma interferon were decreased in the CD4(+) lymphocytes from the alcohol-consuming mice.	Alcohols	110-117	CD4 antigen	Mus musculus	82-85
15102763-8	2004	In conclusion, murine alcohol consumption is associated with decreased control of pulmonary infection with M. tuberculosis, which is accompanied by alterations in the region-specific CD4(+)- and CD8(+)-lymphocyte responses and defective lung granuloma formation.	Alcohols	22-29	CD4 antigen	Mus musculus	183-186
15096484-0	2004	Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse.	Fluorescein-5-isothiocyanate	105-131	CD4 antigen	Mus musculus	37-40
15096484-10	2004	These findings indicate a contribution of MHC II-independent CD4(+) T cells and/or CD4(+) NKT cells to the Th2 response triggered by FITC in vivo, and makes FITC-induced CHS a suitable animal model for atopic dermatitis.	Fluorescein-5-isothiocyanate	133-137	CD4 antigen	Mus musculus	61-64
15096484-10	2004	These findings indicate a contribution of MHC II-independent CD4(+) T cells and/or CD4(+) NKT cells to the Th2 response triggered by FITC in vivo, and makes FITC-induced CHS a suitable animal model for atopic dermatitis.	Fluorescein-5-isothiocyanate	133-137	CD4 antigen	Mus musculus	83-86
15096484-10	2004	These findings indicate a contribution of MHC II-independent CD4(+) T cells and/or CD4(+) NKT cells to the Th2 response triggered by FITC in vivo, and makes FITC-induced CHS a suitable animal model for atopic dermatitis.	Fluorescein-5-isothiocyanate	157-161	CD4 antigen	Mus musculus	61-64
15096484-10	2004	These findings indicate a contribution of MHC II-independent CD4(+) T cells and/or CD4(+) NKT cells to the Th2 response triggered by FITC in vivo, and makes FITC-induced CHS a suitable animal model for atopic dermatitis.	Fluorescein-5-isothiocyanate	157-161	CD4 antigen	Mus musculus	83-86
15100256-5	2004	Introducing a combination of the inflammatory cytokines TNF-alpha, IL-1, and IL-6, or the use of an adjuvant such as CFA that induces these cytokines, markedly enhanced responses of these aged CD4 T cells, so that they proliferated and produced IL-2 similar to young cells.	3-chloro-4-fluoroaniline	117-120	CD4 antigen	Mus musculus	193-196
15100273-0	2004	In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.	Cyclophosphamide	8-24	CD4 antigen	Mus musculus	82-85
15193227-6	2004	RESULTS: (1) mPEG nearly completely covered up the CD4 and CD8 antigens on T cells, while the number of CFU-GM did not show any obvious change between the modified and non-modified cell groups.	monomethoxypolyethylene glycol	13-17	CD4 antigen	Mus musculus	51-54
15064401-2	2004	Here, we describe a N-ethyl-N-nitrosourea induced recessive mouse mutant, Ms. T-less, which lacks T cells in the peripheral blood because of a complete block of thymocyte development at the CD4(+)CD8(+) stage.	Ethylnitrosourea	20-41	CD4 antigen	Mus musculus	190-193
15034032-9	2004	The GRP94/gp96-dependent induction of CD4(+) T cell cytokine production was markedly inhibited by carrageenan, indicating an essential role for APC in this response.	Carrageenan	98-109	CD4 antigen	Mus musculus	38-41
15034040-3	2004	The present study uses a family of murine IL-2-dependent CD4(+) T cell clonal variants in which anti-TCRCbeta signaling is impaired in an lck-dependent fashion.	tcrcbeta	101-109	CD4 antigen	Mus musculus	57-60
15034040-5	2004	We have previously demonstrated that anti-TCRCbeta responsiveness in this system correlates with the presence of kinase-active, membrane-associated lck and preformed hypophosphorylated TCRzeta:zeta-associated protein of 70 kDa complexes, a phenotype recapitulated in primary resting CD4(+) T cells.	tcrcbeta	42-50	CD4 antigen	Mus musculus	283-286
15004147-4	2004	The activation of mHAg-specific TCR-Tg CD4+ T cells after their adoptive transfer into recipient mice given MHC-matched, but mHAg-disparate, airway allografts was associated with their movement into the allograft and the near uniform destruction of the transplanted airway tissue secondary to the development of obliterative airways disease.	mhag	18-22	CD4 antigen	Mus musculus	39-42
15004147-4	2004	The activation of mHAg-specific TCR-Tg CD4+ T cells after their adoptive transfer into recipient mice given MHC-matched, but mHAg-disparate, airway allografts was associated with their movement into the allograft and the near uniform destruction of the transplanted airway tissue secondary to the development of obliterative airways disease.	mhag	125-129	CD4 antigen	Mus musculus	39-42
15203320-3	2004	CTX and CR prevented the increase in and activation of B cells, the decline in CD8(+) T cells, and maintained a higher proportion of naive CD4(+) and CD8(+) cells.	Chromium	8-10	CD4 antigen	Mus musculus	139-142
14991599-6	2004	As judged from carboxyfluorescein diacetate succinimidyl ester-labeling experiments, 4-5% of the CD4+CD25- T cells respond to enteroantigen.	5-(6)-carboxyfluorescein diacetate succinimidyl ester	15-62	CD4 antigen	Mus musculus	97-100
14991602-7	2004	The CD4+ SP/CD8+ SP T cell ratio was decreased in Trp53(-/-) splenocytes and thymocytes.	sp	9-11	CD4 antigen	Mus musculus	4-7
14991602-7	2004	The CD4+ SP/CD8+ SP T cell ratio was decreased in Trp53(-/-) splenocytes and thymocytes.	sp	17-19	CD4 antigen	Mus musculus	4-7
14991616-0	2004	Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death.	Dexamethasone	67-80	CD4 antigen	Mus musculus	32-35
14991616-0	2004	Differential response of murine CD4+CD25+ and CD4+CD25- T cells to dexamethasone-induced cell death.	Dexamethasone	67-80	CD4 antigen	Mus musculus	46-49
14991616-2	2004	Administration of Dex enhanced the proportion of CD4+CD25+ cells and the ratio of CD4+CD25+ cells to CD4+CD25- cells in the lymphoid organs, especially in the thymus.	Dexamethasone	18-21	CD4 antigen	Mus musculus	49-52
14991616-2	2004	Administration of Dex enhanced the proportion of CD4+CD25+ cells and the ratio of CD4+CD25+ cells to CD4+CD25- cells in the lymphoid organs, especially in the thymus.	Dexamethasone	18-21	CD4 antigen	Mus musculus	82-85
14991616-2	2004	Administration of Dex enhanced the proportion of CD4+CD25+ cells and the ratio of CD4+CD25+ cells to CD4+CD25- cells in the lymphoid organs, especially in the thymus.	Dexamethasone	18-21	CD4 antigen	Mus musculus	82-85
14991616-3	2004	This correlates with our in vitro observation that CD4+CD25+ T cells express higher levels of glucocorticoid receptor and Bcl-2, and are therefore more resistant to Dex-mediated cell death than CD4+CD25- T cells.	Dexamethasone	165-168	CD4 antigen	Mus musculus	51-54
14991616-4	2004	Furthermore, IL-2 selectively protected CD4+CD25+ T cells from Dex-induced cell death, while IL-7 and IL-15 did not exert preferential protective effects.	Dexamethasone	63-66	CD4 antigen	Mus musculus	40-43
14991616-5	2004	Dex-treated CD4+CD25+ T cells expressed higher levels of intracellular CTLA-4 and surface glucocorticoid-induced TNF receptor than fresh CD4+CD25+ T cells, but still failed to respond to TCR stimulation and inhibited proliferation of CD4+CD25- T cells.	Dexamethasone	0-3	CD4 antigen	Mus musculus	12-15
14991616-5	2004	Dex-treated CD4+CD25+ T cells expressed higher levels of intracellular CTLA-4 and surface glucocorticoid-induced TNF receptor than fresh CD4+CD25+ T cells, but still failed to respond to TCR stimulation and inhibited proliferation of CD4+CD25- T cells.	Dexamethasone	0-3	CD4 antigen	Mus musculus	137-140
14991616-5	2004	Dex-treated CD4+CD25+ T cells expressed higher levels of intracellular CTLA-4 and surface glucocorticoid-induced TNF receptor than fresh CD4+CD25+ T cells, but still failed to respond to TCR stimulation and inhibited proliferation of CD4+CD25- T cells.	Dexamethasone	0-3	CD4 antigen	Mus musculus	137-140
14991616-6	2004	These results suggest that, in addition to suppressing cytokine transcription, Dex treatment is permissive for the survival of functional CD4+CD25+ T regulatory cells, and this property may contribute to the anti-inflammatory and immunosuppressive efficacy of glucocorticoids.	Dexamethasone	79-82	CD4 antigen	Mus musculus	138-141
15021962-0	2004	Regulation of Con A-dependent cytokine production from CD4+ and CD8+ T lymphocytes by autosecretion of histamine.	Histamine	103-112	CD4 antigen	Mus musculus	55-58
15021962-1	2004	OBJECTIVES: Previously we have shown that both CD4+ T cells and CD8+ T cells produce histamine when activated with Con A.	Histamine	85-94	CD4 antigen	Mus musculus	47-50
15021962-7	2004	Both CD4+ and CD8+ T cell fractions synthesized histamine, which was enhanced in the H1R-deficient CD8+ T cells.	Histamine	48-57	CD4 antigen	Mus musculus	5-8
15021962-9	2004	CONCLUSION: These results suggest that cytokine production by CD4+ and CD8+ T lymphocytes is regulated by autosecretion of histamine.	Histamine	123-132	CD4 antigen	Mus musculus	62-65
15204774-7	2004	Following silica exposure, CD4+ T cells significantly increased threefold within the superficial cervical lymph nodes.	Silicon Dioxide	10-16	CD4 antigen	Mus musculus	27-30
15204774-8	2004	During this increase in the number of CD4+ T cells, the number of CD4+CD25+ regulatory T cells was not significantly changed, altering the ratio of regulatory T cells to T helper cells from 1:5 to 1:8 following silica exposure.	Silicon Dioxide	211-217	CD4 antigen	Mus musculus	38-41
15204774-9	2004	Therefore, the silica-induced alterations in immunoglobulin levels, increased TNF-alpha, increased B1a B cells and CD4+ T cells, with decreased regulatory T cells, may provide an environment that allows for increased autoreactivity.	Silicon Dioxide	15-21	CD4 antigen	Mus musculus	115-118
14747060-8	2004	Examination of spleen lymphocytes from 4NQO induced mice revealed enlargement of the spleens and a significant decrease in the CD3, CD4, CD8 and CD19 cells.	4-Nitroquinoline-1-oxide	39-43	CD4 antigen	Mus musculus	132-135
15114497-11	2004	In addition, 4-hydroxyderricin (50 mg/kg x 2/day) inhibited the reduction of the numbers of lymphocytes, CD4+, CD8+ and natural killer (NK)-T cells in the spleen of tumor-removed mice.	4-hydroxyderricin	13-30	CD4 antigen	Mus musculus	105-108
15114497-12	2004	Doxorubicin reduced the numbers of lymphocytes, CD4+, CD8+ and NK cells compared to those in LLC-removed mice.	Doxorubicin	0-11	CD4 antigen	Mus musculus	48-51
14718643-9	2004	Furthermore, apoptosis-associated phenotypic changes were found in thymocytes of mice perinatally exposed to TCDD, characterized by an increase in expression of CD3, alphabetaTCR, IL-2R, and CD44, and a decrease in CD4, CD8, and J11d markers.	Polychlorinated Dibenzodioxins	109-113	CD4 antigen	Mus musculus	191-194
14764697-2	2004	In this study we show that CD4(+) T cells restrict the development and expansion of hapten-specific CD8(+) T cells mediating CHS responses to 2,4-dinitrofluorobenzene.	Dinitrofluorobenzene	142-166	CD4 antigen	Mus musculus	27-30
14962305-5	2004	RESULTS: Compared with untransfused animals, mice transfused with ABT showed higher expression of CD95 (MFI = 94.4 +/- 8.6 vs. 73.1 +/- 7.9, p = 0.02) and CD95L (23.5 +/- 6.9 vs. 8.1 +/- 2.0, p = 0.008) on CD4+ spleen cells.	abt	66-69	CD4 antigen	Mus musculus	206-209
15315261-2	2004	TJ-41 administration for 32 weeks increased the splenic NK cell population and CD4/CD8 significantly, but TJ-41 for 1 week was not affected.	tj-41	0-5	CD4 antigen	Mus musculus	79-82
15142267-8	2004	We also observed greater induction of IL-10-producing CD4+CD25+ subsets among CII-stimulated splenic T cells from tolerized mice.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	78-81	CD4 antigen	Mus musculus	54-57
15142267-9	2004	These data suggest that when these IL-10-producing CD4+CD25+ T cells encounter CII antigen in affected joints they become activated to exert an anti-inflammatory effect.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	79-82	CD4 antigen	Mus musculus	51-54
14971027-1	2004	In normal mice, more than 10% of thymocytes in the CD4+CD8- and CD4-CD8+ single-positive (SP) subsets express a medium level of CD3 on the cell surface.	sp	90-92	CD4 antigen	Mus musculus	64-67
14971027-6	2004	CD3medium thymocytes of both CD4+CD8- and CD4-CD8+ subsets were also considerably more responsive than CD3high SP cells to apoptotic signals induced in vitro by ligation of CD95 (Fas/APO-1) or by dexamethasone.	Dexamethasone	196-209	CD4 antigen	Mus musculus	29-32
14971027-6	2004	CD3medium thymocytes of both CD4+CD8- and CD4-CD8+ subsets were also considerably more responsive than CD3high SP cells to apoptotic signals induced in vitro by ligation of CD95 (Fas/APO-1) or by dexamethasone.	Dexamethasone	196-209	CD4 antigen	Mus musculus	42-45
14688381-6	2004	Beginning on the day of bone marrow transplantation, groups of control and CsA-treated animals were treated with mAb against either CD4 or CD8 for 21 days.	Cyclosporine	75-78	CD4 antigen	Mus musculus	132-135
14698844-0	2004	Reduced susceptibility to kainic acid-induced excitoxicity in T-cell deficient CD4/CD8(-/-) and middle-aged C57BL/6 mice.	Kainic Acid	26-37	CD4 antigen	Mus musculus	79-82
15645745-4	2004	Fludarabine-treated mice also had an almost 10-fold increase in percentile of CD8+CD25+ T cells in the spleen and a smaller but significant increase in CD4+CD25+ cells.	fludarabine	0-11	CD4 antigen	Mus musculus	152-155
15286391-6	2004	Mice receiving CD4+ T cells demethylated by a variety of agents, including procainamide and hydralazine, develop a lupuslike disease.	Procainamide	75-87	CD4 antigen	Mus musculus	15-18
15286391-6	2004	Mice receiving CD4+ T cells demethylated by a variety of agents, including procainamide and hydralazine, develop a lupuslike disease.	Hydralazine	92-103	CD4 antigen	Mus musculus	15-18
14555839-6	2004	In the delayed-type hypersensitivity (DTH) model elicited by DNFB, the number of CD8+ T cells among DNFB-2,4,6-trinitrobenzenesulfonic acid (TNBS)-peritoneal exudate cells was significantly higher in OPN-T than nontransgenic mice, while there was almost no difference in that of CD4+ T cells.	Trinitrobenzenesulfonic Acid	141-145	CD4 antigen	Mus musculus	279-282
14695478-4	2003	In this study, we generated an influenza virus hemagglutinin (HA) peptide-specific CD4(+) T cell clone from the HNT-TCR transgenic mice and induced anergy using APCs which were treated with the crosslinker, ECDI (1-ethyl-3-3(3-dimethylaminopropyl) carbodiimide).	1-ethyl-3-3(3-dimethylaminopropyl) carbodiimide	213-260	CD4 antigen	Mus musculus	83-86
14687711-6	2003	The administration of PCC and/or DX for 2 days resulted in a decreased DP cell number and a significantly increased CD4 SP cell ratio.	pyridinium chlorochromate	22-25	CD4 antigen	Mus musculus	116-119
14687711-11	2003	MHC-II bound PCC peptides in the presence of GCs enhanced the maturation of Vbeta3+ DP cells into CD4 SP stage, therefore, the Vbeta3- cells remained mostly in the DP immature stage.	TFF2 protein, human	102-104	CD4 antigen	Mus musculus	98-101
14677113-9	2003	T cells obtained from GCV-treated mice also had significantly higher in vitro proliferative responses after posttransplantation inoculation with ovalbumin than GVHD animals, indicating that CD4(+) T-cell responses against a nominal antigen were better preserved in these chimeras.	Ganciclovir	22-25	CD4 antigen	Mus musculus	190-193
12920018-3	2003	A short incubation of mRNA-transfected dendritic cells with antisense oligonucleotides directed against the invariant chain enhances the presentation of mRNA-encoded class II epitopes and activation of CD4+ T-cell responses in vitro and in vivo.	Oligonucleotides	70-86	CD4 antigen	Mus musculus	202-205
14670449-0	2003	Extracellular ATP induces cell death in CD4+/CD8+ double-positive thymocytes in mice infected with Trypanosoma cruzi.	Adenosine Triphosphate	14-17	CD4 antigen	Mus musculus	40-43
14670449-7	2003	We observed that ATP induces an increase in plasma membrane permeabilization and cellular death in CD4+/CD8+ double-positive thymocytes collected from infected mice during the atrophy phase.	Adenosine Triphosphate	17-20	CD4 antigen	Mus musculus	99-102
14578884-2	2003	We show here that mouse CD4+CD25+ cells, either resting or induced to overexpress CTLA-4 by treatment with antibody to CD3, initiated tryptophan catabolism in dendritic cells through a CTLA-4-dependent mechanism.	Tryptophan	134-144	CD4 antigen	Mus musculus	24-27
14679052-7	2003	During spontaneous and cyclophosphamide diabetes, it was observed in a higher proportion of islet infiltrating macrophages than in CD4 and CD8 cells.	Cyclophosphamide	23-39	CD4 antigen	Mus musculus	131-134
14679052-8	2003	In the cyclophosphamide group, Fas expression in intra-islet CD4 and CD8 cells showed an increase close to the onset of diabetes.	Cyclophosphamide	7-23	CD4 antigen	Mus musculus	61-64
14679052-8	2003	In the cyclophosphamide group, Fas expression in intra-islet CD4 and CD8 cells showed an increase close to the onset of diabetes.	ammonium ferrous sulfate	31-34	CD4 antigen	Mus musculus	61-64
12928768-7	2003	Mercury ranging from 1.5 to 37.5 ppm dose-dependently decreased CD3(+) T lymphocytes in spleen; both CD4(+) and CD8(+) single-positive lymphocyte populations were decreased.	Mercury	0-7	CD4 antigen	Mus musculus	101-104
14632799-8	2003	A significant reduction in the CD4/CD8 ratio was found in axillary and inguinal lymph nodes in tacrolimus-treated mice, supporting the presumption that the immunosuppressive effect of the drug was responsible for its effect in promoting tumorigenesis.	Tacrolimus	95-105	CD4 antigen	Mus musculus	31-34
14565934-8	2003	Galphai2(-/-) CD4(+) T cells were distinguished from wild-type or Galphai3(-/-) T cells by a globally augmented TCR-induced calcium response.	Calcium	124-131	CD4 antigen	Mus musculus	14-17
14568923-5	2003	Accordingly, CD4(+) T cells from Notch3-transgenic mice inhibit the development of hyperglycemia and insulitis when injected into streptozotocin-treated wild-type mice and display in vitro suppressive activity.	Streptozocin	130-144	CD4 antigen	Mus musculus	13-16
14515253-6	2003	Altogether, these results suggest that the altered development of CD4(+) T cells is not due to qualitative differences in TCR-mediated signals, but more consistent with the hypothesis that it is due to reduced signaling strength mediated through the FcRgamma chain containing only one immunoreceptor tyrosine-based activation motif.	Tyrosine	300-308	CD4 antigen	Mus musculus	66-69
13679386-7	2003	Splenocytes and, particularly, CD4(+) T cells from mice immunized with STxB-OVA also produced higher amounts of the T(h)1 cytokine IFN-gamma and IgG2a-type antibodies than mice immunized with non-vectorized ovalbumin.	stxb-ova	71-79	CD4 antigen	Mus musculus	31-34
12947044-8	2003	We propose that SEREX identifies a pool of autoantigens that maintains and regulates immunological homeostasis via CD4+ CD25+ regulatory T cells.	serex	16-21	CD4 antigen	Mus musculus	115-118
12938221-4	2003	In vitro analyses revealed that cell populations rapidly extruding Rhodamine-123 (R123) (referred to as R123(lo) cells) in aged CD4(+)CD25(-) T cells have a more potent suppressive function compared with R123(hi) populations.	Rhodamine 123	67-80	CD4 antigen	Mus musculus	128-131
12907949-6	2003	PEI+ resulted in: a mixed Th1/Th2 response; activation of both CD8(+) and CD4(+) T cells, with a larger effect on CD4(+); and FasL-mediated antigen-induced cell death.	Polyethyleneimine	0-4	CD4 antigen	Mus musculus	74-77
12907949-6	2003	PEI+ resulted in: a mixed Th1/Th2 response; activation of both CD8(+) and CD4(+) T cells, with a larger effect on CD4(+); and FasL-mediated antigen-induced cell death.	Polyethyleneimine	0-4	CD4 antigen	Mus musculus	114-117
12902504-5	2003	Saline injections of DNAs expressing cell-associated Ags strongly biased responses toward type 1, inducing IFN-gamma-producing CD8(+) and CD4(+) cells.	Sodium Chloride	0-6	CD4 antigen	Mus musculus	138-141
12902504-7	2003	Saline injections of secreted Ags raised a weakly type 1-biased response characterized by only slightly higher frequencies of IFN-gamma- than IL-4-producing CD4(+) and CD8(+) T cells.	Sodium Chloride	0-6	CD4 antigen	Mus musculus	157-160
12921756-1	2003	The effects of hyperbaric oxygen (HBO(2)) therapy on the immune system are reported including potential changes to the CD4/CD8 ratio and a decreased proliferation of lymphocytes during exposure.	Oxygen	26-32	CD4 antigen	Mus musculus	119-122
12887606-2	2003	It has been found that fluoroquinolones can modulate CD3+, CD4+ and CD8+ marker expression on thymocytes, splenocytes and lymphocytes of mesenteric lymph nodes.	Fluoroquinolones	23-39	CD4 antigen	Mus musculus	59-62
12887606-3	2003	Flumequine (15 mg/kg) decreased the percentage of immature CD4+CD8+ thymic cells and increased the percentage of mature CD4+ and CD8+.	flumequine	0-10	CD4 antigen	Mus musculus	59-62
12887606-3	2003	Flumequine (15 mg/kg) decreased the percentage of immature CD4+CD8+ thymic cells and increased the percentage of mature CD4+ and CD8+.	flumequine	0-10	CD4 antigen	Mus musculus	120-123
12887606-5	2003	Administration of flumequine, norfloxacin and ciprofloxacin, irrespective of doses applied, increased the percentages of CD3+ splenocytes of CD4+ spleen cells.	flumequine	18-28	CD4 antigen	Mus musculus	141-144
12887606-5	2003	Administration of flumequine, norfloxacin and ciprofloxacin, irrespective of doses applied, increased the percentages of CD3+ splenocytes of CD4+ spleen cells.	Norfloxacin	30-41	CD4 antigen	Mus musculus	141-144
12887606-5	2003	Administration of flumequine, norfloxacin and ciprofloxacin, irrespective of doses applied, increased the percentages of CD3+ splenocytes of CD4+ spleen cells.	Ciprofloxacin	46-59	CD4 antigen	Mus musculus	141-144
12887606-8	2003	In contrast, norfloxacin and enrofloxacin decreased the percentage of CD3+ mesenteric lymph node cells and the percentage of CD4+ cells.	Norfloxacin	13-24	CD4 antigen	Mus musculus	125-128
12887606-8	2003	In contrast, norfloxacin and enrofloxacin decreased the percentage of CD3+ mesenteric lymph node cells and the percentage of CD4+ cells.	Enrofloxacin	29-41	CD4 antigen	Mus musculus	125-128
12887606-10	2003	Flumequine and ciprofloxacin administered to mice pior to LPS potentiated its stimulant effect on the maturation of thymic cells ( increased percentage of mature CD4+ and CD8+ thymocytes).	flumequine	0-10	CD4 antigen	Mus musculus	162-165
12887606-10	2003	Flumequine and ciprofloxacin administered to mice pior to LPS potentiated its stimulant effect on the maturation of thymic cells ( increased percentage of mature CD4+ and CD8+ thymocytes).	Ciprofloxacin	15-28	CD4 antigen	Mus musculus	162-165
12887606-12	2003	Flumequine, norfloxacin, enrofloxacin and ciprofloxacin administered prior to LPS decreased the percentage of CD8+ splenocytes and increased the percentage of CD4+ spleen cells.	flumequine	0-10	CD4 antigen	Mus musculus	159-162
12887606-12	2003	Flumequine, norfloxacin, enrofloxacin and ciprofloxacin administered prior to LPS decreased the percentage of CD8+ splenocytes and increased the percentage of CD4+ spleen cells.	Norfloxacin	12-23	CD4 antigen	Mus musculus	159-162
12887606-12	2003	Flumequine, norfloxacin, enrofloxacin and ciprofloxacin administered prior to LPS decreased the percentage of CD8+ splenocytes and increased the percentage of CD4+ spleen cells.	Enrofloxacin	25-37	CD4 antigen	Mus musculus	159-162
12887606-12	2003	Flumequine, norfloxacin, enrofloxacin and ciprofloxacin administered prior to LPS decreased the percentage of CD8+ splenocytes and increased the percentage of CD4+ spleen cells.	Ciprofloxacin	42-55	CD4 antigen	Mus musculus	159-162
12736267-8	2003	We further demonstrated that orally tolerant CD4 T cells could not form normal TCR signaling complexes associated with GADS and showed down-regulated phospholipase C-gamma1 activation, which is likely to contribute to the impairment of TCR-induced calcium signaling.	Calcium	248-255	CD4 antigen	Mus musculus	45-48
12874260-0	2003	Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.	alpha-galactosylceramide	40-64	CD4 antigen	Mus musculus	173-176
12818356-8	2003	TPA and Thapsigargin were capable of decreasing the level of CD4 molecules on the cell surface, probably due to the loss of these molecules.	Tetradecanoylphorbol Acetate	0-3	CD4 antigen	Mus musculus	61-64
12818356-8	2003	TPA and Thapsigargin were capable of decreasing the level of CD4 molecules on the cell surface, probably due to the loss of these molecules.	Thapsigargin	8-20	CD4 antigen	Mus musculus	61-64
12810350-6	2003	Annexin V-fluorescein isothiocyanate (FITC)-propidium iodide (PI) apoptosis flow cytometric assay showed that early apoptotic CD4(+) T cells (annexin V-FITC(+)PI(-)), but not late apoptotic CD4(+) T cells (annexin V-FITC(+)PI(+)), increased in the inflamed skin of mice with CH.	Fluorescein-5-isothiocyanate	38-42	CD4 antigen	Mus musculus	126-129
12810350-6	2003	Annexin V-fluorescein isothiocyanate (FITC)-propidium iodide (PI) apoptosis flow cytometric assay showed that early apoptotic CD4(+) T cells (annexin V-FITC(+)PI(-)), but not late apoptotic CD4(+) T cells (annexin V-FITC(+)PI(+)), increased in the inflamed skin of mice with CH.	Propidium	44-60	CD4 antigen	Mus musculus	126-129
12791541-5	2003	Simazine treatment (600 mg/kg) induced an increase in the percentage of CD4(+) cells in spleen and CD8 + in thymus.	Simazine	0-8	CD4 antigen	Mus musculus	72-75
12832200-7	2003	The number of CD4(+) cells and macrophage/microglial cells, but not CD8(+) cells, infiltrating the hippocampal gyrus was correlated with the number of terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling positive pyramidal neurons.	deoxyuridine triphosphate	197-201	CD4 antigen	Mus musculus	14-17
14768939-6	2003	These thymic SP and DP populations with reduced levels of CD4 and/or CD8 markers had a lower rate of apoptosis in the tg than in the non-tg mice.	TFF2 protein, human	13-15	CD4 antigen	Mus musculus	58-61
14768939-6	2003	These thymic SP and DP populations with reduced levels of CD4 and/or CD8 markers had a lower rate of apoptosis in the tg than in the non-tg mice.	dp	20-22	CD4 antigen	Mus musculus	58-61
12696121-2	2003	VP1-ps (1 or 10 microg) were administered subcutaneously, alone or together with Freund"s complete and incomplete adjuvant, to CD4(-/-)8(-/-) T-cell deficient or normal C57Bl/6 mice on four occasions.	vp1-ps	0-6	CD4 antigen	Mus musculus	127-130
12738742-15	2003	RESULTS: The CEA/TRICOM vaccination regimen induced a therapeutic antitumor response as measured by increased survival, which was due largely to induced T-cell responses (both CD4(+) and CD8(+)) as determined by selective T-cell subset depletion.	Metronidazole	17-23	CD4 antigen	Mus musculus	176-179
21432090-1	2003	OBJECTIVES: To clarify whether di (2-ethylhexyl) phthalate (DEHP) has immunotoxic effects on both the expression of surface molecules (CD3, CD4, CD8 and CD28) on T cells of the thymus and spleen in male C57BL/6 mice.	Diethylhexyl Phthalate	31-58	CD4 antigen	Mus musculus	140-143
21432090-1	2003	OBJECTIVES: To clarify whether di (2-ethylhexyl) phthalate (DEHP) has immunotoxic effects on both the expression of surface molecules (CD3, CD4, CD8 and CD28) on T cells of the thymus and spleen in male C57BL/6 mice.	Diethylhexyl Phthalate	60-64	CD4 antigen	Mus musculus	140-143
12731049-0	2003	Idiotype-specific CD4+CD25+ T suppressor cells prevent, by limiting antibody diversity, the occurrence of anti-dextran antibodies crossreacting with histone H3.	Dextrans	111-118	CD4 antigen	Mus musculus	18-21
12709015-5	2003	DC treated with anti-pan CD44 and anti-CD44v4 mAbs induced CD4+ T-cell apoptosis, as shown by annexin V staining and TdT-mediated biotin-dUTP nick-end labelling (TUNEL) assays.	biotin-dutp	130-141	CD4 antigen	Mus musculus	25-28
12709015-8	2003	Interestingly, calcium signalling in CD4+ T cells was significantly diminished following interaction with CD44 mAb-treated DC, but this was not observed in CD8+ T cells.	Calcium	15-22	CD4 antigen	Mus musculus	37-40
12700420-9	2003	Exposure to all three allergens, however, resulted in a marked increase in the percentages of both CD4+ and CD8+ cells undergoing division, with up to 5% and 3% of these cells, respectively, proliferating in response to DNCB and oxazolone, and with lower levels of proliferation stimulated by HCA.	Dinitrochlorobenzene	220-224	CD4 antigen	Mus musculus	99-102
12698107-7	2003	In cyclosporine- or FK506-treated mice, T-cell proliferation was suppressed in the CD4 subset but not in the CD8 subset.	Cyclosporine	3-15	CD4 antigen	Mus musculus	83-86
12698107-7	2003	In cyclosporine- or FK506-treated mice, T-cell proliferation was suppressed in the CD4 subset but not in the CD8 subset.	Tacrolimus	20-25	CD4 antigen	Mus musculus	83-86
12826081-0	2003	Glucuronoxylomannan of Cryptococcus neoformans exacerbates in vitro yeast cell growth by interleukin 10-dependent inhibition of CD4+ T lymphocyte responses.	glucuronoxylomannan	0-19	CD4 antigen	Mus musculus	128-131
12684434-4	2003	At a histological level, cannabinoids reduced microglial activation, abrogated major histocompatibility complex class II antigen expression, and decreased the number of CD4+ infiltrating T cells in the spinal cord.	Cannabinoids	25-37	CD4 antigen	Mus musculus	169-172
12662296-4	2003	Anti-CD4 was found to perturb proximal signalling events upon TCR/CD3 ligation, resulting in reduced tyrosine phosphorylation of Zap-70 and LAT (linker for activation of T cells) and reduced association of tyrosine-phosphorylated LAT with lck.	Tyrosine	101-109	CD4 antigen	Mus musculus	5-8
12662296-4	2003	Anti-CD4 was found to perturb proximal signalling events upon TCR/CD3 ligation, resulting in reduced tyrosine phosphorylation of Zap-70 and LAT (linker for activation of T cells) and reduced association of tyrosine-phosphorylated LAT with lck.	Tyrosine	206-214	CD4 antigen	Mus musculus	5-8
12642393-4	2003	(3) Anti-CD4 mAb (1 mg kg(-1)) clearly inhibited allergen-induced increases in airway responsiveness to acetylcholine, the number of eosinophils in BAL fluid, serum OA-specific IgE levels, IL-13 and transforming growth factor-beta1 levels in BAL fluid, and amount of hydroxyproline in the lung by 100, 99, 100, 100, 84, and 60%, respectively.	Acetylcholine	104-117	CD4 antigen	Mus musculus	9-12
12642393-4	2003	(3) Anti-CD4 mAb (1 mg kg(-1)) clearly inhibited allergen-induced increases in airway responsiveness to acetylcholine, the number of eosinophils in BAL fluid, serum OA-specific IgE levels, IL-13 and transforming growth factor-beta1 levels in BAL fluid, and amount of hydroxyproline in the lung by 100, 99, 100, 100, 84, and 60%, respectively.	Hydroxyproline	267-281	CD4 antigen	Mus musculus	9-12
12657528-7	2003	Phenotyping of lymphoid cells from both mouse strains cultured in the presence of low concentrations of MeHgCl and stimulated with ConA, indicated that CD4+ T cells from SJL mice increased while the corresponding cell subset from C57BL/6 mice became apoptotic.	methylmercuric chloride	104-110	CD4 antigen	Mus musculus	152-155
12657528-8	2003	The resistance to apoptosis of ConA-activated lymphoid cells from SJL mice seemed related to an increase of CD4+ cells induced by the lower concentrations of MeHgCl (0.001 and 0.01 microM).	methylmercuric chloride	158-164	CD4 antigen	Mus musculus	108-111
12594306-4	2003	After adoptive macrophage transfer, FPP recipient mice transferred with macrophages from CD4(+) T cell-reconstituted mice demonstrated xenograft destruction along with massive macrophage infiltration at day 4 and complete graft destruction at day 8 postmacrophage transfer.	farnesyl pyrophosphate	36-39	CD4 antigen	Mus musculus	89-92
12574364-2	2003	Previous studies have implicated T cells in the pathogenesis of abscess formation, and we have recently shown that CD4(+) T cells activated in vitro by zwitterionic capsular polysaccharides from abscess-inducing bacteria such as Staphylococcus aureus and Bacteroides fragilis initiate this host response when transferred to naive rats.	Polysaccharides	174-189	CD4 antigen	Mus musculus	115-118
12574375-6	2003	5-Bromo-2-deoxyuridine incorporation studies indicated a relatively high rate of cell division among both total CD4 and ESAT-6(1-20)/IA(b)-specific CD4 T cells during acute infection, but the degree of 5-bromo-2-deoxyuridine incorporation by both the CD4 T cells and the Ag-specific cells declined at least 3-fold during chronic infection.	Bromodeoxyuridine	0-22	CD4 antigen	Mus musculus	112-115
12645950-0	2003	Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo.	Estradiol	0-9	CD4 antigen	Mus musculus	44-47
12645950-4	2003	We show that administration of low doses of 17beta-estradiol (E2) to castrated female mice results in a striking increase of antigen-specific CD4 T cell responses and in the selective development of IFN-gamma-producing cells.	Estradiol	44-60	CD4 antigen	Mus musculus	142-145
12520519-6	2003	CD4(+)CD25(+) cells, able to inhibit the T cell response to a pancreatic autoantigen and to significantly delay disease transfer by pathogenic CD4(+)CD25(-) cells, are also induced by treatment of adult nonobese diabetic (NOD) mice with 1,25-dihydroxy-16,23Z-diene-26,27-hexafluoro-19-nor vitamin D(3) (BXL-698).	1,25-dihydroxy-16,23z-diene	237-264	CD4 antigen	Mus musculus	0-3
12520519-6	2003	CD4(+)CD25(+) cells, able to inhibit the T cell response to a pancreatic autoantigen and to significantly delay disease transfer by pathogenic CD4(+)CD25(-) cells, are also induced by treatment of adult nonobese diabetic (NOD) mice with 1,25-dihydroxy-16,23Z-diene-26,27-hexafluoro-19-nor vitamin D(3) (BXL-698).	,27-hexafluoro-19-nor vitamin d	267-298	CD4 antigen	Mus musculus	0-3
12718754-7	2003	Moreover, CD28-deficient mice, which have very few CD4+CD25+ T cells, were highly resistant to PGIA.	pgia	95-99	CD4 antigen	Mus musculus	51-54
12853729-6	2003	The proliferative responses to TNBS of spleen T cells were partially inhibited by the addition of antimouse CD4 or CD8 antibodies to the mixed-lymphocyte culture.	Trinitrobenzenesulfonic Acid	31-35	CD4 antigen	Mus musculus	108-111
12853729-11	2003	Both CD4+ and CD8+ T cell subsets responded to TNBS, and the rate of CD8+ TCR V beta 14 T cells changed with histological inflammatory activity in TNBS-induced colitis.	Trinitrobenzenesulfonic Acid	47-51	CD4 antigen	Mus musculus	5-8
12478617-2	2003	Sp-EAE can be prevented after transfer of CD4+splenocytes from naive immunocompetent mice.	sp-eae	0-6	CD4 antigen	Mus musculus	42-45
12478617-5	2003	Only the CD4+BV8S2- T cell population conferred complete protection against Sp-EAE, similar to unfractionated splenocytes from non-Tg donors, whereas CD4-CD8-BV8S2+ and CD4+BV8S2+ T cells conferred partial protection.	sp-eae	76-82	CD4 antigen	Mus musculus	9-12
12454844-1	2002	BACKGROUND &amp; AIMS: Regulatory CD4(+) cells secreting the anti-inflammatory cytokine interleukin (IL)-10 play a key role in maintaining the immune balance in the intestinal mucosa.	Adenosine Monophosphate	12-15	CD4 antigen	Mus musculus	34-37
12454848-10	2002	Consistent with these findings, CD4(+) T-cell infiltration and NF-kappaB activation in colonic mucosa were suppressed in the curcumin-treated group.	Curcumin	125-133	CD4 antigen	Mus musculus	32-35
12444113-9	2002	Normal intestinal lamina propria CD4(+) T cells had Tr1-like activity when stimulated with CBA-pulsed APCs.	cba	91-94	CD4 antigen	Mus musculus	33-36
12444132-5	2002	Using a series of point mutations, we have precisely mapped the dimerization site at residues K318 and Q344 within the fourth extracellular domain of CD4.	D-(-)-Fructose	94-98	CD4 antigen	Mus musculus	150-153
12444132-5	2002	Using a series of point mutations, we have precisely mapped the dimerization site at residues K318 and Q344 within the fourth extracellular domain of CD4.	2,6-DIMETHYLBENZOIC ACID	103-107	CD4 antigen	Mus musculus	150-153
12468615-8	2002	The striking Th2 enhancement was also observed when only antigen-presenting cells were treated with atRA before stimulation of untreated CD4(+) transgenic T cells, but not vice versa.	Tretinoin	100-104	CD4 antigen	Mus musculus	137-140
12490139-0	2002	T lymphocytes are direct, aryl hydrocarbon receptor (AhR)-dependent targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): AhR expression in both CD4+ and CD8+ T cells is necessary for full suppression of a cytotoxic T lymphocyte response by TCDD.	Polychlorinated Dibenzodioxins	79-114	CD4 antigen	Mus musculus	146-149
12490139-0	2002	T lymphocytes are direct, aryl hydrocarbon receptor (AhR)-dependent targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): AhR expression in both CD4+ and CD8+ T cells is necessary for full suppression of a cytotoxic T lymphocyte response by TCDD.	Polychlorinated Dibenzodioxins	116-120	CD4 antigen	Mus musculus	146-149
12490139-0	2002	T lymphocytes are direct, aryl hydrocarbon receptor (AhR)-dependent targets of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): AhR expression in both CD4+ and CD8+ T cells is necessary for full suppression of a cytotoxic T lymphocyte response by TCDD.	Polychlorinated Dibenzodioxins	242-246	CD4 antigen	Mus musculus	146-149
12490139-12	2002	These results indicate that direct AhR-dependent effects of TCDD occur in both CD4+ and CD8+ T cell subsets and both T cell subsets contribute to the full suppression of the CTL response by TCDD.	Polychlorinated Dibenzodioxins	60-64	CD4 antigen	Mus musculus	79-82
12424339-13	2002	The fraction of newly divided naive-phenotype T cells after 9 weeks of labeling with (2)H(2)O was 0.056 (CD4(+)) and 0.043 (CD8(+)) (replacement rate &lt;0.1% per day).	(2)h(2)o	85-93	CD4 antigen	Mus musculus	105-112
12438422-4	2002	The kinetics of bromodeoxyuridine labeling and the results of transfer to normal recipient mice indicate that CD4(-) p-preDCs are the immediate precursors of CD4(+) p-preDCs.	Bromodeoxyuridine	16-33	CD4 antigen	Mus musculus	110-113
12379675-6	2002	Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling staining revealed that the CD4(+) T cells from Mf-infected wild-type mice were preferentially susceptible to apoptosis compared to CD4(+) T cells from IFN-gammaR(-/-) mice.	dutp-biotin	46-57	CD4 antigen	Mus musculus	103-106
12429713-0	2002	Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin.	Tetradecanoylphorbol Acetate	131-134	CD4 antigen	Mus musculus	39-42
12429713-0	2002	Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin.	Ionomycin	139-148	CD4 antigen	Mus musculus	39-42
12429713-3	2002	We show that CD80, CD86, and CTLA4 are induced on purified CD4(+) T cells after in vitro activation with phorbol 12-myristate 13-acetate (PMA) and ionomycin, and they play an essential role for proliferation and survival.	Tetradecanoylphorbol Acetate	105-136	CD4 antigen	Mus musculus	59-62
12429713-3	2002	We show that CD80, CD86, and CTLA4 are induced on purified CD4(+) T cells after in vitro activation with phorbol 12-myristate 13-acetate (PMA) and ionomycin, and they play an essential role for proliferation and survival.	Tetradecanoylphorbol Acetate	138-141	CD4 antigen	Mus musculus	59-62
12429713-4	2002	Blockade of CTLA4-CD80/CD86 interactions greatly reduces PMA and ionomycin-mediated mouse CD4(+) T cell activation.	Ionomycin	65-74	CD4 antigen	Mus musculus	90-93
12429713-9	2002	This study reveals a functional role for CD80, CD86, and CTLA4 on CD4(+) T lymphocytes and sheds light on the mechanisms by which these molecules enhance activation and survival with PMA and ionomycin.	Tetradecanoylphorbol Acetate	183-186	CD4 antigen	Mus musculus	66-69
12429713-9	2002	This study reveals a functional role for CD80, CD86, and CTLA4 on CD4(+) T lymphocytes and sheds light on the mechanisms by which these molecules enhance activation and survival with PMA and ionomycin.	Ionomycin	191-200	CD4 antigen	Mus musculus	66-69
12421842-0	2002	Antigen-driven murine CD4+ T lymphocyte proliferation and interleukin-2 production are diminished by dietary (n-3) polyunsaturated fatty acids.	Fatty Acids, Omega-3	109-142	CD4 antigen	Mus musculus	22-25
12421842-1	2002	This study is the first to describe the impact of consuming a diet rich in (n-3) polyunsaturated fatty acids (PUFA) from fish oil on antigen-driven activation of naive CD4+ T lymphocytes.	Fatty Acids, Omega-3	75-108	CD4 antigen	Mus musculus	168-171
12421842-1	2002	This study is the first to describe the impact of consuming a diet rich in (n-3) polyunsaturated fatty acids (PUFA) from fish oil on antigen-driven activation of naive CD4+ T lymphocytes.	Fatty Acids, Unsaturated	110-114	CD4 antigen	Mus musculus	168-171
12421842-10	2002	In summary, we report for the first time that feeding mice a diet enriched with (n-3) PUFA reduces in vitro antigen-stimulated production of IL-2 and subsequent proliferation of naive CD4+ T lymphocytes.	Fatty Acids, Omega-3	80-90	CD4 antigen	Mus musculus	184-187
12451483-5	2002	Flow cytometric examination of thymic lymphocyte populations showed that the absolute numbers of CD4 + and CD8 + positive T-lymphocytes were increased by silymarin.	Silymarin	154-163	CD4 antigen	Mus musculus	97-100
12323091-5	2002	CD4+ T-cells from the mesenteric lymph nodes of the raffinose-fed mice secreted significantly (P&lt;0.05) higher levels of IL-2 and significantly (P&lt;0.05) lower levels of IL-4 following in vitro antigenic stimulation compared with those of the control mice.	Raffinose	52-61	CD4 antigen	Mus musculus	0-3
12355444-4	2002	The synthetic hydroxamate metalloproteinase inhibitor (BB-3103), specifically inhibits activation-induced shedding of CD62L from CD4(+) T cells by TCR cross-linking and lowers proliferation in part by reducing rapid tyrosine phosphorylation of zeta-associated protein 70 kDa (ZAP-70) and by increasing cytosolic free Ca(2+) concentration mobilization.	BB 3103	55-62	CD4 antigen	Mus musculus	129-132
12355444-5	2002	BB-3103 also inhibited the proliferative response of both murine CD4(+) Th1 and Th2 subsets in vitro but the inhibitory effects were sustained only in Th2-type cells.	BB 3103	0-7	CD4 antigen	Mus musculus	65-68
12355444-8	2002	The differential effects of BB-3103 on primed effector CD4(+) T cells may provide new insights into generating therapeutic agents capable of redressing the Th2/Th1 imbalance in allergic diseases.	BB 3103	28-35	CD4 antigen	Mus musculus	55-58
12160618-5	2002	Nevertheless, DES treatment of female or male mice induced a dose-related apoptosis of CD4(+)8(+), CD4(+)8(-) and CD4(-)8(+) subsets as analyzed by 7-amino-actinomycin D (7-AAD).	Diethylstilbestrol	14-17	CD4 antigen	Mus musculus	87-90
12160618-5	2002	Nevertheless, DES treatment of female or male mice induced a dose-related apoptosis of CD4(+)8(+), CD4(+)8(-) and CD4(-)8(+) subsets as analyzed by 7-amino-actinomycin D (7-AAD).	Diethylstilbestrol	14-17	CD4 antigen	Mus musculus	99-102
12160618-5	2002	Nevertheless, DES treatment of female or male mice induced a dose-related apoptosis of CD4(+)8(+), CD4(+)8(-) and CD4(-)8(+) subsets as analyzed by 7-amino-actinomycin D (7-AAD).	Diethylstilbestrol	14-17	CD4 antigen	Mus musculus	99-102
12160618-6	2002	Immature CD4(-)8(-) subset of thymocytes from females was also affected by high dose DES.	Diethylstilbestrol	85-88	CD4 antigen	Mus musculus	9-12
12198661-1	2002	Bacterial DNA containing unmethylated CpG dinucleotide motifs is immunostimulatory to mammals, skewing CD4(+) T-cell responses toward the Th1 phenotype.	cytidylyl-3'-5'-guanosine	38-54	CD4 antigen	Mus musculus	103-106
12163562-2	2002	Here we demonstrate that CD4(+) T cells from CD28-deficient mice show increased susceptibility to Fas-mediated apoptosis via a phosphatidylinositol 3-kinase (PI3K)-dependent pathway.	ammonium ferrous sulfate	98-101	CD4 antigen	Mus musculus	25-28
12096892-6	2002	Compared with control infected mice, significant reductions in the number of thymic CD4(+)CD8(+), CD4(+), CD8(+), and CD4(-)CD8(-) T cells were observed in Pb-exposed mice.	Lead	156-158	CD4 antigen	Mus musculus	84-87
12096892-6	2002	Compared with control infected mice, significant reductions in the number of thymic CD4(+)CD8(+), CD4(+), CD8(+), and CD4(-)CD8(-) T cells were observed in Pb-exposed mice.	Lead	156-158	CD4 antigen	Mus musculus	98-101
12096892-6	2002	Compared with control infected mice, significant reductions in the number of thymic CD4(+)CD8(+), CD4(+), CD8(+), and CD4(-)CD8(-) T cells were observed in Pb-exposed mice.	Lead	156-158	CD4 antigen	Mus musculus	98-101
12375734-0	2002	Detection of DNA adducts in developing CD4+ CD8+ thymocytes and splenocytes following in utero exposure to benzo[a]pyrene.	Benzo(a)pyrene	107-121	CD4 antigen	Mus musculus	39-42
12121437-3	2002	There was a lower ratio of CD4 single-positive (SP) to CD8 SP cells and decreased apoptosis of CD4+CD8+ (DP) thymocytes from Apaf-1-/- mice compared with wild-type.	sp	48-50	CD4 antigen	Mus musculus	27-30
12097413-4	2002	Infiltrating CD4(+) T cells, but not CD8(+) T cells, identified significant (51)Cr release against mouse salivary gland cells.	Chromium	80-82	CD4 antigen	Mus musculus	13-16
12094019-5	2002	Peripheral CD4(+) and CD8(+) T cell populations were significantly lower in tg than in Ntg, df, or Ndf mice.	Thioguanine	76-78	CD4 antigen	Mus musculus	11-14
12094019-5	2002	Peripheral CD4(+) and CD8(+) T cell populations were significantly lower in tg than in Ntg, df, or Ndf mice.	Nitroglycerin	87-90	CD4 antigen	Mus musculus	11-14
12094019-5	2002	Peripheral CD4(+) and CD8(+) T cell populations were significantly lower in tg than in Ntg, df, or Ndf mice.	N-(CARBOXYCARBONYL)-D-PHENYLALANINE	99-102	CD4 antigen	Mus musculus	11-14
12072531-2	2002	Adoptive transfer of MHV-immune splenocytes depleted of either CD4 or CD8 T cells to infected mice deficient in recombination activation gene 1 resulted in demyelination.	mhv	21-24	CD4 antigen	Mus musculus	63-66
12055220-5	2002	In contrast, immunization with H11.1 peptide, using an immunostimulatory CpG oligonucleotide or CFA as adjuvant, engaged approximately 25- or approximately 10-fold higher clonal sizes of type 1 polarized CD4 cells, respectively.	CPG-oligonucleotide	73-92	CD4 antigen	Mus musculus	204-207
12045240-4	2002	N15betaDeltaFG facilitates transition from DN to CD4(+)8(+) double-positive (DP) thymocytes in recombinase activating gene (RAG)-2(-/-) mice, showing that pre-TCR function remains.	n15betadeltafg	0-14	CD4 antigen	Mus musculus	49-52
12107651-2	2002	TCDD is reported to reduce thymocyte numbers and skew the lineage commitment of thymocytes toward CD4(-)CD8(+) T (CD8 T) cells.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	98-112
12107651-5	2002	On days 4 and 6 of culture, the numbers of total cells and CD4(+)CD8(+) (DP) cells were significantly decreased by TCDD.	Polychlorinated Dibenzodioxins	115-119	CD4 antigen	Mus musculus	59-62
12115200-11	2002	In addition, CD4+CD25+ T cells from treated mice were able to suppress anti-CII IFNgamma production by CII-primed lymph node cells.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	76-79	CD4 antigen	Mus musculus	13-16
12115200-14	2002	Instead, EtxB mediates its effects through enhancing the activity of a population of CD4+ regulatory T cells.	etxb	9-13	CD4 antigen	Mus musculus	85-88
12012107-5	2002	The therapeutic effect of CY followed by DNP-modified ATC vaccine was abrogated by depletion of CD4(+) or CD8(+) T-cells, illustrating the importance of both T-cell subsets for the anti-metastatic effect of this therapeutic protocol.	Cyclophosphamide	26-28	CD4 antigen	Mus musculus	96-99
12012107-5	2002	The therapeutic effect of CY followed by DNP-modified ATC vaccine was abrogated by depletion of CD4(+) or CD8(+) T-cells, illustrating the importance of both T-cell subsets for the anti-metastatic effect of this therapeutic protocol.	dnp	41-44	CD4 antigen	Mus musculus	96-99
12115657-8	2002	EtxB induces the activation of NF-kappaB in both CD8+ and CD4+ T cells.	etxb	0-4	CD4 antigen	Mus musculus	58-61
11992736-13	2002	Finally, an increase in the intracellular level of IL-4, but not INFgamma, was detected in CD4(+) PLN cells following the injection of diclofenac mixed with TNP-OVA.	Diclofenac	135-145	CD4 antigen	Mus musculus	91-94
11978632-4	2002	Thus, a short treatment of adult NOD mice with an analog of 1,25-dihydroxyvitamin D(3) inhibits IL-12 production, blocks pancreatic infiltration of Th1 cells, enhances CD4(+)CD25(+) regulatory cells, and arrests the progression of type 1 diabetes, suggesting its possible application in the treatment of human autoimmune diabetes.	1,25-dihydroxyvitamin D	60-83	CD4 antigen	Mus musculus	168-171
12061425-3	2002	RESULTS: Pretreatment of C57BL/6 mice primarily with PGM-Zn over 6 days (10/mg/kg intraperitoneally) significantly enhanced the proportions of NK1.1high+, CD4-CD8-, CD69+, and CD3intermediate/NK1.1+/IL2R-beta+ (NKT) cells in the liver, and major histocompatibility complex class II+, CD69+, and CD8+ cells in the spleen.	pgm-zn	53-59	CD4 antigen	Mus musculus	155-158
11884445-6	2002	Blocking CD40L in vitro decreased the IgM response to caps-PS and abolished the helper effect of CD4(+) T lymphocytes.	caps-ps	54-61	CD4 antigen	Mus musculus	9-12
11884471-5	2002	IFN-gamma- and TNF-alpha-producing LP CD4(+) T cells synergize with infected mIC(cl2) and enhance the production of several inflammatory chemokines including macrophage-inflammatory protein-2, monocyte chemoattractant protein-1, monocyte chemoattractant protein-3, macrophage-inflammatory protein-1alphabeta, and IFN-gamma-inducible protein-10.	Chlorine	81-84	CD4 antigen	Mus musculus	38-41
11877484-3	2002	Activation of natural killer T (NKT) cells by the glycolipid ligand, alpha-galactosylceramide (alpha-GalCer), causes bystander activation of NK, B, CD4(+), and CD8(+) T cells.	Glycolipids	50-60	CD4 antigen	Mus musculus	148-151
11877484-3	2002	Activation of natural killer T (NKT) cells by the glycolipid ligand, alpha-galactosylceramide (alpha-GalCer), causes bystander activation of NK, B, CD4(+), and CD8(+) T cells.	alpha-galactosylceramide	69-93	CD4 antigen	Mus musculus	148-151
11877484-3	2002	Activation of natural killer T (NKT) cells by the glycolipid ligand, alpha-galactosylceramide (alpha-GalCer), causes bystander activation of NK, B, CD4(+), and CD8(+) T cells.	alpha-galactosylceramide	95-107	CD4 antigen	Mus musculus	148-151
11870630-5	2002	Using TdT-mediated dUTP-biotin nick end labeling for flow cytometry, CD4(+) lymphocytes from Mf-infected mice cultured with Ag showed high levels of apoptosis when compared to those from L3-infected mice which proliferated well in response to Ag.	dutp-biotin	19-30	CD4 antigen	Mus musculus	69-72
11870630-6	2002	Treatment of Ag-stimulated cultures with aminoguanidine (AMG), an inhibitor of inducible nitric oxide synthase, rescued the CD4(+) T cells from apoptosis and reversed the proliferative defect.	pimagedine	41-55	CD4 antigen	Mus musculus	124-127
11870630-6	2002	Treatment of Ag-stimulated cultures with aminoguanidine (AMG), an inhibitor of inducible nitric oxide synthase, rescued the CD4(+) T cells from apoptosis and reversed the proliferative defect.	pimagedine	57-60	CD4 antigen	Mus musculus	124-127
11870630-7	2002	Furthermore, carboxyfluorescein diacetate succinimidyl ester labeling allowed the visualization of dividing CD4(+) T cells in cultures from Mf-infected animals only in the presence of AMG.	5-(6)-carboxyfluorescein diacetate succinimidyl ester	13-60	CD4 antigen	Mus musculus	108-111
11870630-8	2002	We hypothesize that CD4(+) T cells indirectly trigger their own apoptosis by secreting significant quantities of IFN-gamma resulting in the induction of high levels of nitric oxide, and the subsequent elimination of effector T cells.	Nitric Oxide	168-180	CD4 antigen	Mus musculus	20-23
11823480-2	2002	We showed previously that adoptive transfer of MHV-immune splenocytes depleted of either CD4 or CD8 T cells to infected RAG1(-/-) recipients (mice deficient in recombination activation gene 1) resulted in demyelination.	mhv	47-50	CD4 antigen	Mus musculus	89-92
11853160-0	2002	Induction of CD4+ regulatory T cells by TPA in mice: contra-suppression by CD8+ T cells.	Tetradecanoylphorbol Acetate	40-43	CD4 antigen	Mus musculus	13-16
11853160-1	2002	Among the eight inbred mouse strains employed in our preceding report, 12-O-tetradecanoylphorbol 13-acetate (TPA) painting alone induced CD4+ regulatory T (Tr) cells in four strains (e.g., C3H/He) at 6-8 weeks of age, but not in the remaining strains (e.g., C57BL/6, BALB/c).	Tetradecanoylphorbol Acetate	71-107	CD4 antigen	Mus musculus	137-140
11853160-1	2002	Among the eight inbred mouse strains employed in our preceding report, 12-O-tetradecanoylphorbol 13-acetate (TPA) painting alone induced CD4+ regulatory T (Tr) cells in four strains (e.g., C3H/He) at 6-8 weeks of age, but not in the remaining strains (e.g., C57BL/6, BALB/c).	Tetradecanoylphorbol Acetate	109-112	CD4 antigen	Mus musculus	137-140
11853160-8	2002	ICAM-1 expression on CD4 T cells greatly increased following growth in 10 week-BALB/c mice receiving TPA than 6-week-old mice, however, a slight increase in growth occurred in 6-to-10-week-old animals in which TPA was absent.	Tetradecanoylphorbol Acetate	101-104	CD4 antigen	Mus musculus	21-24
11853160-8	2002	ICAM-1 expression on CD4 T cells greatly increased following growth in 10 week-BALB/c mice receiving TPA than 6-week-old mice, however, a slight increase in growth occurred in 6-to-10-week-old animals in which TPA was absent.	Tetradecanoylphorbol Acetate	210-213	CD4 antigen	Mus musculus	21-24
11788555-5	2002	In vivo migration of T cells was assessed by adoptive transfer of (51)Cr labelled CD4(+)CD25(-)alpha beta(+) T cells.	Chromium	70-72	CD4 antigen	Mus musculus	82-85
11750091-0	2002	Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced decrease in anti-CD3-activated CD4(+) T cells: the roles of apoptosis, Fas, and TNF.	Polychlorinated Dibenzodioxins	13-48	CD4 antigen	Mus musculus	95-98
11750091-0	2002	Mechanism of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced decrease in anti-CD3-activated CD4(+) T cells: the roles of apoptosis, Fas, and TNF.	Polychlorinated Dibenzodioxins	50-54	CD4 antigen	Mus musculus	95-98
11750091-6	2002	Our results show that the TCDD-induced decrease in CD4(+) T cell number correlated with an increase in the percentage of dead cells, but not with cells expressing an early apoptotic phenotype.	Polychlorinated Dibenzodioxins	26-30	CD4 antigen	Mus musculus	51-54
11750091-7	2002	The TCDD-induced decrease in CD4(+) T cells was attenuated in Fas- and FasL-deficient mice (lpr and gld, respectively), but not by treatment with a neutralizing antibody to TNF.	Polychlorinated Dibenzodioxins	4-8	CD4 antigen	Mus musculus	29-32
11750091-9	2002	Taken together, our data suggest that TCDD-induced suppression of CD4(+) T cells involves, in part, increased cell death that may be mediated by Fas/FasL interaction.	Polychlorinated Dibenzodioxins	38-42	CD4 antigen	Mus musculus	66-69
11777987-4	2002	In addition, the airway reactivity to methacholine was elevated moderately in DQ6/CD4(null) mice compared with the high response in DQ/CD4(+) counterparts and was only partially augmented by CD4(+) T cell transfer.	Methacholine Chloride	38-50	CD4 antigen	Mus musculus	82-85
11809589-3	2002	We used a model of antigen-specific skin inflammation, the contact hypersensitivity (CHS) reaction to DNFB, which is mediated by CD8+ effector T cells and down-regulated by CD4+ T cells.	Dinitrofluorobenzene	102-106	CD4 antigen	Mus musculus	173-176
11809589-8	2002	Indeed, UVB-irradiated CD4+ T cell-deficient mice have a normal frequency of IFN-gamma-producing hapten-specific CD8+ T cells in the lymphoid organs and develop a normal CHS reaction to DNFB.	Dinitrofluorobenzene	186-190	CD4 antigen	Mus musculus	23-26
11928640-5	2002	After prolonged (for 18 months) administration of epithalamine the portion of CD44+, CD44+Thy-1- and CD3- 8(+)-cells in the old thymus has been shown to be decreased, while that of CD25+, CD3+, CD3+CD8+, CD4+CD8/and CD4-CD8(+)-cells increased.	epithalamin	50-62	CD4 antigen	Mus musculus	78-81
11928640-5	2002	After prolonged (for 18 months) administration of epithalamine the portion of CD44+, CD44+Thy-1- and CD3- 8(+)-cells in the old thymus has been shown to be decreased, while that of CD25+, CD3+, CD3+CD8+, CD4+CD8/and CD4-CD8(+)-cells increased.	epithalamin	50-62	CD4 antigen	Mus musculus	85-88
12365794-11	2002	In cyclophosphamide-treated mice, the proportion of Fas-positive intra-islet CD4 and CD8 T cells at day 14 (with and without diabetes) was considerably higher than at days 0, 4, 7 and 11.	Cyclophosphamide	3-19	CD4 antigen	Mus musculus	77-80
12365794-11	2002	In cyclophosphamide-treated mice, the proportion of Fas-positive intra-islet CD4 and CD8 T cells at day 14 (with and without diabetes) was considerably higher than at days 0, 4, 7 and 11.	ammonium ferrous sulfate	52-55	CD4 antigen	Mus musculus	77-80
11789673-6	2002	Sevoflurane diminished the number of peripheral blood lymphocytes and splenic B-cell counts, enhancing CD4+ lymphocytes in spleen.	Sevoflurane	0-11	CD4 antigen	Mus musculus	103-106
11745142-6	2001	Each indirect labeling scheme incorporated a primary mouse anti-CD4 FITC antibody that provides both FITC and mouse-specific binding sites for two different secondary antibody-magnetic nanoparticle conjugates: either anti-FITC MACS magnetic nanoparticle antibody or anti-mouse MACS magnetic nanoparticle antibody.	Fluorescein-5-isothiocyanate	68-72	CD4 antigen	Mus musculus	64-67
11745142-6	2001	Each indirect labeling scheme incorporated a primary mouse anti-CD4 FITC antibody that provides both FITC and mouse-specific binding sites for two different secondary antibody-magnetic nanoparticle conjugates: either anti-FITC MACS magnetic nanoparticle antibody or anti-mouse MACS magnetic nanoparticle antibody.	Fluorescein-5-isothiocyanate	101-105	CD4 antigen	Mus musculus	64-67
11745142-6	2001	Each indirect labeling scheme incorporated a primary mouse anti-CD4 FITC antibody that provides both FITC and mouse-specific binding sites for two different secondary antibody-magnetic nanoparticle conjugates: either anti-FITC MACS magnetic nanoparticle antibody or anti-mouse MACS magnetic nanoparticle antibody.	Fluorescein-5-isothiocyanate	101-105	CD4 antigen	Mus musculus	64-67
11745142-8	2001	The results indicate that an average of 3.4 anti-FITC MACS magnetic nanoparticle antibodies bind to each primary CD4 FITC antibody, Psi(1,2f) = 3.4 +/- 0.33, and that approximately one, Psi(1,2m) = 0.98 +/- 0.081, anti-mouse MACS magnetic nanoparticle antibody binds to each primary mouse CD4 FITC antibody on a CD4 positive lymphocyte.	Fluorescein-5-isothiocyanate	49-53	CD4 antigen	Mus musculus	113-116
11745142-8	2001	The results indicate that an average of 3.4 anti-FITC MACS magnetic nanoparticle antibodies bind to each primary CD4 FITC antibody, Psi(1,2f) = 3.4 +/- 0.33, and that approximately one, Psi(1,2m) = 0.98 +/- 0.081, anti-mouse MACS magnetic nanoparticle antibody binds to each primary mouse CD4 FITC antibody on a CD4 positive lymphocyte.	Fluorescein-5-isothiocyanate	49-53	CD4 antigen	Mus musculus	289-292
11745142-8	2001	The results indicate that an average of 3.4 anti-FITC MACS magnetic nanoparticle antibodies bind to each primary CD4 FITC antibody, Psi(1,2f) = 3.4 +/- 0.33, and that approximately one, Psi(1,2m) = 0.98 +/- 0.081, anti-mouse MACS magnetic nanoparticle antibody binds to each primary mouse CD4 FITC antibody on a CD4 positive lymphocyte.	Fluorescein-5-isothiocyanate	49-53	CD4 antigen	Mus musculus	289-292
11745142-8	2001	The results indicate that an average of 3.4 anti-FITC MACS magnetic nanoparticle antibodies bind to each primary CD4 FITC antibody, Psi(1,2f) = 3.4 +/- 0.33, and that approximately one, Psi(1,2m) = 0.98 +/- 0.081, anti-mouse MACS magnetic nanoparticle antibody binds to each primary mouse CD4 FITC antibody on a CD4 positive lymphocyte.	Fluorescein-5-isothiocyanate	117-121	CD4 antigen	Mus musculus	113-116
11745142-8	2001	The results indicate that an average of 3.4 anti-FITC MACS magnetic nanoparticle antibodies bind to each primary CD4 FITC antibody, Psi(1,2f) = 3.4 +/- 0.33, and that approximately one, Psi(1,2m) = 0.98 +/- 0.081, anti-mouse MACS magnetic nanoparticle antibody binds to each primary mouse CD4 FITC antibody on a CD4 positive lymphocyte.	Fluorescein-5-isothiocyanate	117-121	CD4 antigen	Mus musculus	289-292
11745142-8	2001	The results indicate that an average of 3.4 anti-FITC MACS magnetic nanoparticle antibodies bind to each primary CD4 FITC antibody, Psi(1,2f) = 3.4 +/- 0.33, and that approximately one, Psi(1,2m) = 0.98 +/- 0.081, anti-mouse MACS magnetic nanoparticle antibody binds to each primary mouse CD4 FITC antibody on a CD4 positive lymphocyte.	Fluorescein-5-isothiocyanate	117-121	CD4 antigen	Mus musculus	289-292
11745142-8	2001	The results indicate that an average of 3.4 anti-FITC MACS magnetic nanoparticle antibodies bind to each primary CD4 FITC antibody, Psi(1,2f) = 3.4 +/- 0.33, and that approximately one, Psi(1,2m) = 0.98 +/- 0.081, anti-mouse MACS magnetic nanoparticle antibody binds to each primary mouse CD4 FITC antibody on a CD4 positive lymphocyte.	Fluorescein-5-isothiocyanate	117-121	CD4 antigen	Mus musculus	113-116
11745142-8	2001	The results indicate that an average of 3.4 anti-FITC MACS magnetic nanoparticle antibodies bind to each primary CD4 FITC antibody, Psi(1,2f) = 3.4 +/- 0.33, and that approximately one, Psi(1,2m) = 0.98 +/- 0.081, anti-mouse MACS magnetic nanoparticle antibody binds to each primary mouse CD4 FITC antibody on a CD4 positive lymphocyte.	Fluorescein-5-isothiocyanate	117-121	CD4 antigen	Mus musculus	289-292
11745142-8	2001	The results indicate that an average of 3.4 anti-FITC MACS magnetic nanoparticle antibodies bind to each primary CD4 FITC antibody, Psi(1,2f) = 3.4 +/- 0.33, and that approximately one, Psi(1,2m) = 0.98 +/- 0.081, anti-mouse MACS magnetic nanoparticle antibody binds to each primary mouse CD4 FITC antibody on a CD4 positive lymphocyte.	Fluorescein-5-isothiocyanate	117-121	CD4 antigen	Mus musculus	289-292
11748274-3	2001	We show that loss of CD4 decreases the steady-state proliferation of T cells as monitored by in vivo labeling with bromo-deoxyuridine.	Bromodeoxyuridine	115-133	CD4 antigen	Mus musculus	21-24
11739495-7	2001	As few as 10(2) bulk T cells, consisting of both CD4(+) and CD8(+) cells, were able to specifically transfer tolerance to nickel.	Nickel	122-128	CD4 antigen	Mus musculus	49-52
11696409-0	2001	Effects of cadmium and vanadium ions on antigen-induced signaling in CD4(+) T cells.	Cadmium	11-18	CD4 antigen	Mus musculus	69-72
11696409-0	2001	Effects of cadmium and vanadium ions on antigen-induced signaling in CD4(+) T cells.	Vanadium	23-31	CD4 antigen	Mus musculus	69-72
11696409-2	2001	We tested the hypothesis that cadmium and vanadium ions alter antigen-induced T cell signal transduction pathways in CD4(+) T helper cells.	Cadmium	30-37	CD4 antigen	Mus musculus	117-120
11696409-2	2001	We tested the hypothesis that cadmium and vanadium ions alter antigen-induced T cell signal transduction pathways in CD4(+) T helper cells.	Vanadium	42-50	CD4 antigen	Mus musculus	117-120
11696410-0	2001	Effects of heavy metal ions on resting and antigen-activated CD4(+) T cells.	Metals	17-22	CD4 antigen	Mus musculus	61-64
11696410-6	2001	We measured the effects of the four heavy metals cadmium, lead, mercury, and vanadium on cytokine and proliferation responses by purified CD4(+) T cell to antigenic stimulation.	Mercury	64-71	CD4 antigen	Mus musculus	138-141
11696410-6	2001	We measured the effects of the four heavy metals cadmium, lead, mercury, and vanadium on cytokine and proliferation responses by purified CD4(+) T cell to antigenic stimulation.	Vanadium	77-85	CD4 antigen	Mus musculus	138-141
11696410-12	2001	These in vitro systems can now be applied to test whether heavy metal ions alter antigen-induced T cell signal transduction pathways in CD4(+) T helper cells.	Metals	64-69	CD4 antigen	Mus musculus	136-139
11675368-6	2001	Stimulation by peptide or carbohydrate resulted in loss of L-selectin on CD4+ T cells confirming a Th1 phenotype.	Carbohydrates	26-38	CD4 antigen	Mus musculus	73-76
11673504-0	2001	1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells.	Calcitriol	0-29	CD4 antigen	Mus musculus	59-62
11673545-0	2001	The schistosome oligosaccharide lacto-N-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections.	schistosome oligosaccharide	4-31	CD4 antigen	Mus musculus	149-152
11673545-0	2001	The schistosome oligosaccharide lacto-N-neotetraose expands Gr1(+) cells that secrete anti-inflammatory cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune polarization in helminth infections.	lacto-N-neotetraose	32-51	CD4 antigen	Mus musculus	149-152
11588111-0	2001	Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway.	Auranofin	43-52	CD4 antigen	Mus musculus	96-99
11683952-4	2001	The administration of alpha-galactosylceramide induced severe cytopenia (due to apoptosis) of CD4+ NKT cells in the liver on day 1, but subsequent expansion of these NKT cells occurred in thymectomized mice similar to the case in normal mice.	alpha-galactosylceramide	22-46	CD4 antigen	Mus musculus	94-97
11710991-10	2001	Moreover, immunoblots of lysates precipitated with anti-p56(lck), phosphotyrosine, or CD4 demonstrated that in FSK-treated, anti-CD3-stimulated cells, p56(lck) is not associated with CD4 zeta chain, nor is p56(lck) or zeta chain phosphorylated.	Colforsin	111-114	CD4 antigen	Mus musculus	86-89
11710991-10	2001	Moreover, immunoblots of lysates precipitated with anti-p56(lck), phosphotyrosine, or CD4 demonstrated that in FSK-treated, anti-CD3-stimulated cells, p56(lck) is not associated with CD4 zeta chain, nor is p56(lck) or zeta chain phosphorylated.	Colforsin	111-114	CD4 antigen	Mus musculus	183-186
11544289-4	2001	In this study, we used high-density oligonucleotide arrays to produce a comprehensive picture of gene expression in murine CD4(+) Th1 and Th2 cells, as well as CD8(+) type 1 and type 2 T cells.	density oligonucleotide	28-51	CD4 antigen	Mus musculus	123-126
11531960-4	2001	CD4 T cells stimulated with alphaCD3/alphaCD28 or PMA/Ionomycin proliferated and produced principally IL-2 (i.e. a Th1 phenotype), whereas the proliferation of CD4 T cells stimulated with alphaCD3/PMA was apparently driven principally by IL-4 (i.e. a Th2 phenotype).	Ionomycin	54-63	CD4 antigen	Mus musculus	0-3
11531960-5	2001	The IL-4 driven proliferation of putative Th2 CD4 cells was enhanced by dietary n-3 fatty acids (P = 0.02).	Fatty Acids, Omega-3	80-95	CD4 antigen	Mus musculus	46-49
11531960-9	2001	These data suggest that dietary n-3 fatty acids down-regulated IL-2 driven CD4 and CD8 activation, while up-regulating the activation of the Th2 CD4 T-cell subset.	Fatty Acids, Omega-3	32-47	CD4 antigen	Mus musculus	75-78
11531960-9	2001	These data suggest that dietary n-3 fatty acids down-regulated IL-2 driven CD4 and CD8 activation, while up-regulating the activation of the Th2 CD4 T-cell subset.	Fatty Acids, Omega-3	32-47	CD4 antigen	Mus musculus	145-148
11562067-3	2001	The results, obtained by estimation of subdiploid peak of DNA and ladder DNA formation, have shown that SMS given in vivo, may potentiate the early phase of DEX-induced nuclear fragmentation (at 24 h), accelerating simultaneously the elimination of thymic cells with double positive (DP) CD4high CD8high phenotype (expressed both as percentage and absolute number).	Dexamethasone	157-160	CD4 antigen	Mus musculus	288-291
11489974-8	2001	These results demonstrate that a short treatment with immunosuppressive agents, such as 1alpha,25-dihydroxyvitamin D3/mycophenolate mofetil, induces tolerance to islet allografts associated with an increased frequency of CD4+CD25+ regulatory cells that can adoptively transfer transplantation tolerance.	1alpha	88-94	CD4 antigen	Mus musculus	221-224
11489974-8	2001	These results demonstrate that a short treatment with immunosuppressive agents, such as 1alpha,25-dihydroxyvitamin D3/mycophenolate mofetil, induces tolerance to islet allografts associated with an increased frequency of CD4+CD25+ regulatory cells that can adoptively transfer transplantation tolerance.	25-dihydroxyvitamin d3	95-117	CD4 antigen	Mus musculus	221-224
11489974-8	2001	These results demonstrate that a short treatment with immunosuppressive agents, such as 1alpha,25-dihydroxyvitamin D3/mycophenolate mofetil, induces tolerance to islet allografts associated with an increased frequency of CD4+CD25+ regulatory cells that can adoptively transfer transplantation tolerance.	Mycophenolic Acid	118-139	CD4 antigen	Mus musculus	221-224
11489988-0	2001	Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production.	Testosterone	0-12	CD4 antigen	Mus musculus	30-33
11489988-10	2001	CD4+ T lymphocytes were then shown to express the androgen receptor, raising the possibility that testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production.	Testosterone	98-110	CD4 antigen	Mus musculus	0-3
11489988-10	2001	CD4+ T lymphocytes were then shown to express the androgen receptor, raising the possibility that testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production.	Testosterone	98-110	CD4 antigen	Mus musculus	128-131
11489988-11	2001	In vitro experiments demonstrated increased IL-10 production following treatment of CD4+ T lymphocytes with DHT.	Dihydrotestosterone	108-111	CD4 antigen	Mus musculus	84-87
11489988-12	2001	Thus, testosterone can act directly via androgen receptors on CD4+ T lymphocytes to increase IL-10 gene expression.	Testosterone	6-18	CD4 antigen	Mus musculus	62-65
11470145-0	2001	The majority of lamina propria CD4(+) T-cells from scid mice with colitis undergo Fas-mediated apoptosis in vivo.	ammonium ferrous sulfate	82-85	CD4 antigen	Mus musculus	31-34
11476900-2	2001	In mouse thymocytes, CD4(+)8(+) double-positive (DP) cells which were treated with a proper combination of calcium ionophore ionomycin and phorbol 12-myristate 13-acetate (PMA) have been reported to differentiate into CD4 single positive cells.	Ionomycin	125-134	CD4 antigen	Mus musculus	21-24
11476900-2	2001	In mouse thymocytes, CD4(+)8(+) double-positive (DP) cells which were treated with a proper combination of calcium ionophore ionomycin and phorbol 12-myristate 13-acetate (PMA) have been reported to differentiate into CD4 single positive cells.	Tetradecanoylphorbol Acetate	139-170	CD4 antigen	Mus musculus	21-24
11476900-2	2001	In mouse thymocytes, CD4(+)8(+) double-positive (DP) cells which were treated with a proper combination of calcium ionophore ionomycin and phorbol 12-myristate 13-acetate (PMA) have been reported to differentiate into CD4 single positive cells.	Tetradecanoylphorbol Acetate	139-170	CD4 antigen	Mus musculus	218-221
11476900-2	2001	In mouse thymocytes, CD4(+)8(+) double-positive (DP) cells which were treated with a proper combination of calcium ionophore ionomycin and phorbol 12-myristate 13-acetate (PMA) have been reported to differentiate into CD4 single positive cells.	Tetradecanoylphorbol Acetate	172-175	CD4 antigen	Mus musculus	21-24
11476900-2	2001	In mouse thymocytes, CD4(+)8(+) double-positive (DP) cells which were treated with a proper combination of calcium ionophore ionomycin and phorbol 12-myristate 13-acetate (PMA) have been reported to differentiate into CD4 single positive cells.	Tetradecanoylphorbol Acetate	172-175	CD4 antigen	Mus musculus	218-221
11470767-6	2001	Moreover, addition of CLIK148 in incubation of a SLA-specific CD4 (+) T cell line with APC up-regulated the production of IL-4.	CLIK 148	22-29	CD4 antigen	Mus musculus	62-65
11441123-2	2001	Previous studies have demonstrated spontaneous reactivity to self-Ags within the CD4+ T cell compartment in this strain.	Silver	66-69	CD4 antigen	Mus musculus	81-84
11427413-0	2001	Induction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10.	Lactic Acid	15-26	CD4 antigen	Mus musculus	56-59
19003325-3	2001	We investigated the intracellular signaling pathways, which were Ca/CN cascade and Ras/MAPK cascade, of these tolerant CD4 T cells using phorbol-12-myristate-13-acetate (PMA) and ionomycin, which are known to directly stimulate these pathways.	Tetradecanoylphorbol Acetate	137-168	CD4 antigen	Mus musculus	119-122
19003325-3	2001	We investigated the intracellular signaling pathways, which were Ca/CN cascade and Ras/MAPK cascade, of these tolerant CD4 T cells using phorbol-12-myristate-13-acetate (PMA) and ionomycin, which are known to directly stimulate these pathways.	Tetradecanoylphorbol Acetate	170-173	CD4 antigen	Mus musculus	119-122
19003325-3	2001	We investigated the intracellular signaling pathways, which were Ca/CN cascade and Ras/MAPK cascade, of these tolerant CD4 T cells using phorbol-12-myristate-13-acetate (PMA) and ionomycin, which are known to directly stimulate these pathways.	Ionomycin	179-188	CD4 antigen	Mus musculus	119-122
11454058-6	2001	Furthermore, CD4-deficient mice had lower antibody responses to CII, explaining the lower disease susceptibility.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	64-67	CD4 antigen	Mus musculus	13-16
11407309-0	2001	Induction of CD4+ regulatory T cells by 12-O-tetradecanoylphorbol 13-acetate in mice.	Tetradecanoylphorbol Acetate	40-76	CD4 antigen	Mus musculus	13-16
11407309-4	2001	TPA painting induced CD4+Tr cells in C3H/He (H-2k), C3H/HeN (H-2k), DBA/2 (H-2d) and AKR/N (H-2k) mice, but not in C57BL/6 (H-2b), C57BL/10 (H-2b), BALB/c (H-2d) and A/J (H-2a).	Tetradecanoylphorbol Acetate	0-3	CD4 antigen	Mus musculus	21-24
11678592-5	2001	Moreover, different subsets of thymocytes possessed different susceptibility to the apoptotic effect of Cd, in the order of CD8+ &gt; CD4- CD8- (double negative cells, DN) &gt; CD4+ CD8+ (double positive cells, DP) &gt; CD4+.	Cadmium	104-106	CD4 antigen	Mus musculus	134-137
11678592-5	2001	Moreover, different subsets of thymocytes possessed different susceptibility to the apoptotic effect of Cd, in the order of CD8+ &gt; CD4- CD8- (double negative cells, DN) &gt; CD4+ CD8+ (double positive cells, DP) &gt; CD4+.	Cadmium	104-106	CD4 antigen	Mus musculus	177-180
11678592-5	2001	Moreover, different subsets of thymocytes possessed different susceptibility to the apoptotic effect of Cd, in the order of CD8+ &gt; CD4- CD8- (double negative cells, DN) &gt; CD4+ CD8+ (double positive cells, DP) &gt; CD4+.	Cadmium	104-106	CD4 antigen	Mus musculus	177-180
11411790-6	2001	Corticosterone-treatment of thymocytes in vitro decreased the number of CD4 and CD8 double positive cells, while co-culturing the cells with dehydrocorticosterone significantly attenuated this corticosterone effect (p&lt;0.0001).	Corticosterone	0-14	CD4 antigen	Mus musculus	72-75
11313415-7	2001	hyaluronan to cultures of splenocytes or purified CD4(+) T cells from infected mice resulted in the production of high levels of IFN-gamma, which was dependent on IL-12 and TCR stimulation.	Hyaluronic Acid	0-10	CD4 antigen	Mus musculus	50-53
11274422-1	2001	CD4(+) T lymphocyte clones, generated from mice immunized with the methylcholanthrene-induced fibrosarcoma Meth A (H-2(d)), are restricted by I-E(d) and recognize a unique antigen on Meth A.	Methylcholanthrene	67-85	CD4 antigen	Mus musculus	0-3
11246170-2	2001	At the same doses, ethyl carbamate decreased in the numbers of splenic macrophages, B cells, total T cells, CD4(+) T cells and CD8(+) T cells.	Urethane	19-34	CD4 antigen	Mus musculus	108-111
11246170-7	2001	The splenic numbers of total cells, macrophages, B and T cells, and CD4(+) cells were decreased by ethyl carbamate in naive and sham-operated mice.	Urethane	99-114	CD4 antigen	Mus musculus	68-71
11290858-10	2001	Although a 10 day exposure of Tat transgenic and nontransgenic mice to a combination of ethanol and AZT had no suppressive effect on the erythropoietic and granulopoietic progenitor cells, there was a marked decrease (40-60%) in CFU-GM in mice made immunodeficient by CD4+ T-lymphocyte depletion.	Ethanol	88-95	CD4 antigen	Mus musculus	268-271
11290858-10	2001	Although a 10 day exposure of Tat transgenic and nontransgenic mice to a combination of ethanol and AZT had no suppressive effect on the erythropoietic and granulopoietic progenitor cells, there was a marked decrease (40-60%) in CFU-GM in mice made immunodeficient by CD4+ T-lymphocyte depletion.	Zidovudine	100-103	CD4 antigen	Mus musculus	268-271
11231349-2	2001	A previous study suggested a role for cytotoxic T lymphocytes in the damaging effect of CD4(+) T-cell depletion in murine adriamycin (ADR) nephropathy, a model of focal segmental glomerulosclerosis (FSGS), and tubulointerstitial inflammation.	Doxorubicin	122-132	CD4 antigen	Mus musculus	88-91
11231352-0	2001	Depletion of CD4(+) T cells aggravates glomerular and interstitial injury in murine adriamycin nephropathy.	Doxorubicin	84-94	CD4 antigen	Mus musculus	13-16
11231352-6	2001	Anti-CD4 was given by intraperitoneal injection following the development of proteinuria at days 5, 6, 7, 21, and 37 after adriamycin.	Doxorubicin	123-133	CD4 antigen	Mus musculus	5-8
11231352-9	2001	Adriamycin plus CD4(+) depletion mice had significantly greater mesangial expansion, glomerular sclerosis, and interstitial expansion than the mice on adriamycin alone.	Doxorubicin	151-161	CD4 antigen	Mus musculus	16-19
11231352-11	2001	Creatinine clearance (17.5 +/- 0.54 vs. 29.2 +/- 0.89 microL/min, P &lt; 0.001) was significantly worse in the adriamycin plus CD4(+) depletion mice than in adriamycin alone mice and correlated with histologic change in glomeruli and interstitium.	Creatinine	0-10	CD4 antigen	Mus musculus	127-130
11231352-11	2001	Creatinine clearance (17.5 +/- 0.54 vs. 29.2 +/- 0.89 microL/min, P &lt; 0.001) was significantly worse in the adriamycin plus CD4(+) depletion mice than in adriamycin alone mice and correlated with histologic change in glomeruli and interstitium.	Doxorubicin	157-167	CD4 antigen	Mus musculus	127-130
11231352-12	2001	CONCLUSIONS: Depletion of CD4(+) T cells promotes glomerular and interstitial injury in mice with established adriamycin nephropathy.	Doxorubicin	110-120	CD4 antigen	Mus musculus	26-29
11231352-13	2001	These findings suggest that CD4(+) T cells have a protective role against the progression of adriamycin nephropathy.	Doxorubicin	93-103	CD4 antigen	Mus musculus	28-31
11160289-4	2001	DNFB sensitization of CD154(-/-) mice primed IFN-gamma-producing CD8(+) T cells and IL-4-producing CD4(+) T cells.	Dinitrofluorobenzene	0-4	CD4 antigen	Mus musculus	99-102
11292254-7	2001	In nadolol-treated old mice, the frequency of the immature CD4-8- population was increased, and the intermediate CD4+8+ population was reduced.	Nadolol	3-10	CD4 antigen	Mus musculus	59-62
11292254-7	2001	In nadolol-treated old mice, the frequency of the immature CD4-8- population was increased, and the intermediate CD4+8+ population was reduced.	Nadolol	3-10	CD4 antigen	Mus musculus	113-116
11292254-10	2001	The percentage of CD8+44low naive cells in peripheral blood increased in nadolol-treated mice, suggesting that more CD4-8+ cells were exported from the thymus to the periphery.	Nadolol	73-80	CD4 antigen	Mus musculus	116-119
11360932-6	2001	Although both androgens and oestrogens proved thymolytic, a significantly decreased percentage of CD4+ CD8+ thymocytes was observed by flow cytometry after treatment of mice with the androgen methyltestosterone, but not with the oestrogen ethinylestradiol.	androgen methyltestosterone	183-210	CD4 antigen	Mus musculus	98-101
11360932-6	2001	Although both androgens and oestrogens proved thymolytic, a significantly decreased percentage of CD4+ CD8+ thymocytes was observed by flow cytometry after treatment of mice with the androgen methyltestosterone, but not with the oestrogen ethinylestradiol.	Ethinyl Estradiol	239-255	CD4 antigen	Mus musculus	98-101
11160262-6	2001	Flow cytometric analyses showed that the RM134L treatment inhibited the accumulation of OX40-expressing CD4(+) T cells and the migration of adoptively transferred CD4(+) T cells in the spinal cord.	rm134l	41-47	CD4 antigen	Mus musculus	104-107
11160262-6	2001	Flow cytometric analyses showed that the RM134L treatment inhibited the accumulation of OX40-expressing CD4(+) T cells and the migration of adoptively transferred CD4(+) T cells in the spinal cord.	rm134l	41-47	CD4 antigen	Mus musculus	163-166
11169440-4	2001	CD4(+) T cell hybridomas took longer to recognize an epitope derived from the disulfide-bonded region whether native parasite or recombinant MSP-1 antigen was used.	Disulfides	78-87	CD4 antigen	Mus musculus	0-3
11276924-4	2001	CD4+CD8- cells and CD4+CD8-/CD4-CD8+ ratio in splenocytes were significantly higher in B-12-deficient mice than in control mice.	zwittergent 3-12	87-91	CD4 antigen	Mus musculus	0-3
11276924-4	2001	CD4+CD8- cells and CD4+CD8-/CD4-CD8+ ratio in splenocytes were significantly higher in B-12-deficient mice than in control mice.	zwittergent 3-12	87-91	CD4 antigen	Mus musculus	19-22
11276924-4	2001	CD4+CD8- cells and CD4+CD8-/CD4-CD8+ ratio in splenocytes were significantly higher in B-12-deficient mice than in control mice.	zwittergent 3-12	87-91	CD4 antigen	Mus musculus	19-22
11276924-5	2001	CD4+IFN-gamma+ cells was significantly lower in B-12-deficient mice than in control mice, and CD4+IL-4+ was significantly higher in B-12-deficient mice than in control mice.	zwittergent 3-12	48-52	CD4 antigen	Mus musculus	0-3
11276924-5	2001	CD4+IFN-gamma+ cells was significantly lower in B-12-deficient mice than in control mice, and CD4+IL-4+ was significantly higher in B-12-deficient mice than in control mice.	zwittergent 3-12	132-136	CD4 antigen	Mus musculus	94-97
11123297-0	2001	IFN-gamma production by Th1 cells generated from naive CD4+ T cells exposed to norepinephrine.	Norepinephrine	79-93	CD4 antigen	Mus musculus	55-58
11123297-1	2001	During activation in vivo, naive CD4(+) T cells are exposed to various endogenous ligands, such as cytokines and the neurotransmitter norepinephrine (NE).	Norepinephrine	134-148	CD4 antigen	Mus musculus	33-36
11474253-10	2001	Injecting the anti-thy 1,2 (CD90), anti-CD4 or anti-CD8 monoclonal antibody into conventional BALB/c mice resulted in the resumption of in vivo growth of Meth-A/IL-17 cells, but injecting the anti-asialo GM1 antibody did not.	meth-a	154-160	CD4 antigen	Mus musculus	40-43
11120799-3	2000	Mice lacking either CD4(+) or CD8(+) T cells demonstrated depressed CHS responses to dinitrofluorobenzene and oxazolone compared with wild-type C57BL/6 mice.	Dinitrofluorobenzene	85-105	CD4 antigen	Mus musculus	20-23
11120799-3	2000	Mice lacking either CD4(+) or CD8(+) T cells demonstrated depressed CHS responses to dinitrofluorobenzene and oxazolone compared with wild-type C57BL/6 mice.	Oxazolone	110-119	CD4 antigen	Mus musculus	20-23
11120799-11	2000	Collectively, these results suggest that both CD4(+) Th1 and CD8(+) type 1 cytotoxic T cells are crucial effector cells in CHS responses to dinitrofluorobenzene and oxazolone in C57BL/6 mice.	Dinitrofluorobenzene	140-160	CD4 antigen	Mus musculus	46-49
11120799-11	2000	Collectively, these results suggest that both CD4(+) Th1 and CD8(+) type 1 cytotoxic T cells are crucial effector cells in CHS responses to dinitrofluorobenzene and oxazolone in C57BL/6 mice.	Oxazolone	165-174	CD4 antigen	Mus musculus	46-49
11120804-4	2000	One phenotypic change seen in the AML1-diminished mice was the reduction in the numbers of both CD4 SP and CD8 SP thymocytes, reflecting the partial impairment of the transition from the double-positive to SP stage.	sp	100-102	CD4 antigen	Mus musculus	96-99
11120804-7	2000	These differential effects are most likely related to the reduction in the peripheral CD4 SP/CD8 SP ratio observed in the AML1-diminished mice.	cd8 sp	93-99	CD4 antigen	Mus musculus	86-89
11120865-0	2000	Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate.	Glatiramer Acetate	109-127	CD4 antigen	Mus musculus	17-20
11087837-3	2000	Here, we show that despite the comparable expression of I-A(b)-peptide complex in the thymus, this substitution from leucine to lysine affects efficiency of positive selection, resulting in extremely small numbers of CD4(+) T cells to be selected to mature on I-A(b)-(p)60K complex.	Leucine	117-124	CD4 antigen	Mus musculus	217-220
11087837-3	2000	Here, we show that despite the comparable expression of I-A(b)-peptide complex in the thymus, this substitution from leucine to lysine affects efficiency of positive selection, resulting in extremely small numbers of CD4(+) T cells to be selected to mature on I-A(b)-(p)60K complex.	Lysine	128-134	CD4 antigen	Mus musculus	217-220
11120596-5	2000	Corticosterone preferentially depleted CD4+CD8+ cells in the thymus, whereas the same corticosterone exposure produced by restraint stress did not.	Corticosterone	0-14	CD4 antigen	Mus musculus	39-42
11122447-0	2000	Role of CD4(+) T helper 2-type cells in cutaneous inflammatory responses induced by fluorescein isothiocyanate.	Fluorescein-5-isothiocyanate	84-110	CD4 antigen	Mus musculus	8-11
11122447-4	2000	A biphasic pattern of cutaneous inflammatory reactions was elicited by exposure to FITC, the early phase of which could be transferred passively with serum (presumably immunoglobulin E [IgE] antibody), whereas adoptive transfer experiments demonstrated that Th2-type CD4(+) cells were responsible for the delayed-type component of the dermal hypersensitivity reaction.	Fluorescein-5-isothiocyanate	83-87	CD4 antigen	Mus musculus	267-270
11146394-6	2000	In mice it delayed the CBDL-induced decline of CD4+ CD8+ thymocytes, decreased the proportion of CD8+ T cells, and increased the percentage of CD4- CD8- thymocytes, augmenting simultaneously the proportion of thymic cells in S and G2 + M phase of cycle.	cbdl	23-27	CD4 antigen	Mus musculus	47-50
11146394-6	2000	In mice it delayed the CBDL-induced decline of CD4+ CD8+ thymocytes, decreased the proportion of CD8+ T cells, and increased the percentage of CD4- CD8- thymocytes, augmenting simultaneously the proportion of thymic cells in S and G2 + M phase of cycle.	cbdl	23-27	CD4 antigen	Mus musculus	143-146
11137612-3	2000	We have previously demonstrated that thymosin alpha1 (Talpha1) antagonizes dexamethasone-induced apoptosis of CD4+CD8+ thymocytes.	Dexamethasone	75-88	CD4 antigen	Mus musculus	110-113
11086037-7	2000	The data indicate that IFN-gamma, myeloid cells, and a combination of NO and reactive oxygen intermediates all contribute to a common pathway of T cell death that targets activated or responding CD4 T cells.	reactive oxygen	77-92	CD4 antigen	Mus musculus	195-198
11086060-6	2000	TCR signal-dependent, sequential commitment from CD8(+) SP to CD4(+) SP was also shown in a class I-restricted TCR-Tg system.	cd8(+) sp	49-58	CD4 antigen	Mus musculus	62-65
11086073-7	2000	Using murine T cell hybridomas transfected to express native or mutated forms of CD4, it was determined that IL-16/CD4 induces a p56(lck)-dependent inhibitory signal for CXCR4, which is independent of its tyrosine catalytic activity.	Tyrosine	205-213	CD4 antigen	Mus musculus	81-84
11086073-7	2000	Using murine T cell hybridomas transfected to express native or mutated forms of CD4, it was determined that IL-16/CD4 induces a p56(lck)-dependent inhibitory signal for CXCR4, which is independent of its tyrosine catalytic activity.	Tyrosine	205-213	CD4 antigen	Mus musculus	115-118
11155934-2	2000	In a reconstituted SCID mouse model, CD4+ Th2 cells can mediate resistance to infection in the absence of antibody (Else &amp; Grencis, 1996).	Adenosine Monophosphate	122-125	CD4 antigen	Mus musculus	37-40
11103813-7	2000	AdVmIL-12 treatment was associated with an immune cellular infiltrate consisting of CD4 and CD8 T lymphocytes, macrophages, NK cells, and NK T cells.	advmil-12	0-9	CD4 antigen	Mus musculus	84-87
11062154-4	2000	Mice maintained on a CR diet for 28 days also displayed a significant depletion in the cell numbers of all four major thymocyte subsets defined by CD4 and CD8 expression.	Chromium	21-23	CD4 antigen	Mus musculus	147-150
11035056-0	2000	Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis.	Calcitriol	64-88	CD4 antigen	Mus musculus	13-16
11035056-0	2000	Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis.	Prostaglandins	176-189	CD4 antigen	Mus musculus	13-16
11041252-7	2000	Splenic CD4+ cells were also greatly enhanced by PMC treatment as compared with the treatment of ethanol alone.	Ethanol	97-104	CD4 antigen	Mus musculus	8-11
11129575-5	2000	CD3+ CD28+ (CD28 is an accessory molecule related to IL-2 production) and CD4+ CD28+ in splenocytes were higher in all the Cbl-administered groups.	Vitamin B 12	123-126	CD4 antigen	Mus musculus	74-77
11129575-6	2000	However, CD3+ CD28-, CD4+ CD28- and CD5+ CD25- (CD25: IL-2 R alpha/p55) were lower in the Cbl-administered groups.	Vitamin B 12	90-93	CD4 antigen	Mus musculus	21-24
11040184-1	2000	BACKGROUND &amp; AIMS: Interleukin (IL)-16 is a T lymphocyte- derived cytokine that uses CD4 as its receptor and hence selectively recruits CD4-bearing cells.	Adenosine Monophosphate	12-15	CD4 antigen	Mus musculus	89-92
11040184-1	2000	BACKGROUND &amp; AIMS: Interleukin (IL)-16 is a T lymphocyte- derived cytokine that uses CD4 as its receptor and hence selectively recruits CD4-bearing cells.	Adenosine Monophosphate	12-15	CD4 antigen	Mus musculus	140-143
11040185-1	2000	BACKGROUND &amp; AIMS: T-cell receptor alpha mutant (TCRalpha(-/-)) mice spontaneously develop chronic colitis mediated by CD4(+) TCRalpha(-)beta(+) T cells.	Adenosine Monophosphate	12-15	CD4 antigen	Mus musculus	123-126
10963854-7	2000	Splenic CD4(+)cells were significantly increased by MLT treatment when compared with treatment of Pb alone.	Lead	98-100	CD4 antigen	Mus musculus	8-11
11006364-0	2000	CD4(+) T-cell activation and induction of autoimmune hepatitis following trichloroethylene treatment in MRL+/+ mice.	Trichloroethylene	73-90	CD4 antigen	Mus musculus	0-3
11006364-2	2000	The trichloroethylene-induced autoimmune response was associated with an increase in activated CD4(+) T cells, producing Th(1)-like cytokines.	Trichloroethylene	4-21	CD4 antigen	Mus musculus	95-98
11006364-9	2000	There was a dose-related increase in the percentage of activated CD4(+) T cells in both the spleens and lymph nodes of mice treated for 32 weeks with trichloroethylene when compared to controls.	Trichloroethylene	150-167	CD4 antigen	Mus musculus	65-68
11006364-10	2000	CD4(+) T cells isolated from MRL+/+ mice after either 4 or 32 weeks of treatment with trichloroethylene secreted inflammatory or Th(1)-like cytokines.	Trichloroethylene	86-103	CD4 antigen	Mus musculus	0-3
10975810-5	2000	Production of CD4+ T cells required TCR signaling in the reaggregates, indicating that transient recognition of self-ligands by DP is inadequate for full differentiation.	dp	128-130	CD4 antigen	Mus musculus	14-17
10975865-5	2000	However, administration of sIL-15Ralpha together with a single dose of a nondepleting anti-CD4 mAb (YTS 177.9) delayed mononuclear cell infiltration of the grafts and markedly prolonged graft survival (MST of 60 days vs MST of 20 days for treatment with anti-CD4 alone).	sil-15ralpha	27-39	CD4 antigen	Mus musculus	259-262
10990162-9	2000	Immunophenotypic analysis of BAL cells shows that, when compared with BAL cells from infected controls, exposure to TCDD caused a 50% decrease in the percentage and number of both CD4+ and CD8+ cells.	Polychlorinated Dibenzodioxins	116-120	CD4 antigen	Mus musculus	180-183
11017783-4	2000	Infection of SJL CD4((-/-)) mice with DA-VP1-99(Ser) or DA-VP1-100(Asp) resulted in virus persistence and prominent demyelination in the spinal cord.	Serine	48-51	CD4 antigen	Mus musculus	17-20
11017783-8	2000	Therefore, the nondemyelinating phenotype observed with DA-VP1-99(Ser) and DA-VP1-100(Asp) viruses is dependent in part on the CD4-mediated host immune response.	Serine	66-69	CD4 antigen	Mus musculus	127-130
10966932-5	2000	At 48 h postischemia, CD4/CD8-knockout (KO) mice had marked improvement in renal function compared with control C57BL/6 mice (serum creatinine: 0.7 +/- 0.4 vs. 2.5 +/- 0.3 mg/dl, respectively; P &lt; 0.05).	Creatinine	132-142	CD4 antigen	Mus musculus	22-25
11025179-1	2000	The alkaloid oxoglaucine reduced CD4+ cell clones in adult mice and decreased CD4+, CD8+ and Ig+ levels in newborn mice.	oxoglaucine	13-24	CD4 antigen	Mus musculus	33-36
11025179-1	2000	The alkaloid oxoglaucine reduced CD4+ cell clones in adult mice and decreased CD4+, CD8+ and Ig+ levels in newborn mice.	oxoglaucine	13-24	CD4 antigen	Mus musculus	78-81
10925362-1	2000	Elimination of CD4(+) T cells by anti-CD4 antibody caused regression of a methylcholanthrene-induced S713a sarcoma growing in syngeneic A/J mice, and the tumor regression was essentially required for CD8(+) T cells.	Methylcholanthrene	74-92	CD4 antigen	Mus musculus	15-18
10925362-1	2000	Elimination of CD4(+) T cells by anti-CD4 antibody caused regression of a methylcholanthrene-induced S713a sarcoma growing in syngeneic A/J mice, and the tumor regression was essentially required for CD8(+) T cells.	Methylcholanthrene	74-92	CD4 antigen	Mus musculus	38-41
10903722-2	2000	We used confocal immunofluorescence methods to show that the adapter protein LAT (linker for activation of T cells) and the guanine nucleotide exchange factor Vav also move to the APC interface in mouse CD4 T cells conjugated to anti-CD3 hybridoma cells, and in TCR-transgenic CD4 cells conjugated to APC bearing agonist (but not closely related nonagonist) peptides.	Guanine	124-131	CD4 antigen	Mus musculus	203-206
10903722-2	2000	We used confocal immunofluorescence methods to show that the adapter protein LAT (linker for activation of T cells) and the guanine nucleotide exchange factor Vav also move to the APC interface in mouse CD4 T cells conjugated to anti-CD3 hybridoma cells, and in TCR-transgenic CD4 cells conjugated to APC bearing agonist (but not closely related nonagonist) peptides.	Guanine	124-131	CD4 antigen	Mus musculus	277-280
10903722-3	2000	The proportion of CD4+ T cells able to relocalize LAT or Vav, or to relocate cytoplasmic NT-AT (NF-ATc) from cytoplasm to nucleus, declines about 2-fold in aged mice.	nt-at	89-94	CD4 antigen	Mus musculus	18-21
10903722-4	2000	The decline in LAT relocalization is accompanied by a similar decline in tyrosine phosphorylation of LAT in CD4 cells stimulated by CD3/CD4 cross-linking.	Tyrosine	73-81	CD4 antigen	Mus musculus	108-111
10903722-4	2000	The decline in LAT relocalization is accompanied by a similar decline in tyrosine phosphorylation of LAT in CD4 cells stimulated by CD3/CD4 cross-linking.	Tyrosine	73-81	CD4 antigen	Mus musculus	136-139
10936423-9	2000	Therefore, although the vSAg-induced response stimulated by vSAg29 expressing lymphoma cells in syngeneic TCR Vbeta-restricted CD4(+) T cells is an important etiologic factor in this type of B cell neoplasm both in C57L and in SJL mice, the final outcome of the spontaneous neoplastic process appears strongly influenced by endogenous NK activity in aging mice.	vsag	24-28	CD4 antigen	Mus musculus	127-130
10910992-0	2000	The effects of TCDD on the activation of ovalbumin (OVA)-specific DO11.10 transgenic CD4(+) T cells in adoptively transferred mice.	Polychlorinated Dibenzodioxins	15-19	CD4 antigen	Mus musculus	85-88
10910992-3	2000	We hypothesized that exposure to TCDD suppresses the activation of naive CD4(+) T cells and prevents their expansion and differentiation into effector T-helper cells capable of driving T cell-dependent immune responses.	Polychlorinated Dibenzodioxins	33-37	CD4 antigen	Mus musculus	73-76
10910992-6	2000	Although TCDD exposure had little effect on the expansion or activation of the adoptively transferred, OVA-specific CD4(+) T cells, these cells disappeared from the spleen more rapidly in TCDD-treated mice and produced significantly decreased levels of the T cell-derived cytokines IL-2 and IL-10.	Polychlorinated Dibenzodioxins	188-192	CD4 antigen	Mus musculus	116-119
10878345-0	2000	Activation of antigen-specific CD4+ Th2 cells and B cells in vivo increases norepinephrine release in the spleen and bone marrow.	Norepinephrine	76-90	CD4 antigen	Mus musculus	31-34
10963810-0	2000	CD4 Th1 but not Th2 clones efficiently activate macrophages to eliminate Trypanosoma cruzi through a nitric oxide dependent mechanism.	Nitric Oxide	101-113	CD4 antigen	Mus musculus	0-3
10880242-7	2000	Our results indicate that activities by membrane gangliosides can influence the cytokine programs in CD4(+)T cells, possibly through the modulation of calcium responses induced by T cell activation.	Gangliosides	49-61	CD4 antigen	Mus musculus	101-104
10880242-7	2000	Our results indicate that activities by membrane gangliosides can influence the cytokine programs in CD4(+)T cells, possibly through the modulation of calcium responses induced by T cell activation.	Calcium	151-158	CD4 antigen	Mus musculus	101-104
10882414-8	2000	However, chronically rIL-12-treated mice exhibited increased numbers of non-B/non-T cells that when re-stimulated with specific allergen, produce IL-4 at levels 20-fold higher than did CD4 T cells while IL-13 responses are unaffected.	ril-12	21-27	CD4 antigen	Mus musculus	185-188
10821786-0	2000	Retinoid-mediated inhibition of interleukin-12 production in mouse macrophages suppresses Th1 cytokine profile in CD4(+) T cells.	Retinoids	0-8	CD4 antigen	Mus musculus	114-117
10821786-2	2000	In this study we investigated whether retinoid-mediated inhibition of interleukin-12 production in mouse macrophages could regulate cytokine profile of antigen (Ag)-primed CD4(+) Th cells.	Retinoids	38-46	CD4 antigen	Mus musculus	172-175
10821786-4	2000	Retinoid-pretreated macrophages reduced their ability to induce IFN-gamma and increased the ability to induce IL-4 in Ag-primed CD4(+) T cells.	Retinoids	0-8	CD4 antigen	Mus musculus	128-131
10821786-5	2000	Addition of recombinant IL-12 to cultures of retinoid-pretreated macrophages and CD4(+) T cells restored IFN-gamma production in CD4(+) T cells.	Retinoids	45-53	CD4 antigen	Mus musculus	129-132
10821786-6	2000	The in vivo administration of 9-cis-RA resulted in the inhibition of IL-12 production by macrophages stimulated in vitro with either LPS or HKL, leading to the inhibition of Th1 cytokine profile (decreased IFN-gamma and increased IL-4 production) in CD4(+) T cells.	Tretinoin	30-38	CD4 antigen	Mus musculus	250-253
10822084-6	2000	Flow cytometric analysis of peripheral blood cells showed that BB caused a decrease in the number of CD3(+), CD4(+), CD8(+), and sIg(+) lymphocytes in comparison with TIN mice.	Berberine	63-65	CD4 antigen	Mus musculus	109-112
10822084-8	2000	The control animals treated only with BB showed a decrease in the number of CD3(+), CD4(+), CD8(+) T-lymphocytes in comparison with control nontreated mice.	Berberine	38-40	CD4 antigen	Mus musculus	84-87
10886394-0	2000	Generation of alphabeta T-cell receptor+ CD4- CD8+ cells in major histocompatibility complex class I-deficient mice upon activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin.	Polychlorinated Dibenzodioxins	168-203	CD4 antigen	Mus musculus	41-44
10886394-2	2000	We show here that both in vitro and in vivo treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a trans-activating ligand of the endogenous aryl hydrocarbon receptor (Ah-R), bypasses the need for MHC class I molecules for selection into the CD4- CD8+ cell pool.	Polychlorinated Dibenzodioxins	59-94	CD4 antigen	Mus musculus	248-251
10886394-2	2000	We show here that both in vitro and in vivo treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a trans-activating ligand of the endogenous aryl hydrocarbon receptor (Ah-R), bypasses the need for MHC class I molecules for selection into the CD4- CD8+ cell pool.	Polychlorinated Dibenzodioxins	96-100	CD4 antigen	Mus musculus	248-251
10886394-3	2000	When beta2m-/- dams were given a single dose of 50 microg of TCDD, approximately 13% of CD4- CD8+ thymocytes could be detected in their newborn pups.	Polychlorinated Dibenzodioxins	61-65	CD4 antigen	Mus musculus	88-91
10886394-4	2000	In TCDD-exposed fetal thymus organ cultures of beta2m-/- mice, approximately 35% CD4- CD8+ thymocytes were detectable.	Polychlorinated Dibenzodioxins	3-7	CD4 antigen	Mus musculus	81-84
10886394-8	2000	Thus, TCDD leads to a significant increase of mature CD4- CD8+ thymocytes in relative and absolute numbers.	Polychlorinated Dibenzodioxins	6-10	CD4 antigen	Mus musculus	53-56
10886394-9	2000	High numbers of CD4- CD8+ thymocytes developed also in organ cultures from thymi, lacking both MHC class I and class II molecules, exposed to TCDD.	Polychlorinated Dibenzodioxins	142-146	CD4 antigen	Mus musculus	16-19
10886394-10	2000	A 10-fold transient increase of Notch1 mRNA in thymocytes from fetal thymus organ culture, exposed for 4 days to TCDD, was detected in CD4+ CD8+ cells compared with controls.	Polychlorinated Dibenzodioxins	113-117	CD4 antigen	Mus musculus	135-138
10886394-11	2000	We suggest that TCDD affects thymic selection and directs the lineage commitment of CD4+ CD8+ thymocytes towards CD4- CD8+ cells, possibly via up-regulation of the Notch1 gene.	Polychlorinated Dibenzodioxins	16-20	CD4 antigen	Mus musculus	84-87
10886394-11	2000	We suggest that TCDD affects thymic selection and directs the lineage commitment of CD4+ CD8+ thymocytes towards CD4- CD8+ cells, possibly via up-regulation of the Notch1 gene.	Polychlorinated Dibenzodioxins	16-20	CD4 antigen	Mus musculus	113-116
10841521-2	2000	A novel, humanized anti-ganglioside-GD(2)-IL-2 immunocytokine (hu14.18-IL-2) induced CD8(+) T cells to eradicate established pulmonary metastases of B78-D14 murine melanoma, in a process that required help by CD4(+) T cells and was mediated by the CD40/CD40 ligand (CD40L) interaction.	Gangliosides	24-35	CD4 antigen	Mus musculus	209-212
10799884-11	2000	CD4+ cells from IL-12-/- mice secreted less IFN-gamma, but more IL-4 and IL-10 than WT mice, suggesting that they developed a stronger Th2 response to TAChR.	th2	135-138	CD4 antigen	Mus musculus	0-3
10836388-0	2000	Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade.	Tacrolimus	19-29	CD4 antigen	Mus musculus	114-117
10836388-0	2000	Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade.	Cyclosporine	34-46	CD4 antigen	Mus musculus	114-117
10727416-6	2000	Only a modest increase in intracellular oxygen species was found in thymocytes stimulated by strong cross-linking of TCR together with CD4 or CD28.	Oxygen	40-46	CD4 antigen	Mus musculus	135-138
10982153-7	2000	In addition, immunohistochemistry showed a reduction in tumor-infiltrating lymphocytes containing CD4 and CD8 antigens in the mice treated with phenytoin and zonisamide.	Phenytoin	144-153	CD4 antigen	Mus musculus	98-101
10982153-7	2000	In addition, immunohistochemistry showed a reduction in tumor-infiltrating lymphocytes containing CD4 and CD8 antigens in the mice treated with phenytoin and zonisamide.	Zonisamide	158-168	CD4 antigen	Mus musculus	98-101
10729246-6	2000	RESULTS/CONCLUSION: These results show that mucosal CD4(+) T cells and B cells increase in animals treated with curcumin, suggesting that curcumin modulates lymphocyte-mediated immune functions.	Curcumin	112-120	CD4 antigen	Mus musculus	52-55
10729246-6	2000	RESULTS/CONCLUSION: These results show that mucosal CD4(+) T cells and B cells increase in animals treated with curcumin, suggesting that curcumin modulates lymphocyte-mediated immune functions.	Curcumin	138-146	CD4 antigen	Mus musculus	52-55
10774820-0	2000	Inhibition of CYP2E1 reverses CD4+ T-cell alterations in trichloroethylene-treated MRL+/+ mice.	Trichloroethylene	57-74	CD4 antigen	Mus musculus	30-33
10774820-10	2000	In addition, the reduction in interleukin-4 levels secreted by activated CD4+ T cells from trichloroethylene-treated mice was reversed if the mice were also treated with diallyl sulfide.	Trichloroethylene	91-108	CD4 antigen	Mus musculus	73-76
10774820-10	2000	In addition, the reduction in interleukin-4 levels secreted by activated CD4+ T cells from trichloroethylene-treated mice was reversed if the mice were also treated with diallyl sulfide.	allyl sulfide	170-185	CD4 antigen	Mus musculus	73-76
10774820-11	2000	Taken collectively, metabolism of trichloroethylene by CYP2E1 is responsible, at least in part, for the CD4+ T cell alterations associated with exposure to this environmental toxicant.	Trichloroethylene	34-51	CD4 antigen	Mus musculus	104-107
10728758-9	2000	Anti-TNFalpha therapy was also more effective than anti-CD4 in reducing Thl activity, as assessed by the production of interferon-gamma in lymph node cell cultures.	Orlistat	72-75	CD4 antigen	Mus musculus	56-59
10679103-3	2000	These mice, termed muMT (-CD4), showed 80% mortality after infection with a small dose of PR8, which resulted in insignificant mortality in intact or Th cell-depleted BALB/c mice.	mumt	19-23	CD4 antigen	Mus musculus	26-29
10679103-9	2000	Treatment of infected muMT(-CD4) mice with normal mouse serum spiked with hemagglutinin-specific IgM did not reduce mortality.	mumt	22-26	CD4 antigen	Mus musculus	28-31
10673344-0	2000	Trypanosoma cruzi: the effect of nitric oxide synthesis inhibition on the CD4 T cell response to the trans-sialidase superfamily.	Nitric Oxide	33-45	CD4 antigen	Mus musculus	74-77
10683375-0	2000	IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes.	ammonium ferrous sulfate	55-58	CD4 antigen	Mus musculus	97-100
10670579-5	2000	The latter effect of BQ-123 was due to inhibition of CD4+ and CD8+ T lymphocytes.	cyclo(Trp-Asp-Pro-Val-Leu)	21-27	CD4 antigen	Mus musculus	53-56
10670579-6	2000	Treatment with BQ-123 also inhibited interleukin-5 levels in the exudate and plasma as well as intracellular staining of interleukin-4, interleukin-5, and interferon-gamma in CD4+ lymphocytes.	cyclo(Trp-Asp-Pro-Val-Leu)	15-21	CD4 antigen	Mus musculus	175-178
10637279-0	2000	Tetracycline-controllable selection of CD4(+) T cells: half-life and survival signals in the absence of major histocompatibility complex class II molecules.	Tetracycline	0-12	CD4 antigen	Mus musculus	39-42
10637279-3	2000	This resulted in tet-responsive display of cell surface E complexes, positive selection of CD4(+)8(-) thymocytes, and generation of a CD4(+) T cell compartment in a class II-barren periphery.	Tetracycline	17-20	CD4 antigen	Mus musculus	134-137
10640982-10	2000	Chronic alcohol consumption by CD4-depleted mice resulted in larger tumors, compared with mice that did not receive ethanol in their diet (P = 0.05).	Alcohols	8-15	CD4 antigen	Mus musculus	31-34
11268383-8	2000	The seasonal effects of rotational stress, and the reduction of the effects of cyclophosphamide caused by rotational stress, are accompanied by corresponding variations in the number of CD3+ and CD4+ splenic T-lymphocyte subsets and in the CD4+/CD8+ ratio, respectively.	Cyclophosphamide	79-95	CD4 antigen	Mus musculus	195-198
11268383-8	2000	The seasonal effects of rotational stress, and the reduction of the effects of cyclophosphamide caused by rotational stress, are accompanied by corresponding variations in the number of CD3+ and CD4+ splenic T-lymphocyte subsets and in the CD4+/CD8+ ratio, respectively.	Cyclophosphamide	79-95	CD4 antigen	Mus musculus	240-243
11097211-5	2000	Examination of the CD4/CD8 populations in dy/dy thymi showed large relative increases in the DN (CD4- CD8-) and SP (CD4+ CD8-, CD4- CD8+) populations and a significant decrease in the DP (CD4+ CD8+) population.	dn	93-95	CD4 antigen	Mus musculus	19-22
11097211-5	2000	Examination of the CD4/CD8 populations in dy/dy thymi showed large relative increases in the DN (CD4- CD8-) and SP (CD4+ CD8-, CD4- CD8+) populations and a significant decrease in the DP (CD4+ CD8+) population.	TFF2 protein, human	112-114	CD4 antigen	Mus musculus	19-22
11097211-5	2000	Examination of the CD4/CD8 populations in dy/dy thymi showed large relative increases in the DN (CD4- CD8-) and SP (CD4+ CD8-, CD4- CD8+) populations and a significant decrease in the DP (CD4+ CD8+) population.	dp	184-186	CD4 antigen	Mus musculus	19-22
10602051-0	2000	Human CD4 residue Phe 43 is critical for repertoire development and maturation of MHC class II restricted CD4 single-positive T lineage cells in vivo.	Phenylalanine	18-21	CD4 antigen	Mus musculus	6-9
10602051-0	2000	Human CD4 residue Phe 43 is critical for repertoire development and maturation of MHC class II restricted CD4 single-positive T lineage cells in vivo.	Phenylalanine	18-21	CD4 antigen	Mus musculus	106-109
10695925-7	2000	DHA-Et reduced the infiltration of CD4-positive T lymphocytes into the ears.	Docosahexaenoic Acids	0-3	CD4 antigen	Mus musculus	35-38
10586049-5	1999	Moreover, the Ab stimulated a distinct pattern of tyrosine phosphorylation in T cells even in the absence of TCR triggering, suggesting that signaling through CD4 alone induces significant physiological changes in T cell function.	Tyrosine	50-58	CD4 antigen	Mus musculus	159-162
10594563-0	1999	Effects of cocaine administration to influenza virus-immunized mice on cytokine profiles of individual splenic CD4+ and CD8+ T cells.	Cocaine	11-18	CD4 antigen	Mus musculus	111-114
10606004-6	1999	TCDD exposure interferes with thymocyte development; for instance, it reduces the proliferation rate of the very immature (CD4- CD8- and CD4- CD8+ HSA+) thymocytes, leads to preferential emigration of very immature cells, and drastically skews the differentiation of thymocyte subpopulations towards mature CD4- CD8+ alphabeta TCRhigh thymocytes.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	123-126
10606004-6	1999	TCDD exposure interferes with thymocyte development; for instance, it reduces the proliferation rate of the very immature (CD4- CD8- and CD4- CD8+ HSA+) thymocytes, leads to preferential emigration of very immature cells, and drastically skews the differentiation of thymocyte subpopulations towards mature CD4- CD8+ alphabeta TCRhigh thymocytes.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	137-140
10606004-6	1999	TCDD exposure interferes with thymocyte development; for instance, it reduces the proliferation rate of the very immature (CD4- CD8- and CD4- CD8+ HSA+) thymocytes, leads to preferential emigration of very immature cells, and drastically skews the differentiation of thymocyte subpopulations towards mature CD4- CD8+ alphabeta TCRhigh thymocytes.	Polychlorinated Dibenzodioxins	0-4	CD4 antigen	Mus musculus	137-140
10638706-0	1999	Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization.	Mannans	56-62	CD4 antigen	Mus musculus	32-35
10776840-6	1999	MC treatment lowered the in vitro response to concanavalin A (Con A) of spleen cells, the secretion of interleukin-2 in spleen cell culture after stimulation of the cells with Con A and the proportions of CD3+ CD4+ and CD8 + splenic cells.	Methylcholanthrene	0-2	CD4 antigen	Mus musculus	210-213
10540183-6	1999	A significantly higher fraction of CD4+ LPL were found to enter the cell cycle, i.e. to incorporate bromo-deoxy-uridine, and to undergo apoptosis in vivo in WT-transplanted compared with IFN-gammaKO-transplanted SCID mice.	Bromodeoxyuridine	100-119	CD4 antigen	Mus musculus	35-38
10575554-0	1999	Trichloroethylene activates CD4+ T cells: potential role in an autoimmune response.	Trichloroethylene	0-17	CD4 antigen	Mus musculus	28-31
10575554-3	1999	After only 4 weeks of treatment, trichloroethylene was shown to promote the expansion of CD4+ T cells that expressed a memory/activation phenotype (i.e., CD44hi CD45RBlo) and secreted high levels of IFN-gamma, but not IL-4.	Trichloroethylene	33-50	CD4 antigen	Mus musculus	89-92
10531206-0	1999	CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.	Peptides	118-126	CD4 antigen	Mus musculus	0-3
10531206-2	1999	We recently reported that immunization of A/J mice with an 18-amino-acid synthetic linear peptide from Plasmodium yoelii sporozoite surface protein 2 (SSP2) in TiterMax adjuvant induces sterile protection that is dependent on CD4(+) T cells and gamma interferon (IFN-gamma).	18-amino-acid	59-72	CD4 antigen	Mus musculus	226-229
10531206-6	1999	Data represented here demonstrate that CD4(+) T-cell-dependent protection can be induced by immunization with linear synthetic peptides.	Peptides	127-135	CD4 antigen	Mus musculus	39-42
10583610-6	1999	Disruption of the CD4 gene in MRL-lpr/lpr mice led to a substantial decrease in the concentration of circulating IgG, but IgG galactose levels remained low.	Galactose	126-135	CD4 antigen	Mus musculus	18-21
10584210-4	1999	Cocaine only decreased the absolute number of Thy 1+, CD4+, CD8+, IL-2R+, Mac 1+ and B cells, in the spleen of old mice.	Cocaine	0-7	CD4 antigen	Mus musculus	54-57
10584210-8	1999	Short term cocaine administration provoked a decrease in the number of CD4+ cells in young mice ILP and of CD8+ cells in old mice ILP.	Cocaine	11-18	CD4 antigen	Mus musculus	71-74
10516078-6	1999	Apparently B-cell-CD4(+)-T-cell interactions play a part in the gammaHV-68 induction of both splenomegaly and non-MHC-restricted Vbeta4(+) CD8(+)-T-cell expansion.	gammahv	64-71	CD4 antigen	Mus musculus	18-21
10516121-4	1999	Immunocytochemical staining revealed that CD4(+)CD8(+) double positive cells markedly decreased after GA treatment.	Glycyrrhetinic Acid	102-104	CD4 antigen	Mus musculus	42-45
10598321-7	1999	We hypothesized that mediators released by pulmonary CD4+ T cells may upregulate and maintain of 5-LO metabolism in PBM as they enter the alveolar space and differentiate into AM.	pbm	116-119	CD4 antigen	Mus musculus	53-56
10502060-7	1999	In vivo treatment with anti-CD4 monoclonal antibody inhibited development of EAU in a dose-dependent manner, while in vivo treatment with other monoclonal antibodies did not cause significant suppression of EAU.	Water	77-80	CD4 antigen	Mus musculus	28-31
10502060-9	1999	However, in in vivo treatment with monoclonal antibodies to these molecules, only anti-CD4 monoclonal antibody had a strong inhibitory effect on the development of EAU.	Water	164-167	CD4 antigen	Mus musculus	87-90
10499914-9	1999	They also indicate that the TCR-MHC class II interaction(s) required for the intrathymic development of long-lived CD4(+) SP cells occurs before the CD4(hi) SP stage of development.	sp	122-124	CD4 antigen	Mus musculus	115-118
10477569-4	1999	When examined biochemically, effector and memory CD4 T cells are strikingly distinct and exhibit qualitative and quantitative differences in tyrosine phosphorylation.	Tyrosine	141-149	CD4 antigen	Mus musculus	49-52
10477603-6	1999	Specifically, a dramatic increase in the CD4low/-CD8+CD5lowHSA+TCRlow/- immature single positive population and a concomitant decrease in the subsequent DP population are observed.	dp	153-155	CD4 antigen	Mus musculus	41-44
10508261-3	1999	Both hpH4 and mH4 (1) are selectively expressed by activated T cells and mature thymocytes, (2) are disulfide-linked dimers of two chains (29/37 kDa in humans, 25/29 kDa in mice), whose N-deglycosylation produces a single band at 20 - 21 kDa, and (3) display a low association with CD4 and the TCR.	CHEMBL1169805	14-17	CD4 antigen	Mus musculus	282-285
10448009-3	1999	Addition of IL-2, anti-CD28 antibodies, or phorbol esters, but not IL-1, IL-4, or ionomycin, blocked CD4-mediated inhibition and restored the response to levels equal or higher than those of cultures activated by anti-CD3 alone.	Phorbol Esters	43-57	CD4 antigen	Mus musculus	101-104
10448009-6	1999	The analysis of early tyrosine phosphorylation in CD4(+) T cells shows that phosphorylation of many cell substrates is clearly enhanced upon CD3-CD4 coligation using indirectly or directly bound antibodies, yet certain substrates are mainly phosphorylated under inhibitory conditions.	Tyrosine	22-30	CD4 antigen	Mus musculus	50-53
10448009-6	1999	The analysis of early tyrosine phosphorylation in CD4(+) T cells shows that phosphorylation of many cell substrates is clearly enhanced upon CD3-CD4 coligation using indirectly or directly bound antibodies, yet certain substrates are mainly phosphorylated under inhibitory conditions.	Tyrosine	22-30	CD4 antigen	Mus musculus	145-148
10458754-1	1999	We report that MHC class II (MHC-II)-restricted antigen processing of two CD4(+) T cell epitopes from the surface M protein of Streptococcus pyogenes in murine macrophages is dependent on intact calcium homeostasis and flux.	Calcium	195-202	CD4 antigen	Mus musculus	74-77
10415045-2	1999	When hemopoietic cells from CD43-/- mice were stained with 1B11, CD43-independent binding of 1B11 was observed on peripheral CD8 T cells and at low levels on thymocytes, while no binding was detected on CD4 T cells, B cells, or bone marrow cells.	tl-3-093	59-63	CD4 antigen	Mus musculus	28-31
10415045-2	1999	When hemopoietic cells from CD43-/- mice were stained with 1B11, CD43-independent binding of 1B11 was observed on peripheral CD8 T cells and at low levels on thymocytes, while no binding was detected on CD4 T cells, B cells, or bone marrow cells.	tl-3-093	93-97	CD4 antigen	Mus musculus	28-31
10415045-6	1999	We show that neuraminidase-enhanced 1B11 binding in CD43-/- LNC and EL4 thymoma cells is CD43 independent and that 1B11 detects a novel target of apparent mass of approximately 200 kDa identified as a hyposialylated form of CD45RB preferentially expressed on peripheral CD8, but not CD4, T cells.	tl-3-093	36-40	CD4 antigen	Mus musculus	52-55
10440405-4	1999	RESULTS: Discrete generations of CD4+ responder lymphocytes proliferating specifically in response to allogeneic MHC class II were distinguished by fluorescein intensity.	Fluorescein	148-159	CD4 antigen	Mus musculus	33-36
10428275-2	1999	Previous studies in vitro demonstrated that CD4+ cytotoxic T lymphocytes use the Fas pathway as a primary cytotoxic mechanism, but the cytotoxic mechanisms used by CD4+ T cells in vivo are unclear.	ammonium ferrous sulfate	81-84	CD4 antigen	Mus musculus	44-47
10428275-5	1999	RESULTS: The skin allografts from Fas-deficient mice were readily rejected by the athymic mice reconstituted with purified CD4+ T cells.	ammonium ferrous sulfate	34-37	CD4 antigen	Mus musculus	123-126
10428275-6	1999	Perforin-deficient CD4+ T cells could also reject Fas-deficient skin allografts.	ammonium ferrous sulfate	50-53	CD4 antigen	Mus musculus	19-22
10393955-7	1999	In vivo experiments in hen egg lysozyme (HEL) T cell receptor transgenic mice show that CD4(+) T cells from HEL-naive mice are killed by Fas ligation, but CD4(+) T cells from long-term HEL-exposed mice are costimulated by Fas ligation.	ammonium ferrous sulfate	137-140	CD4 antigen	Mus musculus	88-91
10410976-7	1999	Polyclonal activation of lung T cells from OA/OA mice with 12-myristate 13-acetate (PMA), ionomycin, anti-CD3 mAb, and anti-CD28 mAb resulted in higher percentages of IL-2+ (43%) and IL-5+ (7%) CD4 cells when compared to CD4+ T cells from non-OA sensitized, challenged mice.	Tetradecanoylphorbol Acetate	84-87	CD4 antigen	Mus musculus	194-197
10410976-7	1999	Polyclonal activation of lung T cells from OA/OA mice with 12-myristate 13-acetate (PMA), ionomycin, anti-CD3 mAb, and anti-CD28 mAb resulted in higher percentages of IL-2+ (43%) and IL-5+ (7%) CD4 cells when compared to CD4+ T cells from non-OA sensitized, challenged mice.	Tetradecanoylphorbol Acetate	84-87	CD4 antigen	Mus musculus	221-224
10410976-7	1999	Polyclonal activation of lung T cells from OA/OA mice with 12-myristate 13-acetate (PMA), ionomycin, anti-CD3 mAb, and anti-CD28 mAb resulted in higher percentages of IL-2+ (43%) and IL-5+ (7%) CD4 cells when compared to CD4+ T cells from non-OA sensitized, challenged mice.	Ionomycin	90-99	CD4 antigen	Mus musculus	194-197
10410976-7	1999	Polyclonal activation of lung T cells from OA/OA mice with 12-myristate 13-acetate (PMA), ionomycin, anti-CD3 mAb, and anti-CD28 mAb resulted in higher percentages of IL-2+ (43%) and IL-5+ (7%) CD4 cells when compared to CD4+ T cells from non-OA sensitized, challenged mice.	Ionomycin	90-99	CD4 antigen	Mus musculus	221-224
10383160-6	1999	Moreover, a substantial number of CD8+ T cells in mice with large primary MC tumors were undergoing apoptosis, correlating with alterations in CD4/CD8 ratios.	Methylcholanthrene	74-76	CD4 antigen	Mus musculus	143-146
10233928-2	1999	This gender difference in disease susceptibility correlates with selective induction of CD4(+) Th1 (gamma interferon-positive) cell responses in animals with testosterone, whereas estradiol promotes preferential CD4(+) Th2 (interleukin-4 positive [IL-4(+)]) cell responses.	Testosterone	158-170	CD4 antigen	Mus musculus	88-91
10233928-2	1999	This gender difference in disease susceptibility correlates with selective induction of CD4(+) Th1 (gamma interferon-positive) cell responses in animals with testosterone, whereas estradiol promotes preferential CD4(+) Th2 (interleukin-4 positive [IL-4(+)]) cell responses.	Estradiol	180-189	CD4 antigen	Mus musculus	212-215
10233928-7	1999	Taken together, our results indicate that testosterone promotes a CD4(+) Th1 cell response and myocarditis by promoting increased gammadelta+ cell activation.	Testosterone	42-54	CD4 antigen	Mus musculus	66-69
10229835-7	1999	Furthermore, resting CD4+ T cells from mutant Abetak transgenic mice expressed higher levels of cell surface CD95 (Fas, APO-1).	ammonium ferrous sulfate	115-118	CD4 antigen	Mus musculus	21-24
10229852-6	1999	Although the Fas/Fas ligand system has been reported to be the most important mechanism for CD4+ CTL-mediated cytotoxicity in the murine system, the present findings strongly suggest that granule exocytosis, not the Fas/Fas ligand system, is the main pathway for the cytotoxicity mediated by HSV-specific human CD4+ CTLs.	ammonium ferrous sulfate	13-16	CD4 antigen	Mus musculus	92-95
10222057-0	1999	Corynebacterium parvum- and Mycobacterium bovis Bacillus Calmette and Guerin-induced granuloma formation in mice lacking CD4 and CD8.	guerin	70-76	CD4 antigen	Mus musculus	121-124
10222057-2	1999	The role of CD4 and CD8 molecules in the development of Corynebacterium parvum- and Mycobacterium bovis Bacillus Calmette and Guerin (BCG)-induced granulomas was examined in CD4/CD8 knockout (KO) mice.	guerin	126-132	CD4 antigen	Mus musculus	12-15
10222057-5	1999	On the other hand, CD4/CD8 KO mice challenged with live BCG showed initially fewer and smaller granulomas but later more and larger granulomas than control mice.	bcg	56-59	CD4 antigen	Mus musculus	19-22
10222057-6	1999	CD4/CD8 KO mice had a greater BCG load than control mice.	bcg	30-33	CD4 antigen	Mus musculus	0-3
10359118-3	1999	ATP4-, but not UTP or GTP, activated a sustained non-selective cation current in voltage-clamped CD4- CD8- and CD4+ CD8+ thymocytes that was reversed by apyrase, which hydrolyzes ATP, and by the P2XR antagonists suramin and pyridoxalphosphate-6-azophenyl-2",4"-disulfonic acid (PPADS).	atp4	0-4	CD4 antigen	Mus musculus	97-100
10359118-3	1999	ATP4-, but not UTP or GTP, activated a sustained non-selective cation current in voltage-clamped CD4- CD8- and CD4+ CD8+ thymocytes that was reversed by apyrase, which hydrolyzes ATP, and by the P2XR antagonists suramin and pyridoxalphosphate-6-azophenyl-2",4"-disulfonic acid (PPADS).	atp4	0-4	CD4 antigen	Mus musculus	111-114
10359118-3	1999	ATP4-, but not UTP or GTP, activated a sustained non-selective cation current in voltage-clamped CD4- CD8- and CD4+ CD8+ thymocytes that was reversed by apyrase, which hydrolyzes ATP, and by the P2XR antagonists suramin and pyridoxalphosphate-6-azophenyl-2",4"-disulfonic acid (PPADS).	Adenosine Triphosphate	0-3	CD4 antigen	Mus musculus	97-100
10359118-3	1999	ATP4-, but not UTP or GTP, activated a sustained non-selective cation current in voltage-clamped CD4- CD8- and CD4+ CD8+ thymocytes that was reversed by apyrase, which hydrolyzes ATP, and by the P2XR antagonists suramin and pyridoxalphosphate-6-azophenyl-2",4"-disulfonic acid (PPADS).	Adenosine Triphosphate	0-3	CD4 antigen	Mus musculus	111-114
10359118-3	1999	ATP4-, but not UTP or GTP, activated a sustained non-selective cation current in voltage-clamped CD4- CD8- and CD4+ CD8+ thymocytes that was reversed by apyrase, which hydrolyzes ATP, and by the P2XR antagonists suramin and pyridoxalphosphate-6-azophenyl-2",4"-disulfonic acid (PPADS).	Suramin	212-219	CD4 antigen	Mus musculus	97-100
10359118-3	1999	ATP4-, but not UTP or GTP, activated a sustained non-selective cation current in voltage-clamped CD4- CD8- and CD4+ CD8+ thymocytes that was reversed by apyrase, which hydrolyzes ATP, and by the P2XR antagonists suramin and pyridoxalphosphate-6-azophenyl-2",4"-disulfonic acid (PPADS).	pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid	224-276	CD4 antigen	Mus musculus	97-100
10340710-3	1999	Short-term administration of diets containing Nisaplin induced an increase of both CD4 and CD8 T-lymphocyte cell counts and also a decrease of B-lymphocyte counts.	Nisaplin	46-54	CD4 antigen	Mus musculus	83-86
10461865-16	1999	The present results show that cyclophosphamide administration to female NOD mice results in a rapid influx of CD4 and CD8 cells and macrophages.	Cyclophosphamide	30-46	CD4 antigen	Mus musculus	110-113
10341316-6	1999	Immunostimulatory effects and isotype switching to IgG1 and IgG2a correlated with the changes in splenic CD4+, CD8+, CD5+ cells, pointing to the regulatory role of these cells and/or their cytokines in PGM-Zn-induced immunostimulation.	Zinc	206-208	CD4 antigen	Mus musculus	105-108
10228035-2	1999	Immune-stimulating complexes (ISCOMS) containing the saponin adjuvant Quil A are potential vaccine vectors that induce a wide range of Ag-specific responses in vivo encompassing both humoral and CD4 and CD8 cell-mediated immune responses.	Saponins	53-60	CD4 antigen	Mus musculus	195-198
10228035-2	1999	Immune-stimulating complexes (ISCOMS) containing the saponin adjuvant Quil A are potential vaccine vectors that induce a wide range of Ag-specific responses in vivo encompassing both humoral and CD4 and CD8 cell-mediated immune responses.	Quil A	70-76	CD4 antigen	Mus musculus	195-198
10219253-9	1999	Upon rechallenge, mice in which EAM was prevented by CD4+ cell depletion developed EAE not EAM.	molibresib	32-35	CD4 antigen	Mus musculus	53-56
10085011-4	1999	We investigated the CD4(+) Th cell response of infected BL/6 mice to egg antigens fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and found a prominent lymphoproliferative response to be directed against a 62-kDa component.	polyacrylamide	121-135	CD4 antigen	Mus musculus	20-23
10363718-4	1999	We demonstrate that two linear peptides (aa 124-138 and 130-143) and a cyclic one (aa 121-138) specifically bind to CD4-sepharose affinity columns.	Sepharose	120-129	CD4 antigen	Mus musculus	116-119
10087179-0	1999	Both CD4(+) T cells and CD8(+) T cells are required for iodine accelerated thyroiditis in NOD mice.	Iodine	56-62	CD4 antigen	Mus musculus	5-8
10219657-0	1999	Regulation of histamine synthesis in mouse CD4+ and CD8+ T lymphocytes.	Histamine	14-23	CD4 antigen	Mus musculus	43-46
10219657-4	1999	RESULTS: Both CD4+ T cells and CD8+ T cells released histamine when treated with Con A as a function of incubation time.	Histamine	53-62	CD4 antigen	Mus musculus	14-17
10219657-10	1999	CONCLUSIONS: These results suggest that GM-CSF and IL-3 enhance histamine synthesis in CD4+ T cells and CD8+ T cells.	Histamine	64-73	CD4 antigen	Mus musculus	87-90
10072535-7	1999	However, tg7 CD4+ T cells that had been primed in vitro with VSV-G peptide were able to adoptively transfer protection against Vacc-IND-G.	vacc-ind	127-135	CD4 antigen	Mus musculus	13-16
10229117-0	1999	Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor.	Acetylcholine	169-182	CD4 antigen	Mus musculus	139-142
10028017-1	1999	The interaction of CD40 on antigen presenting cells (APC) with CD40L on mouse thyroglobulin (MTg)-specific T cells may deliver an essential signal for the development of CD4(+) experimental autoimmune thyroiditis (EAT) effector cells and anti-MTg producing B cells.	(Methylthio)acetic acid	93-96	CD4 antigen	Mus musculus	19-22
9892623-6	1999	In AIM-deficient mice, the thymocyte numbers were diminished to half those in wild-type mice, and CD4/CD8 double-positive (DP) thymocytes were strikingly more susceptible to apoptosis induced by both dexamethasone and irradiation in vivo.	Dexamethasone	200-213	CD4 antigen	Mus musculus	98-101
9989281-4	1999	As the dietary DHA concentration increased, the surface expression of CD4 and CD8 on splenic T cells decreased, while that of CD28 increased.	Docosahexaenoic Acids	15-18	CD4 antigen	Mus musculus	70-73
9989281-7	1999	These observations suggest that diets rich in DHA exert some of their immunomodulatory effects by a downregulation of surface expression of CD4 and CD8 and by an upregulation of CD28-mediated costimulatory signal.	Docosahexaenoic Acids	46-49	CD4 antigen	Mus musculus	140-143
10433086-6	1999	With fractionated CD4 + and CD8 + T cells, we found a cell-specific effect of DFMO on chimeric ETn/fas expression in CD8 + cells.	Eflornithine	78-82	CD4 antigen	Mus musculus	18-21
9884358-0	1999	Linomide induces apoptotic death of cortical CD4/CD8 double positive thymocytes and thymic atrophy by a corticosteroid-independent pathway.	roquinimex	0-8	CD4 antigen	Mus musculus	45-48
9892218-5	1999	In contrast, Fas was expressed on CD4+ T-cells, CD8+ T-cells, and beta-cells in islet grafts from diabetic mice, but it was nearly or totally absent on these cells in islet grafts from normoglycemic mice.	ammonium ferrous sulfate	13-16	CD4 antigen	Mus musculus	34-37
9933118-2	1999	Here we assessed the therapeutic effect of a synthetic mimetic of CD4 designed to mimic both the sequence and conformation of the complementarity-determining region 3 of murine CD4 V1 domain (rD-mPGPtide) in a mouse colitis model using immunization with 2,4,6-trinitrobenzene sulfonic acid (TNB).	reverse D amino acid mouse proline-glycine-proline peptide	192-203	CD4 antigen	Mus musculus	66-69
9933118-2	1999	Here we assessed the therapeutic effect of a synthetic mimetic of CD4 designed to mimic both the sequence and conformation of the complementarity-determining region 3 of murine CD4 V1 domain (rD-mPGPtide) in a mouse colitis model using immunization with 2,4,6-trinitrobenzene sulfonic acid (TNB).	reverse D amino acid mouse proline-glycine-proline peptide	192-203	CD4 antigen	Mus musculus	177-180
9933118-2	1999	Here we assessed the therapeutic effect of a synthetic mimetic of CD4 designed to mimic both the sequence and conformation of the complementarity-determining region 3 of murine CD4 V1 domain (rD-mPGPtide) in a mouse colitis model using immunization with 2,4,6-trinitrobenzene sulfonic acid (TNB).	Trinitrobenzenesulfonic Acid	254-289	CD4 antigen	Mus musculus	66-69
9933118-2	1999	Here we assessed the therapeutic effect of a synthetic mimetic of CD4 designed to mimic both the sequence and conformation of the complementarity-determining region 3 of murine CD4 V1 domain (rD-mPGPtide) in a mouse colitis model using immunization with 2,4,6-trinitrobenzene sulfonic acid (TNB).	Trinitrobenzenesulfonic Acid	291-294	CD4 antigen	Mus musculus	66-69
9925961-8	1999	CONCLUSION: CD4-positive T cells play an important role in the induction of IgE-mediated nasal allergy, occurrence of late-phase allergic inflammation and histamine hypersensitivity, but not in antigen-induced early-phase nasal symptoms in the murine model.	Histamine	155-164	CD4 antigen	Mus musculus	12-15
10455518-0	1999	Estradiol prevents and testosterone promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression.	Estradiol	0-9	CD4 antigen	Mus musculus	72-75
10455518-0	1999	Estradiol prevents and testosterone promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression.	Testosterone	23-35	CD4 antigen	Mus musculus	72-75
10455518-0	1999	Estradiol prevents and testosterone promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression.	ammonium ferrous sulfate	45-48	CD4 antigen	Mus musculus	72-75
10624708-2	1999	In C57/BL6J mice bearing LLC, the weight of the thymus decreased, the proportion of CD4(+)-positive T lymphocytes and the ratio of CD4+ to CD8+ decreased, luminol-enhanced chemiluminescence of white blood cells in peripheral blood stimulated by zymosan increased, and plaque-forming cells (PFC) decreased.	Luminol	155-162	CD4 antigen	Mus musculus	84-87
10370033-6	1999	The ratio of CD8(+) and CD4(+) lymphocytes was significantly higher (P &lt; 0.001) in the control mice compared to the UBTT group (1.3 +/- 0.3 vs 0.5 +/- 0.01).	ubtt	119-123	CD4 antigen	Mus musculus	24-27
10370033-7	1999	The results suggest that UBTT alters the CD8(+)/CD4(+) ratio in the contralateral testis, which may have an important bearing on the pathogenesis of infertility in cases of testicular injury.	ubtt	25-29	CD4 antigen	Mus musculus	48-51
9862682-2	1998	Mice expressing a class II protein carrying the EA137/VA142 double mutation in the CD4 binding domain develop fewer than one-third the number of CD4+ T cells found in wild-type mice.	ea137	48-53	CD4 antigen	Mus musculus	83-86
9862682-2	1998	Mice expressing a class II protein carrying the EA137/VA142 double mutation in the CD4 binding domain develop fewer than one-third the number of CD4+ T cells found in wild-type mice.	ea137	48-53	CD4 antigen	Mus musculus	145-148
9862682-2	1998	Mice expressing a class II protein carrying the EA137/VA142 double mutation in the CD4 binding domain develop fewer than one-third the number of CD4+ T cells found in wild-type mice.	va142	54-59	CD4 antigen	Mus musculus	83-86
9862682-2	1998	Mice expressing a class II protein carrying the EA137/VA142 double mutation in the CD4 binding domain develop fewer than one-third the number of CD4+ T cells found in wild-type mice.	va142	54-59	CD4 antigen	Mus musculus	145-148
9862682-7	1998	Nevertheless, CD4+ T cells from EA137/VA142 class II mutant mice can respond to T-dependent Ags and support Ig isotype switching.	Silver	92-95	CD4 antigen	Mus musculus	14-17
9878110-1	1998	Aging diminishes the amount of phosphotyrosine in the CD3zeta chains of resting and activated mouse CD4 T cells by about threefold and might therefore be expected to a corresponding decline in Zap-70 association with CD3zeta and in Zap-70 kinase function in CD3zeta complexes.	Phosphotyrosine	31-46	CD4 antigen	Mus musculus	100-103
9878110-9	1998	The increase with age in CD3zeta-Zap association, despite the loss with age in CD3zeta tyrosine phosphorylation, suggests that the pattern of tyrosine phosphate groups among CD3zeta ITAM groups may be different in T cells from young and old donors or that access to ITAM regions within CD3zeta may be blocked by inter- or intramolecular steric hindrance in young CD4 T cells.	Phosphotyrosine	142-160	CD4 antigen	Mus musculus	363-366
9881968-5	1998	Activation of the Notch signaling pathway also upregulated a number of other markers that, like steroid resistance, correlate with DP maturation into both the CD4 and CD8 lineages.	Steroids	96-103	CD4 antigen	Mus musculus	159-162
9881968-5	1998	Activation of the Notch signaling pathway also upregulated a number of other markers that, like steroid resistance, correlate with DP maturation into both the CD4 and CD8 lineages.	dp	131-133	CD4 antigen	Mus musculus	159-162
9885906-10	1998	Similar cytokine profiles were obtained when the CD4+ T cells were stimulated by Leishmania major-antigen instead of PMA/ionomycin.	Tetradecanoylphorbol Acetate	117-120	CD4 antigen	Mus musculus	49-52
9885906-10	1998	Similar cytokine profiles were obtained when the CD4+ T cells were stimulated by Leishmania major-antigen instead of PMA/ionomycin.	Ionomycin	121-130	CD4 antigen	Mus musculus	49-52
9848396-8	1998	The exposure of thymocytes to HCA or BCA for 48 h accelerated T-cell differentiation from CD4 and CD8 double positive cells to CD4 or CD8 single positive cells.	2'-benzoxycinnamaldehyde	37-40	CD4 antigen	Mus musculus	90-93
9848396-8	1998	The exposure of thymocytes to HCA or BCA for 48 h accelerated T-cell differentiation from CD4 and CD8 double positive cells to CD4 or CD8 single positive cells.	2'-benzoxycinnamaldehyde	37-40	CD4 antigen	Mus musculus	127-130
9806067-5	1998	Interventions known to prevent fatal outcome from ECM, such as splenectomy or treatment with anti-CD4 or anti-CD8 monoclonal antibodies, also prevented sensitivity to folic acid-induced convulsions.	Folic Acid	167-177	CD4 antigen	Mus musculus	98-101
9711803-3	1998	Functional depletion of CD4+ and CD8+ and IFN gamma was obtained in vivo by intraperitoneal injection of alginate-encapsulated anti-CD4, -CD8 or -IFN gamma producing hybridoma"s before and at the moment of vaccination.	Alginates	105-113	CD4 antigen	Mus musculus	24-27
9711803-3	1998	Functional depletion of CD4+ and CD8+ and IFN gamma was obtained in vivo by intraperitoneal injection of alginate-encapsulated anti-CD4, -CD8 or -IFN gamma producing hybridoma"s before and at the moment of vaccination.	Alginates	105-113	CD4 antigen	Mus musculus	132-135
9733785-5	1998	We expressed a secreted form of the ectoapyrase in COS-7 cells by fusing the signal peptide of murine CD4 with the extracellular domain of the ectoapyrase.	carbonyl sulfide	51-54	CD4 antigen	Mus musculus	102-105
9737667-3	1998	Buccal sensitization with DNFB elicited a specific contact sensitivity (CS) in response to skin challenge, mediated by class I-restricted CD8+ effector T cells and down-regulated by class II-restricted CD4+ T cells, demonstrated by the lack of priming of class I-deficient mice and the enhanced response of class II-deficient mice, respectively.	Dinitrofluorobenzene	26-30	CD4 antigen	Mus musculus	202-205
9754575-6	1998	Surprisingly, CD4-/- mice, but not MHC class II-/- mice, had significantly reduced numbers of TNC and ROS, in particular, a severe defect in ROS formation with thymic dendritic cells.	ros	102-105	CD4 antigen	Mus musculus	14-17
9754575-6	1998	Surprisingly, CD4-/- mice, but not MHC class II-/- mice, had significantly reduced numbers of TNC and ROS, in particular, a severe defect in ROS formation with thymic dendritic cells.	ros	141-144	CD4 antigen	Mus musculus	14-17
9703223-0	1998	Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action.	Dextran Sulfate	50-72	CD4 antigen	Mus musculus	15-18
9703223-10	1998	The results suggest that CD4+ T cells play an important role in the development of DSS-induced experimental colitis and that IgG may modulate the development of colitis through interaction with pathogenic T cells.	Dextran Sulfate	83-86	CD4 antigen	Mus musculus	25-28
9786433-8	1998	While a low concentration of MCC peptide (0.01-0.1 microM) significantly enhanced the accumulation of CD4 SP cells, higher concentrations of peptide (1-10 microM) resulted in recovery of predominantly CD4- CD8- and CD4(low) CD8- cells.	mcc peptide	29-40	CD4 antigen	Mus musculus	102-105
9707604-0	1998	Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking.	ammonium ferrous sulfate	0-3	CD4 antigen	Mus musculus	35-38
9686595-5	1998	Cell lines and clones established from unirradiated and UV-irradiated, FITC-sensitized mice were CD4+, CD8-, TCR-alpha/beta+, MHC restricted, and hapten specific.	Fluorescein-5-isothiocyanate	71-75	CD4 antigen	Mus musculus	97-100
9707661-7	1998	The UV- and gamma-irradiated groups showed a significant elevation in CD4+ T-cells when compared with control group throughout the time of experiment, whereas, PZQ-treated group showed a significant increase at the 2nd and 4th week P.I.	(R)-(-)-Praziquantel	160-163	CD4 antigen	Mus musculus	70-73
9692880-4	1998	Possession of a Valpha chain which is inefficiently positively selected appears to increase the likelihood that a second Valpha chain will be co-expressed, whilst the relative cell surface levels of a given pair of Valpha chains differ between CD4 and CD8 subsets.	valpha	16-22	CD4 antigen	Mus musculus	244-247
9634475-8	1998	In particular, a GATA/c-Ets motive was identified in a short segment homologous to the mouse CD4 distal enhancer, suggesting that LAG-3, which is embedded in the CD4 locus, may be controlled by some CD4 regulatory elements.	gata	17-21	CD4 antigen	Mus musculus	93-96
9634475-8	1998	In particular, a GATA/c-Ets motive was identified in a short segment homologous to the mouse CD4 distal enhancer, suggesting that LAG-3, which is embedded in the CD4 locus, may be controlled by some CD4 regulatory elements.	gata	17-21	CD4 antigen	Mus musculus	162-165
9634475-8	1998	In particular, a GATA/c-Ets motive was identified in a short segment homologous to the mouse CD4 distal enhancer, suggesting that LAG-3, which is embedded in the CD4 locus, may be controlled by some CD4 regulatory elements.	gata	17-21	CD4 antigen	Mus musculus	162-165
9634475-8	1998	In particular, a GATA/c-Ets motive was identified in a short segment homologous to the mouse CD4 distal enhancer, suggesting that LAG-3, which is embedded in the CD4 locus, may be controlled by some CD4 regulatory elements.	Carbon	8-9	CD4 antigen	Mus musculus	93-96
9634475-8	1998	In particular, a GATA/c-Ets motive was identified in a short segment homologous to the mouse CD4 distal enhancer, suggesting that LAG-3, which is embedded in the CD4 locus, may be controlled by some CD4 regulatory elements.	Carbon	8-9	CD4 antigen	Mus musculus	162-165
9634475-8	1998	In particular, a GATA/c-Ets motive was identified in a short segment homologous to the mouse CD4 distal enhancer, suggesting that LAG-3, which is embedded in the CD4 locus, may be controlled by some CD4 regulatory elements.	Carbon	8-9	CD4 antigen	Mus musculus	162-165
9647252-1	1998	The efficacy of a synthetic peptide analogue (rD-mPGPtide), mimicking the CDR3 region in the first domain of the CD4 surface molecule, was investigated in a murine model for CD4+ T cell-mediated skin allograft rejection.	reverse D amino acid mouse proline-glycine-proline peptide	46-57	CD4 antigen	Mus musculus	113-116
9647252-1	1998	The efficacy of a synthetic peptide analogue (rD-mPGPtide), mimicking the CDR3 region in the first domain of the CD4 surface molecule, was investigated in a murine model for CD4+ T cell-mediated skin allograft rejection.	reverse D amino acid mouse proline-glycine-proline peptide	46-57	CD4 antigen	Mus musculus	174-177
9616158-11	1998	In contrast, recipients that had received CD4-depleted BMCs with CY plus fractionated irradiation (5Gy x 2) survived for more than 40 weeks without showing graft-versus-host reaction (GVHR).	S-benzyl-N-malonylcysteine	55-59	CD4 antigen	Mus musculus	42-45
9616158-11	1998	In contrast, recipients that had received CD4-depleted BMCs with CY plus fractionated irradiation (5Gy x 2) survived for more than 40 weeks without showing graft-versus-host reaction (GVHR).	Cyclophosphamide	65-67	CD4 antigen	Mus musculus	42-45
9603915-2	1998	Here, we examined and compared the disulfide linkage status of newly synthesized TCR proteins in murine CD4(+)CD8(+) thymocytes and splenic T cells.	Disulfides	35-44	CD4 antigen	Mus musculus	104-107
9603915-3	1998	These studies demonstrate that CD3delta proteins exist as both monomeric and oligomeric (disulfide-linked) species that differentially assemble with CD3epsilon subunits in CD4(+)CD8(+) thymocytes and splenic T cells.	Disulfides	89-98	CD4 antigen	Mus musculus	172-175
9649213-4	1998	CD4+ T cells infiltrating the colonic lamina propria of diseased SCID mice displayed the surface phenotype of mucosa-seeking memory/effector cells, expressed interferon-gamma (IFN-gamma), and lysed targets in a Fas (CD95)/FasL-dependent pathway.	ammonium ferrous sulfate	211-214	CD4 antigen	Mus musculus	0-3
9645355-0	1998	Chimeric CD4/CD44 molecules associate with CD44 via the transmembrane region and reduce hyaluronan binding in T cell lines.	Hyaluronic Acid	88-98	CD4 antigen	Mus musculus	9-12
9645355-7	1998	In addition, the association of chimeric CD4/CD44 molecules with endogenous CD44 correlated with reduced hyaluronan binding.	Hyaluronic Acid	105-115	CD4 antigen	Mus musculus	41-44
9652304-2	1998	Chronic exposure of mice to contact allergens, such as 2,4-dinitrochlorobenzene (DNCB), resulted in the secretion by LNC of low or undetectable levels of interleukins 4 and 10 (IL-4 and IL-10), but comparatively high levels of interferon gamma (IFN-gamma); the latter cytokine being produced by both CD4+ and CD8+ cells.	Dinitrochlorobenzene	55-79	CD4 antigen	Mus musculus	300-303
9652304-2	1998	Chronic exposure of mice to contact allergens, such as 2,4-dinitrochlorobenzene (DNCB), resulted in the secretion by LNC of low or undetectable levels of interleukins 4 and 10 (IL-4 and IL-10), but comparatively high levels of interferon gamma (IFN-gamma); the latter cytokine being produced by both CD4+ and CD8+ cells.	Dinitrochlorobenzene	81-85	CD4 antigen	Mus musculus	300-303
9652304-12	1998	Moreover, it is clear that exposure to TMA initially induces the production of IFN-gamma by both CD4+ and CD8+ cells, whereas after more chronic treatment the secretion of this cytokine is a function of CD8+ cells exclusively.	trimellitic anhydride	39-42	CD4 antigen	Mus musculus	97-100
9652309-0	1998	Role of CD4+ and CD8+ T cells in regulating the chronic development of liver injury induced by delayed-type hypersensitivity to picryl chloride.	Picryl Chloride	128-143	CD4 antigen	Mus musculus	8-11
9682964-2	1998	In the accompanying paper, the resistance to infections with HSV type 1 (HSV-1) and Candida albicans was improved in thermally injured mice treated with benzoylmesaconine (BEN), an aconitine-hydrolysate isolated from heated Aconiti tuber, or inoculated with splenic CD4+ T cells from BEN-treated mice (BEN T cells).	benzoylmesaconine	153-170	CD4 antigen	Mus musculus	266-269
9600964-7	1998	Chronic morphine administration induced lymphoid organ atrophy, diminished the ratio of CD4(+)CD8(+) cells in the thymus and strongly reduced natural killer activity in wild-type mice.	Morphine	8-16	CD4 antigen	Mus musculus	88-91
9622447-4	1998	We find that mice administered alcohol in drinking water and then inoculated with P. carinii show significantly decreased recruitment of CD4+ and CD8+ T lymphocytes into lung tissue in comparison with control mice.	Alcohols	31-38	CD4 antigen	Mus musculus	137-140
9622447-4	1998	We find that mice administered alcohol in drinking water and then inoculated with P. carinii show significantly decreased recruitment of CD4+ and CD8+ T lymphocytes into lung tissue in comparison with control mice.	Drinking Water	42-56	CD4 antigen	Mus musculus	137-140
9574568-6	1998	In separate experiments, the selective inhibition of MCP-1 synthesis by lung fibroblasts and splenic macrophages using an MCP-1 antisense oligonucleotide significantly enhanced the proliferation of CD4+ T cells during a 96-h coculture.	Oligonucleotides	138-153	CD4 antigen	Mus musculus	198-201
9630460-4	1998	Interestingly, in thymocytes from mice treated with a single dose of 50 micrograms/kg body wt of TCDD, there was a significant increase in the density of expression of CD3, alpha beta TCR, CD44, and IL-2R, and a decrease in the expression of J11d, CD4, and CD8 molecules when compared to the control thymocytes.	Polychlorinated Dibenzodioxins	97-101	CD4 antigen	Mus musculus	189-192
9558079-8	1998	However, low avidity engagement of the TCR on Fas-sensitive CD4+CD8+ thymocytes before GD 17 induced resistance to Fas-mediated apoptosis.	ammonium ferrous sulfate	46-49	CD4 antigen	Mus musculus	60-63
9558079-8	1998	However, low avidity engagement of the TCR on Fas-sensitive CD4+CD8+ thymocytes before GD 17 induced resistance to Fas-mediated apoptosis.	ammonium ferrous sulfate	115-118	CD4 antigen	Mus musculus	60-63
9558120-6	1998	In sensitized thymidine kinase-transgenic mice, a significant decrease in the number of bronchoalveolar CD4 and CD8 T lymphocytes and B lymphocytes was seen after ganciclovir treatment.	Ganciclovir	163-174	CD4 antigen	Mus musculus	104-107
9539765-4	1998	We demonstrate that the mutation, EA137 and VA142 in the beta2 domain of I-Ab, is sufficient to disrupt CD4-MHC class II interactions in vivo.	ea137	34-39	CD4 antigen	Mus musculus	104-107
9539765-4	1998	We demonstrate that the mutation, EA137 and VA142 in the beta2 domain of I-Ab, is sufficient to disrupt CD4-MHC class II interactions in vivo.	va142	44-49	CD4 antigen	Mus musculus	104-107
9539772-2	1998	Although the mechanisms involved in TCV-mediated protection are not completely known, there is some evidence that TCV induces CD8(+) regulatory T cells that are specific for pathogenic CD4(+) T cells.	TCVS	114-117	CD4 antigen	Mus musculus	185-188
9539772-5	1998	We now show that similar Vbeta8-specific Qa-1-restricted CD8(+) T cells are also induced by TCV with activated CD4(+) Vbeta8(+) T cells.	TCVS	92-95	CD4 antigen	Mus musculus	111-114
9566798-4	1998	In fact, rapamycin and FK-506 block both alphabeta+, CD4+ and gammadelta+ T lymphocytes, while CsA inhibits only the alphabeta+, CD4+ T lymphocyte.	Sirolimus	9-18	CD4 antigen	Mus musculus	53-56
9566798-4	1998	In fact, rapamycin and FK-506 block both alphabeta+, CD4+ and gammadelta+ T lymphocytes, while CsA inhibits only the alphabeta+, CD4+ T lymphocyte.	Tacrolimus	23-29	CD4 antigen	Mus musculus	53-56
9566798-4	1998	In fact, rapamycin and FK-506 block both alphabeta+, CD4+ and gammadelta+ T lymphocytes, while CsA inhibits only the alphabeta+, CD4+ T lymphocyte.	Cyclosporine	95-98	CD4 antigen	Mus musculus	129-132
9529058-1	1998	We have shown previously that intravenous injection of Candida albicans mannan (MAN) into naive mice induced CD8+ effector downregulatory cells and that such cells were not produced if mice were deficient in CD4+ or I-A+ cells during the early interval (&lt; or =30 h) following the introduction of MAN.	Mannans	72-78	CD4 antigen	Mus musculus	208-211
9529058-1	1998	We have shown previously that intravenous injection of Candida albicans mannan (MAN) into naive mice induced CD8+ effector downregulatory cells and that such cells were not produced if mice were deficient in CD4+ or I-A+ cells during the early interval (&lt; or =30 h) following the introduction of MAN.	Mannans	80-83	CD4 antigen	Mus musculus	208-211
9620597-1	1998	This paper investigates the mechanisms responsible for the generation of IL-4-producing CD4+ T cells during contact sensitization with the hapten trinitrochlorobenzene (TNCB).	Picryl Chloride	146-167	CD4 antigen	Mus musculus	88-91
9620597-1	1998	This paper investigates the mechanisms responsible for the generation of IL-4-producing CD4+ T cells during contact sensitization with the hapten trinitrochlorobenzene (TNCB).	Picryl Chloride	169-173	CD4 antigen	Mus musculus	88-91
9579368-0	1998	Cyclophosphamide given after active specific immunization augments antitumor immunity by modulation of Th1 commitment of CD4+ T cells.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	121-124
9579368-5	1998	In early stage (day 0) after ASI-CPA treatment, the CD4+ T cells were determined to play an important role in the protective immunity for the following reasons: 1) the CD4+/CD8+ ratio of spleen cells from immunized mice was higher than that of the control or CPA alone treated group; and 2) the tumor neutralizing activity of fresh spleen cells was abrogated by CD4+ T-cell depletion in vitro.	asi-cpa	29-36	CD4 antigen	Mus musculus	52-55
9579368-5	1998	In early stage (day 0) after ASI-CPA treatment, the CD4+ T cells were determined to play an important role in the protective immunity for the following reasons: 1) the CD4+/CD8+ ratio of spleen cells from immunized mice was higher than that of the control or CPA alone treated group; and 2) the tumor neutralizing activity of fresh spleen cells was abrogated by CD4+ T-cell depletion in vitro.	asi-cpa	29-36	CD4 antigen	Mus musculus	168-171
9579368-5	1998	In early stage (day 0) after ASI-CPA treatment, the CD4+ T cells were determined to play an important role in the protective immunity for the following reasons: 1) the CD4+/CD8+ ratio of spleen cells from immunized mice was higher than that of the control or CPA alone treated group; and 2) the tumor neutralizing activity of fresh spleen cells was abrogated by CD4+ T-cell depletion in vitro.	asi-cpa	29-36	CD4 antigen	Mus musculus	168-171
9579368-5	1998	In early stage (day 0) after ASI-CPA treatment, the CD4+ T cells were determined to play an important role in the protective immunity for the following reasons: 1) the CD4+/CD8+ ratio of spleen cells from immunized mice was higher than that of the control or CPA alone treated group; and 2) the tumor neutralizing activity of fresh spleen cells was abrogated by CD4+ T-cell depletion in vitro.	Cyclophosphamide	33-36	CD4 antigen	Mus musculus	52-55
9579368-6	1998	CD4+ T cells of mice treated with ASI-CPA produced more interferon (IFN)-gamma and IL-2 and less IL-4 than those of the ASI alone group.	asi-cpa	34-41	CD4 antigen	Mus musculus	0-3
9579368-6	1998	CD4+ T cells of mice treated with ASI-CPA produced more interferon (IFN)-gamma and IL-2 and less IL-4 than those of the ASI alone group.	asi	34-37	CD4 antigen	Mus musculus	0-3
9506537-13	1998	As revealed by LAKC recovered from the SCID mice, the efficacy of the bAB was based on prolonged persistence of CD8-positive cells as well as on expansion and activation of CD4-positive cells, which was observed only in bAB-treated tumour-bearing mice.	bab	70-73	CD4 antigen	Mus musculus	173-176
9510174-0	1998	CD4+, but not CD8+, T cells from mammary tumor-bearing mice have a down-regulated production of IFN-gamma: role of phosphatidyl serine.	Phosphatidylserines	115-134	CD4 antigen	Mus musculus	0-3
9510174-4	1998	Pretreatment with granulocyte-macrophage CSF resulted in increased IFN-gamma levels by T cells, while PGE2 pretreatment equally decreased the levels of this cytokine in CD4+ and CD8+ T cells from normal mice.	Dinoprostone	102-106	CD4 antigen	Mus musculus	169-172
9510174-5	1998	Interestingly, phosphatidyl serine (PS) down-regulated the IFN-gamma production of CD4+, but not that of CD8+, T cells.	Phosphatidylserines	15-34	CD4 antigen	Mus musculus	83-86
9510174-5	1998	Interestingly, phosphatidyl serine (PS) down-regulated the IFN-gamma production of CD4+, but not that of CD8+, T cells.	Phosphatidylserines	36-38	CD4 antigen	Mus musculus	83-86
9510174-6	1998	Methylation analysis indicated that the CpG dinucleotide in SnaBI site of the IFN-gamma 5" promoter flank region was hypermethylated in CD4+, but not in CD8+, T cells of large tumor bearers and of normal mice pretreated with PS.	cytidylyl-3'-5'-guanosine	40-56	CD4 antigen	Mus musculus	136-139
9510174-6	1998	Methylation analysis indicated that the CpG dinucleotide in SnaBI site of the IFN-gamma 5" promoter flank region was hypermethylated in CD4+, but not in CD8+, T cells of large tumor bearers and of normal mice pretreated with PS.	Phosphatidylserines	225-227	CD4 antigen	Mus musculus	136-139
9510174-7	1998	Electrophoresis mobility shift assay using an oligonucleotide probe corresponding to the IFN-gamma promoter core region sequence showed a greatly reduced binding of a 90-kDa nuclear protein in CD4+ T cells from tumor bearers and in those from PS-pretreated normal mice.	Oligonucleotides	46-61	CD4 antigen	Mus musculus	193-196
9570859-4	1998	Flow cytometry of splenic T-lymphocyte subsets in normal mice indicates a significant decrease in the number of CD3+, CD4+, and CD8+ subsets after treatment with cyclophosphamide and after application of restraint stress; the interaction of the two treatments is significant for CD3+ and marginally significant for CD4+ subsets.	Cyclophosphamide	162-178	CD4 antigen	Mus musculus	118-121
9570859-4	1998	Flow cytometry of splenic T-lymphocyte subsets in normal mice indicates a significant decrease in the number of CD3+, CD4+, and CD8+ subsets after treatment with cyclophosphamide and after application of restraint stress; the interaction of the two treatments is significant for CD3+ and marginally significant for CD4+ subsets.	Cyclophosphamide	162-178	CD4 antigen	Mus musculus	315-318
9543703-12	1998	In conclusion, we have found that Milife can stimulate leuko- and lymphopoesis in BLRB mice, in particular, accumulation of CD4+ T cells in peripheral lymphoid organs.	milife	34-40	CD4 antigen	Mus musculus	124-127
9557948-5	1998	For this purpose, we compare the effects of PMA alone or combined with PGE2 on CD3, CD4 and CD8 expression on mouse thymocytes by flow-cytometric analysis.	Dinoprostone	71-75	CD4 antigen	Mus musculus	84-87
9557948-8	1998	Combined with PMA, PGE2 can overcome the decrease induced by PMA of the CD3 expression and partially reduced the disappearance of the CD4 molecule.	Tetradecanoylphorbol Acetate	14-17	CD4 antigen	Mus musculus	134-137
9557948-8	1998	Combined with PMA, PGE2 can overcome the decrease induced by PMA of the CD3 expression and partially reduced the disappearance of the CD4 molecule.	Dinoprostone	19-23	CD4 antigen	Mus musculus	134-137
9557951-0	1998	Signalling initiated with CD4-TCR or TCR-TCR interactions: comparison of tyrosine phosphorylation patterns and CD45 effects.	Tyrosine	73-81	CD4 antigen	Mus musculus	26-29
9576593-5	1998	One month after implantation, the mean fluorescence intensity of CD4, CD8 or Smig, in the peripheral blood lymphocytes (PBL) of the nickel alloy-implanted animals, was significantly higher than that prior to this procedure.	Nickel	132-138	CD4 antigen	Mus musculus	65-68
18726275-5	1998	Phenotype analysis showed that MTSC4 induced the deletion of CD4 + CD8 + cells and CD4 + CD8-.cells in 18 h of coculture.	mtsc4	31-36	CD4 antigen	Mus musculus	61-64
18726275-5	1998	Phenotype analysis showed that MTSC4 induced the deletion of CD4 + CD8 + cells and CD4 + CD8-.cells in 18 h of coculture.	mtsc4	31-36	CD4 antigen	Mus musculus	83-86
9507739-7	1998	Furthermore, administration of cyclosporine and anti-CD8 monoclonal antibodies to II-4+ recipients prolonged xenograft survival to at least the same extent as allograft survival, demonstrating that the strength of cell-mediated xenograft rejection resides in the CD4+ indirect response.	Cyclosporine	31-43	CD4 antigen	Mus musculus	263-266
9551905-5	1998	Surprisingly, when rat and mouse CD4+8+ thymocytes were stimulated with PMA/ionomycin under identical conditions, the opposite lineage commitment was observed, i.e., mouse thymocytes responded with the generation of CD4+8- and rat thymocytes with the generation of CD4-8+ cells.	Ionomycin	76-85	CD4 antigen	Mus musculus	33-36
9551905-5	1998	Surprisingly, when rat and mouse CD4+8+ thymocytes were stimulated with PMA/ionomycin under identical conditions, the opposite lineage commitment was observed, i.e., mouse thymocytes responded with the generation of CD4+8- and rat thymocytes with the generation of CD4-8+ cells.	Ionomycin	76-85	CD4 antigen	Mus musculus	216-219
9419364-3	1998	We have generated an altered peptide (Q144) from an autoantigenic peptide of myelin proteolipid protein 139-151 by a single amino acid substitution (from tryptophan to glutamine) in the primary TCR contact at position 144 that is capable of inducing CD4(+) T cell responses in H-2(s) mice.	Tryptophan	154-164	CD4 antigen	Mus musculus	250-253
9782318-3	1998	Single positive (SP) CD4+ or CD8+ cells strongly increased in the liver.	sp	17-19	CD4 antigen	Mus musculus	21-24
9950097-8	1998	The spleen cells of the ASI-CY treated mice responded to SS in vitro in the presence of IL-2, more profoundly in CD4 enriched population which produced high amount of TNF-alpha.	asi-cy	24-30	CD4 antigen	Mus musculus	113-116
9950097-10	1998	These results suggest that antitumor activity by ASI and CY is transduced by sequential population shift from CD4 alone to both of CD4 and CD8.	asi	49-52	CD4 antigen	Mus musculus	110-113
9950097-10	1998	These results suggest that antitumor activity by ASI and CY is transduced by sequential population shift from CD4 alone to both of CD4 and CD8.	asi	49-52	CD4 antigen	Mus musculus	131-134
9950097-10	1998	These results suggest that antitumor activity by ASI and CY is transduced by sequential population shift from CD4 alone to both of CD4 and CD8.	Cyclophosphamide	57-59	CD4 antigen	Mus musculus	110-113
9950097-10	1998	These results suggest that antitumor activity by ASI and CY is transduced by sequential population shift from CD4 alone to both of CD4 and CD8.	Cyclophosphamide	57-59	CD4 antigen	Mus musculus	131-134
9434804-3	1998	Previously, we showed that rD-mPGPtide, a structure-base designed peptide analog of the CDR3-like region of domain 1 of the murine CD4 molecule, suppressed the development of GVHD in a MHC-haploidentical murine BMT model when administered early in the course of disease.	reverse D amino acid mouse proline-glycine-proline peptide	27-38	CD4 antigen	Mus musculus	131-134
9434804-8	1998	Therefore, the use of a CD4-CDR3 peptide can complement and potentiate the immunosuppressive effects of CsA in the prevention of GVHD following allogeneic BMT.	Cyclosporine	104-107	CD4 antigen	Mus musculus	24-27
9607025-4	1998	The protection was impaired by treatment of the mice with either anti-CD4, anti-CD8 IgG, anti asialo GM1 antiserum or dextrane sulfate, which deplete the CD4+, CD8+ and NK cells or the macrophages, respectively.	G(M1) Ganglioside	101-104	CD4 antigen	Mus musculus	154-157
9607025-4	1998	The protection was impaired by treatment of the mice with either anti-CD4, anti-CD8 IgG, anti asialo GM1 antiserum or dextrane sulfate, which deplete the CD4+, CD8+ and NK cells or the macrophages, respectively.	dextrane sulfate	118-134	CD4 antigen	Mus musculus	154-157
9403722-7	1997	In the peripheral blood, both CD4 and CD8 T-cell subsets showed an initial increase in P-selectin ligand expression after I.T.-SRBC challenge.	srbc	127-131	CD4 antigen	Mus musculus	30-33
9398598-3	1997	Here, we report that a transfected Chinese hamster ovary (CHO) cell line expressing a murine CD4 fragment containing the first two N-terminal domains secretes both monomeric molecules and disulfide-linked multimers.	Disulfides	188-197	CD4 antigen	Mus musculus	93-96
9366440-5	1997	In addition, a switch from Th1 to Th0 subtype was observed in proliferating CD4+ T cells derived from chronic ethanol-fed mice.	Ethanol	110-117	CD4 antigen	Mus musculus	76-79
9366440-8	1997	Coimmunization of chronic ethanol-fed mice with either IL-2 or GM-CSF expression plasmids restored cellular immunity and induced CD4+ inflammatory T cell and CD8+ CTL responses comparable with control mice immunized with pHCV2-2 alone.	Ethanol	26-33	CD4 antigen	Mus musculus	129-132
9371682-3	1997	RESULTS: Dexamethasone injection in mice reduced the number of CD4+CD8+ thymocytes by increasing DNA fragmentation.	Dexamethasone	9-22	CD4 antigen	Mus musculus	63-66
9669211-6	1997	In vitro studies on spleen cell composition showed that halothane re-exposure diminished the number of CD4+, CD8+ and B-cells.	Halothane	56-65	CD4 antigen	Mus musculus	103-106
9393631-0	1997	Linomide enhances apoptosis in CD4+CD8+ thymocytes.	roquinimex	0-8	CD4 antigen	Mus musculus	31-34
9393631-8	1997	In addition to this, and supporting a glucocorticoid independent mode of action, Linomide treatment of thymocytes in vitro resulted in a significant increase in the number of apoptotic cells, specifically in the CD4+CD8+ subset, implicating apopotosis as one component in the course of thymocyte reduction.	roquinimex	81-89	CD4 antigen	Mus musculus	212-215
9393631-9	1997	In addition to this, in vivo treatment with Linomide resulted in an identical pattern to that seen in vitro in that there was significantly increased apoptosis only in the CD4+CD8+.	roquinimex	44-52	CD4 antigen	Mus musculus	172-175
9393631-10	1997	These data indicate that Linomide modifies thymocyte development using a glucocorticoid independent pathway and results in the increased apoptosis of the CD4+CD8+ subset.	roquinimex	25-33	CD4 antigen	Mus musculus	154-157
9378954-0	1997	CD4+ Th2 cells specific for mycobacterial 65-kilodalton heat shock protein protect against pristane-induced arthritis.	pristane	91-99	CD4 antigen	Mus musculus	0-3
9326394-2	1997	To address this issue, a novel CD45+/major histocompatibility complex class I+ (H-2k)/II-/CD80+ dendritic cell line, termed 80/1, which is capable of stimulating naive, allogeneic CD8+ but not CD4+ T cells in vitro, was derivatized with trinitrobenzenesulfonic acid and co-cultured for 4 d with syngeneic, naive CD8+ T cells.	Trinitrobenzenesulfonic Acid	237-265	CD4 antigen	Mus musculus	31-34
9503420-11	1997	Improvement of the changes of CD4+ and CD8+ T cells in the spleen by dulcitol may suggest its modulatory effect on cellular immunity.	Galactitol	69-77	CD4 antigen	Mus musculus	30-33
9281578-8	1997	Phenotyping experiments illustrate that both immature (CD4-CD8-, CD4+CD8+) and mature (CD4+CD8-, CD4-CD8+) thymocyte populations respond to ATP.	Adenosine Triphosphate	140-143	CD4 antigen	Mus musculus	55-58
9281578-8	1997	Phenotyping experiments illustrate that both immature (CD4-CD8-, CD4+CD8+) and mature (CD4+CD8-, CD4-CD8+) thymocyte populations respond to ATP.	Adenosine Triphosphate	140-143	CD4 antigen	Mus musculus	65-68
9281578-8	1997	Phenotyping experiments illustrate that both immature (CD4-CD8-, CD4+CD8+) and mature (CD4+CD8-, CD4-CD8+) thymocyte populations respond to ATP.	Adenosine Triphosphate	140-143	CD4 antigen	Mus musculus	65-68
9281578-8	1997	Phenotyping experiments illustrate that both immature (CD4-CD8-, CD4+CD8+) and mature (CD4+CD8-, CD4-CD8+) thymocyte populations respond to ATP.	Adenosine Triphosphate	140-143	CD4 antigen	Mus musculus	65-68
9341751-4	1997	We show that selection of CD4 T cell lineage cells in mice deficient for MHC class I and MHC class II expression can be reconstituted in vivo by two separable T cell receptor signaling steps, whereas a single TCR signal leads only to induction of short-lived CD4+CD8lo intermediates.	cd8lo	263-268	CD4 antigen	Mus musculus	26-29
9278315-2	1997	Multicolor FACS analysis of T cells from 8-wk-old mice receiving bromodeoxyuridine (BrdUrd) for 9 days showed that higher proportions of CD4+ and CD8+ lymph node cells were dividing (BrdUrd(high)) in lpr (15%) than in +/+ mice (3%), and the proportion of cycling cells was even higher in the DN (71%) and CD4+ B220+ (54%) lpr subsets.	Bromodeoxyuridine	65-82	CD4 antigen	Mus musculus	137-140
9278315-2	1997	Multicolor FACS analysis of T cells from 8-wk-old mice receiving bromodeoxyuridine (BrdUrd) for 9 days showed that higher proportions of CD4+ and CD8+ lymph node cells were dividing (BrdUrd(high)) in lpr (15%) than in +/+ mice (3%), and the proportion of cycling cells was even higher in the DN (71%) and CD4+ B220+ (54%) lpr subsets.	Bromodeoxyuridine	65-82	CD4 antigen	Mus musculus	305-308
9285387-7	1997	The percentage of intraepithelial lymphocytes expressing TCR alpha beta, CD4, CD5, and CD54, as well as the levels of expression of these antigens, increased after spermine treatment on day 12, similarly to natural maturation.	Spermine	164-172	CD4 antigen	Mus musculus	73-76
9261398-6	1997	These data explain the previous finding that the murine CD4 protein, which has an alanine at residue 405, is refractory to downregulation by SIV, but not HIV-1, Nef (J. L. Foster, S.J.	Alanine	82-89	CD4 antigen	Mus musculus	56-59
9299591-7	1997	In mice treated with the allergen trinitrochlorobenzene an increase in the percentage of CD4+ cells expressing CD62LloCD44(hi) was observed compared to cells isolated from mice treated with the irritant benzalkonium chloride or vehicle treated mice.	Picryl Chloride	34-55	CD4 antigen	Mus musculus	89-92
9299591-7	1997	In mice treated with the allergen trinitrochlorobenzene an increase in the percentage of CD4+ cells expressing CD62LloCD44(hi) was observed compared to cells isolated from mice treated with the irritant benzalkonium chloride or vehicle treated mice.	Benzalkonium Compounds	203-224	CD4 antigen	Mus musculus	89-92
9299591-8	1997	Mice treated with dintrochlorobenzene had an increase in the percentage of CD4+ cells expressing CD62LloCD44(hi) that was dose dependent and peaked at 72 hr following the final allergen treatment.	dintrochlorobenzene	18-37	CD4 antigen	Mus musculus	75-78
9299591-10	1997	Increases in the percentage of CD4+ and CD8+ cells expressing CD62LloCD44(hi) were observed with other allergens including oxazolone and alpha-hexylcinnamaldehyde, but not the irritant sodium lauryl sulfate.	Oxazolone	123-132	CD4 antigen	Mus musculus	31-34
9299591-10	1997	Increases in the percentage of CD4+ and CD8+ cells expressing CD62LloCD44(hi) were observed with other allergens including oxazolone and alpha-hexylcinnamaldehyde, but not the irritant sodium lauryl sulfate.	alpha-hexylcinnamaldehyde	137-162	CD4 antigen	Mus musculus	31-34
9295025-4	1997	In vitro acridine orange staining indicated that most of the rapidly accumulating memory phenotype CD4+ T cells of 4-month-old male BXSB mice are G1 arrested.	Acridine Orange	9-24	CD4 antigen	Mus musculus	99-102
9295025-5	1997	Long-term bromodeoxyuridine in vivo labeling also showed that with advanced age, there was a shift of the CD4+ CD44(hi) male cells from predominantly cycling to predominantly noncycling.	Bromodeoxyuridine	10-27	CD4 antigen	Mus musculus	106-109
9295041-1	1997	Thymocytes with a CD4(hi)CD8(lo) coreceptor-skewed (CRS) phenotype have been shown to contain precursors for CD8 single-positive (SP) thymocytes, in addition to precursors for CD4 SP cells.	sp	130-132	CD4 antigen	Mus musculus	18-21
20654322-6	1997	Both CD4(+) and CD8(+) T lymphocytes depleted of GSH by greater than 40% were found to have a decreased [Ca(2+)](i) mobilization following anti-CD3 mAb stimulation.	Glutathione	49-52	CD4 antigen	Mus musculus	5-8
9200451-8	1997	We furthermore demonstrated that CD4 T cells in spleen cells from C3H/He mice that had rejected C3H Tg.Con.3-1 skin showed a weak, but significant, proliferative response to in vitro stimulation with mitomycin C-treated C3H Tg.Con.3-1 spleen cells.	c3h tg	96-102	CD4 antigen	Mus musculus	33-36
9200451-8	1997	We furthermore demonstrated that CD4 T cells in spleen cells from C3H/He mice that had rejected C3H Tg.Con.3-1 skin showed a weak, but significant, proliferative response to in vitro stimulation with mitomycin C-treated C3H Tg.Con.3-1 spleen cells.	Mitomycin	200-211	CD4 antigen	Mus musculus	33-36
9200451-8	1997	We furthermore demonstrated that CD4 T cells in spleen cells from C3H/He mice that had rejected C3H Tg.Con.3-1 skin showed a weak, but significant, proliferative response to in vitro stimulation with mitomycin C-treated C3H Tg.Con.3-1 spleen cells.	c3h tg	220-226	CD4 antigen	Mus musculus	33-36
9224809-3	1997	We previously analyzed the interference of TCDD with differentiation processes in fetal thymus organ cultures and found that in the presence of TCDD, the proliferation rate of immature (CD4- CD8- and CD4- CD8+ HSA+) thymocytes is inhibited, whereas the maturation along the CD4/CD8 path is accelerated.	Polychlorinated Dibenzodioxins	43-47	CD4 antigen	Mus musculus	186-189
9224809-3	1997	We previously analyzed the interference of TCDD with differentiation processes in fetal thymus organ cultures and found that in the presence of TCDD, the proliferation rate of immature (CD4- CD8- and CD4- CD8+ HSA+) thymocytes is inhibited, whereas the maturation along the CD4/CD8 path is accelerated.	Polychlorinated Dibenzodioxins	43-47	CD4 antigen	Mus musculus	200-203
9224809-3	1997	We previously analyzed the interference of TCDD with differentiation processes in fetal thymus organ cultures and found that in the presence of TCDD, the proliferation rate of immature (CD4- CD8- and CD4- CD8+ HSA+) thymocytes is inhibited, whereas the maturation along the CD4/CD8 path is accelerated.	Polychlorinated Dibenzodioxins	43-47	CD4 antigen	Mus musculus	200-203
9224809-3	1997	We previously analyzed the interference of TCDD with differentiation processes in fetal thymus organ cultures and found that in the presence of TCDD, the proliferation rate of immature (CD4- CD8- and CD4- CD8+ HSA+) thymocytes is inhibited, whereas the maturation along the CD4/CD8 path is accelerated.	Polychlorinated Dibenzodioxins	144-148	CD4 antigen	Mus musculus	186-189
9166429-0	1997	9-O-Acetylation of sialomucins: a novel marker of murine CD4 T cells that is regulated during maturation and activation.	9-o	0-3	CD4 antigen	Mus musculus	57-60
9166429-3	1997	Using a recombinant soluble form of the Influenza C virus hemagglutinin-esterase as a probe for 9-O-acetylated sialic acids, we demonstrate here their preferential expression on the CD4 T cell lineage in normal B10.A mouse lymphoid organs.	Sialic Acids	111-123	CD4 antigen	Mus musculus	182-185
9166429-6	1997	Correlation with CD4 and CD8 levels suggests that 9-O-acetylation appears as an early differentiation marker as cells mature from the DP to the CD4 SP phenotype.	sp	148-150	CD4 antigen	Mus musculus	144-147
9166429-10	1997	Digestions with trypsin and O-sialoglycoprotease (OSGPase) and ELISA studies of lipid extracts indicate that the 9-O-acetylated sialic acids on peripheral CD4 T cells are predominantly on O-linked mucintype glycoproteins and to a lesser degree, on sialylated glycolipids (gangliosides).	Sialic Acids	128-140	CD4 antigen	Mus musculus	155-158
9166429-11	1997	In contrast, sialic acids on mucin type molecules of CD8 T cells are not O-acetylated; instead these molecules mask the recognition of O-acetylated gangliosides that seem to be present at similar levels as on CD4 cells.	Sialic Acids	13-25	CD4 antigen	Mus musculus	209-212
9166429-11	1997	In contrast, sialic acids on mucin type molecules of CD8 T cells are not O-acetylated; instead these molecules mask the recognition of O-acetylated gangliosides that seem to be present at similar levels as on CD4 cells.	o-acetylated gangliosides	135-160	CD4 antigen	Mus musculus	209-212
9166429-15	1997	Thus, 9-O-acetylation of sialic acids on cell surface mucins is a novel marker on CD4 T cells that appears on maturation and is modulated downwards upon activation.	9-o	6-9	CD4 antigen	Mus musculus	82-85
9166429-15	1997	Thus, 9-O-acetylation of sialic acids on cell surface mucins is a novel marker on CD4 T cells that appears on maturation and is modulated downwards upon activation.	Sialic Acids	25-37	CD4 antigen	Mus musculus	82-85
9178680-1	1997	BACKGROUND &amp; AIMS: Increase of T cells expressing CD4 and T-cell receptor (TCR) alpha- beta+ (beta[dim]) was observed in the mucosal and peripheral lymphoid tissues of TCR alpha-/- mice with inflammatory bowel disease (IBD).	Adenosine Monophosphate	12-15	CD4 antigen	Mus musculus	54-57
9164953-6	1997	Consistent with this association, CD4+ T cells from PAR-immunized mice released INF-gamma and stimulated T. cruzi-infected macrophages to release nitric oxide.	Nitric Oxide	146-158	CD4 antigen	Mus musculus	34-37
9180188-4	1997	CD4 T cells from spleens of iron-overloaded mice were found to produce high levels of IL-4 and IL-10 and low levels of interferon-gamma.	Iron	28-32	CD4 antigen	Mus musculus	0-3
9180188-5	1997	Treatment of iron-overloaded mice with the iron chelator, deferoxamine, resulted in the cure of mice from infection, restored the antifungal effector and immunomodulatory functions of the phagocytic cells, and allowed the occurrence of CD4 Th1 protective antifungal responses.	Iron	13-17	CD4 antigen	Mus musculus	236-239
9180188-5	1997	Treatment of iron-overloaded mice with the iron chelator, deferoxamine, resulted in the cure of mice from infection, restored the antifungal effector and immunomodulatory functions of the phagocytic cells, and allowed the occurrence of CD4 Th1 protective antifungal responses.	Iron	43-47	CD4 antigen	Mus musculus	236-239
9180188-5	1997	Treatment of iron-overloaded mice with the iron chelator, deferoxamine, resulted in the cure of mice from infection, restored the antifungal effector and immunomodulatory functions of the phagocytic cells, and allowed the occurrence of CD4 Th1 protective antifungal responses.	Deferoxamine	58-70	CD4 antigen	Mus musculus	236-239
9180188-6	1997	These data indicate that iron overload may negatively affect CD4 Th1 development in mice with candidiasis, a function efficiently restored by therapy with deferoxamine.	Iron	25-29	CD4 antigen	Mus musculus	61-64
9180188-6	1997	These data indicate that iron overload may negatively affect CD4 Th1 development in mice with candidiasis, a function efficiently restored by therapy with deferoxamine.	Deferoxamine	155-167	CD4 antigen	Mus musculus	61-64
9144482-10	1997	Even in a viable DP population, high incidences of DNA strand breaks were detected in the CD4(low)CD8(low) compartment.	dp	17-19	CD4 antigen	Mus musculus	90-93
9144485-4	1997	Isolation of hapten-presenting Langerhans cells from the lymph nodes of oxazolone-sensitized mice and transfer to naive mice resulted in the induction of both the regulatory CD4+ and the effector CD8+ T populations.	Oxazolone	72-81	CD4 antigen	Mus musculus	174-177
9175517-6	1997	Preincubation of T. spiralis L1 larvae with nitrite also caused an increase in the number of CD4(+) and CD8(+) cells as well as IL-2, IL-5, and INF-gamma levels.	Nitrites	44-51	CD4 antigen	Mus musculus	93-96
9174603-4	1997	However, in intact animals, treatment with MEL-14 resulted in the loss of naive CD4 cells (CD45RBhi, CD44lo from peripheral lymph nodes but not Peyer"s patches, whereas mesenteric lymph nodes were intermediate in this regard.	mel-14	43-49	CD4 antigen	Mus musculus	80-83
9175834-6	1997	These data suggest that interactions between the TCR, MHC II-peptide complex and CD4 may be involved in Th2 development.	th2	104-107	CD4 antigen	Mus musculus	81-84
9151790-4	1997	In rIL-12-treated mice, CD4+ lymphocytes made the largest contribution to IFN-gamma mRNA, RSV clearance, and illness, while in anti-IL-4 treated mice, CD8+ lymphocytes were the major effector.	ril-12	3-9	CD4 antigen	Mus musculus	24-27
9103422-5	1997	Injection of the anti-delta-chain Ab (GL3) down-modulated the expression of gamma delta TCR and inhibited the induction of oral tolerance to OVA, as measured by Ab, CD4+, and CD8+ T cell responses.	GL3	38-41	CD4 antigen	Mus musculus	165-168
9116299-0	1997	Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.	mc-38	127-132	CD4 antigen	Mus musculus	40-43
9116299-2	1997	This study compares the therapeutic efficacy of anti-CD3-activated CD4+ or CD8+ T-cell subsets, when given with cyclophosphamide (Cy) and liposome-encapsulated IL-2 (L-IL2) in a murine model.	Cyclophosphamide	130-132	CD4 antigen	Mus musculus	67-70
9116299-8	1997	Mice receiving activated CD4+ T cells showed significantly reduced tumor growth or complete remissions with prolonged disease-free survival in MC-38, 3LL, and 38C13.	mc-38	143-148	CD4 antigen	Mus musculus	25-28
9116299-9	1997	The timing of Cy doses in relation to adoptive transfer was critical in obtaining the optimal antitumor effect by CD4+ cells.	Cyclophosphamide	14-16	CD4 antigen	Mus musculus	114-117
9116299-10	1997	Injecting Cy 4 days before the infusion of CD4+ cells greatly enhanced the antitumor effect of the CD4+ cells and improved survival of the mice compared with other Cy regimens.	Cyclophosphamide	10-12	CD4 antigen	Mus musculus	43-46
9116299-10	1997	Injecting Cy 4 days before the infusion of CD4+ cells greatly enhanced the antitumor effect of the CD4+ cells and improved survival of the mice compared with other Cy regimens.	Cyclophosphamide	10-12	CD4 antigen	Mus musculus	99-102
9116299-11	1997	C57BL/6 mice cured of MC-38 after treatment with CD4+ T cells developed tumor-type immunologic memory as demonstrated by their ability to reject rechallenges with MC-38, but not 3LL.	mc-38	22-27	CD4 antigen	Mus musculus	49-52
9116299-11	1997	C57BL/6 mice cured of MC-38 after treatment with CD4+ T cells developed tumor-type immunologic memory as demonstrated by their ability to reject rechallenges with MC-38, but not 3LL.	mc-38	163-168	CD4 antigen	Mus musculus	49-52
9107568-2	1997	In this study, we report that SCID-bg mice, which were originally generated by mating CB-17-scid mice with KSN-bg mice, spontaneously develop dominant CD4+ CD8+ double positive (DP) thymocytes.	cb-17	86-91	CD4 antigen	Mus musculus	151-154
9107568-2	1997	In this study, we report that SCID-bg mice, which were originally generated by mating CB-17-scid mice with KSN-bg mice, spontaneously develop dominant CD4+ CD8+ double positive (DP) thymocytes.	ksn-bg	107-113	CD4 antigen	Mus musculus	151-154
9058803-2	1997	Recent evidence suggests that TCDD interferes with the initial activation of CD4+ Th cells, possibly through an indirect mechanism.	Polychlorinated Dibenzodioxins	30-34	CD4 antigen	Mus musculus	77-80
9126704-11	1997	The mechanisms that contribute to TNF mRNA accumulation also may differ in the two CD4+ T cell subsets, because cycloheximide superinduced TNF mRNA in Th2 cells, but not in Th1 cells.	Cycloheximide	112-125	CD4 antigen	Mus musculus	83-86
9147362-0	1997	Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways.	Dexamethasone	29-42	CD4 antigen	Mus musculus	72-75
9147362-0	1997	Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways.	Cyclic AMP	119-123	CD4 antigen	Mus musculus	72-75
9045912-0	1997	MRL/lpr CD4- CD8- and CD8+ T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.	ammonium ferrous sulfate	58-61	CD4 antigen	Mus musculus	8-11
9143938-5	1997	Some of the V beta 8+CD4-CD8- T-cells might be autoreactive because they could be stimulated to proliferative by syngenic mitomycin C-treated splenocytes.	Mitomycin	122-133	CD4 antigen	Mus musculus	21-24
9042429-9	1997	Moreover, by using anti-TCR/CD3 antibodies, the authors have confirmed the importance of CD4-associated tyrosine kinase activity in early TCR/CD3 signalling in this Th2 cell line, as (1) upon TCR/CD3 ligation, tyrosine phosphorylation is detected only in those CD3 chains co-precipitating with CD4; and (2) CD4 expression is needed for efficient early tyrosine phosphorylation and detectable p56lck-TCR co-precipitation.	Tyrosine	104-112	CD4 antigen	Mus musculus	89-92
9042429-9	1997	Moreover, by using anti-TCR/CD3 antibodies, the authors have confirmed the importance of CD4-associated tyrosine kinase activity in early TCR/CD3 signalling in this Th2 cell line, as (1) upon TCR/CD3 ligation, tyrosine phosphorylation is detected only in those CD3 chains co-precipitating with CD4; and (2) CD4 expression is needed for efficient early tyrosine phosphorylation and detectable p56lck-TCR co-precipitation.	Tyrosine	104-112	CD4 antigen	Mus musculus	294-297
9042429-9	1997	Moreover, by using anti-TCR/CD3 antibodies, the authors have confirmed the importance of CD4-associated tyrosine kinase activity in early TCR/CD3 signalling in this Th2 cell line, as (1) upon TCR/CD3 ligation, tyrosine phosphorylation is detected only in those CD3 chains co-precipitating with CD4; and (2) CD4 expression is needed for efficient early tyrosine phosphorylation and detectable p56lck-TCR co-precipitation.	Tyrosine	104-112	CD4 antigen	Mus musculus	294-297
9042429-9	1997	Moreover, by using anti-TCR/CD3 antibodies, the authors have confirmed the importance of CD4-associated tyrosine kinase activity in early TCR/CD3 signalling in this Th2 cell line, as (1) upon TCR/CD3 ligation, tyrosine phosphorylation is detected only in those CD3 chains co-precipitating with CD4; and (2) CD4 expression is needed for efficient early tyrosine phosphorylation and detectable p56lck-TCR co-precipitation.	Tyrosine	210-218	CD4 antigen	Mus musculus	89-92
9015188-0	1997	Differential tyrosine phosphorylation of zeta chain dimers in mouse CD4 T lymphocytes: effect of age.	Tyrosine	13-21	CD4 antigen	Mus musculus	68-71
9015188-2	1997	Stimulation of resting mouse splenic CD4 T cells by cross-linking CD3 to CD4 leads to increases in tyrosine phosphorylation of five such proteins, of which three are likely to be dimeric forms of zeta as judged by behavior on two-dimensional gels.	Tyrosine	99-107	CD4 antigen	Mus musculus	37-40
9015188-2	1997	Stimulation of resting mouse splenic CD4 T cells by cross-linking CD3 to CD4 leads to increases in tyrosine phosphorylation of five such proteins, of which three are likely to be dimeric forms of zeta as judged by behavior on two-dimensional gels.	Tyrosine	99-107	CD4 antigen	Mus musculus	73-76
9038716-0	1997	Pristane-induced arthritis is CD4+ T-cell dependent.	pristane	0-8	CD4 antigen	Mus musculus	30-33
9038716-1	1997	The development of arthritis induced in mice by intraperitoneal injection of the non-antigenic mineral oil pristane (2,6,10,14-tetramethylpentadecane) was shown to depend on the presence of CD4+ T cells.	mineral oil pristane	95-115	CD4 antigen	Mus musculus	190-193
9038716-1	1997	The development of arthritis induced in mice by intraperitoneal injection of the non-antigenic mineral oil pristane (2,6,10,14-tetramethylpentadecane) was shown to depend on the presence of CD4+ T cells.	pristane	117-149	CD4 antigen	Mus musculus	190-193
8989204-3	1997	Examination of these mutant CD4 molecules for gp120 binding indicated that murine CD4 molecule does not bind gp120 for the following three reasons: (a) The loops flanking the C" strand are longer than their human counterparts, causing significant difference in local tertiary structure; (b) valin, rather than phenylalanine, which is the key amino acid for the binding occupies position 43; (c) amino acids at positions 45 and 46 are different, causing further decrease in binding affinity.	DL-Valine	291-296	CD4 antigen	Mus musculus	82-85
8989204-3	1997	Examination of these mutant CD4 molecules for gp120 binding indicated that murine CD4 molecule does not bind gp120 for the following three reasons: (a) The loops flanking the C" strand are longer than their human counterparts, causing significant difference in local tertiary structure; (b) valin, rather than phenylalanine, which is the key amino acid for the binding occupies position 43; (c) amino acids at positions 45 and 46 are different, causing further decrease in binding affinity.	Phenylalanine	310-323	CD4 antigen	Mus musculus	82-85
9049788-2	1997	Fas apoptosis occurs primarily in the CD4+CD8+ subpopulations of thymocytes.	ammonium ferrous sulfate	0-3	CD4 antigen	Mus musculus	38-41
9049788-7	1997	CD4+8+CD3dull thymocytes were sensitive to Fas apoptosis, whereas more mature CD4+8+CD3bright thymocytes were resistant to Fas apoptosis.	ammonium ferrous sulfate	43-46	CD4 antigen	Mus musculus	0-3
9049788-7	1997	CD4+8+CD3dull thymocytes were sensitive to Fas apoptosis, whereas more mature CD4+8+CD3bright thymocytes were resistant to Fas apoptosis.	ammonium ferrous sulfate	123-126	CD4 antigen	Mus musculus	78-81
9049789-5	1997	Although flow cytometric analyses did not reveal differences for CD4, CD8, and Ig+ cells with age, a significant rise in memory T cells (Ox-22low) in both CD4+ and CD8+ T-cell subset lineage was noted in AL-fed rats at 30 months of age.	Aluminum	204-206	CD4 antigen	Mus musculus	155-158
9249940-7	1997	When CyA treatment was continued throughout the period during which unresponsiveness to the graft is induced by anti-CD4 mAb therapy, 50% of the grafted hearts were rejected once the CyA was discontinued.	Cyclosporine	5-8	CD4 antigen	Mus musculus	117-120
8977307-4	1996	Almost all CD4+ T cells from repopulated lymphoid tissues of transplanted SCID mice express CD95 (Fas) on the cell surface, and a large fraction of CD4+ T cells from the gut lamina propria of transplanted SCID mice express the Fas ligand on the surface.	ammonium ferrous sulfate	98-101	CD4 antigen	Mus musculus	11-14
8977307-5	1996	Gut lamina propria CD4+ T cells show Fas-dependent cytotoxicity.	ammonium ferrous sulfate	37-40	CD4 antigen	Mus musculus	19-22
9014813-6	1996	It was found that the high levels of IL-4 and IL-10 secretion stimulated by TMA or MDI, and the lower levels of these cytokines induced by DNCB or formaldehyde, were in all cases dependent upon the presence of CD4- cells.	trimellitic anhydride	76-79	CD4 antigen	Mus musculus	210-213
9014813-6	1996	It was found that the high levels of IL-4 and IL-10 secretion stimulated by TMA or MDI, and the lower levels of these cytokines induced by DNCB or formaldehyde, were in all cases dependent upon the presence of CD4- cells.	Dinitrochlorobenzene	139-143	CD4 antigen	Mus musculus	210-213
9014813-6	1996	It was found that the high levels of IL-4 and IL-10 secretion stimulated by TMA or MDI, and the lower levels of these cytokines induced by DNCB or formaldehyde, were in all cases dependent upon the presence of CD4- cells.	Formaldehyde	147-159	CD4 antigen	Mus musculus	210-213
8975760-0	1996	Gallium arsenide augments antigen processing by peritoneal macrophages for CD4+ helper T cell stimulation.	gallium arsenide	0-16	CD4 antigen	Mus musculus	75-78
8943566-7	1996	In comparison with their CD4+Thy-1+ counterparts, CD4+Thy-1- T cells had blunted calcium responses in controls, as well as in infected mice.	Calcium	81-88	CD4 antigen	Mus musculus	50-53
8900315-2	1996	In agreement with previous reports, CD4 mAbs of different species (mouse, rat, humanized), isotypes (IgG1, IgG2a, and IgG2b) and different epitope specificities decreased 3H-TdR incorporation in MLR, using monocyte-depleted or CD4+ T lymphocyte-enriched blood mononuclear cells as responders.	Tritium	171-173	CD4 antigen	Mus musculus	36-39
8840982-16	1996	Most of the lymphocytes from control thymuses and ddC-induced lymphomas were positive for Thy-1.2 (pan-T), heat stable antigen, and CD4 and CD8 markers, with no marked differences in the lymphocyte markers of the tumors between sexes or dose groups.	Zalcitabine	50-53	CD4 antigen	Mus musculus	132-135
8874202-2	1996	Earlier in vitro experiments indicated that this analog, known as rD-mPGPtide, inhibited T-cell proliferation in mixed lymphocyte reactions and blocked activation of both normal CD4+ T cells and T-cell lines after T-cell receptor triggering.	reverse D amino acid mouse proline-glycine-proline peptide	66-77	CD4 antigen	Mus musculus	178-181
8874202-3	1996	In addition, rD-mPGPtide proved to be a potent inhibitor in vivo of CD4+ T-cell-mediated experimental allergic encephalomyelitis disease in the SJL mouse model.	reverse D amino acid mouse proline-glycine-proline peptide	13-24	CD4 antigen	Mus musculus	68-71
8826970-5	1996	By performing two-color immunostaining of cell surface antigens and intracellular IFN-gamma, we found that IFN-gamma positive cells in islet grafts from CFA- and PBS-injected mice were approximately equally divided between CD4+ and CD8+ T-cell subsets.	pbs	162-165	CD4 antigen	Mus musculus	223-226
8943722-7	1996	However, IL-1 beta, IL-2 and TNF-alpha mRNA levels of lymph node cells from CD4- mice could be upregulated by phorbol myristate acetate in vitro.	Tetradecanoylphorbol Acetate	110-135	CD4 antigen	Mus musculus	76-79
8903460-6	1996	Phenotypic analysis of cellular subset of spleen by flow cytometry revealed that low-dose CY, when given to both naive and tumor-bearing mice, causes significant reduction of both absolute number and percentage of cells with CD4-CD8- subset in the spleens of TBM.	Cyclophosphamide	90-92	CD4 antigen	Mus musculus	225-228
8855300-1	1996	The CD4 receptor contributes to T-cell activation by coligating major histocompatibility complex class II on antigen presenting cells with the T-cell receptor (TCR)/CD3 complex, and triggering a cascade of signaling events including tyrosine phosphorylation of intracellular proteins.	Tyrosine	233-241	CD4 antigen	Mus musculus	4-7
8855300-4	1996	We have found that CD4 cross-linking results in a small but rapid increase in levels of cell surface Fas, a member of the tumor necrosis factor receptor family implicated in apoptotic death and maintenance of immune homeostasis.	ammonium ferrous sulfate	101-104	CD4 antigen	Mus musculus	19-22
8855300-6	1996	Subsequent to CD4 cross-linking, CD4+ splenocytes cultured overnight became sensitive to Fas-mediated death.	ammonium ferrous sulfate	89-92	CD4 antigen	Mus musculus	14-17
8855300-6	1996	Subsequent to CD4 cross-linking, CD4+ splenocytes cultured overnight became sensitive to Fas-mediated death.	ammonium ferrous sulfate	89-92	CD4 antigen	Mus musculus	33-36
8805628-12	1996	Based on similar temporal effects produced by TCDD and anti-CD4 Ab on alloimmune responses, we postulate that TCDD interferes with the initial activation of CD4+ T cells, which leads to downstream inhibition of the activation and/or differentiation of CD8+ T cells and B cells.	Polychlorinated Dibenzodioxins	46-50	CD4 antigen	Mus musculus	157-160
8805628-12	1996	Based on similar temporal effects produced by TCDD and anti-CD4 Ab on alloimmune responses, we postulate that TCDD interferes with the initial activation of CD4+ T cells, which leads to downstream inhibition of the activation and/or differentiation of CD8+ T cells and B cells.	Polychlorinated Dibenzodioxins	110-114	CD4 antigen	Mus musculus	60-63
8805628-12	1996	Based on similar temporal effects produced by TCDD and anti-CD4 Ab on alloimmune responses, we postulate that TCDD interferes with the initial activation of CD4+ T cells, which leads to downstream inhibition of the activation and/or differentiation of CD8+ T cells and B cells.	Polychlorinated Dibenzodioxins	110-114	CD4 antigen	Mus musculus	157-160
8805628-13	1996	In addition, since delayed treatment with either anti-CD4 Ab or TCDD suppressed the alloantibody but not the CTL response, TCDD may also affect later CD4+ T helper-B cell interactions.	Polychlorinated Dibenzodioxins	123-127	CD4 antigen	Mus musculus	150-153
8790380-7	1996	Biochemical analysis revealed that, in response to TCR or TCR/CD4 stimulation, thymocytes lacking SHPTP1 showed increased tyrosyl phosphorylation of several cellular substrates, which correlated with increased activation of the src-family kinases Lck and Fyn.	cyclo(tyrosyl-tyrosyl)	122-129	CD4 antigen	Mus musculus	62-65
8781428-2	1996	In the peripheral immune system, CD43 130 kD, which carries core 2 O-glycan structures on its surface, is an activation antigen expressed on both CD4 and CD8 single-positive (SP) T cells.	o-glycan	67-75	CD4 antigen	Mus musculus	33-36
8886616-7	1996	After a low intravenous dose to CD4+ mice, rapid loss of [3H]CE9.1 from plasma (mean residence time &lt; 1 hr) was accompanied by accumulation of radioactivity in the spleen (a maximum of 18% of the administered dose at 2 hr).	Tritium	58-60	CD4 antigen	Mus musculus	32-35
8812236-5	1996	Flow cytometric analyses of thymuses from propanil- and vehicle-treated mice indicate that the CD4(+) CD8(+) population of immature cells, is most significantly decreased in propanil-exposed mice.	Propanil	42-50	CD4 antigen	Mus musculus	95-98
8812236-5	1996	Flow cytometric analyses of thymuses from propanil- and vehicle-treated mice indicate that the CD4(+) CD8(+) population of immature cells, is most significantly decreased in propanil-exposed mice.	Propanil	174-182	CD4 antigen	Mus musculus	95-98
8814250-6	1996	Functional helper T cells (Th1 and Th2) were induced from the CD4 lineage-committed cells upon secondary stimulation with a combination of ionomycin and PMA followed by lymphokine treatment.	Ionomycin	139-148	CD4 antigen	Mus musculus	62-65
8814250-6	1996	Functional helper T cells (Th1 and Th2) were induced from the CD4 lineage-committed cells upon secondary stimulation with a combination of ionomycin and PMA followed by lymphokine treatment.	Tetradecanoylphorbol Acetate	153-156	CD4 antigen	Mus musculus	62-65
8911138-3	1996	Several studies using 15 16-mer peptides previously demonstrated that CD4 helper T cells are required to induce optimal CTL responses with synthetic peptides.	Peptides	32-40	CD4 antigen	Mus musculus	70-73
8819508-0	1996	Gallium arsenide selectively suppresses antigen processing by splenic macrophages for CD4+ T cell activation.	gallium arsenide	0-16	CD4 antigen	Mus musculus	86-89
8895611-0	1996	Interleukin-1beta and ibuprofen effects on CD4/CD8 cells after endotoxic challenge.	Ibuprofen	22-31	CD4 antigen	Mus musculus	43-46
8895611-6	1996	CD4/CD8 ratio increased in groups treated with IL-1beta (11,9) and IL-1beta plus ibuprofen (11,2) compared with sham (3,4), LPS (4,2), and ibuprofen alone (4,1) (P &lt; 0.05).	Ibuprofen	81-90	CD4 antigen	Mus musculus	0-3
8895611-6	1996	CD4/CD8 ratio increased in groups treated with IL-1beta (11,9) and IL-1beta plus ibuprofen (11,2) compared with sham (3,4), LPS (4,2), and ibuprofen alone (4,1) (P &lt; 0.05).	Ibuprofen	139-148	CD4 antigen	Mus musculus	0-3
8806805-2	1996	Murine splenic CD4+ T cells, activated in the presence of phorbol ester and immobilized anti-CD4 mAb, adhered to the plastic surface and formed extended cytoplasmic projections (pseudopodia).	Phorbol Esters	58-71	CD4 antigen	Mus musculus	15-18
8806805-8	1996	A combination of IL-4 plus phorbol ester, but not IL-2 plus phorbol ester, induced pseudopod formation in concert with CD4 ligation.	Phorbol Esters	27-40	CD4 antigen	Mus musculus	119-122
8806807-3	1996	First, contrasting with the classical mitogens, CAA induces the proliferation of a fraction of the CD4+ and CD8+ mouse T-lymphocytes.	caa	48-51	CD4 antigen	Mus musculus	99-102
8806807-4	1996	Second, the CAA-induced proliferation requires MHC class II and CD4 molecules.	caa	12-15	CD4 antigen	Mus musculus	64-67
8759743-4	1996	rIL-12, administered in vivo to the DC recipient mice, could substitute for the T helper peptide in initiating skin test reactivity following transfer of DC pulsed with P815AB alone, leading to Ag-specific production of IFN-gamma by CD4+ and CD8+ T cells.	ril-12	0-6	CD4 antigen	Mus musculus	233-236
8765017-2	1996	The aim of this study was to investigate the implication of the major histocompatibility complex (MHC) class II presentation pathway to CD4+ T cells in oral tolerance of contact sensitivity (CS) to the hapten dinitrofluorobenzene (DNFB).	Dinitrofluorobenzene	231-235	CD4 antigen	Mus musculus	136-139
8765017-6	1996	Moreover, a single oral administration of DNFB, without skin sensitization, could prime A beta 0/0, Ii0/0 as well as anti-CD4-depleted C57BL/6 mice for DNFB-specific CS.	Dinitrofluorobenzene	42-46	CD4 antigen	Mus musculus	122-125
8765017-8	1996	Furthermore, our data provide evidence that a single oral feeding with DNFB is able to prime mice for hapten-specific CS, provided that the class II/ CD4 pathway is bypassed.	Dinitrofluorobenzene	71-75	CD4 antigen	Mus musculus	150-153
8757838-8	1996	Furthermore, CD4+ and CD8+ T-cell-dependent acquired immunity is essential for long-term survival of ts-4-infected mice.	6-isopropyl-4-methyl-2-p-tolyl-5,6-dihydro-4H-1,3-selenazin-4-ol	101-105	CD4 antigen	Mus musculus	13-16
9023586-0	1996	The effect of nicotine on murine CD4 T cell responses.	Nicotine	14-22	CD4 antigen	Mus musculus	33-36
9023586-5	1996	Exposure to nicotine decreased the percentage of CD4+ T cells expressing both CD28 and CTLA-4 and decreased the intensity of CD28 expression.	Nicotine	12-20	CD4 antigen	Mus musculus	49-52
9023586-8	1996	Thus, exposure of T cells to physiological concentrations of STE or nicotine can alter the T cell expression of CD28 and CTLA-4, and the CD4 T cell cytokine expression pattern.	ste	61-64	CD4 antigen	Mus musculus	137-140
9023586-8	1996	Thus, exposure of T cells to physiological concentrations of STE or nicotine can alter the T cell expression of CD28 and CTLA-4, and the CD4 T cell cytokine expression pattern.	Nicotine	68-76	CD4 antigen	Mus musculus	137-140
8760788-5	1996	Clinical EAMG was nearly completely prevented in CD4-8-, CD4-/-, and CD8-/- mice.	eamg	9-13	CD4 antigen	Mus musculus	49-52
8760788-5	1996	Clinical EAMG was nearly completely prevented in CD4-8-, CD4-/-, and CD8-/- mice.	eamg	9-13	CD4 antigen	Mus musculus	57-60
8755495-1	1996	The tissue distribution of CD4 lymphocytes in normal C57/BL mice and CD4 knockout mice was determined by biodistribution measurements and gamma camera imaging with an 111In-labeled rat IgG2b monoclonal antibody directed against the murine CD-4 antigen.	Indium-111	167-172	CD4 antigen	Mus musculus	27-30
8755570-3	1996	We report that mice homozygous for the Ebeta deletion, whether a selectable marker gene is present or not, show a block in alphabeta T-cell development at the CD4-CD8- double-negative cell stage, whereas the number of gammadelta+ T cells is normal, few CD4+CD8+ double-positive thymocytes and no alphabeta+ T cells are produced.	ebeta	39-44	CD4 antigen	Mus musculus	159-162
8755570-3	1996	We report that mice homozygous for the Ebeta deletion, whether a selectable marker gene is present or not, show a block in alphabeta T-cell development at the CD4-CD8- double-negative cell stage, whereas the number of gammadelta+ T cells is normal, few CD4+CD8+ double-positive thymocytes and no alphabeta+ T cells are produced.	ebeta	39-44	CD4 antigen	Mus musculus	253-256
8683140-9	1996	These findings indicate that rmIL-10 displays anti-allergic activity in sensitized BALB/c mice by preventing Ag-induced CD4+ T lymphocyte and eosinophil accumulation as well as IL-5 release in the peritoneal cavity.	rmil-10	29-36	CD4 antigen	Mus musculus	120-123
8752836-2	1996	The latter pathway is mediated by antigen-specific, CD4+ suppressor T cells (CPS-Ts) that are Th2 cells.	cps	77-80	CD4 antigen	Mus musculus	52-55
8752846-2	1996	Since Fas mediates apoptosis, this defect results in CD4-CD8- double negative T-cell proliferation, lupus nephritis, and macroscopic lupus erythematosus-like skin lesions.	ammonium ferrous sulfate	6-9	CD4 antigen	Mus musculus	53-56
8652191-11	1996	Thus, although CsA administration attenuated spleen cell activation and was associated with a marked attenuation of airway responsiveness in mice with genetically hyperresponsive airways, CD4+ and CD8+ T cells do not appear to mediate this response.	Cyclosporine	15-18	CD4 antigen	Mus musculus	188-191
8647197-10	1996	Conversely, we have observed that CD4 co-precipitates small quantities of p56fyn in a TcR/CD3-independent manner.	p56fyn	74-80	CD4 antigen	Mus musculus	34-37
8673701-4	1996	In contrast, CD4 T cells of mice expressing beta-gal in mTE were tolerized.	methylthioethanol	56-59	CD4 antigen	Mus musculus	13-16
8812696-0	1996	Isolation of CD4+ and CD8+ T-Cell Clones from Mice Immunized with Synthetic Peptides on Splenic Dendritic Cells Splenic dendritic cells (DC) express high levels of MHC, co-stimulator, and adhesion molecules and have been shown to be extremely potent antigen-presenting cells for both CD4(+) and CD8(+) T-cell responses.	Peptides	76-84	CD4 antigen	Mus musculus	13-16
8812696-0	1996	Isolation of CD4+ and CD8+ T-Cell Clones from Mice Immunized with Synthetic Peptides on Splenic Dendritic Cells Splenic dendritic cells (DC) express high levels of MHC, co-stimulator, and adhesion molecules and have been shown to be extremely potent antigen-presenting cells for both CD4(+) and CD8(+) T-cell responses.	Peptides	76-84	CD4 antigen	Mus musculus	284-287
8658534-0	1996	Vomitoxin-mediated IL-2, IL-4, and IL-5 superinduction in murine CD4+ T cells stimulated with phorbol ester calcium ionophore: relation to kinetics of proliferation.	deoxynivalenol	0-9	CD4 antigen	Mus musculus	65-68
8658534-0	1996	Vomitoxin-mediated IL-2, IL-4, and IL-5 superinduction in murine CD4+ T cells stimulated with phorbol ester calcium ionophore: relation to kinetics of proliferation.	phorbol ester calcium	94-115	CD4 antigen	Mus musculus	65-68
8658534-1	1996	The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4+ T cells.	trichothecene vomitoxin	19-42	CD4 antigen	Mus musculus	135-138
8658534-1	1996	The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4+ T cells.	deoxynivalenol	44-46	CD4 antigen	Mus musculus	135-138
8658534-2	1996	The CD4+ cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	Tetradecanoylphorbol Acetate	39-70	CD4 antigen	Mus musculus	4-7
8658534-2	1996	The CD4+ cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	Tetradecanoylphorbol Acetate	72-75	CD4 antigen	Mus musculus	4-7
8658534-2	1996	The CD4+ cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	Ionomycin	81-90	CD4 antigen	Mus musculus	4-7
8658534-2	1996	The CD4+ cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	Calcium	150-157	CD4 antigen	Mus musculus	4-7
8658534-2	1996	The CD4+ cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	deoxynivalenol	187-189	CD4 antigen	Mus musculus	4-7
8658534-11	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4+ cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	CD4 antigen	Mus musculus	65-68
8658534-13	1996	Taken together, VT enhanced and/or delayed peak IL-2, IL-4, and IL-5 gene expression and secretion in CD4+ T cells stimulated with PMA and ionomycin.	Tetradecanoylphorbol Acetate	131-134	CD4 antigen	Mus musculus	102-105
8658534-13	1996	Taken together, VT enhanced and/or delayed peak IL-2, IL-4, and IL-5 gene expression and secretion in CD4+ T cells stimulated with PMA and ionomycin.	Ionomycin	139-148	CD4 antigen	Mus musculus	102-105
8661368-0	1996	Vomitoxin-Mediated IL-2, IL-4, and IL-5 Superinduction in Murine CD4+ T Cells Stimulated with Phorbol Ester and Calcium Ionophore: Relation to Kinetics of Proliferation The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4(+) T cells.	deoxynivalenol	0-9	CD4 antigen	Mus musculus	65-68
8661368-0	1996	Vomitoxin-Mediated IL-2, IL-4, and IL-5 Superinduction in Murine CD4+ T Cells Stimulated with Phorbol Ester and Calcium Ionophore: Relation to Kinetics of Proliferation The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4(+) T cells.	deoxynivalenol	0-9	CD4 antigen	Mus musculus	304-307
8661368-0	1996	Vomitoxin-Mediated IL-2, IL-4, and IL-5 Superinduction in Murine CD4+ T Cells Stimulated with Phorbol Ester and Calcium Ionophore: Relation to Kinetics of Proliferation The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4(+) T cells.	Phorbol Esters	94-107	CD4 antigen	Mus musculus	65-68
8661368-0	1996	Vomitoxin-Mediated IL-2, IL-4, and IL-5 Superinduction in Murine CD4+ T Cells Stimulated with Phorbol Ester and Calcium Ionophore: Relation to Kinetics of Proliferation The effects of the trichothecene vomitoxin (VT) on the kinetics of cell proliferation and cytokine production were evaluated in murine CD4(+) T cells.	Calcium	112-119	CD4 antigen	Mus musculus	65-68
8661368-1	1996	The CD4(+) cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	Tetradecanoylphorbol Acetate	41-72	CD4 antigen	Mus musculus	4-7
8661368-1	1996	The CD4(+) cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	Tetradecanoylphorbol Acetate	74-77	CD4 antigen	Mus musculus	4-7
8661368-1	1996	The CD4(+) cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	Ionomycin	83-92	CD4 antigen	Mus musculus	4-7
8661368-1	1996	The CD4(+) cultures were stimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin to activate protein kinase C and increase cytoplasmic free calcium, respectively, in a range of VT concentrations.	Calcium	152-159	CD4 antigen	Mus musculus	4-7
8661368-10	1996	Pulsed VT (8 to 48 hr) or cycloheximide (4 to 48 hr) exposure of CD4(+) cells enhanced supernatant levels of IL-2 but not IL-4 upon incubation for 24 hr in fresh medium.	Cycloheximide	26-39	CD4 antigen	Mus musculus	65-68
8661368-12	1996	Taken together, VT enhanced andsolidusor delayed peak IL-2, IL-4, and IL-5 gene expression and secretion in CD4(+) T cells stimulated with PMA and ionomycin.	Tetradecanoylphorbol Acetate	139-142	CD4 antigen	Mus musculus	108-111
8661368-12	1996	Taken together, VT enhanced andsolidusor delayed peak IL-2, IL-4, and IL-5 gene expression and secretion in CD4(+) T cells stimulated with PMA and ionomycin.	Ionomycin	147-156	CD4 antigen	Mus musculus	108-111
8671654-5	1996	Here we evaluated the importance of the Fas pathway in regulating immune responses by male antigen-specific CD4(-)CD8(+) T cells.	ammonium ferrous sulfate	40-43	CD4 antigen	Mus musculus	108-111
8726930-0	1996	Integrin alpha E beta 7 expression on BAL CD4+, CD8+, and gamma delta T-cells in bleomycin-induced lung fibrosis in mouse.	Bleomycin	81-90	CD4 antigen	Mus musculus	42-45
8793567-6	1996	In addition, the two neuropeptides in a range of 10(-7)-10(-10) M induced a rapid and dose-dependent increase in intracellular cAMP in CD4 and CD8 T cells.	Cyclic AMP	127-131	CD4 antigen	Mus musculus	135-138
8741008-4	1996	It was shown that dextran sulfate induced colitis could be induced in Balb/c mice depleted of CD4(+) helper T cells by treatment with monoclonal antibodies preceded by adult thymectomy.	Dextran Sulfate	18-33	CD4 antigen	Mus musculus	94-97
8601219-3	1996	In this report, BHH was tested in CD4-deficient mice.	N-butyl-N'-hydroxyguanidine	16-19	CD4 antigen	Mus musculus	34-37
8738973-4	1996	We now report that cyclophosphamide constitutes an apoptosis signal to peripheral lymphocytes and we provide evidence that NOD B cells as well as both CD4 and CD8 T cells display resistance to cyclophosphamide-induced apoptosis.	Cyclophosphamide	193-209	CD4 antigen	Mus musculus	151-154
8607184-3	1996	The administration of GN for 30 days (s.c. 30 mg/kg elemental gallium on days 0 and 3, 10 mg/kg every third day) resulted in &gt;60-day graft survival in 78% (25 of 32) of the graft recipients, whereas 2 perioperative injections of anti-CD4 monoclonal antibody (mAb) resulted in &gt;60-day graft survival in 58% (24 of 41) of the graft recipients.	gallium nitrate	22-24	CD4 antigen	Mus musculus	237-240
8593938-5	1996	Immunohistochemical staining of pancreatic lesions in young NOD mice receiving either BDC-2.5 or BDC-6.9 showed the presence of CD4+, CD8+, Vbeta4+, and MAC-1+ cells within the infiltrate, similar to infiltrates in lesions of spontaneously diabetic female NOD mice.	bdc-2	86-91	CD4 antigen	Mus musculus	128-131
8593938-5	1996	Immunohistochemical staining of pancreatic lesions in young NOD mice receiving either BDC-2.5 or BDC-6.9 showed the presence of CD4+, CD8+, Vbeta4+, and MAC-1+ cells within the infiltrate, similar to infiltrates in lesions of spontaneously diabetic female NOD mice.	bdc-6	97-102	CD4 antigen	Mus musculus	128-131
8593938-6	1996	In contrast, NOD- scid mice that received BDC-6.9 showed only the presence of CD4+Vb4+ T-cells and a large population of MAC-1+ cells in islet lesions.	bdc-6	42-47	CD4 antigen	Mus musculus	78-81
8593938-7	1996	NOD-scid recipients of cotransferred BDC- 2.5/CD8+ splenic T-cells showed a small population of CD4+ T-cells and a larger population of CD8+ T-cells within the infiltrated islets, whereas no infiltrate was detectable in recipients of CD8+ splenocytes or BDC-2.5 alone.	bdc- 2	37-43	CD4 antigen	Mus musculus	96-99
8671615-7	1996	We found that pretreatment of DP thymocytes with ionomycin and PMA followed by 1 day culture of the cells without the reagents resulted in the differentiation of the cells into CD4 SP and CD4+ CD8lo T cells that have mostly committed to the CD4 lineage.	Ionomycin	49-58	CD4 antigen	Mus musculus	177-180
8671615-7	1996	We found that pretreatment of DP thymocytes with ionomycin and PMA followed by 1 day culture of the cells without the reagents resulted in the differentiation of the cells into CD4 SP and CD4+ CD8lo T cells that have mostly committed to the CD4 lineage.	Ionomycin	49-58	CD4 antigen	Mus musculus	188-191
8671615-7	1996	We found that pretreatment of DP thymocytes with ionomycin and PMA followed by 1 day culture of the cells without the reagents resulted in the differentiation of the cells into CD4 SP and CD4+ CD8lo T cells that have mostly committed to the CD4 lineage.	Ionomycin	49-58	CD4 antigen	Mus musculus	188-191
8671615-7	1996	We found that pretreatment of DP thymocytes with ionomycin and PMA followed by 1 day culture of the cells without the reagents resulted in the differentiation of the cells into CD4 SP and CD4+ CD8lo T cells that have mostly committed to the CD4 lineage.	Tetradecanoylphorbol Acetate	63-66	CD4 antigen	Mus musculus	177-180
8671615-7	1996	We found that pretreatment of DP thymocytes with ionomycin and PMA followed by 1 day culture of the cells without the reagents resulted in the differentiation of the cells into CD4 SP and CD4+ CD8lo T cells that have mostly committed to the CD4 lineage.	Tetradecanoylphorbol Acetate	63-66	CD4 antigen	Mus musculus	188-191
8671615-7	1996	We found that pretreatment of DP thymocytes with ionomycin and PMA followed by 1 day culture of the cells without the reagents resulted in the differentiation of the cells into CD4 SP and CD4+ CD8lo T cells that have mostly committed to the CD4 lineage.	Tetradecanoylphorbol Acetate	63-66	CD4 antigen	Mus musculus	188-191
8671615-7	1996	We found that pretreatment of DP thymocytes with ionomycin and PMA followed by 1 day culture of the cells without the reagents resulted in the differentiation of the cells into CD4 SP and CD4+ CD8lo T cells that have mostly committed to the CD4 lineage.	sp	181-183	CD4 antigen	Mus musculus	177-180
8613668-7	1996	Dexamethasone kills a broad spectrum of the CD4/8 immunophenotypes with no selectively for cell cycle stage.	Dexamethasone	0-13	CD4 antigen	Mus musculus	44-47
8613668-8	1996	Ionomycin selectively deplete CD4+8+ cells, especially those in the Go/G1 region of the cell cycle, and spared CD4-8+ cells.	Ionomycin	0-9	CD4 antigen	Mus musculus	30-33
8740725-5	1996	The peripheral CD4/CD8 ratio was partially augmented by lycopene treatment which resulted from an increased CD4+ subpopulation.	Lycopene	56-64	CD4 antigen	Mus musculus	15-18
8740725-5	1996	The peripheral CD4/CD8 ratio was partially augmented by lycopene treatment which resulted from an increased CD4+ subpopulation.	Lycopene	56-64	CD4 antigen	Mus musculus	108-111
8603426-1	1996	CD4+ T cells from mice with murine AIDS (MAIDS) have been shown to be unable to respond to TCR stimulation as measured by proliferation, IL-2 production, or IL-2R upregulation, although responsiveness was restored with PMA and ionomycin.	Tetradecanoylphorbol Acetate	219-222	CD4 antigen	Mus musculus	0-3
8603426-1	1996	CD4+ T cells from mice with murine AIDS (MAIDS) have been shown to be unable to respond to TCR stimulation as measured by proliferation, IL-2 production, or IL-2R upregulation, although responsiveness was restored with PMA and ionomycin.	Ionomycin	227-236	CD4 antigen	Mus musculus	0-3
8603430-0	1996	Cellular induction mechanism of CD8+ suppressor T cells by DMBA and TPA: formation of CD4+ suppressor-inducer T cells.	9,10-Dimethyl-1,2-benzanthracene	59-63	CD4 antigen	Mus musculus	86-89
8603430-0	1996	Cellular induction mechanism of CD8+ suppressor T cells by DMBA and TPA: formation of CD4+ suppressor-inducer T cells.	Tetradecanoylphorbol Acetate	68-71	CD4 antigen	Mus musculus	86-89
8603430-3	1996	And the macrophages plus TPA induced CD4+ T suppressor inducer cells in the mice spleens.	Tetradecanoylphorbol Acetate	25-28	CD4 antigen	Mus musculus	37-40
8617314-5	1996	Glucocorticoids (GC) are known to be potent inducers of apoptosis in CD4+ CD8+ thymocytes, and we have earlier shown that anti-CD3-induced thymic apoptosis can be blocked by RU486 in vivo.	Mifepristone	174-179	CD4 antigen	Mus musculus	69-72
8698383-11	1996	Furthermore, CT adjuvant increased the frequency of CD4+ T cells expressing a memory phenotype, i.e. CD44high, LECAM-1low and CD45RBlow.	ct adjuvant	13-24	CD4 antigen	Mus musculus	52-55
8852764-3	1996	The sulfated polymer (2d) induced mitogenic activities, and specifically activated the CD4(-)CD8(-) subset of lymphocytes.	Polymers	13-20	CD4 antigen	Mus musculus	87-90
8601723-1	1996	Whether the chemokines macrophage inflammatory protein-1 beta (MIP-1 beta) and regulated on activation normal T expressed and secreted (RANTES), which interact specifically with glycosaminoglycans and thus mediate the recruitment, attachment, and migration of leukocytes to vascular endothelia and extracellular matrix, are also involved in interactions between CD4+ murine T lymphocytes and keratinocytes was examined.	Glycosaminoglycans	178-196	CD4 antigen	Mus musculus	362-365
8632053-2	1996	Labelling thymocytes in situ with fluorescein isothiocyanate (FITC) we note that the export of immature cells, CD4+CD8+, double positive (DP), and double negative, CD4-CD8- (DN), from the thymus was consistently increased 24 and 48 h after vagotomy.	Fluorescein-5-isothiocyanate	34-60	CD4 antigen	Mus musculus	164-171
8632053-2	1996	Labelling thymocytes in situ with fluorescein isothiocyanate (FITC) we note that the export of immature cells, CD4+CD8+, double positive (DP), and double negative, CD4-CD8- (DN), from the thymus was consistently increased 24 and 48 h after vagotomy.	Fluorescein-5-isothiocyanate	62-66	CD4 antigen	Mus musculus	111-114
8632053-2	1996	Labelling thymocytes in situ with fluorescein isothiocyanate (FITC) we note that the export of immature cells, CD4+CD8+, double positive (DP), and double negative, CD4-CD8- (DN), from the thymus was consistently increased 24 and 48 h after vagotomy.	Fluorescein-5-isothiocyanate	62-66	CD4 antigen	Mus musculus	164-171
8915030-0	1996	Abnormal signal transduction through CD4 leads to altered tyrosine phosphorylation in T cells derived from MRL-lpr/lpr mice.	Tyrosine	58-66	CD4 antigen	Mus musculus	37-40
8915030-6	1996	In constrast, cross-linking of surface CD4 resulted in deficient tyrosine phosphorylation of cellular proteins in MRL T cells.	Tyrosine	65-73	CD4 antigen	Mus musculus	39-42
8828007-0	1996	Cross-linking the TCR complex induces apoptosis in CD4+8+ thymocytes in the presence of cyclosporin A.	Cyclosporine	88-101	CD4 antigen	Mus musculus	51-54
8666433-3	1996	Transfer of these CD4+ cytotoxic T cells (CTL) into naive mice protects against a lethal challenge with MHV.	mhv	104-107	CD4 antigen	Mus musculus	18-21
8852598-0	1996	Anti-CD4 monoclonal antibody reduces the dose of cyclophosphamide required to induce tolerance to H-2 haplotype identical skin allografts in mice.	Cyclophosphamide	49-65	CD4 antigen	Mus musculus	5-8
8671594-7	1996	The size of the F3Ag- DP subset is positively correlated with the efficacy of positive selection into the CD4(+) SP compartment.	dp	22-24	CD4 antigen	Mus musculus	106-109
8671597-6	1996	In this report we demonstrate that treatment with SCH94.03 reduced by 2- to 3-fold the number of CD4(+) and CD8(+) cells infiltrating the CNS of SJL/J mice chronically infected with TMEV, in the absence of global lymphocyte depletion.	sch94	50-55	CD4 antigen	Mus musculus	97-100
8598456-3	1996	Such CD4+ CTL lysed both Fas+ and Fas- target cells and developed in Fas ligand-deficient gld mice.	ammonium ferrous sulfate	25-28	CD4 antigen	Mus musculus	5-8
8598456-3	1996	Such CD4+ CTL lysed both Fas+ and Fas- target cells and developed in Fas ligand-deficient gld mice.	ammonium ferrous sulfate	34-37	CD4 antigen	Mus musculus	5-8
8598498-3	1996	CD4+ T cells from CD40L-knockout mice were fourfold less effective than +/+ T cells in activating the nitric oxide response in allogeneic macrophages.	Nitric Oxide	102-114	CD4 antigen	Mus musculus	0-3
8560498-0	1995	Effects of trichothecene structure on cytokine secretion and gene expression in murine CD4+ T-cells.	Trichothecenes	11-24	CD4 antigen	Mus musculus	87-90
8560498-10	1995	Taken together, the results suggest that trichothecenes as a group can either inhibit or superinduce both IL secretion and mRNA levels in CD4+ T-cells.	Trichothecenes	41-55	CD4 antigen	Mus musculus	138-141
8748695-3	1995	Upon exposure of murine fetal thymi in organ cultures to TCDD the distribution of mature and immature thymocytes is skewed towards apparently mature, prospective cytotoxic cells of the CD4-CD8+T cell receptor+ phenotype.	Polychlorinated Dibenzodioxins	57-61	CD4 antigen	Mus musculus	185-188
8566012-3	1995	In mice bearing transgenic alpha/beta T cell receptor (TCR) specific for a class I-restricted male-specific peptide, the superoxide-mediated oxidation of HE into ethidium (Eth) is enhanced among thymocytes which are being deleted due to negative selection (CD4+ CD8+ cells expressing the transgenic TCR in male mice) or lack of positive selection (CD4+ CD8- thymocytes from female mice).	Superoxides	121-131	CD4 antigen	Mus musculus	257-260
8566012-3	1995	In mice bearing transgenic alpha/beta T cell receptor (TCR) specific for a class I-restricted male-specific peptide, the superoxide-mediated oxidation of HE into ethidium (Eth) is enhanced among thymocytes which are being deleted due to negative selection (CD4+ CD8+ cells expressing the transgenic TCR in male mice) or lack of positive selection (CD4+ CD8- thymocytes from female mice).	Superoxides	121-131	CD4 antigen	Mus musculus	348-351
8566012-3	1995	In mice bearing transgenic alpha/beta T cell receptor (TCR) specific for a class I-restricted male-specific peptide, the superoxide-mediated oxidation of HE into ethidium (Eth) is enhanced among thymocytes which are being deleted due to negative selection (CD4+ CD8+ cells expressing the transgenic TCR in male mice) or lack of positive selection (CD4+ CD8- thymocytes from female mice).	hydroethidine	154-156	CD4 antigen	Mus musculus	257-260
8566012-3	1995	In mice bearing transgenic alpha/beta T cell receptor (TCR) specific for a class I-restricted male-specific peptide, the superoxide-mediated oxidation of HE into ethidium (Eth) is enhanced among thymocytes which are being deleted due to negative selection (CD4+ CD8+ cells expressing the transgenic TCR in male mice) or lack of positive selection (CD4+ CD8- thymocytes from female mice).	hydroethidine	154-156	CD4 antigen	Mus musculus	348-351
8566012-3	1995	In mice bearing transgenic alpha/beta T cell receptor (TCR) specific for a class I-restricted male-specific peptide, the superoxide-mediated oxidation of HE into ethidium (Eth) is enhanced among thymocytes which are being deleted due to negative selection (CD4+ CD8+ cells expressing the transgenic TCR in male mice) or lack of positive selection (CD4+ CD8- thymocytes from female mice).	Ethidium	162-170	CD4 antigen	Mus musculus	257-260
8566012-3	1995	In mice bearing transgenic alpha/beta T cell receptor (TCR) specific for a class I-restricted male-specific peptide, the superoxide-mediated oxidation of HE into ethidium (Eth) is enhanced among thymocytes which are being deleted due to negative selection (CD4+ CD8+ cells expressing the transgenic TCR in male mice) or lack of positive selection (CD4+ CD8- thymocytes from female mice).	Ethidium	162-170	CD4 antigen	Mus musculus	348-351
8566012-3	1995	In mice bearing transgenic alpha/beta T cell receptor (TCR) specific for a class I-restricted male-specific peptide, the superoxide-mediated oxidation of HE into ethidium (Eth) is enhanced among thymocytes which are being deleted due to negative selection (CD4+ CD8+ cells expressing the transgenic TCR in male mice) or lack of positive selection (CD4+ CD8- thymocytes from female mice).	Ethidium	172-175	CD4 antigen	Mus musculus	257-260
8566012-3	1995	In mice bearing transgenic alpha/beta T cell receptor (TCR) specific for a class I-restricted male-specific peptide, the superoxide-mediated oxidation of HE into ethidium (Eth) is enhanced among thymocytes which are being deleted due to negative selection (CD4+ CD8+ cells expressing the transgenic TCR in male mice) or lack of positive selection (CD4+ CD8- thymocytes from female mice).	Ethidium	172-175	CD4 antigen	Mus musculus	348-351
8566012-7	1995	More importantly, as compared to normal controls, CD4+ or CD8+ cells from clinically asymptomatic human immunodeficiency virus-1 (HIV-1) carriers also contain a significantly elevated percentage of cells endowed with reduced DiOC6(3) uptake.	3,3'-dihexyl-2,2'-oxacarbocyanine	225-233	CD4 antigen	Mus musculus	50-53
8824708-10	1995	The possibility of treating longstanding autoimmune conditions with anti-CD4 MAb was examined by giving euthymic SJL mice HgCl2 for 3 months, followed by a mercury-free interval of 3 months and finally 7 weekly injections of 1 mg anti-CD4 MAb.	Mercury	156-163	CD4 antigen	Mus musculus	73-76
8824708-12	1995	In conclusion, induction of systemic autoimmunity by mercury was strictly dependent on T cells, specifically T-helper (CD4+) cells, and mercury-induced ANoA persisted for a long time after stopping mercury treatment.	Mercury	53-60	CD4 antigen	Mus musculus	119-122
7594455-4	1995	The 3G11-6C10- subset of CD4+CD8- thymocytes is enriched in GL7-expressing cells.	8,9,10-TRIHYDROXY-7-HYDROXYMETHYL-3-METHYL-6-OXA-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE	60-63	CD4 antigen	Mus musculus	25-28
7594455-5	1995	2) Strain differences exist in the expression of GL7 on adult CD4+CD8- thymocytes; 21.9 +/- 5.9% of BALB/c CD4+CD8- thymocytes are GL7+, whereas 4.4 +/- 1.7% of C57BL/6 CD4+CD8- thymocytes are GL7+.	8,9,10-TRIHYDROXY-7-HYDROXYMETHYL-3-METHYL-6-OXA-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE	49-52	CD4 antigen	Mus musculus	62-65
7594455-5	1995	2) Strain differences exist in the expression of GL7 on adult CD4+CD8- thymocytes; 21.9 +/- 5.9% of BALB/c CD4+CD8- thymocytes are GL7+, whereas 4.4 +/- 1.7% of C57BL/6 CD4+CD8- thymocytes are GL7+.	8,9,10-TRIHYDROXY-7-HYDROXYMETHYL-3-METHYL-6-OXA-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE	49-52	CD4 antigen	Mus musculus	107-110
7594455-5	1995	2) Strain differences exist in the expression of GL7 on adult CD4+CD8- thymocytes; 21.9 +/- 5.9% of BALB/c CD4+CD8- thymocytes are GL7+, whereas 4.4 +/- 1.7% of C57BL/6 CD4+CD8- thymocytes are GL7+.	8,9,10-TRIHYDROXY-7-HYDROXYMETHYL-3-METHYL-6-OXA-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE	49-52	CD4 antigen	Mus musculus	107-110
7594455-10	1995	Thus, GL7 expression defines a subpopulation of functionally competent TCR-alpha beta+ CD4+CD8- thymocytes as well as TCR-gamma delta+ and TCR- subpopulations of fetal CD4-CD8- thymocytes.	8,9,10-TRIHYDROXY-7-HYDROXYMETHYL-3-METHYL-6-OXA-1,3-DIAZA-SPIRO[4.5]DECANE-2,4-DIONE	6-9	CD4 antigen	Mus musculus	87-90
7591249-6	1995	The specific anti-EL4 effector cell from the cyclophosphamide-induced immune-LTS was CD4- CD8+; however, approximately 50% of those from combination-treated immune-LTS appeared to be CD4+CD8+.	Cyclophosphamide	45-61	CD4 antigen	Mus musculus	85-88
7489735-0	1995	Major histocompatibility complex class I-restricted CD8+ T cells and class II-restricted CD4+ T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene.	Dinitrofluorobenzene	161-181	CD4 antigen	Mus musculus	89-92
7489735-8	1995	These data clearly demonstrate that class I-restricted CD8+ T cells are sufficient for the induction of CS to DNFB, and further support the idea that MHC class II-restricted CD4+ T cells down-regulate this inflammatory response.	Dinitrofluorobenzene	110-114	CD4 antigen	Mus musculus	174-177
7489761-7	1995	Interestingly, B220+ Thy-1+ CD4-CD8- T lymphocytes from MRL-lpr mice were most sensitive to H-7 for apoptosis induction.	1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine	92-95	CD4 antigen	Mus musculus	28-31
7584154-5	1995	These results suggest that glucocorticoids are necessary for survival and maturation of thymocytes, and are consistent with a role for steroids in both the transition from CD4-CD8- to CD4+CD8+ cells and the survival of CD4+CD8+ cells stimulated via the TCR.	Steroids	135-143	CD4 antigen	Mus musculus	172-175
7584154-5	1995	These results suggest that glucocorticoids are necessary for survival and maturation of thymocytes, and are consistent with a role for steroids in both the transition from CD4-CD8- to CD4+CD8+ cells and the survival of CD4+CD8+ cells stimulated via the TCR.	Steroids	135-143	CD4 antigen	Mus musculus	184-187
7584154-5	1995	These results suggest that glucocorticoids are necessary for survival and maturation of thymocytes, and are consistent with a role for steroids in both the transition from CD4-CD8- to CD4+CD8+ cells and the survival of CD4+CD8+ cells stimulated via the TCR.	Steroids	135-143	CD4 antigen	Mus musculus	184-187
7594578-4	1995	Most of the TCR-alpha beta i-IEL whose development was inhibited by CSA belonged to the CD4-CD8+ alpha alpha subset.	Cyclosporine	68-71	CD4 antigen	Mus musculus	88-91
7561090-4	1995	Adhesion to antigenic class II proteins was CD4 dependent and inhibited by pretreatment of T cells with the protein tyrosine kinase inhibitor herbimycin A, suggesting that adhesion requires TCR- and/or CD4-derived signal transduction.	herbimycin	142-154	CD4 antigen	Mus musculus	44-47
7561090-4	1995	Adhesion to antigenic class II proteins was CD4 dependent and inhibited by pretreatment of T cells with the protein tyrosine kinase inhibitor herbimycin A, suggesting that adhesion requires TCR- and/or CD4-derived signal transduction.	herbimycin	142-154	CD4 antigen	Mus musculus	202-205
8589919-8	1995	Cleavage of HSA on KC surfaces by a phosphoinositol-specific phospholipase C (PI-PLC) also significantly inhibited the costimulatory capacity of KC for naive CD4+ T cells.	phosphoinositol	36-51	CD4 antigen	Mus musculus	158-161
7561048-4	1995	That anti-CD40L mAb also inhibited PC-specific IgG production is consistent with the possibility that cognate CD4+ T cell-B cell interactions are important in PCP resolution.	pcp	159-162	CD4 antigen	Mus musculus	10-13
7561696-6	1995	OvAg-stimulated lymph node and spleen cell cytokine production was dependent on CD4 cells and included interleukin (IL)-4 and IL-5, but not interferon gamma, indicating a predominant T helper type 2 cell-like response.	ovag	0-4	CD4 antigen	Mus musculus	80-83
7673702-7	1995	Flow cytometry revealed that NO treatment as well as heat shock or dexamethasone incubation is accompanied by reduction in the CD4+ CD8+ thymocyte subpopulation.	Dexamethasone	67-80	CD4 antigen	Mus musculus	127-130
8582785-11	1995	The inhibiting effect of Zn2+ on apoptosis is related to an increase in the number of CD4+CD8+ thymocytes.	Zinc	25-29	CD4 antigen	Mus musculus	86-89
8582785-12	1995	Concentrations of Zn2+ inducing apoptosis sometimes cause a decrease of CD4+CD8+ cells with a corresponding increase of CD4+CD8-thymocytes.	Zinc	18-22	CD4 antigen	Mus musculus	72-75
8582785-12	1995	Concentrations of Zn2+ inducing apoptosis sometimes cause a decrease of CD4+CD8+ cells with a corresponding increase of CD4+CD8-thymocytes.	Zinc	18-22	CD4 antigen	Mus musculus	120-123
8786341-9	1995	Cell phenotyping demonstrated that SWAC transients are primarily associated with immature CD4-CD8- and CD4+CD8+ thymocytes.	swac	35-39	CD4 antigen	Mus musculus	90-93
8786341-9	1995	Cell phenotyping demonstrated that SWAC transients are primarily associated with immature CD4-CD8- and CD4+CD8+ thymocytes.	swac	35-39	CD4 antigen	Mus musculus	103-106
8786341-17	1995	TG stimulated the CRAC influx pathway in all four thymic CD4/CD8 subsets and in mature T cells.	crac	18-22	CD4 antigen	Mus musculus	57-60
7621990-5	1995	Streptozotocin (STZ)-treated syngeneic islets were transplanted into the thymuses of C57BL/KsJ mice, and CD4+, CD8+, or both subsets of cells were transiently depleted with monoclonal antibodies (mAbs).	Streptozocin	0-14	CD4 antigen	Mus musculus	105-108
8522358-5	1995	In the recipient C3H mice treated with anti-CD4 mAb, F344 s.c. plus BMC and CY, mixed chimerism in the periphery was detected for a few days after CY administration, although intrathymic chimerism was not detected throughout this study.	Cyclophosphamide	147-149	CD4 antigen	Mus musculus	44-47
7543492-6	1995	Increased thymic apoptosis resulted in the disappearance of CD4+ CD8+ thymocytes after anti-CD3 Ab/FK506 treatment.	Tacrolimus	99-104	CD4 antigen	Mus musculus	60-63
7543525-0	1995	The antirheumatic drug disodium aurothiomalate inhibits CD4+ T cell recognition of peptides containing two or more cysteine residues.	Gold Sodium Thiomalate	23-46	CD4 antigen	Mus musculus	56-59
7543525-0	1995	The antirheumatic drug disodium aurothiomalate inhibits CD4+ T cell recognition of peptides containing two or more cysteine residues.	Peptides	83-91	CD4 antigen	Mus musculus	56-59
7543525-0	1995	The antirheumatic drug disodium aurothiomalate inhibits CD4+ T cell recognition of peptides containing two or more cysteine residues.	Cysteine	115-123	CD4 antigen	Mus musculus	56-59
8569276-9	1995	Collectively, Gx appeared to promote immigration of thymocyte precursors into the thymus and to enhance proliferation and differentiation of thymocytes towards CD4+CD8- T cells, in an age-related manner.	glycinexylidide	14-16	CD4 antigen	Mus musculus	160-163
8586490-0	1995	Suppressive effect of actarit on IgA production in mice: activation of CD4+ suppressor T-cells in Peyer"s patches.	4-(acetylamino)benzeneacetic acid	22-29	CD4 antigen	Mus musculus	71-74
8586490-6	1995	The suppressive effect of PP lymphocytes from mice treated with actarit was abrogated by the elimination of CD4+ cells (not CD8+ cells) from PP lymphocytes.	4-(acetylamino)benzeneacetic acid	64-71	CD4 antigen	Mus musculus	108-111
8586490-7	1995	These results suggest that actarit activates CD4+ suppressor T-cells in the PP, resulting in a specific suppression of IgA production after LPS stimulation.	4-(acetylamino)benzeneacetic acid	27-34	CD4 antigen	Mus musculus	45-48
7602121-2	1995	These mice develop lymphadenopathy because of an age-related accumulation of nonmalignant CD4- CD8- T cells in the peripheral lymphoid organs, suggesting a role for Fas-mediated apoptosis in peripheral T cell homeostasis.	ammonium ferrous sulfate	165-168	CD4 antigen	Mus musculus	90-93
7614232-6	1995	Using a fusion protein containing the SH2 domains of PLC gamma 1 and human IgG1 heavy chain, we identified three additional proteins that bind to the SH2 domains which were tyrosine phosphorylated following CD3 x CD4 ligation to a lesser degree with age.	Tyrosine	173-181	CD4 antigen	Mus musculus	213-216
7759895-9	1995	Treatment with 2"-beta-fluoro-2",3"-dideoxyadenosine, a nucleoside analogue, significantly reduced CD4+ T cell depletion (CD4 = 13 +/- 1; n = 59; p &lt; 0.001) and the frequency of virus isolation (70%; p = 0.015) in the hu-HIV/PBL-SCID model.	lodenosine	15-52	CD4 antigen	Mus musculus	99-102
7759895-9	1995	Treatment with 2"-beta-fluoro-2",3"-dideoxyadenosine, a nucleoside analogue, significantly reduced CD4+ T cell depletion (CD4 = 13 +/- 1; n = 59; p &lt; 0.001) and the frequency of virus isolation (70%; p = 0.015) in the hu-HIV/PBL-SCID model.	lodenosine	15-52	CD4 antigen	Mus musculus	122-125
7759895-9	1995	Treatment with 2"-beta-fluoro-2",3"-dideoxyadenosine, a nucleoside analogue, significantly reduced CD4+ T cell depletion (CD4 = 13 +/- 1; n = 59; p &lt; 0.001) and the frequency of virus isolation (70%; p = 0.015) in the hu-HIV/PBL-SCID model.	Nucleosides	56-66	CD4 antigen	Mus musculus	99-102
7759895-9	1995	Treatment with 2"-beta-fluoro-2",3"-dideoxyadenosine, a nucleoside analogue, significantly reduced CD4+ T cell depletion (CD4 = 13 +/- 1; n = 59; p &lt; 0.001) and the frequency of virus isolation (70%; p = 0.015) in the hu-HIV/PBL-SCID model.	Nucleosides	56-66	CD4 antigen	Mus musculus	122-125
7564569-0	1995	Rapid tyrosine phosphorylation of Grb2 and Shc in T cells exposed to anti-CD3, anti-CD4, and anti-CD45 stimuli: differential effects of aging.	Tyrosine	6-14	CD4 antigen	Mus musculus	84-87
7791081-4	1995	[D-Ala2]-deltorphin 1 (deltorphin) dose-dependently inhibited the proliferation of C57BL/6 CD4+ T cells by approximately 50%.	deltorphin	9-19	CD4 antigen	Mus musculus	91-94
7791081-7	1995	Naltrindole 10(-12) M abolished the antiproliferative effect of 10(-7) M deltorphin on CD4+ T cells.	naltrindole	0-11	CD4 antigen	Mus musculus	87-90
7791081-7	1995	Naltrindole 10(-12) M abolished the antiproliferative effect of 10(-7) M deltorphin on CD4+ T cells.	deltorphin	73-83	CD4 antigen	Mus musculus	87-90
7759164-8	1995	B16 or 3LL-TBH that received ACIT using CY with B16 or 3LL-derived CD4-depleted ALT cells also cured metastatic disease but only if CD4+ T cells were depleted after T3CS activation.	tbh	11-14	CD4 antigen	Mus musculus	67-70
7759164-8	1995	B16 or 3LL-TBH that received ACIT using CY with B16 or 3LL-derived CD4-depleted ALT cells also cured metastatic disease but only if CD4+ T cells were depleted after T3CS activation.	tbh	11-14	CD4 antigen	Mus musculus	132-135
7767963-11	1995	Since the main phenotype of MNU induced lymphomas in these mice, CD4+CD8+J11d+, is also the cell phenotype which expresses the MGMT-CD2 transgene at high levels, it appears that MGMT-induced protection has occurred in the cell target for MNU induced transformation.	Methylnitrosourea	28-31	CD4 antigen	Mus musculus	65-68
7774650-5	1995	Among mature thymocytes, P-gly activity is absent in the CD4+ subset but present in the more mature (HSAlow) fraction of CD8+ cells.	Glycine	27-30	CD4 antigen	Mus musculus	57-60
7722287-7	1995	These data suggest that the spleens of both young and old mice contain two kinds of Con A-responsive CD4 cell: one that proliferates vigorously, and a second, calcium ionophore-resistant type that proliferates less well, that can interfere with proliferation of the first cell type, and whose frequency increases with age.	Calcium	159-166	CD4 antigen	Mus musculus	101-104
7697735-3	1995	In contrast, the late-acting, NiSO4-specific DTH-effector T cells were: Thy-1+, CD5+, CD3+, CD4+, CD8-, CD23-, B220-, IL-2R+, IL-3R-, sIg-, MHC Class II-, Mel-14+, CD44- (Pgp-1-), J11d- (HSA-), MAC-1-, LFA-1+, and Fc gamma II-R-.	nickel sulfate	30-35	CD4 antigen	Mus musculus	92-95
7790024-7	1995	Transfer studies using a MHV-A59-specific CD4+ CTL clone showed significant protection against a lethal challenge with MHV-A59, implicating that these CD4+ CTL play a pivotal role in the protection against MHV-A59 infections.	mhv-a59	25-32	CD4 antigen	Mus musculus	42-45
7790024-7	1995	Transfer studies using a MHV-A59-specific CD4+ CTL clone showed significant protection against a lethal challenge with MHV-A59, implicating that these CD4+ CTL play a pivotal role in the protection against MHV-A59 infections.	mhv-a59	25-32	CD4 antigen	Mus musculus	151-154
7547689-4	1995	Consistent with the conclusion that activated p56lck causes lower TCR expression, the PTK inhibitor, herbimycin A, was able to restore TCR expression to normal levels in CD4+CD8+ thymocytes from TCR/lckF505 doubly transgenic mice.	herbimycin	101-113	CD4 antigen	Mus musculus	170-173
7547689-5	1995	However, despite lower TCR expression, calcium mobilization was only moderately reduced in CD4+CD8+ thymocytes from H-Y TCR/lckF505 doubly transgenic mice.	Calcium	39-46	CD4 antigen	Mus musculus	91-94
7698979-6	1995	Replacing the GPI addition signal with the transmembrane and cytoplasmic domains of mouse CD4 rendered chimeric CD4PrPC soluble in cold Triton X-100.	Octoxynol	136-148	CD4 antigen	Mus musculus	90-93
7897203-6	1995	Both T lymphocytes and adherent cells were required for activation, and anti-CD4 Ab completely abrogated HgCl2-induced proliferation, suggesting the involvement of T helper cells.	Mercuric Chloride	105-110	CD4 antigen	Mus musculus	77-80
7540861-5	1995	When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin.	Cyclosporine	168-171	CD4 antigen	Mus musculus	20-23
7540861-5	1995	When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin.	immunomycin	173-179	CD4 antigen	Mus musculus	20-23
7540861-5	1995	When we used either CD4+CD8+ thymocytes or peripheral T cells activated by phorbol ester and ionomycin, the cell surface induction of CD5 was also partially blocked by CsA, FK-520 and rapamycin.	Sirolimus	184-193	CD4 antigen	Mus musculus	20-23
7751034-2	1995	One widely used method of inducing anergy of CD4+Th is presentation of antigen by ECDI (1-ethyl-3-(3-dimethylamino-propyl)carbodiimide)-fixed antigen-presenting cells (APCs).	Ethyldimethylaminopropyl Carbodiimide	88-134	CD4 antigen	Mus musculus	45-48
7775156-5	1995	Chronic morphine treatment increased the percentage (25-30%) of CD3+ CD4+ and CD8+, but not Ig+ cells in the spleen relative to saline-treated controls.	Morphine	8-16	CD4 antigen	Mus musculus	69-72
7775156-6	1995	Pretreatment of mice with the mu-selective antagonist, beta-funaltrexamine blocked morphine-mediated suppression of splenic and peritoneal CTL activity as well as the increase in CD3+ CD4+ and CD8+ splenic lymphocytes.	beta-funaltrexamine	55-74	CD4 antigen	Mus musculus	184-187
7775160-4	1995	Morphine (administered as subcutaneous implants) had profound inhibitory effects on the development of alloreactivity manifested as a suppression of: (1) lymph node hyperplasia, (2) mixed lymphocyte reactivity (MLR) in PLN cells and (3) the number of CD4+ and Thy 1.2 lymphoid subsets.	Morphine	0-8	CD4 antigen	Mus musculus	251-254
7532685-3	1995	The effect of FK506, an inhibitor of calcineurin activation, on positive and negative selection in CD4+CD8+ double positive (DP) thymocytes was examined in normal mice and in a TCR transgenic mouse model.	Tacrolimus	14-19	CD4 antigen	Mus musculus	99-102
7532685-5	1995	In addition, the shutdown of recombination activating gene 1 (RAG-1) transcription and the downregulation of CD4 and CD8 expression were inhibited by FK506 treatment suggesting that the activation of calcineurin is required for the first step (or the very early intracellular signaling events) of TCR-mediated positive selection of DP thymocytes.	Tacrolimus	150-155	CD4 antigen	Mus musculus	109-112
7750993-7	1995	Examination of cells from pp59fyn-deficient mice showed that pp59fyn deficiency affects the amplitude and probability, but not the latency or synchrony, of CD3-mediated [Ca2+]i responses of CD4+ CD8+ and CD4+ CD8- thymocytes.	pp59fyn	26-33	CD4 antigen	Mus musculus	190-193
7759770-5	1995	While demonstrating no obvious morphological toxicity in vivo in mice at concentrations of 75 and 150 mg/kg, 2",3"-dideoxy-beta-L-5-fluorocytidine- treated animals were shown to have considerable increases in CD4/CD8 double positive T lymphocyte population in their blood circulation.	2',3'-dideoxy-beta-5-fluorocytidine	109-146	CD4 antigen	Mus musculus	209-212
7530758-5	1995	Little or low levels of Fas were expressed in CD4-CD8- double negative thymocytes except for the CD4-CD8-CD3+ phenotype, which expresses Fas as abundantly as double positive or single positive subsets.	ammonium ferrous sulfate	24-27	CD4 antigen	Mus musculus	46-49
7822814-7	1995	Unexpectedly, the CD28-induced calcium response was mainly limited to T cells of the CD4+ subset, whereas both CD4+ and CD8+ T cell subsets showed increases in [Ca2+]i of similar magnitude after CD3 epsilon ligation.	Calcium	31-38	CD4 antigen	Mus musculus	85-88
7863263-3	1995	Nitric oxide release and inducible nitric oxide synthase mRNA accumulation by cells from Tulahuen infected CD4- mice was also diminished.	Nitric Oxide	0-12	CD4 antigen	Mus musculus	107-110
7613876-2	1995	The full-length CD4 cDNA from murine eggs was synthesised by the reverse transcriptase-polymerase chain reaction (RT-PCR) method and its authenticity verified by Southern blot hybridisation using an end-labelled internal oligonucleotide.	Oligonucleotides	221-236	CD4 antigen	Mus musculus	16-19
7668157-5	1995	Previous experiments had shown that deltorphin and [D-Ala2]-met-enkephalinamide (DAME), at concentrations from 10(-11) to 10(-7) M, dose dependently inhibited the proliferation of CD4+ and CD8+ T-cells obtained from female C57BL/6 or CD1 mice.	deltorphin	36-46	CD4 antigen	Mus musculus	180-183
7668157-5	1995	Previous experiments had shown that deltorphin and [D-Ala2]-met-enkephalinamide (DAME), at concentrations from 10(-11) to 10(-7) M, dose dependently inhibited the proliferation of CD4+ and CD8+ T-cells obtained from female C57BL/6 or CD1 mice.	[d-ala2]-met-enkephalinamide	51-79	CD4 antigen	Mus musculus	180-183
7668157-6	1995	Similarly, the experiments herein demonstrate that proliferation of CD4+ T-cells from female CD1 mice was inhibited by 2,5 DPDP-enkephalin (DPDP-E), in direct relation to dose.	2,5 dpdp-enkephalin	119-138	CD4 antigen	Mus musculus	68-71
7668157-6	1995	Similarly, the experiments herein demonstrate that proliferation of CD4+ T-cells from female CD1 mice was inhibited by 2,5 DPDP-enkephalin (DPDP-E), in direct relation to dose.	dpdp-e	140-146	CD4 antigen	Mus musculus	68-71
7578872-10	1995	In parallel studies, normal Swiss male mice given stz at a similar dose developed diabetes (10/10) associated with insulitis which consisted predominantly of CD4, CD8 and MAC-1 cells.	Streptozocin	50-53	CD4 antigen	Mus musculus	158-161
7803485-4	1994	Treatment with Dex alone most extensively depleted the high- and medium-density thymocytes and also those expressing both CD4 and CD8 double positive (DP) phenotypes in all three subpopulations.	Dexamethasone	15-18	CD4 antigen	Mus musculus	122-125
7803485-5	1994	The CD4+ and CD8+ single positive (SP) and CD4-CD8- double negative (DN) subsets, in the low-density subpopulation in particular, were most resistant to the Dex-mediated depletion, thus giving rise to an enrichment of SP (2-fold) and particularly DN subset in the medium- and low-density populations (5-fold) recovered.	sp	35-37	CD4 antigen	Mus musculus	4-7
7803485-5	1994	The CD4+ and CD8+ single positive (SP) and CD4-CD8- double negative (DN) subsets, in the low-density subpopulation in particular, were most resistant to the Dex-mediated depletion, thus giving rise to an enrichment of SP (2-fold) and particularly DN subset in the medium- and low-density populations (5-fold) recovered.	Dexamethasone	157-160	CD4 antigen	Mus musculus	4-7
7803485-5	1994	The CD4+ and CD8+ single positive (SP) and CD4-CD8- double negative (DN) subsets, in the low-density subpopulation in particular, were most resistant to the Dex-mediated depletion, thus giving rise to an enrichment of SP (2-fold) and particularly DN subset in the medium- and low-density populations (5-fold) recovered.	Dexamethasone	157-160	CD4 antigen	Mus musculus	43-46
7803485-5	1994	The CD4+ and CD8+ single positive (SP) and CD4-CD8- double negative (DN) subsets, in the low-density subpopulation in particular, were most resistant to the Dex-mediated depletion, thus giving rise to an enrichment of SP (2-fold) and particularly DN subset in the medium- and low-density populations (5-fold) recovered.	sp	218-220	CD4 antigen	Mus musculus	4-7
7803485-5	1994	The CD4+ and CD8+ single positive (SP) and CD4-CD8- double negative (DN) subsets, in the low-density subpopulation in particular, were most resistant to the Dex-mediated depletion, thus giving rise to an enrichment of SP (2-fold) and particularly DN subset in the medium- and low-density populations (5-fold) recovered.	dn	69-71	CD4 antigen	Mus musculus	4-7
7527069-1	1994	Monoclonal antibodies were generated against the feline homologue of CD4 (fCD4) by immunisation of mice with solid matrix antigen-antibody complexes of monoclonal antibody Fel7 (anti-fCD4) and formalin-fixed Staphylococcus A (SMAA-fCD4).	Formaldehyde	193-201	CD4 antigen	Mus musculus	69-72
7525854-4	1994	To examine the role of L-selectin in helper T cell migration, we studied the effects of in vivo administration of MEL-14 on CD4 cell responses.	mel-14	114-120	CD4 antigen	Mus musculus	124-127
7525854-5	1994	Systemic exposure of mice to MEL-14 depleted CD4 cells expressing a naive phenotype (CD45RBhi, CD44lo) from PLN but not from spleen.	mel-14	29-35	CD4 antigen	Mus musculus	45-48
7525854-7	1994	MEL-14 treatment prevented priming of naive CD4 cells for proliferation and cytokine production (IL-2 and IL-4) to keyhole limpet hemocyanin in PLN draining the site of Ag injection, but not in the spleen.	mel-14	0-6	CD4 antigen	Mus musculus	44-47
7949193-7	1994	Transplantation of B10 cells in LP recipients triggered an important T-cell-dependent 125I-dUrd uptake in several organs that involved both CD4+ and CD8+ cells.	125i-durd	86-95	CD4 antigen	Mus musculus	140-143
7851158-6	1994	The combination of saponin and digitonin treatment was also compatible with the staining of sCD3 and other lymphocyte surface antigens such as Thy1, CD4, CD8, B220, and IgM.	Saponins	19-26	CD4 antigen	Mus musculus	149-152
7851158-6	1994	The combination of saponin and digitonin treatment was also compatible with the staining of sCD3 and other lymphocyte surface antigens such as Thy1, CD4, CD8, B220, and IgM.	Digitonin	31-40	CD4 antigen	Mus musculus	149-152
7835966-3	1994	In this study we have shown that CD3 ligation on murine T-cell hybridomas induces tyrosine phosphorylation of proteins, including phospholipase C-gamma 1 (PLC gamma 1), both in the presence as well as in the absence of CD4-linked p56lck.	Tyrosine	82-90	CD4 antigen	Mus musculus	219-222
7835966-5	1994	Not even co-aggregation of CD4 with CD3 triggers tyrosine phosphorylation of proteins in these cells.	Tyrosine	49-57	CD4 antigen	Mus musculus	27-30
7523511-4	1994	Purified CD4+ T cells injected into B6 nude mice are able to generate DNT cells; furthermore, phenotypic and functional characterizations of the DNT cells generated in vivo show that they share the same properties as DNT cells from B6-lpr/lpr mice.	2,6-dinitrotoluene	70-73	CD4 antigen	Mus musculus	9-12
7523511-4	1994	Purified CD4+ T cells injected into B6 nude mice are able to generate DNT cells; furthermore, phenotypic and functional characterizations of the DNT cells generated in vivo show that they share the same properties as DNT cells from B6-lpr/lpr mice.	2,6-dinitrotoluene	145-148	CD4 antigen	Mus musculus	9-12
7523511-4	1994	Purified CD4+ T cells injected into B6 nude mice are able to generate DNT cells; furthermore, phenotypic and functional characterizations of the DNT cells generated in vivo show that they share the same properties as DNT cells from B6-lpr/lpr mice.	2,6-dinitrotoluene	145-148	CD4 antigen	Mus musculus	9-12
7925567-9	1994	More strikingly, deletion of CD4+8+ thymocytes from BM3.3-Tg increased, whilst activation was partially inhibited by CsA.	Cyclosporine	117-120	CD4 antigen	Mus musculus	29-32
7826942-5	1994	The anti-CD3-induced generation of CD4-CD8+ cells from scid and normal fetal thymus cultures was inhibited by tyrosine kinase inhibitors Herbimycin A and Tyrphostin.	herbimycin	137-149	CD4 antigen	Mus musculus	35-38
7826942-5	1994	The anti-CD3-induced generation of CD4-CD8+ cells from scid and normal fetal thymus cultures was inhibited by tyrosine kinase inhibitors Herbimycin A and Tyrphostin.	Tyrphostins	154-164	CD4 antigen	Mus musculus	35-38
7931071-4	1994	CIC complexes are expressed in normal mice on early thymocytes through the CD4+CD8+ stage of development, but not on mature peripheral T cells.	cic	0-3	CD4 antigen	Mus musculus	75-78
7929062-12	1994	The effects of CD4/Lck on tyrosine phosphorylation and activation of PLC correlated well with the effects on PTK activation.	Tyrosine	26-34	CD4 antigen	Mus musculus	15-18
7819141-0	1994	cAMP up-regulates IL-4 and IL-5 production from activated CD4+ T cells while decreasing IL-2 release and NF-AT induction.	Cyclic AMP	0-4	CD4 antigen	Mus musculus	58-61
7819141-7	1994	These results suggest that, in activated CD4+ T cells, cAMP-elevating agents induce a switch of lymphokine production towards a Th2-like phenotype through regulation at the transcriptional level.	Cyclic AMP	55-59	CD4 antigen	Mus musculus	41-44
7819141-8	1994	This is supported by the fact that complex formation between a synthetic nuclear factor of activated T cells (NF-AT) binding site from the IL-2 promoter and nuclear extracts was decreased when cholera toxin was added to re-activated CD4+ T cells, suggesting that cholera toxin and cAMP down-regulate IL-2 expression via decreased NF-AT binding.	Cyclic AMP	281-285	CD4 antigen	Mus musculus	233-236
7819141-9	1994	Finally, since IL-4 has been reported to amplify IL-4 release from activated CD4+ T cells, the autoinduction of IL-4 may very well function via cAMP.	Cyclic AMP	144-148	CD4 antigen	Mus musculus	77-80
7821962-2	1994	In this study, mice were immunized subcutaneously with alum-precipitated keyhole limpet haemocyanin (KLH) in adjuvant to activate interleukin-4 (IL-4)-producing CD4+ T cells.	aluminum sulfate	55-59	CD4 antigen	Mus musculus	161-164
8051402-8	1994	Finally, the cells responding to IL-1 + IL-7 were identified as mature CD4-CD8-TCR+ thymocytes by the use of bromodeoxyuridine (BrdUrd), suggesting that the GM-CSF produced by thymic accessory cells in response to IL-1 participates in IL-7-dependent, intrathymic expansion of the CD4-CD8-TCR+ compartment.	Bromodeoxyuridine	109-126	CD4 antigen	Mus musculus	71-74
7916376-3	1994	The dietary alpha-linolenate to linoleate balance was reflected in the proportion of (n-3) and (n-6) highly unsaturated fatty acids with 20- and 22-carbon chains in spleen phospholipids, but the ratio did not affect the proportion of T lymphocyte subsets expressing CD4 and CD8 antigens in splenic leukocytes.	alpha-Linolenic Acid	12-28	CD4 antigen	Mus musculus	266-269
7914155-6	1994	Depletion of CD4+ T cells inhibited the transfer of arthritis to SCID mice, with a decrease in CII antibody titre in chimaeras.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	95-98	CD4 antigen	Mus musculus	13-16
8000708-2	1994	Our results show that alpha beta TCR-bearing T cells of both the CD4+ and CD8+ subtypes from lymph nodes of DNFB-skin-painted mice proliferate specifically to dinitrobenzene sulfonate (DNBS) in vitro.	Dinitrofluorobenzene	108-112	CD4 antigen	Mus musculus	65-68
8000708-2	1994	Our results show that alpha beta TCR-bearing T cells of both the CD4+ and CD8+ subtypes from lymph nodes of DNFB-skin-painted mice proliferate specifically to dinitrobenzene sulfonate (DNBS) in vitro.	dinitrobenzene sulfonate	159-183	CD4 antigen	Mus musculus	65-68
7798591-7	1994	Furthermore, flow cytometric analysis using monoclonal antibodies (mAbs) specific for thymocyte subsets confirmed that CsA induces a large decrease in the relative number of mature single positive (SP) CD4+CD8- and CD8+CD4- thymocytes expressing high densities of CD3 and T cell receptor ab (TCR alpha beta) surface molecules, but also a decrease in the absolute number of the other thymocyte subsets.	Cyclosporine	119-122	CD4 antigen	Mus musculus	202-205
7798591-7	1994	Furthermore, flow cytometric analysis using monoclonal antibodies (mAbs) specific for thymocyte subsets confirmed that CsA induces a large decrease in the relative number of mature single positive (SP) CD4+CD8- and CD8+CD4- thymocytes expressing high densities of CD3 and T cell receptor ab (TCR alpha beta) surface molecules, but also a decrease in the absolute number of the other thymocyte subsets.	Cyclosporine	119-122	CD4 antigen	Mus musculus	219-222
7981142-0	1994	3H11, a unique cell surface molecule involved in the function of the CD45RA+ subset of CD4+ cells.	3h11	0-4	CD4 antigen	Mus musculus	69-72
7981142-2	1994	Anti-3H11 is reactive with approximately 48% of unfractionated T cells, 62% of CD4+ cells and 39% of CD8+ cells.	3h11	5-9	CD4 antigen	Mus musculus	79-82
7981142-3	1994	Among CD4 cells, anti-3H11 preferentially reacts with the CD45RA+ T cell subset.	3h11	22-26	CD4 antigen	Mus musculus	6-9
7981142-7	1994	Interestingly, addition of anti-3H11 to the combination of CD4 and B cells in the presence of CD8 cells but not to the combination of CD4 and B cells resulted in enhancement of the suppression of PWM-driven B cell IgG synthesis.	3h11	32-36	CD4 antigen	Mus musculus	59-62
8035512-4	1994	Treatment of females with testosterone or males with estradiol prior to infection alters subsequent Th subset differentiation, suggesting that the sex-associated hormones have either a direct or indirect effect on CD4+ lymphocyte responses in this model.	Testosterone	26-38	CD4 antigen	Mus musculus	214-217
7912705-0	1994	Extrusion of the P glycoprotein substrate rhodamine-123 distinguishes CD4 memory T cell subsets that differ in IL-2-driven IL-4 production.	Rhodamine 123	42-55	CD4 antigen	Mus musculus	70-73
8033411-6	1994	After administration of CsA to newborn NOD mice, there was a reduction (P &lt; 0.01) of both CD4+CD8- and CD4-CD8+ thymocytes, whereas the number of double positive CD4+CD8+ thymocytes was increased.	Cyclosporine	24-27	CD4 antigen	Mus musculus	93-96
8033411-6	1994	After administration of CsA to newborn NOD mice, there was a reduction (P &lt; 0.01) of both CD4+CD8- and CD4-CD8+ thymocytes, whereas the number of double positive CD4+CD8+ thymocytes was increased.	Cyclosporine	24-27	CD4 antigen	Mus musculus	106-109
8033411-6	1994	After administration of CsA to newborn NOD mice, there was a reduction (P &lt; 0.01) of both CD4+CD8- and CD4-CD8+ thymocytes, whereas the number of double positive CD4+CD8+ thymocytes was increased.	Cyclosporine	24-27	CD4 antigen	Mus musculus	106-109
7953532-5	1994	We therefore used a dual imaging system that provides simultaneous transmission and fluorescence images to study the morphological changes and variations of intracellular calcium concentration ([Ca2+]i) triggered in a human CD4+ antigen-specific T-cell clone in response to antigen presented by a class II-transfected murine fibroblast.	Calcium	171-178	CD4 antigen	Mus musculus	224-227
7913905-4	1994	However, on 24-hr pulsed co-exposure to vomitoxin and the mitogen concanavalin A (ConA), CD4+/CD8+ cells were capable of inducing a three- to five-fold increase in production of IgA, but not IgG and IgM by cocultured B cells when compared with B cells cocultured with control T cells exposed to the mitogen only.	deoxynivalenol	40-49	CD4 antigen	Mus musculus	89-92
7913905-6	1994	48-hr pulsed exposure of CD4+ cells to ConA and vomitoxin resulted in significantly increased production of the T helper cytokines IL-4, IL-5 and IL-6 after 5 additional days of culture, compared with ConA-stimulated CD4+ cells alone.	deoxynivalenol	48-57	CD4 antigen	Mus musculus	25-28
7913905-6	1994	48-hr pulsed exposure of CD4+ cells to ConA and vomitoxin resulted in significantly increased production of the T helper cytokines IL-4, IL-5 and IL-6 after 5 additional days of culture, compared with ConA-stimulated CD4+ cells alone.	deoxynivalenol	48-57	CD4 antigen	Mus musculus	217-220
7913905-7	1994	These results suggest that vomitoxin was capable of enhancing CD4(+)-mediated help for IgA production by B cells and that this could possibly be mediated by way of increased cytokine production.	deoxynivalenol	27-36	CD4 antigen	Mus musculus	62-65
7959869-3	1994	However, when spleen cells were obtained from Orx-0 mice that had received a dihydrotestosterone (DHT) pellet when adult to develop a mature prostate, prostatitis could be prevented, suggesting that immune tolerance to prostate antigen(s) is maintained by a CD4+ tissue-specific suppressor T cell (Ts) population(s), which is activated by a specific autoantigen(s) in the mature prostate.	Dihydrotestosterone	77-96	CD4 antigen	Mus musculus	258-261
7959869-4	1994	The result that even CD4+ cells from Orx-0 mice that were thymectomized as adults and treated thereafter with DHT were effective for prevention of prostatitis suggests that activation of this Ts population takes place in the peripheral lymphoid organs, and that it maintains peripheral tolerance to autoantigen in the prostate of these mice and probably also in normal mice.	Dihydrotestosterone	110-113	CD4 antigen	Mus musculus	21-24
8006585-3	1994	The CD4-8+ T cells require I-Ed class II MHC molecules for positive selection and can be activated to proliferate and to kill by I-Ed molecules presenting the relevant peptide.	i-ed	27-31	CD4 antigen	Mus musculus	4-7
8006585-3	1994	The CD4-8+ T cells require I-Ed class II MHC molecules for positive selection and can be activated to proliferate and to kill by I-Ed molecules presenting the relevant peptide.	i-ed	129-133	CD4 antigen	Mus musculus	4-7
8034756-5	1994	The 2-DG-induced inhibition of T cell proliferation was not attributable to 2-DG-induced cytolysis, as in vitro incubation of naive T cells with varying concentrations of 2-DG did not result in a reduction in cell number or viability, and flow cytometric analysis demonstrated that percentages of CD3, CD4, and CD8 splenic T cells were not altered as a result of 2-DG-induced stress.	Deoxyglucose	4-8	CD4 antigen	Mus musculus	302-305
8021962-4	1994	Flow cytometric analysis indicated that the BaP treatment resulted in a significant decrease in the percentage of CD4+8+ fetal thymocytes, as well as significantly increased CD4-8- and CD4-8+ thymocytes.	Benzo(a)pyrene	44-47	CD4 antigen	Mus musculus	114-117
8021962-4	1994	Flow cytometric analysis indicated that the BaP treatment resulted in a significant decrease in the percentage of CD4+8+ fetal thymocytes, as well as significantly increased CD4-8- and CD4-8+ thymocytes.	Benzo(a)pyrene	44-47	CD4 antigen	Mus musculus	174-177
8021962-4	1994	Flow cytometric analysis indicated that the BaP treatment resulted in a significant decrease in the percentage of CD4+8+ fetal thymocytes, as well as significantly increased CD4-8- and CD4-8+ thymocytes.	Benzo(a)pyrene	44-47	CD4 antigen	Mus musculus	174-177
7520709-7	1994	The supernatants from both HSA-primed CD4+ and CD8+ T cells suppressed the PFC response to SRBC in vitro, and the suppressive activity was abrogated by anti-IFN-gamma mAb, but increased by anti-IL 4 mAb.	srbc	91-95	CD4 antigen	Mus musculus	38-41
7515103-2	1994	However, CD4- variants could only respond to peptides containing the two COOH-terminal tryptophans at positions 62 and 63.	Tryptophan	87-98	CD4 antigen	Mus musculus	9-12
7514297-11	1994	Our study demonstrates that CD4+ Th1 cells and CD8+ CTLs differ in their (Ca2+)ext-dependent cytotoxicity but share a (Ca2+)ext-independent cytotoxicity that requires participation of Fas molecules for cytotoxic signal transduction leading to target apoptosis.	ammonium ferrous sulfate	184-187	CD4 antigen	Mus musculus	28-31
7519170-0	1994	Residues within the alpha subunit sequence 304-322 of muscle acetylcholine receptor forming autoimmune CD4+ epitopes in BALB/c mice.	Acetylcholine	61-74	CD4 antigen	Mus musculus	103-106
7519170-13	1994	Substitution of Q310 had minimal or no effects, while those of K314 or D318 strongly affected the CD4+ cell response.	k314	63-67	CD4 antigen	Mus musculus	98-101
7519170-13	1994	Substitution of Q310 had minimal or no effects, while those of K314 or D318 strongly affected the CD4+ cell response.	d318	71-75	CD4 antigen	Mus musculus	98-101
15275471-2	1994	Because of the probable causal relationships between CD4(+) T-cell differentiation, cytokine production and disease outcome, this cytokine may prove useful as a component of cytokine-bosed therapies and Thl-selective vaccines, as discussed here by Frederick Heinzel.	Orlistat	203-206	CD4 antigen	Mus musculus	53-56
8191223-8	1994	The inhibition of cell proliferation induced by TCB treatment affected mainly the CD4-CD8- (double-negative, DN) and CD4-CD8+ (single-positive, SP) subsets, and these inhibition appeared mainly in more immature thymocytes, i.e. DNCD3- and CD8+CD3- subpopulations, whereas no effect of TCB on CD4+CD8+ (double-positive, DP) cell proliferative activity was observed.	3,4,3',4'-tetrachlorobiphenyl	48-51	CD4 antigen	Mus musculus	82-85
8191223-8	1994	The inhibition of cell proliferation induced by TCB treatment affected mainly the CD4-CD8- (double-negative, DN) and CD4-CD8+ (single-positive, SP) subsets, and these inhibition appeared mainly in more immature thymocytes, i.e. DNCD3- and CD8+CD3- subpopulations, whereas no effect of TCB on CD4+CD8+ (double-positive, DP) cell proliferative activity was observed.	3,4,3',4'-tetrachlorobiphenyl	48-51	CD4 antigen	Mus musculus	117-120
8191223-8	1994	The inhibition of cell proliferation induced by TCB treatment affected mainly the CD4-CD8- (double-negative, DN) and CD4-CD8+ (single-positive, SP) subsets, and these inhibition appeared mainly in more immature thymocytes, i.e. DNCD3- and CD8+CD3- subpopulations, whereas no effect of TCB on CD4+CD8+ (double-positive, DP) cell proliferative activity was observed.	3,4,3',4'-tetrachlorobiphenyl	48-51	CD4 antigen	Mus musculus	117-120
8168122-5	1994	Cell sorting revealed that both CD8+ and CD4+ T cells mediated SDCC but the former were more effective.	sdcc	63-67	CD4 antigen	Mus musculus	41-44
7911123-8	1994	Furthermore, a non-cytolytic tumor-associated antigen-specific CD4+ T cell clone able to induce the DTH response in concert with lentinan reconstituted the antitumor effects in B6 nude mice when administered with lentinan.	Lentinan	129-137	CD4 antigen	Mus musculus	63-66
7911123-8	1994	Furthermore, a non-cytolytic tumor-associated antigen-specific CD4+ T cell clone able to induce the DTH response in concert with lentinan reconstituted the antitumor effects in B6 nude mice when administered with lentinan.	Lentinan	213-221	CD4 antigen	Mus musculus	63-66
8144909-2	1994	The deficiency of MHC class II, and therefore, CD4+ T cells, completely prevented the C57BL6 MHC class II mutant (-/-) mice from mounting an autoimmune response to the nicotinic acetylcholine receptor.	Acetylcholine	178-191	CD4 antigen	Mus musculus	47-50
7907006-7	1994	Finally, the presence and activity of opioid receptors in cultures of CD4+ T cells were substantiated by the fact that the opioid receptor antagonist naloxone by itself enhanced cytokine synthesis, which points to the endogenous production by lymphocytes of down-regulating opioid peptides.	Naloxone	150-158	CD4 antigen	Mus musculus	70-73
7510235-4	1994	Furthermore, lpr CD4-CD8-T cells contain high levels of transcripts for the src-family tyrosine kinase p59fyn, and express a constitutively tyrosine-phosphorylated CD3-zeta chain.	Tyrosine	87-95	CD4 antigen	Mus musculus	17-20
7510235-6	1994	These similarities are extended to show that culturing of lpr CD4-CD8- T cells in the presence of IL-2 in combination with phorbol 12-myristate 13-acetate and ionomycin initiates cell cycling and results in the gain of function; re-stimulation now yields IL-2-dependent proliferation in the absence of exogenous IL-2.	Tetradecanoylphorbol Acetate	123-154	CD4 antigen	Mus musculus	62-65
7510235-6	1994	These similarities are extended to show that culturing of lpr CD4-CD8- T cells in the presence of IL-2 in combination with phorbol 12-myristate 13-acetate and ionomycin initiates cell cycling and results in the gain of function; re-stimulation now yields IL-2-dependent proliferation in the absence of exogenous IL-2.	Ionomycin	159-168	CD4 antigen	Mus musculus	62-65
8114715-6	1994	Upon stimulation of CD4 or CD8 either in a T-cell hybridoma cell line or in primary thymocytes, SH-PTP1 becomes tyrosyl phosphorylated.	cyclo(tyrosyl-tyrosyl)	112-119	CD4 antigen	Mus musculus	20-23
8198207-9	1994	Both liquid control and liquid ethanol diets caused a slight decrease in the CD4:CD8 ratios of splenic T-lymphocytes.	Ethanol	31-38	CD4 antigen	Mus musculus	77-80
8198230-8	1994	Mice receiving ethanol in the drinking water showed alterations in the CD4 CD45RC subsets and in the CD8 CD45RC subsets.	Ethanol	15-22	CD4 antigen	Mus musculus	71-74
8198230-8	1994	Mice receiving ethanol in the drinking water showed alterations in the CD4 CD45RC subsets and in the CD8 CD45RC subsets.	Water	39-44	CD4 antigen	Mus musculus	71-74
8198230-11	1994	But, a decrease in the percentage of CD4- CD8+ cells was observed in the thymus of mice receiving ethanol in the drinking water.	Ethanol	98-105	CD4 antigen	Mus musculus	37-40
8198230-11	1994	But, a decrease in the percentage of CD4- CD8+ cells was observed in the thymus of mice receiving ethanol in the drinking water.	Water	122-127	CD4 antigen	Mus musculus	37-40
7905794-0	1994	Inhibition of CD4+ T lymphocyte binding to fibronectin and immune-cell accumulation in inflammatory sites by non-peptidic mimetics of Arg-Gly-Asp.	Arginine	134-137	CD4 antigen	Mus musculus	14-17
7905794-0	1994	Inhibition of CD4+ T lymphocyte binding to fibronectin and immune-cell accumulation in inflammatory sites by non-peptidic mimetics of Arg-Gly-Asp.	Glycine	138-141	CD4 antigen	Mus musculus	14-17
7905794-0	1994	Inhibition of CD4+ T lymphocyte binding to fibronectin and immune-cell accumulation in inflammatory sites by non-peptidic mimetics of Arg-Gly-Asp.	Aspartic Acid	142-145	CD4 antigen	Mus musculus	14-17
8169326-7	1994	Depending on the time of exposure to cyclophosphamide, DTC either increased the percentage of CD4 thymocytes or decreased the percentage of CD8, which subsequently led increased CD4/CD8 coefficient.	Cyclophosphamide	37-53	CD4 antigen	Mus musculus	94-97
8169326-7	1994	Depending on the time of exposure to cyclophosphamide, DTC either increased the percentage of CD4 thymocytes or decreased the percentage of CD8, which subsequently led increased CD4/CD8 coefficient.	Cyclophosphamide	37-53	CD4 antigen	Mus musculus	178-181
8169326-7	1994	Depending on the time of exposure to cyclophosphamide, DTC either increased the percentage of CD4 thymocytes or decreased the percentage of CD8, which subsequently led increased CD4/CD8 coefficient.	Ditiocarb	55-58	CD4 antigen	Mus musculus	94-97
8169326-7	1994	Depending on the time of exposure to cyclophosphamide, DTC either increased the percentage of CD4 thymocytes or decreased the percentage of CD8, which subsequently led increased CD4/CD8 coefficient.	Ditiocarb	55-58	CD4 antigen	Mus musculus	178-181
8294879-6	1994	Consistent with this data, antiphosphotyrosine immunoblotting revealed greater tyrosine phosphorylation of intracellular substrates after TCR/CD4 cross-linking compared with TCR/CD8 cross-linking.	Tyrosine	38-46	CD4 antigen	Mus musculus	142-145
7507957-4	1994	Through the cross-linkage by thiol-reactive bivalent mercury, transmembrane CD4, CD3, and CD45 and glycosylphosphatidylinositol-anchored Thy-1 were aggregated together on thymocytes or T lymphocytes.	Sulfhydryl Compounds	29-34	CD4 antigen	Mus musculus	76-79
7507960-5	1994	Indeed, Fas- but not mock-transfected RT2.3 proved to be more sensitive to lysis by either Ag specifically or nonspecifically activated CD4+ CTL.	ammonium ferrous sulfate	8-11	CD4 antigen	Mus musculus	136-139
7507960-6	1994	Similarly, MHC class II-negative, Fas-transfected L1210 leukemia cells were lysed with nonspecifically activated CD4+ CTL.	ammonium ferrous sulfate	34-37	CD4 antigen	Mus musculus	113-116
7509391-7	1994	In addition, there was a GaAs-induced decrease in the CD4+/CD8+ thymocyte subpopulations and a concomitant increase in CD4+ and CD8+ cells.	gallium arsenide	25-29	CD4 antigen	Mus musculus	54-57
8114793-6	1994	Cells expressing CD4 and CD8 antigens were observed in the injected muscles of mice treated with CsA alone.	Cyclosporine	97-100	CD4 antigen	Mus musculus	17-20
7904066-0	1994	Oligosaccharide-specific induction of interleukin 10 production by B220+ cells from schistosome-infected mice: a mechanism for regulation of CD4+ T-cell subsets.	Oligosaccharides	0-15	CD4 antigen	Mus musculus	141-144
7904066-7	1994	We found that LNFP-III and related sugars did induce proliferation of splenic non-T cells, B220+,CD4-,CD8- cells (B cells) of schistosome-infected and naive mice.	Sugars	35-41	CD4 antigen	Mus musculus	97-100
7826668-0	1994	Proliferation inhibition and CD4/CD8 thymocyte subset skewing by in vivo exposure of C57BL/6 mice to Ah receptor-binding 3,3",4,4"-tetrachlorobiphenyl.	3,4,3',4'-tetrachlorobiphenyl	121-150	CD4 antigen	Mus musculus	29-32
7826668-4	1994	Already 2 days after exposure to TCB, fewer of the more immature thymocytes (CD4-CD8-, CD4-CD8+ alpha beta TCR-) were proliferating than in thymi from control animals.	3,4,3',4'-tetrachlorobiphenyl	33-36	CD4 antigen	Mus musculus	77-80
7826668-4	1994	Already 2 days after exposure to TCB, fewer of the more immature thymocytes (CD4-CD8-, CD4-CD8+ alpha beta TCR-) were proliferating than in thymi from control animals.	3,4,3',4'-tetrachlorobiphenyl	33-36	CD4 antigen	Mus musculus	87-90
7511929-8	1994	Both single-positive (SP) subsets were largely Fas+ (CD8 SP &lt; CD4 SP) but expressed lower levels of Fas than DP cells.	sp	22-24	CD4 antigen	Mus musculus	65-68
8114610-6	1994	Murine retrovirus infection alone decreased the number of IgA+ and CD4+ cells in the ILP, and this decreased was even more marked when MAIDS mice also received cocaine.	Cocaine	160-167	CD4 antigen	Mus musculus	67-70
7521743-3	1994	Continuous daily treatment of syngeneically reconstituted B10 mice with FK506 delayed the development of thymocytes from the CD4+CD8+ to CD4+CD8- stage, while no effect was observed at the earlier CD4-CD8- to CD4+CD8+ stage.	Tacrolimus	72-77	CD4 antigen	Mus musculus	125-128
7521743-3	1994	Continuous daily treatment of syngeneically reconstituted B10 mice with FK506 delayed the development of thymocytes from the CD4+CD8+ to CD4+CD8- stage, while no effect was observed at the earlier CD4-CD8- to CD4+CD8+ stage.	Tacrolimus	72-77	CD4 antigen	Mus musculus	137-140
7521743-3	1994	Continuous daily treatment of syngeneically reconstituted B10 mice with FK506 delayed the development of thymocytes from the CD4+CD8+ to CD4+CD8- stage, while no effect was observed at the earlier CD4-CD8- to CD4+CD8+ stage.	Tacrolimus	72-77	CD4 antigen	Mus musculus	137-140
7521743-3	1994	Continuous daily treatment of syngeneically reconstituted B10 mice with FK506 delayed the development of thymocytes from the CD4+CD8+ to CD4+CD8- stage, while no effect was observed at the earlier CD4-CD8- to CD4+CD8+ stage.	Tacrolimus	72-77	CD4 antigen	Mus musculus	137-140
7831928-0	1994	CD4+ and CD8+ cells in mice infected with Trichinella spiralis and treated with cyclosporine A.	Cyclosporine	80-94	CD4 antigen	Mus musculus	0-3
7831928-5	1994	It was found that the number of CD4+ cells in the control and in the CyA-treated mice was similar but in the animals receiving the drug the reaction was less intensive.	Cyclosporine	69-72	CD4 antigen	Mus musculus	32-35
7831929-0	1994	The influence of adriamycin on the CD4+ and CD8+ cells in the course of trichinellosis in mice.	Doxorubicin	17-27	CD4 antigen	Mus musculus	35-38
7831929-1	1994	The effect of adriamycin on the behaviour of CD4+ and CD8+ cells in the course of trichinellosis in mice has been studied.	Doxorubicin	14-24	CD4 antigen	Mus musculus	45-48
7903096-5	1993	Furthermore, when these CD4-bearing T cells from mice orally immunized with SRBC were co-cultured with B cells and adherent cells in the presence of unrelated Ag (e.g., horse RBC), SRBC-specific B cell responses were not induced.	srbc	76-80	CD4 antigen	Mus musculus	24-27
8265609-4	1993	AgAbs were then used as immunogens in rabbits and mice to elicit a humoral response against CD4.	agabs	0-5	CD4 antigen	Mus musculus	92-95
8288876-3	1993	Agarose blocks containing supernatants from ConA activated rat spleen cells attracted neutrophils within 4 h. These cells were followed by lymphocytes and macrophages in 24 h. Flow cytometry analysis of lymphoid cells on day 1 revealed that 38% were Ig+ (B cell marker), 60% MAC-2,3+ and 20% Thy 1.2+ of which only a small fraction were expressing CD4 on their surface.	Sepharose	0-7	CD4 antigen	Mus musculus	348-351
8228214-2	1993	Phorbol esters are known to induce a loss of CD4 from the surface of mouse and human T cells, presumably through activation of protein kinase C. Here we describe additional, calcium-dependent processes that remove CD4 and CD8 from the surface of T cells and thymocytes, and that differ from the protein kinase C-mediated effect in that they require the expression of new gene products.	Phorbol Esters	0-14	CD4 antigen	Mus musculus	45-48
8228214-2	1993	Phorbol esters are known to induce a loss of CD4 from the surface of mouse and human T cells, presumably through activation of protein kinase C. Here we describe additional, calcium-dependent processes that remove CD4 and CD8 from the surface of T cells and thymocytes, and that differ from the protein kinase C-mediated effect in that they require the expression of new gene products.	Phorbol Esters	0-14	CD4 antigen	Mus musculus	214-217
8228214-2	1993	Phorbol esters are known to induce a loss of CD4 from the surface of mouse and human T cells, presumably through activation of protein kinase C. Here we describe additional, calcium-dependent processes that remove CD4 and CD8 from the surface of T cells and thymocytes, and that differ from the protein kinase C-mediated effect in that they require the expression of new gene products.	Calcium	174-181	CD4 antigen	Mus musculus	45-48
8228214-2	1993	Phorbol esters are known to induce a loss of CD4 from the surface of mouse and human T cells, presumably through activation of protein kinase C. Here we describe additional, calcium-dependent processes that remove CD4 and CD8 from the surface of T cells and thymocytes, and that differ from the protein kinase C-mediated effect in that they require the expression of new gene products.	Calcium	174-181	CD4 antigen	Mus musculus	214-217
8228214-4	1993	When T cells are exposed to a combination of PMA and the calcium ionophore, ionomycin (Cal), surface CD4 virtually disappears for a period of at least 24 h, and CD8 expression is also diminished.	Calcium	57-64	CD4 antigen	Mus musculus	101-104
8228214-4	1993	When T cells are exposed to a combination of PMA and the calcium ionophore, ionomycin (Cal), surface CD4 virtually disappears for a period of at least 24 h, and CD8 expression is also diminished.	Ionomycin	76-85	CD4 antigen	Mus musculus	101-104
8228214-4	1993	When T cells are exposed to a combination of PMA and the calcium ionophore, ionomycin (Cal), surface CD4 virtually disappears for a period of at least 24 h, and CD8 expression is also diminished.	palmatine	87-90	CD4 antigen	Mus musculus	101-104
8228214-5	1993	This additional, calcium-dependent effect, on both CD4 and CD8 expression, is abrogated by either cycloheximide or actinomycin D, and so depends on new RNA and protein synthesis.	Calcium	17-24	CD4 antigen	Mus musculus	51-54
8228214-5	1993	This additional, calcium-dependent effect, on both CD4 and CD8 expression, is abrogated by either cycloheximide or actinomycin D, and so depends on new RNA and protein synthesis.	Cycloheximide	98-111	CD4 antigen	Mus musculus	51-54
8228214-5	1993	This additional, calcium-dependent effect, on both CD4 and CD8 expression, is abrogated by either cycloheximide or actinomycin D, and so depends on new RNA and protein synthesis.	Dactinomycin	115-128	CD4 antigen	Mus musculus	51-54
8228258-4	1993	In addition, phenotyping studies revealed that RAPA causes a massive reduction of immature CD4+CD8+ T cells in the thymus, indicating that RAPA probably interferes with maturation of immature CD3-CD4-CD8- T cells to CD4+CD8+ T cells.	Sirolimus	47-51	CD4 antigen	Mus musculus	91-94
8228258-4	1993	In addition, phenotyping studies revealed that RAPA causes a massive reduction of immature CD4+CD8+ T cells in the thymus, indicating that RAPA probably interferes with maturation of immature CD3-CD4-CD8- T cells to CD4+CD8+ T cells.	Sirolimus	47-51	CD4 antigen	Mus musculus	196-199
8228258-4	1993	In addition, phenotyping studies revealed that RAPA causes a massive reduction of immature CD4+CD8+ T cells in the thymus, indicating that RAPA probably interferes with maturation of immature CD3-CD4-CD8- T cells to CD4+CD8+ T cells.	Sirolimus	47-51	CD4 antigen	Mus musculus	196-199
8123217-6	1993	There was also an increase in the number of CD4+ and CD8+ cells in the ILP of well-nourished mature mice consuming ethanol, and an increase in the number of CD4+ cells in the ILP of undernourished mice.	Ethanol	115-122	CD4 antigen	Mus musculus	44-47
8405701-0	1993	Tolerance to IDDM induced by CD4 antibodies in nonobese diabetic mice is reversed by cyclophosphamide.	Cyclophosphamide	85-101	CD4 antigen	Mus musculus	29-32
8405701-2	1993	It has previously been established that transferred diabetes can be prevented by treatment with a nondepleting CD4 monoclonal antibody; however, we report herein that cyclophosphamide-induced diabetes also can be prevented using this antibody.	Cyclophosphamide	167-183	CD4 antigen	Mus musculus	111-114
7903158-8	1993	Stimulation with anti-CD28 mAb in conjunction with phorbol myristate acetate and ionomycin promotes cell cycling in the CD2- subset of CD4-CD8- T cells, and results in a slight induction of CD2 levels during the course of the culture period.	Tetradecanoylphorbol Acetate	51-76	CD4 antigen	Mus musculus	135-138
7903158-8	1993	Stimulation with anti-CD28 mAb in conjunction with phorbol myristate acetate and ionomycin promotes cell cycling in the CD2- subset of CD4-CD8- T cells, and results in a slight induction of CD2 levels during the course of the culture period.	Ionomycin	81-90	CD4 antigen	Mus musculus	135-138
8106273-0	1993	Regulation by heparan sulfate and interleukin 1 alpha of the ontogenic expression of T-cell receptor, CD4, and CD8 in developing thymus.	Heparitin Sulfate	14-29	CD4 antigen	Mus musculus	102-105
8106273-4	1993	Inhibition of GAG synthesis prevented elaboration of cortical thymocyte-associated HS, IL-1, and de novo expression of the TCR, CD4, and CD8.	Glycosaminoglycans	14-17	CD4 antigen	Mus musculus	128-131
8106273-6	1993	Synthesis of IL-1 alpha, TCR, CD4, and CD8 was restored by addition of HS to the cultured organs.	Hydrogen	71-73	CD4 antigen	Mus musculus	30-33
8253540-7	1993	Morphine treatment induced a decrease in the total number of cells and therefore in the absolute number of T-(Thy 1, CD4, CD8), B- and Mac 1+ (macrophages) cells in protein-undernourished mice.	Morphine	0-8	CD4 antigen	Mus musculus	117-120
8253540-12	1993	In well-nourished mice, morphine treatment reduced the number of Thy 1+, CD4+ and CD8+ cells per thymus to 30% of that found in untreated mice and to 40% of the cells in those saline-treated controls.	Morphine	24-32	CD4 antigen	Mus musculus	73-76
7901313-6	1993	In vivo administration of anti-CD4 and anti-CD8 monoclonal antibodies to sensitized mice prevented the development of immune-mediated lung inflammation and was effective in reducing hydroxyproline deposition.	Hydroxyproline	182-196	CD4 antigen	Mus musculus	31-34
8231237-0	1993	Cyclophosphamide treatment of an SJL murine B-cell lymphoma increases the proportion of suppressive CD8+ over tumor-stimulatory CD4+ T-lymphocytes.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	128-131
8231237-3	1993	Cyclophosphamide treatment of tumor-bearing mice (RCS/Cy) decreases in vitro tumor-stimulated CD4+ T-cell proliferation and, in turn, tumor growth, in part, through the suppressive action of CD8+ T-lymphocytes.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	94-97
7904343-1	1993	The ectodomains of the T cell surface glycoproteins CD4 and CD8 bind to membrane-proximal domains of MHC class II and class I molecules, respectively, while both cytoplasmic domains interact with the protein tyrosine kinase (PTK) p56lck (lck) through a shared cysteine-containing motif.	Cysteine	260-268	CD4 antigen	Mus musculus	52-55
8104712-7	1993	Induction of apoptosis was associated with defective signaling through the TcR complex, since anti-CD3 stimulation in vitro of CD4+ T cells from infected mice caused a diminished calcium response, yet no cellular proliferation.	Calcium	179-186	CD4 antigen	Mus musculus	127-130
8402924-3	1993	Fetal thymus organ cultures containing 0.2 or 0.4% ethanol produced fewer total thymocytes, proportionately fewer CD4+CD8+ (immature) thymocytes, and proportionately more CD4+CD8- (mature) cells than untreated control cultures after 5 days of culture.	Ethanol	51-58	CD4 antigen	Mus musculus	114-117
8402924-3	1993	Fetal thymus organ cultures containing 0.2 or 0.4% ethanol produced fewer total thymocytes, proportionately fewer CD4+CD8+ (immature) thymocytes, and proportionately more CD4+CD8- (mature) cells than untreated control cultures after 5 days of culture.	Ethanol	51-58	CD4 antigen	Mus musculus	171-174
8402924-4	1993	Total cell numbers and proportions of CD4+CD8+ thymocytes declined in a dose-dependent manner with increasing ethanol concentrations from 0.2 to 0.8%.	Ethanol	110-117	CD4 antigen	Mus musculus	38-41
8402924-5	1993	In time course studies, thymuses cultured with 0.4% ethanol had an increased percentage of CD4+CD8- cells at all days examined between Days 4 and 6.	Ethanol	52-59	CD4 antigen	Mus musculus	91-94
8103677-9	1993	Treatment of CD4+ cells with HMA caused a corresponding decrease in the amount of CD4-associated p56lck.	alpha-hydroxymyristic acid	29-32	CD4 antigen	Mus musculus	13-16
8103677-9	1993	Treatment of CD4+ cells with HMA caused a corresponding decrease in the amount of CD4-associated p56lck.	alpha-hydroxymyristic acid	29-32	CD4 antigen	Mus musculus	82-85
8103063-0	1993	Reduced CD3-mediated protein tyrosine phosphorylation in anergic CD4+ and CD8+ T cells.	Tyrosine	29-37	CD4 antigen	Mus musculus	65-68
8103063-9	1993	Both CD4+ and CD8+ T cells exhibit altered tyrosine phosphorylation of two protein substrates upon CD3-mediated restimulation.	Tyrosine	43-51	CD4 antigen	Mus musculus	5-8
7691279-0	1993	The 3G11+ antigen, a marker for murine CD4+ TH1 lymphocytes, is a ganglioside.	Gangliosides	66-77	CD4 antigen	Mus musculus	39-42
8335907-5	1993	We show that CD4-CD8-, but not CD4-CD8+, thymocytes expressing the H-Y TCR responded with high intracellular calcium fluxes to TCR/CD3 stimulation without extensive receptor cross-linking.	Calcium	109-116	CD4 antigen	Mus musculus	13-16
8335907-7	1993	The expression of the CD8 alpha alpha homodimer in the CD4-CD8-thymocytes led to impaired intracellular calcium responses and less efficient protein tyrosine phosphorylation of substrates after TCR engagement.	Calcium	104-111	CD4 antigen	Mus musculus	55-58
8335907-7	1993	The expression of the CD8 alpha alpha homodimer in the CD4-CD8-thymocytes led to impaired intracellular calcium responses and less efficient protein tyrosine phosphorylation of substrates after TCR engagement.	Tyrosine	149-157	CD4 antigen	Mus musculus	55-58
8325329-5	1993	The TPK inhibitor genistein, however, strongly suppressed TLTF-induced activation of both types of responder cells to IFN-gamma secretion and the TLTF-induced proliferation of mouse CD8+ CD4- MNC.	Genistein	18-27	CD4 antigen	Mus musculus	187-190
7686923-0	1993	Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.	Azacitidine	94-107	CD4 antigen	Mus musculus	19-22
7686923-0	1993	Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.	Procainamide	111-123	CD4 antigen	Mus musculus	19-22
7686923-1	1993	Human antigen-specific CD4+ T cells become autoreactive after treatment with various DNA methylation inhibitors, including 5-azacytidine, procainamide, and hydralazine.	Azacitidine	123-136	CD4 antigen	Mus musculus	23-26
7686923-1	1993	Human antigen-specific CD4+ T cells become autoreactive after treatment with various DNA methylation inhibitors, including 5-azacytidine, procainamide, and hydralazine.	Procainamide	138-150	CD4 antigen	Mus musculus	23-26
7686923-1	1993	Human antigen-specific CD4+ T cells become autoreactive after treatment with various DNA methylation inhibitors, including 5-azacytidine, procainamide, and hydralazine.	Hydralazine	156-167	CD4 antigen	Mus musculus	23-26
7686923-4	1993	Murine CD4+ T cells were treated with 5-azacytidine or procainamide and were shown to respond to syngeneic antigen-presenting cells, similar to CD4+ human T cell clones treated with these drugs.	Azacitidine	38-51	CD4 antigen	Mus musculus	7-10
7686923-4	1993	Murine CD4+ T cells were treated with 5-azacytidine or procainamide and were shown to respond to syngeneic antigen-presenting cells, similar to CD4+ human T cell clones treated with these drugs.	Procainamide	55-67	CD4 antigen	Mus musculus	7-10
7684652-7	1993	Cell sorting with a fluorescein-activated cell sorter showed that CD4+ T cells developed during the incubation to lyse syngeneic tumor cells directly by themselves, macrophages not being involved in this tumour cell lysis.	Fluorescein	20-31	CD4 antigen	Mus musculus	66-69
8359866-1	1993	CD8 (Ly-2) expression was suppressed in purified murine CD4-CD8+ thymocytes at the mRNA level upon continuous stimulation with PMA and ionomycin in the presence of rIL-2.	Tetradecanoylphorbol Acetate	127-130	CD4 antigen	Mus musculus	56-59
8359866-1	1993	CD8 (Ly-2) expression was suppressed in purified murine CD4-CD8+ thymocytes at the mRNA level upon continuous stimulation with PMA and ionomycin in the presence of rIL-2.	Ionomycin	135-144	CD4 antigen	Mus musculus	56-59
7686620-6	1993	CD4 antibodies precipitated only the form of the CD4-C kappa light chain protein which appears as a monomer by polyacrylamide gel electrophoresis.	polyacrylamide	111-125	CD4 antigen	Mus musculus	0-3
7686620-6	1993	CD4 antibodies precipitated only the form of the CD4-C kappa light chain protein which appears as a monomer by polyacrylamide gel electrophoresis.	polyacrylamide	111-125	CD4 antigen	Mus musculus	49-52
8097472-0	1993	A monoclonal antibody reactive with a glycophosphatidylinositol-anchored molecule on T cells defines CD4+ T cell subsets.	glycophosphatidylinositol	38-63	CD4 antigen	Mus musculus	101-104
8365828-8	1993	Flow cytometric analysis showed that TCDD treatment increased the percentage of both CD4+ and CD8+ cells cycling in S and G2M.	Polychlorinated Dibenzodioxins	37-41	CD4 antigen	Mus musculus	85-88
8386745-4	1993	When CD4 T cells from transgenic mice were stimulated with the superantigen staphylococcal enterotoxin A (SEA) in the presence of GANC, proliferation and IL-2 production were almost completely inhibited and the activated CD4+V beta 3+ T cell population, eliminated.	Ganciclovir	130-134	CD4 antigen	Mus musculus	221-233
8478606-3	1993	In contrast, coadministration of RU-38486 counteracts a SEB-induced early (12 h) reduction of V beta 8+CD4+ and V beta 8+CD8+ spleen cells.	Mifepristone	33-41	CD4 antigen	Mus musculus	103-106
8478606-7	1993	Adrenalectomy, injection of RU-38486 and priming with GalN per se provoke the programmed death of peripheral CD4+ and CD8+ T cells.	Mifepristone	28-36	CD4 antigen	Mus musculus	109-112
8478606-7	1993	Adrenalectomy, injection of RU-38486 and priming with GalN per se provoke the programmed death of peripheral CD4+ and CD8+ T cells.	Galactosamine	54-58	CD4 antigen	Mus musculus	109-112
8097908-0	1993	Inhibition of calcium signalling in murine splenocytes by polyamines: differential effects on CD4 and CD8 T-cells.	Polyamines	58-68	CD4 antigen	Mus musculus	94-97
8097908-12	1993	In experiments using monoclonal anti-CD4 and anti-CD8 antibodies, we found a differential effect of putrescine on Ca2+ influx in CD4 and CD8 subpopulations of T cells.	Putrescine	100-110	CD4 antigen	Mus musculus	37-40
8097908-12	1993	In experiments using monoclonal anti-CD4 and anti-CD8 antibodies, we found a differential effect of putrescine on Ca2+ influx in CD4 and CD8 subpopulations of T cells.	Putrescine	100-110	CD4 antigen	Mus musculus	129-132
8097908-13	1993	For CD4+ cells, [Ca2+]i decreased from 625 nM to 420 nM in the presence of 500 microM putrescine, whereas [Ca2+]i was not affected by putrescine in CD8+ cells.	Putrescine	86-96	CD4 antigen	Mus musculus	4-7
8098666-11	1993	Consideration of our results together with earlier findings led to the conclusion that CD4+ T cells are primarily responsible for insulitis and that CD8+ T cells migrate into islets and are differentiated into mature killer cells against beta-cells with the aid of CD4+ T cells in both spontaneous and cyclophosphamide-induced diabetes.	Cyclophosphamide	302-318	CD4 antigen	Mus musculus	265-268
8495490-9	1993	Mice implanted with corticosterone pellets experienced severe losses of CD4+/CD8+ cells, resulting in thymocyte subpopulation and CD3 profiles more similar to those of hydrocortisone-injected mice than those of PD mice.	Corticosterone	20-34	CD4 antigen	Mus musculus	72-75
8474033-7	1993	Kinetic studies of morphine"s effect on the thymocyte subpopulations revealed that the maximal depletion of the CD4+/CD8+ cells occurs approximately 4 days after pellet implantation.	Morphine	19-27	CD4 antigen	Mus musculus	112-115
8450209-9	1993	Preliminary examinations of the density of 5-methylcytosine within the CD4 and CD8 loci in various phenotypic populations separated by FACS from within heterogeneous clones revealed a correlation between surface expression of the mouse CD8 protein and a lack of methylation around the mouse CD8 gene.	5-Methylcytosine	43-59	CD4 antigen	Mus musculus	71-74
8095166-0	1993	Interleukin-4 protects double-negative and CD4 single-positive thymocytes from dexamethasone-induced apoptosis.	Dexamethasone	79-92	CD4 antigen	Mus musculus	43-46
8095557-5	1993	Murine T-cell hybridoma lines expressing mutant forms of CD4 were used to demonstrate that the 31 carboxyterminal aminoacids of its cytoplasmic domain, in particular cysteine-420 and cysteine-422, are crucial for the formation of CD4:p56lck complexes in vivo.	Cysteine	166-174	CD4 antigen	Mus musculus	57-60
8095557-5	1993	Murine T-cell hybridoma lines expressing mutant forms of CD4 were used to demonstrate that the 31 carboxyterminal aminoacids of its cytoplasmic domain, in particular cysteine-420 and cysteine-422, are crucial for the formation of CD4:p56lck complexes in vivo.	Cysteine	166-174	CD4 antigen	Mus musculus	230-233
8095557-5	1993	Murine T-cell hybridoma lines expressing mutant forms of CD4 were used to demonstrate that the 31 carboxyterminal aminoacids of its cytoplasmic domain, in particular cysteine-420 and cysteine-422, are crucial for the formation of CD4:p56lck complexes in vivo.	Cysteine	183-191	CD4 antigen	Mus musculus	57-60
8255161-3	1993	There was an increase in the relative percentages of neonate thymic CD4 and CD8 cells at 5 days of age when mothers were injected with 100 micrograms of CB-154 2 x daily from day 1 to 5 of lactation, however, there was no alteration in absolute thymic subset cell numbers.	Bromocriptine	153-159	CD4 antigen	Mus musculus	68-71
8255161-4	1993	The relative percentage of pup spleen CD4, CD8 and B cells were increased when mothers were administered 50 or 100 micrograms of CB-154 and the 50 micrograms dose resulted in a significant increase in the absolute number of CD4 cells while the 100 micrograms dose induced a significant decrease in the three splenic cell subsets examined.	Bromocriptine	129-135	CD4 antigen	Mus musculus	38-41
8255161-4	1993	The relative percentage of pup spleen CD4, CD8 and B cells were increased when mothers were administered 50 or 100 micrograms of CB-154 and the 50 micrograms dose resulted in a significant increase in the absolute number of CD4 cells while the 100 micrograms dose induced a significant decrease in the three splenic cell subsets examined.	Bromocriptine	129-135	CD4 antigen	Mus musculus	224-227
8255161-11	1993	Con-A stimulation of neonatal splenocytes resulted in a significant increase in proliferation for mothers administered CB-154 in keeping with the increase relative percentage of CD4 and CD8 cells observed.	Bromocriptine	119-125	CD4 antigen	Mus musculus	178-181
1282000-3	1992	Using this and immunohistochemical staining, we found that the immunosuppressants cyclosporin A and FK506 decreased CD4 expression in cultured murine microglia without causing any significant decrease in cell viability.	Cyclosporine	82-95	CD4 antigen	Mus musculus	116-119
1282000-3	1992	Using this and immunohistochemical staining, we found that the immunosuppressants cyclosporin A and FK506 decreased CD4 expression in cultured murine microglia without causing any significant decrease in cell viability.	Tacrolimus	100-105	CD4 antigen	Mus musculus	116-119
21584620-5	1992	A small but selective increase in CD4+ cells without an apparent change in CD8+ subset of T cells was observed following treatment with ADM. ADM potentiated augmentation of NK activity by IL2, but had no effect on the production of lymphokine activated killer (LAK) cells by IL2.	Doxorubicin	136-139	CD4 antigen	Mus musculus	34-37
1433525-0	1992	Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.	Formaldehyde	83-91	CD4 antigen	Mus musculus	159-162
1299800-4	1992	SE plus SRBC-primed mice showed markedly depressed CD4/CD8 ratios relative to phosphate-buffered saline plus SRBC- or SRBC-immunized mice.	srbc	8-12	CD4 antigen	Mus musculus	51-54
1452400-4	1992	A daily cocaine injection in some mice as well as a saline injection in others showed a decrease in the percentage of Thy 1.2+, CD4+ and CD8+ cells, while both treatments increased the percentage and absolute numbers of B-cells per spleen.	Cocaine	8-15	CD4 antigen	Mus musculus	128-131
1452400-4	1992	A daily cocaine injection in some mice as well as a saline injection in others showed a decrease in the percentage of Thy 1.2+, CD4+ and CD8+ cells, while both treatments increased the percentage and absolute numbers of B-cells per spleen.	Sodium Chloride	52-58	CD4 antigen	Mus musculus	128-131
1452414-12	1992	Down-modulation of CD3 expression on CD4+ and CD8+ cells was apparent as early as 1 h after treatment with less than 10% of CD4+ and CD8+ cells expressing CD3 by 12 h. Induction of IL-2R expression and IL-2-driven 3H-TdR incorporation was maximal at 12 h after anti-CD3.	Tritium	214-216	CD4 antigen	Mus musculus	37-40
1452414-15	1992	Concurrently, anti-CD3-induced increases in the percentage of CD4+ and CD8+ cells cycling were inhibited by CsA.	Cyclosporine	108-111	CD4 antigen	Mus musculus	62-65
1489728-1	1992	Antibody binding of CD3, CD4, or CD8 molecules can induce cytoplasmic calcium mobilization in T lymphocytes, usually interpreted as indicating signal transduction.	Calcium	70-77	CD4 antigen	Mus musculus	25-28
1489734-4	1992	The T cell-specific DH sites are located in four regions: (i) 5" of the first exon of CD4, (ii) in the first intron, (iii) near the second and third exons, and (iv) 3" of the CD4 gene.	2-(3,5-dihydroxyphenyl)-6-hydroxybenzothiazole	20-22	CD4 antigen	Mus musculus	86-89
1489734-4	1992	The T cell-specific DH sites are located in four regions: (i) 5" of the first exon of CD4, (ii) in the first intron, (iii) near the second and third exons, and (iv) 3" of the CD4 gene.	2-(3,5-dihydroxyphenyl)-6-hydroxybenzothiazole	20-22	CD4 antigen	Mus musculus	175-178
1355103-8	1992	Thus, resolution of PCP in CD4+ lymphocyte-depleted mice by heat-treated E. coli aerosols was not dependent on either CD8+ or asialo GM1+ cells but was dependent on Thy-1+CD4-CD8- lymphocytes and on the participation of TNF.	pcp	20-23	CD4 antigen	Mus musculus	27-30
1355103-8	1992	Thus, resolution of PCP in CD4+ lymphocyte-depleted mice by heat-treated E. coli aerosols was not dependent on either CD8+ or asialo GM1+ cells but was dependent on Thy-1+CD4-CD8- lymphocytes and on the participation of TNF.	pcp	20-23	CD4 antigen	Mus musculus	171-174
1432998-4	1992	Treatment with L3T4, a monoclonal antibody specific for murine CD4+ T cells, significantly reduced the incidence of pristane arthritis, and delayed the disease onset.	pristane	116-124	CD4 antigen	Mus musculus	63-66
1412420-5	1992	In contrast, proliferation stimulated by allogeneic cells and mitogens was more pronounced in the subpopulation reactive with CA13.1E4 (CD4).	ca13.1e4	126-134	CD4 antigen	Mus musculus	136-139
1497662-3	1992	This DNase I, which most probably originates from the accumulated CD4-CD8-T-cells, cleaves nuclear DNA with a strong preference for internucleosomal sites yielding, in the presence of both Ca2+ and Mg2+, a pattern of fragments typical for apoptosis.	magnesium ion	198-202	CD4 antigen	Mus musculus	66-69
1358081-6	1992	Although moderately low intakes of ethanol did not significantly modify percentages of T and B cells, they increased the absolute number of mature T, B, and CD4+ cells and decreased percentages of Thy 1.2+ cells.	Ethanol	35-42	CD4 antigen	Mus musculus	157-160
1358081-9	1992	Moderate decreases in percentages of CD4+, CD8+, CD5+ cells and an increase in Ia+ cells were also observed in the retrovirus/infected ethanol-treated mice.	Ethanol	135-142	CD4 antigen	Mus musculus	37-40
1535365-4	1992	The subsets of T cells proliferating with the assistance of retinol cofactor are both CD4+ and CD8+ thymic T cells, and CD4+ peripheral T cells.	Vitamin A	60-67	CD4 antigen	Mus musculus	86-89
1535365-4	1992	The subsets of T cells proliferating with the assistance of retinol cofactor are both CD4+ and CD8+ thymic T cells, and CD4+ peripheral T cells.	Vitamin A	60-67	CD4 antigen	Mus musculus	120-123
1607663-9	1992	These in vitro generated CD3-CD4-CD8 alpha + thymocytes expanded and differentiated into the CD4+CD8+ stage as well as mature (CD3+) single positive (CD4+CD8-) and CD4-CD8+) stages in fetal thymus organ culture that had been depleted of lymphoid cells by treatment with 2-deoxyguanosine.	Deoxyguanosine	270-286	CD4 antigen	Mus musculus	29-32
1350288-6	1992	In contrast, CD4+ T cells from infected mice could be induced to proliferate by stimulation with PMA and ionomycin resulting in IL-2R up-regulation, IL-2 production, and proliferation.	Tetradecanoylphorbol Acetate	97-100	CD4 antigen	Mus musculus	13-16
1350288-6	1992	In contrast, CD4+ T cells from infected mice could be induced to proliferate by stimulation with PMA and ionomycin resulting in IL-2R up-regulation, IL-2 production, and proliferation.	Ionomycin	105-114	CD4 antigen	Mus musculus	13-16
1351322-2	1992	Activated CD4+ Th2 cells release cytokines (IL-4,-10) that block activation &amp; cytokine (IL-2/IFN-gamma) release by proinflammatory T (CD4+,CD8+) effector cells.	Adenosine Monophosphate	77-80	CD4 antigen	Mus musculus	10-13
1351322-2	1992	Activated CD4+ Th2 cells release cytokines (IL-4,-10) that block activation &amp; cytokine (IL-2/IFN-gamma) release by proinflammatory T (CD4+,CD8+) effector cells.	Adenosine Monophosphate	77-80	CD4 antigen	Mus musculus	138-141
1350565-3	1992	The CD4+ T cell dependency is demonstrated by anti-CD4 antibody treatment which suppresses CIA in mice if injected before CII immunization.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	122-125	CD4 antigen	Mus musculus	4-7
1350565-3	1992	The CD4+ T cell dependency is demonstrated by anti-CD4 antibody treatment which suppresses CIA in mice if injected before CII immunization.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	122-125	CD4 antigen	Mus musculus	51-54
1350565-6	1992	To address this question, the proliferative capacity of CII reactive CD4+ lymph node (LN) T cells, in mice treated with anti-CD4 antibodies before or after the CII immunization, was analyzed.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	56-59	CD4 antigen	Mus musculus	69-72
1350565-10	1992	We propose that activation render CII reactive T cells more resistant to anti-CD4 treatment than virgin T cells are and suggest that the lack of therapeutic effect of late anti-CD4 treatment in CIA does not necessarily implicate that CD4+ T cells are unimportant in that stage of the disease.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	34-37	CD4 antigen	Mus musculus	78-81
1592441-1	1992	The new mutation at the lpr locus, lprcg, induces massive lymphoproliferation characterized by the selective expansion of CD4-, CD8-, B220+, Thy-1+ cells or double-negative T lymphocytes and production of autoantibodies as does lpr.	lprcg	35-40	CD4 antigen	Mus musculus	122-125
1352686-0	1992	Activation of CD4+ and CD8+ lymphocyte subsets by streptozotocin in murine popliteal lymph node (PLN) test.	Streptozocin	50-64	CD4 antigen	Mus musculus	14-17
1352686-6	1992	The activation characteristics for CD4+ and CD8+ cell subsets in STZ-induced node enlargement were found to be analogous with T cell activation in acute allogeneic graft-versus-host (GVH) reaction in which the F1 recipient differed from the parent at both class I and II MHC loci.	Streptozocin	65-68	CD4 antigen	Mus musculus	35-38
1532002-3	1992	We have now expressed, in a murine T cell hybridoma, mutated forms of CD4 containing cysteine to serine point mutations at positions 420, 422, or 430.	Cysteine	85-93	CD4 antigen	Mus musculus	70-73
1532002-3	1992	We have now expressed, in a murine T cell hybridoma, mutated forms of CD4 containing cysteine to serine point mutations at positions 420, 422, or 430.	Serine	97-103	CD4 antigen	Mus musculus	70-73
1347668-3	1992	The cells from immunized mice which proliferated most actively in response to MHV were positive for the CD4 antigen and secreted interferon-gamma.	mhv	78-81	CD4 antigen	Mus musculus	104-107
1347302-4	1992	When mouse spleen cells were exposed in vitro to both SRBC and monoclonal anti-CD4, there was 55% reduction of the anti-SRBC response.	srbc	120-124	CD4 antigen	Mus musculus	79-82
1311423-5	1992	In T cells, co-activation of the T-cell receptor and the accessory CD4 cell-surface protein also results in the phosphorylation of the endogenous p95vav protein in tyrosine residues.	Tyrosine	164-172	CD4 antigen	Mus musculus	67-70
1547544-9	1992	Our data do confirm the general finding in AKR mice, a strain with a high incidence of spontaneous thymic lymphosarcoma, that cells with immature phenotypes, particularly CD4-CD8+J11d+, make up MNU-induced thymic lymphosarcomas.	Methylnitrosourea	194-197	CD4 antigen	Mus musculus	171-174
1311128-2	1992	The 42-kilodalton mitogen-activated protein (MAP) kinase (p42mapk) was tyrosyl-phosphorylated and activated after treatment of the murine T lymphoma cell line 171CD4+, which expresses CD4, with antibody to CD3.	cyclo(tyrosyl-tyrosyl)	71-78	CD4 antigen	Mus musculus	162-165
1347015-6	1992	It was of interest to determine if the functional difference observed between the CD4 T cells of the two strains was due to the presentation of different peptides of the hCol IV molecule by the two MHC class II molecules.	hcol	170-174	CD4 antigen	Mus musculus	82-85
1535784-0	1992	A cortisone sensitive CD3low subset of CD4+CD8- thymocytes represents an intermediate stage in intrathymic repertoire selection.	Cortisone	2-11	CD4 antigen	Mus musculus	39-42
1535784-3	1992	Intravenous transfer of CD3low CD4 SP cells into nude mice resulted in significant peripheral expansion of these cells with apparent upregulation of CD3.	sp	35-37	CD4 antigen	Mus musculus	31-34
1373061-0	1992	T helper function of CD4+ cells specific for defined epitopes on the acetylcholine receptor in congenic mouse strains.	Acetylcholine	69-82	CD4 antigen	Mus musculus	21-24
1373061-1	1992	We previously identified sequence segments of Torpedo acetylcholine receptor (TAChR) alpha subunit recognized by CD4+ cells of congenic mouse strains of different H-2 haplotypes, susceptible to experimental autoimmune myasthenia gravis.	Acetylcholine	54-67	CD4 antigen	Mus musculus	113-116
1531708-1	1992	We previously reported that thymic atrophy and reduced thymic cellularity associated with prenatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice are characterized by quantitative alerations in the number of thymocytes expressing CD4 and CD8 surface antigens.	Polychlorinated Dibenzodioxins	111-146	CD4 antigen	Mus musculus	246-249
1531708-1	1992	We previously reported that thymic atrophy and reduced thymic cellularity associated with prenatal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice are characterized by quantitative alerations in the number of thymocytes expressing CD4 and CD8 surface antigens.	Polychlorinated Dibenzodioxins	148-152	CD4 antigen	Mus musculus	246-249
1531708-4	1992	Flow cytometry analysis of gd 18 fetal thymocytes revealed a reduction in the number of small CD4+CD8+ double positive (DP) and PNA+, small thymocytes in the TCDD-exposed groups.	Polychlorinated Dibenzodioxins	158-162	CD4 antigen	Mus musculus	94-97
1531708-7	1992	The CD4-CD8+J11d+ thymocytes were increased in TCDD-treated mice while the more mature CD4-CD8+J11d- thymocyte numbers were similar to controls.	Polychlorinated Dibenzodioxins	47-51	CD4 antigen	Mus musculus	4-7
1531708-8	1992	Taken together, these data indicate that TCDD inhibits thymocyte maturation at the transition phase between the CD4-CD8+J11d+ phenotype and the DP/J11d+ thymocytes.	Polychlorinated Dibenzodioxins	41-45	CD4 antigen	Mus musculus	112-115
1361881-5	1992	The immune effectors generated by TSTA plus CY bear the Thy 1, L3T4, Lyt 2 phenotype.	Cyclophosphamide	44-46	CD4 antigen	Mus musculus	63-67
1364176-1	1992	In vivo administration in mice of a synthetic analog of prostaglandin E2 (PGE2) caused a selective and dramatic decrease of CD4+CD8+ double-positive, CD3/T-cell-receptor-alpha beta(lo) cells in the thymus.	Dinoprostone	56-72	CD4 antigen	Mus musculus	124-127
1364176-1	1992	In vivo administration in mice of a synthetic analog of prostaglandin E2 (PGE2) caused a selective and dramatic decrease of CD4+CD8+ double-positive, CD3/T-cell-receptor-alpha beta(lo) cells in the thymus.	Dinoprostone	74-78	CD4 antigen	Mus musculus	124-127
1364177-0	1992	The acquisition of a memory phenotype by murine CD4+ T cells is accompanied by a loss in their capacity to increase intracellular calcium.	Calcium	130-137	CD4 antigen	Mus musculus	48-51
1364177-2	1992	Total CD4+ T cells from aged mice displayed a diminished calcium response to anti-CD3 and even ionomycin as compared to the cells from young mice, and this was related to the changed composition of the CD4+ T-cell population.	Calcium	57-64	CD4 antigen	Mus musculus	6-9
1364177-2	1992	Total CD4+ T cells from aged mice displayed a diminished calcium response to anti-CD3 and even ionomycin as compared to the cells from young mice, and this was related to the changed composition of the CD4+ T-cell population.	Ionomycin	95-104	CD4 antigen	Mus musculus	6-9
1364177-3	1992	Regardless the age of the donor mice, naive CD4+ T cells effectively increased intracellular calcium, whereas memory CD4+ T cells were impaired in this regard.	Calcium	93-100	CD4 antigen	Mus musculus	44-47
1364177-4	1992	In addition, a heterogeneity in the differentiation stage of the naive CD4+ T cells was shown by the observation that calcium mobilization in naive CD4+ T cells from young mice was more profound than that in their aged counterparts.	Calcium	118-125	CD4 antigen	Mus musculus	71-74
1364177-4	1992	In addition, a heterogeneity in the differentiation stage of the naive CD4+ T cells was shown by the observation that calcium mobilization in naive CD4+ T cells from young mice was more profound than that in their aged counterparts.	Calcium	118-125	CD4 antigen	Mus musculus	148-151
1364177-5	1992	These data thus indicate that during the acquisition of a memory phenotype, murine CD4+ T cells lose the capacity to increase intracellular calcium, which in turn may be responsible for the decreased level of IL-2 production by these cells.	Calcium	140-147	CD4 antigen	Mus musculus	83-86
1530960-4	1992	Cell-depletion studies revealed that L3T4 (CD4)+ T cells, but not Lyt-2 (CD8)+ T cells, are required in the rhuIL-11-stimulated augmentation of SRBC-specific antibody responses.	srbc	144-148	CD4 antigen	Mus musculus	37-41
1530960-4	1992	Cell-depletion studies revealed that L3T4 (CD4)+ T cells, but not Lyt-2 (CD8)+ T cells, are required in the rhuIL-11-stimulated augmentation of SRBC-specific antibody responses.	srbc	144-148	CD4 antigen	Mus musculus	43-46
1381802-1	1992	In vitro immunomodulatory properties of gangliosides have been well characterized such as the ganglioside-induced modulation of CD4 on T lymphocytes and inhibition of lectin-induced proliferative response of lymphocytes.	Gangliosides	40-52	CD4 antigen	Mus musculus	128-131
1381802-1	1992	In vitro immunomodulatory properties of gangliosides have been well characterized such as the ganglioside-induced modulation of CD4 on T lymphocytes and inhibition of lectin-induced proliferative response of lymphocytes.	Gangliosides	40-51	CD4 antigen	Mus musculus	128-131
1721313-0	1991	Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells.	Tacrolimus	100-106	CD4 antigen	Mus musculus	139-142
1680568-5	1991	Mice given CD4 mAb 24 hr before dMTg (2 doses, 7 days apart) were resistant to EAT induction when immunized with MTg and LPS 20 days later.	(Methylthio)acetic acid	33-36	CD4 antigen	Mus musculus	11-14
1680568-8	1991	Moreover, mice given CD4 mAb and dMTg, then challenged after only 10 days, when CD4 mAb was still circulating, developed a significantly higher incidence of thyroid damage than controls.	dmtg	33-37	CD4 antigen	Mus musculus	80-83
1834454-5	1991	Testosterone replacement resulted in thymic regression, with a shift toward expression of mature thymocyte phenotypes, a decrease in the double-positive phenotype (CD4+CD8+), and a relative predominance of the CD4-CD8+ suppressor/cytotoxic phenotype over the CD4+CD8- helper phenotype.	Testosterone	0-12	CD4 antigen	Mus musculus	164-167
1834454-5	1991	Testosterone replacement resulted in thymic regression, with a shift toward expression of mature thymocyte phenotypes, a decrease in the double-positive phenotype (CD4+CD8+), and a relative predominance of the CD4-CD8+ suppressor/cytotoxic phenotype over the CD4+CD8- helper phenotype.	Testosterone	0-12	CD4 antigen	Mus musculus	210-213
1834454-5	1991	Testosterone replacement resulted in thymic regression, with a shift toward expression of mature thymocyte phenotypes, a decrease in the double-positive phenotype (CD4+CD8+), and a relative predominance of the CD4-CD8+ suppressor/cytotoxic phenotype over the CD4+CD8- helper phenotype.	Testosterone	0-12	CD4 antigen	Mus musculus	210-213
1835127-2	1991	Injection of 0.5 mg/100 g body weight of DT during 2 weeks decreased significantly the number and proportion of double positive (DP) (CD4+ CD8+) and increased the percentage of single positive (SP) CD4+ (CD4+ CD8-), whereas there was a slight decrease in the Thy 1.2+ cells in the thymus.	testosterone 17 beta-cypionate	41-43	CD4 antigen	Mus musculus	134-137
1835127-2	1991	Injection of 0.5 mg/100 g body weight of DT during 2 weeks decreased significantly the number and proportion of double positive (DP) (CD4+ CD8+) and increased the percentage of single positive (SP) CD4+ (CD4+ CD8-), whereas there was a slight decrease in the Thy 1.2+ cells in the thymus.	testosterone 17 beta-cypionate	41-43	CD4 antigen	Mus musculus	198-201
1835127-2	1991	Injection of 0.5 mg/100 g body weight of DT during 2 weeks decreased significantly the number and proportion of double positive (DP) (CD4+ CD8+) and increased the percentage of single positive (SP) CD4+ (CD4+ CD8-), whereas there was a slight decrease in the Thy 1.2+ cells in the thymus.	testosterone 17 beta-cypionate	41-43	CD4 antigen	Mus musculus	198-201
1835127-7	1991	These data indicate the main role of testosterone in the distribution of CD4+ and CD8+ cells in male mice.	Testosterone	37-49	CD4 antigen	Mus musculus	73-76
1666830-2	1991	This molecule showed slightly larger size than that of the authentic CD4 molecule from T-cells on SDS-PAGE.	Sodium Dodecyl Sulfate	98-101	CD4 antigen	Mus musculus	69-72
1834164-8	1991	Using three-colour immunofluorescence, we show that (i) while most CD45RA+ cells are present amongst the CD4-CD8- thymocyte subset in the normal thymus, after cortisone treatment or irradiation, all four thymocyte subsets co-express significant amounts of CD45RA.	Cortisone	159-168	CD4 antigen	Mus musculus	67-70
1715360-0	1991	The I-Abm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor.	Acetylcholine	170-183	CD4 antigen	Mus musculus	135-138
1880414-3	1991	The recombinant soluble mouse CD4 (smCD4) retained the native conformation of the external portion, as indicated by the binding of L3T4 mAb.	smcd4	35-40	CD4 antigen	Mus musculus	30-33
1880414-3	1991	The recombinant soluble mouse CD4 (smCD4) retained the native conformation of the external portion, as indicated by the binding of L3T4 mAb.	smcd4	35-40	CD4 antigen	Mus musculus	131-135
1880414-6	1991	These antibodies showed some binding to native cell surface CD4, indicating that immunization with smCD4 generated an anti-self response.	smcd4	99-104	CD4 antigen	Mus musculus	60-63
1715603-4	1991	Furthermore CD4+ T cells from the NA fraction but not from the NP fraction are activated cells: their inhibitory activity is abrogated after preincubation with cycloheximide.	Cycloheximide	160-173	CD4 antigen	Mus musculus	12-15
1908465-3	1991	Here we report that pp56lck-catalyzed angiotensin II phosphorylations are activated 20-fold in vitro by synthetic peptides reproducing portions of the murine CD4 cytoplasmic domain.	Peptides	114-122	CD4 antigen	Mus musculus	158-161
1722778-9	1991	On the other hand, the number of CD4+ CD8+ thymocytes did not decrease significantly in the 0.3 mg/kg/day-treated group, whereas it did decrease significantly in the 1 mg/kg/day-treated group, decreased further with the increase in dosage of FK-506, and decreased markedly in the 30 mg/kg/day group, The number of CD4-CD8-thymocytes did not show any change, even in the high-dosage groups.	Tacrolimus	242-248	CD4 antigen	Mus musculus	33-36
1841658-6	1991	Cultured CD4+ and CD8+ T cells had similar oligonucleotide uptake that was less than one-third of that in cultured B cells, but CD4-CD8- T cells had a higher percentage of cells taking up oligonucleotide than did B cells.	Oligonucleotides	43-58	CD4 antigen	Mus musculus	9-12
1841658-6	1991	Cultured CD4+ and CD8+ T cells had similar oligonucleotide uptake that was less than one-third of that in cultured B cells, but CD4-CD8- T cells had a higher percentage of cells taking up oligonucleotide than did B cells.	Oligonucleotides	188-203	CD4 antigen	Mus musculus	9-12
1841658-6	1991	Cultured CD4+ and CD8+ T cells had similar oligonucleotide uptake that was less than one-third of that in cultured B cells, but CD4-CD8- T cells had a higher percentage of cells taking up oligonucleotide than did B cells.	Oligonucleotides	188-203	CD4 antigen	Mus musculus	128-131
1799373-1	1991	Murine T cell surface antigens, CD4 and CD8 are phosphorylated in response to phorbol 12-myristate 13-acetate, a protein kinase C activator, but not phosphorylated after concanavalin A, Ca2+ ionophore or dibutyryl-cAMP treatment.	Tetradecanoylphorbol Acetate	78-109	CD4 antigen	Mus musculus	32-35
1799373-1	1991	Murine T cell surface antigens, CD4 and CD8 are phosphorylated in response to phorbol 12-myristate 13-acetate, a protein kinase C activator, but not phosphorylated after concanavalin A, Ca2+ ionophore or dibutyryl-cAMP treatment.	dibutyryl	204-213	CD4 antigen	Mus musculus	32-35
1799373-1	1991	Murine T cell surface antigens, CD4 and CD8 are phosphorylated in response to phorbol 12-myristate 13-acetate, a protein kinase C activator, but not phosphorylated after concanavalin A, Ca2+ ionophore or dibutyryl-cAMP treatment.	Cyclic AMP	214-218	CD4 antigen	Mus musculus	32-35
2018981-0	1991	L3T4 (CD4+) cells that mediate contact sensitivity to trinitrochlorobenzene express I-A determinants.	Picryl Chloride	54-75	CD4 antigen	Mus musculus	0-4
1708703-2	1991	In this work, we have studied the effect of the steroid hormone 17 beta-estradiol (E2) on the different subsets of CD4-/CD8- double-negative (DN) thymocytes by analyzing the expression of CD5, CD3-epsilon and of several V beta gene family products of the T cell antigen receptor (TCR).	Estradiol	67-81	CD4 antigen	Mus musculus	115-118
2022315-5	1991	Adrenalectomy abolished this effect of morphine in CD4+ T but not CD4-, CD8- spleen cells (most likely Thy 1.2- B cells).	Morphine	39-47	CD4 antigen	Mus musculus	51-54
2022315-6	1991	Moreover, simultaneous administration of the opiate antagonist naltrexone blocked the effect of morphine in CD4-, CD8- spleen cells, but not in CD4+ T cells.	Naltrexone	63-73	CD4 antigen	Mus musculus	108-111
2022315-6	1991	Moreover, simultaneous administration of the opiate antagonist naltrexone blocked the effect of morphine in CD4-, CD8- spleen cells, but not in CD4+ T cells.	Morphine	96-104	CD4 antigen	Mus musculus	108-111
1674386-8	1991	When spleen cells from partially CD4-depleted mice were challenged in vitro with SRBC, they mounted a direct PFC response that was more than four times the observed PFC response of mice that received either saline or rat IgG.	srbc	81-85	CD4 antigen	Mus musculus	33-36
1903221-4	1991	Thymuses from the day-18 embryos exposed to CsA were partially depleted of CD4+CD8- single positive cells.	Cyclosporine	44-47	CD4 antigen	Mus musculus	75-78
2013099-1	1991	The immunogenicity of a CD4 peptide sequence 303-315 (V4 domain) was determined for three forms of the peptide: (a) a polymer consisting of repeating peptide units, (b) a peptide linked to a large protein carrier, chicken serum albumin, and (c) unmodified free peptide.	Polymers	118-125	CD4 antigen	Mus musculus	24-27
1826279-7	1991	Administration of cyclophosphamide (CY), which accelerates the appearance of diabetes in NOD mice, caused similar depletions of CD4+CD8+ and V beta 8lo thymic T lymphocytes.	Cyclophosphamide	18-34	CD4 antigen	Mus musculus	128-131
1826279-7	1991	Administration of cyclophosphamide (CY), which accelerates the appearance of diabetes in NOD mice, caused similar depletions of CD4+CD8+ and V beta 8lo thymic T lymphocytes.	Cyclophosphamide	36-38	CD4 antigen	Mus musculus	128-131
1679332-4	1991	After cyclophosphamide, the CD4:CD8 ratio of pancreatic lymphocytes increased to 2.30 +/- 0.24 at day 7.	Cyclophosphamide	6-22	CD4 antigen	Mus musculus	28-31
1706380-1	1991	Although cortical (CD4+CD8+) thymocytes mobilize intracellular calcium poorly when CD3/TCR is ligated, we have found that murine cortical thymocytes can transduce strong biochemical signals in response to ligation of the CD3/Ti TCR complex (CD3/TCR) and that the signals are regulated by CD4 and CD8 interactions with CD3/TCR.	Calcium	63-70	CD4 antigen	Mus musculus	19-22
1706380-2	1991	Striking increases in intracellular calcium were observed in cortical thymocytes from transgenic mice containing productively rearranged alpha and beta TCR genes, when CD3 or TCR was cross-linked with CD4 or CD8 using heteroconjugated mAb.	Calcium	36-43	CD4 antigen	Mus musculus	201-204
1706380-5	1991	Cross-linking of CD4 or CD8 molecules to CD3/TCR induced strong calcium responses in these cells.	Calcium	64-71	CD4 antigen	Mus musculus	17-20
1706380-8	1991	Enhanced tyrosine phosphorylation was observed when CD3 or TCR was cross-linked with CD4 or CD8 on transgenic thymocytes or on the thymocyte cell line, in comparison with aggregation of CD3/TCR alone.	Tyrosine	9-17	CD4 antigen	Mus musculus	85-88
1706070-1	1991	Lymphocyte-specific tyrosine protein kinase p56lck is physically associated with CD4 and CD8 T-cell surface molecules, suggesting that it may transduce CD4/CD8-triggered tyrosine phosphorylation signals during antigen stimulation.	Tyrosine	20-28	CD4 antigen	Mus musculus	81-84
1706070-1	1991	Lymphocyte-specific tyrosine protein kinase p56lck is physically associated with CD4 and CD8 T-cell surface molecules, suggesting that it may transduce CD4/CD8-triggered tyrosine phosphorylation signals during antigen stimulation.	Tyrosine	20-28	CD4 antigen	Mus musculus	152-155
1706070-2	1991	Indeed, antibody-mediated aggregation of CD4 (to mimic interaction with its ligand, major histocompatibility complex (MHC) class II molecules), rapidly elevates the kinase activity of p56lck and is associated with marked changes in tyrosine protein phosphorylation.	Tyrosine	232-240	CD4 antigen	Mus musculus	41-44
1993845-7	1991	IL-7 administration to cyclophosphamide-treated mice also resulted in an accelerated recovery of peripheral CD4+ and CD8+ cell numbers in the spleen and lymph node.	Cyclophosphamide	23-39	CD4 antigen	Mus musculus	108-111
1671050-5	1991	The generation of the anti-TNP CTL responses that require self H-2-restricted CD4+ Th cells was markedly suppressed by addition of the ascites or SN under conditions in which these samples did not inhibit anti-allo CTL responses capable of using alternate pathways of allo-restricted CD4+ and CD8+ Th.	Thorium	0-2	CD4 antigen	Mus musculus	78-81
1671050-5	1991	The generation of the anti-TNP CTL responses that require self H-2-restricted CD4+ Th cells was markedly suppressed by addition of the ascites or SN under conditions in which these samples did not inhibit anti-allo CTL responses capable of using alternate pathways of allo-restricted CD4+ and CD8+ Th.	Thorium	0-2	CD4 antigen	Mus musculus	284-287
1671051-5	1991	The RNA synthesis inhibitor, actinomycin D, and the protein synthesis inhibitor, cycloheximide, strongly inhibited the ability of CD4 cells, but not CD8 cells, to induce target DNA fragmentation.	Dactinomycin	29-42	CD4 antigen	Mus musculus	130-133
1671051-5	1991	The RNA synthesis inhibitor, actinomycin D, and the protein synthesis inhibitor, cycloheximide, strongly inhibited the ability of CD4 cells, but not CD8 cells, to induce target DNA fragmentation.	Cycloheximide	81-94	CD4 antigen	Mus musculus	130-133
1671051-7	1991	Although cyclosporin A inhibited CD4 cells to fragment target DNA during the early phase (90 min) of E:T interaction, this inhibition was not sustained in the later phase (210 min) of the assay.	Cyclosporine	9-22	CD4 antigen	Mus musculus	33-36
1898715-0	1991	N-methyl-N-nitrosourea alters thymocyte subset distribution and targets immature CD4-8+ cells for lymphoma development.	Methylnitrosourea	0-22	CD4 antigen	Mus musculus	81-84
1898715-1	1991	The majority of N-methyl-N-nitrosourea (MNU)-induced lymphomas in AKR/J mice express a CD4-8+ phenotype.	Methylnitrosourea	16-38	CD4 antigen	Mus musculus	87-90
1898715-1	1991	The majority of N-methyl-N-nitrosourea (MNU)-induced lymphomas in AKR/J mice express a CD4-8+ phenotype.	Methylnitrosourea	40-43	CD4 antigen	Mus musculus	87-90
1898715-3	1991	This study demonstrates that MNU-induced lymphomas correspond to the immature CD4-8+ subset.	Methylnitrosourea	29-32	CD4 antigen	Mus musculus	78-81
1898715-4	1991	In addition, specific changes in the distribution of thymocyte subsets defined by CD4 and CD8 expression were observed after MNU treatment.	Methylnitrosourea	125-128	CD4 antigen	Mus musculus	82-85
1898715-8	1991	The data suggest that MNU induces neoplastic conversion in progenitor cells corresponding to the CD4-8- or immature CD4-8+ stages of thymocyte maturation.	Methylnitrosourea	22-25	CD4 antigen	Mus musculus	97-100
1898715-8	1991	The data suggest that MNU induces neoplastic conversion in progenitor cells corresponding to the CD4-8- or immature CD4-8+ stages of thymocyte maturation.	Methylnitrosourea	22-25	CD4 antigen	Mus musculus	116-119
1987274-3	1991	Released serotonin locally recruits and activates CD4+ Th-1 classical DTH effector T cells that secrete lymphokines that attract and activate a nonspecific perivascular infiltrate of circulating, bone marrow-derived leukocytes.	Serotonin	9-18	CD4 antigen	Mus musculus	50-53
1840380-5	1991	D-ROS were enriched in thymocytes expressing high levels of surface T-cell antigen receptor (TcR) and the associated CD3 complex, and these included both CD4+CD8-CD3++ and CD4-CD8+CD3++ mature thymocytes.	d-ros	0-5	CD4 antigen	Mus musculus	154-157
1840380-5	1991	D-ROS were enriched in thymocytes expressing high levels of surface T-cell antigen receptor (TcR) and the associated CD3 complex, and these included both CD4+CD8-CD3++ and CD4-CD8+CD3++ mature thymocytes.	d-ros	0-5	CD4 antigen	Mus musculus	172-175
1840380-6	1991	M-ROS were enriched in CD4-CD8- thymocytes and had a reduced content of thymocytes expressing high TcR-CD3 levels; they nevertheless contained some mature thymocytes, but only of the CD4+CD8-CD3++ category.	ros	2-5	CD4 antigen	Mus musculus	23-26
1840380-9	1991	The CD4+CD8+CD3++ subpopulation, believed to be a developmental intermediate between cortical thymocytes and mature T cells, was present in both ROS populations.	ros	145-148	CD4 antigen	Mus musculus	4-7
1840416-1	1991	N-methyl-N-nitrosourea induces murine CD4-8+ T-lymphomas that express high levels of J11d and low levels of CD5 antigens, a phenotype characteristic of immature CD4-8+ thymocytes.	Methylnitrosourea	0-22	CD4 antigen	Mus musculus	38-41
1840416-1	1991	N-methyl-N-nitrosourea induces murine CD4-8+ T-lymphomas that express high levels of J11d and low levels of CD5 antigens, a phenotype characteristic of immature CD4-8+ thymocytes.	Methylnitrosourea	0-22	CD4 antigen	Mus musculus	161-164
1822437-3	1991	From the results it is possible to conclude that: (1) subcutaneous administration of a small dose (2.5-3.0 mg/kg) of cephalosporins, together with antigen, enhanced primary antibody production and persistence; (2) the increase in serum antibodies was preceded by a change in percentage of L3T4+ cells within the regional (popliteal) lymph node.	Cephalosporins	117-131	CD4 antigen	Mus musculus	289-293
1822437-4	1991	In comparison to antigen alone, cephalosporins (during early immune response) increased the percentage of L3T4+ cells; (3) LN cellularity was strongly enhanced by cephalosporins; (4) cefotaxime influenced the kinetics of the cellularity and the L3T4/Lyt-2 index differently than cefodizime and HBW 538.	Cephalosporins	32-46	CD4 antigen	Mus musculus	106-110
1822437-4	1991	In comparison to antigen alone, cephalosporins (during early immune response) increased the percentage of L3T4+ cells; (3) LN cellularity was strongly enhanced by cephalosporins; (4) cefotaxime influenced the kinetics of the cellularity and the L3T4/Lyt-2 index differently than cefodizime and HBW 538.	Cephalosporins	32-46	CD4 antigen	Mus musculus	245-249
1822437-4	1991	In comparison to antigen alone, cephalosporins (during early immune response) increased the percentage of L3T4+ cells; (3) LN cellularity was strongly enhanced by cephalosporins; (4) cefotaxime influenced the kinetics of the cellularity and the L3T4/Lyt-2 index differently than cefodizime and HBW 538.	Cefotaxime	183-193	CD4 antigen	Mus musculus	106-110
1822437-4	1991	In comparison to antigen alone, cephalosporins (during early immune response) increased the percentage of L3T4+ cells; (3) LN cellularity was strongly enhanced by cephalosporins; (4) cefotaxime influenced the kinetics of the cellularity and the L3T4/Lyt-2 index differently than cefodizime and HBW 538.	Cefotaxime	183-193	CD4 antigen	Mus musculus	245-249
1783466-4	1991	Study of thymocyte surface markers revealed that CD4+/CD8+, Thy-1+, PNA+ immature thymocytes were relatively decreased in EGME-gavaged mice and that, thus, ratios of CD4-/CD8+, H2+ mature thymocytes were enriched.	methyl cellosolve	122-126	CD4 antigen	Mus musculus	49-52
1783466-4	1991	Study of thymocyte surface markers revealed that CD4+/CD8+, Thy-1+, PNA+ immature thymocytes were relatively decreased in EGME-gavaged mice and that, thus, ratios of CD4-/CD8+, H2+ mature thymocytes were enriched.	methyl cellosolve	122-126	CD4 antigen	Mus musculus	166-169
1824637-2	1991	Transgenic double-positive (CD4+CD8+) thymocytes, which are present in dramatically reduced numbers, exhibit increased T cell receptor (TCR) expression and increased mobilization of calcium mediated by these receptors.	Calcium	182-189	CD4 antigen	Mus musculus	28-31
1824637-3	1991	In contrast, transgenic single-positive (CD4+CD8- and CD4-CD8+) thymocytes and peripheral T cells exhibit decreased TCR-mediated calcium mobilization.	Calcium	129-136	CD4 antigen	Mus musculus	41-44
1824637-3	1991	In contrast, transgenic single-positive (CD4+CD8- and CD4-CD8+) thymocytes and peripheral T cells exhibit decreased TCR-mediated calcium mobilization.	Calcium	129-136	CD4 antigen	Mus musculus	54-57
1824589-3	1991	Morphine produced a significant decrease in both the number and proportion of CD4+/CD8+ double positive (DP) cells.	Morphine	0-8	CD4 antigen	Mus musculus	78-81
1824589-8	1991	Furthermore, adrenalectomy abolished the morphine-induced decrease in CD4+/CD8+ thymocytes relative to a sham-operated group.	Morphine	41-49	CD4 antigen	Mus musculus	70-73
1943440-8	1991	Cocaine as well as saline injected mice showed a decrease in the percentage of CD4+ CD8+ and Mac-1+ cells and an increase in B cells in the spleens of well nourished mice.	Cocaine	0-7	CD4 antigen	Mus musculus	79-82
1943440-8	1991	Cocaine as well as saline injected mice showed a decrease in the percentage of CD4+ CD8+ and Mac-1+ cells and an increase in B cells in the spleens of well nourished mice.	Sodium Chloride	19-25	CD4 antigen	Mus musculus	79-82
1672730-3	1991	The protein synthesis inhibitors cycloheximide (CHX) and pactamycin rapidly and reversibly increased CD4 and CD8 mRNA in the cloned cell lines, suggesting that a labile inhibitor protein(s) may regulate the expression of these transcripts.	Cycloheximide	33-46	CD4 antigen	Mus musculus	101-104
1672730-3	1991	The protein synthesis inhibitors cycloheximide (CHX) and pactamycin rapidly and reversibly increased CD4 and CD8 mRNA in the cloned cell lines, suggesting that a labile inhibitor protein(s) may regulate the expression of these transcripts.	Cycloheximide	48-51	CD4 antigen	Mus musculus	101-104
1672730-3	1991	The protein synthesis inhibitors cycloheximide (CHX) and pactamycin rapidly and reversibly increased CD4 and CD8 mRNA in the cloned cell lines, suggesting that a labile inhibitor protein(s) may regulate the expression of these transcripts.	Pactamycin	57-67	CD4 antigen	Mus musculus	101-104
1987697-1	1991	Sensitivity of the L3T4+Lyt-2- subset to cortisone.	Cortisone	41-50	CD4 antigen	Mus musculus	19-23
1987697-10	1991	Following cortisone treatment the ratio of L3T4/Lyt-2 single positive thymocytes in normal F1 mice was approximately 3:1, whereas in GVH animals this ratio was reversed (1:2).	Cortisone	10-19	CD4 antigen	Mus musculus	43-47
1987697-13	1991	However, when these animals were treated with cortisone, the L3+T4/Lyt-2- population was more sensitive than was the L3T4- Lyt2+ population, thereby resulting in a 1:2 L3T4/Lyt-2 ratio.	Cortisone	46-55	CD4 antigen	Mus musculus	117-121
1987697-13	1991	However, when these animals were treated with cortisone, the L3+T4/Lyt-2- population was more sensitive than was the L3T4- Lyt2+ population, thereby resulting in a 1:2 L3T4/Lyt-2 ratio.	Cortisone	46-55	CD4 antigen	Mus musculus	168-172
1711508-1	1990	The IgM antibody response of BALB/c mice to bacterial (Leuconostoc) dextran B1355 is influenced in a positive and negative manner by regulatory CD4+ and CD8+ T cells, respectively.	Dextrans	68-75	CD4 antigen	Mus musculus	144-147
1711508-6	1990	By contrast, the transfer of T cells from mice, which had been given an immunogenic dose of dextran 4 days previously, increased the antibody response in immunized recipients; such enhancement was abolished by treating transferred cells with anti Thy 1.2 or anti L3T4 (CD4) antibody in the presence of complement.	Dextrans	92-99	CD4 antigen	Mus musculus	269-272
1711508-7	1990	These findings indicate that the immune response to dextran B1355 is regulated by CD4+ T-amplifier cells (Ta cells) and by CD8+ T-suppressor cells (Ts cells) which are activated during the course of a normal antibody response.	Dextrans	52-59	CD4 antigen	Mus musculus	82-85
2147194-4	1990	We previously reported that the chimeric IL-2 toxin (DAB486-IL-2) prevents DTH responses and selectively eliminates activated IL-2R bearing CD4 and CD8 T cells from lymph nodes draining the site of inflammation.	dab486	53-59	CD4 antigen	Mus musculus	140-143
2149719-5	1990	Treatment of C57BL/6 mice with 5 intraperitoneal injections of 20 mg/kg body weight of BCNU or CLZ caused an increase in the percentage of CD4(-)CD8- T cells and a decrease in the percentage of CD4(+)CD8+ T cells in the thymus.	Carmustine	87-91	CD4 antigen	Mus musculus	139-142
2149719-5	1990	Treatment of C57BL/6 mice with 5 intraperitoneal injections of 20 mg/kg body weight of BCNU or CLZ caused an increase in the percentage of CD4(-)CD8- T cells and a decrease in the percentage of CD4(+)CD8+ T cells in the thymus.	Carmustine	87-91	CD4 antigen	Mus musculus	194-197
2149719-9	1990	Also BCNU and CLZ but not STZ treatment caused a 50% decrease in the total number of CD4+ and CD8+ T cells in the spleen.	Carmustine	5-9	CD4 antigen	Mus musculus	85-88
2149719-9	1990	Also BCNU and CLZ but not STZ treatment caused a 50% decrease in the total number of CD4+ and CD8+ T cells in the spleen.	chlorozotocin	14-17	CD4 antigen	Mus musculus	85-88
1976707-0	1990	Intact antigen receptor-mediated generation of inositol phosphates and increased intracellular calcium in CD4 CD8 T lymphocytes from MRL lpr mice.	Calcium	95-102	CD4 antigen	Mus musculus	106-109
1976707-10	1990	The data demonstrate that the CD3 complex in lpr CD4-CD8- T cells can couple to phospholipase C to hydrolyze phosphoinositides.	Phosphatidylinositols	109-126	CD4 antigen	Mus musculus	49-52
2212677-4	1990	LATI, in fact, is abolished when recipient mice are sublethally irradiated or treated with cyclosporin A, or when the reactivity of CD4+ lymphocytes is suppressed, whereas it is not affected by anti-asialo GM1 antibody.	lati	0-4	CD4 antigen	Mus musculus	132-135
1700755-9	1990	GB113-induced T cell activation is enhanced by soluble anti-CD4 and anti-Thy-1 mAb.	gb113	0-5	CD4 antigen	Mus musculus	60-63
2228019-5	1990	It has been demonstrated that only the CD3/TcR alpha beta+ J11d- CD25- subpopulation is susceptible to the suppressive effects of CsA among CD4-8- cells, whereas all the other four subpopulations, including CD3/TcR gamma delta+ cells, are resistant.	Cyclosporine	130-133	CD4 antigen	Mus musculus	140-143
2228019-6	1990	Thus, all of the TcR alpha beta-bearing cells, including CD4-8- cells but none of the TcR alpha beta- cells, are CsA sensitive.	Cyclosporine	113-116	CD4 antigen	Mus musculus	57-60
2228019-7	1990	Because it is known that CsA inhibits the TcR-mediated signalling events in mature T cells and that signallings mediated via the interaction of TcR with major histocompatibility complex (MHC) molecules on thymic stroma cells are crucial for thymic selection of T cells, these results indicate that TcR alpha beta-bearing CD4-8- cells but not TcR gamma delta-bearing CD4-8- cells undergo thymic positive selection.	Cyclosporine	25-28	CD4 antigen	Mus musculus	321-324
2228019-7	1990	Because it is known that CsA inhibits the TcR-mediated signalling events in mature T cells and that signallings mediated via the interaction of TcR with major histocompatibility complex (MHC) molecules on thymic stroma cells are crucial for thymic selection of T cells, these results indicate that TcR alpha beta-bearing CD4-8- cells but not TcR gamma delta-bearing CD4-8- cells undergo thymic positive selection.	Cyclosporine	25-28	CD4 antigen	Mus musculus	366-369
2118992-2	1990	Cross-linking of CD4 expressed on the surface of murine thymocytes, splenocytes, and CD4+ T-cell lines induced tyrosine phosphorylation of p56lck dramatically.	Tyrosine	111-119	CD4 antigen	Mus musculus	17-20
2118992-2	1990	Cross-linking of CD4 expressed on the surface of murine thymocytes, splenocytes, and CD4+ T-cell lines induced tyrosine phosphorylation of p56lck dramatically.	Tyrosine	111-119	CD4 antigen	Mus musculus	85-88
2118992-11	1990	Therefore, the effect of antibody-induced aggregation of CD4 and CD8 on the tyrosine phosphorylation of p56lck differs, at least quantitatively, from what occurs during antigen-induced T-cell activation.	Tyrosine	76-84	CD4 antigen	Mus musculus	57-60
2250907-1	1990	Antibody-mediated aggregation of the CD4 T-cell surface antigen activates bound p56lck molecules and can result in increased intracellular tyrosine protein phosphorylation.	Tyrosine	139-147	CD4 antigen	Mus musculus	37-40
2250907-2	1990	To evaluate the basis of the CD4 induced tyrosine phosphorylation signal, we have studied the ability of CD4 to regulate the function of p56lck when these two molecules are co-expressed in non-lymphoid cells.	Tyrosine	41-49	CD4 antigen	Mus musculus	29-32
2250907-5	1990	Contrary to what we have previously reported for an antigen-dependent murine T-cell clone, as well as murine thymocytes, the CD4 induced activation of p56lck observed in fibroblasts does not result in marked changes in Lck tyrosine phosphorylation, suggesting that other lymphoid specific components may be required for these tyrosine phosphorylation changes.	Tyrosine	223-231	CD4 antigen	Mus musculus	125-128
2250907-5	1990	Contrary to what we have previously reported for an antigen-dependent murine T-cell clone, as well as murine thymocytes, the CD4 induced activation of p56lck observed in fibroblasts does not result in marked changes in Lck tyrosine phosphorylation, suggesting that other lymphoid specific components may be required for these tyrosine phosphorylation changes.	Tyrosine	326-334	CD4 antigen	Mus musculus	125-128
2129070-9	1990	The absolute cell numbers of CD4+SP and CD8+SP subsets in the spleen were also reduced on Days 2 and 7.	TFF2 protein, human	33-35	CD4 antigen	Mus musculus	29-32
2129070-10	1990	The reduction of the CD4+SP/CD8+SP ratio was found in the thymocytes on Days 2 and 7 but not in spleen cells.	cd8+sp	28-34	CD4 antigen	Mus musculus	21-24
1975751-0	1990	Modulation of CD4 expression on lymphoma cells transplanted to mice fed (n - 3) polyunsaturated fatty acids.	Fatty Acids, Omega-3	72-107	CD4 antigen	Mus musculus	14-17
2118453-7	1990	In TCDD-treated mice, the percentage and the total number of double-positive CD4+ CD8+ thymocytes were significantly decreased while the percentage but not the total number of double-negative CD4- CD8- thymocytes was significantly increased.	Polychlorinated Dibenzodioxins	3-7	CD4 antigen	Mus musculus	77-80
2118453-7	1990	In TCDD-treated mice, the percentage and the total number of double-positive CD4+ CD8+ thymocytes were significantly decreased while the percentage but not the total number of double-negative CD4- CD8- thymocytes was significantly increased.	Polychlorinated Dibenzodioxins	3-7	CD4 antigen	Mus musculus	192-195
2118453-11	1990	A small but significant decrease in the percentage of CD4- CD8+ T cells was observed on Day 3 in mice treated with 2 or 5 micrograms/kg TCDD when compared to that of vehicle-treated mice.	Polychlorinated Dibenzodioxins	136-140	CD4 antigen	Mus musculus	54-57
2146233-8	1990	Effects seen following vinblastine treatment may be a result of drug-induced alterations in leukocyte chemotaxis, toxicity to other effector T cell populations, or a specific depletion of a functional Lyt-2+ T cell population that is required in addition to L3T4+ T cells for the expression of resistance to primary infection with T. taeniaeformis.	Vinblastine	23-34	CD4 antigen	Mus musculus	258-262
2147072-6	1990	Altered thymic production of CD4 and CD8 cells could be excluded by intrathymic injection of FITC (fluorescein isothiocyanate).	Fluorescein-5-isothiocyanate	99-125	CD4 antigen	Mus musculus	29-32
1972723-6	1990	When Ca2+ influx was induced by calcium ionophore A23187 or ionomycin, the clone produced IL-2 in response to anti-CD3 in the presence of anti-CD4.	Calcium	32-39	CD4 antigen	Mus musculus	143-146
1972723-6	1990	When Ca2+ influx was induced by calcium ionophore A23187 or ionomycin, the clone produced IL-2 in response to anti-CD3 in the presence of anti-CD4.	Calcimycin	50-56	CD4 antigen	Mus musculus	143-146
1972723-6	1990	When Ca2+ influx was induced by calcium ionophore A23187 or ionomycin, the clone produced IL-2 in response to anti-CD3 in the presence of anti-CD4.	Ionomycin	60-69	CD4 antigen	Mus musculus	143-146
1972943-0	1990	The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties.	Melatonin	24-33	CD4 antigen	Mus musculus	55-58
1972943-4	1990	Here we demonstrate that physiologic concentrations of melatonin stimulate, in vitro, activated L3T4+ (CD4+) cells to release opioid agonist(s) that can reproduce in vivo the immunoenhancing and anti-stress effects on thymus cellularity and antibody production of melatonin and compete with specific binding of [3H]naloxone to mouse brain membranes.	Melatonin	55-64	CD4 antigen	Mus musculus	103-106
1972943-4	1990	Here we demonstrate that physiologic concentrations of melatonin stimulate, in vitro, activated L3T4+ (CD4+) cells to release opioid agonist(s) that can reproduce in vivo the immunoenhancing and anti-stress effects on thymus cellularity and antibody production of melatonin and compete with specific binding of [3H]naloxone to mouse brain membranes.	Melatonin	264-273	CD4 antigen	Mus musculus	103-106
1972943-4	1990	Here we demonstrate that physiologic concentrations of melatonin stimulate, in vitro, activated L3T4+ (CD4+) cells to release opioid agonist(s) that can reproduce in vivo the immunoenhancing and anti-stress effects on thymus cellularity and antibody production of melatonin and compete with specific binding of [3H]naloxone to mouse brain membranes.	3h]naloxone	312-323	CD4 antigen	Mus musculus	103-106
1972170-5	1990	In our study we observed that immediately after BCNU treatment, there was a dramatic increase in the percentage of CD4+ T cells at the site of tumor growth in the peritoneal cavity.	Carmustine	48-52	CD4 antigen	Mus musculus	115-118
1972170-6	1990	The percentage of CD4+ T cells increased from approximately 3 to 4% found in normal or tumor-bearing mice to approximately 41% in BCNU-treated tumor-bearing mice.	Carmustine	130-134	CD4 antigen	Mus musculus	18-21
2372503-0	1990	Stem cell recovery from cyclophosphamide-induced myelosuppression requires the presence of CD4+ cells.	Cyclophosphamide	24-40	CD4 antigen	Mus musculus	91-94
2116595-0	1990	Anti-idiotypic antibodies of a predefined specificity generated against CDR3VH synthetic peptides define a private anti-CD4 idiotype.	Peptides	89-97	CD4 antigen	Mus musculus	120-123
2158393-5	1990	PLC among thymocytes of BL/6 mice + D-RadLV, identified among the medium and large cell fractions, were shown to be cortisone-resistant Thy-, CD4-CD8- lymphocytes.	Cortisone	116-125	CD4 antigen	Mus musculus	142-145
1972374-9	1990	In contrast, the increase in HLA-ABC expression by CD8+ lymphocytes was associated with transition from 2H4+ to 2H4int status, which suggests that increased HLA-ABC expression occurs at an earlier stage in the acquisition of CD45RO in CD8+ cells than for CD4+ cells.	2h4int	112-118	CD4 antigen	Mus musculus	225-228
2139884-2	1990	Calcium response was reduced in both CD4+ and CD8+ subsets, after stimulation with concanavalin A or anti-CD3 monoclonal antibody over a broad range of concentrations.	Calcium	0-7	CD4 antigen	Mus musculus	37-40
2139885-5	1990	Both CD4 (helper) and CD8 (killer) T cells show poor calcium responses.	Calcium	53-60	CD4 antigen	Mus musculus	5-8
1971316-4	1990	However, after stimulation of the T cells with the combination of phorbol-12-myristate-13-acetate (PMA) and ionomycin to bypass CD3, 3 out of 6 old mice still exhibited 2-fold lower proliferative responses than T cells from young mice; IL-2 production by the CD4+ T cells was lower in all old mice tested.	Tetradecanoylphorbol Acetate	66-97	CD4 antigen	Mus musculus	259-262
1971316-4	1990	However, after stimulation of the T cells with the combination of phorbol-12-myristate-13-acetate (PMA) and ionomycin to bypass CD3, 3 out of 6 old mice still exhibited 2-fold lower proliferative responses than T cells from young mice; IL-2 production by the CD4+ T cells was lower in all old mice tested.	Tetradecanoylphorbol Acetate	99-102	CD4 antigen	Mus musculus	259-262
1971316-4	1990	However, after stimulation of the T cells with the combination of phorbol-12-myristate-13-acetate (PMA) and ionomycin to bypass CD3, 3 out of 6 old mice still exhibited 2-fold lower proliferative responses than T cells from young mice; IL-2 production by the CD4+ T cells was lower in all old mice tested.	Ionomycin	108-117	CD4 antigen	Mus musculus	259-262
2107031-2	1990	We now report a robust, sustained elevation in the ratio of CD4+/CD8+ cells in the spleen and thymus of mice chronically treated with morphine.	Morphine	134-142	CD4 antigen	Mus musculus	60-63
2140977-7	1990	These observations suggest that CD4 positive T-lymphocyte-dependent B-lymphocyte infiltration in and around islet cells may be associated with islet cell destruction and the development of diabetes in CD-1 mice treated with multiple low doses of streptozocin.	Streptozocin	246-258	CD4 antigen	Mus musculus	32-35
1971792-0	1990	CD4+CD8+ thymocytes are susceptible to DNA fragmentation induced by phorbol ester, calcium ionophore and anti-CD3 antibody.	Phorbol Esters	68-81	CD4 antigen	Mus musculus	0-3
1971792-0	1990	CD4+CD8+ thymocytes are susceptible to DNA fragmentation induced by phorbol ester, calcium ionophore and anti-CD3 antibody.	Calcium	83-90	CD4 antigen	Mus musculus	0-3
1690248-8	1990	These spleen cells contained antigen-specific CD4+, CD8- suppressor T cells (Ts) that functioned in the induction phase of CPS.	cps	123-126	CD4 antigen	Mus musculus	46-49
1690767-5	1990	Among the CD4+ T cells, we observed a variety of specificities, including an autoreactive I-Aq specific clone, a minor lymphocyte stimulating determinant (Mls)-reactive clone, and five allo-I-Ad-specific CD4+ clones; a class II-specific CD4-CD8+ clone was also obtained.	i-aq	90-94	CD4 antigen	Mus musculus	10-13
1969500-2	1990	This 29-amino-acid peptide blocked [3H]thymidine uptake 30 to 50% by concanavalin A-stimulated CD4(+)--but not CD8(+)-enriched murine splenocytes.	Tritium	36-38	CD4 antigen	Mus musculus	95-98
1968930-11	1990	Injection of anti-CD4 antibody led 1 x 10(6) EL-4 tumor cells to grow and kill the C3H and DBA mice.	1,2,5,6-dibenzanthracene	91-94	CD4 antigen	Mus musculus	18-21
1968486-5	1990	Ly-6C (AL-21) is expressed on roughly 50% of CD4+ and CD8+ cells in C57BL/6 mice.	Aluminum	7-9	CD4 antigen	Mus musculus	45-48
2303704-7	1990	Intrathymic CD4/CD8 and IL-2R expression demonstrated only mild alterations after exposure to 30 micrograms TCDD/kg.	Polychlorinated Dibenzodioxins	108-112	CD4 antigen	Mus musculus	12-15
2137031-2	1990	6B10 immunoprecipitated the 55-kDa CD4 molecule and detected an epitope of CD4 that overlapped with that detected by OKT4A, B, and D. 6B10, 6B10 Fab fragments and recombinant HIV envelope glycoprotein (gp120) induced calcium mobilization in PBMC.	Calcium	217-224	CD4 antigen	Mus musculus	75-78
2137031-3	1990	6B10 stimulation also resulted in calcium mobilization in murine L cells expressing transfected CD4 gene products, indicating that CD4-mediated calcium mobilization occurred independently of the CD3/T cell receptor (TCR) complex.	Calcium	34-41	CD4 antigen	Mus musculus	96-99
2137031-3	1990	6B10 stimulation also resulted in calcium mobilization in murine L cells expressing transfected CD4 gene products, indicating that CD4-mediated calcium mobilization occurred independently of the CD3/T cell receptor (TCR) complex.	Calcium	144-151	CD4 antigen	Mus musculus	131-134
2140562-6	1990	The proportion of J11d+ cells in the CD4+ SP thymocytes transiently increased from day 12 to 14 and decreased thereafter, even though almost half of CD4+ SP cells were still dull J11d+ at day 35 after BMT.	sp	42-44	CD4 antigen	Mus musculus	37-40
2105273-5	1990	We demonstrated that the amplifier cells were nylon-wool-nonadherent, antigen-specific, CD4 (L3T4+ Lyt-2-) T lymphocytes which appear in the spleens of mice 5 days postimmunization with cryptococcal culture filtrate antigen in complete Freund adjuvant.	complete freund adjuvant	227-251	CD4 antigen	Mus musculus	88-91
2136889-3	1990	Low density nylon wool nonadherent BM from 5- to 8-wk-old nude and normal mice was found to contain dim CD3+ CD4- CD8- cells.	Nylons	12-17	CD4 antigen	Mus musculus	109-112
2096080-2	1990	Recently it has been shown that CD4+ TH1 lymphocytes ("inflammatory type") play a central role in DTH reaction.	D-threonine	98-101	CD4 antigen	Mus musculus	32-35
1969857-9	1990	These results indicate that the induction of AnuA by MC depend primarily on L3T4-positive T cells.	Mercuric Chloride	53-55	CD4 antigen	Mus musculus	76-80
1876108-4	1990	Adrenalectomy abolished this effect of morphine in CD4+ but not B cells.	Morphine	39-47	CD4 antigen	Mus musculus	51-54
1972820-7	1990	DMBA treatment had no effect on B cells or Ia expression, but decreased levels of the T lymphocyte cell surface molecule Thy-1, and increased L3T4 and Lyt-2 as quantitated by flow cytofluorimetry.	6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene	0-4	CD4 antigen	Mus musculus	142-146
2076177-4	1990	Plasma IgG2a elevation after LDV infection was greatly delayed and reduced by depletion of the mice of CD4+, but not of CD8+, T cells by administration of protein-G-purified anti-CD4 or anti-CD8 mAbs, and completely inhibited by repeated treatment of the mice with cyclophosphamide.	Cyclophosphamide	265-281	CD4 antigen	Mus musculus	103-106
33941757-9	2021	Multivariable linear regression analysis showed that C4 levels were closely related to DP (P<0.05) and that CD4 and CD8 levels were closely related to PA (P<0.01).	Protactinium	151-153	CD4 antigen	Mus musculus	108-111
33773998-2	2021	This study describes for the first time individual phases of microsporidiosis caused by E. cuniculi genotype I and efficacy of albendazole treatment in immunocompetent BALB/c and C57Bl/6 mice and immunodeficient SCID, CD4-/- and CD8-/- mice using molecular detection and quantification methods.	Albendazole	127-138	CD4 antigen	Mus musculus	218-221
33773998-4	2021	Albendazole application led to loss E. cuniculi genotype I infection in immunocompetent mouse strains, decreased spore burden by half in CD4-/- and CD8-/- mice, and prolongation of survival of SCID mice.	Albendazole	0-11	CD4 antigen	Mus musculus	137-140
33814018-7	2022	n-3 LCPUFA supplementation in n-3FAS mice lowered lung bacterial loads (P=0 003), T cells (P=0 019), CD4+ T cells (P=0 014), IFN-gamma (P<0 001) and promoted a pro-resolving lung lipid mediator profile.	n-3 lcpufa	0-10	CD4 antigen	Mus musculus	101-104
33811359-13	2021	Correspondingly, treatment with AFL + imiquimod had the greatest effects on the adaptive immune cell recruitment: CD4+ T-helper cells increased threefold at Day 7 compared with untreated SCCs (P = 0.0001) and, notably, cytotoxic CD8+ T cells increased 14-fold at Day 14 (P = 0.0112).	afl + imiquimod	32-47	CD4 antigen	Mus musculus	114-117
33811359-15	2021	AFL treatment alone induced a moderate immune cell infiltration (a twofold increase in CD4+ T-helper cells, P = 0.0200; a threefold increase in CD8+ T cells, P = 0.0100; and a 14-fold increase in FOXP3+ Tregs at Day 14, P = 0.0021), whereas imiquimod alone did not significantly increase cell counts.	aflatoxicol	0-3	CD4 antigen	Mus musculus	87-90
33811972-2	2021	Compared to scl-GVHD controls, ruxolitinib-treated recipients showed significantly attenuated clinical and pathological severities of scl-GVHD in the skin and decreased frequencies of effector cells, CD4+ T cells, and CD11b+ macrophage/monocytes.	ruxolitinib	31-42	CD4 antigen	Mus musculus	200-203
33811972-3	2021	Regulatory CD4+ Foxp3+ T cells were expanded while IFN-gamma producing CD4+ T cells were significantly decreased in ruxolitinib-treated recipients.	ruxolitinib	116-127	CD4 antigen	Mus musculus	11-14
33811972-3	2021	Regulatory CD4+ Foxp3+ T cells were expanded while IFN-gamma producing CD4+ T cells were significantly decreased in ruxolitinib-treated recipients.	ruxolitinib	116-127	CD4 antigen	Mus musculus	71-74
33811972-4	2021	Ruxolitinib suppressed not only the production of IFN-gamma from CD4+ T cells and MCP-1 from CD11b+ macrophage/monocytes, but also the proliferation of these cells in vitro.	ruxolitinib	0-11	CD4 antigen	Mus musculus	65-68
33812403-10	2021	The CD3, CD4 and CD8 showed positive in mice, and the propotation was imbalance, but it showed reserved after treated by FA-2-b-beta.	fa-2-b-beta	121-132	CD4 antigen	Mus musculus	9-12
33808404-8	2021	Combination of dulaglutide and empagliflozin further decreased MoMFLy6CHigh and CD4+Foxp3+ T cells.	empagliflozin	31-44	CD4 antigen	Mus musculus	80-83
33805383-9	2021	BBR-treated mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of co-stimulatory molecules CD28 and CD154 at both endpoints.	Berberine	0-3	CD4 antigen	Mus musculus	58-61
33805383-9	2021	BBR-treated mice had significantly reduced populations of CD4+Th and CD4+CXCR5+ Tfh cells, and an increased proportion of Foxp3+ Treg at days 14 and 28, as well as reduced expression of co-stimulatory molecules CD28 and CD154 at both endpoints.	Berberine	0-3	CD4 antigen	Mus musculus	69-72
33815130-1	2021	Anti-inflammatory regulatory T cells (Tregs) are the most metabolically flexible CD4+ T cells by using both glycolysis and fatty acid oxidation (FAO) which allow them to migrate in tissues.	Fatty Acids	123-133	CD4 antigen	Mus musculus	81-84
33803441-4	2021	Surprisingly, we found that CD4-IRF4KO mice are resistant to EAU.	Water	61-64	CD4 antigen	Mus musculus	28-31
33800208-7	2021	CerS2 null CD4+ T cells showed impaired Th2 and increased Th17 responses with concomitant higher T cell receptor (TCR) signal strength after TCR stimulation.	th2	40-43	CD4 antigen	Mus musculus	11-14
29752615-0	2018	Effects of simvastatin on the function of splenic CD4+ and CD8+ T cells in sepsis mice.	Simvastatin	11-22	CD4 antigen	Mus musculus	50-53
29752615-9	2018	Simvastatin-treated mice had significantly decreased the percentages of negative costimulatory receptor BTLA on CD4 T cell expression.	Simvastatin	0-11	CD4 antigen	Mus musculus	112-115
29752615-11	2018	There was significantly less depletion of splenic CD4+ and CD8+ T cells in simvastatin-treated mice.	Simvastatin	75-86	CD4 antigen	Mus musculus	50-53
22844709-10	2012	Five exposures to betulinic acid (0.5 mg/kg) decreased the percentage of immature CD4+CD8+ thymic cells with corresponding increases in the percentage and absolute count of mature, single-positive CD4+ thymocytes and decreased the percentage and total count of CD3+ splenocytes and mesenteric lymph node cells with corresponding decreases in the percentage and absolute count of CD4+ and CD8+ cells.	betulinic acid	18-32	CD4 antigen	Mus musculus	82-85
22844709-10	2012	Five exposures to betulinic acid (0.5 mg/kg) decreased the percentage of immature CD4+CD8+ thymic cells with corresponding increases in the percentage and absolute count of mature, single-positive CD4+ thymocytes and decreased the percentage and total count of CD3+ splenocytes and mesenteric lymph node cells with corresponding decreases in the percentage and absolute count of CD4+ and CD8+ cells.	betulinic acid	18-32	CD4 antigen	Mus musculus	197-200
22844709-10	2012	Five exposures to betulinic acid (0.5 mg/kg) decreased the percentage of immature CD4+CD8+ thymic cells with corresponding increases in the percentage and absolute count of mature, single-positive CD4+ thymocytes and decreased the percentage and total count of CD3+ splenocytes and mesenteric lymph node cells with corresponding decreases in the percentage and absolute count of CD4+ and CD8+ cells.	betulinic acid	18-32	CD4 antigen	Mus musculus	197-200
10357208-11	1999	Here we report that: (a) BFA, but not Monensin, is able to completely block extracellular CD69 expression on mice splenocytes after in vitro stimulation with PMA/ionomycin; (b) Monensin is more toxic than BFA and increases the relative amount of CD4+ cells due to a more profound increase in dead cells in the CD4- population; (c) CD69 is a useful marker when setting up intracellular staining of cytokines for flow cytometry.	Brefeldin A	25-28	CD4 antigen	Mus musculus	246-249
10357208-11	1999	Here we report that: (a) BFA, but not Monensin, is able to completely block extracellular CD69 expression on mice splenocytes after in vitro stimulation with PMA/ionomycin; (b) Monensin is more toxic than BFA and increases the relative amount of CD4+ cells due to a more profound increase in dead cells in the CD4- population; (c) CD69 is a useful marker when setting up intracellular staining of cytokines for flow cytometry.	Brefeldin A	25-28	CD4 antigen	Mus musculus	310-313
34954267-16	2022	Moreover, in vivo the treatment with cucurbitacin B enhanced anti-tumor immunity by regulating M2-like macrophages and promoted the expression of CD4 and CD8 in tumor microenvironment.	cucurbitacin B	37-51	CD4 antigen	Mus musculus	146-149
34896656-10	2022	Interestingly, we observed that blood glucose levels and insulin resistance may be related to the increase in activated CD4+ T-cells in the bone marrow.	Glucose	38-45	CD4 antigen	Mus musculus	120-123
34758202-1	2022	INTRODUCTION: This study investigates the synergistic effect of TGF-beta1 and Nrp-1 on CD4+ CD25+ Tregs " stabilization, and the associated pathways of signal transduction, in vitro models in the presence of LPS.	tregs	98-103	CD4 antigen	Mus musculus	87-90
34794340-7	2022	The pharmacological blockade of the CCL5 receptor reduced renal fibrosis and the CD4+ Th cell infiltration induced by NAS.	nas	118-121	CD4 antigen	Mus musculus	81-84
34954557-10	2022	Notably, TSA treatment of prediabetic mice abolished the ability of CD4+ T-cells to differentiate into diabetogenic Th1 and Th17 cells ex vivo.	trichostatin A	9-12	CD4 antigen	Mus musculus	68-71
34961636-6	2022	HIVBr18 elicited broad, polyfunctional, and durable CD4+and CD8+ T cell responses in BALB/c and mice transgenic to HLA class II alleles, showing cross-species promiscuity.	hivbr18	0-7	CD4 antigen	Mus musculus	52-55
34814011-5	2022	Importantly, D-m treatment prevented relapses in a relapsing-remitting model of EAE, which mimics the most common clinical manifestation of MS. EAE suppression was accompanied by increased frequency of CD4+FoxP3+ Tregs in the central nervous system, suggesting that EAE suppression resulted from Treg cell induction by D-m.	Mannose	319-322	CD4 antigen	Mus musculus	202-205
34823118-5	2022	In PP, IFN-gamma+/CD4+ T or IL-6+/CD4+ T cell numbers were higher in the muscarine or atropine groups, respectively.	Atropine	86-94	CD4 antigen	Mus musculus	18-21
34823118-5	2022	In PP, IFN-gamma+/CD4+ T or IL-6+/CD4+ T cell numbers were higher in the muscarine or atropine groups, respectively.	Atropine	86-94	CD4 antigen	Mus musculus	34-37
34823118-6	2022	In LP, TNF-alpha+/CD4+ T cell number was higher in the muscarine group and lower in the atropine.	Atropine	88-96	CD4 antigen	Mus musculus	18-21
34688555-9	2022	Intraperitoneal naloxone methiodide injection reduced effector CD4+ T cell elevation associated with increased eosinophil numbers in bronchoalveolar lavage fluid of GG mice to the levels in AA mice, suggesting that elevated Th2 cell generation in the bronchial lymph node (BLN) of GG mice induces enhanced eosinophilic inflammation.	Naloxone	16-24	CD4 antigen	Mus musculus	63-66
34688555-9	2022	Intraperitoneal naloxone methiodide injection reduced effector CD4+ T cell elevation associated with increased eosinophil numbers in bronchoalveolar lavage fluid of GG mice to the levels in AA mice, suggesting that elevated Th2 cell generation in the bronchial lymph node (BLN) of GG mice induces enhanced eosinophilic inflammation.	methyl iodide	25-35	CD4 antigen	Mus musculus	63-66
34779254-0	2022	Vitamin D supplementation induces CatG-mediated CD4+ T cell inactivation and restores pancreatic beta-cell function in mice with type 1 diabetes.	Vitamin D	0-9	CD4 antigen	Mus musculus	48-51
34872800-8	2022	In NOD mice, treatment with Abn-CBD significantly reduced the severity of insulitis and reduced the pro-inflammatory profile of CD4+ T cells compared to vehicle.	4-(3-3,4-p-menthadien-(1,8)-yl)olivetol	28-35	CD4 antigen	Mus musculus	128-131
34536451-7	2022	RESULTS: Deficiency of GPR120 in CD4+T cells resulted in more severe colitis in mice upon DSS insult and enteric infection.	dss	90-93	CD4 antigen	Mus musculus	33-36
34536451-9	2022	Treatment with GPR120 agonist, CpdA, promoted CD4+T cell production of IL-10 by upregulating Blimp1 and enhancing glycolysis, which was regulated by mTOR.	CPDA	31-35	CD4 antigen	Mus musculus	46-49
34364883-10	2022	Further, IMQ increased CD8+ and CD4+ T cell infiltration in TG>WT>KO mice.	Imiquimod	9-12	CD4 antigen	Mus musculus	32-35
34734364-10	2022	By 2 weeks post-FUS, we noted emergence of adaptive resistance mechanisms, including upregulation of TIGIT on CD4 + T cells and CD155 on non-immune tumor and stromal cells.	fusarubin	16-19	CD4 antigen	Mus musculus	110-113
34922011-12	2022	Applying THC protected corneal nerve morphology, thus maintained corneal sensitivity and reduced CD4+ T-cell infiltration.	Dronabinol	9-12	CD4 antigen	Mus musculus	97-100
34716962-8	2022	Lycopene also increased Treg differentiation in splenic naive CD4+ T cells.	Lycopene	0-8	CD4 antigen	Mus musculus	62-65
34915497-2	2022	It has been recently reported that 5-ASA induces CD4 + Foxp3 + regulatory T cells (Tregs) in the colon via the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that regulates inflammation.	Mesalamine	35-40	CD4 antigen	Mus musculus	49-52
34915497-7	2022	In addition, the treatment of mouse splenic cells with 300 muM 5-ASA in a primary culture assay significantly induced CD4+CD25 + Foxp3 + Tregs (control vs. 5-ASA: 9.0% vs. 12.65%, p < 0.05), while 0.1 nM TCDD also showed significant induction of Tregs (control vs. TCDD: 9.0% vs. 14.1%, p < 0.05).	Mesalamine	63-68	CD4 antigen	Mus musculus	118-121
34915497-7	2022	In addition, the treatment of mouse splenic cells with 300 muM 5-ASA in a primary culture assay significantly induced CD4+CD25 + Foxp3 + Tregs (control vs. 5-ASA: 9.0% vs. 12.65%, p < 0.05), while 0.1 nM TCDD also showed significant induction of Tregs (control vs. TCDD: 9.0% vs. 14.1%, p < 0.05).	Mesalamine	156-161	CD4 antigen	Mus musculus	118-121
34931339-0	2022	Decreased microRNA-126 expression in psoriatic CD4+ T cells promotes T-helper 17 cell differentiation and the formation of dermatitis in imiquimod-induced psoriasis-like mice.	Imiquimod	137-146	CD4 antigen	Mus musculus	47-50
34931339-4	2022	Conditional Mir126 knockout in mouse CD4+ T cells can obviously aggravate the psoriasis-like dermatitis and promote T-helper (Th)1 and Th17 cells" infiltration in spleen of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	173-182	CD4 antigen	Mus musculus	37-40
34931339-4	2022	Conditional Mir126 knockout in mouse CD4+ T cells can obviously aggravate the psoriasis-like dermatitis and promote T-helper (Th)1 and Th17 cells" infiltration in spleen of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	184-187	CD4 antigen	Mus musculus	37-40
34932195-0	2022	Platelets differentially modulate CD4+ Treg activation via GPIIa/IIIb-, fibrinogen-, and PAR4-dependent pathways.	treg	39-43	CD4 antigen	Mus musculus	34-37
34932195-3	2022	We hypothesized that platelet activation mechanisms via GPIIb/IIIa, fibrinogen, and PAR4 have an immunological effect and modulate CD4+ Treg activation early after trauma.	treg	136-140	CD4 antigen	Mus musculus	131-134
34923183-9	2021	Subcutaneous tumors volume were reduced considerably after gemcitabine plus alphaPD-1 treatment compared with gemcitabine (P<0.01) or alphaPD-1 monotherapy (P<0.001) with the increased proportion of IL-2+CD8+T, CD8+T central memory cells (TCM), CD4 TCM, up-regulated IL12p70 and IFN-gamma secretion, and down-regulated TGF-beta.	gemcitabine	59-70	CD4 antigen	Mus musculus	245-248
34923183-9	2021	Subcutaneous tumors volume were reduced considerably after gemcitabine plus alphaPD-1 treatment compared with gemcitabine (P<0.01) or alphaPD-1 monotherapy (P<0.001) with the increased proportion of IL-2+CD8+T, CD8+T central memory cells (TCM), CD4 TCM, up-regulated IL12p70 and IFN-gamma secretion, and down-regulated TGF-beta.	gemcitabine	110-121	CD4 antigen	Mus musculus	245-248
34944945-8	2021	Similar to AFL alone, combined aPD-1 and AFL increased neutrophil counts (4-fold, p = 0.0242), the proportion of MHCII-positive neutrophils (p = 0.0121), and concordantly, CD4+ and CD8+ T-cell infiltration (p = 0.0061-0.0242).	aflatoxicol	41-44	CD4 antigen	Mus musculus	172-175
34910890-4	2022	Furthermore, by administering soluble RAGE (sRAGE) after stroke, we demonstrate that neutralization of RAGE reversed the enhanced fatty acid synthesis of CD4+ T cells and the post-stroke imbalance of Treg/Th17.	Fatty Acids	130-140	CD4 antigen	Mus musculus	154-157
34910890-6	2022	In conclusion, sRAGE can serve as a novel immunometabolic modulator that ameliorates ischemic stroke recovery by inhibiting fatty acid synthesis and thus favoring CD4+ T cells polarization toward Treg after cerebral ischemia injury.	treg	196-200	CD4 antigen	Mus musculus	163-166
34906138-16	2021	Inhibition of IRAK1 using pacritinib suppresses leukemogenesis with impaired induction of MDSCs and attenuated suppression of CD4+/CD8+ T-cells.	11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene	26-36	CD4 antigen	Mus musculus	126-129
34895467-5	2021	CIC deficiency attenuated TCR signaling in CD4+CD8+ double-positive (DP) cells, as evidenced by a decrease in CD5 and phospho-ERK levels and calcium flux.	Calcium	141-148	CD4 antigen	Mus musculus	43-46
34955841-7	2021	Conclusion: Our results suggest that OMSC treatment delayed the onset and promoted the neural functional recovery in the EAE mouse model possibly by suppressing CD4+IFN-gamma+ T cells.	omsc	37-41	CD4 antigen	Mus musculus	161-164
34956183-9	2021	Of note, praziquantel treatment of infected mice left them at a higher baseline of serum IL-4, IgE and liver cytokines but lower CD4+ T cell -derived cytokines when compared to infected non-treated mice supporting an immunological treatment-induced advantage of previously infected mice over naive mice and infected/not treated mice.	Praziquantel	9-21	CD4 antigen	Mus musculus	129-132
34956237-5	2021	Furthermore, quantitative high-resolution immune positron emission tomography (immunoPET)/MR of a human CD4 knock-in mouse model showed rapid accumulation of 64Cu-radiolabeled CD4-Nb1 in CD4+ T cell-rich tissues.	Copper-64	158-162	CD4 antigen	Mus musculus	176-179
34956237-5	2021	Furthermore, quantitative high-resolution immune positron emission tomography (immunoPET)/MR of a human CD4 knock-in mouse model showed rapid accumulation of 64Cu-radiolabeled CD4-Nb1 in CD4+ T cell-rich tissues.	Copper-64	158-162	CD4 antigen	Mus musculus	187-190
34882304-0	2021	Intravenous calcitriol administration modulates mesenteric lymph node CD4+ T-cell polarization and attenuates intestinal inflammation in obese mice complicated with polymicrobial sepsis.	Calcitriol	12-22	CD4 antigen	Mus musculus	70-73
34882304-4	2021	This study investigated treatment with calcitriol on mesenteric lymph node (MLN) CD4+ T cell polarization and intestinal injury in obese mice with sepsis.	Calcitriol	39-49	CD4 antigen	Mus musculus	81-84
34882304-13	2021	CONCLUSIONS: Intravenous calcitriol treatment after sepsis can elicit more-balanced CD4 T cell subsets in lymph nodes near the intestines and alleviate intestinal inflammation and injury in obese mice complicated with sepsis.	Calcitriol	25-35	CD4 antigen	Mus musculus	84-87
34947972-9	2021	To further investigate, immunohistochemical staining showed DFMO diminished MYC expression and increased tumor infiltration of macrophages, CD86+ cells, CD4+ and CD8+ T lymphocytes.	Eflornithine	60-64	CD4 antigen	Mus musculus	153-156
34854376-0	2021	Histone deacetylase 3 represses cholesterol efflux during CD4+ T-cell activation.	Cholesterol	32-43	CD4 antigen	Mus musculus	58-61
34854376-6	2021	HDAC3-deficient CD4+ T cells had reduced levels of cellular cholesterol both before and after activation.	Cholesterol	60-71	CD4 antigen	Mus musculus	16-19
34854376-8	2021	Repression of these genes is the primary function for HDAC3 in peripheral CD4+ T cells, as addition of exogenous cholesterol restored proliferative capacity.	Cholesterol	113-124	CD4 antigen	Mus musculus	74-77
34854376-9	2021	Collectively, these findings demonstrate HDAC3 is essential during CD4+ T-cell activation to repress cholesterol efflux.	Cholesterol	101-112	CD4 antigen	Mus musculus	67-70
34529884-6	2021	GO-Y030 also controlled the metabolism in cultured CD4+ T cells in the presence of TGF-beta + IL-6; however, it did not prevent Th17 differentiation.	1,5-bis(3,5-bis(methoxymethoxy)phenyl)penta-1,4-dien-3-one	0-7	CD4 antigen	Mus musculus	51-54
34496685-7	2021	Furthermore, the 0.01% TCP mixture group also showed higher tear film lipid layer grades and conjunctival goblet cell density and lower corneal fluorescein staining scores, number of CD4 + IFN-gamma+ T cells, and levels of TNF-alpha, IL-1beta, and CCL4 than the DQS alone group (P < 0.05).	Tocopherols	23-26	CD4 antigen	Mus musculus	183-186
33866918-6	2021	The results demonstrate that NPPA-PTX NPs induce ICD of MDA-MB-231 and 4T1 cells through upregulation of CRT and HMGB1, reactivating the antitumor immunity via recruitment of infiltrating CD3+, CD4+, CD8+ T cells, secreting IFN-gamma, TNF-alpha, and the enhanced antitumor activity by combining with aPD-L1.	ptx	34-37	CD4 antigen	Mus musculus	194-197
34626682-6	2021	In in vitro experiment of co-cultures of purified CD4+T cells of DO11.10 mice with OVA/LPS-stimulated BM-DCs, the CTX or CB induced lowest percentage of Th1 and Th2 and CTX induced increase of Treg cells.	ova	83-86	CD4 antigen	Mus musculus	50-53
34673300-10	2021	At the same time, matrine increased Treg ratio and decreased CD4+/CD8 + ratio in mice.	matrine	18-25	CD4 antigen	Mus musculus	61-64
33770444-8	2021	Levels of CD4+IFNgamma+ (TH1) and CD4+IL-17A+ (TH17) cells in the spinal cords of EAE mice administered galangin were reduced and both cell types were not capable of expansion.	galangin	104-112	CD4 antigen	Mus musculus	10-13
33770444-8	2021	Levels of CD4+IFNgamma+ (TH1) and CD4+IL-17A+ (TH17) cells in the spinal cords of EAE mice administered galangin were reduced and both cell types were not capable of expansion.	galangin	104-112	CD4 antigen	Mus musculus	34-37
33556301-8	2021	Alantolactone also reduced the number of splenic Th17 cells and the capability of naive CD4+ T cells to differentiate into the Th17 subset by downregulating STAT3/RORgammat signalling by as early as 24 h of treatment.	alantolactone	0-13	CD4 antigen	Mus musculus	88-91
34773881-7	2021	The population of CD8+T cells, the ratio of CD8/CD4, and plasma interleukin-6 levels were increased by Ang II infusion, and were decreased by AC-11 both in pregnant and non-pregnant mice.	AC-11	142-147	CD4 antigen	Mus musculus	48-51
33380272-5	2021	In this study, we investigated the effects of cervical vagotomy and the alpha7nAChR agonist pnu282987 on CD4+ T cell differentiation in a murine myocarditis model (BALB/c) infected with coxsackievirus B3 (CVB3).	PNU-282987	92-101	CD4 antigen	Mus musculus	105-108
34912349-4	2021	As previously shown by our group, injecting mice with IL-2/anti-IL-2 complexes (IL-2cplx) to augment expansion of CD4 T regulatory cells (Tregs) induces tolerance towards islet allografts, and also to skin allografts when IL-2cplx treatment is supplemented with rapamycin and a short-term treatment of anti-IL-6.	Sirolimus	262-271	CD4 antigen	Mus musculus	114-117
34843953-7	2022	Moreover, the combined application of the TTVP and anti-programmed death-1 monoclonal antibody (aPD-1) produced a synergistic antitumor effect, which could be related to the infiltration of more CD4+ and CD8+ T cells in the tumor tissues.	ttvp	42-46	CD4 antigen	Mus musculus	195-198
34848335-8	2022	However, flow cytometry revealed that both the expression of CD4+Foxp3+ regulatory T cells and of IL-17-producing T cells were increased in the butyrate and SCFA mix groups.	Butyrates	144-152	CD4 antigen	Mus musculus	61-64
34848335-8	2022	However, flow cytometry revealed that both the expression of CD4+Foxp3+ regulatory T cells and of IL-17-producing T cells were increased in the butyrate and SCFA mix groups.	Fatty Acids, Volatile	157-161	CD4 antigen	Mus musculus	61-64
34900690-0	2021	Alphataxin, a Small-Molecule Drug That Elevates Tumor-Infiltrating CD4+ T Cells, in Combination With Anti-PD-1 Therapy, Suppresses Murine Renal Cancer and Metastasis.	alphataxin	0-10	CD4 antigen	Mus musculus	67-70
34900690-13	2021	Orally available Alphataxin, the first and only drug developed to increase CD4+ T cells, in combination with anti-PD-1, is a powerful therapeutic method that provides long-term remission in renal cell carcinoma and potentially other T cell-responsive cancers by increasing the number of CD4+ tumor-infiltrating T cells.	alphataxin	17-27	CD4 antigen	Mus musculus	75-78
34900690-13	2021	Orally available Alphataxin, the first and only drug developed to increase CD4+ T cells, in combination with anti-PD-1, is a powerful therapeutic method that provides long-term remission in renal cell carcinoma and potentially other T cell-responsive cancers by increasing the number of CD4+ tumor-infiltrating T cells.	alphataxin	17-27	CD4 antigen	Mus musculus	287-290
34900985-3	2021	We found that TNFR2 antagonistic antibody reduced Foxp3 expression and the proliferation of Tregs and impaired the inhibitory effect of Tregs on CD4+CD25- effector T (Teff) cells in a dose-dependent manner.	tregs	136-141	CD4 antigen	Mus musculus	145-148
34824364-7	2021	BT942 resulted in a higher expansion of CD8+ T cells and CD4+ T cells in tumor microenvironment in mouse MC38 model compared to BA9.	bt942	0-5	CD4 antigen	Mus musculus	57-60
34824364-8	2021	BT942 also demonstrated significant higher tumor growth inhibition and higher expansion of CD8+ T cells and CD4+ T cells in combination with an anti-PD1 antibody.	bt942	0-5	CD4 antigen	Mus musculus	108-111
34852131-6	2021	The combined (NTZ+ IVC) treatment demonstrated the highest level of CD4 T cell expression.	nitazoxanide	14-17	CD4 antigen	Mus musculus	68-71
34852131-7	2021	Taken together, NTZ and IVC combined therapy showed remarkable anti-parasitic and immunostimulatory effects, specifically towards the CD4 population that seem to be promising in controlling cryptosporidiosis in diabetic individuals.	nitazoxanide	16-19	CD4 antigen	Mus musculus	134-137
34887868-9	2021	Furthermore, in vitro studies uncovered that hPMSC-Exo attenuated CD4+ T cell senescence by improving the PTEN/PI3K-Nrf2 axis by using the PTEN inhibitor bpV (HOpic).	bromopyruvate	154-157	CD4 antigen	Mus musculus	66-69
34815397-5	2021	Mechanistically, CD4 T cells release the putative P2Y10 ligands lysophosphatidylserine and ATP upon chemokine exposure, and these mediators induce P2Y10-dependent RhoA activation in an autocrine/paracrine fashion.	lysophosphatidylserine	64-86	CD4 antigen	Mus musculus	17-20
34815397-5	2021	Mechanistically, CD4 T cells release the putative P2Y10 ligands lysophosphatidylserine and ATP upon chemokine exposure, and these mediators induce P2Y10-dependent RhoA activation in an autocrine/paracrine fashion.	Adenosine Triphosphate	91-94	CD4 antigen	Mus musculus	17-20
34665782-5	2021	In vitro, 4MU directly attenuated activation, proliferation, and differentiation of naive CD4+ T-cells into Th1 cells.	Hymecromone	10-13	CD4 antigen	Mus musculus	90-93
34799427-5	2021	Nimodipine was found to not only decrease the clinical and histopathological inflammation score of EAU (C57BL/6J mice) but also dwindle the infiltration of uveitogenic CD4+ T cells into the retina.	Nimodipine	0-10	CD4 antigen	Mus musculus	168-171
34799427-7	2021	In vitro, nimodipine reduced the effector T cell differentiation of the IRBP1-20-specific CD4+ T cells of EAU mice and LPS-stimulated PBMCs of uveitis patients.	Nimodipine	10-20	CD4 antigen	Mus musculus	90-93
34624356-9	2021	Levels of platelet-leukocyte aggregates, platelet macroparticles, and proportion of CD4+ and CD8+ T-cells were also significantly elevated in the blood of the benzene-exposed mice.	Benzene	159-166	CD4 antigen	Mus musculus	84-87
34858817-9	2021	Moreover, increased infiltration of both CD4+ and CD8+ T cells was found in tumors from PPA1-DOX treated mice.	Doxorubicin	93-96	CD4 antigen	Mus musculus	41-44
34751838-3	2021	AIMS: In this study, we investigated the effect of conivaptan on the modulation of CD4+ T cell homeostasis and the progression of experimental colitis.	conivaptan	51-61	CD4 antigen	Mus musculus	83-86
34751838-6	2021	CD4+ T cells were injected into DNBS-induced mice through the tail vein.	2,4-dinitrofluorobenzene sulfonic acid	32-36	CD4 antigen	Mus musculus	0-3
34751838-8	2021	Intracellular Ca2+ ((Ca2+)i) signaling in CD4+ T cells was measured using the Fluo-3 AM loading method.	Fluo-3	78-87	CD4 antigen	Mus musculus	42-45
34831261-4	2021	Partial blockade of NAADP signaling in naive CD4+ T cells in vitro promoted the differentiation of Th17 cells.	NAADP	20-25	CD4 antigen	Mus musculus	45-48
34831261-8	2021	Thus, these results reveal a novel function of NAADP in controlling the differentiation and plasticity of CD4+ T cells.	NAADP	47-52	CD4 antigen	Mus musculus	106-109
34731632-2	2021	Here we show that cell-permeable alpha-ketoglutarate (alphaKG) alters the DNA methylation profile of naive CD4 T cells activated under Treg polarizing conditions, markedly attenuating FoxP3+ Treg differentiation and increasing inflammatory cytokines.	Ketoglutaric Acids	33-52	CD4 antigen	Mus musculus	107-110
34731632-2	2021	Here we show that cell-permeable alpha-ketoglutarate (alphaKG) alters the DNA methylation profile of naive CD4 T cells activated under Treg polarizing conditions, markedly attenuating FoxP3+ Treg differentiation and increasing inflammatory cytokines.	treg	135-139	CD4 antigen	Mus musculus	107-110
34771674-6	2021	In contrast, DCs pulsed with LPs induced CD4+ and CD8+ T cell responses and one of them, designated L82, delayed LLC1 growth in vivo.	lps	29-32	CD4 antigen	Mus musculus	41-44
34403737-8	2021	MPTP induced dopaminergic neuronal loss in the nigrostriatal system, motor coordinative and behavioral impairments, microglial activation, and CD4+ T-cell polarization to pro-inflammatory T-helper (Th)1 and Th17 phenotypes.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	CD4 antigen	Mus musculus	143-146
34403737-9	2021	Importantly, either Drd2-/- or Drd2fl/fl/CD4Cre mice manifested more severe dopaminergic neurodegeneration, motor deficits, microglial activation, and CD4+ T-cell bias towards Th1 and Th17 phenotypes in response to MPTP, but Drd1-/- did not further alter MPTP intoxication.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	215-219	CD4 antigen	Mus musculus	41-44
34403737-9	2021	Importantly, either Drd2-/- or Drd2fl/fl/CD4Cre mice manifested more severe dopaminergic neurodegeneration, motor deficits, microglial activation, and CD4+ T-cell bias towards Th1 and Th17 phenotypes in response to MPTP, but Drd1-/- did not further alter MPTP intoxication.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	215-219	CD4 antigen	Mus musculus	151-154
34403737-10	2021	DRD2 agonist sumanirole inhibited shift of CD4+ T cells obtained from MPTP-intoxicated mice to Th1 and Th17 phenotypes and DRD2 antagonist L-741,626 reversed sumanirole effects.	U 95666E	13-23	CD4 antigen	Mus musculus	43-46
34403737-10	2021	DRD2 agonist sumanirole inhibited shift of CD4+ T cells obtained from MPTP-intoxicated mice to Th1 and Th17 phenotypes and DRD2 antagonist L-741,626 reversed sumanirole effects.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	70-74	CD4 antigen	Mus musculus	43-46
34403737-10	2021	DRD2 agonist sumanirole inhibited shift of CD4+ T cells obtained from MPTP-intoxicated mice to Th1 and Th17 phenotypes and DRD2 antagonist L-741,626 reversed sumanirole effects.	l-741	139-144	CD4 antigen	Mus musculus	43-46
34500034-0	2021	Elevated beta-secretase 1 expression mediates CD4+ T cell dysfunction via PGE2 signalling in Alzheimer"s disease.	Dinoprostone	74-78	CD4 antigen	Mus musculus	46-49
34500034-5	2021	Moreover, administration of peripheral PGE2 signalling antagonists partially ameliorates CD4+ T cell overactivation and AD pathology in 5xFAD mice.	Dinoprostone	39-43	CD4 antigen	Mus musculus	89-92
34537997-6	2021	Besides, we found that imiquimod upregulated the expression of OX40 on CD4+ T cells and thus enhanced the effectiveness of OX40 agonist.	Imiquimod	23-32	CD4 antigen	Mus musculus	71-74
34556823-8	2021	Moreover, there was a marked increase in renal tissue CD4+ T cells after UUO or FA treatment and a significant decrease following renal tubule-specific ablation of H2-Ab1.	uuo	73-76	CD4 antigen	Mus musculus	54-57
34363211-7	2021	Expression of a constitutively activated form of Akt2 in CD4 T cells was sufficient to increase glycolysis in Tregs and drive changes in Treg subsets.	treg	137-141	CD4 antigen	Mus musculus	57-60
34492537-5	2021	In the mix lymphocyte reaction, we found that Asarinin pre-treated UC-MSC can exert significantly greater inhibition towards the proliferation of CD4 and CD8 + T cells, down-regulate Th1 type cytokines, up-regulate Th2 type cytokines, and reduce the inflammatory damage to liver, lung and intestine of aGVHD mice model.	sesamin	46-54	CD4 antigen	Mus musculus	146-149
34543978-4	2021	Significantly, G-Rg1 effectively decreased the amounts of CD4+CXCR5+IL-9+(Tfh9), CD4+ CXCR5+IL-17+(Tfh17), and increased CD4+CXCR5+Foxp3+(Tfr) and CD4+CD25+ Foxp3+(Treg) cells.	ginsenoside Rg1	15-20	CD4 antigen	Mus musculus	58-61
34543978-4	2021	Significantly, G-Rg1 effectively decreased the amounts of CD4+CXCR5+IL-9+(Tfh9), CD4+ CXCR5+IL-17+(Tfh17), and increased CD4+CXCR5+Foxp3+(Tfr) and CD4+CD25+ Foxp3+(Treg) cells.	ginsenoside Rg1	15-20	CD4 antigen	Mus musculus	81-84
34543978-4	2021	Significantly, G-Rg1 effectively decreased the amounts of CD4+CXCR5+IL-9+(Tfh9), CD4+ CXCR5+IL-17+(Tfh17), and increased CD4+CXCR5+Foxp3+(Tfr) and CD4+CD25+ Foxp3+(Treg) cells.	ginsenoside Rg1	15-20	CD4 antigen	Mus musculus	121-124
34543978-4	2021	Significantly, G-Rg1 effectively decreased the amounts of CD4+CXCR5+IL-9+(Tfh9), CD4+ CXCR5+IL-17+(Tfh17), and increased CD4+CXCR5+Foxp3+(Tfr) and CD4+CD25+ Foxp3+(Treg) cells.	ginsenoside Rg1	15-20	CD4 antigen	Mus musculus	147-150
34792393-6	2021	Oral FDE intake increased cell counts for major histocompatibility complex (MHC) I, MHC II, CD4(+) T cells, and CD8(+) T cells compared with controls.	fde	5-8	CD4 antigen	Mus musculus	92-95
34390765-10	2021	However, adoptive transfer of CD4+ splenocytes isolated from the mutant or wild type CPAF immunized mice resulted in a significant and comparable reduced oviduct pathology.	1-O-hexadecyl-2-N-methylcarbamol -sn-glycerol-3-phosphocholine	85-89	CD4 antigen	Mus musculus	30-33
34390765-11	2021	Our results indicate mutant CPAF vaccination is as same efficacy as wild type, and the protection relies on CD4+ T cells, which will further promote the development of CPAF as clinical chlamydial vaccine.	1-O-hexadecyl-2-N-methylcarbamol -sn-glycerol-3-phosphocholine	28-32	CD4 antigen	Mus musculus	108-111
34390765-11	2021	Our results indicate mutant CPAF vaccination is as same efficacy as wild type, and the protection relies on CD4+ T cells, which will further promote the development of CPAF as clinical chlamydial vaccine.	1-O-hexadecyl-2-N-methylcarbamol -sn-glycerol-3-phosphocholine	168-172	CD4 antigen	Mus musculus	108-111
34298481-0	2021	Dietary omega-3 polyunsaturated fatty acids modulate CD4+ T-cell subset markers, adipocyte antigen-presentation potential, and NLRP3 inflammasome activity in a coculture model of obese adipose tissue.	omega-3 polyunsaturated fatty acids	8-43	CD4 antigen	Mus musculus	53-56
34298481-1	2021	OBJECTIVES: Chronic low-grade inflammation in obesity is partly driven by inflammatory cross talk between adipocytes and interferon-gamma-secreting CD4+ T-helper (Th)1 cells, a process we have shown may be mitigated by long-chain (LC) omega-3 polyunsaturated fatty acids (PUFAs).	omega-3 polyunsaturated fatty acids	235-270	CD4 antigen	Mus musculus	148-151
34298481-1	2021	OBJECTIVES: Chronic low-grade inflammation in obesity is partly driven by inflammatory cross talk between adipocytes and interferon-gamma-secreting CD4+ T-helper (Th)1 cells, a process we have shown may be mitigated by long-chain (LC) omega-3 polyunsaturated fatty acids (PUFAs).	Fatty Acids, Unsaturated	272-277	CD4 antigen	Mus musculus	148-151
34592487-12	2021	In addition, Curcumin inhibited expression of CD4+CD25+FoxP3+ Treg cells as well as PD-1 and TIM-3.	Curcumin	13-21	CD4 antigen	Mus musculus	46-49
34274493-3	2021	Murine models demonstrate that prebiotics such as fructo-oligosaccharides (FOS) may increase gut levels of short-chain fatty acids (SCFAs) such as butyrate, and consequently induce proliferation of immunomodulatory FOXP3+ CD4+ T-regulatory cells (Tregs), that impact GVHD risk.	fructooligosaccharide	50-73	CD4 antigen	Mus musculus	222-225
34274493-3	2021	Murine models demonstrate that prebiotics such as fructo-oligosaccharides (FOS) may increase gut levels of short-chain fatty acids (SCFAs) such as butyrate, and consequently induce proliferation of immunomodulatory FOXP3+ CD4+ T-regulatory cells (Tregs), that impact GVHD risk.	fructooligosaccharide	75-78	CD4 antigen	Mus musculus	222-225
34606953-8	2021	Severe abacavir-induced skin hypersensitivity was observed in 01Tg/PD1 mice after depletion of CD4 T cells, in addition to significant CD8 T cell activation and dendritic cell maturation.	abacavir	7-15	CD4 antigen	Mus musculus	95-98
34702807-7	2021	Interestingly, Tipe2 KO mice treated with D-Gal showed a less serious inverse of CD4:CD8 ratio, a lower percentage of Treg compared to WT.	Galactose	42-47	CD4 antigen	Mus musculus	81-84
34702961-6	2021	In luCldn-18-deficient mice, production of cytokines including IFN-gamma was significantly decreased compared to wild-type mice, although infiltration of inflammatory cells including CD4+ T cells into the alveolar space was significantly increased.	lucldn-18	3-12	CD4 antigen	Mus musculus	183-186
34500237-4	2021	The results showed that total flavonoids significantly increased body weight, routine blood indices, bone marrow DNA cells, and also markedly caused lymphocyte proliferation by increasing the percentages of CD4+ and CD8+.	Flavonoids	30-40	CD4 antigen	Mus musculus	207-210
34744730-4	2021	We found that in contrast to AMD3100, an antagonist of CXCR4 and agonist of CXCR7, LIT-927 reduces the excessive number of several B/T lymphocyte subsets occurring in the blood of sick MRL/lpr mice (including CD3+/CD4-/CD8-/B220+ double negative T cells).	plerixafor	29-36	CD4 antigen	Mus musculus	214-217
34737699-10	2021	The reduction of CD4+ and CD8+ T lymphocytes in CY-treated mice was also highly increased in XFBD groups.	Cyclophosphamide	48-50	CD4 antigen	Mus musculus	17-20
34737699-10	2021	The reduction of CD4+ and CD8+ T lymphocytes in CY-treated mice was also highly increased in XFBD groups.	xfbd	93-97	CD4 antigen	Mus musculus	17-20
34712101-6	2021	In addition, while the STZ-treated group showed a decrease in total CD3+, CD4-CD8+, and CD4+CD8+ T lymphocytes in the thymus and CD19+ B lymphocytes in the pancreas and spleen, the ALX group showed an increase in CD4-CD8+ and CD19+ only in the thymus.	Streptozocin	23-26	CD4 antigen	Mus musculus	74-77
34712101-6	2021	In addition, while the STZ-treated group showed a decrease in total CD3+, CD4-CD8+, and CD4+CD8+ T lymphocytes in the thymus and CD19+ B lymphocytes in the pancreas and spleen, the ALX group showed an increase in CD4-CD8+ and CD19+ only in the thymus.	Streptozocin	23-26	CD4 antigen	Mus musculus	88-91
34712101-6	2021	In addition, while the STZ-treated group showed a decrease in total CD3+, CD4-CD8+, and CD4+CD8+ T lymphocytes in the thymus and CD19+ B lymphocytes in the pancreas and spleen, the ALX group showed an increase in CD4-CD8+ and CD19+ only in the thymus.	Streptozocin	23-26	CD4 antigen	Mus musculus	213-216
34662393-8	2022	Of importance, vecabrutinib treatment significantly reduced frequency of regulatory CD4+ T-cells (Tregs) in vivo.	Vecabrutinib	15-27	CD4 antigen	Mus musculus	84-87
34733288-8	2021	Moreover, splenic CD4+ T cells from naive KS mice expressed higher levels of Il17a mRNA compared to WT naive mice.	ks	42-44	CD4 antigen	Mus musculus	18-21
34733288-9	2021	Under Th17 polarization conditions, KS mice exhibited enhanced differentiation of naive CD4+ T cells into Th17 cells compared to WT controls.	ks	36-38	CD4 antigen	Mus musculus	88-91
34638488-6	2021	(3) Results: Treatment of established tumors in immunocompetent models of HER2-positive breast cancer and Kras-driven lung cancer with MSU42011 significantly decreased the tumor burden and increased the ratio of CD8/CD4, CD25 T cells, which correlates with enhanced anti-tumor efficacy.	msu42011	135-143	CD4 antigen	Mus musculus	216-219
34602068-11	2021	Treatment with endocrine therapy using the aromatase inhibitor letrozole increases CD4+ T cell infiltration into ER+ breast cancer tumours in immune competent mice.	Letrozole	63-72	CD4 antigen	Mus musculus	83-86
34680083-6	2021	The complete anti-allodynia effect of IB-MECA in H4R-/- mice was restored after intravenous administration of CD4+ T cells obtained from naive wild type mice.	N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine	38-45	CD4 antigen	Mus musculus	110-113
34363796-4	2021	When formulated in vaccines, Mn2+ could activate murine CD4+ T cells, CD8+T cells, B cells and DCs, and induce the expression and phosphorylation of TANK-binding kinase 1 (TBK1) and IRF5 in the splenocytes of the immunized mice, resulting in the increased expression of type-I IFNs, TNF-alpha, B cell-activating factor of the TNF family (BAFF) and B lymphocyte-induced maturation protein-1 (Blimp-1).	Manganese(2+)	29-33	CD4 antigen	Mus musculus	56-59
34119606-8	2021	Analysis of residual tumour tissues remaining after treatment revealed increased levels of infiltrating CD4+ and CD8+ T-lymphocytes (respectively 4.65 and 3.16-fold more) in the off-target tumours of animals where the target tumour was treated with SDT and anti-PD-L1, when compared to untreated tumours.	3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione	249-252	CD4 antigen	Mus musculus	104-107
34170298-8	2021	Additionally, the T cell response induced by mating with CD-fed males was blunted after mating with HFD-fed males, with 27% fewer CD4 + T cells, 26% fewer FOXP3 +CD4 + regulatory T cells (Treg) cells, and 19% fewer CTLA4 + Treg cells, particularly within the NRP1 + thymic Treg cell population.	Cadmium	57-59	CD4 antigen	Mus musculus	130-133
34170298-8	2021	Additionally, the T cell response induced by mating with CD-fed males was blunted after mating with HFD-fed males, with 27% fewer CD4 + T cells, 26% fewer FOXP3 +CD4 + regulatory T cells (Treg) cells, and 19% fewer CTLA4 + Treg cells, particularly within the NRP1 + thymic Treg cell population.	Cadmium	57-59	CD4 antigen	Mus musculus	162-165
34224738-8	2021	CsA suppressed activation of ITK in cultured CD4+ T cells and calcineurin-containing microclusters adjacent to the T cell receptor signaling complex.	Cyclosporine	0-3	CD4 antigen	Mus musculus	45-48
34388063-7	2021	OVA + TDCIPP-H treatment tended to increase the total cell number and promoted CD4+ cell activation compared with OVA alone treatment in mediastinal lymph nodes.	tdcipp-h	6-14	CD4 antigen	Mus musculus	79-82
34790387-7	2021	AOM/DSS induction also resulted in an increase in INF-gamma, IL-2, and TNF-alpha expression in serum, and a decrease in the percentages of CD4+, CD8+, CD4+/CD8+, and NK cells(P<0.05).	azomethane	0-3	CD4 antigen	Mus musculus	139-142
34790387-7	2021	AOM/DSS induction also resulted in an increase in INF-gamma, IL-2, and TNF-alpha expression in serum, and a decrease in the percentages of CD4+, CD8+, CD4+/CD8+, and NK cells(P<0.05).	azomethane	0-3	CD4 antigen	Mus musculus	151-154
34790387-7	2021	AOM/DSS induction also resulted in an increase in INF-gamma, IL-2, and TNF-alpha expression in serum, and a decrease in the percentages of CD4+, CD8+, CD4+/CD8+, and NK cells(P<0.05).	Dextran Sulfate	4-7	CD4 antigen	Mus musculus	139-142
34790387-7	2021	AOM/DSS induction also resulted in an increase in INF-gamma, IL-2, and TNF-alpha expression in serum, and a decrease in the percentages of CD4+, CD8+, CD4+/CD8+, and NK cells(P<0.05).	Dextran Sulfate	4-7	CD4 antigen	Mus musculus	151-154
34790387-9	2021	Further, in comparison with the AOM/DSS group, all three doses of TXD and celecoxib caused an increase in the contents of CD4+, CD8+, CD4+/CD8+, and NK cells in plasma.	Celecoxib	74-83	CD4 antigen	Mus musculus	122-125
34790387-9	2021	Further, in comparison with the AOM/DSS group, all three doses of TXD and celecoxib caused an increase in the contents of CD4+, CD8+, CD4+/CD8+, and NK cells in plasma.	Celecoxib	74-83	CD4 antigen	Mus musculus	134-137
34790387-12	2021	This decoction significantly decreased the levels of INF-gamma, IL-2, and TNF-alpha in serum, and increased the contents of CD4+, CD8+, CD4+/CD8+, and NK cell in the plasma of mice with AOM/DSS-induced CRC.	Dextran Sulfate	190-193	CD4 antigen	Mus musculus	124-127
34790387-12	2021	This decoction significantly decreased the levels of INF-gamma, IL-2, and TNF-alpha in serum, and increased the contents of CD4+, CD8+, CD4+/CD8+, and NK cell in the plasma of mice with AOM/DSS-induced CRC.	Dextran Sulfate	190-193	CD4 antigen	Mus musculus	136-139
34347892-6	2021	GA reported a reduction in parasite burden and augmentation of CD4+ and CD8+ T lymphocytes.	Gallic Acid	0-2	CD4 antigen	Mus musculus	63-66
34391754-5	2021	In tumor tissues of groups that received 5-FU and andrographolide sulfonate, CD4+ and CD8+ T cell infiltration was increased, and the expression of IFN-gamma and Granzyme B detected by immunohistochemistry and qPCR was upregulated, reflecting improved antitumor immunity.	Fluorouracil	41-45	CD4 antigen	Mus musculus	77-80
34391754-5	2021	In tumor tissues of groups that received 5-FU and andrographolide sulfonate, CD4+ and CD8+ T cell infiltration was increased, and the expression of IFN-gamma and Granzyme B detected by immunohistochemistry and qPCR was upregulated, reflecting improved antitumor immunity.	andrographolide sulfonate	50-75	CD4 antigen	Mus musculus	77-80
34630778-9	2021	LJZD increased the number of CD4+CD25+Foxp3+ TReg cells in blood mononuclear cells from asthmatic mice.	ljzd	0-4	CD4 antigen	Mus musculus	29-32
34583939-5	2021	Repeated weekly cycles of IL-2 mutein doses (day 0) followed by ASI (day 3) resulted in a 3- to 5-fold enrichment in Treg among Ag-responsive CD4 T cells.	treg	117-121	CD4 antigen	Mus musculus	142-145
34583939-7	2021	Combining Treg enrichment with ASI has the potential to durably treat autoimmune disease or allergy by increasing the Treg/conventional CD4 T cell ratio among autoantigen- or allergen-specific T cells.	treg	10-14	CD4 antigen	Mus musculus	136-139
34551205-6	2022	Administering taurodeoxycholic acid (TDCA) and valine, metabolites depleted in DIO-mice and restored through SGx, prolonged graft survival in DIO-mice comparable to SGx an dampened Th1 and Th17 allo-immune responses while Treg frequencies and CD4+ T-cell-derived IL-10 production were augmented.	Taurodeoxycholic Acid	14-35	CD4 antigen	Mus musculus	243-246
34551205-6	2022	Administering taurodeoxycholic acid (TDCA) and valine, metabolites depleted in DIO-mice and restored through SGx, prolonged graft survival in DIO-mice comparable to SGx an dampened Th1 and Th17 allo-immune responses while Treg frequencies and CD4+ T-cell-derived IL-10 production were augmented.	Valine	47-53	CD4 antigen	Mus musculus	243-246
34580637-14	2021	These findings indicate that an increase in IL-4+ CD4+ T cells in the LLN and splenocyte resulted in increased Th2 response to AE exposure.	th2	111-114	CD4 antigen	Mus musculus	50-53
34580637-15	2021	Exposure of the respiratory system to AE resulted in an increased allergen-induced Th2 inflammatory response and AHR through accumulation of inflammatory and IL-4+ CD4+ T cells and collagen deposition.	th2	83-86	CD4 antigen	Mus musculus	164-167
34604232-7	2021	In addition, UDP-treated tumors showed a higher presence of MHCIIhi tumor-associated macrophage (TAM) and of CD3+CD8+ and CD3+CD4+ tumor-infiltrating T-lymphocytes (TILs), both markers of anti-tumor immune response.	Uridine Diphosphate	13-16	CD4 antigen	Mus musculus	126-129
34577127-0	2021	Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-gamma-, Producing Murine CD4+ and CD8+ T Cells and Counteracts the Induction of Type 1 Regulatory T Cells.	oclacitinib	0-11	CD4 antigen	Mus musculus	119-122
34577127-2	2021	The results indicate that beneficial effects of OCL in the treatment of skin allergic diseases may be partially mediated by the inhibition of IL-4 production in CD4+ and CD8+ T cells.	oclacitinib	48-51	CD4 antigen	Mus musculus	161-164
34577127-5	2021	Moreover, OCL was found to counteract the induction of type 1 regulatory T (Tr1) cells and to act as a strong inhibitor of IL-10 production in both CD4+ and CD8+ T cells.	oclacitinib	10-13	CD4 antigen	Mus musculus	148-151
34481337-6	2021	Furthermore, immunohistochemistry analysis demonstrated thatcompound II-14 activated the immune microenvironment by promoting the infiltration of CD4+ T cells into tumor tissues.	ii-14	69-74	CD4 antigen	Mus musculus	146-149
34659889-7	2021	In vivo studies revealed that matrine decreased the ratio of CD206+/F4/80+, promoted the expression of CD4+ and CD8+ T cells, and inhibited the expression of Th2 in tumor and spleen tissues.	matrine	30-37	CD4 antigen	Mus musculus	103-106
34576080-4	2021	Remarkably, the percentage of CNS-infiltrated CD4+ T cells, the major drivers of neuroinflammation, was decreased to 40.98 +- 3.28% in ASA-treated mice compared to 56.11 +- 1.46% in control animals at the disease maximum as revealed by flow cytometry.	Aspirin	135-138	CD4 antigen	Mus musculus	46-49
34571785-6	2021	Production of inflammatory cytokines, recruitment of innate immune cells and antigen-specific CD4/CD8 memory T cell at the immunized site had been significantly enhanced by MPL+Poly I:C combination.	Poly I	177-183	CD4 antigen	Mus musculus	94-97
34571785-6	2021	Production of inflammatory cytokines, recruitment of innate immune cells and antigen-specific CD4/CD8 memory T cell at the immunized site had been significantly enhanced by MPL+Poly I:C combination.	Carbon	184-185	CD4 antigen	Mus musculus	94-97
34571785-7	2021	Moreover, MPL+Poly I:C combination enhanced ovalbumin-specific serum IgG, IgG1, and IgG2c production and proliferative function of CD4 and CD8 T cells after in vitro ovalbumin peptide stimulation.	Poly I	14-20	CD4 antigen	Mus musculus	131-134
34571785-7	2021	Moreover, MPL+Poly I:C combination enhanced ovalbumin-specific serum IgG, IgG1, and IgG2c production and proliferative function of CD4 and CD8 T cells after in vitro ovalbumin peptide stimulation.	Carbon	21-22	CD4 antigen	Mus musculus	131-134
34482409-5	2022	Tumor infiltration of T cells and dendritic cells was also enhanced in mice treated with DGKAI, and the production of cytokines and cytotoxic molecules by CD4+ and CD8+ T cells was increased.	dgkai	89-94	CD4 antigen	Mus musculus	155-158
34214903-9	2021	Further, highly autophagic Tregs had stronger inhibitory effects on CD4+ T cells in vitro, prolonged allograft survival and alleviated rejection in vivo.	tregs	27-32	CD4 antigen	Mus musculus	68-71
34455723-16	2021	Conclusion: The protective effect of SE extract in MLDS-induced diabetes could be partly due to a decrease of CD4+ and CD8+ T cells and an increase of Treg cells resulting in an inflammation reduction in the pancreatic islets.	se extract	37-47	CD4 antigen	Mus musculus	110-113
34455723-16	2021	Conclusion: The protective effect of SE extract in MLDS-induced diabetes could be partly due to a decrease of CD4+ and CD8+ T cells and an increase of Treg cells resulting in an inflammation reduction in the pancreatic islets.	mlds	51-55	CD4 antigen	Mus musculus	110-113
34261220-0	2021	Zearalenone and deoxynivalenol reduced Th1-mediated cellular immune response after Listeria monocytogenes infection by inhibiting CD4+ T cell activation and differentiation.	Zearalenone	0-11	CD4 antigen	Mus musculus	130-133
34261220-0	2021	Zearalenone and deoxynivalenol reduced Th1-mediated cellular immune response after Listeria monocytogenes infection by inhibiting CD4+ T cell activation and differentiation.	deoxynivalenol	16-30	CD4 antigen	Mus musculus	130-133
34261220-3	2021	The present study showed that both ZEA and DON aggravated Listeria monocytogenes infection in mice and affected the activation of CD4+ T cells and Th1 differentiation, including the effects on costimulatory molecules CD28 and CD152 and on cross-linking of IL-12 and IL-12R, by inhibiting T cell receptor (TCR) signaling.	Zearalenone	35-38	CD4 antigen	Mus musculus	130-133
34261220-3	2021	The present study showed that both ZEA and DON aggravated Listeria monocytogenes infection in mice and affected the activation of CD4+ T cells and Th1 differentiation, including the effects on costimulatory molecules CD28 and CD152 and on cross-linking of IL-12 and IL-12R, by inhibiting T cell receptor (TCR) signaling.	deoxynivalenol	43-46	CD4 antigen	Mus musculus	130-133
34261220-6	2021	Our findings more clearly revealed that exposure to low-dose ZEA and DON caused immunosuppression in the body by mechanisms including inhibition of CD4+ T cells activation and reduction of Th1 cell differentiation, thus exacerbating infection of animals by Listeria monocytogenes.	Zearalenone	61-64	CD4 antigen	Mus musculus	148-151
34261220-6	2021	Our findings more clearly revealed that exposure to low-dose ZEA and DON caused immunosuppression in the body by mechanisms including inhibition of CD4+ T cells activation and reduction of Th1 cell differentiation, thus exacerbating infection of animals by Listeria monocytogenes.	deoxynivalenol	69-72	CD4 antigen	Mus musculus	148-151
34174704-8	2021	NAD+ intervention relieved inflammatory infiltration and CD3+ and CD4+ cell infiltration and decreased the number and activation of microglia and astrocytes in the optic nerve.	NAD	0-4	CD4 antigen	Mus musculus	66-69
34318604-8	2021	Dex significantly increased the Prdm1 and Stat5b mRNA expression and decreased the Bcl-6 and c-Maf mRNA expression of CD4+ T cells.	Dexamethasone	0-3	CD4 antigen	Mus musculus	118-121
34183776-3	2021	It has been well-documented that granzyme B, a potent serine protease involved in cell-mediated cytotoxicity, is readily expressed by certain CD4+ T cells, such as regulatory T cells and CD4+CD8alphaalpha+ intestinal intraepithelial lymphocytes, both of which display cytotoxicity associated with granzyme B.	Serine	54-60	CD4 antigen	Mus musculus	142-145
34816649-6	2021	The CD4+ T cells were isolated from the mouse spleen tissues in CIA mice and treated with NE or alpha1-AR agonist phenylephrine.	Phenylephrine	114-127	CD4 antigen	Mus musculus	4-7
34816649-12	2021	Moreover, the alpha1-AR agonist phenylephrine increased the Treg cell function in CD4+ T cells of CIA mice relative to that of nothing-treated CD4+T cells of CIA mice.	Phenylephrine	32-45	CD4 antigen	Mus musculus	82-85
34816649-13	2021	Conclusion: Activating alpha1-AR on CD4+T cells of CIA mice enhances Treg cell function,facilitating a shift of CD4+T cells toward Treg polarization.	treg	131-135	CD4 antigen	Mus musculus	36-39
34816649-13	2021	Conclusion: Activating alpha1-AR on CD4+T cells of CIA mice enhances Treg cell function,facilitating a shift of CD4+T cells toward Treg polarization.	treg	131-135	CD4 antigen	Mus musculus	112-115
34461944-9	2021	Meanwhile, ADQ remodeled the immunosuppressive tumor microenvironment (TME) by increasing the infiltration of tumor-infiltrating lymphocytes (TILs) and cytotoxic CD8+ T cells, and decreasing the infiltration of Tregs, naive CD4+ T cells, and tumor-associated macrophages (TAMs).	ADP-glucose	11-14	CD4 antigen	Mus musculus	224-227
34461944-10	2021	Molecular mechanism studies revealed that ADQ remarkably inhibited CXCL1 expression and secretion from TAMs and thus suppressed the chemotaxis and differentiation of naive CD4+ T cells into Tregs, leading to the enhanced cytotoxic effects of CD8+ T cells.	ADP-glucose	42-45	CD4 antigen	Mus musculus	172-175
34461944-11	2021	Mechanistically, TAM-derived CXCL1 promoted the differentiation of naive CD4+ T cells into Tregs by transcriptionally activating the NF-kappaB/FOXP3 signaling.	tam	17-20	CD4 antigen	Mus musculus	73-76
34461944-11	2021	Mechanistically, TAM-derived CXCL1 promoted the differentiation of naive CD4+ T cells into Tregs by transcriptionally activating the NF-kappaB/FOXP3 signaling.	tregs	91-96	CD4 antigen	Mus musculus	73-76
34158413-5	2021	At the 42nd day of intradermal injection of HOCl, the symptoms showed up by skin and alveolar wall thickening, lymphocytic infiltration, increased collagen in skin/lung, and the increased proportion of CD3+CD4+CD25+FoxP3+ cells (a Treg subset) in spleen.	Hypochlorous Acid	44-48	CD4 antigen	Mus musculus	206-209
34426581-5	2021	Preclinical studies revealed decreased collagen deposition, lower levels of myeloid-derived suppressor cells, and higher CD4+ T-cell infiltration in TM-treated mice compared with controls.	tetrathiomolybdate	149-151	CD4 antigen	Mus musculus	121-124
34451922-8	2021	In animal models, dexmedetomidine inhibited the proliferation of CD4+ and CD8+ T cells and TNF-alpha production in a dose-dependent manner.	Dexmedetomidine	18-33	CD4 antigen	Mus musculus	65-68
34440235-4	2021	We first defined the effects of AAV-mIL-30 in vivo by administering it to a well-known concanavalin A (ConA)-induced hepatitis model of mice and found that AAV-mIL-30 reduced the numbers of activated CD25+CD4+ T cells and the levels of serum IFN-gamma and IL-12.	aav-mil-30	32-42	CD4 antigen	Mus musculus	205-208
34440235-4	2021	We first defined the effects of AAV-mIL-30 in vivo by administering it to a well-known concanavalin A (ConA)-induced hepatitis model of mice and found that AAV-mIL-30 reduced the numbers of activated CD25+CD4+ T cells and the levels of serum IFN-gamma and IL-12.	aav-mil-30	156-166	CD4 antigen	Mus musculus	205-208
34440235-5	2021	In autoimmune cholangitis, decreased numbers of activated CD4+ T cells and Foxp3+ regulatory T cells were noted in the mice treated with AAV-mIL-30 at 3 weeks after the 2-OA-OVA immunization.	aav-mil-30	137-147	CD4 antigen	Mus musculus	58-61
34404751-8	2021	Moreover, cs-130Fc efficiently inhibited the expansion of T helper 17 (TH17) cells in cultures of mouse CD4+ T cells treated with IL-6:sIL-6R.	cs-130fc	10-18	CD4 antigen	Mus musculus	104-107
34483908-10	2021	DHA recovered Th17-related profile with decreased frequency of IL-17+CD4+T cells from splenocyte of mice.	artenimol	0-3	CD4 antigen	Mus musculus	69-72
34483908-10	2021	DHA recovered Th17-related profile with decreased frequency of IL-17+CD4+T cells from splenocyte of mice.	th17	14-18	CD4 antigen	Mus musculus	69-72
34388730-12	2022	Immunofluorescence and flow cytometry demonstrated increased CD4+ T cells and decreased Foxp3+ T cells in mice that received BHV-4157 treatment.	tert-butyl 4-(2-{3-[3-{[(3-methylbut-2-enoyl)amino]methyl}-4-(trifluoromethyl)phenyl]-1-[3-(morpholin-4-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoethyl)piperidine-1-carboxylate	125-128	CD4 antigen	Mus musculus	61-64
34388730-15	2022	The authors provide a possible mechanism for this synergistic benefit by showing that BHV-4157 relies on CD4+ and CD8+ T cells.	tert-butyl 4-(2-{3-[3-{[(3-methylbut-2-enoyl)amino]methyl}-4-(trifluoromethyl)phenyl]-1-[3-(morpholin-4-yl)propyl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}-2-oxoethyl)piperidine-1-carboxylate	86-89	CD4 antigen	Mus musculus	105-108
34485396-12	2021	IL-2C treatment resulted in an eight-fold elevation of peripheral CD4+CD25+Foxp3+ Tregs compared to mice administered with anti-CD25 mAb.	tregs	82-87	CD4 antigen	Mus musculus	66-69
34880854-4	2021	We identified iron-interacting proteins in CD4+ and CD8+ T-cell proteomes that were differentially expressed during activation, suggesting that pathways enriched with such proteins, including histone demethylation, may be impaired by iron deficiency.	Iron	14-18	CD4 antigen	Mus musculus	43-46
34378880-0	2021	Cyclophosphamide abrogates the expansion of CD4+Foxp3+ regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas.	Cyclophosphamide	0-16	CD4 antigen	Mus musculus	44-47
34378880-1	2021	OBJECTIVE: Promotion of the proliferative expansion of CD4+Foxp3+ regulatory T cells (Tregs) is one of the side effects that limits the use of bleomycin (BLM) in the treatment of tumors.	Bleomycin	143-152	CD4 antigen	Mus musculus	55-58
34342231-5	2021	Moreover, phloridzin augmented the number of CD8+CD122+PD-1+ Tregs and CD4+FoxP3+ Tregs in HFD-fed C57BL/6J mice and HFD-fed aP2-SREBF1c mice and downregulated the mTORC1/SREBP-1c signaling pathway-related protein expressions in vivo and in vitro.	Phlorhizin	10-20	CD4 antigen	Mus musculus	71-74
34216540-2	2021	Here, we show that polyamine metabolism is a fundamental process governing the ability of CD4+ helper T cells (TH) to polarize into different functional fates.	Polyamines	19-28	CD4 antigen	Mus musculus	90-93
34216540-3	2021	Deficiency in ornithine decarboxylase, a crucial enzyme for polyamine synthesis, results in a severe failure of CD4+ T cells to adopt correct subset specification, underscored by ectopic expression of multiple cytokines and lineage-defining transcription factors across TH cell subsets.	Polyamines	60-69	CD4 antigen	Mus musculus	112-115
34413774-13	2021	FLX administration not only significantly reversed chronic unpredictable mild stress (CUMS)-induced reduction of 5-HT and Trp, increment of kynurenine, but increased CD4+ Th and CD8+ Tc cells, and reduced CD25+ FOXP3+ Tregs.	Fluoxetine	0-3	CD4 antigen	Mus musculus	166-169
34408746-2	2021	Despite an indispensable role of CD4+ T cells in inducing DTHA, a potential role for CD4+ T cell subsets is lacking.	dtha	58-62	CD4 antigen	Mus musculus	33-36
34408746-3	2021	Here we have quantified CD4+ subsets during DTHA development and found that levels of activated, pro-inflammatory Th1, Th17, and memory CD4+ T cells in draining lymph nodes were increased with differential dynamic patterns after DTHA induction.	dtha	44-48	CD4 antigen	Mus musculus	24-27
34408746-3	2021	Here we have quantified CD4+ subsets during DTHA development and found that levels of activated, pro-inflammatory Th1, Th17, and memory CD4+ T cells in draining lymph nodes were increased with differential dynamic patterns after DTHA induction.	dtha	44-48	CD4 antigen	Mus musculus	136-139
34408746-3	2021	Here we have quantified CD4+ subsets during DTHA development and found that levels of activated, pro-inflammatory Th1, Th17, and memory CD4+ T cells in draining lymph nodes were increased with differential dynamic patterns after DTHA induction.	dtha	229-233	CD4 antigen	Mus musculus	24-27
34408746-3	2021	Here we have quantified CD4+ subsets during DTHA development and found that levels of activated, pro-inflammatory Th1, Th17, and memory CD4+ T cells in draining lymph nodes were increased with differential dynamic patterns after DTHA induction.	dtha	229-233	CD4 antigen	Mus musculus	136-139
34088571-7	2021	Icariside I exhibited strong immunological anti-tumor activity, directly manifested by up-regulation of multiple lymphocyte subsets including CD4+ and CD8+ T cells or NK and NKT cells in peripheral blood of tumor-bearing mice.	icariside I	0-11	CD4 antigen	Mus musculus	142-145
34148144-8	2021	Under in vitro conditions, D-serine suppressed the proliferation of activated CD4 T cells and limited their ability to differentiate to Th1 and Th17 cells.	Serine	29-35	CD4 antigen	Mus musculus	78-81
34278410-6	2021	Flow cytometric analyses of eWAT indicated that HFD mice had significantly higher percentages of both CD4+ and CD8+ T cells compared to NMD mice, which was attenuated by treatment with atrasentan or bosentan.	Atrasentan	185-195	CD4 antigen	Mus musculus	102-105
34278410-6	2021	Flow cytometric analyses of eWAT indicated that HFD mice had significantly higher percentages of both CD4+ and CD8+ T cells compared to NMD mice, which was attenuated by treatment with atrasentan or bosentan.	Bosentan	199-207	CD4 antigen	Mus musculus	102-105
34327917-8	2021	These pathways and important differential proteins related to immunomodulatory functions were ultimately regulated by adriamycin on CD4+ T cells, CD8+ T cells and regulatory T cells, thereby affecting the prognosis of breast cancer.	Doxorubicin	118-128	CD4 antigen	Mus musculus	132-135
34327917-9	2021	Moreover, adriamycin significantly increased interleukin 2, CD4+ T and CD8+ T (P<0.01) and markedly reduced regulatory T cells (P<0.05).	Doxorubicin	10-20	CD4 antigen	Mus musculus	60-63
34327917-11	2021	Adriamycin could regulate the content of helper T cells 1 cytokines, CD4+ T and CD8+ T lymphocytes in breast cancer and reduce the number of regulatory T cells to produce immunomodulatory effects.	Doxorubicin	0-10	CD4 antigen	Mus musculus	69-72
34235533-6	2021	Moreover, DS-1055a decreased FoxP3 +CD4 + T cells in the TME and exhibited remarkable antitumor activity in a humanized mouse bearing HT29 tumor.	ds-1055a	10-18	CD4 antigen	Mus musculus	36-39
34360627-7	2021	Moreover, 2-D-gal treatment suppressed the levels of inflammatory cytokines in the ocular surface and the percentages of IFN-gamma+CD4+ cells in draining lymph nodes, whereas it did not affect the number of conjunctival goblet cells, the MUC5AC level or the meibomian gland area.	2-deoxy-lyxo-hexose	10-17	CD4 antigen	Mus musculus	131-134
34321879-12	2021	Meanwhile, Ng(-)pIL-12 adjuvant generated robust HBV-specific CD8+ T and CD4+ T cell responses.	pil-12 adjuvant	16-31	CD4 antigen	Mus musculus	73-76
34321879-14	2021	Conclusion: Chitosan nanovaccines as an efficient carrier adjuvant system for pIL-12 combined with HBsAg induced protective anti-HBs IgG and enhanced HBV-specific CD8+ T and CD4+ T cell responses, and achieved long-term memory response against HBV, making it a promising candidate for prophylactic HBV vaccines.	chitosan nanovaccines	12-33	CD4 antigen	Mus musculus	174-177
34321879-14	2021	Conclusion: Chitosan nanovaccines as an efficient carrier adjuvant system for pIL-12 combined with HBsAg induced protective anti-HBs IgG and enhanced HBV-specific CD8+ T and CD4+ T cell responses, and achieved long-term memory response against HBV, making it a promising candidate for prophylactic HBV vaccines.	pil-12	78-84	CD4 antigen	Mus musculus	174-177
34267342-5	2022	We showed that in naive T cells under Th17-polarizing condition, the addition of bergenin (3, 10, 30 muM) concentration-dependently decreased the percentage of CD4+ IL-17A+ T cells and mRNA expression of specific transcription factor RORgammat, and function-related factors IL-17A/F, IL-21, and IL-22, but did not affect the cell vitality and apoptosis.	bergenin	81-89	CD4 antigen	Mus musculus	160-163
34271910-14	2021	In co-culture experiments with splenic CD4+ T cells isolated from elastase-exposed mice, AAT-Fc treatment prior to EP-priming of bone marrow-derived dendritic cells inhibited the production of IFNgamma and IL-17.	aat-fc	89-95	CD4 antigen	Mus musculus	39-42
34359943-4	2021	When BMDCs were stimulated with the mannooligosaccharides, only beta-Man-(1 4)-Man significantly induced production of cytokines that included IL-6, IL-10, TNF-alpha, and IFN-beta, and enhanced CD4+ T-cell stimulatory capacity.	mannooligosaccharides	36-57	CD4 antigen	Mus musculus	194-197
34359943-4	2021	When BMDCs were stimulated with the mannooligosaccharides, only beta-Man-(1 4)-Man significantly induced production of cytokines that included IL-6, IL-10, TNF-alpha, and IFN-beta, and enhanced CD4+ T-cell stimulatory capacity.	beta-man-(1 4)-man	64-82	CD4 antigen	Mus musculus	194-197
34299138-12	2021	These results identified that IL-27 signaling plays a suppressive role in EAU by regulating multiple CD4+ cell subsets, including the effector Th1 and Th17 cells and the regulatory Tr1 cells.	Water	74-77	CD4 antigen	Mus musculus	101-104
34262061-6	2021	Additionally, CKD-506 decreased the leakage of intravenously administered Evans blue into the spinal cord; CD4+ T cells and CD4-CD11b+CD45+ macrophage/microglia in the spinal cord was also decreased.	ckd-506	14-21	CD4 antigen	Mus musculus	107-110
34262061-6	2021	Additionally, CKD-506 decreased the leakage of intravenously administered Evans blue into the spinal cord; CD4+ T cells and CD4-CD11b+CD45+ macrophage/microglia in the spinal cord was also decreased.	ckd-506	14-21	CD4 antigen	Mus musculus	124-127
34356353-0	2021	Miquelianin Inhibits Allergic Responses in Mice by Suppressing CD4+ T Cell Proliferation.	quercetin 3-O-glucopyranoside	0-11	CD4 antigen	Mus musculus	63-66
34356353-5	2021	Ex vivo MQL suppressed Th1- and Th2-related immune responses by inhibiting CD4+ T cell proliferation, and upregulated HO-1 in CD4+ T cells by activating C-Raf-ERK1/2-Nrf2 pathway via induction of reactive oxygen species generation.	Reactive Oxygen Species	196-219	CD4 antigen	Mus musculus	126-129
34299063-4	2021	The number of CD4+ forkhead box protein P3 (Foxp3)+ Tregs was higher in 4% SDS-treated skins than in controls.	Sodium Dodecyl Sulfate	75-78	CD4 antigen	Mus musculus	14-17
34299013-3	2021	Here, we show that IL-10-deficient mice treated with piroxicam exhibited significant alterations of the intestinal barrier function, including permeability, inflammation-related bioactive lipid mediators, and mucosal CD4+ T lymphocyte subsets.	Piroxicam	53-62	CD4 antigen	Mus musculus	217-220
34279352-5	2021	In vivo, MAN-CS-OVA-PLGA-MPs significantly increased the ratio of CD3+CD4+/CD3+CD8+ T cells, increased CD80+, CD86+, and MHC II expression in DCs, and improved OVA-specific IgG, IgG1, IgG2a, and IgG2b antibodies.	man-cs	9-15	CD4 antigen	Mus musculus	70-73
34188173-0	2021	SCD2-mediated monounsaturated fatty acid metabolism regulates cGAS-STING-dependent type I IFN responses in CD4+ T cells.	Fatty Acids, Monounsaturated	14-40	CD4 antigen	Mus musculus	107-110
34209797-0	2021	Iron Released after Cryo-Thermal Therapy Induced M1 Macrophage Polarization, Promoting the Differentiation of CD4+ T Cells into CTLs.	Iron	0-4	CD4 antigen	Mus musculus	110-113
34209797-9	2021	In addition, iron-induced M1 macrophages and mature DCs promoted the differentiation of CD4+ T cells into the CD4 cytolytic T lymphocytes (CTL) subset and inhibited differentiation into Th2 and Th17 cells.	Iron	13-17	CD4 antigen	Mus musculus	88-91
34209797-9	2021	In addition, iron-induced M1 macrophages and mature DCs promoted the differentiation of CD4+ T cells into the CD4 cytolytic T lymphocytes (CTL) subset and inhibited differentiation into Th2 and Th17 cells.	Iron	13-17	CD4 antigen	Mus musculus	110-113
34249005-11	2021	Alloreactive CD4+ T-cell death may be attributable to pre-cDC1s and provides a potential mechanism by which BEN+TBI conditioning limits GvHD and yields T-cells tolerant to host antigen.	Bendamustine Hydrochloride	108-112	CD4 antigen	Mus musculus	13-16
34249101-7	2021	PolyPEPI-SCoV-2 administered with Montanide ISA 51 VG generated robust, Th1-biased CD8+, and CD4+ T cell responses against all represented proteins, as well as binding antibodies upon subcutaneous injection into BALB/c and hCD34+ transgenic mice modeling human immune system.	montanide	34-43	CD4 antigen	Mus musculus	93-96
34147127-0	2021	Taurine promotes the production of CD4+CD25+FOXP3+ Treg cells through regulating IL-35/STAT1 pathway in a mouse allergic rhinitis model.	Taurine	0-7	CD4 antigen	Mus musculus	35-38
34143400-13	2022	Allicin increased the proportion of CD4+ T cells and decreased the proportion of CD8+ T cells in the peripheral blood and spleen.	allicin	0-7	CD4 antigen	Mus musculus	36-39
34132158-8	2021	Furthermore, in an adoptive transfer model, Treg-specific GnRHR knockdown increased Foxp3 expression in decidual Tregs while decreasing the production of IFN-gamma and IL-17 in decidual effector CD4+ T cells and reducing the production of IFN-gamma in decidual effector CD8+ T cells.	treg	44-48	CD4 antigen	Mus musculus	195-198
34220551-0	2021	Deficiency in CD4 T Cells Leads to Enhanced Postpartum Internal Carotid Artery Vasoconstriction in Mice: The Role of Nitric Oxide.	Nitric Oxide	117-129	CD4 antigen	Mus musculus	14-17
34220551-13	2021	ICAs from WT and CD4KO mice were equally sensitive to ACh with a significant rightward shift of dose-response curves after L-NNA treatment.	Acetylcholine	54-57	CD4 antigen	Mus musculus	17-20
34133541-7	2021	The positive expression of DX5+/CD25+/FOXP3+/CD45+/CD4+ in the VitD3 and progesterone groups was significantly higher than that in the autoimmune RSA group, and the expression was highest in the progesterone treatment group.	Progesterone	73-85	CD4 antigen	Mus musculus	51-54
34133541-7	2021	The positive expression of DX5+/CD25+/FOXP3+/CD45+/CD4+ in the VitD3 and progesterone groups was significantly higher than that in the autoimmune RSA group, and the expression was highest in the progesterone treatment group.	rabbit sperm membrane autoantigen	146-149	CD4 antigen	Mus musculus	51-54
34133541-7	2021	The positive expression of DX5+/CD25+/FOXP3+/CD45+/CD4+ in the VitD3 and progesterone groups was significantly higher than that in the autoimmune RSA group, and the expression was highest in the progesterone treatment group.	Progesterone	195-207	CD4 antigen	Mus musculus	51-54
34091018-5	2022	Disease protection by farnesol was associated with a significant reduction in spinal cord infiltration by monocytes-macrophages, dendritic cells, CD4+ T cells, and a significant gut change microbiota composition, including a decrease in the Firmicutes:Bacteroidetes ratio.	Farnesol	22-30	CD4 antigen	Mus musculus	146-149
34135557-13	2021	In the DSS group, there was an increase in colonic T helper CD4+ and T cytotoxic CD8+ cells by flow cytometry.	dss	7-10	CD4 antigen	Mus musculus	60-63
34085156-11	2022	In addition, Gly supplementation attenuated infiltration of CD4+, CD8+ T-lymphocytes, CD11b+ and F4/80+ macrophages in the colon.	Glycine	13-16	CD4 antigen	Mus musculus	60-63
34149615-14	2021	The activation of this pathway is reduced by treatment with 2DG and metformin, which also reverted imbalances in CD4+ T cell differentiation.	Deoxyglucose	60-63	CD4 antigen	Mus musculus	113-116
34149615-14	2021	The activation of this pathway is reduced by treatment with 2DG and metformin, which also reverted imbalances in CD4+ T cell differentiation.	Metformin	68-77	CD4 antigen	Mus musculus	113-116
34082780-12	2021	Furthermore, after transfection with siRNA028466, IL-2 production was facilitated and IL-10 production was suppressed in naive CD4+ T cells.	sirna028466	37-48	CD4 antigen	Mus musculus	127-130
34083417-8	2021	The response to ICI in the subcutaneous SB28 model required CD4 T cells and NK cells, but not CD8 T cells.	sb28	40-44	CD4 antigen	Mus musculus	60-63
34122327-5	2021	Interference with the testosterone surge significantly de-masculinized the male CD4+, but not CD8+ splenic profile.	Testosterone	22-34	CD4 antigen	Mus musculus	80-83
34122327-8	2021	These sex steroid effects affected both CD4+ and CD8+ cells and yet interference with the testosterone surge only significantly de-masculinized the splenic content of CD4+ cells.	Steroids	10-17	CD4 antigen	Mus musculus	40-43
34122327-8	2021	These sex steroid effects affected both CD4+ and CD8+ cells and yet interference with the testosterone surge only significantly de-masculinized the splenic content of CD4+ cells.	Steroids	10-17	CD4 antigen	Mus musculus	167-170
34122327-8	2021	These sex steroid effects affected both CD4+ and CD8+ cells and yet interference with the testosterone surge only significantly de-masculinized the splenic content of CD4+ cells.	Testosterone	90-102	CD4 antigen	Mus musculus	167-170
34122400-13	2021	CbTP successfully inhibited immunosuppression and weight loss, increased immune organ indices, and improved CD4+/CD8+ T lymphocyte subsets.	cbtp	0-4	CD4 antigen	Mus musculus	108-111
34122406-9	2021	Further, MK-2206 administration improved BCG-induced CD4+ and CD8+ effector T cells responses and its ability to induce both effector and central memory T cells.	MK 2206	9-16	CD4 antigen	Mus musculus	53-56
34135978-10	2021	On the contrary, baicalin increased anti-inflammatory M2 ATMs and liver CD4+ T cells and CD4/CD8 ratio.	baicalin	17-25	CD4 antigen	Mus musculus	72-75
34135978-10	2021	On the contrary, baicalin increased anti-inflammatory M2 ATMs and liver CD4+ T cells and CD4/CD8 ratio.	baicalin	17-25	CD4 antigen	Mus musculus	89-92
34134952-7	2021	The mice in DSS group had severe pathologies in the colon with significantly increased ratios of CD4+ and CD4+/CD8+ T cells in peripheral blood and LPL, increased levels of IL-6 and MCP-1 but no obvious changes in IL-10 in colon homogenate, and significantly augmented phosphorylation levels of ERK1/2, JNK and P38.	dss	12-15	CD4 antigen	Mus musculus	97-100
34134952-7	2021	The mice in DSS group had severe pathologies in the colon with significantly increased ratios of CD4+ and CD4+/CD8+ T cells in peripheral blood and LPL, increased levels of IL-6 and MCP-1 but no obvious changes in IL-10 in colon homogenate, and significantly augmented phosphorylation levels of ERK1/2, JNK and P38.	dss	12-15	CD4 antigen	Mus musculus	106-109
34134952-8	2021	Compared with those in DSS group, the mice in DSS+ rCsHscB group showed ameliorated colon pathologies with decreased CD4+T/CD8+T cell ratio in the peripheral blood and LPL, significantly decreased IL-6 and MCP-1 levels and increased IL-10 in colon homogenate, and lowered phosphorylation levels of ERK1/2, JNK and P38.	dss	23-26	CD4 antigen	Mus musculus	117-120
34134952-8	2021	Compared with those in DSS group, the mice in DSS+ rCsHscB group showed ameliorated colon pathologies with decreased CD4+T/CD8+T cell ratio in the peripheral blood and LPL, significantly decreased IL-6 and MCP-1 levels and increased IL-10 in colon homogenate, and lowered phosphorylation levels of ERK1/2, JNK and P38.	dss	46-49	CD4 antigen	Mus musculus	117-120
34134952-8	2021	Compared with those in DSS group, the mice in DSS+ rCsHscB group showed ameliorated colon pathologies with decreased CD4+T/CD8+T cell ratio in the peripheral blood and LPL, significantly decreased IL-6 and MCP-1 levels and increased IL-10 in colon homogenate, and lowered phosphorylation levels of ERK1/2, JNK and P38.	rcshscb	51-58	CD4 antigen	Mus musculus	117-120
34134952-9	2021	OBJECTIVE: rCsHscB can produce therapeutic effect on DSS-induced chronic ulcerative colitis in mice possibly by inhibiting the production of pro-inflammatory factors and regulating the balance of CD4+/CD8+T cells through the MAPK pathway.	rcshscb	11-18	CD4 antigen	Mus musculus	196-199
34602421-5	2021	Elevated CD4+ T and CD8+ T cells and macrophages in spleen, decreased serum IL-6 level and increased serum IFN-gamma and TNF-alpha levels were observed in mice treated with the combination of aconitine and CMP compare with control group (P<0.05).	Aconitine	192-201	CD4 antigen	Mus musculus	9-12
34602421-5	2021	Elevated CD4+ T and CD8+ T cells and macrophages in spleen, decreased serum IL-6 level and increased serum IFN-gamma and TNF-alpha levels were observed in mice treated with the combination of aconitine and CMP compare with control group (P<0.05).	4-chloro-2-cresol	206-209	CD4 antigen	Mus musculus	9-12
34273876-1	2021	The T-cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) is a validated immune checkpoint protein expressed on memory CD4+T-cellls, Tregs, CD8+T-cell and natural killer (NK) cells.	Tyrosine	53-61	CD4 antigen	Mus musculus	169-172
35608941-7	2022	LysoPS-induced aggravation of colitis was impaired in mice lacking P2ry10 and P2ry10b, and their CD4+ T cells were hyporesponsive to LysoPS.	lysophosphatidylserine	133-139	CD4 antigen	Mus musculus	97-100
35533917-0	2022	Vitamin D3 reverses the transcriptional profile of offspring CD4+ T lymphocytes exposed to intrauterine inflammation.	Cholecalciferol	0-10	CD4 antigen	Mus musculus	61-64
35183690-6	2022	RESULTS: Khasianine reduced infiltration of CD4+ T helper cells (Th cells) and macrophages in mice psoriatic lesions.	khasianine	9-19	CD4 antigen	Mus musculus	44-47
35500401-7	2022	Flow-cytometry analysis revealed that the administration of UV-PS (30 and 100 mg/kg) or UV-P (100 mg/kg) significantly increased the population of CD4+-/CD25+-/Foxp3+ Tregs in the spleen.	2-(5-tert-Butyl-2-hydroxyphenyl)benzotriazole	60-65	CD4 antigen	Mus musculus	147-150
35500401-7	2022	Flow-cytometry analysis revealed that the administration of UV-PS (30 and 100 mg/kg) or UV-P (100 mg/kg) significantly increased the population of CD4+-/CD25+-/Foxp3+ Tregs in the spleen.	Drometrizole	88-92	CD4 antigen	Mus musculus	147-150
35533447-0	2022	Asthma susceptibility in prenatal nicotine-exposed mice attributed to beta-catenin increase during CD4+ T cell development.	Nicotine	34-42	CD4 antigen	Mus musculus	99-102
35533447-3	2022	Our previous studies demonstrated that prenatal exposure to nicotine (PNE), the major active product of smoking, impairs fetal thymopoiesis and CD4+ T cell development after birth.	Nicotine	60-68	CD4 antigen	Mus musculus	144-147
35533447-3	2022	Our previous studies demonstrated that prenatal exposure to nicotine (PNE), the major active product of smoking, impairs fetal thymopoiesis and CD4+ T cell development after birth.	pne	70-73	CD4 antigen	Mus musculus	144-147
35509138-4	2022	In response to paclitaxel, females had reduced mechanical hypersensitivity and a greater frequency of anti-inflammatory CD4+ T cells (FoxP3, IL-10, IL-4) in the DRG than male and ovariectomized female mice.	Paclitaxel	15-25	CD4 antigen	Mus musculus	120-123
35604005-3	2022	GOS administration significantly improved epidermal thickness and decreased CD4+ cell numbers.	D-Glucitol-1,6-bisphosphate	0-3	CD4 antigen	Mus musculus	76-79
35435531-7	2022	Deletion of mTOR relieved autophagosome-lysosome fusion dysfunction and ameliorated apoptosis of CD4 + T cells in CLP mice, but this rescued phenotype was abolished by treatment with bafilomycin A1, a specific A-L fusion inhibitor.	bafilomycin A1	183-197	CD4 antigen	Mus musculus	97-100
34999930-11	2022	Subsequently, Naticol Gut delivery modulated CD4 T cells in favor of a Th2 response and dampened CD8 T-cell activation.	naticol	14-21	CD4 antigen	Mus musculus	45-48
34999930-11	2022	Subsequently, Naticol Gut delivery modulated CD4 T cells in favor of a Th2 response and dampened CD8 T-cell activation.	th2	71-74	CD4 antigen	Mus musculus	45-48
35577367-8	2022	Instead, transcriptomic analysis of the lungs revealed that dietary cholesterol caused upregulation of genes involved in viral-response pathways and leukocyte trafficking, which coincided with increased numbers of cytokine-producing CD4+ and CD8+ T cells and infiltrating dendritic cells.	Cholesterol	68-79	CD4 antigen	Mus musculus	233-236
35514318-4	2022	The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice.	Prednisone	49-59	CD4 antigen	Mus musculus	33-36
35514318-4	2022	The frequency of CD138+ cells in CD4+ T cells of prednisone-treated MRL/lpr mice was also significantly reduced, which subsequently contributed to reduced production of anti-dsDNA antibody in the prednisone-treated MRL/lpr mice.	Prednisone	196-206	CD4 antigen	Mus musculus	33-36
35634683-6	2022	Moreover, SHE significantly inhibited the proliferation of mast cells and decreased the expression of IL-13 on CD4+ cells prompted by elevated thymic stromal lymphopoietin (TSLP) expression in DNCB-induced AD in mice.	Dinitrochlorobenzene	193-197	CD4 antigen	Mus musculus	111-114
35440172-5	2022	CD4-targeted KLF10 (Kruppel like factor 10)-deficient (Klf10fl/flCD4Cre+; (TKO)) and CD4-Cre (Klf10+/+CD4Cre+; (Cre)) control mice were subjected to Ang II infusion.	flcd4cre	63-71	CD4 antigen	Mus musculus	0-3
35624463-9	2022	RESULTS: Flow cytometry on brains from mice following tMCAO identified a novel population of cells IL-21 producing CXCR5+ CD4+ ICOS-1+ T follicular helper cells (TFH) in the ischemic brain early after injury.	tmcao	54-59	CD4 antigen	Mus musculus	122-125
35624485-9	2022	Reactive-oxygen species (ROS) from CD4 + T cells was tested via flow cytometry.	Reactive Oxygen Species	0-23	CD4 antigen	Mus musculus	35-38
35624485-9	2022	Reactive-oxygen species (ROS) from CD4 + T cells was tested via flow cytometry.	Reactive Oxygen Species	25-28	CD4 antigen	Mus musculus	35-38
35606804-9	2022	Additionally, the population of intra-tumor CD4+CD25+Foxp3+ T cells was significantly lower in naringenin + CPT treated animals than that in controls.	naringenin	95-105	CD4 antigen	Mus musculus	44-47
35606923-8	2022	RESULTS: The combination of anti-CD4 mAb with autoantigen-specific peptide Ro480 generates SSA/Ro-antigen specific Tregs in vivo, which can suppress IFN-gamma production of CD4+ T cells and the inflammation infiltration in SG, and maintain the function of SG.	ro480	75-80	CD4 antigen	Mus musculus	33-36
35606923-8	2022	RESULTS: The combination of anti-CD4 mAb with autoantigen-specific peptide Ro480 generates SSA/Ro-antigen specific Tregs in vivo, which can suppress IFN-gamma production of CD4+ T cells and the inflammation infiltration in SG, and maintain the function of SG.	ro480	75-80	CD4 antigen	Mus musculus	173-176
35605008-0	2022	CD4 T-cell depletion prevents Lassa fever associated hearing loss in the mouse model.	lassa	30-35	CD4 antigen	Mus musculus	0-3
35606518-5	2022	The TLR-agonist-based adjuvants CpG1018 (TLR9) and AS37 (TLR7) induced Th1-skewed CD4+ T cell responses, while alum, O/W, and AS03 induced a balanced Th1/Th2 response.	1018 oligonucleotide	32-39	CD4 antigen	Mus musculus	82-85
35606518-5	2022	The TLR-agonist-based adjuvants CpG1018 (TLR9) and AS37 (TLR7) induced Th1-skewed CD4+ T cell responses, while alum, O/W, and AS03 induced a balanced Th1/Th2 response.	as37	51-55	CD4 antigen	Mus musculus	82-85
35609857-0	2022	CD4+ and CD8+ T-cell responses in bone marrow to fatty acids in high-fat diets.	Fatty Acids	49-60	CD4 antigen	Mus musculus	0-3
35609857-7	2022	These findings reveal an undervalued critical role for dietary fatty acids in the selective acquisition of T-cell subsets in BM, highlighting that oleic acid existing in the surroundings of T-cell niches during HFD-induced obesity could be instrumental in the maintenance of CD4+ T cells.	Oleic Acid	147-157	CD4 antigen	Mus musculus	275-278
35589717-8	2022	As a consequence, Cul5 deficient CD4+ T cells deviate from Treg to Th9 differentiation in low IL-4 conditions.	TH9	67-70	CD4 antigen	Mus musculus	33-36
35550500-0	2022	Tim-3+ decidual Mphis induced Th2 and Treg bias in decidual CD4+T cells and promoted pregnancy maintenance via CD132.	th2	30-33	CD4 antigen	Mus musculus	60-63
35550500-0	2022	Tim-3+ decidual Mphis induced Th2 and Treg bias in decidual CD4+T cells and promoted pregnancy maintenance via CD132.	treg	38-42	CD4 antigen	Mus musculus	60-63
35546754-11	2022	Knockdown of gal-9 in MSCs using small interfering RNA blunted the therapeutic effect of MSCs, and blockade of the Gal-9/Tim-3 pathway using alpha-lactose or anti-Tim-3 inhibited the induction of Tregs and suppressed the inhibition of the differentiation to Th17 cells by MSCs after coculture of MSCs with CD4+ T cells(P > 0.05).	alpha-lactose	141-154	CD4 antigen	Mus musculus	306-309
35631161-0	2022	Ripe Tomato Saponin Esculeoside A and Sapogenol Esculeogenin A Suppress CD4+ T Lymphocyte Activation by Modulation of Th2/Th1/Treg Differentiation.	sapogenol esculeogenin a	38-62	CD4 antigen	Mus musculus	72-75
35631161-8	2022	We suggest the immune nutrition function by tomato component, and highlight that EsA/Esg-A are capable of reducing CD4+ T-lymphocyte activation via a reduction in Th2-lymphocyte activity by modulation of Th2/Th1/Treg subunit differentiation.	esculeoside A	81-84	CD4 antigen	Mus musculus	115-118
35631161-8	2022	We suggest the immune nutrition function by tomato component, and highlight that EsA/Esg-A are capable of reducing CD4+ T-lymphocyte activation via a reduction in Th2-lymphocyte activity by modulation of Th2/Th1/Treg subunit differentiation.	isoesculeogenin A	85-90	CD4 antigen	Mus musculus	115-118
35600488-8	2022	Silencing Maclpil also markedly attenuated the accumulation of monocyte-derived macrophages, CD4+ T cells, and CD8+ T cells in the ischemic hemisphere without affecting microglia cellularity.	maclpil	10-17	CD4 antigen	Mus musculus	93-96
35511824-9	2022	RESULTS: The systemic injection of DFMSCs significantly reduced intracellular IFN-gamma and IL-17 secreting CD4+ T cells in splenocytes (p<0.05), and decreased inflammatory cell deposits and fibrosis in the glandular tissues.	dfmscs	35-41	CD4 antigen	Mus musculus	108-111
35504893-6	2022	Chemical inhibition of beta-glucosylceramide synthesis greatly reduces inflammatory CD4+ T cells in the central nervous system and inhibits EAE progression in mice.	beta-glucosylceramide	23-44	CD4 antigen	Mus musculus	84-87
35499081-7	2022	This work identifies a role for iron in CD4+ T cell biology and the development of pathogenic effectors in SLE.	Iron	32-36	CD4 antigen	Mus musculus	40-43
35179565-4	2022	Using humanized HLA/TCR mice we observed that TCRs reactive to the native or deamidated GAD65115-127 led to efficient development of CD4+ effector T cells; however, regulatory T cell development was reduced in mice expressing the PTM reactive TCR, which was partially restored with exogenous PTM peptide.	gad65115	88-96	CD4 antigen	Mus musculus	133-136
35478105-6	2022	Melatonin alleviated WBI-induced myelosuppression and pancytopenia, and increased white blood cell, red blood cell, platelet, and lymphocyte (CD4+ and CD8+) counts in peripheral blood.	Melatonin	0-9	CD4 antigen	Mus musculus	142-145
35478153-7	2022	RESULTS: Identical thymus histopathology and an extent of double-positive CD4+CD8+ subset depletion was found in day 11 tumor-bearing mice (TBM-11) and in DOX-administered animals.	Tobramycin	140-143	CD4 antigen	Mus musculus	74-77
35478153-7	2022	RESULTS: Identical thymus histopathology and an extent of double-positive CD4+CD8+ subset depletion was found in day 11 tumor-bearing mice (TBM-11) and in DOX-administered animals.	Doxorubicin	155-158	CD4 antigen	Mus musculus	74-77
35123286-6	2022	Additionally, coculture of acteoside-treated DCs with CD4+ T cells promoted the generation of forkhead box P3-positive (Foxp3+) regulatory T cells (Tregs) via AhR activation.	acteoside	27-36	CD4 antigen	Mus musculus	54-57
35123286-7	2022	Using a murine asthma model, our results demonstrated that oral administration of 50 mg/kg of acteoside decreased levels of Th2-type cytokines, such as IL-4, IL-5, and IL-13, whereas the level of IL-10 and the frequency of CD4+Foxp3+ Tregs were augmented.	acteoside	94-103	CD4 antigen	Mus musculus	223-226
35124415-6	2022	We determined the level of intracellular free iron in CD4+ T cells by PGSK probe and examined the expression of the Fth and Tfrc genes by qPCR.	Iron	46-50	CD4 antigen	Mus musculus	54-57
35058409-10	2022	Masson"s trichome staining showed cardiac fibrosis in the AAC+vehicle group, and the immunofluorescence assay revealed infiltration of CD4+ cells in both the AAC+vehicle and AAC+EGCG groups.	epigallocatechin gallate	178-182	CD4 antigen	Mus musculus	135-138
35603647-6	2022	In addition, compared with control group, CIA group showed higher proportion of CD4+IL-22+ cells and higher level of IL-22 which then interestingly decreased after H2 therapy.	Deuterium	164-166	CD4 antigen	Mus musculus	80-83
35603647-8	2022	Conclusion H2 can reduce the levels of CD4+IL-22+ cells and IL-22, and alleviate arthritis symptoms in CIA mice by inhibiting STAT3/NF-kappaB pathway.	Deuterium	11-13	CD4 antigen	Mus musculus	39-42
35474079-0	2022	Self-adjuvanting nanovaccines boost lung-resident CD4+ T cell immune responses in BCG-primed mice.	nanovaccines	17-29	CD4 antigen	Mus musculus	50-53
35514978-0	2022	Chronic Exposure to the Combination of Cigarette Smoke and Morphine Decreases CD4+ Regulatory T Cell Numbers by Reprogramming the Treg Cell Transcriptome.	Morphine	59-67	CD4 antigen	Mus musculus	78-81
35563702-5	2022	Specifically, the homeostasis of CD4+CD25+Foxp3+ but not the CD4+CD25-Foxp3+ fraction is severely perturbed when NFAT signaling is blocked, leading to a strongly reduced Treg population.	treg	170-174	CD4 antigen	Mus musculus	33-36
35450821-3	2022	Additionally, ZIP1642 vaccination in mice expanded both S- and N-specific CD3+CD4+ and CD3+CD8+ T cells and caused a Th1 shifted cytokine response.	zip1642	14-21	CD4 antigen	Mus musculus	78-81
35439922-8	2022	In addition, DHA-fed mice showed reductions in the total numbers and activation levels of CD4+ and CD8+ T cells.	Docosahexaenoic Acids	13-16	CD4 antigen	Mus musculus	90-93
35438354-12	2022	Nivolumab and Ipilimumab synergized with cisplatin in increasing CD8 + and CD4 + T cell population, while decreasing Treg population in LTEP-P tumor-bearing mice.	Cisplatin	41-50	CD4 antigen	Mus musculus	75-78
35562873-8	2022	Imiquimod-induced increases in the CD4+IL-17A+ T cell population in lymph nodes and spleens were suppressed by Compound A treatment in FFA4 WT mice; however, this was not seen in FFA4 KO mice.	Imiquimod	0-9	CD4 antigen	Mus musculus	35-38
35259519-9	2022	Systemic exposure to DOX@PMO-hT induced an immune response, activated DCs and CD4+ and CD8+ T cells, and significantly suppressed tumor growth in a 4T1-bearing immunocompetent mouse model.	Doxorubicin	21-24	CD4 antigen	Mus musculus	78-81
35259519-9	2022	Systemic exposure to DOX@PMO-hT induced an immune response, activated DCs and CD4+ and CD8+ T cells, and significantly suppressed tumor growth in a 4T1-bearing immunocompetent mouse model.	pmo-ht	25-31	CD4 antigen	Mus musculus	78-81
35379749-9	2022	The finding is mirrored in chronic dextran sulfate sodium-induced colitis in Rorcfl /fl Cd4-Cre mice that showed lower frequency of brain-infiltrating CD4+ T cells and astrogliosis despite onset of significantly more severe colitis compared with wild-type mice.	Dextran Sulfate	35-57	CD4 antigen	Mus musculus	88-91
35379749-9	2022	The finding is mirrored in chronic dextran sulfate sodium-induced colitis in Rorcfl /fl Cd4-Cre mice that showed lower frequency of brain-infiltrating CD4+ T cells and astrogliosis despite onset of significantly more severe colitis compared with wild-type mice.	Dextran Sulfate	35-57	CD4 antigen	Mus musculus	151-154
35493453-0	2022	Commentary: Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.	Cyclophosphamide	33-49	CD4 antigen	Mus musculus	82-85
35509689-6	2022	Macrophages only showed significant Tnfa downregulation and CD4+ T cells only showed significant Ifng downregulation at high moscatilin doses.	dendrophenol	125-135	CD4 antigen	Mus musculus	60-63
35494242-0	2022	Microbiota-mediated skewing of tryptophan catabolism modulates CD4+ T cells in lupus-prone mice.	Tryptophan	31-41	CD4 antigen	Mus musculus	63-66
35397061-11	2022	MLR showed suppression of the donor-specific proliferation of CD4 + T and CD19 + B cells in the spleens of 17-DMAG-treated mice.	17-(dimethylaminoethylamino)-17-demethoxygeldanamycin	107-114	CD4 antigen	Mus musculus	62-65
35464441-0	2022	Topical Application of Tetrandrine Nanoemulsion Promotes the Expansion of CD4+Foxp3+ Regulatory T Cells and Alleviates Imiquimod-Induced Psoriasis in Mice.	tetrandrine	23-34	CD4 antigen	Mus musculus	74-77
35455695-0	2022	Decrease of Hyaluronidase Activity and Suppression of Mouse CD4+ T Lymphocyte Activation by Tomato Juice Saponin Esculeoside B, and Its Sapogenol Esculeogenin B.	Saponins	105-112	CD4 antigen	Mus musculus	60-63
35455695-0	2022	Decrease of Hyaluronidase Activity and Suppression of Mouse CD4+ T Lymphocyte Activation by Tomato Juice Saponin Esculeoside B, and Its Sapogenol Esculeogenin B.	Esculeoside B	113-126	CD4 antigen	Mus musculus	60-63
35455695-0	2022	Decrease of Hyaluronidase Activity and Suppression of Mouse CD4+ T Lymphocyte Activation by Tomato Juice Saponin Esculeoside B, and Its Sapogenol Esculeogenin B.	esculeogenin B	146-160	CD4 antigen	Mus musculus	60-63
35455695-4	2022	(2) Methods: The present study tested the effects of EsB on hyaluronidase activity and CD4+ T lymphocyte activation using concanavalin A (ConA)-blast mouse splenocyte primary culture.	esb	53-56	CD4 antigen	Mus musculus	87-90
35444659-7	2022	Our results highlight TACs as a novel approach for reinstating immune tolerance in CD4 and CD8 mediated autoimmune diseases.	tacs	22-26	CD4 antigen	Mus musculus	83-86
35235429-4	2022	In EAE, Npnt induced SeP and glutathione peroxidase 1 (GPx1) expression, followed by reactive oxygen species (ROS) inhibition in CD4+ T cells; these changes were disturbed by Npnt-FD antibody treatment, which also caused decreased differentiation of interleukin (IL)-17-producing CD4+ T-helper cells (Th17s) and increased differentiation of regulatory T cells (Tregs).	Reactive Oxygen Species	85-108	CD4 antigen	Mus musculus	129-132
35235429-4	2022	In EAE, Npnt induced SeP and glutathione peroxidase 1 (GPx1) expression, followed by reactive oxygen species (ROS) inhibition in CD4+ T cells; these changes were disturbed by Npnt-FD antibody treatment, which also caused decreased differentiation of interleukin (IL)-17-producing CD4+ T-helper cells (Th17s) and increased differentiation of regulatory T cells (Tregs).	Reactive Oxygen Species	110-113	CD4 antigen	Mus musculus	129-132
35286851-7	2022	Ex vivo co-cultures of PLG-Ag-treated KCs or LSECs with Ag-specific CD4 T cells resulted in PGE2 and IL-10 or PGE2 secretion, respectively.	Dinoprostone	92-96	CD4 antigen	Mus musculus	68-71
35286851-7	2022	Ex vivo co-cultures of PLG-Ag-treated KCs or LSECs with Ag-specific CD4 T cells resulted in PGE2 and IL-10 or PGE2 secretion, respectively.	Dinoprostone	110-114	CD4 antigen	Mus musculus	68-71
35306230-3	2022	Utilizing the male non-obese diabetic (NOD) mouse model of SS, this work: 1) identifies clinically-relevant elevations in cytokines (IL-17A, IL-2) in LG-derived CD4+ T cells; and 2) explores tissue-specific immunosuppression of SS using a novel protein-based drug carrier to concentrate cyclosporine A (CsA) directly in the LG.	Cyclosporine	287-301	CD4 antigen	Mus musculus	161-164
35306230-3	2022	Utilizing the male non-obese diabetic (NOD) mouse model of SS, this work: 1) identifies clinically-relevant elevations in cytokines (IL-17A, IL-2) in LG-derived CD4+ T cells; and 2) explores tissue-specific immunosuppression of SS using a novel protein-based drug carrier to concentrate cyclosporine A (CsA) directly in the LG.	Cyclosporine	303-306	CD4 antigen	Mus musculus	161-164
35453586-10	2022	Moreover, the generation rate of FoxP3+ regulatory T cells (Tregs) from spleen naive CD4+ T cells was increased by intermittent exposure to carbon dioxide.	Carbon Dioxide	140-154	CD4 antigen	Mus musculus	85-88
35202987-5	2022	We showed that the treatment with 300 microg/mL of LAEPAL induces a significant decrease in the CD4 and CD8 T effector lymphocytes proliferation from diabetic but not in non-diabetic mice, followed by a reduction of the IL-6 and IFN-gamma cytokines release in the cell cultures supernatants.	laepal	51-57	CD4 antigen	Mus musculus	96-99
35202987-8	2022	These results contribute to a better understanding of the polyphenols" immunomodulatory properties, meaning they could induce tolerogenic antigen-presenting cells, which could polarize T cells to a Treg profile and decrease the activity of CD4+ and CD8+ T effector cells.	Polyphenols	58-69	CD4 antigen	Mus musculus	240-243
35151653-3	2022	Using mouse models of infection, we have previously shown that FhTeg induces a novel phenotype of dendritic cells that induce anergic CD4+ T-cells.	fhteg	63-68	CD4 antigen	Mus musculus	134-137
35156158-5	2022	Primary CD4+ T cells and CD8+ T cells preferentially express differing ganglioside series: a-series and o-series, respectively.	Gangliosides	71-82	CD4 antigen	Mus musculus	8-11
35156158-8	2022	Ganglioside GM3 synthase deficiency, which results in lack of a-series gangliosides, ameliorated CD4+ T cell-mediated airway hypersensitivity in a mouse model of allergic asthma.	Gangliosides	71-83	CD4 antigen	Mus musculus	97-100
35259423-5	2022	We also explored the possible molecular mechanism underlying the effects of MeHgCl administration on IFN-gamma-, T-bet-, IL-9-, and IL-17A-producing CD4+, CXCR5+, CXCR6+, and CCR9+ cells isolated from spleens.	methylmercuric chloride	76-82	CD4 antigen	Mus musculus	149-152
35259423-8	2022	MeHgCl exposure also significantly increased the production of CD4+IFN-gamma+, CD4+T-bet+, CCR9+T-bet+, CXCR5+IL-9+, CD4+IL-9+, CXCR6+IL-17A+, and CD4+IL-17A+ cells in the spleen.	methylmercuric chloride	0-6	CD4 antigen	Mus musculus	63-66
35259423-8	2022	MeHgCl exposure also significantly increased the production of CD4+IFN-gamma+, CD4+T-bet+, CCR9+T-bet+, CXCR5+IL-9+, CD4+IL-9+, CXCR6+IL-17A+, and CD4+IL-17A+ cells in the spleen.	methylmercuric chloride	0-6	CD4 antigen	Mus musculus	79-82
35259423-8	2022	MeHgCl exposure also significantly increased the production of CD4+IFN-gamma+, CD4+T-bet+, CCR9+T-bet+, CXCR5+IL-9+, CD4+IL-9+, CXCR6+IL-17A+, and CD4+IL-17A+ cells in the spleen.	methylmercuric chloride	0-6	CD4 antigen	Mus musculus	117-120
35259423-8	2022	MeHgCl exposure also significantly increased the production of CD4+IFN-gamma+, CD4+T-bet+, CCR9+T-bet+, CXCR5+IL-9+, CD4+IL-9+, CXCR6+IL-17A+, and CD4+IL-17A+ cells in the spleen.	methylmercuric chloride	0-6	CD4 antigen	Mus musculus	147-150
35131877-10	2022	(64Cu)Cu-NOTA-IAB41 is able to visualize human CD4+ T cells in humanized mice and can provide non-invasive quantification of CD4+ T cell distribution on the organismal scale.	cu-nota	6-13	CD4 antigen	Mus musculus	125-128
35388299-9	2022	Flow cytometry showed that the percentages of CD4+ and CD8+ expressions on central memory T cells were enhanced after SSP treatment, while the CD4+ T cm, CD4+ mTfh (memory T follicular helper) cells and their subpopulations were also significantly increased.	ssp	118-121	CD4 antigen	Mus musculus	46-49
35401507-9	2022	In systemic immune response, HCQ inhibited the activation of naive CD4+T cells and frequencies of T effector cells, and promoted T regulatory cells.	Hydroxychloroquine	29-32	CD4 antigen	Mus musculus	67-70
35401514-8	2022	We found that in wild-type mice, CD4+ Tregs exhibit a significant upregulation of VISTA which correlates with higher Treg abundance in the spleen and small intestine following septic insult.	treg	117-121	CD4 antigen	Mus musculus	33-36
35343948-4	2022	The Th-GM subset in effector CD4+ T cells generated upon immunization with the hapten was analyzed by flow cytometry.	th-gm	4-9	CD4 antigen	Mus musculus	29-32
35085518-6	2022	Compared to fully mature DCs, these Sch B-treated DCs displayed a regulatory ability to promote CD4+Foxp3+ Treg cell generation via upregulation of heme oxygenase (HO)-1 expression.	schizandrin B	36-41	CD4 antigen	Mus musculus	96-99
35246034-6	2022	Interestingly, stimulated ERAP1-/- BMDMs and CD4+ T cells simultaneously demonstrated exaggerated ER stress, assessed by increased expression of ER stress-associated genes, a state that could be reverted to WT levels with use of the ER stress inhibitor Tauroursodeoxycholic acid (TUDCA).	ursodoxicoltaurine	253-278	CD4 antigen	Mus musculus	45-48
35246034-6	2022	Interestingly, stimulated ERAP1-/- BMDMs and CD4+ T cells simultaneously demonstrated exaggerated ER stress, assessed by increased expression of ER stress-associated genes, a state that could be reverted to WT levels with use of the ER stress inhibitor Tauroursodeoxycholic acid (TUDCA).	ursodoxicoltaurine	280-285	CD4 antigen	Mus musculus	45-48
35343082-4	2022	In the CD4cre Aim2fl/fl conditional knockout mice, a markedly reduced TFH cell response was observed, with significantly lower levels of serum autoantibodies and proteinuria, as well as profoundly reduced renal IgG deposition in pristane-induced lupus mice.	tfh	70-73	CD4 antigen	Mus musculus	7-10
35343082-4	2022	In the CD4cre Aim2fl/fl conditional knockout mice, a markedly reduced TFH cell response was observed, with significantly lower levels of serum autoantibodies and proteinuria, as well as profoundly reduced renal IgG deposition in pristane-induced lupus mice.	pristane	229-237	CD4 antigen	Mus musculus	7-10
35241835-4	2022	Reconstitution of Tht cells in vitro and in an ovalbumin-specific alphabeta TCR CD4+ T-cell mouse model, shows that the Tht program is primed in tumor-draining lymph nodes by dendritic cells presenting tumor antigens, and that their function is important for harnessing the antitumor response of anti-PD-1 treatment.	tetrahydrothiophene	120-123	CD4 antigen	Mus musculus	80-83
35016995-9	2022	These findings collectively suggest that inhaled MVE-exposure may mediate estrogen receptor expression alterations associated with increased CD4+/CD8+ infiltration, regional demyelination, and ROS production in the CNS of female ApoE-/- mice.	cyclopropyl-[4-[6-[5-(4-ethoxy-1-propan-2-yl-piperidin-4-yl)pyridin-2-yl]pyrrolo[1,2-b]pyridazin-4-yl]piperazin-1-yl]methanone	49-52	CD4 antigen	Mus musculus	141-144
35101322-7	2022	Moreover, flow cytometric study showed that the percentage of CD4+CD25+Foxp3+ cell (regulatory T cell (Treg)) populations were increased in GA-treated CBA recipients.	Glycyrrhizic Acid	140-142	CD4 antigen	Mus musculus	62-65
35281908-12	2022	JG remarkably enhanced the anticancer effect of PTX by increasing the red blood cell and platelet counts; increasing hemoglobin, interleukin (IL)-2, and tumor necrosis factor-alpha levels; increasing CD4+T cells and the CD4+/CD8+ ratio; and decreasing IL-10 levels.	Paclitaxel	48-51	CD4 antigen	Mus musculus	200-203
35281908-12	2022	JG remarkably enhanced the anticancer effect of PTX by increasing the red blood cell and platelet counts; increasing hemoglobin, interleukin (IL)-2, and tumor necrosis factor-alpha levels; increasing CD4+T cells and the CD4+/CD8+ ratio; and decreasing IL-10 levels.	Paclitaxel	48-51	CD4 antigen	Mus musculus	220-223
35216600-8	2022	Additionally, the combination treatment upregulated Treg-related genes-Nt5e, Foxp3, Ikzf2, Nrp1 and Itgb8-in murine CD4+-T cells.	treg	52-56	CD4 antigen	Mus musculus	116-119
35196494-6	2022	DC-intrinsic IFN-gamma-JAK1-STAT1 signaling induces PD-L1, which is required for DCs to convert CD4+ T cells into Tregs in vitro and attenuated upon JAK1 deficiency and filgotinib treatment.	GLPG0634	169-179	CD4 antigen	Mus musculus	96-99
35192456-5	2022	PHD2 deficiency in Tregs led to an increased number of activated CD4 conventional T cells expressing a Th1-like effector phenotype.	tregs	19-24	CD4 antigen	Mus musculus	65-68
35085377-7	2022	Results: Feeding with EEN decreased the percentages of IgA- and IgG-coated bacteria and the levels of soluble IgA and IgG in the feces of EEN-feeding mice compared with the controls, but did not affect the compositions of different immune cells including CD4+, CD8+ T cells and B220+ B cells in the spleens and MLNs.	estradiol enanthate	22-25	CD4 antigen	Mus musculus	255-258
35088782-0	2022	Polysaccharide from Ganoderma lucidum alleviates cognitive impairment in a mouse model of chronic cerebral hypoperfusion by regulating CD4+CD25+Foxp3+ regulatory T cells.	Polysaccharides	0-14	CD4 antigen	Mus musculus	135-138
35216453-9	2022	This allowed identification of relative amounts of neutrophils and CD4+ T cells in mixed cell suspensions, by using NADH signals as a differentiation marker.	NAD	116-120	CD4 antigen	Mus musculus	67-70
35172762-13	2022	The addition of chemotherapy was associated with reduced number of myeloid and lymphoid cell types, except for CD4 + cells whose levels were largely unaltered only in tumors treated with gemcitabine/nab-paclitaxel.	gemcitabine	187-198	CD4 antigen	Mus musculus	111-114
35172762-13	2022	The addition of chemotherapy was associated with reduced number of myeloid and lymphoid cell types, except for CD4 + cells whose levels were largely unaltered only in tumors treated with gemcitabine/nab-paclitaxel.	nab	199-202	CD4 antigen	Mus musculus	111-114
35172762-13	2022	The addition of chemotherapy was associated with reduced number of myeloid and lymphoid cell types, except for CD4 + cells whose levels were largely unaltered only in tumors treated with gemcitabine/nab-paclitaxel.	Paclitaxel	203-213	CD4 antigen	Mus musculus	111-114
35242129-0	2022	Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4+ T-Cell Proliferation and Differentiation After Murine MHC-Haploidentical Hematopoietic Cell Transplantation.	Cyclophosphamide	21-37	CD4 antigen	Mus musculus	70-73
35242129-7	2022	However, cyclophosphamide was unique in consistently reducing proliferation and expression of the activation marker CD25 by alloreactive CD4+Foxp3- conventional T cells at day +7.	Cyclophosphamide	9-25	CD4 antigen	Mus musculus	137-140
35242129-8	2022	Furthermore, cyclophosphamide restrained the differentiation of alloreactive CD4+Foxp3- conventional T cells at both days +7 and +21, whereas methotrexate and cytarabine only restrained differentiation at day +7.	Cyclophosphamide	13-29	CD4 antigen	Mus musculus	77-80
35242129-8	2022	Furthermore, cyclophosphamide restrained the differentiation of alloreactive CD4+Foxp3- conventional T cells at both days +7 and +21, whereas methotrexate and cytarabine only restrained differentiation at day +7.	Methotrexate	142-154	CD4 antigen	Mus musculus	77-80
35242129-8	2022	Furthermore, cyclophosphamide restrained the differentiation of alloreactive CD4+Foxp3- conventional T cells at both days +7 and +21, whereas methotrexate and cytarabine only restrained differentiation at day +7.	Cytarabine	159-169	CD4 antigen	Mus musculus	77-80
35242129-11	2022	Additionally, these results reveal that PTCy uniquely restrains alloreactive CD4+Foxp3- conventional T-cell proliferation and differentiation, which may explain the superior effects of PTCy in preventing GVHD.	ptcy	40-44	CD4 antigen	Mus musculus	77-80
35242129-11	2022	Additionally, these results reveal that PTCy uniquely restrains alloreactive CD4+Foxp3- conventional T-cell proliferation and differentiation, which may explain the superior effects of PTCy in preventing GVHD.	ptcy	185-189	CD4 antigen	Mus musculus	77-80
35211629-6	2022	Additionally, BPTES downregulated the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) values of activated CD4+ T cells from SS mice.	bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide	14-19	CD4 antigen	Mus musculus	132-135
35211629-6	2022	Additionally, BPTES downregulated the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) values of activated CD4+ T cells from SS mice.	Oxygen	82-88	CD4 antigen	Mus musculus	132-135
35211629-8	2022	Histological and qRT-PCR analyses showed that this concentration of BPTES attenuated lymphocytic infiltration and the numbers of PCNA-positive cells and CD4+ T cells.	bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide	68-73	CD4 antigen	Mus musculus	153-156
35211629-12	2022	Pharmacological inhibition of Gls1 with BPTES could normalize the effector functions of CD4+ T cells and effectively attenuate the symptoms of SS.	bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide	40-45	CD4 antigen	Mus musculus	88-91
35140185-8	2022	Xk and Vps13a formed a complex in mouse splenic T cells, and Xk was crucial for ATP-induced PtdSer exposure and cytolysis in CD25+CD4+ T cells.	vps13a	7-13	CD4 antigen	Mus musculus	130-133
35140185-8	2022	Xk and Vps13a formed a complex in mouse splenic T cells, and Xk was crucial for ATP-induced PtdSer exposure and cytolysis in CD25+CD4+ T cells.	Adenosine Triphosphate	80-83	CD4 antigen	Mus musculus	130-133
35148758-8	2022	Number of CD4 + IL-17 + cells decreased whereas the number of CD4 + CD25 + Foxp3 + cells increased in spleens from MTX- NPs-treated CIA mice compared to MTX-treated CIA mice.	Methotrexate	115-118	CD4 antigen	Mus musculus	62-65
35208981-7	2022	In addition, in DSS-induced mice, the densities of CD4- and CD11b-positive cells, apoptotic rates, and activation of NF-kappaB and p-ERK1/2 MAPK intracellular signaling pathways were higher in those treated with BPE and BPFPE than in those not treated.	dss	16-19	CD4 antigen	Mus musculus	51-54
35216061-9	2022	Mice vaccinated with HCl- and NOH-induced LMGs, respectively, significantly increased in specific IgG antibodies, bactericidal activities of serum, and CD4+ and CD8+ T-cell population.	Hydrochloric Acid	21-24	CD4 antigen	Mus musculus	152-155
35216061-9	2022	Mice vaccinated with HCl- and NOH-induced LMGs, respectively, significantly increased in specific IgG antibodies, bactericidal activities of serum, and CD4+ and CD8+ T-cell population.	2-amino-5-chlorobenzophenone N-hydroxyamidinohydrazone	30-33	CD4 antigen	Mus musculus	152-155
35178106-13	2022	IHC assay shows that CD4+ and CD8+ expression levels were notably upregulated after CIAA treatment.	ciaa	84-88	CD4 antigen	Mus musculus	21-24
35211114-7	2022	The identical conclusion was obtained by overexpression of mmu-miR-126a-5p in primary naive CD4+ T cells in mice.	-mir-126a-5p	62-74	CD4 antigen	Mus musculus	92-95
35178163-7	2022	Further research revealed that (R)-sal mitigated colonic CD4 leukocyte infiltration, decreased NF-kappaB signaling pathway activation, improved the Nrf-2/HO-1 signaling pathway, and increased the expression of ZO-1 and occludin.	(r)-sal	31-38	CD4 antigen	Mus musculus	57-60
35121767-7	2022	Specifically, in the presence of zinc, CD4+ T cells show impaired expression of cell cycle, glycolytic and tricarboxylic acid cycle genes, which functionally cumulates in reduced glycolysis, oxidative phosphorylation, metabolic fitness and viability.	Tricarboxylic Acids	107-125	CD4 antigen	Mus musculus	39-42
35185546-10	2021	Flow cytometry analysis of CD4+ spleen cells showed that O-1966 treated animals had almost a 3-fold increase in CD25+Foxp3+ Treg cells compared to controls.	1-(4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl)-3-methylcyclohexanol	57-63	CD4 antigen	Mus musculus	27-30
35001849-4	2022	First, CD4 + T cells treated with H2O2 were injected into the tail vein of mice to establish a lupus model.	Hydrogen Peroxide	34-38	CD4 antigen	Mus musculus	7-10
35064693-0	2022	Metformin ameliorates chronic colitis in a mouse model by regulating interferon-gamma-producing lamina propria CD4+ T cells through AMPK activation.	Metformin	0-9	CD4 antigen	Mus musculus	111-114
35064693-3	2022	Metformin is also reported to elicit anti-inflammatory responses in CD4+ T cells, resulting in improvement in experimental chronic inflammatory diseases, such as systemic lupus erythematosus.	Metformin	0-9	CD4 antigen	Mus musculus	68-71
35064693-6	2022	We observed that metformin suppresses the frequency of interferon (IFN) -gamma-producing LP CD4+ T cells in vitro, which were regulated by AMPK activation, a process possibly induced by the inhibition of oxidative phosphorylation.	Metformin	17-26	CD4 antigen	Mus musculus	92-95
35064693-8	2022	Metformin-treated mice showed AMPK activation in LP CD4+ T cells and ameliorated colitis.	Metformin	0-9	CD4 antigen	Mus musculus	52-55
35064693-9	2022	Our study demonstrates that metformin-induced AMPK activation in mucosal CD4+ T cells contributes to the improvement of IBD by suppressing IFN-gamma production.	Metformin	28-37	CD4 antigen	Mus musculus	73-76
35039641-4	2022	In naive CD4+ T cells, LINE1-containing transcripts are regulated by the transcription factor IRF4 and kept at chromatin by nucleolin; these transcripts act in cis, hampering levels of histone 3 (H3) lysine 36 trimethyl (H3K36me3) and stalling gene expression.	Lysine	200-206	CD4 antigen	Mus musculus	9-12
35173615-9	2022	Compared with WT mice, CB2R deficiency exacerbated IMQ-induced PsD and scratching bouts and upregulated the expression of proinflammatory cytokines by increasing the infiltration of CD4+ T cells and the Th17/Treg ratio.	Imiquimod	51-54	CD4 antigen	Mus musculus	182-185
35126822-10	2022	Dapagliflozin remarkably reduced aortic accumulation of macrophages, CD4+ T cells, and B cells particularly following dapagliflozin treatment at 5 mg/kg.	dapagliflozin	0-13	CD4 antigen	Mus musculus	69-72
35126822-10	2022	Dapagliflozin remarkably reduced aortic accumulation of macrophages, CD4+ T cells, and B cells particularly following dapagliflozin treatment at 5 mg/kg.	dapagliflozin	118-131	CD4 antigen	Mus musculus	69-72
35386464-6	2022	The Rh2@HMnO2-AM nanoparticles can effectively trigger immunogenic cell death (ICD), activate CD4+/CD8+ T cells in vivo, and upregulate BAX, BCL-2 and Caspase-3 in cellular level.	rh2	4-7	CD4 antigen	Mus musculus	94-97
35386464-6	2022	The Rh2@HMnO2-AM nanoparticles can effectively trigger immunogenic cell death (ICD), activate CD4+/CD8+ T cells in vivo, and upregulate BAX, BCL-2 and Caspase-3 in cellular level.	hmno2-am	8-16	CD4 antigen	Mus musculus	94-97
35415672-16	2022	Flow cytometry studies revealed significantly increased M2 (CD206+ ) macrophages and Tregs (CD25+ ) relative to the M1 macrophage population and CD4+ T cells respectively in NaB treated mice, suggesting its potential role in alleviating the inflammatory profile.	nab	174-177	CD4 antigen	Mus musculus	145-148
35095344-0	2022	CD4+ T Cells Promote IgG Production in MHC-Independent and ICAM-1-Dependent Manners in Pristane-Induced Lupus Mice.	pristane	87-95	CD4 antigen	Mus musculus	0-3
35095344-3	2022	In this study, we investigated the manners of CD4+ T cells in antibody production in a lupus-like mouse model through peritoneal injection of pristane reagent.	pristane reagent	142-158	CD4 antigen	Mus musculus	46-49
35095344-6	2022	When adoptively transferring CD4+ T cells into T cell-deficient mice or coculturing CD4+ T cells and B cells in vitro, it was found that CD4+ T cells derived from pristane-treated mice could help the production of total IgG as well as IgG1/IgG2a in a more efficient manner both in vivo and in vitro.	pristane	163-171	CD4 antigen	Mus musculus	29-32
35095344-6	2022	When adoptively transferring CD4+ T cells into T cell-deficient mice or coculturing CD4+ T cells and B cells in vitro, it was found that CD4+ T cells derived from pristane-treated mice could help the production of total IgG as well as IgG1/IgG2a in a more efficient manner both in vivo and in vitro.	pristane	163-171	CD4 antigen	Mus musculus	84-87
35095344-6	2022	When adoptively transferring CD4+ T cells into T cell-deficient mice or coculturing CD4+ T cells and B cells in vitro, it was found that CD4+ T cells derived from pristane-treated mice could help the production of total IgG as well as IgG1/IgG2a in a more efficient manner both in vivo and in vitro.	pristane	163-171	CD4 antigen	Mus musculus	137-140
35095344-8	2022	Our study thus reveals that CD4+ T cells in pristane-treated mice play important roles in IgG production, which implies the critical roles in the induction of pathological autoantibodies in MHC-independent and ICAM-1-dependent manners.	pristane	44-52	CD4 antigen	Mus musculus	28-31
35064103-5	2022	Quantitative RT-PCR confirmed that (R)-ketamine significantly attenuated the increased gene expression of NFATc4 signaling (Nfatc4, Cd4, Cd79b, H2-ab1, H2-aa) in the PFC of LPS-treated mice.	(R)-Ketamine	35-47	CD4 antigen	Mus musculus	132-135
35083095-6	2022	Moreover, TBCM-induced DCs can also generate memory CD4 T cells and exert long-term tumor prevention effects.	4-tert-butyl-2-hydroxycyclohexylmethacrylate	10-14	CD4 antigen	Mus musculus	52-55
35087510-0	2021	Prenatal Cadmium Exposure Alters Proliferation in Mouse CD4+ T Cells via LncRNA Snhg7.	Cadmium	9-16	CD4 antigen	Mus musculus	56-59
34986869-12	2022	A reduction in frequency of CD4+ and T effector memory cells and an increase in the percentage of CD4+ T naive cells in spleen and lung of acazicolcept-treated Fra-2 Tg mice was observed as compared to Fc control-treated Fra-2 Tg mice.	acazicolcept	139-151	CD4 antigen	Mus musculus	98-101
35247631-9	2022	Adoptive transfer of intrahepatic TCRalphabeta+ DNT cells from control mice increased intrahepatic CD4 and CD8 T cell apoptosis and inhibited NAFLD progression.	2,6-dinitrotoluene	48-51	CD4 antigen	Mus musculus	99-102
34648636-10	2022	These observations suggest that the differences in Plasmodium-specific CD4 + T-cell responses between PbA- and Pcc-infected mice were associated with the difference in type I IFN production during the early phase of the infection.	4-phenylbutyric acid	102-105	CD4 antigen	Mus musculus	71-74
34648636-10	2022	These observations suggest that the differences in Plasmodium-specific CD4 + T-cell responses between PbA- and Pcc-infected mice were associated with the difference in type I IFN production during the early phase of the infection.	pyridinium chlorochromate	111-114	CD4 antigen	Mus musculus	71-74
35039461-10	2022	Concurrent anti-PD-L1 antibody administration or depletion of CD4+ T cells containing a population of regulatory T cells markedly increased T cell-mediated antitumor immunity and tumor growth suppression at distant, untreated tumor sites in M-HIFU treated mice compared with M-HIFU monotherapy.	m-hifu	241-247	CD4 antigen	Mus musculus	62-65
35039461-10	2022	Concurrent anti-PD-L1 antibody administration or depletion of CD4+ T cells containing a population of regulatory T cells markedly increased T cell-mediated antitumor immunity and tumor growth suppression at distant, untreated tumor sites in M-HIFU treated mice compared with M-HIFU monotherapy.	m-hifu	275-281	CD4 antigen	Mus musculus	62-65
35118195-4	2022	The mice treated with a single dose of BBzeta CD4/CD8 mixture (CAR4/8) showed complete tumor remission and remained tumor-free 72 days after CAR-T cells infusion.	bbzeta	39-45	CD4 antigen	Mus musculus	46-49
2531775-5	1989	A suboptimal dose of CsA was synergistic with an anti-CD4 mAb but not with an anti-CD8 antibody for whole MHC-mismatched grafts.	Cyclosporine	21-24	CD4 antigen	Mus musculus	54-57
2592374-0	1989	Protein and carbohydrate structural analysis of a recombinant soluble CD4 receptor by mass spectrometry.	Carbohydrates	12-24	CD4 antigen	Mus musculus	70-73
2573433-3	1989	Bone marrow from mice treated with 5-fluorouracil was depleted of cells expressing Mac-1, CD4, and CD8 and incubated on lymphocyte-free monolayer cultures of adherent thymic stromal cells.	Fluorouracil	35-49	CD4 antigen	Mus musculus	90-93
2805452-3	1989	Flow cytometry analysis showed that NTA260 is positive on subpopulations of peripheral T cells from young mice, in which approximately 65% of CD4+ and 85% of CD8+ T cells were NTA260+.	nta260	36-42	CD4 antigen	Mus musculus	142-145
2573634-10	1989	The 5-FU-sensitive T cell is the only target of Thy-1+CD5+CD4+CD8- suppressor cell.	Fluorouracil	4-8	CD4 antigen	Mus musculus	58-61
2572556-3	1989	The reactivity transferred by L3T4+ cells was a radiosensitive (2,500 rads in vitro) phenomenon that required collaboration with radioresistant, silica-sensitive syngeneic cells in the host and was inhibited by treatment of recipient mice with antibodies to the L3T4 antigen or murine gamma interferon.	Silicon Dioxide	145-151	CD4 antigen	Mus musculus	30-34
2572556-3	1989	The reactivity transferred by L3T4+ cells was a radiosensitive (2,500 rads in vitro) phenomenon that required collaboration with radioresistant, silica-sensitive syngeneic cells in the host and was inhibited by treatment of recipient mice with antibodies to the L3T4 antigen or murine gamma interferon.	Silicon Dioxide	145-151	CD4 antigen	Mus musculus	262-266
2572669-2	1989	Purified CD4+ BALB/c spleen T cells obtained 4-6 wk after total lymphoid irradiation (TLI) helped normal syngeneic B cells to produce a vigorous antibody response to TNP keyhole limpet hemocyanin in adoptive cell transfer experiments.	picric acid	166-169	CD4 antigen	Mus musculus	9-12
2572669-4	1989	In addition, purified CD4+ cells from TLI-treated mice were unable to induce graft vs. host disease in lethally irradiated allogeneic C57BL/Ka recipient mice.	tli	38-41	CD4 antigen	Mus musculus	22-25
2557544-0	1989	Tyrosine phosphorylation of a c-Src-like protein is increased in membranes of CD4- CD8- T lymphocytes from lpr/lpr mice.	Tyrosine	0-8	CD4 antigen	Mus musculus	78-81
2557544-3	1989	We compared membrane tyrosine phosphorylation in lpr/lpr CD4- CD8- T cells and control T cells, lpr membranes exhibited a 7.3-fold increase (n = 16) in tyrosine phosphorylation of a 60-kilodalton protein.	Tyrosine	21-29	CD4 antigen	Mus musculus	57-60
2807375-12	1989	Together, these results demonstrate that resting CD4+ thymocytes can be induced to proliferation and lymphokine secretion by IL-2 alone in a process that is dependent on interaction with accessory cells, involves CD4 adhesion molecules and triggers activation through a CsA-sensitive pathway.	Cyclosporine	270-273	CD4 antigen	Mus musculus	49-52
2571187-5	1989	Thus targeted to CD4, the gp120-specific antibody functions as an antibody to CD4; it cross-links and modulates the CD4 molecules and suppresses the activation of T cells as measured by mobilization of intracellular calcium (Ca2i+).	Calcium	216-223	CD4 antigen	Mus musculus	17-20
2571187-5	1989	Thus targeted to CD4, the gp120-specific antibody functions as an antibody to CD4; it cross-links and modulates the CD4 molecules and suppresses the activation of T cells as measured by mobilization of intracellular calcium (Ca2i+).	Calcium	216-223	CD4 antigen	Mus musculus	78-81
2571187-5	1989	Thus targeted to CD4, the gp120-specific antibody functions as an antibody to CD4; it cross-links and modulates the CD4 molecules and suppresses the activation of T cells as measured by mobilization of intracellular calcium (Ca2i+).	Calcium	216-223	CD4 antigen	Mus musculus	78-81
2571187-5	1989	Thus targeted to CD4, the gp120-specific antibody functions as an antibody to CD4; it cross-links and modulates the CD4 molecules and suppresses the activation of T cells as measured by mobilization of intracellular calcium (Ca2i+).	ca2i+	225-230	CD4 antigen	Mus musculus	17-20
2571187-5	1989	Thus targeted to CD4, the gp120-specific antibody functions as an antibody to CD4; it cross-links and modulates the CD4 molecules and suppresses the activation of T cells as measured by mobilization of intracellular calcium (Ca2i+).	ca2i+	225-230	CD4 antigen	Mus musculus	78-81
2571187-5	1989	Thus targeted to CD4, the gp120-specific antibody functions as an antibody to CD4; it cross-links and modulates the CD4 molecules and suppresses the activation of T cells as measured by mobilization of intracellular calcium (Ca2i+).	ca2i+	225-230	CD4 antigen	Mus musculus	78-81
2475571-5	1989	Depletion of the CD4 and CD8 T lymphocytes by an in vivo treatment with mAb prevented the bleomycin-induced increase of TNF mRNA level and fibrosis.	Bleomycin	90-99	CD4 antigen	Mus musculus	17-20
2545782-0	1989	Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV.	Dextran Sulfate	0-15	CD4 antigen	Mus musculus	42-45
2545782-0	1989	Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV.	Heparin	20-27	CD4 antigen	Mus musculus	42-45
2545782-1	1989	Dextran sulfate, heparin, and certain other sulfated polysaccharides potently inhibit the adsorption of HIV to CD4+ cells.	Dextran Sulfate	0-15	CD4 antigen	Mus musculus	111-114
2545782-1	1989	Dextran sulfate, heparin, and certain other sulfated polysaccharides potently inhibit the adsorption of HIV to CD4+ cells.	Heparin	17-24	CD4 antigen	Mus musculus	111-114
2545782-1	1989	Dextran sulfate, heparin, and certain other sulfated polysaccharides potently inhibit the adsorption of HIV to CD4+ cells.	Polysaccharides	53-68	CD4 antigen	Mus musculus	111-114
2545782-9	1989	Taken together, these data suggest that while both sulfated polysaccharides and anti-CD4 mAb inhibit gp120 binding, the sulfated polysaccharides interact with sites on CD4 that are distinct from those with which the antibodies bind.	Polysaccharides	129-144	CD4 antigen	Mus musculus	168-171
2570035-5	1989	In vivo depletion of CD4+ T cells resulted in a dramatic reduction in immunity induced by one (up to 100%) and two (up to 70%) vaccinations with 20 krad-irradiated cercariae and also of resistance induced by Ro 11-attenuated infections (up to 100%).	Ro 11	208-213	CD4 antigen	Mus musculus	21-24
2545779-6	1989	Assays of CTL responses generated by mixtures of spleen cells from normal and infected mice suggested that active suppression of Ly-4(CD4)+ Th function may contribute to this defect.	LY-4	129-133	CD4 antigen	Mus musculus	134-137
2600268-3	1989	Results showed that the percentages and absolute numbers of Lyt2+ L3T4- cells, Lyt2- L3T4+ cells, Lyt2+ IJk+ cells, and Lyt2+ IJk- cells in the spleens of the DNFB-treated mice were not significantly different from those in the non-treated mice.	Dinitrofluorobenzene	159-163	CD4 antigen	Mus musculus	85-89
2787934-3	1989	Exposure of human T cells and some mouse T cells to the tumor promoter 12-O-tetradecanoyl phorbol-13-acetate (TPA), an activator of protein kinase C, caused the dissociation of p56lck and CD4.	Tetradecanoylphorbol Acetate	71-108	CD4 antigen	Mus musculus	188-191
2787934-3	1989	Exposure of human T cells and some mouse T cells to the tumor promoter 12-O-tetradecanoyl phorbol-13-acetate (TPA), an activator of protein kinase C, caused the dissociation of p56lck and CD4.	Tetradecanoylphorbol Acetate	110-113	CD4 antigen	Mus musculus	188-191
2472442-7	1989	We propose this new murine CD4+ cell subset with an unrestricted pattern of cytokine production be called Th0.	2,4-Dihydroxythiophenol	106-109	CD4 antigen	Mus musculus	27-30
2568932-2	1989	Defective thymic education of CD4 T helper cell function in cyclosporin A-treated mice.	Cyclosporine	60-73	CD4 antigen	Mus musculus	30-33
2660341-3	1989	A 10-day course of cyclosporine treatment inhibits the capacity of DA rats to reject PVG heart grafts and leads to the development of specific unresponsiveness and indefinite graft survival, which is mediated by a W3/25+ (CD4+) suppressor cell.	Cyclosporine	19-31	CD4 antigen	Mus musculus	222-225
2651520-3	1989	In this report, we investigate the effect of cyclosporin A (CsA) on lymphopoiesis, and demonstrate that CsA selectively abrogates the development of CD4+CD8- and CD4-CD8+ T cells (single positive cells) in the thymus.	Cyclosporine	104-107	CD4 antigen	Mus musculus	149-152
2651520-3	1989	In this report, we investigate the effect of cyclosporin A (CsA) on lymphopoiesis, and demonstrate that CsA selectively abrogates the development of CD4+CD8- and CD4-CD8+ T cells (single positive cells) in the thymus.	Cyclosporine	104-107	CD4 antigen	Mus musculus	162-165
2651520-6	1989	In the thymus, the generation of CD4+CD8+ thymocytes was not affected by CsA treatment, and CD4-CD8- thymocytes of CsA-treated mice expressed surface markers characteristic of normal CD4-CD8- thymocytes, and exhibited normal functional activity when stimulated with anti-CD3 antibody.	Cyclosporine	115-118	CD4 antigen	Mus musculus	92-95
2651520-6	1989	In the thymus, the generation of CD4+CD8+ thymocytes was not affected by CsA treatment, and CD4-CD8- thymocytes of CsA-treated mice expressed surface markers characteristic of normal CD4-CD8- thymocytes, and exhibited normal functional activity when stimulated with anti-CD3 antibody.	Cyclosporine	115-118	CD4 antigen	Mus musculus	92-95
2566170-0	1989	Specific interaction of aurintricarboxylic acid with the human immunodeficiency virus/CD4 cell receptor.	Aurintricarboxylic Acid	24-47	CD4 antigen	Mus musculus	86-89
2566170-1	1989	The triphenylmethane derivative aurintricarboxylic acid (ATA), but not aurin, selectively prevented the binding of OKT4A/Leu-3a monoclonal antibody (mAb) and, to a lesser extent, OKT4 mAb to the CD4 cell receptor for human immunodeficiency virus type 1 (HIV-1).	triphenylmethane	4-20	CD4 antigen	Mus musculus	195-198
2566170-1	1989	The triphenylmethane derivative aurintricarboxylic acid (ATA), but not aurin, selectively prevented the binding of OKT4A/Leu-3a monoclonal antibody (mAb) and, to a lesser extent, OKT4 mAb to the CD4 cell receptor for human immunodeficiency virus type 1 (HIV-1).	Aurintricarboxylic Acid	32-55	CD4 antigen	Mus musculus	195-198
2566170-1	1989	The triphenylmethane derivative aurintricarboxylic acid (ATA), but not aurin, selectively prevented the binding of OKT4A/Leu-3a monoclonal antibody (mAb) and, to a lesser extent, OKT4 mAb to the CD4 cell receptor for human immunodeficiency virus type 1 (HIV-1).	Aurintricarboxylic Acid	57-60	CD4 antigen	Mus musculus	195-198
2566170-1	1989	The triphenylmethane derivative aurintricarboxylic acid (ATA), but not aurin, selectively prevented the binding of OKT4A/Leu-3a monoclonal antibody (mAb) and, to a lesser extent, OKT4 mAb to the CD4 cell receptor for human immunodeficiency virus type 1 (HIV-1).	aurin	32-37	CD4 antigen	Mus musculus	195-198
2566170-4	1989	ATA prevented the attachment of radiolabeled HIV-1 particles to MT-4 cells, which could be expected as the result of its specific binding to the HIV/CD4 receptor.	Aurintricarboxylic Acid	0-3	CD4 antigen	Mus musculus	149-152
2495186-3	1989	Among thymocyte subpopulations identified on the basis of CD4/CD8 labeling, DBA bound to a substantial percentage of the CD4-8- thymocyte subpopulation.	dba	76-79	CD4 antigen	Mus musculus	58-61
2495186-4	1989	In addition, small populations of thymocytes expressing CD4 and/or CD8 were also labeled with DBA, but with less intensity then seen on many CD4-8- cells.	dba	94-97	CD4 antigen	Mus musculus	56-59
2564328-0	1989	Resistance to experimental autoimmune thyroiditis: L3T4+ cells as mediators of both thyroglobulin-activated and TSH-induced suppression.	Thyrotropin	112-115	CD4 antigen	Mus musculus	51-55
2564328-3	1989	The cells required at the time of MTg pretreatment were L3T4+, Lyt-2- and low anti-L3T4 doses had no effect on their activation.	(Methylthio)acetic acid	34-37	CD4 antigen	Mus musculus	56-60
2564328-4	1989	The cells that mediated the strong MTg-induced resistance following pretreatment were also L3T4+; their suppressor function could only be abrogated by depletion of L3T4+, but not Lyt-2+, cells.	(Methylthio)acetic acid	35-38	CD4 antigen	Mus musculus	91-95
2564328-4	1989	The cells that mediated the strong MTg-induced resistance following pretreatment were also L3T4+; their suppressor function could only be abrogated by depletion of L3T4+, but not Lyt-2+, cells.	(Methylthio)acetic acid	35-38	CD4 antigen	Mus musculus	164-168
2564328-6	1989	Similarly, the suppressor state evoked by TSH infusion could only be abrogated by anti-L3T4 treatment.	Thyrotropin	42-45	CD4 antigen	Mus musculus	87-91
2564328-7	1989	These findings indicate that both MTg-activated and TSH-induced suppression are mediated by L3T4+ cells.	(Methylthio)acetic acid	34-37	CD4 antigen	Mus musculus	92-96
2564328-7	1989	These findings indicate that both MTg-activated and TSH-induced suppression are mediated by L3T4+ cells.	Thyrotropin	52-55	CD4 antigen	Mus musculus	92-96
2669797-13	1989	Old NZB.xid donor marrow reconstituted splenic Thy-1, L3T4 and Lyt2 T cells to levels less than observed with NZB donor cells.	[(5-{4-fluoro-2-[2-(pyridin-3-yl)ethoxy]phenyl}-1H-indazol-3-yl)methyl]dimethylamine	4-7	CD4 antigen	Mus musculus	54-58
2521924-6	1989	The results show that development of V beta 17+ CD4-CD8+ T cells in the SJL H-2s mouse strain is selectively abrogated by blocking class I-Ks molecules but is unaffected by blocking class I-Ds molecules.	Potassium	139-141	CD4 antigen	Mus musculus	48-51
2783943-0	1989	Requirements for modulation of the CD4 molecule in response to phorbol myristate acetate.	Tetradecanoylphorbol Acetate	63-88	CD4 antigen	Mus musculus	35-38
2783943-5	1989	CD4 is phosphorylated on serine residues within the cytoplasmic domain and its cell surface expression is decreased in response to PMA, APC bearing the appropriate Ag or HIV infection.	Serine	25-31	CD4 antigen	Mus musculus	0-3
2783943-12	1989	In both of these hybridomas, CD4 is phosphorylated on serine residues in response to PMA.	Serine	54-60	CD4 antigen	Mus musculus	29-32
2518399-0	1989	The CD4 cell dependency of SJL/J B-cell lymphomas as a target for cyclophosphamide therapy.	Cyclophosphamide	66-82	CD4 antigen	Mus musculus	4-7
2518399-2	1989	We sought to determine whether cyclophosphamide (CY) treatment of tumor-bearing mice would be successful through effects on tumor cells, CD4 cells, or both.	Cyclophosphamide	31-47	CD4 antigen	Mus musculus	137-140
2518399-2	1989	We sought to determine whether cyclophosphamide (CY) treatment of tumor-bearing mice would be successful through effects on tumor cells, CD4 cells, or both.	Cyclophosphamide	49-51	CD4 antigen	Mus musculus	137-140
2518399-5	1989	We concluded that CY affected the tumor-stimulated environment of SJL/J mice by killing CD4 cells that had been activated by a pre-existing tumor stimulus and by promoting the appearance of a population of CD8 cells that suppressed the ability of residual or recovering CD4 cells to proliferate in response to tumor.	Cyclophosphamide	18-20	CD4 antigen	Mus musculus	88-91
2518399-5	1989	We concluded that CY affected the tumor-stimulated environment of SJL/J mice by killing CD4 cells that had been activated by a pre-existing tumor stimulus and by promoting the appearance of a population of CD8 cells that suppressed the ability of residual or recovering CD4 cells to proliferate in response to tumor.	Cyclophosphamide	18-20	CD4 antigen	Mus musculus	270-273
2562439-4	1989	IL-2-induced proliferation, as well as that induced by concanavalin A or phorbol-ionophore mixture, was inhibited by monoclonal antibodies specific for L3T4 or Lyt-2 cell surface markers.	phorbol	73-80	CD4 antigen	Mus musculus	152-156
2518729-4	1989	However, stimulation of these precursor cells with phorbyl ester and ionomycin prevented this acquisition of CD4 and CD8.	phorbyl ester	51-64	CD4 antigen	Mus musculus	109-112
2518729-4	1989	However, stimulation of these precursor cells with phorbyl ester and ionomycin prevented this acquisition of CD4 and CD8.	Ionomycin	69-78	CD4 antigen	Mus musculus	109-112
2525534-4	1989	To investigate the role of dipeptidylpeptidase IV on CD4 positive cells in wound healing we used Lys-[Z(NO2)]-Pro, a chemically modified dipeptide which may result by degradation of polypeptides by this peptidase.	Lys(Z(NO2))-Pro	97-113	CD4 antigen	Mus musculus	53-56
2525534-5	1989	It was possible to restore the diminished capability of granulation tissue proliferation in CD4-depleted mice by a single treatment with the dipeptide Lys-[Z(NO2)]-Pro.	Dipeptides	141-150	CD4 antigen	Mus musculus	92-95
2525534-5	1989	It was possible to restore the diminished capability of granulation tissue proliferation in CD4-depleted mice by a single treatment with the dipeptide Lys-[Z(NO2)]-Pro.	Lys(Z(NO2))-Pro	151-167	CD4 antigen	Mus musculus	92-95
2623737-4	1989	Thymuses from CsA-treated mice lacked the SP L3T4(CD4)+ subset, DN and double positive (DP) thymocytes were still present.	Cyclosporine	14-17	CD4 antigen	Mus musculus	50-53
2623743-11	1989	We concluded that these OX-44+ cells were mainly CD4-CD8- thymocytes and that the thymocyte subpopulation of this phenotype, i.e. CD4-CD8-OX-44+, may be the target cell for DBTC.	dibutyldichlorotin	173-177	CD4 antigen	Mus musculus	49-52
2623743-11	1989	We concluded that these OX-44+ cells were mainly CD4-CD8- thymocytes and that the thymocyte subpopulation of this phenotype, i.e. CD4-CD8-OX-44+, may be the target cell for DBTC.	dibutyldichlorotin	173-177	CD4 antigen	Mus musculus	130-133
2972933-4	1988	There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules.	Cyclosporine	60-63	CD4 antigen	Mus musculus	111-114
2972933-4	1988	There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules.	Cyclosporine	60-63	CD4 antigen	Mus musculus	143-146
2972933-4	1988	There are two different effects, the first of which is that CsA seems to block the differentiation of immature CD4+CD8+ thymocytes into mature CD4+CD8- and CD4-CD8+ cells expressing a high density of T-cell receptors and CD3 molecules.	Cyclosporine	60-63	CD4 antigen	Mus musculus	143-146
3140821-4	1988	Immunohistochemical analysis of gamma-IFN-treated paws from CII-immunized mice revealed an increase in the numbers of class II antigen-expressing cells and an infiltration of CD4+ lymphocyte-like cells.	N-[(1S)-2-methyl-1-(pyridin-4-ylcarbamoyl)propyl]cyclohexanecarboxamide	60-63	CD4 antigen	Mus musculus	175-178
3137569-4	1988	Induction with a calcium ionophore and phorbol ester revealed that potential IL-2 producers not only constitute greater than 85% of the cells with a CD4+ "helper/inducer" phenotype but also constitute over half of the cells with a CD8+ "killer/suppressor" phenotype.	Calcium	17-24	CD4 antigen	Mus musculus	149-152
3260917-6	1988	One heterodimer, composed of disulfide-linked 41- to 45-kDa protein (including a V gamma/C gamma 4 component), is expressed on a T cell hybridoma, DN-1.21, which was derived from fused splenic CD3+, CD4-, CD8- T cells.	Disulfides	29-38	CD4 antigen	Mus musculus	199-202
2456858-2	1988	A new B220+ L3T4+ phenotype was demonstrated in T-cell populations of these mice by two-color flow cytometry with phycoerythrin-conjugated monoclonal antibodies (MoAb) to L3T4 and FITC-anti-B220 MoAb.	Fluorescein-5-isothiocyanate	180-184	CD4 antigen	Mus musculus	12-16
2979010-3	1988	The level of expression of the function-associated antigens CD4 (L3T4) and CD8 (Ly-2) decreased transiently early after activation with PMA/ionomycin, but not after stimulation with Con-A.	Ionomycin	140-149	CD4 antigen	Mus musculus	60-63
3136564-9	1988	Also, when we eliminate CD4 T cells from the diseased animals and graft islet tissue prior to the administration of cyclosporine, we are unable to maintain a graft with low-dose cyclosporine therapy.	Cyclosporine	116-128	CD4 antigen	Mus musculus	24-27
2900151-8	1988	From PMA plus ionomycin-stimulated double-negative Thy-1+ spleen cells, 14 T cell clones were established in long-term culture which displayed the CD3+CD4+CD8- surface phenotype and were self-reactive.	Ionomycin	14-23	CD4 antigen	Mus musculus	151-154
3260616-3	1988	Estradiol treatment for 2 days resulted in a significant increase in the number of uterine eosinophils, CD4 (W3/W25)-positive helper/inducer T lymphocytes, macrophages (MRC OX-42-positive cells), and Ia (MRC OX-6)-positive cells.	Estradiol	0-9	CD4 antigen	Mus musculus	104-107
2895062-0	1988	Lethal vaccinia infection in cyclophosphamide-suppressed mice is associated with decreased expression of Thy-1, Lyt-2 and L3T4 and diminished IL-2 production in surviving T cells.	Cyclophosphamide	29-45	CD4 antigen	Mus musculus	122-126
2963718-0	1987	L3T4 and Lyt-2 T cells are both involved in the generation of low-dose streptozotocin-induced diabetes in mice.	Streptozocin	71-85	CD4 antigen	Mus musculus	0-4
2963718-2	1987	Treatment depleted target cells in peripheral blood and spleen; decreased the ability of spleen cells to respond to mitogens; and, in the case of depletion of the L3T4 T cell subset, prevented a humoral immune response to SRBC.	srbc	222-226	CD4 antigen	Mus musculus	163-167
2960731-3	1987	We have now evaluated the generality and mechanism(s) of ganglioside-induced modulation of CD4 expressed by mouse, rat, and human T helper lymphocytes.	Gangliosides	57-68	CD4 antigen	Mus musculus	91-94
2445493-9	1987	Moreover, this clone is activated by F23.1, linked to Sepharose 4B beads, which was believed previously to activate only Lyt 2+, L3T4 T cells.	Sepharose	54-66	CD4 antigen	Mus musculus	129-133
3308122-4	1987	CDF is required for the development of Thy-1+, CD8+, CD4- CTL in this assay.	4-AMINO-1-{5-O-[(R)-HYDROXY(PHOSPHONOOXY)PHOSPHORYL]-ALPHA-D-ARABINOFURANOSYL}PYRIMIDIN-2(1H)-ONE	0-3	CD4 antigen	Mus musculus	53-56
3116077-2	1987	Immunoprecipitation of CD8 with OKT8 from a CD8+ and CD4+ T cell line prelabeled with [32P]phosphate demonstrates that CD8 can be constitutively labeled with phosphate.	Phosphates	91-100	CD4 antigen	Mus musculus	53-56
3116077-2	1987	Immunoprecipitation of CD8 with OKT8 from a CD8+ and CD4+ T cell line prelabeled with [32P]phosphate demonstrates that CD8 can be constitutively labeled with phosphate.	Phosphates	158-167	CD4 antigen	Mus musculus	53-56
3498751-0	1987	Selective down modulation of L3T4 molecules on murine thymocytes by the tumor promoter, phorbol 12-myristate 13-acetate.	Tetradecanoylphorbol Acetate	88-119	CD4 antigen	Mus musculus	29-33
3498751-1	1987	Treatment of murine thymocytes, but not mature peripheral T cells, with the tumor promoter, phorbol 12-myristate 13-acetate (PMA), 3 results in a rapid disappearance of L3T4 molecules from the surface of thymocytes.	Tetradecanoylphorbol Acetate	92-123	CD4 antigen	Mus musculus	169-173
3498751-1	1987	Treatment of murine thymocytes, but not mature peripheral T cells, with the tumor promoter, phorbol 12-myristate 13-acetate (PMA), 3 results in a rapid disappearance of L3T4 molecules from the surface of thymocytes.	Tetradecanoylphorbol Acetate	125-128	CD4 antigen	Mus musculus	169-173
3498751-4	1987	L3T4 molecules on cortisone-resistant thymocytes were significantly less sensitive to the effect of PMA than were L3T4 molecules on cortisone-sensitive thymocytes.	Cortisone	18-27	CD4 antigen	Mus musculus	0-4
3498751-4	1987	L3T4 molecules on cortisone-resistant thymocytes were significantly less sensitive to the effect of PMA than were L3T4 molecules on cortisone-sensitive thymocytes.	Cortisone	132-141	CD4 antigen	Mus musculus	0-4
3668694-6	1987	The number of Lyt-2 positive cells in the spleen was lower and the ratio of L3T4 to Lyt-2 positive cells, reflecting the balance of immunoregulatory T-lymphocytes, was higher after cadmium treatment than in untreated controls.	Cadmium	181-188	CD4 antigen	Mus musculus	76-80
2955046-7	1987	If TCR stimulation does indeed activate T cells by activating protein kinase and increasing intracellular free calcium, then our data suggest that anti-L3T4 and anti-Lyt-2 mAb inhibit TCR-driven proliferation at some step before the activation of protein kinase C and the stimulation of a rise in intracellular free calcium concentration.	Calcium	111-118	CD4 antigen	Mus musculus	152-156
2955046-7	1987	If TCR stimulation does indeed activate T cells by activating protein kinase and increasing intracellular free calcium, then our data suggest that anti-L3T4 and anti-Lyt-2 mAb inhibit TCR-driven proliferation at some step before the activation of protein kinase C and the stimulation of a rise in intracellular free calcium concentration.	Calcium	316-323	CD4 antigen	Mus musculus	152-156
3034434-6	1987	The anti-L3T4-insensitive increase in [Ca2+]i induced by Con A was inhibited by EGTA, suggesting that this mitogen also stimulated an influx of Ca2+ via an additional transport mechanism distinct from that stimulated by antigen.	Egtazic Acid	80-84	CD4 antigen	Mus musculus	9-13
2820635-3	1987	The pyrimidinone compound, bropirimine, when administered to MCMV infected mice was able to restore mitogen-induced proliferative and IL-2 responses of splenic cells, to increase the number of cells expressing Thy-1 or L3T4, to restore the ratio of T helper/T suppressor cells and to increase the number of cells inducible for expression of IL-2 receptors.	Pyrimidinones	4-16	CD4 antigen	Mus musculus	219-223
2820635-3	1987	The pyrimidinone compound, bropirimine, when administered to MCMV infected mice was able to restore mitogen-induced proliferative and IL-2 responses of splenic cells, to increase the number of cells expressing Thy-1 or L3T4, to restore the ratio of T helper/T suppressor cells and to increase the number of cells inducible for expression of IL-2 receptors.	bropirimine	27-38	CD4 antigen	Mus musculus	219-223
2435798-10	1987	The induction of IL 3 production by suboptimal doses of either Con A or plastic-adsorbed F23.1 was inhibited by the anti-L3T4 antibody GK1.5, as was the response to F23.1 coupled to Sepharose-4B beads.	4b	192-194	CD4 antigen	Mus musculus	121-125
3106196-4	1987	The optimal times for the inhibitory effect of anti-L3T4 Mab was 7 days after Cy treatment, when the number of spleen cells increased to a maximum following a regenerative phase.	Cyclophosphamide	78-80	CD4 antigen	Mus musculus	52-56
3106196-6	1987	A short time exposure of the Cy-SCs to the anti-L3T4 Mabs was sufficient to decrease the response to Con A.	Cyclophosphamide	29-31	CD4 antigen	Mus musculus	48-52
2879623-6	1987	Further examination of the nylon-nonadherent inducer population indicated that the phenotype is L3T4 + Lyt-1+2-.	Nylons	27-32	CD4 antigen	Mus musculus	96-100
2891627-0	1987	Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.	Melphalan	0-9	CD4 antigen	Mus musculus	127-131
2891627-3	1987	This immunopotentiating activity of the Sephadex G-10-adherent spleen cells from L-PAM treated MOPC-315 tumor bearers was attributed to T-cells which co-express the Lyt 2 and the L3T4 antigens based on results of experiments employing negative selection.	sephadex	40-53	CD4 antigen	Mus musculus	179-183
2891627-3	1987	This immunopotentiating activity of the Sephadex G-10-adherent spleen cells from L-PAM treated MOPC-315 tumor bearers was attributed to T-cells which co-express the Lyt 2 and the L3T4 antigens based on results of experiments employing negative selection.	Melphalan	81-86	CD4 antigen	Mus musculus	179-183
2891627-4	1987	Specifically, depletion of Lyt 2+ cells or of L3T4+ cells abolished the ability of the Sephadex G-10-adherent splenic cell population from L-PAM treated MOPC-315 tumor bearers to bring about the generation of enhanced antitumor cytotoxicity when added to the immunization culture of normal spleen cells.	sephadex	87-100	CD4 antigen	Mus musculus	46-50
2891627-4	1987	Specifically, depletion of Lyt 2+ cells or of L3T4+ cells abolished the ability of the Sephadex G-10-adherent splenic cell population from L-PAM treated MOPC-315 tumor bearers to bring about the generation of enhanced antitumor cytotoxicity when added to the immunization culture of normal spleen cells.	Melphalan	139-144	CD4 antigen	Mus musculus	46-50
2891627-6	1987	In light of the unusual phenotype of the immunopotentiating cells in the spleens of L-PAM treated MOPC-315 tumor bearing mice (i.e. Lyt 2+ L3T4+), and since the vast majority of thymocytes in normal adult BALB/c mice co-express the Lyt 2 and the L3T4 antigens, we evaluated the effect of low dose L-PAM therapy on the antitumor immune reactivity of thymocytes from MOPC-315 tumor bearing mice.	Melphalan	84-89	CD4 antigen	Mus musculus	139-143
2891627-6	1987	In light of the unusual phenotype of the immunopotentiating cells in the spleens of L-PAM treated MOPC-315 tumor bearing mice (i.e. Lyt 2+ L3T4+), and since the vast majority of thymocytes in normal adult BALB/c mice co-express the Lyt 2 and the L3T4 antigens, we evaluated the effect of low dose L-PAM therapy on the antitumor immune reactivity of thymocytes from MOPC-315 tumor bearing mice.	Melphalan	84-89	CD4 antigen	Mus musculus	246-250
2891627-9	1987	The possibility that the Lyt 2+ L3T4+ immunopotentiating cells in the spleens of L-PAM treated MOPC-315 tumor bearers represent immature cells that have been induced by the chemotherapy to migrate from the thymus into the spleen is discussed.	Melphalan	81-86	CD4 antigen	Mus musculus	32-36
2946780-4	1987	The capacity to generate CTL from both L3T4 (+) and Lyt-2 (+) precursors was lost after Leu-Leu-OMe treatment, whereas alloantigen-induced proliferation and interleukin 2 (IL 2) production by L3T4 (+) T helper cells remained intact.	leucyl-leucine-methyl ester	88-99	CD4 antigen	Mus musculus	39-43
2853271-11	1987	By 18 days post-infection, when 3H-thymidine uptake could be induced at control level, Thy 1.2+, L3T4+, and Lyt 2+ (T-cytotoxic/suppressor) cells were each responsive to Con A activation at levels comparable to control but Lyt 1+ and IL2 R+ cells were still substantially suppressed (ca.	3h-thymidine	32-44	CD4 antigen	Mus musculus	97-101
3919141-2	1985	Treatment with anti-L3T4 depleted circulating target cells, reduced autoantibody production, retarded renal disease, and prolonged life relative to control mice treated either with saline or with purified nonimmune rat IgG.	Sodium Chloride	181-187	CD4 antigen	Mus musculus	20-24
6415170-1	1983	Monoclonal antibody GK1.5 recognizes a previously undescribed murine T cell surface molecule, designated L3T4, which migrates on SDS-PAGE under reducing conditions as a single band with an apparent m.w.	Sodium Dodecyl Sulfate	129-132	CD4 antigen	Mus musculus	105-109